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Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB) [(Zopf 1883) Lehmann and
Neumann 1896], is a major cause of morbidity and mortality. Nearly one-third of the world’s population is
infected with MTB; TB has an annual incidence of 9 million new cases and each year causes 2 million
deaths worldwide.
Objectives: To investigate the clinical effectiveness and cost-effectiveness of screening tests [interferon-
gamma release assays (IGRAs) and tuberculin skin tests (TSTs)] in latent tuberculosis infection (LTBI)
diagnosis to support National Institute for Health and Care Excellence (NICE) guideline development for
three population groups: children, immunocompromised people and those who have recently arrived in
the UK from high-incidence countries. All of these groups are at higher risk of progression from LTBI to
active TB.
Data sources: Electronic databases including MEDLINE, EMBASE, The Cochrane Library and Current
Controlled Trials were searched from December 2009 up to December 2014.
Review methods: English-language studies evaluating the comparative effectiveness of commercially
available tests used for identifying LTBI in children, immunocompromised people and recent arrivals to the
UK were eligible. Interventions were IGRAs [QuantiFERON®-TB Gold (QFT-G), QuantiFERON®-TB Gold-In-
Tube (QFT-GIT) (Cellestis/Qiagen, Carnegie, VA, Australia) and T-SPOT.TB (Oxford Immunotec, Abingdon,
UK)]. The comparator was TST 5mm or 10mm alone or with an IGRA. Two independent reviewers
screened all identified records and undertook a quality assessment and data synthesis. A de novo model,
structured in two stages, was developed to compare the cost-effectiveness of diagnostic strategies.
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Results: In total, 6687 records were screened, of which 53 unique studies were included (a further 37 studies
were identified from a previous NICE guideline). The majority of the included studies compared the strength
of association for the QFT-GIT/G IGRA with the TST (5mm or 10mm) in relation to the incidence of active TB
or previous TB exposure. Ten studies reported evidence on decision-analytic models to determine the
cost-effectiveness of IGRAs compared with the TST for LTBI diagnosis. In children, TST (≥ 5mm) negative
followed by QFT-GIT was the most cost-effective strategy, with an incremental cost-effectiveness ratio (ICER)
of £18,900 per quality-adjusted life-year (QALY) gained. In immunocompromised people, QFT-GIT negative
followed by the TST (≥ 5mm) was the most cost-effective strategy, with an ICER of approximately £18,700
per QALY gained. In those recently arrived from high TB incidence countries, the TST (≥ 5mm) alone was less
costly and more effective than TST (≥ 5mm) positive followed by QFT-GIT or T-SPOT.TB or QFT-GIT alone.
Limitations: The limitations and scarcity of the evidence, variation in the exposure-based definitions of
LTBI and heterogeneity in IGRA performance relative to TST limit the applicability of the review findings.
Conclusions: Given the current evidence, TST (≥ 5mm) negative followed by QFT-GIT for children,
QFT-GIT negative followed by TST (≥ 5mm) for the immunocompromised population and TST (≥ 5mm)
for recent arrivals were the most cost-effective strategies for diagnosing LTBI that progresses to active TB.
These results should be interpreted with caution given the limitations identified. The evidence available
is limited and more high-quality research in this area is needed including studies on the inconsistent
performance of tests in high-compared with low-incidence TB settings; the prospective assessment of
progression to active TB for those at high risk; the relative benefits of two-compared with one-step testing
with different tests; and improved classification of people at high and low risk for LTBI.
Study registration: This study is registered as PROSPERO CRD42014009033.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Acid-fast bacilli Bacteria that, having been stained with a dye, retain their colour in acid alcohol. Used as
a technique for the microscopic detection of mycobacteria.
Active tuberculosis Infection with mycobacteria of the Mycobacterium tuberculosis (MTB) [(Zopf 1883)
Lehmann and Neumann 1896] complex in which mycobacteria are growing and causing symptoms and
signs of disease. This is distinct from latent tuberculosis, in which mycobacteria are present, and may be
dormant, but are not causing disease. The symptoms of disease include weakness, weight loss, fever, no
appetite, chills and sweating at night. Other symptoms of tuberculosis disease depend on where in the body
the bacteria are growing. If tuberculosis is in the lungs (pulmonary tuberculosis), the symptoms may include
a cough, pain in the chest and coughing up blood [source: www.hpa.org.uk (accessed 12 December 2015)].
Adherence Refers to the patient’s ability or choice to adhere to a treatment regimen. Also see Concordance.
Algorithm (in guidelines) A flow chart of the clinical decision pathway described in the guideline in
which decision points are represented with boxes, linked by arrows.
Atypical mycobacteria Mycobacteria other than those of the Mycobacterium tuberculosis complex.
Bacillus Calmette–Guérin vaccine A vaccine for tuberculosis named after the French scientists Calmette
and Guerin [source: www.hpa.org.uk (accessed 12 December 2015)].
Bias Deviation of results from the truth because of systematic error(s) in the methods used.
Cochrane review A systematic review of the evidence from randomised controlled trials relating to a
particular health problem or health-care intervention, produced by the Cochrane Collaboration. Available
electronically as part of The Cochrane Library.
Cohort study A retrospective or prospective follow-up study. Groups of individuals to be followed up are
defined on the basis of the presence or absence of exposure to a suspected risk factor or intervention.
A cohort study can be comparative, in which case two or more groups are selected on the basis of
differences in their exposure to the agent of interest.
Compliance The extent to which a patient complies with a recommended treatment regimen. In recent
years, use of the term ‘compliance’ has been discouraged because of its connotations of patient
subservience (see Concordance and Adherence).
Concordance The percentage of agreement between two tests.
Confidence interval A range of values that contains the true value for the population with a stated
‘confidence’ (conventionally 95%). The interval is calculated from sample data and generally straddles the
sample estimate. The 95% confidence value means that, if the study, and the method used to calculate
the interval, is repeated many times, 95% of the calculated intervals will actually contain the true value.
Contact (domestic, close, casual and workplace) A person who has spent time with a person with
infectious tuberculosis [source: www.hpa.org.uk (accessed 12 December 2015)].
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxv
Cost-effectiveness analysis An economic study design in which the consequences of different
interventions are measured using a single outcome, usually in natural units (e.g. life-years gained, deaths
avoided, heart attacks avoided, cases detected). Alternative interventions are then compared in terms of
cost per unit of effectiveness.
Cost–utility analysis A form of cost-effectiveness analysis in which the units of effectiveness are
quality-adjusted life-years.
Culture The process of growing tuberculosis bacteria from sputum or other samples for identification
and diagnosis.
Discordance The percentage of disagreement between two tests.
Heterogeneity Variability or differences between studies in the estimates of effects (when the results or
estimates from individual studies appear to have a different magnitude, if not a different sign or direction).
High-incidence country Following the widely used threshold, any country with an incidence of
tuberculosis that is ≥ 40 cases per 100,000 population per year. A similar definition is made for areas
within countries and may be used to decide on the local need for vaccination, for instance for neonatal
bacillus Calmette–Guérin vaccination.
Immunocompromised Refers to an individual who has a significantly impaired immune system. This may
be caused by prolonged steroid use, tumour necrosis factor alpha antagonists, antirejection therapy,
immunosuppression-causing medication or comorbid states that affect the immune system, for example
human immunodeficiency virus infection, chronic renal disease, many haematological and solid cancers,
and diabetes.
Infectious tuberculosis Active sputum smear-positive pulmonary tuberculosis, that is, with acid-fast
bacilli visible on microscopy. Active tuberculosis affecting other parts of the respiratory tract or oral cavity,
although rare, is also considered infectious.
Interferon gamma test A blood test used to diagnose latent tuberculosis (which may be used as an
alternative, or an addition, to tuberculin skin tests) based on detecting the response of white blood cells to
tuberculosis antigens.
Latent tuberculosis Infection with mycobacteria of the Mycobacterium tuberculosis complex in which the
bacteria are alive but are not currently causing active disease. Also known as latent tuberculosis infection.
Mantoux test A type of tuberculin skin test in which tuberculin is injected intracutaneously. The injection
site is examined for signs of an immune response after 2–3 days.
Multidrug-resistant tuberculosis Tuberculosis resistant to isoniazid and rifampicin, with or without any
other resistance.
Mycobacterium tuberculosis complex The related mycobacterial species Mycobacterium tuberculosis,
Mycobacterium bovis [(Hale et al. 1962) Askaa and Erno 1976] and Mycobacterium africanum [Castets
et al. 1969], which can cause tuberculosis in humans.
Skin test See Tuberculin skin test.
Smear positive See Sputum smear positive.
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Specificity (of a test) The proportion of individuals classified as negative by the gold (or reference)
standard who are correctly identified by the study test.
Sputum Mucus expelled from the bronchi and lungs by coughing (or retrieved from gastric washings).
Sputum is examined for tuberculosis bacteria by microscopic examination of a stained smear; part of the
sputum can also be used for culture.
Sputum smear positive (‘smear positive’) Respiratory tuberculosis in which mycobacteria (‘acid-fast
bacilli’) have been seen in a stained smear of sputum examined under a microscope [source: www.hpa.
org.uk (accessed 12 December 2015)].
Weighted contact score The weighted contact score represents a weight based on the relationship
(e.g. primary caregiver, secondary caregiver, relative or non-household contact) between the tuberculosis
index case and an individual, the type (e.g. sleeps in the same house or lives in the same house) and
duration (e.g. 0–3 hours or 4–7 hours of contact per day) of exposure to the index case and the infectivity
(sputum acid-fast bacilli positivity) of the index case (Tieu HV, Suntarattiwong P, Puthanakit T,
Chotpitayasunondh T, Chokephaibulkit K, Sirivichayakul S, et al. Comparing interferon-gamma release
assays to tuberculin skin test in Thai children with tuberculosis exposure. PLOS ONE 2014;9:e105003).
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CEAC cost-effectiveness
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CG clinical guideline
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Plain English summary
Tuberculosis (TB) is one of the biggest causes of illness and death worldwide. People with TB who arenot infectious and have no symptoms (the majority) have latent tuberculosis infection (LTBI). Some
people with LTBI may develop active TB during their lifetime.
There are two types of tests used to identify LTBI in the UK: (1) the tuberculin skin test (TST) and
(2) interferon gamma release assays (IGRAs). This review compares whether the TST or IGRAs offer better
value for money in detecting LTBI in children, in people who have low immunity and in recent arrivals from
countries with high levels of TB.
We searched the evidence available and built a model to determine which test offers the best value for
money in detecting LTBI.
We identified 90 studies. In children we found no difference between IGRAs and TST 5mm but IGRAs
performed better than TST 10mm in identifying LTBI. In people with low immunity, IGRAs and TST
performed better at ruling out LTBI than identifying people who did have LTBI. There was considerable
variability in the results between different studies. For people recently arrived in the UK from
high-incidence countries, TST performed better than IGRAs at identifying LTBI.
The economic model showed that the best-available options were:
l in children: TST followed by IGRAs if negative
l in people with low immunity: IGRAs followed by TST if negative
l in the recently arrived population: TST alone.
The evidence was limited and future research is needed.
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Scientific summary
Background
Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. The timely identification and
prophylactic treatment of people with latent tuberculosis infection (LTBI) is of public health and clinical
importance. Unfortunately, there is no diagnostic gold standard for identification of LTBI. Instead, the
available screening tests provide indirect and imperfect information. There are two types of tests in
use in the UK: (1) the tuberculin skin test (TST), read at two levels (5 mm and 10mm) and (2) the
interferon gamma release assays (IGRAs).
In this review we updated a previous clinical guideline (CG) [National Collaborating Centre for Chronic
Conditions, Centre for Clinical Practice at the National Institute for Health and Care Excellence.
Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and
Control. CG117. London: NICE; 2011. URL: www.ncbi.nlm.nih.gov/books/NBK97852/ (accessed
27 February 2014)] and investigated the clinical effectiveness and cost-effectiveness of screening tests
(IGRAs and TST) in LTBI diagnosis in three population groups: children, immunocompromised people and
those who have recently arrived in the UK from high-incidence countries. All of these groups are at higher
risk of progression from LTBI to active TB.
This review addressed the following questions:
1. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying latent TB
in children?
2. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying latent TB
in people who are immunocompromised?
3. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying latent TB
in people who are recent arrivals from countries with a high incidence of TB?
Methods
Clinical effectiveness
Search strategy
Search strategies included the following main elements: (1) search of electronic bibliographic databases
(including MEDLINE, EMBASE, The Cochrane Library, the Science Citation Index and Conference
Proceedings Citation Index, Health Economic Evaluations Database) (updated on 2 December 2014);
(2) contact with experts in the field; (3) scrutiny of references of included studies and systematic reviews;
and (4) screening of manufacturers’ and other relevant websites.
Study eligibility criteria
English-language studies evaluating and comparing the effectiveness of commercially available tests used
for identifying people with LTBI were eligible for inclusion in the review.
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Populations
l Children (both sexes, aged < 18 years, immunocompetent).
l Those who are immunocompromised or at risk of immunosuppression [both sexes, any age, transplant
recipients, human immunodeficiency virus (HIV) infection, renal disease, haematological disease,
autoimmune disease, recipients of antitumour necrosis factor alpha treatment, steroids or ciclosporins].
l People recently arrived from regions with a high incidence/prevalence of TB (both sexes, any age,
immunocompetent, areas with an estimated incidence of ≥ 40 per 100,000).
Interventions
Two IGRAs:
l QuantiFERON®-TB Gold-in-Tube (QFT-GIT) [old version QuantiFERON®-TB Gold (QFT-G)]
(Cellestis/Qiagen, Carnegie, VA, Australia)
l T-SPOT.TB (Oxford Immunotec, Abingdon, UK).
Comparator
l TST 5mm or 10mm (Mantoux test) alone or plus IGRA (one- or two-step testing).
Outcomes
Associations between test results and validity constructs for LTBI:
l progression to active TB
l previous exposure to Mycobacterium tuberculosis [(Zopf 1883) Lehmann and Neumann 1896]
(MTB; defined by proximity, duration, geographical location or dose–response gradient)
l people at low risk of MTB infection or healthy populations.
Studies
l Randomised controlled trials and retrospective or prospective cohort studies.
l Cross-sectional or case–control studies.
Economics
l Decision-analytic models investigating cost-effectiveness.
l Cost studies.
Exclusions
l Studies using test results as proxies for LTBI.
l Non-commercial/in-house IGRAs, first-generation QFT or tests unavailable in the UK.
l Studies reporting only between-test agreement.
Study selection, data extraction and quality assessment
Two independent reviewers screened all identified records. Disagreements were resolved by discussion and
recourse to a third reviewer.
Similarly, relevant data were extracted independently and disagreements were resolved by recourse to
a third reviewer. For each test, summary parameters (e.g. sensitivity, specificity, diagnostic odds ratios,
cumulative incidence ratios, per cent concordance, kappa statistic) with corresponding measures of
variability [95% confidence intervals (CIs), p-value] were extracted or calculated (e.g. using construct
validity categories of exposure levels or progression to active TB, when data permitted).
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Risk of bias and methodological quality were also assessed independently using the Quality in Prognosis
Studies tool and a modified tool by Dinnes et al. [Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E,
Waugh N, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection.
Health Technol Assess 2007;11(3)] for incidence and exposure studies and the Consolidated Health
Economic Evaluation Reporting Standards and Philips et al.’s checklists for economics studies [Philips Z,
Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in
decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36)].
Data synthesis and analysis
Predictive values for IGRAs and TST for progression to active TB (incidence studies), the degree of
association of IGRA and TST results with previous exposure to MTB (defined by proximity, duration or
dose–response gradient) and the specificity of IGRAs and TST in healthy populations were assessed.
We measured concordance/discordance between IGRAs and TST.
Summary effectiveness measures were pooled using a random-effects model. Heterogeneity was
determined visually and by the I2 statistic and chi-squared test (two tailed, p≤ 0.10). Subgroup analyses
(by TST threshold, IGRA type, setting, TB burden and clinical condition) were undertaken to explore
heterogeneity. Calculations were performed with Meta-DiSc version 1.4 (Unit of Clinical Biostatistics,
Ramón y Cajal Hospital, Madrid, Spain) and Stata version 14 (StataCorp LP, College Station, TX, USA).
Cost-effectiveness
A de novo model structured in two stages (decision tree for LTBI diagnosis and infectious disease model)
was developed in R (version 3.1.1; The R Foundation for Statistical Computing, Vienna, Austria) to
compare the cost-effectiveness of diagnostic strategies. The first stage included pathways following testing
for 1 year before entering the second stage – an infectious disease model. Four diagnostic strategies were
examined for each population:
l TST alone
l IGRA alone
l combinations of sequential TST and IGRA
l simultaneous testing.
For the infectious disease stage the following states were modelled:
l active TB
l LTBI – treated for LTBI
l LTBI – untreated
l no TB/LTBI – treated for LTBI
l no TB/LTBI – untreated.
Information required to parameterise the model included prevalence, sensitivity and specificity, adverse
events, resource use, and costs and utilities. We used clinical information from the review. We used
Bayesian Markov chain Monte Carlo methods to estimate study prevalence and test performance,
accounting for the underlying prevalence in each of the studies in the evidence base. We then made a
further assumption about the relationship between prevalence in the studies and that in the decision
population. In the models, we used QFT-GIT results as the base-case values for the analysis.
Resource use and costs were obtained from the cost-effectiveness review, NHS reference costs 2012/13,
the NHS drug tariffs and clinical experts. Costs were adjusted to 2012/13 prices. The simulation was run
for 100 years with a 3.5% discount rate and from a NHS and Personal Social Services perspective. A utility
decrement of 0.15 was applied to Health Survey for England values for people who received treatment for
active TB.
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Outcomes were expressed as incremental cost-effectiveness ratios (ICERs) for cost per quality-adjusted
life-year (QALY) and cost per diagnostic error avoided. Univariate and probabilistic sensitivity analyses
were undertaken.
Results
Clinical effectiveness
We identified 6687 records. After removing duplicates, 3757 records were screened, of which 54
(53 unique studies) were included. We included 37 additional studies from CG117.
The majority of included studies compared the strength of association between QFT-GIT/G IGRA and TST
(5mm or 10mm) in relation to the incidence of active TB or previous TB exposure (e.g. proximity to,
relationship with an active case or weighted contact score). Seven of the 15 incidence group studies had
a high risk of bias, six had a moderate risk of bias and two had a low risk of bias. Twenty-nine of the
38 exposure studies were of lower quality.
Children
The results of the 27 studies were:
l Incidence studies:
¢ TST 5mm: there was no difference between TST 5mm and QFT-GIT [two studies; pooled ratio of
cumulative incidence ratios (R-CIR) 1.12, 95% CI 0.72 to 1.75].
¢ TST 10mm: QFT-GIT was better than TST 10mm (three studies; pooled R-CIR 4.33, 95% CI 1.32
to 14.23).
l Sensitivity and specificity:
¢ TST 5mm: IGRA (QFT-GIT/G) had similar sensitivity (48–100% vs. 57–100%) to and slightly better
specificity (49–90% vs. 45–65%) than TST 5mm.
¢ TST 10mm: IGRA had a higher sensitivity (48–100% vs. 30–56%) and a slightly lower specificity
(49–90% vs. 63–93%) than TST 10mm.
l Exposure studies: IGRA performed better than TST 5mm/10mm in 14 studies [pooled ratio of
diagnostic odds ratios (R-DOR) 1.98, 95% CI 1.19 to 3.28; I2= 89%].
l Subgroup analyses (stratified by TB burden setting):
¢ In low TB burden settings IGRAs were superior to TST 5mm/10mm (six studies; pooled R-DOR
4.74, 95% CI 2.15 to 10.44).
¢ In high TB burden settings there was no difference between the tests (eight studies; pooled R-DOR
1.13, 95% CI 0.78 to 1.65).
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Immunocompromised people
The 48 studies were stratified into those including participants with HIV infection, solid organ
transplantation, post-kidney transplantation, haemodialysis (end-stage renal disease), immune-mediated
inflammatory diseases before antitumour necrosis factor alpha (TNF-α) therapy, hepatitis C and lupus
erythematosus. The results of the studies were as follows:
l Incidence studies: in the two studies reporting data, R-CIR estimates were non-significant with wide
95% CIs.
l Exposure studies:
¢ IGRAs performed better than TST 5mm/10mm in people with:
¢ haemodialysis (four studies; pooled R-DOR 2.53, 95% CI 1.48 to 4.34)
¢ hepatitis C (one study; R-DOR 8.45, 95% CI 3.71 to 19.24).
¢ TST 10mm performed significantly better than QFT-GIT for people with HIV/acquired
immunodeficiency syndrome (AIDS) (two studies; pooled R-DOR 0.35, 95% CI 0.15 to 0.83).
l Subgroup analysis (stratified by condition): R-DOR estimates were non-significant/inconclusive with
wide 95% CIs in:
¢ people with lupus erythematosus
¢ people with immune-mediated inflammatory diseases before antiTNF-α therapy
¢ solid organ transplantation candidates
¢ kidney transplant recipients.
Recent arrivals from countries with a high incidence of tuberculosis
The results of the 15 studies were:
l Incidence studies:
¢ There was no significant difference between TST 5mm/10mm and QFT-GIT (two studies; pooled
R-CIR 1.57, 95% CI 0.52 to 4.76).
¢ There was no significant difference between TST 10mm and T.SPOT.TB (one study; R-CIR 0.37,
95% CI 0.10 to 1.41).
l Exposure studies: there was no significant difference between TST 10mm and QFT-GIT (three studies;
pooled R-DOR 0.96, 95% CI 0.69 to 1.33).
Cost-effectiveness
Ten relevant studies were identified and all performed well against frameworks for best practice for
reporting economic evaluations.
Bayesian meta-analysis of relevant studies gave the following values with 95% credible intervals for use in
the models:
l in children:
¢ TST (≥ 5mm): sensitivity 72.80% (60.59% to 72.94%); specificity 49.03% (47.96% to 50.08%)
¢ TST (≥ 10mm): sensitivity 53.51% (38.21% to 67.69%); specificity 74.81% (34.34% to 76.18%)
¢ QFT-GIT: sensitivity 68.84% (58.56% to 78.20%); specificity 61.03% (60.30% to 61.76%)
¢ T-SPOT.TB: sensitivity 50.00% (2.45% to 97.64%); specificity 77.58% (67.38% to 86.40%).
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l In immunocompromised people:
¢ TST (≥ 5mm): sensitivity 32.42% (11.19% to 58.48%); specificity 74.22% (72.88% to 75.57%)
¢ TST (≥ 10mm): sensitivity 16.82% (2.52% to 38.99%); specificity 83.97% (78.99% to 88.31%)
¢ QFT-GIT: sensitivity 55.48% (24.73% to 83.73%); specificity 82.27% (80.52% to 83.96%)
¢ T-SPOT.TB: sensitivity 66.65% (35.17% to 91.44%); specificity 68.46% (63.46% to 73.37%).
l In recently arrived populations:
¢ TST (≥ 5mm): sensitivity 93.56% (77.86% to 99.77%); specificity 50.11% (47.90% to 52.29%)
¢ QFT-GIT: sensitivity 59.15% (35.84% to 81.42%); specificity 79.29% (77.80% to 80.73%)
¢ T-SPOT.TB: sensitivity 70.01% (39.78% to 92.42%); specificity 39.92% (34.39% to 45.54%).
Model outputs: incremental cost-effectiveness ratios – cost per quality-adjusted
life-year and cost per diagnostic error avoided
l In children:
¢ TST (≥ 5mm) negative followed by QFT-GIT was the most cost-effective strategy with an ICER of
£18,900 per QALY gained.
¢ T-SPOT.TB was the most cost-effective strategy with an ICER of approximately £2700 per
diagnostic error avoided compared with TST (≥ 10mm).
l In immunocompromised people:
¢ QFT-GIT negative followed by TST (≥ 5mm) was the most cost-effective strategy with an ICER of
approximately £18,700 per QALY gained.
¢ QFT-GIT positive followed by TST (≥ 5mm) was the most cost-effective strategy with an ICER of
approximately £300 per diagnostic error avoided compared with TST (≥ 10mm).
l In the recently arrived population:
¢ TST (≥ 5mm) alone was the most cost-effective strategy with an ICER of approximately £1500 per
QALY gained compared with QFT-GIT.
¢ TST (≥ 5mm) positive followed by QFT-GIT was the most cost-effective strategy with an ICER of
approximately £700 per diagnostic error avoided compared with QFT-GIT alone.
Discussion
Summary of results
In children the limited evidence suggested that TST 5mm was the best test for predicting LTBI. TST
(≥ 5mm) negative followed by QFT-GIT was the most cost-effective strategy.
Interferon gamma release assays appeared to outperform TST in low TB burden settings but not high TB
burden settings, a finding that is consistent with a growing body of evidence showing reduced sensitivity
and specificity of IGRAs in high TB burden settings. This type of effect modification could be explained
by higher frequency of exposure to MTB, different transmission dynamics, malnutrition, comorbidity,
coinfection with HIV or helminthic infection.
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For immunocompromised people most of the evidence was insufficient and inconsistent. There was large
variation in the performance of IGRAs compared with TST across different clinical subgroups. QFT-GIT and
T-SPOT.TB performed better than TST 5mm/10mm in those undergoing haemodialysis and those with
hepatitis C. In contrast, QFT-GIT performed significantly worse than TST 10mm in people with HIV/AIDS.
This observation could potentially be explained by T-lymphocyte depletion. For other clinical subgroups of
immunocompromised people the evidence was inconclusive because of the high level of uncertainty
around the statistically non-significant effect estimates. The QFT-GIT negative followed by TST (≥ 5mm)
strategy was the most cost-effective in this group with an ICER of approximately £18,700 per QALY.
Among recently arrived people from countries with a high TB burden, there was no significant difference
between the performance of IGRAs and the performance of TST in identifying LTBI. The TST (≥ 5mm)
alone strategy was the most cost-effective with an ICER of approximately £1500 per QALY.
Strengths and limitations
The findings of this review warrant a cautious interpretation. The evidence was inconclusive, in large part
because of unexplained heterogeneity, poor reporting, missing data and great uncertainty around the
effect estimates for the association between test results and the constructs of validity for LTBI. With no
‘gold standard’ and an inadequate definition of construct validity for LTBI (e.g. definitions of previous
exposure may not represent the true presence of LTBI), exposure misclassification was probably an
important issue.
Other factors that may have contributed to this variability are study setting, type of population, type of
test, previous bacillus Calmette–Guérin (BCG) vaccination and the limitations of screening tests (inter-/
intrarater variability in the interpretation of test results, boosting, conversion, reversion, different cut-offs
for test positivity, assay manufacturing, pre-analytical processing and/or incubation delay). Apart from
these issues, various sources of methodological bias may have independently distorted the review findings.
For example, the study findings may have been biased because of a lack of blinding, selection bias, partial
verification bias because of incomplete outcome data assessment and incorporation bias.
The strengths of the cost-effectiveness assessment include the building of a de novo two-stage model and
the use of the review findings (coupled with Bayesian meta-analysis) to derive summary estimates of
diagnostic accuracy, although we did not adjust for BCG status because of a lack of data. A number of
assumptions were made, including that the TST was costed similarly for those that were read and those
that were not read. Resource use was estimated with input from our clinical advisors.
Implications
The findings should be viewed by clinicians and policy makers cautiously because of the limited evidence,
the lack of a gold standard diagnostic test and the assumptions made. Clinicians should be mindful of the
variation in performance of the different testing strategies among different populations.
Research priorities
l The inconsistent performance of IGRAs in high- and low-TB settings should be investigated to see
whether or not it is replicable.
l Prospective studies are needed for people at high risk of TB to assess progression to active TB.
l The relative benefits of two-step testing with different combinations of IGRAs and TST compared with
single-step testing should be investigated.
l For retrospective or cross-sectional studies a standard set of component exposures to aid classification
into high and low risk for LTBI is needed, alongside identification of more accurate markers of LTBI.
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Chapter 1 Background
Overview
Tuberculosis (TB) is a major cause of morbidity and mortality globally. Nearly one-third of the world’s
population is infected with Mycobacterium tuberculosis (MTB) [(Zopf 1883) Lehmann and Neumann 1896];
TB has an annual incidence of 9 million new cases and each year causes 2 million deaths annually
worldwide. TB ranks as the second leading cause of death from an infectious disease.1–3
In the UK, the prevalence of TB steadily decreased until the mid-1980s but has started to rise over the last
20 years, especially in ethnic minorities born in places with a high TB prevalence.4,5 Between 1998 and
2009, annual TB notifications in the UK rose by 44%, from 6167 to 8900 cases.4,6 Since 2005, this rate
has remained high, leading to projections that in 2 years there will be more TB cases in the UK than in the
USA,7 thereby posing a major public health challenge. The re-emergence has been largely driven by
recently arriving immigrants in whom latent infection has been reactivated or who have acquired new
infection as a result of their maintaining links with high-prevalence countries.
Aetiology and pathology of tuberculosis
Tuberculosis infection is transmitted to a healthy person through the air by inhaling respiratory fluids/
sputum droplets containing MTB discharged by a person with active TB. The infected sputum droplets can
dry and form into droplet nuclei, which can float in the air for a long period of time and penetrate the
host.8 TB can be transmitted through other routes including ingestion (e.g. from drinking unpasteurised
cow’s milk)9 and inoculation (e.g. Prosector’s wart), although such cases are rare in the UK.
Once the bacteria are inhaled, the droplet nuclei travel through the mouth or nasal passages to the upper
respiratory tract, bronchi and finally the alveoli of the lungs. The bacteria grow slowly and multiply in the
alveoli over several weeks. Sometimes a small number of tubercle bacilli enter the bloodstream and spread
throughout the body such as to the bones, lymph nodes or brain.8 In > 80% of cases the immune system
kills and removes the bacteria from the body.10 If the immune system does not kill the bacteria, macrophages
within the immune system ingest and surround the tubercle bacilli within 2–8 weeks. The cells form a barrier
shell that keeps the bacteria suppressed and under control, resulting in latent tuberculosis infection (LTBI).
Individuals with LTBI do not exhibit any clinical, radiological or bacteriological evidence of the pathogen. They
are not infectious and may remain asymptomatic.11 However, the latent infection may reactivate later in life,
causing the individual to develop symptoms and become infectious. It has been estimated that people with
LTBI are at 5–10% risk for developing active TB during their lifetime.12,13 Therefore, this large pool of LTBI is
an important reservoir of infection.8,12
If the immune system cannot keep the bacteria suppressed or the barrier fails later, the bacilli begin to
multiply and the individual develops active TB disease. Individuals who have active TB are infectious and
each can spread MTB to up to 10–15 close contacts within a year.14 The pathogen affects primarily the
lungs (pulmonary TB) but can also involve other organs of the body (extrapulmonary TB). In the UK in
2012, pulmonary TB accounted for about 53% of all TB cases.5
The period between infection and first signs of illness (incubation period) varies between 8 weeks and
decades. The greatest chance of progressing to disease is within the first 2 years after infection, when
approximately 50% of the 5–10% lifetime risk occurs.15 The risk of infection and progression to active TB
disease depends mostly on the host’s immune function as well as on the duration and proximity of
exposure to a source afflicted with active MTB.16 Therefore, certain population groups have a higher
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lifetime risk of developing TB. These vulnerable groups with low immunity and/or high exposure include
long-term care facility workers, people born in or coming from countries with a high prevalence of TB,
infants, children, those infected with human immunodeficiency virus (HIV), people with close contacts
suspected of having active TB or those living in confined facilities (e.g. prison, homeless shelters).5 These
groups are particularly important as a reservoir of latent infection that could reactivate, and explain the
trends observed for TB in the UK.17
Active tuberculosis
When infection with MTB becomes active TB disease, the symptoms that occur are non-specific and
depend on the site of TB infection.18,19 Common signs and symptoms of active pulmonary TB may include
a chronic cough for weeks or months accompanied by the coughing up of blood or blood-stricken mucus,
pain in the chest, weight loss, intermittent fever and/or night sweats, poor appetite, chills, weakness or
fatigue, and listlessness.1,18,20 The clinical diagnosis of TB is based on TB-characteristic clinical signs and
symptoms, chest radiography and microscopy of tissue biopsy or sputum samples. A definitive diagnosis of
TB, however, is made through the identification of MTB in clinical samples (e.g. pus, tissue biopsy, sputum)
using culture.21,22 TB is difficult to culture and it takes several weeks to obtain a definitive result.
Tuberculosis is a curable disease; however, treatment is long and requires adherence, even through the side
effects of treatment.23 In the UK, most MTB infections are sensitive to the antibiotics used.10 The routine
management of active pulmonary TB includes a combination of antibiotics (e.g. isoniazid, rifampicin,
pyrazinamide and ethambutol) given over 6 months.18 Although patients start to feel better after 2 months
of treatment and are not infectious any longer, it is vital that they complete their treatment.24,25 This ensures
that the TB bacteria are completely killed off, preventing the return of symptoms and the risk of bacteria
becoming drug resistant. Treatment of drug-resistant forms of TB is less effective, requires longer than
6 months and causes greater side effects.10,26
Measurement of latent tuberculosis infection
Unfortunately, there is no diagnostic gold standard for the identification of individuals with LTBI. Instead,
the available screening tests for LTBI provide an indirect assessment of the presence of LTBI by relying on a
host’s immunological response to TB antigens.27 In addition, none of the available LTBI tests can accurately
differentiate between people with LTBI and people with active TB.11
There are two types of commercially available tests used to identify LTBI in the UK: (1) the tuberculin skin
test (TST) and (2) the interferon gamma (IFN-γ) release assays (IGRAs).5 Until recently, the TST (introduced
by Mantoux in 1907) has been the only standard test used for the identification of LTBI.13 The
administration of the TST involves an intradermal injection of purified protein derivative (PPD) in the
forearm. The immune response (i.e. delayed hypersensitivity caused by T cells) to the TST is determined
48–72 hours after the injection by measuring the transverse diameter (in mm) of skin induration.13,16
There is no international agreement on cut-off values for the definition of a positive tuberculin reaction.12
The choice among commonly used cut-off values (e.g. a diameter of induration of ≥ 5mm, ≥ 10mm or
≥ 15mm) depends on an individual’s risk factor profile for TB. Usually, a lower cut-off value of ≥ 5mm is
used for individuals at higher risk of TB (e.g. patients with organ transplants, immunocompromised
patients, patients with HIV infection and those who have had recent contacts with an active TB patient)
and a higher cut-off value of ≥ 10mm is applied for individuals at lower risk of TB (e.g. high-risk racial
minorities, children, recently arrived immigrants from high-prevalence countries and patients with diabetes,
malignancies or renal failure).16 The administration of the TST is relatively cheap and does not require a
laboratory, but it does require a skilled operator.
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Interferon gamma release assays have been recently developed as alternative screening tests for LTBI.
There are two types of IGRA: QuantiFERON®-TB Gold-in-Tube (QFT-GIT) [old version: QuantiFERON®-TB
Gold (QFT-G)] (Cellestis/Qiagen, Carnegie, Australia) and T-SPOT.TB (Oxford Immunotec, Abingdon, UK).
Both tests are commercially available in the UK. The QFT test is a whole-blood test based on an
enzyme-linked immunosorbent assay whereas the T-SPOT.TB test uses peripheral blood mononuclear cells
and is based on an enzyme-linked immunospot (ELISPOT) assay.11 Both tests measure the cluster of
differentiation 4 (CD4) cell-released IFN-γ response to MTB-specific antigens [early secretion antigen
target 6 (ESAT-6), culture filtrate protein 10 (CFP-10) and tb7.7] in in vitro blood samples.12,13,16
Treatment of latent tuberculosis infection
The aim of LTBI treatment is to prevent MTB bacteria from developing into active TB disease. Before
treatment, all individuals found to have LTBI need to be tested for active TB. For individuals in whom active TB
is ruled out, the prophylactic treatment of choice is isoniazid. For adults and children, the treatment should be
given for between 3 and 6 months depending on the treatment regime. For individuals affected by HIV,
treatment is given for 6 months. Rifampicin given for 4 months is the second-line treatment that can be used
as an alternative in individuals who are resistant to isoniazid or at high risk of side effects from isoniazid.16
Incidence, prevalence and epidemiology
All forms of active TB are legally notifiable by the physician making or suspecting the diagnosis under
the Public Health (Control of Disease) Act 198428 in England and Wales. It first became a statutory
requirement to notify TB cases in 1913. Known as the Notifications of Infectious Diseases system, it
continues to play a valuable role in the surveillance of TB; however, the information collected is limited
and trends within subgroups of the population cannot be monitored.29
In 1999, the Enhanced Tuberculosis Surveillance system was established to collect more detailed
information on annual TB cases, including patient age, sex, ethnic group, country of birth, site of disease,
NHS region and treatment outcomes. It has been reported that the Enhanced Tuberculosis Surveillance
system reflects the true incidence of TB better than the Notifications of Infectious Diseases system as many
measures are used to ensure that quality standards are met annually, thereby providing a corrected
analysis of TB cases.30 In 2012, completeness of data was 100% for mandatory fields and approximately
91% across other key fields for England and 89% for Wales.5 This system provides the most
comprehensive, timely and accurate information on active TB incidence in the UK29 and is therefore robust.
There is no national system that collects data for LTBI. For this reason there are no robust data for LTBI,
although we can predict that for every person with active TB there are likely to be several with
undiagnosed LTBI. Therefore, it seems reasonable to extrapolate from active TB and make the assumption
that LTBI will follow a similar epidemiological pattern.
The rates of active TB peaked during the early 1900s with an annual incidence rate of approximately 320 per
100,000. The rate declined dramatically until at least 1987 to as low as 10.1 per 100,000 population per
year. However, since the 1980s, the incidence rate began reversing and has reached highs of between 13.6
and 14.4 per 100,000 since 2005.5 The most recent figures in 2012 report a total of 8751 active TB cases
across the UK, giving an incidence rate of 13.9 per 100,000.5 The burden of TB is highest in England, where
in 2012 there were 8130 cases of active TB, a rate of 15.2 per 100,000; in Wales there were 136 active TB
cases, a rate of 4.4 per 100,000.5 Between 2010 and 2011, a total of 436 people died of TB in the UK.5
Place of birth and ethnic minorities
The re-emergence of TB has been attributed to international migration, as recently arriving migrants have
accounted for the majority of TB cases since 2000. In 2011 and 2012, foreign-born individuals accounted
for 73% of reported TB cases.5 It has been reported that there has been a 98% increase in the number of
TB cases in individuals born overseas.4,6,31 The rate of TB among the non-UK-born population is 80 per
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100,000, which is almost 20 times the rate in the UK-born population. Almost half of the patients born
outside the UK were diagnosed within 5 years of coming to the UK, with another 30% diagnosed within
2 years.5 In total, 60% of foreign-born patients originated from South Asia, followed by 22% from
sub-Saharan Africa. With respect to country of origin of foreign-born patients, the highest proportions are
from India (31%), Pakistan (18%) and Somalia (6%). Similarly, a higher proportion of non-UK-born
patients (> 50%) than UK-born patients (31%) present with extrapulmonary TB.32
Among UK-born individuals, the highest rate of TB is found in ethnic minority groups. The largest
proportions of cases are found in those of Indian (27%, 2296/8525), white (21%, 1814/8525) and
Pakistani (17%, 1418/8525) ethnic origin. The highest rates of TB per 100,000 population are found in
Indian, Pakistani and black ethnic groups (155, 132 and 97 per 100,000, respectively).5 It has been
indicated that recently arriving immigrants and ethnic minorities are vulnerable as a result of reactivation of
latent infection once in the country or acquiring new infection as a result of their maintaining links with
high-prevalence countries (e.g. they may visit rural Pakistan or they may have relatives from high-prevalence
areas visit them).33 In addition, having diabetes increases the likelihood of reactivation of TB, and diabetes is
more common in individuals from South-East Asia, including the ethnic groups highlighted above.34
Geographical difference
Since the establishment of the enhanced TB surveillance system, it has become clear that there is a drastic
regional variation in the burden of TB. Active TB is highly concentrated in large cities, with London
consistently accounting for the highest rates and sharpest increases since the early 1990s. In 2012, London
accounted for almost 40% of all TB cases, with an annual rate of 41.8 per 100,000. London has the
highest TB rate among all high-income European countries.35,36 London is followed by the West Midlands,
which accounts for 12% of the burden and has an annual rate of 19.3 per 100,000.5 Both London and
the West Midlands have high rates of immigration.37
Within London there is great variation between boroughs. Twelve of the 33 local authorities have an
annual incidence rate of 40 per 100,000. The boroughs with the highest annual incidence rates of TB are
Newham (122 per 100,000) and Brent (100 per 100,000). However, other boroughs, such as Havering and
Richmond-upon-Thames, have an annual incidence rate of < 10 per 100,000.38 Similar to regional
variation, borough variation within London may reflect demographic characteristics as Newham and Brent
have some of the highest rates of immigrants and ethnic minorities.39
A similar picture is seen in Birmingham. Annual incidence rates for Birmingham as a whole fluctuated
between 33.7 and 44.8 cases per 100,000 between 2009 and 2013. In the fourth quarter of 2013,
Sandwell and West Birmingham Clinical Commissioning Group had an annual incidence rate of 49.6 per
100,000 [95% confidence interval (CI) 43.5 per 100,000 to 56.4 per 100,000] whereas in Solihull it was
1.9 per 100,000 (95% CI 0.5 per 100,000 to 4.9 per 100,000). Again, this reflects the ethnic make-up of
the areas [Helen Bagnall, Public Health England (PHE), West Midlands, May 2014, personal communication].
Age differences
The majority of patients with TB (60%) are aged between 15 and 44 years, followed by patients aged
45–64 years (21%) and patients aged ≥ 65 years (14%). The groups with the lowest rates of TB are those
aged 5–14 years (3%) and those aged < 5 years (2%). Although children have a low burden of overall TB
cases, once TB is transmitted to them they are more likely than adult hosts to develop active TB. Most
cases in those aged 0–14 years are in the UK-born population from black African, Pakistani and white
ethnic groups.5
Immunosuppression and tuberculosis
In addition to young children, the risk of progression from LTBI to active TB is higher in people coinfected
with HIV, patients immunocompromised because of comorbidity (e.g. diabetes, malignancy, renal disease)
and/or people with long-term use of immunosuppressant medications [e.g. corticosteroids, tumour necrosis
factor alpha (TNF-α) antagonists].11,16,40 Coinfection with HIV and TB has been internationally well
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documented.41–43 In the UK there has been a decrease in the number of coinfected HIV–TB cases, from 9%
of TB cases in 2003/4 to 3.6% of TB cases in 2013.5 This has been in line with the general downward trends
in HIV and TB in migrants from sub-Saharan Africa.32
Social risk factors
There are defined social factors that contribute to the burden of TB in the UK. These social risk factors
include homelessness (2.4%), a history of imprisonment (2.8%), and drug (2.8%) and alcohol (3.2%)
misuse.5 It is indicated that approximately 7.7% of TB cases present with at least one of these risk factors.
These social risk factors are more common in UK-born (13.4%) than foreign-born (5.4%) cases. Within
UK-born cases, almost half with at least one risk factor (46%) are from the white ethnic group.5
Impact of the health problem
Significance for patients
For the 5–10% of patients who develop active TB, those with pulmonary TB can suffer extreme pain from
the symptoms for weeks to months.44 Similarly, extrapulmonary TB can result in serious complications for
the bones, brain, liver, kidneys and heart.44 Tissue damage can be permanent if TB is not treated early.45
As a result of tissue damage, active TB can be fatal. In addition to the impact on physical functioning,
active TB can also have psychosocial impacts, in particular from the isolation experienced during the
treatment of TB. This can include anxiety, depression, disorientation, feelings of loss of control and mood
swings.46,47 A diagnosis of TB can also bring related stigma through which individuals face social and
economic consequences.48
Treatment of active TB causes many side effects depending on the regimen prescribed. Some symptoms
are mild but other side effects can be serious and potentially life-threatening. These can include loss of
appetite, nausea, vomiting, jaundice, fever, abdominal pain, lower chest pain or heartburn, skin rash,
bleeding gums and nose, blurred vision, ringing sounds, hearing loss, peripheral neuropathy and
hepatotoxicity.16 Individuals on antiretroviral treatment for HIV infection may suffer more side effects with
certain TB drugs. These side effects cause poor adherence to treatment. If treatment is incomplete, active
TB is more likely to be complex and drug-resistant and result in the need for treatments with greater side
effects.16,49 To avoid the consequences of the disease and the side effects of treatment, it would be easier
for patients to undergo LTBI treatment and prevent active disease.
However, the treatment of LTBI uses the same medication, with the same side effects, albeit usually for a
shorter period of time. Adherence to treatment is likely to be a factor as taking medicines when you feel
well is much harder than taking them when you feel unwell.
Significance for the NHS
The impact of TB as a health problem is extensive. As TB possesses the capacity to spread through the air
to practically anyone it is a serious public health threat, although, in practice, infection beyond family
members or close contacts is unusual. TB is on the increase in the UK and is decreasing in the USA.
It has been estimated that in 2–5 years the burden of TB in the UK will be higher than that in the whole
of the USA.7 Furthermore, drug-resistant TB is increasing in the UK, which means that transmission of
drug-resistant strains of TB may continue to increase and complicate the fight against TB.
The health-care costs associated with active TB include the costs of diagnosing and treating pulmonary TB,
extrapulmonary TB, multidrug-resistant TB and extensively drug-resistant TB. In the UK, the normal cost of
treating a case of active TB is £5000 but the cost of treating multidrug-resistant TB is between £50,000
and £70,000 and the cost of treating extensively drug-resistant TB can be up to £100,000.35,50 Using 2012
figures, we have estimated that annually TB treatment could cost approximately £50M. Given that LTBI
represents a reservoir of potential TB disease, it is important to identify and, if appropriate, treat people
with LTBI to reduce the spread and burden of TB disease.13,18
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Current service provision
Management of latent tuberculosis infection
The goal of screening for LTBI is to identify individuals who are at high risk of developing active TB who
would potentially benefit from prophylactic treatment. In the UK, LTBI screening is recommended for
contacts of patients diagnosed with active TB and recently arrived migrants. Contacts include household
contacts defined as those who share a bedroom, kitchen, bathroom or sitting room with the index active
TB case, as well as boyfriends or girlfriends and frequent visitors to the home. Workplace associates in
close proximity to a patient for extended periods may be judged to be household contacts; however, the
majority of workplace contacts are not screened. Casual contacts should be assessed only if the index case
is particularly infectious or the contact case is at increased risk from infection. Nevertheless, all contacts
should be offered information and advice about TB. Similar risk assessments take place in schools,
nurseries, institutions such as prisons and hospitals, and for aircraft passengers, leading to screening of
those perceived to be at risk.10,51
Active case finding is recommended for migrants who have recently arrived in the UK from countries with
a TB incidence of ≥ 40 per 100,000.10 Identification of new migrants is recommended from port of arrival
reports, new registrations with primary care, entry to education and links with statutory or voluntary
groups working with new migrants. Health-care professionals responsible for new migrant screening are
advised to co-ordinate a programme to detect and treat active and latent TB, provide the bacillus
Calmette–Guérin (BCG) vaccination when appropriate and provide relevant referrals and information.
Commissioners, NHS employees and providers of TB services, and other statutory and voluntary
organisations, are particularly advised to identify and manage TB in hard-to-reach groups such as the
homeless, substance misusers, prisoners and vulnerable migrants.52
A simplified care pathway for LTBI screening derived from the National Collaborating Centre for Chronic
Conditions10,51 is presented in Figure 1 and further details about testing strategies for people being
screened for LTBI are provided in Box 1.
Contact or new
migrant
LTBI testing (Mantoux 
and/or IGRA)
Offer BCG if no
prior record
Inform and
advise
Assess active
TB
LTBI
treatment
Active TB
treatment
– +
– +
FIGURE 1 Care pathway of LTBI screening.5,51
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BOX 1 Testing strategies for people being screened for LTBI
l Generally, individuals are tested for LTBI using TST (Mantoux), IGRA, both or a dual strategy of TST followed
by IGRA. If the results are positive, individuals are assessed for active TB; if the results are positive they are
treated for active TB and if they are negative they are then treated for LTBI. If the results for LTBI are negative
the individual is offered a BCG vaccination if aged < 16 years or aged 16–35 years and from sub-Saharan
Africa or from an area with an incidence of > 500 per 100,000. Individuals are given information and advice
about TB. However, different testing and treatment pathways are recommended for different populations,
including different age groups, new migrants and immunocompromised individuals.10,51
l TST is recommended for contacts aged > 5 years for the diagnosis of LTBI. IGRA is recommended for
individuals whose TST shows positive results (≥ 5mm diameter for those who have not been vaccinated
with BCG and ≥ 15mm diameter for those who have been vaccinated) or in people for whom TST would
be less reliable, such as BCG-vaccinated people. Individuals with a positive IGRA or inconclusive TST are
referred to specialist TB care. For contacts who are aged 2–5 years, a TST should be offered as the initial
diagnostic test and, if the result if positive, taking BCG history into account, they should be referred to a TB
specialist to exclude the possibility of active disease and to determine treatment, depending on the result.
If the result of the TST is negative but the child is a contact of a person with sputum smear-positive disease,
then an IGRA should be offered after 6 weeks alongside a repeat TST to increase sensitivity.10,51
l For child contacts of a person with sputum smear-positive disease aged 4 weeks to 2 years who have not
been vaccinated, isoniazid should be started and a TST should be performed. If the TST is reported as
positive, the child should be assessed for active TB and if active TB is excluded the child should then be
offered full treatment for LTBI. If the TST is negative (< 5-mm induration), isoniazid should be continued for
6 weeks after which a repeat TST and IGRA should be performed. If repeat tests are negative, isoniazid
should be stopped and BCG offered, whereas if either is positive active TB should be assessed and, if
excluded, treatment for LTBI should be considered. For child contacts of a person with sputum smear-
positive disease aged 4 weeks to 2 years who have been vaccinated, a TST should be performed and any
positive results (≥ 15mm) should be assessed for active TB. If active TB is excluded then a regimen of either
3 months of rifampicin and isoniazid or 6 months of isoniazid should be given. If the TST is negative
(< 15mm) it should be performed again with an IGRA after 6 weeks. If both tests are negative no further
action is needed. If either is positive, active TB has to be excluded and treatment for LTBI followed.10,51
l To diagnose LTBI in recently arriving migrants from high-incidence countries, for children aged 5–15 years a
TST should be offered and if positive an IGRA should be performed. For individuals aged 16–35 years,
either an IGRA alone or in a dual strategy with a TST should be offered. For those aged > 35 years, the
individual risks and benefits of treatment should be considered before testing. For children aged < 5 years,
a TST should be offered and if the initial test is positive taking BCG history into account then active TB
disease should be excluded and LTBI treatment considered.10,51
l Regarding those who are immunocompromised, children should be referred to a TB specialist. For people
with HIV infection and a CD4 count of < 200 cells/mm3 or between 200 and 500 cells/mm3, an IGRA
should be offered with a concurrent TST. If either is positive, active TB should be ruled out before LTBI
treatment is given. For other people who are immunocompromised, an IGRA should be offered alone or
with a TST.10,51
l Once active TB has been excluded by chest radiography and examination, individuals should be offered
treatment. Individuals aged ≥ 35 years without HIV infection should be assessed further and counselled
about treatment because of the increasing risk of hepatotoxicity from medication. For those aged
16–35 years and not known to have HIV infection, treatment should include either 6 months of isoniazid or
3 months of rifampicin and isoniazid.10,51
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Current service cost
Estimates for the costs of diagnosing and treating LTBI have been provided by the National Institute for
Health and Care Excellence (NICE) (Table 1). These costs are based on NICE guidelines from 200651 and the
partial update from 2011.10 The costs shown include the unit costs of the disposables, the time to
administer and read tests and the costs of collecting a blood sample per patient for the tests, calculated in
2011. The cost of chemoprophylaxis includes the cost of drugs, active TB tests, consultations and nurse
visits, which were calculated in 2006. BCG costs are also from 2006. Compared with the cost of treating
active TB (≥ £5000), diagnosing and treating LTBI per patient is less costly.
l Neonates who have been in close contact with people who have sputum smear-positive TB and who have
not received at least 2 weeks of antiTB drug treatment should be started on isoniazid for 3 months and
then a TST performed after 3 months of treatment. If the TST is positive, active TB should be assessed and,
if found negative for active TB, isoniazid should be continued for a total of 6 months. If the TST is negative
it should be repeated with an IGRA and if both are negative isoniazid should be stopped and BCG
vaccination performed. In children aged > 2 years, 3 months of rifampicin and isoniazid or 6 months of
isoniazid should be given.
TABLE 1 Unit costs for LTBI diagnosis and treatment10,51
Description Test type Unit cost (£)
Cost of TST – 16.42
Cost of IGRA – 30.34
Household and other close contacts aged ≥ 5 years TST 16.42
New entrants from high-incidence countries
Children aged < 5 years TST 16.42
Children aged 5–15 years TST 16.42
Adults aged 16–34 years IGRA or dual 30.34 or 46.76
People aged > 35 years Consider individual risk
Household contacts aged 2–5 years TST 16.42
IGRA if contact with a sputum
smear-positive person and TST
is negative
30.34
Contacts aged ≥ 5 years – outbreak IGRA 30.34
Immunocompromised HIV CD4 count < 200 cells/mm3 IGRA with concurrent TST 46.76
Immunocompromised HIV CD4 count 200–500 cells/mm3 IGRA test or 30.34
IGRA with concurrent TST 46.76
Cost of complete chemoprophylaxis treatment – 483.74
BCG vaccination – 11.71
BOX 1 Testing strategies for people being screened for LTBI (continued)
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Variation in services and/or uncertainty about best practice
Limitations of latent tuberculosis infection screening tests
The main limitation of the TST is its inability to distinguish between reactions caused by MTB and those
caused by BCG vaccination or non-tuberculous mycobacteria (NTM).11 The BCG vaccination is routinely
used in countries with a high TB prevalence to prevent the spread of TB infection in infants and young
children. The use of the TST test in such areas results in high false-positive rates. The boosting
phenomenon, which occurs after repeated TSTs, may also lead to false positives, thereby limiting the
specificity of the test. The TST has limited sensitivity when used in certain subpopulations (e.g. people with
active TB, immunocompromised patients, the elderly and people with HIV infection, malnutrition or renal
failure). The above-mentioned limitations are compounded by issues related to the interpretation of test
results, which may independently influence false-positive and false-negative rates of the TST (e.g. different
cut-off values, PPD dose).12,13,16 Two health visits are required for the completion of the TST, which results
in missed diagnoses in 10% of cases.53 Measurement of the TST is also dependent on interobserver
variability, which therefore requires adequate training to reduce variability.54,55
Because the antigens in the IGRA tests are not present in the BCG vaccination and most NTM, the IGRAs are
less influenced by previous BCG vaccinations and are less susceptible to false-positive NTM reactions, leading to
higher specificity of these tests compared with the TST.56 IGRAs also have the advantage of requiring a single
patient visit rather than the sequential two-step testing required with the TST. Automated testing also means
increasing the objectivity in the interpretation of test results. Finally, there is no influence from the boosting
effect and so repeat screening is feasible.57 The IGRAs, however, have their own limitations: specifically, they
are more costly and labour intensive than the TST. Moreover, care in blood sampling is required and the time
available for blood sample storage and analysis is restricted to 8–12 hours after collection.12
Diagnostic accuracy of latent tuberculosis infection tests
Since the introduction of IGRAs evidence on estimating and comparing the performance of the TST and IGRAs
in people with LTBI has emerged; however, this assessment has been hampered by the absence of a gold
standard for the diagnosis of LTBI, which would allow direct calculation of sensitivity and specificity for both
types of tests.11,12,18,40,57–59 Most studies have, instead, determined associations [e.g. diagnostic odds ratios
(DORs) and other regression-based effect measures] between test results (i.e. TST or IGRAs) and surrogate
measures of LTBI such as duration/proximity of exposure to a person with active TB or risk of development of
active TB, or progression from LTBI to active TB [e.g. sensitivity, DORs, positive predictive values (PPVs) and
negative predictive values (NPVs), incidence rate ratios, cumulative incidence ratios (CIRs)].18,58,60 Some studies
have assessed and compared the specificity of these tests in people at very low risk for MTB infection
(e.g. healthy individuals, residents of low-incidence countries)57 or compared sensitivity in culture-confirmed
individuals with active TB (taken as a surrogate reference standard for LTBI).40,57,59 Using suboptimal reference
standards for diagnostic accuracy testing can lead to an overestimation or underestimation of the true accuracy
of a test. The degree of concordance (inter-rater or intrarater agreement, kappa statistic) and discordance
between the results of the two tests (IGRAs and TST) has also been used. In general, both pooled sensitivity
and specificity values of the IGRAs and the TST were similarly high in people who were not vaccinated with
BCG (> 90%); however, the pooled specificity of the TST in BCG-vaccinated populations was much lower than
that of IGRAs (about 56% vs. 96%).11,53,57 In contrast, prospective longitudinal studies showed that neither the
IGRAs nor the TST had a high prognostic value in predicting the risk of progression to active TB.11,18
Treatment of latent tuberculosis infection
Once patients are diagnosed with LTBI using any of the available tests, there are claims of low adherence
to chemotherapy treatment.61 As a result of low adherence, an alternative therapy recommended in the
USA62 has been implemented in some hospitals in the UK. It includes a new combination of isoniazid and a
long-acting rifampicin called rifapentine given weekly for 12 weeks. Each of the 12 doses is directly
observed being taken by a treatment supervisor. After LTBI is confirmed and active TB excluded, individuals
are assessed for suitability for the rifapentine/isoniazid regimen.61 Suitability is based on certain criteria
including normal renal and liver function, aged ≥ 16 years, not pregnant, HIV-infected patients not on
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antiretroviral treatment, agreeable to direct observations and direct observations are feasible. If suitable,
the regimen is prescribed and a TB specialist nurse sets up the direct observations. If it is not suitable other
latent TB treatment is offered. This combination has been found to be as effective as the 9-month daily
isoniazid regime used in the USA, with higher completion rates as only 12 doses are needed.61
Relevant national guidelines including National
Service Frameworks
The latest guidelines on the diagnosis, management and prevention of TB are available from NICE. There is
a 2006 clinical guideline51 on the clinical diagnosis and management of TB and measures for its prevention
and control, with a partial update in 2011,10 as well as 2012 public health guidance52 to identify and
manage TB among hard-to-reach groups. The Department of Health has also published guidelines for the
planning, commissioning and delivery of TB services,63 guidelines for testing health-care workers,64 a wider
action plan for stopping TB in England65 and guidance for the prevention and control of HIV-related and
drug-resistant TB.66 Finally, the British Thoracic Society has published guidelines on the prevention, risk
assessment and management of TB in adult patients with chronic kidney disease67 and in patients due to
start antiTNF-α treatment,68 management of air travel passengers69 and management of opportunist
mycobacterial infections.70
Description of the technology under assessment
Summary of the intervention
As noted earlier, screening for LTBI is crucial to curb the re-emergence of TB as the majority of TB cases
consist of latent TB that has been reactivated.71 Testing and treating high-risk individuals for LTBI would
not only prevent active TB illness for the individual but also would reduce the transmission of TB, thus
reducing the pool of infection.72
There is much interest in using IGRAs to identify individuals at high risk of LTBI because of the advantages
that they have over the traditional TST, particularly that they require only one visit and that previous BCG
status does not interfere with the results. For IGRAs to replace the TST in the current care pathway, they
would have to show improved cost-effectiveness relative to the TST, although in the absence of a gold
standard this is difficult.73 Otherwise, IGRAs may have to be used as complementary tests to the TST, as is
currently recommended in the national guidelines.10
The results of an IGRA test depend on local arrangements but can be available within 1 week.74 The TST
takes 2–3 days as individuals must return to have the test read.13,16 In combination, therefore, both tests
take several days to be completed. IGRA testing comes at a higher cost than the TST and shifts the costs
and labour from the clinic to the laboratory.75 Both the TST and IGRAs require specific equipment either
for administering the injection or taking a blood sample. In addition, IGRA testing requires advanced
laboratory facilities.75 Skilled personnel are needed to administer both tests and, in the case of the TST,
are needed to read the result, whereas for IGRA testing laboratory personnel are needed to process the
result.73 In both cases patients follow a common pathway, with nurses providing patients with the result,
following up patients for testing of active TB and offering treatment and advice.10 IGRAs can be used in
similar settings to the TST as long as there is access to a laboratory and pathways are negotiated so that
samples can be analysed within 12 hours.46
Screening tests for latent tuberculosis infection in special subgroups at risk
It has been suggested that screening tests applied to presumably healthy populations or those at low risk
for progression to active TB may not be justified given the potential harms from unnecessary treatment.16,76
It is also not feasible or cost-effective to universally screen the population as the administrative and clinical
costs outweigh the benefits of identifying TB cases.46 The benefits of screening for LTBI using these tests
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are likely to be maximal in individuals at high risk of contracting MTB (e.g. those recently arrived from
countries with a high TB incidence, close contacts of those with active TB) and those with suspected LTBI
who are at high risk of progression to active TB and complications associated with the infection (e.g.
immunocompromised patients, young children). As these subgroups are at higher risk of developing active
TB, it is of public health importance to identify LTBI in them.
Studies comparing the TST and IGRAs for detecting LTBI in children have mostly demonstrated better
specificity for IGRAs than the TST.59 Sensitivity has been shown to be comparable between the TST and the
IGRAs but to vary considerably between studies. Both specificity and sensitivity depend on an implied
association between LTBI and exposure to TB (as a proxy for true-positive LTBI). The comparative evidence
in immunocompromised people has been too scarce to draw definitive conclusions. One systematic review
showed suboptimal but comparable performance between the TST and the IGRAs for identifying LTBI in
HIV-infected patients.40 In general, based on limited data, the accuracy indices for the TST and IGRAs in the
subgroups of children and immunocompromised people have been shown to be suboptimal. However,
the absence of a gold standard, small samples, indeterminate test results and heterogeneity between the
studies make adequate comparisons between tests difficult.11,16
One study has compared the TST and the two IGRAs (QFT-GIT and T-SPOT.TB) for detecting LTBI in
migrants to the UK.77 However, comparison of the tests was carried out only by evaluating the positive
results of each, concordance between the tests and the factors associated with positivity. Yields of the test
were computed at different incidence thresholds and the cost-effectiveness of the tests was estimated.
The authors found that the TST was positive in 30.3% (53/175) of individuals who completed screening,
QFT-GIT was positive in 16.6% (38/229) of individuals and T-SPOT.TB was positive in 22.5% (36/160) of
individuals. The higher rate for the TST could be a result of the effect of BCG vaccination. Although NICE
recommends that recently arriving migrants from countries with a TB incidence of ≥ 40 per 100,000
should be screened, the study found that this would require 97–99% of the cohort to be screened and
would identify 98–100% of cases of LTBI whereas screening migrants from countries with an incidence of
150 per 100,000 would identify 49–71% of cases of LTBI but would require screening of only half of the
cohort. The most cost-effective option was to screen recently arriving migrants from countries with a TB
incidence of > 250 per 100,000 with one QFT-GIT test (£21,565.3 per case prevented) but, as this would
miss many cases, screening recently arriving migrants from countries with a TB incidence of 150 per
100,000 was recommended as it was only slightly less cost-effective (£31,867 per case prevented) and
would prevent an additional 7.8 cases of TB. This was confirmed in a previous study assessing groups of
new migrants in the UK who should be screened for LTBI.6 Despite these findings it is difficult to draw firm
conclusions about the accuracy of identifying LTBI in immigrants as no reference test was used for LTBI
when comparing the tests.
New evidence is needed to determine the best approaches for identifying LTBI in all three groups of people
(children, immunocompromised individuals and recently arrived immigrants from high-incidence countries).
This will help in deciding whether IGRAs should replace or complement the TST and, if so, in which
circumstances. There is an ongoing large multicentre cohort study assessing the efficacy and
cost-effectiveness of IGRAs compared with the TST for predicting active TB in recently arrived migrants in the
UK from high-incidence countries (> 40 per 100,000) and people who have been in contact with TB cases.
In total, 10,000 participants (aged ≥ 16 years) will be recruited from 12 hospitals and general practitioner
(GP) surgeries and followed up for 24 months; the results from this study will be available in 2017.78
Current usage in the NHS
The UK National Screening Committee decided that TB screening should be organised locally rather than
as a national programme.79 Therefore, the implementation of NICE guidelines on LTBI testing using the TST
and IGRAs has been very ad hoc across the NHS. In London, for example, it is reported that it has not been
fully implemented and that current practice is not effective in detecting LTBI.50
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More recently, in March 2014, a tri-borough Joint Strategic Needs Assessment (JSNA) report80 stated that
‘However, GP screening has to date been inconsistent and no clear assessment and patient pathway exists
for latent TB’. Leicester, Leicestershire and Rutland’s Tuberculosis Summary Needs Assessment from
December 201381 mentions expanding numbers of cases of LTBI from IGRA testing but calls for a more
systematic testing process for testing new entrants to make an impact on active TB cases. In addition,
Kirklees’s JSNA82 mentions exploring funding to develop IGRA testing and Manchester City Council JSNA83
reports needing to improve LTBI screening.
Commissioners are currently looking at models for local service provision. This is in line with the suggested
approach of TB control boards in the recent PHE consultation document Collaborative Tuberculosis
Strategy for England 2014 to 2019.7 There is not one agreed service model and PHE has recently
sponsored several pilot projects, which are ongoing at present, looking at the feasibility of screening in
different settings. These include the identification of eligible individuals from GP practice lists followed
by an invitation for screening at the GP surgery by IGRA (Dr Huda Mohammed, PHE, West Midlands,
12 May 2014, personal communication) and a more innovative approach in which screening for LTBI was
carried out using an IGRA at a college of further education among self-selected individuals taking part in
English for Speakers of Other Languages classes following a campaign of education.84 Neither of these
studies has reported yet but they are expected to show positive result rates of between 17% and 20%
(Dr Huda Mohammed, personal communication).
It is difficult to know how many GPs are identifying new entrants and organising testing for them or how
many new entrants are contacting TB services directly for testing. The websites of several community TB85
teams list testing new entrants for LTBI as part of their remit and give a contact number or e-mail address.
The Birmingham and Solihull Tuberculosis Service86 has a full page on its website with eligibility criteria for
screening, whereas the Liverpool Community Health NHS Trust Tuberculosis Service87 excludes testing of
new entrants who are students.
Taking the Coventry and Warwickshire area as a case study, the Meridian Practice in Coventry, a specialist
service that cares for refugees and asylum seekers, offers IGRA testing to all registered patients (Najeeb
Wai, practice manager, Meridian Practice, 8 July 2014, personal communication). The Coventry and
Warwickshire Tuberculosis Service reports that it ‘indirectly tr[ies] to identify high TB risk individuals
other than identified contacts and offer screening’ (Debbie Crisp, lead TB nurse specialist and primary
care services for the Arden Community TB Service, 9 July 2014, personal communication). Apart
from supporting the work at the Meridian Practice, it also supports the Warwickshire programme for
looked-after children, which has an established TB screening programme incorporated into its medical
review, and has plans to discuss the programme with the Coventry team. In addition, the Coventry and
Warwickshire Partnership Trust commenced a TB screening programme for HIV-infected individuals in
July 2013 and supports the LTBI treatment programme.
In summary, it is difficult to know how much awareness there is for LTBI screening in the primary care
setting in the NHS. Pathways are not widely available, if they exist at all. Secondary care specialist services
are more aware, but do not employ standard criteria for testing. There is great variability within the
system. There is a clear need for new evidence to provide information on the most appropriate strategies
available for identifying LTBI in the three subgroups of interest: children, immunocompromised
individuals and recently arrived immigrants from high-incidence countries. This evidence will aid in the
decision-making process on whether IGRAs should be used as a replacement or as an adjunct to the TST
for the diagnosis of LTBI in these populations.
The next chapter discusses the decision problem and outlines the key clinical questions and objectives of
this work.
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Chapter 2 Definition of the decision problem
Tuberculosis is a major cause of morbidity and mortality worldwide. The timely identification andprophylactic treatment of people with LTBI is of public health and clinical importance. Unfortunately,
there is no diagnostic gold standard for the identification of individuals with LTBI who would benefit from
such prophylactic treatment. Instead, the available screening tests provide indirect and imperfect
assessment of the presence of LTBI. There are two types of tests used to identify LTBI in the UK: (1) the TST
and (2) IGRAs.
In light of new evidence since 2009, this systematic review aimed to compare the clinical effectiveness
and cost-effectiveness of screening tests for LTBI (IGRAs and TST) in children, people who are
immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high
incidence of TB. To do this we updated the searches since 2009 to identify relevant evidence and
incorporate both pre- and post-2009 evidence into the analysis. This review also attempted to determine
the most cost-effective approach for identifying LTBI.
The key clinical questions to be considered were:
1. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying LTBI
in children?
2. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying LTBI in
people who are immunocompromised or at risk of immunosuppression?
3. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying LTBI in
people who are recent arrivals from countries with a high incidence of TB?
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Chapter 3 Clinical effectiveness review methods
A protocol to which we adhered was developed for undertaking this systematic review of the clinicaleffectiveness literature. The presentation of our systematic review is in line with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Identification and selection of studies
Search strategy for clinical effectiveness
Scoping searches were undertaken to inform the development of the overall search strategy. An iterative
procedure was used, with input from the searches and studies included in NICE clinical guideline 117
(CG117)10 and methods manuals.88,89 The bibliographic database search strategies focused on the diagnosis
of LTBI using IGRAs compared with other methods and were limited to articles in English that had been
added to databases since searches for the equivalent questions in CG11710 were run (7–14 December
2009; see Appendix 1). The searches automatically picked up comparisons in performance between IGRAs
and TSTs and therefore it was not necessary to search independently for comparator technologies
(e.g. TSTs). The search strategies used in the major databases are provided in Appendix 2. Bibliographic
database searches were undertaken on 9 and 10 April 2014 and were updated on 2 December 2014
using the same strategies. Supplementary searches were undertaken between 10 June 2014 and
5 August 2014 (see Appendix 2 for exact dates).
The search strategy included the following main elements:
l searching of electronic bibliographic databases
l contact with experts in the field
l scrutiny of references of included studies and relevant systematic reviews
l screening of manufacturers’ and other relevant websites.
The bibliographic databases searched were MEDLINE (Ovid); MEDLINE In-Process & Other Non-Indexed
Citations (Ovid); EMBASE (Ovid); The Cochrane Library incorporating the Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects and
Health Technology Assessment database (Wiley); Science Citation Index and Conference Proceedings
Citation Index (Web of Science); and Medion. ClinicalTrials.gov and the World Health Organization
International Clinical Trials Registry Platform (WHO ICTRP) were searched for ongoing and recently
completed trials.
Specific conference proceedings selected with input from a clinical expert were checked for the last
5 years. The online resources of relevant organisations were also searched. Further details of these
searches are provided in Appendix 2.
Citation searches of included studies were undertaken using the Web of Science and Scopus citation
search facilities. The reference lists of included studies and relevant systematic reviews were checked.
Included papers were checked for errata using PubMed. Identified references were downloaded to
bibliographic management software (EndNote X7; Thomson Reuters, CA, USA).
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Inclusion and exclusion of studies
Inclusion criteria
Primary studies evaluating and comparing the head-to-head effectiveness of commercially available
approaches/tests used for identifying people with LTBI:
l IGRAs, for example:
¢ QFT-GIT (old version: QFT-G)
¢ T-SPOT.TB.
l TST (i.e. Mantoux test).
Head-to-head studies involving a direct comparison between an IGRA and TST only were included.
Type and language of publication
l Full-text reports published in English.
l Abstracts (only if they were companion publications to full-text included studies).
Study design
l Longitudinal studies (randomised controlled trials, retrospective or prospective cohort studies).
l Cross-sectional or case–control studies.
Population
l Children (both sexes, aged < 18 years, immunocompetent) (research question 1).
l People (both sexes, any age) who were immunocompromised or at risk from immunosuppression (e.g.
transplant recipients or those with HIV infection, renal disease, diabetes, liver disease, haematological
disease, cancer or autoimmune disease or those who were on or about to start antiTNF-α treatment,
steroids or ciclosporins) (research question 2).
l People (both sexes, any age, immunocompetent) who had recently arrived from regions with a high
incidence/prevalence of TB (countries/territories with an estimated incidence rate of ≥ 40 per 100,000,
e.g. those in Africa, Central/South America, Eastern Europe and Asia) (research question 3).
Intervention
l Two IGRAs (one- or two-step testing):
¢ QFT-GIT (old version: QFT-G)
¢ T-SPOT.TB.
Comparator
l TST (Mantoux test) alone or plus IGRA (one- or two-step testing).
Construct validity measures (as a proxy for outcomes)
l Progression to active TB.
l Exposure to MTB defined by proximity, duration, geographical location or dose–response gradient.
l People at low risk of MTB infection or healthy populations.
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Exclusion criteria
l Studies not comparing IGRAs with the TST with regard to the prespecified construct validity
(i.e. incidence of TB, exposure to MTB defined by proximity, duration, geographical location,
dose–response gradient).
l Studies not comparing the accuracy of tests (IGRAs with TSTs) in a head-to-head comparison to identify
people with LTBI.
l Studies (involving children, recently arrived immigrants or immunocompromised people) not reporting
subgroup data separately for each relevant population.
l Studies comparing the IGRAs with each other (e.g. QFT-G-IT vs. T-SPOT.TB) in identifying people
with LTBI.
l Studies applying non-commercial IGRAs, in-house IGRAs, older-generation IGRAs [e.g. PPD-based
first-generation QuantiFERON-TB (QFT)] or tests unavailable in the UK.
l Studies assessing the effects of TB treatment on IGRA/TST test results.
l Studies evaluating and/or comparing the reproducibility (test and retest) of tests for identifying LTBI.
l Studies not focusing specifically on LTBI [e.g. studies in which the presence of blood culture-positive TB
(active TB) was used to estimate sensitivity – ‘active TB’ is assumed as the reference standard for the
‘true presence of LTBI’; however, given that active TB and LTBI are two clinically and immunologically
distinct forms of TB, this assumption is problematic].
l Studies using serial testing (e.g. health-care staff/students, military personnel or prisoners) of IGRAs
(or TST) to detect LTBI.
l Studies focusing on a specific biomarker (e.g. IFN-γ-inducible protein 10).
l Systematic/narrative reviews, meta-analyses, case reports, case series, abstracts (see Type and language
of publication), commentaries, letters or editorials.
Review outcomes
Diagnostic accuracy measures
l Measures of association between test (IGRAs, TST) results and construct validity – I [i.e. prognostic
value of tests in predicting the development/risk of active TB (sensitivity, specificity, false-negative and
false-positive rates, PPVs and NPVs, incidence density rate ratios (IDRRs), CIRs].
l Measures of association between test (IGRAs, TST) results and construct validity – II {i.e. exposure
status/level with regard to MTB defined by proximity, length of time and type of contact and including
the dose–response gradient if applicable [sensitivity, specificity, false-negative and false-positive rates,
DORs, regression-based odds ratios (ORs) of test positivity]}.
l Measures of association between test (IGRAs, TST) results and other construct(s) of validity – III
[e.g. people at low risk for LTBI, e.g. healthy people, residents of low-incidence countries (specificity
and false-positive rate)].
Measures of concordance and discordance
l Agreement (inter-rater, intrarater) (kappa statistic, 95% CI).
l Concordance between tests (%, 95% CI).
l Discordance between tests (%, 95% CI).
Other outcomes
l Dependence of test positivity (IGRAs, TST) on previous BCG vaccination.
l Adverse events.
l Likelihood of an indeterminate result.
l Health-related quality of life.
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Study selection strategy
Two independent reviewers screened all identified bibliographic records on title/abstract (screening level I)
using a prespecified and piloted questionnaire form. Full-text reports of all potentially relevant records
passing screening level I were then retrieved and independently reviewed using the same study eligibility
criteria (screening level II). Any disagreements over inclusion/exclusion were resolved by discussion between
two reviewers or by recourse to a third-party reviewer.
Data extraction strategy
Two reviewers independently extracted relevant data using an a priori defined pre-piloted data extraction
sheet (see Appendix 3). Data extracted were cross-checked and any disagreements were resolved by
discussion or by recourse to a third-party reviewer. Data extracted included information on the study
[e.g. author, country, publication year, design, setting, sample size, follow-up duration, risk of bias (ROB)
items such as blinding or incomplete outcome data], participants (e.g. age, sex, study eligibility criteria,
comorbidities, BCG vaccination status/time, immune status), intervention/comparator tests (type of
test/assay used for identification of LTBI, definition of positivity/negativity thresholds/cut-off values for
each test, methods of laboratory analysis used for the derivation of test results, repeat testing), construct
validity (e.g. definition of exposure to MTB in terms of proximity, length of time and/or type of contact;
incidence of progression to active TB; timing of exposure to MTB/incidence of active TB; definition of
low-risk populations; type of summary effect measures).
For individual studies, 2 × 2 contingency tables were constructed by cross-tabulating test results (separately
for IGRAs and TST) with construct validity responses in relation to exposure level or incidence of
progression to active TB. The proportions of subjects with positive and negative test results were extracted.
For each test, all summary parameters of interest (see the list of outcomes) with corresponding measures
of variability (95% CIs, p-values) were ascertained or calculated, if reported data permitted. A value of 0.5
was imputed for incidence studies with zero events for one of the compared tests to allow the calculation
of CIRs and their ratios (R-CIRs). The R-CIRs were rendered indeterminate in the case of zero events in the
2 × 2 tables of both tests compared (no imputation was carried out). All relevant summary parameters
were entered into the data extraction sheets and evidence and summary tables. Calculated parameters
were marked as ‘calculated’.
Study quality assessment
The methodological quality of the incidence and exposure studies included in the current review was
assessed using the Quality in Prognosis Studies (QUIPS) tool90 and a modified tool reported by Dinnes
et al.,44 respectively (see Appendix 4).
The QUIPS tool90 (also referred to as the ‘Methodology checklist: prognostic studies’, developed by
Hayden et al.,90 in the NICE Guidelines Manual89) was used to assess studies reporting the diagnostic
performance/validation of tests (e.g. sensitivity, specificity, incidence density rate/CIRs, PPVs/NPVs, DORs,
regression-based ORs). The QUIPS tool assesses the ROB in the six domains of patient selection/participation,
study sample attrition, index test measurement, outcome/construct validity measurement, confounding and
statistical analysis/outcome reporting. According to responses to prompting items, each of the six domains
is rated as high, moderate or low ROB. The overall summary ROB rating for each study is then derived based
on the domain-specific ROB ratings.
We used a modified tool reported by Dinnes et al.44 to assess the quality of retrospective/cross-sectional
studies reporting associations between test results and exposures. The QUIPS tool is not directly applicable
to assessing the quality of retrospective/cross-sectional studies of association between test results and
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exposure because of the non-prognostic nature of their design (exposure is ascertained retrospectively,
which is then correlated with test results). Appendix 4 outlines the criteria used to appraise these exposure
studies. Each study was assessed for blinding of test results from exposure, description of index test and
threshold (TST and IGRA), definition/description of exposure, completeness of verification of exposure and
sample attrition. Each study was then awarded an overall quality score defined as:
l low quality: studies with 0–2 satisfied (yes response) quality features
l moderate quality: studies with three satisfied (yes response) quality features
l high quality: studies with 4–5 satisfied (yes response) quality features.
Study quality was assessed independently by two reviewers (PS and KF). Any disagreements were resolved
by discussion or by a third reviewer. The evidence across studies was summarised qualitatively using the
overall ROB ratings (low, moderate, high).
Data synthesis and analysis
Given the absence of a gold standard for diagnosing LTBI, the performance of tests was compared using
alternative methodologies that rely on validation of test results against predetermined validity constructs
(i.e. proxies for a reference standard). Thus, our analyses focused on the following recommended
approaches: (1) we evaluated and compared predictive values of IGRAs and the TST in relation to construct
validity I (i.e. progression rate to active TB); (2) we evaluated and compared the degree of association/
correlation of IGRA and TST results with construct validity II (i.e. exposure to MTB defined by proximity,
duration or dose–response gradient); (3) we estimated and compared the specificity (or false positives) of
IGRAs and the TST in relation to construct validity III (i.e. people at low risk of MTB or healthy populations);
and (4) we measured the degree of concordance/discordance between IGRA and TST results.44,91–94
For each index test (TST, IGRAs), if data permitted (either directly reported or, if not reported, calculated if
possible), relevant statistical parameters of diagnostic test accuracy are presented per individual study. For
statistics measuring agreement/disagreement between two tests, values for concordant (both tests positive
or negative) and discordant (one test negative, the other test positive or vice versa) test results are
presented or calculated if data permitted. Moreover, when possible, the likelihood of indeterminate test
results was calculated.
The performance of the tests (in terms of diagnostic accuracy and concordance) was compared (e.g. IGRA
vs. TST) using sensitivity, specificity, PPVs/NPVs, ratio of diagnostic odds ratios (R-DOR), ratio of incidence
density rate ratios (R-IDRR) (or CIRs), regression-based ORs, kappa statistics, per cent discordance and
likelihood of indeterminate test results. Note that, as there is no gold standard for the diagnosis of LTBI,
specificity and sensitivity does not have the same meaning as in the conventional paradigm (i.e. against a
gold standard) but reflects the performance of tests in relation to predetermined proxy constructs of
validity (i.e. past exposure to TB or future progression to active TB).
The association between BCG vaccination and test performance in terms of specificity was explored by
comparing false-positive rates (or odds of false positivity) of the TST and IGRAs in both BCG-vaccinated
and unvaccinated individuals (i.e. dependence of false-positive rates on BCG vaccination status).
Summary measures of effectiveness (e.g. sensitivity, specificity, DOR, R-DOR, R-CIR) were pooled when
deemed appropriate and feasible (based on the absence of clinical/methodological heterogeneity, the
same cut-off values of a test or the absence of a test threshold effect on the DOR) using univariate95
and/or bivariate random-effects meta-analysis models.19 The presence of heterogeneity across studies
was determined using visual inspection of forest plots (of individual study ORs and R-DOR estimates and
degree of overlap across 95% CIs) and chi-squared tests (two tailed, p≤ 0.10).96,97 A series of subgroup
and sensitivity analyses (see below) was undertaken to explore potential reasons for statistical
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heterogeneity, if present. When pooling was not feasible, because of a lack of sufficient data or important
clinical/statistical heterogeneity across studies (e.g. significant test threshold effect),98 the findings from
individual studies were summarised qualitatively.
Data synthesis for the summary outcome measures is presented in evidence/summary tables and text overall
and/or stratified by demographic characteristics (e.g. age), TST thresholds (≥ 5mm, ≥ 10mm, ≥ 15mm),
intervention (T-SPOT.TB vs. QFT) and prevalence/burden of TB in country of origin (high burden vs. low
burden).1 In addition, for people who were immunocompromised or at risk from immunosuppression
(research question 2), when possible outcomes have been stratified by type of immunosuppression, use of
immunosuppressive drugs (e.g. steroids, antiTNF-α treatment, antirheumatic drugs) and comorbidity
condition (e.g. HIV infection, renal disease, diabetes, liver disease, haematological disease, cancer,
autoimmune disease, transplant recipients).
It was planned to conduct subgroup analysis according to BCG vaccination status, TST threshold (≥ 5mm,
≥ 10mm, ≥ 15mm) and prevalence of TB in country of origin, if data permitted.
Calculations were performed using Meta-DiSc version 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal
Hospital, Madrid, Spain)99 and Stata version 14 (StataCorp LP, College Station, TX, USA).100
Overall quality of evidence
There is no formally accepted and validated approach for the assessment of the overall quality of evidence
that would be appropriate to the type of evidence synthesised in this review. Work on the formulation of
this approach is still ongoing [Grading of Recommendations Assessment, Development and Evaluation
Working Group; see www.gradeworkinggroup.org (accessed 15 December 2015)].101
Derivation of summary measures of diagnostic accuracy
We used Bayesian meta-analysis to derive the sensitivity and specificity for various testing strategies for
LTBI in the various population subcategories. The methods and results for this are reported in Chapter 6
[see Performance of screening texts (sensitivity and specificity)].
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Chapter 4 Clinical effectiveness results
Number of studies identified
A total of 6687 bibliographic records were identified through electronic database searches. After removing
duplicates, 3757 records were screened for inclusion. On the basis of title/abstract, 3279 records
were excluded. The remaining 478 records were included for full-text screening. A further 424 records were
excluded at the full-text stage. The remaining 54 records102–155 (53 unique studies) were considered
relevant to the review since the previous NICE clinical guidance work in 2011 (CG117).10 One study by
Rutherford et al.110,111 was presented in two publications. In addition, 37 studies156–192 from CG11710
were included in the current evidence synthesis (see Appendix 5). The study flow and the reasons for
exclusion are shown in Figure 2 and Appendix 6. A search for ongoing trials was undertaken in different
databases (Clinical Trials.gov, WHO ICTRP) up to August 2014. A total of 50 ongoing trials were identified,
of which 30 were excluded; the reasons for exclusion are presented in Appendix 7. Twenty ongoing trials
were therefore considered relevant for inclusion in our review (see Appendix 8).
Description of included studies and synthesis
In the following sections we describe the baseline characteristics and study quality for the incidence and
exposure studies of the three populations of interest: (1) children, (2) immunocompromised individuals and
(3) those recently arrived from countries with a high TB incidence. Full data-extraction sheets including
baseline characteristics for all recently identified studies since CG11710 are provided in Appendix 9. For each
of the three populations we present the synthesis of the evidence in terms of the comparative performance
of tests (diagnostic accuracy indices for identifying LTBI) and between-test concordance, discordance and
agreement. Appendix 10 provides the incidence rates of TB for each included study since CG117.10
Children and adolescents
Description of baseline characteristics
This section included 27 studies (28 publications102–113,148,150–152,154,156–166) in children and adolescents, of
which 11 studies156–166 had already been reviewed in CG11710 (see Appendix 5). Our searches identified 16
additional studies (in 17 publications102–113,148,150–152,154), five102–104,150,152 of which investigated the incidence
of active TB following testing for LTBI (incidence studies) and 11 of which (in 12 publications105–113,148,151,154)
investigated levels of exposure in relation to LTBI test outcomes (exposure studies). Two publications110,111
reported data on the same population and were therefore considered as one study. See Appendix 9 for
the full data-extraction sheets for all new included studies.
Incidence studies
Three102,104,152 of the five incidence studies included close contacts of TB cases and one study150 included only
TST-positive (≥ 15mm) children with no history of close contact with a TB case. Mahomed et al.103 recruited
low-risk high-school students in a high TB burden country, of whom 25% had current or past household
contact with TB. Four studies were carried out in countries with TB vaccination: South Africa,104 Iran,103
Turkey150 and South Korea.152 One study102 was carried out in Germany, in which only 35.7% of participants
were BCG vaccinated. Four studies102–104,152 investigated the agreement of a QFT test with the TST. Four
studies compared QFT-GIT with the TST in community settings102,103,150,152 whereas Noorbakhsh et al.104
investigated the agreement between QFT-G and TST (≥ 10mm) in a hospital setting. Follow-up to confirm
active TB across the five studies ranged from 1 year104 to 3.8–4 years.102,103 Table 2 provides further details
on these studies.
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Total number of records excluded with reasons
(n = 424)
Records identified through
database searching
(n = 6687)
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Additional records identified
through other sources
(n = 0)
Records screened at title and abstract level
(after duplicates removed)
(n = 3757)
Records assessed for eligibility at
full-text level
(n = 478)
Records excluded at
full-text level, with reasons
(n = 424)
Records included in the review
(n = 54) (53 unique studies)a
• Children, n = 16
• Immunocompromised, n = 32
• Recently arrived, n = 5
Records excluded at title and
abstract level
(n = 3279)
• Letter, n = 43
• Abstract, n = 173
• Editorial, n = 6
• Guideline, n = 1
• Review, n = 6
• Presentation, n = 1
• Mixed population and/or no subgroup of 
   interest, n = 33
• Inappropriate proxy for LTBI (e.g. active TB, 
   positive test result, algorithm), n = 8
• Non-standard or in-house IGRA, n = 5
• Economic study, n = 20
• Old pre-2009 study, n = 3
• Included/excluded in CG117, n = 5
• Active TB, n = 10
• Foreign language, n = 6
• IGRA vs. IGRA only (no TST), n = 7
• IGRA only (no TST), n = 8
• Case report, n = 1
• No relevant outcomes, n = 6
• Combined test positive result (either TST+ or 
   IGRA+), n = 1
• Serial testing, conversion and reversion rates, n = 6
• Comparing antigens, n = 1
• Case–control study of test results, n = 1
• Inclusion of TST+ patients, n = 1
• Irrelevant non-TB study, n = 1
• Irrelevant – no tests, n = 1
• QFT used as confirmatory test on subgroup of 
   TST+ patients, n = 1
• Studies without the pre-specified construct validity
   (exposure, active TB incidence), n = 69
FIGURE 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses study flow diagram of studies
identified since 2011. a, An additional 37 studies were included from CG117.10
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Exposure studies
Eleven studies (in 12 publications105–113,148,151,154) compared one or more QFT tests with the TST test in
children and adolescents by relating test results to previous levels of exposure (exposure studies). Five
studies were carried out in countries with a high TB incidence [Gambia,105 South Africa,107,108 Indonesia
(one study in two publications)110,111 and Thailand154], two studies were carried out in countries with TB of
intermediate incidence (Mexico148 and Brazil151) and four studies were carried out in low-incidence
countries (USA,106,112 Croatia109 and Greece113).
The mean and/or median age of the recruited children was reported in eight106–109,112,148,151,154 of the 11
studies. The populations in the studies by Pavic et al.109 and Perez-Porcuna et al.151 had a mean age of
< 4 years. The studies by Laniado-Laborın et al.148 and Tieu et al.154 included children whose mean age was
about 8 years. Cruz et al.106 and Kasambira et al.107 recruited children with a median age of 8.6 and
6 years, respectively. Mahomed et al.108 and Talbot et al.112 investigated adolescents with an age range of
12–18 years and a median age of 20 years, respectively. The reported proportion of females was just
above 50% in the majority of studies105–108,112,148,151,154 and was 40% in one study.109 Eight studies
compared QFT-GIT with the TST ≥ 5mm107,108,148 or the TST ≥ 10mm.109–111,151,154 The T-SPOT.TB test was
compared with the TST (≥ 10mm or ≥ 15mm) in three studies.106,112,154 Adetifa et al.105 compared three
tests [QFT-GIT, T-SPOT.TB and TST (≥ 10mm)] whereas Tsolia et al.113 compared QFT-GIT with TST at two
different thresholds (≥ 5mm and ≥ 10mm).
Exposure to TB was defined as household contacts in one study108 and was further categorised by four
studies to include sleep proximity105 (same room/different room), time spent with contact107,109 (≥ 40 hours
in closed rooms; < 6 hours per day or > 7 hours per day, respectively) or both110,111 (different room/same
room/same bed and < 2 hours per day or 2–8 hours per day or > 8 hours per day). One study described
exposure only as contact with a source case,106 another study described it in terms of country of birth,
residence and extended visit to a high-incidence country,112 and a further study distinguished exposure as
either non-household but regular contact or household contact.113 Three studies used a TB contact
score151,154 or duration of exposure to the TB index case.148,151,154
Studies were either community based105,107,108,112,151,154 or hospital based.106,109–111,113,148 The level of BCG
vaccination was high in six studies,107–109,148,151,154 medium in a further three studies,105,106,110,111 low in one
study112 and not reported in another study.113 Table 3 provides further details on these studies.
Study quality
Incidence of active tuberculosis
Of the five102–104,150,152 newly identified active TB incidence studies in children, three102,103,152 were rated as
having a moderate ROB and two104,150 were rated as having a high ROB. Most studies had a moderate ROB
for the item misclassification of individuals in relation to construct validity groups. The studies also failed to
provide information on prognostic factor and outcome measurement. Table 4 provides further details.
Exposure levels
The majority of the 11 included exposure studies in children105–113,148,151,154 identified since the publication of
CG11710 were rated as being of low quality, with only three109,151,154 studies rated as being of high quality.
One study was of moderate quality.148 Table 5 provides further details.
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Comparative performance of tests (diagnostic accuracy indices for identifying
latent tuberculosis infection): children
Incidence of active tuberculosis
Ratios of cumulative incidence ratios
This analysis included seven studies: two studies161,162 reviewed in CG11710 (see Appendix 5) and five more
recent studies, three published in 2011102–104 and two published in 2014150,152 (see Appendix 9). For
three150,161,162 of the studies, R-CIRs could not be calculated because none of the children developed active
TB. The R-CIRs in the remaining four studies102–104,152 were pooled (Table 6), with one analysis comparing
QFT-GIT with TST 5mm and the other comparing QFT-GIT with TST 10mm (they were pooled separately
because TST performance differs according to its threshold). The pooled estimates indicated that there was
no significant difference in performance between QFT-GIT and TST 5mm (pooled R-CIR 1.12, 95% CI
0.72 to 1.75) (Figure 3),102,103 whereas QFT-GIT was better than TST 10mm in identifying/predicting LTBI
(pooled R-CIR 4.33, 95% CI 1.32 to 14.23) (Figure 4).102,104,152
Sensitivity and specificity
There was wide variability in the sensitivity and specificity of IGRAs (QFT-GIT/G) and the TST (5mm or
10mm) across newly identified studies.102–104,150,152 TST sensitivity was higher at 5mm than at 10mm/
15mm and, vice versa, specificity was better at 10mm/15mm than at 5mm. IGRAs (QFT-GIT/G)
demonstrated a similar sensitivity (range 48–100%) to that of TST 5mm (sensitivity range 57–100%) and
slightly better specificity (range 49–90%) than that of TST 5mm (range 45–65%). Although the
sensitivities of the IGRAs and TST 5mm were higher than those for TST 10mm/15mm (range 30–56%),
the corresponding specificities of these tests were lower than those for TST 10mm/15mm (range
63–93%). Forest plots of sensitivities and specificities were generated and because of high unexplained
heterogeneity (not explained by IGRA type and TST threshold, different methods for diagnosing active TB),
no meta-analysis could be performed (Figures 5–8).
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FIGURE 6 Forest plot of sensitivity based on incidence of active TB (TST) in children and adolescents.
df, degrees of freedom.
0.0 0.2 0.4 0.6
Diel 2011102
Mahomed 2011103
Noorbakhsh 2011104
Song 2014152
χ2 = 1508.45; df = 3 (p = 0.0000)
Inconsistency (I 2) = 99.8%
0.85
0.49
0.84
0.90
(0.76 to 0.91)
(0.48 to 0.51)
(0.70 to 0.93)
(0.88 to 0.91)
0.8 1.0
Specificity
Specificity (95% CI)
FIGURE 7 Forest plot of specificity based on incidence of active TB (QFT-GIT/G) in children and adolescents.
df, degrees of freedom.
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FIGURE 5 Forest plot of sensitivity based on incidence of active TB (QFT-GIT/G) in children and adolescents.
df, degrees of freedom.
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Exposure levels
Ratios of diagnostic odds ratios
This analysis included 17 studies: six studies156,157,160,162–164 from CG11710 (see Appendix 5) and
11 studies105–113,148,151,154 from the updated review (see Appendix 9). The association between the screening
test results and the risk of LTBI/exposure level measured using the R-DORs (IGRA vs. TST) in individual
studies ranged from 0.27105 to 11.01113 (Table 7).
The updated meta-analysis included 14 studies: six studies156,157,160,162–164 from CG11710 (see Appendix 5)
and eight more recent studies105–111,113,154 published from 2009 onwards (see Appendix 9). One study112 did
not provide sufficient information to calculate the R-DOR and therefore this study could not be included in
the meta-analysis. In a random-effects meta-analysis of the 14 studies,105–111,113,154,156,157,160,162–164 of which
two studies106,160 used T-SPOT.TB and the remaining 12 studies used QFT-GIT [or QuantiFERON-Gold
(QFT-G)], the pooled R-DOR showed a significantly stronger association for the IGRAs than for the TST in
relation to a risk of LTBI/exposure level (pooled R-DOR 1.98, 95% CI 1.19 to 3.28; I2= 89%) (Figure 9).
Heterogeneity was high (I2= 89%) and the sources of heterogeneity were explored through subgroup
analyses with regard to burden of TB incidence, IGRA type, TST threshold and study setting. The
simultaneous meta-analytical stratification by IGRA type (QFT-GIT/G and T-SPOT.TB) and TST threshold
(5 mm, 10–15mm) (Figures 10–12) as well as study setting (community-based contact and hospital-based
studies) (Figures 13 and 14) did not help to explain the presence of heterogeneity (i.e. heterogeneity
persisted in these analyses). The study by Adetifa et al.105 displayed a very aberrant result (see Figure 9;
R-DOR 0.27, 95% CI 0.12 to 0.59) indicating a significant superiority of TST (10mm) over IGRA (QFT-GIT),
which could not be readily explained. The report did not provide the raw data needed for the calculation
and verification of the correctness of the reported DORs for the IGRA and TST. The authors explained this
finding by the delayed presentation of TB cases (mean time 9 weeks) with early reversion of the IGRA and
about 30% of TB cases in the Gambia being infected with Mycobacterium africanum (Castets et al. 1969),
which has a reduced response to ESAT-6.
However, the subgroup analysis by country of burden explained some (but not all) of the observed
heterogeneity and revealed an interesting trend, showing no difference between IGRAs and the TST in
identifying LTBI across studies conducted in countries of high TB burden (pooled R-DOR 1.13, 95% CI 0.78
to 1.65; I2= 71%) (Figure 15).
In contrast, IGRAs were significantly superior to the TST in identifying LTBI in the settings of low TB burden
(pooled R-DOR 4.74, 95% CI 2.15 to 10.44; I2= 67%) (Figure 16).
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FIGURE 8 Forest plot of specificity based on incidence of active TB (TST) in children and adolescents.
df, degrees of freedom.
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In five studies, trends for exposure gradient (across more than two ordinal exposure groups) for IGRAs and
the TST were explored with respect to sleeping proximity (same house/same room, same house/different
room, different house),105,110,111 adult index case type of TB diagnosis,107 adult index case smear grade
(negative, scanty, 1+, 2+, 3+),107,110,111 duration of exposure to index case (time spent with child),107,110,111,154
relationship to index case (parent, aunt/uncle, other),110,111,154 TB contact score (score-based categories)154
and type of contact (household, non-household regular, occasional).113 In general, for both IGRAs and the
TST there was an increasing trend in DOR across the exposure groups. In two studies this trend was absent
for both tests in relation to duration of exposure to the index case110,111 and for the TST in relation to type
of contact.113 See Appendix 9 for full extraction sheets.
Sensitivity and specificity
In this analysis, six105,106,112,148,151,154 of the included 11 recent studies105–113,148,151,154 failed to provide sufficient
information for calculating both sensitivity and specificity. There was wide variability in the sensitivity and
specificity of the IGRAs (QFT-GIT/G) and TST (5mm or 10mm), with overlapping values across the five
remaining studies107–111,113 (Figures 17–24).
Both the QFT-GIT/G and TST (5mm or 10mm) demonstrated better specificity (range 36–98%) than
sensitivity (range 20–71%). There was no clear numerical pattern indicating the superiority of the IGRA
over the TST (or vice versa) with respect to sensitivity and specificity. Forest plots of sensitivities and
specificities showed a great extent of heterogeneity that was not explained by IGRA type and/or TST
threshold and therefore a meta-analysis was not performed.
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Kasambira 2011107
Mahomed 2011108
Pavic 2011109
Rutherford 2012110,111
Tsolia 2010113
χ2 = 155.87; df = 4 (p = 0.0000)
Inconsistency (I 2) = 97.4%
Reference standard (exposure groups) in studies
Kasambira 2011:107 exposure to index case (> 7 hours vs. < 6 hours)
Mahomed 2011:108 current or prior TB household contact vs. no such contact
Pavic 2011:109 household contact with active TB (> 40 hours) vs. occasional or unclear contact (< 40 hours)
Rutherford 2012:110,111 time spent with child (number of hours/day; > 8 vs. < 2)
Tsolia 2010:113 contact with an adult TB case (household vs. non-household occasional)
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FIGURE 17 Forest plot of sensitivity based on exposure groups (QFT-GIT) in children and adolescents.
df, degrees of freedom.
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FIGURE 18 Forest plot of sensitivity based on exposure groups (TST) in children and adolescents.
df, degrees of freedom.
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FIGURE 19 Forest plot of sensitivity based on exposure groups (TST 5mm) in children and adolescents.
df, degrees of freedom.
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FIGURE 20 Forest plot of sensitivity based on exposure groups (TST 10mm) in children and adolescents.
df, degrees of freedom.
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FIGURE 21 Forest plot of specificity based on exposure groups (QFT-GIT) in children and adolescents.
df, degrees of freedom.
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
0.0 0.2 0.4 0.6
Kasambira 2011107
Mahomed 2011108
Pavic 2011109
Rutherford 2012110,111
Talbot 2012112
Tsolia 2010113
χ2 = 239.64; df = 5 (p = 0.0000)
Inconsistency (I 2) = 97.9%
Reference standard (exposure) groups
Kasambira 2011:107 exposure to index case (> 7 hours vs. < 6 hours)
Mahomed 2011:108 current or prior TB household contact vs. no such contact
Pavic 2011:109 household contact with active TB (  40 hours) vs. occasional or unclear contact (< 40 hours)
Rutherford 2012:110,111 time spent with child (number of hours/day; > 8 vs. < 2)
Talbot 2012:112 non-low-TB exposure risk vs. low-TB exposure risk group
Tsolia 2010:113 contact with an adult TB case (household vs. non-household occasional)
0.74
0.50
0.98
0.42
0.99
0.36
(0.64 to 0.82)
(0.49 to 0.52)
(0.90 to 1.00)
(0.28 to 0.57)
(0.96 to 1.00)
(0.11 to 0.69)
0.8
TST 10 mm
TST 15 mm
TST 5 mm
TST 5 mm
TST 5 mm
TST 10 mm
1.0
Specificity
Specificity (95% CI)
FIGURE 22 Forest plot of specificity based on exposure groups (TST) in children and adolescents.
df, degrees of freedom.
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FIGURE 23 Forest plot of specificity based on exposure groups (TST 5mm) in children and adolescents.
df, degrees of freedom.
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Influence of bacillus Calmette–Guérin vaccination status on test positivity
In this analysis, four109,112,148,154 of the included 11 recent studies105–113,148,151,154 did not report any
information needed to determine whether or not BCG vaccination status influenced the odds of test
positivity differentially for the IGRAs and TST. Of the seven remaining studies reporting this evidence,
only three106,108,113 demonstrated significantly increased ORs for TST positivity in relation to BCG vaccination
status (range of ORs 1.16–20.34). The odds of test positivity for IGRAs across the seven studies were
not significantly different between the BCG-vaccinated group and the non-vaccinated group (Table 8).
One study with a relatively large sample size and narrow CIs demonstrated more conclusively that BCG
vaccination status was associated with an increased odds of test positivity for TST (OR 1.16, 95% CI 1.0 to
1.33) but not for IGRA (OR 0.99, 95% CI 0.86 to 1.12).108
Between-test concordance, discordance and agreement
This section included five studies156–159,164 reviewed in CG11710 (see Appendix 5) and 16 more recent
studies102–113,148,150–152,154 (see Appendix 9). The agreement kappa statistic was not available for four
studies.102,104,106,150 There was a wide variation in the kappa statistic across the remaining studies, ranging
from 0.13113 to 0.91113 (Table 9). In the post-2009 studies,103,105,107–113,148,151,152,154 the ranges of the kappa
statistic according to specific TST threshold and IGRA type were as follows: QFT-GIT compared with TST
5mm – range 0.27–0.91; QFT-GIT compared with TST 10mm – range 0.13–0.64; and T-SPOT.TB
compared with TST 10mm – range 0.53–0.71. According to one study, both between-test per cent
concordance and the kappa statistic were lower among participants with a BCG vaccination history
(concordance 46.5%, kappa 0.16) than among those without such history (concordance 96.20%,
kappa 0.91).113
Summary of studies in children and adolescents
Although there is a limited amount of evidence, the three prospective studies suggested no significant
difference between QFT-GIT and TST 5mm (pooled R-CIR 1.12, 95% CI 0.72 to 1.75). QFT-GIT performed
significantly better than TST 10mm in identifying LTBI or predicting risk of active TB (pooled R-CIR 4.33,
95% CI 1.32 to 14.23). In five newly identified prospective studies investigating the incidence of active TB,
there was a wide variability in sensitivity and specificity of IGRAs (QFT-GIT/G) and TST (5mm or 10mm).
Because of high unexplained heterogeneity (not explained by IGRA type and TST threshold, similar
diagnostic methods of active TB), no meta-analysis could be performed. IGRAs (QFT-GIT/G) demonstrated
similar sensitivity (range 48–100%) and slightly better specificity (range 49–90%) than TST 5mm
(sensitivity range 57–100%; specificity range 45–65%). Although the sensitivities of the IGRAs and TST
5mm were higher than that for TST 10mm/15mm (range 30–56%), the corresponding specificities of
these tests were lower than that of TST 10mm/15mm (range 63–93%).
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FIGURE 24 Forest plot of specificity based on exposure groups (TST 10mm) in children and adolescents.
df, degrees of freedom.
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TABLE 8 Association between test positivity and BCG vaccination status in children and adolescents:
exposure studies
Study ID, country (burden)
Sample
size, n
Type of IGRA/TST
induration threshold
Association between test positivity and
BCG vaccination status: OR (95% CI)
Crude/unadjusted Adjusted
Adetifa 2010,105 Gambia (low) 199 QFT-GIT 1.10 (0.60 to 2.00) NR
199 T-SPOT.TB 1.10 (0.61 to 2.09) NR
199 TST 10mm 0.89 (0.50 to 1.70) NR
Cruz 2011,106 USA (low) NR T-SPOT.TB 0.69 (0.37 to 1.31) NR
NR TST 15mm 4.32 (1.02 to 18.35) NR
Kasambira 2011,107 South Africa
(high)
262 QFT-GIT 0.62 (0.08 to 4.76) 0.83 (0.08 to 8.33)
247 TST 5mm 0.38 (0.05 to 2.85) 0.52 (0.06 to 4.00)
Laniado-Laborın 2014,148 Mexico
(intermediate)
172 QFT-GIT NR NR
172 TST 5mm NR NR
Mahomed 2011,108 South Africa
(high)
3554 QFT-GIT 0.99 (0.86 to 1.12) NR
3554 TST 5mm 1.16 (1.00 to 1.33) NR
Pavic 2011,109 Croatia (low) NR QFT-GIT NR NR
NR TST 10mm NR NR
Perez-Porcuna 2014,151 Brazil
(intermediate)
116 QFT-GIT 3.89 (0.46 to 32.33) NR
135 TST 10mm 1.85 (0.36 to 9.36) NR
Rutherford 2012,110,111 Indonesia
(high)
260 QFT-GIT 0.51 (0.26 to 1.00) 0.60 (0.26 to 1.38)
272 TST 10mm 0.68 (0.35 to 1.35) NR
Talbot 2012,112 USA (low) NR T-SPOT.TB NR NR
NR TST 15mm NR NR
Tieu 2014,154 Thailand (high) 136 QFT-GIT NR NR
136 TST 10mm NR NR
136 T-SPOT.TB NR NR
136 TST 15mm NR NR
Tsolia 2010,113 Greece (low) NR QFT-GIT 0.19 (0.06 to 0.60) NR
NR TST 5mm 20.34 (5.60 to 73.89) NR
ID, identification; NR, not reported.
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TABLE 9 Between-test concordance and discordance in children and adolescents: exposure and incidence studies
Study ID, country
(burden)
Sample size,
total or by
subgroup, n
Type of IGRA vs. TST
induration threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement
kappa (95% CI)
Adetifa 2010,105
Gambia (low)
217 QFT-GIT vs. TST 10mm 80.00
(74.15 to 84.80)
20.00
(15.2 to 25.85)
0.52
(0.39 to 0.65)
215 T-SPOT.TB vs. TST 10mm 80.47
(74.65 to 85.21)
19.53
(14.79 to 25.35)
0.53
(0.40 to 0.66)
Cruz 2011,106 USA
(low)
NR T-SPOT.TB vs. TST 15mm NR NR NR
Diel 2011,102
Germany (low)
NR QFT-GIT vs. TST
5/10mm
NR NR NR
Kasambira 2011,107
South Africa (high)
254 QFT-GIT vs. TST 5mm 86.86
(81.96 to 90.59)
13.14
(9.41 to 18.04)
0.68
(0.56 to 0.81)
254 QFT-GIT vs. TST 10mm 85.59
(80.54 to 89.5)
14.41
(10.5 to 19.46)
0.64
(0.51 to 0.76)
Laniado-Laborın
2014,148 Mexico
(intermediate)
172 QFT-GIT vs. TST 5mm 59.88
(52.42 to 66.92)
40.12
(33.08 to 47.58)
0.27
(0.17 to 0.38)
Mahomed 2011,108
South Africa (high)
NR QFT-GIT vs. TST 5mm 84.8 (NR) NR 0.70
(0.68 to 0.71)
NR QFT-GIT vs. TST 10mm 81.4 (NR) NR 0.63
(0.61 to 0.65)
NR QFT-GIT vs. TST 15mm 64.3 (NR) NR 0.30
(0.27 to 0.32)
Mahomed 2011,103
South Africa (high)
5244 QFT-GIT vs. TST 5mm 84.80
(83.80 to 85.75)
15.20
(14.25 to 16.20)
0.69
(0.66 to 0.72)
Metin Timur
2014,150 Turkey
(intermediate)
81 QFT-GIT vs. TST 15mm NR NR NR
Noorbakhsh
2011,104 Iran
(intermediate)
NR QFT-GIT vs. TST 10mm NR NR NR
Pavic 2011,109
Croatia (low)
141 QFT-GIT vs. TST 10mm 89.36
(83.19 to 93.45)
10.64
(6.554 to 16.81)
0.59
(0.42 to 0.75)
Perez-Porcuna
2014,151 Brazil
(intermediate)
116 QFT-GIT vs. TST 10mm 71.55
(62.75 to 78.97)
28.44
(21.03 to 37.25)
0.35
(0.16 to 0.53)
Rutherford
2012,110,111
Indonesia (high)
292 QFT-GIT vs. TST 10mm 80.48
(75.55 to 84.62)
19.52
(15.38 to 24.45)
0.61
(0.49 to 0.72)
Song 2014,152 South
Korea (high)
2982 QFT-GIT vs. TST 10mm 82.6
(81.2 to 83.92)
17.4
(16.08 to 18.80)
0.38
(0.34 to 0.42)
2982 QFT-GIT vs. TST 15mm 92.52
(91.51 to 93.41)
7.48
(6.59 to 8.48)
0.55
(0.50 to 0.61)
continued
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The updated meta-analysis of 14 studies showed a significantly stronger association for IGRAs than for the
TST in relation to risk of LTBI/exposure level (pooled R-DOR 1.98, 95% CI 1.19 to 3.28; I2= 89%).
The subgroup analysis by country of burden explained some (but not all) of the observed heterogeneity
and revealed a trend showing no difference between the IGRAs and the TST in identifying LTBI across
studies conducted in countries of high TB burden (pooled R-DOR 1.13, 95% CI 0.78 to 1.65; I2= 71).
In contrast, IGRAs were significantly superior to the TST in identifying LTBI in the settings of low TB burden
(pooled R-DOR 4.74, 95% CI 2.15 to 10.44; I2= 67%). In five studies both tests revealed strong
associations of increasing strength across the exposure gradient for most exposures (sleeping proximity,
adult index case type of TB diagnosis, adult index case smear grade, TB contact score and relationship to
index case).
There was limited evidence of whether or not BCG vaccination status influenced the odds of test positivity
differentially for IGRAs and TST. Out of seven studies reporting relevant data, only three demonstrated a
significantly increased OR for TST positivity in relation to BCG vaccination status (range of ORs 1.16–20.34).
The odds of test positivity for IGRAs across six studies were not significantly different between the BCG
vaccinated and the non-vaccinated groups. One large study showed that there was a statistically significant
association between BCG vaccination status and an increased odds of test positivity for TST (OR 1.16,
95% CI 1.0 to 1.33) but not for IGRA (OR 0.99, 95% CI 0.86 to 1.12).
There was a wide variation in the kappa statistic across 17 studies (five studies from CG11710 and 12 more
recent studies), ranging from 0.13 to 0.91. In the post-2009 studies,103,105,107–113,148,151,152,154 the ranges of the
kappa statistic according to specific TST threshold and IGRA type were as follows: QFT-GIT vs. TST 5mm –
range 0.27–0.91mm; QFT-GIT vs. TST 10mm – range 0.13–0.64mm; and T-SPOT.TB vs. TST 10mm –
range 0.53–0.71mm.
TABLE 9 Between-test concordance and discordance in children and adolescents: exposure and
incidence studies (continued )
Study ID, country
(burden)
Sample size,
total or by
subgroup, n
Type of IGRA vs. TST
induration threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement
kappa (95% CI)
Talbot 2012,112 USA
(low)
143 T-SPOT.TB vs. TST 15mm 97.9
(94.01 to 99.28)
2.01
(0.72 to 5.99)
0.71
(0.55 to 0.88)
Tieu 2014,154
Thailand (high)
131 QFT-GIT vs. TST 10mm 59.54
(50.98 to 67.56)
40.46
(32.44 to 49.02)
0.29
(0.18 to 0.40)
131 QFT-GIT vs. TST 15mm 79.39
(71.67 to 85.43)
20.61
(14.57 to 28.33)
0.53
(0.38 to 0.69)
131 T-SPOT.TB vs. TST 10mm 55.73
(47.18 to 63.95)
44.27
(36.05 to 52.82)
0.23
(0.12 to 0.34)
131 T-SPOT.TB vs. TST 15mm 78.63
(70.84 to 84.78)
21.37
(15.22 to 29.16)
0.51
(0.35 to 0.66)
Tsolia 2010,113
Greece (low)
99 QFT-GIT vs. TST NR 71.58
(61.81 to 79.67)
28.42
(20.33 to 38.19)
0.45
(0.27 to 0.63)
43 with BCG
historya
QFT-GIT vs. TST 10mm 46.50 (NR) NR 0.13 (p= 0.06)
52 no BCG
historya
QFT-GIT vs. TST 5mm 96.20 (NR) NR 0.91 (p= 0.06)
ID, identification; NR, not reported.
a For four people BCG status was unknown.
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Immunocompromised people
Description of baseline characteristics: qualitative synthesis in text
and tables
This section included 48 studies.114–142,149,153,155,167–182 Our searches identified 32 studies114–142,149,153,155 in
immunocompromised patients, of which eight investigated the incidence of active TB following testing for
LTBI (incidence studies) and 24120–142,153 investigated levels of exposure in relationship to LTBI test outcomes
(exposure studies). An additional 16 studies167–182 in immunocompromised patients were identified
in CG117.10
Incidence studies
Eight studies114–119,149,155 compared an IGRA test with the TST in immunocompromised people. Reasons
for immunodeficiency (condition and procedure) varied across studies. We identified the following
subpopulations: (1) HIV patients, (2) haematopoietic stem cell transplantation candidates or recipients,
(3) post-kidney transplantation patients, (4) patients undergoing haemodialysis in end-stage renal disease
(ESRD) and (5) patients with immune-mediated inflammatory disease before antiTNF-α therapy. The
included studies are described below according to these subpopulations. Table 10 provides further details
on these studies.
One study compared the T-SPOT.TB with the TST (≥ 5mm) in a retrospective case study of HIV patients
(31.1% female) with a median age of 33 years.114 The study was carried out in a community setting in
Switzerland with a follow up of 2 years. The proportion of BCG-vaccinated participants was not reported.
Moon et al.115 compared QFT-GIT with TST (≥ 5mm) in haematopoietic stem cell transplantation
candidates in a prospective cohort study in a hospital setting in South Korea. The mean age of patients
was 47 years and 44% were female. The median (interquartile range) follow-up time to assess patients for
active TB was 0.8 (0.1–2.6) years. BCG vaccination was high at 82%. Another study by Lee et al.149
compared QFT-GIT with TST (≥ 5mm or ≥ 10mm) in haematopoietic stem cell transplant recipients who
were followed up for a median of 1.3 years. The patients’ mean age was 42.3 years, 47% were female
and 91% had a BCG immunisation scar.
Post-kidney transplantation patients were investigated by Kim et al.116 in a prospective cohort study
comparing T-SPOT.TB with TST (≥ 10mm). The setting was a tertiary care hospital in South Korea. The age
range reported was 40–46 years, 46% of the participants were female and 79% were BCG vaccinated.
Patients were followed up for a median of 14 months.
Three studies117,118,155 investigated IGRA and TST in haemodialysis patients with ESRD. Tests compared were
QFT-GIT and TST (≥ 5mm),117 T-SPOT.TB and TST (≥ 10mm),155 and QFT-G, T-SPOT.TB and TST (two step;
≥ 10mm).118 Anibarro et al.117 undertook a prospective cohort study in a Spanish dialysis unit following a TB
outbreak in the dialysis centre. Lee et al.118 carried out a prospective, matched cohort study in Taiwan. The
setting was unreported. The mean age and proportion of female patients was 62 years and 40% in the study
by Anibarro et al.,117 44 years and 66% in the study by Sherkat et al.155 and 54 years and 38% in the study by
Lee et al.118 The follow-up across the three studies ranged from 1.5 years117 to 2 years.118 The proportion of
BCG-vaccinated patients was low (13.5%) in the study by Anibarro et al.,117 intermediate (27.3%) in the study
by Sherkat et al.155 and high (82.8%) in the study by Lee et al.118
Chang et al.119 compared QFT-GIT with TST (≥ 10mm) in a prospective cohort study in patients with
immune-mediated inflammatory diseases investigated for LTBI before treatment with antiTNF-α. The study
setting was a hospital in South Korea. Patients were followed up for a median of 18 months. The median
age of patients was 39 years, 41% were female and 59% were BCG vaccinated.
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Exposure studies
Twenty-four newly identified studies120–142,153 compared an IGRA test with the TST in immunocompromised
people, relating test outcome to previous level of exposure. All studies within this group were therefore
classed as having either a retrospective cohort or a cross-sectional design. Reasons for immunodeficiency
(condition and procedure) varied across studies. We identified the following subpopulations: (1) HIV
patients, (2) solid organ transplantation candidates, (3) post-kidney transplantation patients, (4) patients
on haemodialysis for ESRD, (5) patients with immune-mediated inflammatory diseases before antiTNF-α
therapy, (6) patients with hepatitis C and (7) lupus erythematosus patients. The included studies are
described below according to these subpopulations. Table 11 provides further details on these studies.
Three studies125,136,153 assessed the test performance of different IGRA tests compared with that of the TST
in patients with HIV. Chkhartishvili et al.125 compared QFT-GIT and T-SPOT.TB with TST (≥ 5mm) in HIV
patients recruited from a national referral centre for HIV in Georgia, with the non-exposed group having
no household member treated for TB and the exposed group having a household member treated for
active TB. Mutsvangwa et al.136 compared T-SPOT.TB with TST at the ≥ 10mm cut-off value in HIV-positive
household contacts of TB cases identified in a factory in Zimbabwe. The non-exposed control group
consisted of contacts of factory workers without TB. Souza et al.153 compared QFT-GIT with TST (≥ 5mm)
in adults living with HIV and/or acquired immune deficiency syndrome (AIDS) in outpatient sexually
transmitted disease public clinics in a low TB incidence urban area (11.1 per 100,000 inhabitants). The rate
of BCG vaccination across the three studies ranged from 76%153 to 94%125 and the proportion of women
ranged from 28%153 to 89%.136 The median age was reported for only two studies and ranged from 38125
to 40 years.153
Four studies compared either QFT-GIT120,124,131 or T-SPOT.TB130 with TST at the cut-off level of ≥ 5mm,124
≥ 10mm120,131 or both130 in solid organ transplantation candidates. All four studies were hospital based.
Two studies were undertaken in South Korea,130,131 one in Iran120 and one in Spain.124 The mean age was
39.9 years,120 47 years,131 56.4 years124 or not reported.130 The proportion of women was close to 50% in
two studies120,131 and < 25% in one study.124 One study did not report sex.130 BCG vaccination was high
in studies from Korea (78%130 and 91%131) as well as in the study from Iran (91%)120 but low in the
Spanish study (31.6%).124 Exposure to TB was universally defined as a history of (close) contact with active
TB. Two studies also included newly acquired TB130 or a history of active TB130,131 as a risk factor for LTBI.
The non-exposed groups consisted of participants without contact with or at a low risk of LTBI.
Hadaya et al.128 and Kim et al.132 compared one or more IGRA tests with the TST in patients post-kidney
transplantation. Hadaya et al.128 compared QFT-GIT, T-SPOT.TB and TST (≥ 5mm) in the setting of a
Swiss hospital and Kim et al.132 compared QFT-GIT with TST (≥ 10mm) in South Korean kidney transplant
recipients. Exposure was defined as close contact with a TB patient or previous TB according to
(1) chest radiography128 or (2) a history of treated TB or abnormal chest radiography.132
Four studies121,122,126,139 investigated the agreement between IGRA and TST tests in patients on
haemodialysis for ESRD. Three studies121,122,126 compared QFT-GIT with TST (≥ 10mm) and one study139
compared QFT-G with TST (≥ 10mm). Chung et al.126 additionally investigated the T-SPOT.TB.
Three studies121,122,126 reported the setting to be hospital based whereas one study139 did not report the
study setting. The rate of BCG vaccination of the study participants was low in the study from Saudi Arabia
(14%)121 and intermediate in the two studies from Turkey (49%122 and 72%139) and the study from South
Korea (67%).126 The mean age of study participants was similar across all four studies (58,121 52,122 54126
and 56139 years) and the sex distribution within the studies was balanced (52%,121 50%,122 43%126 and
53%139 female). Exposure to TB was not well defined. Three studies121,122,126 described exposure as (close)
contact with a TB case whereas one study139 specified the contact as household contact or working in the
same room with the TB case. History of active TB was included as a risk factor in the exposure group in
two studies.126,139 The comparison group included people who were at low risk of LTBI.
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Patients with immune-mediated inflammatory diseases before antiTNF-α treatment were recruited in nine
studies123,127,129,133–135,137,138,142 comparing IGRA with TST tests. The combination of tests investigated varied
greatly among the studies. Three studies123,129,138 compared QFT-GIT with TST (≥ 5mm) with one study142
additionally including the T-SPOT.TB. One study135 compared the TST with QFT-GIT but did not provide the
threshold for a positive TST test, one study137 compared QFT-GIT with the TST test at two different
thresholds (≥ 5mm and ≥ 10mm) for different subgroups of patients, one study133 compared QFT-G with
the T-SPOT.TB and TST (≥ 5mm), and two studies compared the T-SPOT.TB with the TST at only the
≥ 5mm threshold127 or at two different thresholds (≥ 5mm and ≥ 10mm).134 All studies were undertaken in
low TB incidence countries in either Europe123,127,133–135,137,138,142 or the USA129 and all studies were hospital
based. BCG vaccination was low in studies undertaken in Spain (26%123 and 19%138), the USA (34%),129
Germany (13%)133 and the UK (22%)135 but was higher in studies from France (78%)127 and Greece
(76%),142 and considerably higher in studies from Switzerland (90%)134 and Austria (100%).137 Male and
female participants were generally well balanced in the studies, with two possible exceptions: the study by
Laffitte et al.134 recruited a population with only 30% women and in the study by Hsia et al.129 66% of the
participants were women. One study135 investigated children with a median age of 8.9 years whereas the
participants’ mean age in the remaining studies ranged from 37 years137 to 52 years.142 Exposure to TB was
not well defined in any of the studies. High risk of LTBI was described as a history of contact with a TB case
in the majority of studies.123,127,133–135,137,138,142 Additional risk factors reported were origin or residence in a
high-incidence country129,134,137,138,142 and a history of active TB.123,127,133 The non-exposed group was generally
described as having no history of TB contact.
Shen et al.140 compared a T-SPOT.TB test with the TST (≥ 5mm) in hepatitis C patients in a university
hospital in China. The mean age of participants was 40 years and 47% were women. BCG vaccination
was not reported in this study and exposure was loosely defined as a history of exposure compared with
no exposure to TB.
Takeda et al.141 evaluated the agreement between the QFT-2G (QFT-G) and the TST (≥ 10mm) in a
hospital in Japan in patients with lupus erythematosus. The mean age of participants was 38 years and
82% were women. BCG vaccination of participants was not reported in this study and exposure to TB was
defined as a household TB contact. This was combined with other LTBI risk factors and compared with a
group without LTBI risk factors.
Study quality
Incidence of active tuberculosis
Of the eight included incidence studies114–119,149,155 concerning immunocompromised patients identified
since the publication of CG117,10 one 116 had a low ROB rating, three115,117,149 had a moderate ROB rating
and four114,118,119,155 had a high ROB rating. Potential ROB because of confounding was noted in five
studies.114,117–119,155 Overall, in most of the studies the study design, study attrition, statistical analysis and
reporting was appropriate. Table 12 provides further details of the ROB assessment.
Exposure levels
Of the 24 included exposure studies120–142,153 concerning immunocompromised patients identified since the
publication of CG117,10 19 studies120,122–126,128–136,140–142,153 were identified as being of low quality and the
remaining five studies121,127,137–139 were rated as being of moderate quality. However, all studies failed to
blind the test results from exposure and only two studies126,139 provided an adequate description of
exposure. Table 13 provides further details of the ROB assessment.
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Comparative performance of tests (diagnostic accuracy indices for
identifying latent tuberculosis infection)
Incidence of active tuberculosis
Ratios of cumulative incidence ratios
This section included eight newly identified studies (Table 14).114–119,149,155 Of these, R-CIRs were not
available for four studies114,116,117,119 because of missing incidence data for one or both compared tests. Of
the remaining four studies, R-CIRs in three studies comparing IGRAs (QFT-G/GIT or T-SPOT.TB) with the
TST in haematopoietic stem cell transplant candidates115 and haemodialysis ESRD patients118,155 were not
statistically significant, rendering these results inconclusive (wide 95% CIs). Only one study,149 which was
conducted in haematopoietic stem cell transplant recipients, showed that QFT-GIT performed significantly
better than the TST (at ≥ 5mm or ≥ 10mm) in identifying people with LTBI (TST at ≥ 5mm: R-CIR 9.71,
95% CI 1.71 to 55.15; TST at ≥ 10mm: R-CIR 5.85, 95% CI 1.05 to 32.70). A meta-analysis of R-CIRs
could not be performed because of differences in the study populations and tests used.
Sensitivity and specificity
This section included eight newly identified studies.114–119,149,155 The study by Anibarro et al.117 did not report
test performance parameters of sensitivity and specificity. Across the remaining seven studies there was
wide variability and the absence of a clear pattern in the estimates of sensitivity (IGRA/TST range 0–100%)
(Figures 25 and 26) and specificity (IGRAs range 50–88%; TST range 37–93%) (Figures 27 and 28). Some
or all of this variation was the result of zero count events (unstable estimates) and underlying differences
in study populations/conditions and TST thresholds. No meta-analysis was performed given the
observed heterogeneity.
Exposure levels
Ratios of diagnostic odds ratios
This section included 26 studies: two studies174,180 from CG11710 and 24 more recent studies120–142,153
(Table 15). The association between the screening test results and the risk of LTBI/exposure measured
using the R-DOR (IGRA vs. TST) in individual studies ranged from 0.07131 to 8.45.140 R-DORs for three
studies120,132,135 could not be estimated because of missing data.
The forest plot analysis of R-DORs from the remaining 21 studies is stratified according to specific
conditions/procedures (HIV infection, solid organ transplantation candidates, post-kidney transplantation,
haemodialysis – ESRD, immune-mediated inflammatory diseases before antiTNF-α therapy, hepatitis C and
lupus erythematosus) (Figure 29). There was a significant amount of heterogeneity across all subgroups of
participants except for those with haemodialysis in whom IGRA (QFT-GIT) was more strongly associated
with exposure groups than TST 10mm (pooled R-DOR 2.53, 95% CI 1.48 to 4.34; I2= 40%). Similarly, in
participants with hepatitis C, IGRA (T-SPOT.TB) outperformed TST 5mm in detecting LTBI (R-DOR 8.45,
95% CI 3.71 to 19.24).
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Study or subgroup
HIV infection
Solid organ transplantation candidates
Post-kidney transplantation
Haemodialysis – ESRD
IMID before antiTNF-α therapy
Hepatitis C
Total (95% CI)
Heterogeneity: τ2 = 0.63; χ2 = 115.35, df = 20 (p < 0.00001); I 2 = 83%
Test for overall effect: z = 1.02 (p = 0.31)
Test for subgroup differences: χ2 = 28.59, df = 6 (p < 0.0001); I 2 = 79.0%
Lupus erythematosus
Chkhartishvili 2013125
Mutsvangwa 2010136
Souza 2014153
Subtotal (95% CI)
Heterogeneity: τ2 = 0.49; χ2 = 4.99, df = 2 (p = 0.08); I 2 = 60%
Test for overall effect: z = 0.90 (p = 0.37)
– 1.236
0.313
– 0.62
0.53
0.458
0.781
240
73
293
606
240
73
294
607
4.3%
4.7%
3.2%
12.2%
0.29 (0.10 to 0.82)
1.37 (0.56 to 3.36)
0.54 (0.12 to 2.49)
0.62 (0.22 to 1.74)
Casas 2011124
Kim 2010130
Kim 2013131
Subtotal (95% CI)
Heterogeneity: τ2 = 1.66; χ2 = 20.95, df = 2 (p < 0.0001); I 2 = 90%
Test for overall effect: z = 1.12 (p = 0.26)
– 0.182
0.12
– 2.696
0.39
0.359
0.527
95
209
126
430
95
209
126
430
5.0%
5.2%
4.3%
14.6%
0.83 (0.39 to 1.79)
1.13 (0.56 to 2.28)
0.07 (0.02 to 0.19)
0.42 (0.09 to 1.93)
Hadaya 2013128
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 0.36 (p = 0.72)
0.15 0.422 183
183
183
183
4.9%
4.9%
1.16 (0.51 to 2.66)
1.16 (0.51 to 2.66)
Al Jahdali 2013121
Ates 2009122
Chung 2010126
Seyhan 2010139
Subtotal (95% CI)
Heterogeneity: τ2 = 0.12; χ2 = 5.01, df = 3 (p = 0.17); I 2 = 40%
Test for overall effect: z = 3.38 (p = 0.0007)
0.37
0.975
1.493
1.329
0.305
0.4
0.484
0.582
200
246
146
100
692
200
259
146
100
705
5.5%
5.0%
4.6%
4.1%
19.1%
1.45 (0.80 to 2.63)
2.65 (1.21 to 5.81)
4.45 (1.72 to 11.49)
3.78 (1.21 to 11.82)
2.53 (1.48 to 4.34)
Casas 2011123
Costantino 2013127
Hsia 2012129
Kleinert 2012133
Laffitte 2009134
Papay 2011137
Ramos 2013138
Vassilopoulos 2011142
Subtotal (95% CI)
Heterogeneity: τ2 = 0.34; χ2 = 34.85, df = 3 (p < 0.0001); I 2 = 80%
Test for overall effect: z = 0.33 (p = 0.74)
0
0.325
0.126
– 0.857
1.258
0.003
1.491
– 1.039
0.279
0.209
0.194
0.24
0.53
0.356
0.543
0.421
202
475
2241
685
50
192
152
155
4152
214
514
2282
1529
50
208
153
155
5105
5.6%
5.8%
5.9%
5.7%
4.3%
5.2%
4.3%
4.9%
41.7%
1.00 (0.58 to 1.73)
1.38 (0.92 to 2.08)
1.13 (0.78 to 1.66)
0.42 (0.27 to 0.68)
3.52 (1.25 to 9.94)
1.00 (0.50 to 2.02)
4.44 (1.53 to 12.87)
0.35 (0.16 to 0.81)
1.08 (0.68 to 1.73)
Shen 2012140
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 5.08 (p < 0.00001)
2.134 0.42 70
70
70
70
4.9%
4.9%
8.45 (3.71 to 19.24)
8.45 (3.71 to 19.24)
Takeda 2011141
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.39 (p = 0.16)
1.282 0.922
0.01 0.1 1
Favours IGRAFavours TST
10 100
48
48
43
43
2.7%
2.7%
3.60 (0.59 to 21.96)
3.60 (0.59 to 21.96)
Log-OR SE IGRA total n TST total n Weight
OR
IV, random, 95% CI
OR
IV, random, 95% CI
FIGURE 29 Pooled R-DOR of IGRAs vs. TST in all studies based on high- and low-risk exposure in
immunocompromised patients. df, degrees of freedom; IMID, immune-mediated inflammatory disease;
IV, inverse variance; SE, standard error.
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Within-subgroup heterogeneity by IGRA type (QFT-GIT, T-SPOT.TB) and TST threshold (5 mm, 10mm,
15mm) could not be examined for most subgroups because of sparse data. The underlying differences in
the definition/measurement of exposure and differential performance of tests across the disease spectrum
may have additionally contributed to the non-uniformity observed in the R-DOR estimates (Figures 30–33).
For example, for participants with immune-mediated inflammatory diseases before antiTNF-α therapy, the
non-uniformity persisted even after accounting for the type of IGRA (QFT-GIT) and TST threshold (5 mm)
(pooled R-DOR 0.90, 95% CI 0.52 to 1.54; I2= 80%; see Figure 30). However, the stratification by IGRA
type and TST threshold revealed that the TST 5mm was better than the IGRA (QFT-GIT) at detecting LTBI
in participants with HIV infection (pooled R-DOR 0.35, 95% CI 0.15 to 0.83; I2= 0%; see Figure 30).
Based on the results from two studies of solid organ transplantation candidates, there was no significant
difference between the performance of IGRAs (T-SPOT.TB130 and QFT-GIT124) and the TST 5mm in relation
to the identification of LTBI (see Figures 30, 32 and 33). In contrast, in another study of solid organ
transplantation candidates,131 the TST 10mm outperformed QFT-GIT (R-DOR 0.07, 95% CI 0.02 to 0.19;
see Figure 31). In two studies, the performance of QFT-GIT did not significantly differ from that of the TST
among participants with lupus erythematosus (QFT-GIT vs. TST 10mm: R-DOR 3.60, 95% CI 0.59 to
21.96; see Figure 31)141 and kidney transplant recipients (QFT-GIT vs. TST 5mm: R-DOR 1.16, 95% CI 0.51
to 2.66; see Figure 30).128
Sensitivity and specificity
This section incorporates 24 newly identified studies120–142,153 (see Table 15). Three studies123,125,129 did not
report sensitivity and specificity parameters for both IGRA and TST and one study132 reported them only for
TST. The forest plots for the remaining 21 studies displayed a wide variability in sensitivity (IGRA range
0–75%; TST 5mm range 0–61%; TST 10mm range 0–87%) and specificity (IGRA range 57–100%; TST
5mm range 62–96%; TST 10mm range 64–93%). The heterogeneity persisted even after stratifying the
estimates by type of IGRA (QFT-GIT, T-SPOT.TB) and TST threshold (5 mm, 10mm). Of the two IGRAs,
QFT-GIT/G demonstrated markedly wider variation in the estimates of specificity and sensitivity than
T-SPOT.TB. In general, for both the IGRAs and the TST, specificity tended to be greater than sensitivity
(Figures 34–41). The absence of any clear pattern in the distribution of sensitivity and specificity values
reflects the underlying between-study differences in study populations/conditions and settings and
variation in exposure definitions and measurement. In light of the observed heterogeneity,
no meta-analysis was undertaken.
Influence of bacillus Calmette–Guérin vaccination status on test positivity
Of the 24 newly identified studies included in this section,120–142,153 only 14120,122–125,127,129–131,133,134,138,139,142
reported on the association between test positivity and BCG vaccination status. Overall, there was no evidence
indicating a differential effect of BCG vaccination status on IGRA and TST positivity.120,122–125,130,131,133,134,137–142
In other words, the odds of test positivity for the IGRA and TST were not significantly different between the
BCG vaccinated and the non-vaccinated groups (Table 16). Only one study139 demonstrated a significantly
increased OR for TST 10mm positivity (OR 4.28, 95% CI 1.35 to 13.64) as opposed to a non-significant OR for
the IGRA (OR 1.89, 95% CI 0.75 to 4.73) in relation to BCG vaccination status.
Between-test concordance, discordance and agreement
This section included 16 studies167–182 reviewed in CG11710 (see Appendix 5) and 32 more recent
studies114–142,149,153,155 reviewed in this update (see Appendix 9). Overall, nine studies114,125,136,153,167,170–172,181
were conducted in people with HIV infection, three studies115,149,175 in people with haematological disorders,
four studies120,124,130,131 in solid organ transplantation candidates, three studies116,128,132 in people who
had undergone kidney transplantation, seven studies117,118,121,122,126,139,155 in people with ESRD/haemodialysis,
one study140 in those with hepatitis C, one study141 in those with lupus erythematosus and
18 studies119,123,127,129,133–135,137,138,142,168,169,174,176,178–180,182 in patients with immune-mediated inflammatory diseases
before antiTNF-α therapy (rheumatoid arthritis, rheumatic or inflammatory diseases). The remaining two
studies looked at patients with chronic liver173 and mixed (HIV infection with liver transplantation)177 conditions.
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PKT, post-kidney transplantation; SOTC, solid organ transplantation candidate.
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FIGURE 38 Forest plot of specificity based on exposure groups (QFT-GIT/G) in immunocompromised patients.
df, degrees of freedom; HC, hepatitis C; IMID, immune-mediated inflammatory disease; LE, lupus erythematosus;
PKT, post-kidney transplantation; SOTC, solid organ transplantation candidate.
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135
0.0 0.2 0.4 0.6
Mutsvangwa 2010136
Kim 2010130
Hadaya 2013128
Chung 2010126
Costantino 2013127
Kleinert 2012133
Laffitte 2009134
Vassilopoulos 2011142
Vassilopoulos 2011142
Shen 2012140
χ2 = 244.57; df = 9 (p = 0.0000)
Inconsistency (I 2) = 96.3%
0.83
0.67
0.86
0.42
0.77
0.94
0.93
0.75
0.91
0.90
(0.59 to 0.96)
(0.59 to 0.74)
(0.79 to 0.91)
(0.33 to 0.51)
(0.73 to 0.81)
(0.92 to 0.96)
(0.76 to 0.99)
(0.67 to 0.82)
(0.79 to 0.97)
(0.76 to 0.97)
0.8 1.0
Specificity
Specificity (95% CI)
HIV (1 study)
SOTC (1 study)
PKT (1 study)
ESRD (1 study)
IMID before antiTNF-α
(5 studies)
HC (1 study)
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df, degrees of freedom; HC, hepatitis C; IMID, immune-mediated inflammatory disease; PKT, post-kidney
transplantation; SOTC, solid organ transplantation candidate.
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df, degrees of freedom; HC, hepatitis C; IMID, immune-mediated inflammatory disease; PKT, post-kidney
transplantation; SOTC, solid organ transplantation candidate.
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TABLE 16 Association between test positivity and BCG vaccination status in immunocompromised patients:
exposure studies
Study ID, country
(burden) Sample size, n
Type of IGRA/TST
induration threshold
Association between test positivity and
BCG vaccination status: OR (95% CI)
Crude/unadjusted Adjusted
Ahmadinejad 2013,120
Iran (intermediate)
159 QFT-GIT 0.38 (0.11 to 1.24) NR
164 TST 10mm 0.60 (0.15 to 2.34) NR
Al Jahdali 2013,121
Saudi Arabia (low)
NA QFT-GIT NR NR
NA TST 10mm (two step) NR NR
Ates 2009,122 Turkey
(intermediate)
246 QFT-GIT 1.13 (0.68 to 1.86) 1.14 (0.68 to 1.92)
259 TST 10mm 0.85 (0.51 to 1.43) 0.87 (0.50 to 1.51)
Casas 2011,123 Spain
(low)
214 QFT-GIT 1.20 (0.50 to 3.20) NR
214 TST 5mm 1.70 (0.90 to 3.40) 1.50 (0.70 to 3.40)
Casas 2011,124 Spain
(low)
95 QFT-GIT 0.62 (0.26 to 1.42) NR
95 TST 5mm (two step) 0.83 (0.35 to 2.00) NR
Chkhartishvili 2013,125
Georgia (high)
240 QFT-GIT 1.41 (0.38 to 5.29) NR
240 T-SPOT.TB 1.78 (0.38 to 8.28) NR
240 TST 5mm 2.55 (0.32 to 20.18) NR
Chung 2010,126 South
Korea (high)
146 QFT-GIT NR NR
146 T-SPOT.TB NR NR
146 TST 10mm NR NR
continued
0.0 0.2 0.4 0.6
Mutsvangwa 2010136
Ahmadinejad 2013120
Kim 2010130
Kim 2013131
Al Jahdali 2013121
Ates 2009122
Chung 2010126
Seyhan 2010139
Laffitte 2009134
Takeda 2011141
χ2 = 72.79; df = 9 (p = 0.0000)
Inconsistency (I 2) = 87.6%
0.67
0.84
0.91
0.90
0.85
0.64
0.77
0.68
0.79
0.93
(0.41 to 0.87)
(0.77 to 0.89)
(0.86 to 0.95)
(0.83 to 0.95)
(0.71 to 0.94)
(0.58 to 0.70)
(0.68 to 0.84)
(0.57 to 0.77)
(0.59 to 0.92)
(0.77 to 0.99)
0.8 1.0
Specificity
Specificity (95% CI)
HIV (1 study)
Two-step test
SOTC (3 studies)
Haemodialysis – ESRD (4 studies)
IMID pre antiTNF-α therapy (1 study)
LE (1 study)
FIGURE 41 Forest plot of specificity based on exposure groups (TST 10mm) in immunocompromised patients.
df, degrees of freedom; IMID, immune-mediated inflammatory disease; LE, lupus erythematosus; SOTC, solid organ
transplantation candidate.
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TABLE 16 Association between test positivity and BCG vaccination status in immunocompromised patients:
exposure studies (continued )
Study ID, country
(burden) Sample size, n
Type of IGRA/TST
induration threshold
Association between test positivity and
BCG vaccination status: OR (95% CI)
Crude/unadjusted Adjusted
Costantino 2013,127
France (low)
563 T-SPOT.TB NR 0.39 (0.24 to 0.62)
563 TST 5mm NR NR (p= 0.11, NS)
Hadaya 2013,128
Switzerland (low)
183 QFT-GIT NR NR
183 T-SPOT.TB NR NR
183 TST 5mm NR NR
Hsia 2012,129 USA
(low)
2029 QFT-GIT NR 1.00 (0.66 to 1.51)
2029 TST 5mm NR 2.47 (1.71 to 3.55)
Kim 2010,130 South
Korea (high)
184 T-SPOT.TB 0.69 (0.36 to 1.34) NR
209 TST 5mm 1.25 (0.55 to 2.82) NR
209 TST 10mm 0.89 (0.31 to 2.58) NR
Kim 2013,131 South
Korea (high)
120 QFT-GIT 1.94 (0.48 to 7.91) 2.32 (0.50 to 10.66)
119 TST 10mm 2.56 (0.31 to 21.06) 3.32 (0.38 to 28.97)
Kim 2013,132 South
Korea (high)
93 QFT-GIT NR NR
93 TST 10mm NR NR
Kleinert 2012,133
Germany (low)
685 QFT-G NR 0.43 (0.17 to 1.10)
844 T-SPOT.TB NR 1.07 (0.47 to 2.43)
1529 TST 5mm 3.17 (2.19 to 4.58) 2.95 (2.00 to 4.35)
Laffitte 2009,134
Switzerland (low)
50 T-SPOT.TB 1.00 (0.01 to 10.07) NR
50 TST 5mm 2.92 (0.30 to 28.29) NR
50 TST 10mm 2.43 (0.25 to 23.57) NR
Maritsi 2011135 UK
(low)
NR QFT-GIT NR NR
NR TST NR mm NR NR
Mutsvangwa 2010,136
Zimbabwe (high)
NR T-SPOT.TB NR NR
NR TST 10mm (two step) NR NR
Papay 2011,137
Austria (low)
192 QFT-GIT NR NR
192 TST 5mm NR NR
Ramos 2013,138 Spain
(low)
153 QFT-GIT NR 5.10 (1.50 to 17.50)
153 TST 5mm NR 2.40 (1.01 to 5.80)
Seyhan 2010,139
Turkey (intermediate)
100 QFT-G NR NR
100 TST 10mm NR 4.10 (1.30 to 13.90)
Shen 2012,140 China
(high)
70 T-SPOT.TB NR NR
70 TST 5mm NR NR
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The data on between-test concordance, discordance and agreement from the 32 more recent studies are
presented in Table 17. Six116,126,133,135,140,141 of the 32 studies did not report these data (see Table 17).
Overall, the per cent concordance and kappa ranges between QFT-GIT and TST according to each
condition were as follows: HIV infection – concordance 75–96%, kappa 0.29–0.48; haematological
disorders – concordance 70.6–80%, kappa 0.09–0.16; solid organ transplantation candidates –
concordance 65–80%, kappa 0.19–0.57; post-kidney transplantation – concordance 80%, kappa
0.09–0.27; ESRD/haemodialysis – concordance 60–86.4%, kappa 0.21–0.49; and immune-mediated
inflammatory diseases before antiTNF-α therapy – concordance 60–93%, kappa 0.08–0.56 (see Table 17).
Four studies115,127,129,130 reported between-test agreement parameters by BCG vaccination status,
three127,129,130 of which showed a lower per cent concordance and kappa values for BCG-vaccinated
participants than for non-vaccinated participants (see Table 17).
Indeterminate test results
This section included three studies170,171,181 reviewed in CG11710 (see Appendix 5) and 32 more recent
studies (see previous section) (see Appendix 9). Of the recent studies, six121,126,133,134,136,155 did not report
this outcome.
The proportions of indeterminate results according to each condition and type of IGRA test were follows:
HIV infection – QFT-GIT 0.30–17.87%, T-SPOT.TB 32.80%;114,125,153,170,171,181 haematological disorders –
QFT-GIT 6.00–13.93%;115,149 solid organ transplantation candidates – QFT-GIT 2.11–4.76%, T-SPOT.TB
11.96%;120,124,130,131 post-kidney transplantation – QFT-GIT 1.64–4.30%, T-SPOT.TB 11%;116,128,132 ESRD/
haemodialysis – QFT-GIT 0–10.55%, T-SPOT.TB 0%;117,118,122,139 immune-mediated inflammatory diseases
before antiTNF-α therapy – QFT-GIT 0–7.69%, T-SPOT.TB 0–15.63%;119,123,127,129,137,138,142 hepatitis C –
T-SPOT.TB 0%;140 and lupus erythematosus – QFT-GIT 32.39%.141
TABLE 16 Association between test positivity and BCG vaccination status in immunocompromised patients:
exposure studies (continued )
Study ID, country
(burden) Sample size, n
Type of IGRA/TST
induration threshold
Association between test positivity and
BCG vaccination status: OR (95% CI)
Crude/unadjusted Adjusted
Souza 2014,153 Brazil
(intermediate)
299 QFT-GIT NR NR
300 TST 5mm NR NR
Takeda 2011,141
Japan (low)
71 QFT-2G (QFT-G) NR NR
43 TST 10mm NR NR
Vassilopoulos
2011,142 Greece (low)
157 T-SPOT.TB 0.75 (NR; p= 0.45) 0.51 (NR; p= 0.17)
157 TST 1.36 (NR; p= 0.39) 1.43 (NR; p= 0.34)
157 QFT-GIT 1.14 (NR; p= 0.76) 1.05 (NR; p= 0.90)
ID, identification; NA, not applicable; NR, not reported; NS, not significant.
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TABLE 17 Between-test concordance and discordance in immunocompromised patients: exposure and
incidence studies
Study ID,
country
(burden)
Sample size,
total or by
subgroup, n
Type of
IGRA vs.
TST
induration
threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement kappa
(95% CI)
HIV infection
Chkhartishvili
2013,125
Georgia (high)
233 QFT-GIT vs.
TST 5mm
74.25 (68.27 to 79.44) 25.75 (20.56 to 31.73) 0.29 (0.16 to 0.42)
217 T-SPOT.TB vs.
TST 5mm
75.12 (68.96 to 80.4) 24.88 (19.6 to 31.04) 0.22 (0.07 to 0.29)
Elzi 2011,114
Switzerland
(low)
32 T-SPOT.TB vs.
TST 5mm
56.25 (39.33 to 71.83) 43.75 (28.17 to 60.67) 0.12 (–0.22 to 0.46)
Mutsvangwa
2010,136
Zimbabwe
(high)
Total T-SPOT.TB vs.
TST 10mm
(two step)
NR NR NR
55 TB index
case contacts
T-SPOT.TB vs.
TST 10mm
(two step)
70.91 (57.86 to 81.23) 29.09 (18.77 to 42.14) 0.41 (0.16 to 0.66)
18 control
index contacts
T-SPOT.TB vs.
TST 10mm
(two step)
72.22 (49.13 to 87.5) 27.78 (12.5 to 50.87) 0.28 (–0.13 to 0.70)
Souza 2014,153
Brazil
(intermediate)
299 QFT-GIT vs.
TST 5mm
96.00 (93.12 to 97.69) 4.01 (2.31 to 6.88) 0.48 (0.37 to 0.59)
Haematopoietic stem cell transplantation candidates
Lee 2014,149
South Korea
(high)
159 QFT-GIT vs.
TST 5mm
79.87 (72.97 to 85.37) 20.13 (14.63 to 27.03) 0.16 (0.01 to 0.31)
159 QFT-GIT vs.
TST 10mm
NR NR NR
Moon 2013,115
South Korea
(high)
210 QFT-GIT vs.
TST 5mm
73.81 (67.47 to 79.29) 26.19 (20.71 to 32.53) 0.09 (–0.04 to 0.22)
210 QFT-GIT vs.
TST 10mm
78.57 (72.53 to 83.58) 21.43 (16.42 to 27.47) 0.15 (0.02 to 0.27)
176 with BCG
history
QFT-GIT vs.
TST 5mm
74.43 (67.51 to 80.31) 25.57 (19.69 to 32.49) 0.13 (–0.02 to 0.27)
34 with no
BCG history
QFT-GIT vs.
TST 5mm
70.59 (53.83 to 83.17) 29.41 (16.83 to 46.17) –0.10 (–0.35 to 0.14)
Solid organ transplantation candidates
Ahmadinejad
2013,120 Iran
(intermediate)
159 QFT-GIT vs.
TST 10mm
79.87 (72.97 to 85.37) 20.13 (14.63 to 27.03) 0.32 (0.17 to 0.47)
Casas 2011,124
Spain (low)
95 QFT-GIT vs.
TST 5mm
(two step)
78.95 (69.71 to 85.94) 36.36 (24.93 to 49.58) 0.57 (0.37 to 0.77)
Kim 2010,130
South Korea
(high)
184 total T-SPOT.TB vs.
TST 10mm
71.2 (64.27 to 77.25) 28.8 (22.75 to 35.73) 0.23 (0.12 to 0.34)
145 BCG
vaccinated
T-SPOT.TB vs.
TST 10mm
70.34 (62.46 to 77.18) 29.66 (22.82 to 37.54) 0.19 (0.06 to 0.31)
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TABLE 17 Between-test concordance and discordance in immunocompromised patients: exposure and
incidence studies (continued )
Study ID,
country
(burden)
Sample size,
total or by
subgroup, n
Type of
IGRA vs.
TST
induration
threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement kappa
(95% CI)
Kim 2013,131
South Korea
(high)
119 QFT-G vs.
TST 10mm
65.49 (56.34 to 73.61) 34.51 (26.39 to 43.66) 0.26 (0.10 to 0.41)
Post-kidney transplantation
Hadaya
2013,128
Switzerland
(low)
200 QFT-GIT vs.
TST 5mm
NR NR 0.11 (p= 0.010)
200 T-SPOT.TB vs.
TST 5mm
NR NR 0.09 (p= 0.034)
Kim 2011,116
South Korea
(high)
NR NR NR NR NR
Kim 2013,132
South Korea
(high)
93 QFT-G vs.
TST 10mm
79.57 (70.28 to 86.51) 20.43 (13.49 to 29.72) 0.27 (0.07 to 0.46)
Haemodialysis – ESRD
Al Jahdali
2013,121 Saudi
Arabia (low)
200 QFT-GIT vs.
TST 10mm
(two step)
75.50 (69.10 to 80.94) 24.50 (19.06 to 30.90) 0.34 (0.22 to 0.45)
Anibarro
2012,117 Spain
(low)
52 QFT-GIT vs.
TST 5mm
71.15 (57.73 to 81.67) 28.85 (18.33 to 42.27) 0.21 (0.04 to 0.37)
52 QFT-GIT vs.
TST 5mm
(two step)
78.85 (65.97 to 87.76) 21.15 (12.24 to 34.03) 0.49 (0.22 to 0.74)
Ates 2009,122
Turkey
(intermediate)
230 QFT-GIT vs.
TST 10mm
67.83 (61.54 to 73.53) 32.17 (26.47 to 38.46) 0.34 (0.21 to 0.47)
Chung
2010,126 South
Korea (high)
146 QFT-G vs.
TST 10mm
NR NR NR
146 T-SPOT.TB vs.
TST 10mm
NR NR NR
Lee 2009,118
Taiwan (high)
32 QFT-G vs.
TST 10mm
(two step)
60.00 (NR) 40.00 (NR) 0.25 (–0.06 to 0.56)
32 T-SPOT.TB vs.
TST 10mm
(two step)
65.60 (NR) 34.40 (NR) 0.32 (–0.01 to 0.65)
Seyhan
2010,139
Turkey
(intermediate)
100 QFT-GIT
vs.TST
10mm
65.00 (55.25 to 73.64) 35.00 (26.36 to 44.75) 0.27 (0.07 to 0.46)
Sherkat
2014,155 Iran
(intermediate)
44 T-SPOT.TB vs.
TST 10mm
86.36 (73.29 to 93.6) 13.64 (6.40 to 26.71) 0.49 (0.20 to 0.78)
continued
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TABLE 17 Between-test concordance and discordance in immunocompromised patients: exposure and
incidence studies (continued )
Study ID,
country
(burden)
Sample size,
total or by
subgroup, n
Type of
IGRA vs.
TST
induration
threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement kappa
(95% CI)
Immune-mediated inflammatory diseases before antiTNF-α therapy
Casas 2011,123
Spain (low)
202 QFT-GIT
vs.TST 5mm
84.16 (78.49 to 88.55) 15.84 (11.45 to 21.51) 0.56 (0.42 to 0.70)
Chang
2011,119 South
Korea (high)
100 QFT-GIT vs.
TST 10mm
67.0 (57.31 to 75.44) 33.0 (24.56 to 42.69) 0.26 (0.07 to 0.45)
42 RA sample QFT-GIT vs.
TST 10mm
76.20 (61.47 to 86.52) 23.80 (13.48 to 38.53) 0.46 (0.21 to 0.72)
58 AS sample QFT-GIT vs.
TST 10mm
60.34 (47.49 to 71.91) 39.66 (28.09 to 52.51) 0.14 (–0.10 to 0.39)
Costantino
2013,127
France (low)
444 total T-SPOT.TB vs.
TST 5mm
62.84 (58.25 to 67.2) 37.16 (32.8 to 41.75) 0.16 (0.07 to 0.25)
NR BCG
vaccinated
T-SPOT.TB vs.
TST 5mm
NR NR 0.15 (NR)
NR BCG
non-vaccinated
T-SPOT.TB vs.
TST 5mm
NR NR 0.22 (NR)
Hsia 2012,129
USA (low)
2282 total QFT-GIT vs.
TST 5 mm
NR NR 0.22 (0.15 to 0.27)
781 BCG
vaccinated
QFT-GIT vs.
TST 5mm
82.84 (80.04 to 85.32) 17.16 (14.68 to 19.96) 0.20 (0.13 to 0.27)
1248 BCG
non-vaccinated
QFT-GIT vs.
TST 5mm
93.11 (91.57 to 94.39) 6.89 (5.61 to 8.43) 0.32 (0.26 to 0.37)
Kleinert
2012,133
Germany (low)
685 QFT-G vs.
TST 5mm
NR NR NR
844 T-SPOT.TB vs.
TST 5mm
NR NR NR
Laffitte
2009,134
Switzerland
(low)
50 T-SPOT.TB vs.
TST 5mm
72.00 (58.33 to 82.53) 28.00 (17.47 to 41.67) 0.36 (0.12 to 0.61)
Maritsi
2011,135 South
Africa (high)
NR QFT-G vs.
TST NR mm
NR NR NR
Papay 2011,137
Austria (low)
192 QFT-GIT vs.
TST 5mm
84.90 (79.15 to 89.27) 15.10 (10.73 to 20.85) 0.21 (0.07 to 0.34)
Ramos
2013,138 Spain
(low)
90 QFT-GIT vs.
TST 5mm
75.56 (65.75 to 83.27) 24.44 (16.73 to 34.25) 0.08 (–0.05 to 0.22)
Vassilopolous
2011,142
Greece (low)
155 QFT-GIT vs.
TST 5mm
63.87 (56.06 to 71.01) 36.13 (28.99 to 43.94) 0.15 (0.01 to 0.29)
155 T-SPOT.TB vs.
TST 5mm
71.0 (63.38 to 77.54) 29.03 (22.46 to 36.62) 0.34 (0.17 to 0.50)
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Summary of studies in immunocompromised patients
This section included 48 studies: 16 studies reviewed in CG11710 (see Appendix 5) and 32 more recent
studies published from 2009 onwards (see Appendix 9). The studies were stratified and analysed
according to the following subgroups: HIV infection, solid organ transplantation candidates, post-kidney
transplantation, haemodialysis (ESRD), immune-mediated inflammatory diseases before antiTNF-α therapy,
hepatitis C and lupus erythematosus. The majority of the more recent studies were rated as being at
moderate/high ROB (incidence studies) or of moderate/low methodological quality (exposure studies).
Only two of eight studies reported sufficient data to calculate R-CIRs to compare the performance of
IGRAs and the TST in predicting the incidence of active TB. The R-CIR estimates in both studies were
non-significant with very wide CIs, thereby rendering their interpretation inconclusive. These studies were
not combined because the TST was used with different thresholds and one study used a two-step TST.
Across the 32 newly identified studies there was wide variability and the absence of a clear pattern in the
estimates of sensitivity and specificity. In general, for both the IGRAs and TST, specificity tended to be
greater than sensitivity. Some or all of the observed variation was the result of zero count events (unstable
estimates), underlying differences in study populations/conditions and settings, and variation in exposure
definitions and measurement and TST thresholds. The heterogeneity persisted even after stratifying the
estimates by type of IGRA (QFT-GIT, T-SPOT.TB) and TST threshold (5 mm, 10mm). In light of the observed
heterogeneity, no meta-analysis was undertaken.
The association between the screening test results and the risk of LTBI/exposure level was measured using
the R-DOR (IGRA vs. TST) in individual studies and ranged from 0.07 to 8.45. The forest plot analysis of
R-DORs included 21 studies and revealed a significant amount of heterogeneity across all subgroups of
participants except for those undergoing haemodialysis, in whom the IGRA (QFT-GIT) was more strongly
associated with exposure groups than the TST 10mm (pooled R-DOR 2.53, 95% CI 1.48 to 4.34).
Similarly, in participants with hepatitis C, the IGRA (T-SPOT.TB) outperformed the TST 5mm in detecting
LTBI (R-DOR 8.45, 95% CI 3.71 to 19.24). In people with HIV/AIDS, the TST 10mm performed significantly
better than QFT-GIT (pooled R-DOR 0.35, 95% CI 0.15 to 0.83). For the remaining subgroups (lupus
erythematosus, solid organ transplantation candidates, kidney transplant recipients), the performance of
QFT-GIT did not significantly differ from that of the TST (wide 95% CIs and inconclusive results). For most
subgroups the within-subgroup heterogeneity by IGRA type (QFT-GIT, T-SPOT.TB) and TST threshold
(5 mm, 10mm, 15mm) could not be examined because of sparse data.
TABLE 17 Between-test concordance and discordance in immunocompromised patients: exposure and
incidence studies (continued )
Study ID,
country
(burden)
Sample size,
total or by
subgroup, n
Type of
IGRA vs.
TST
induration
threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement kappa
(95% CI)
Hepatitis C
Shen 2012,140
China (high)
70 T-SPOT.TB vs.
TST 5mm
NR NR NR
Lupus erythematosus
Takeda
2011,141 Japan
(low)
NR QFT-GIT vs.
TST 10mm
NR NR NR
AS, ankylosing spondylitis; ID, identification; NR, not reported; RA, rheumatoid arthritis.
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Overall, there was no evidence indicating a differential effect of BCG vaccination status on IGRA and TST
positivity in the 14 newly identified studies reporting the association between test positivity and BCG
vaccination status. Only one study demonstrated a significantly increased OR for TST 10mm positivity
(OR 4.28, 95% CI 1.35 to 13.64) as opposed to the non-significant OR for IGRA (OR 1.89, 95% CI 0.75 to
4.73) in relation to BCG vaccination status.
Overall, the per cent concordance and kappa ranges between QFT-GIT and TST according to each
condition were as follows: HIV – concordance 75–96%, kappa 0.29–0.48; haematological disorders –
concordance 70.6–80%, kappa 0.09–0.16; solid organ transplantation candidates – concordance
65–80%, kappa 0.19–0.57; post-kidney transplantation – concordance 80%; kappa 0.09–0.27); ESRD/
haemodialysis – concordance 60–86.4%, kappa 0.21–0.49; and immune-mediated inflammatory diseases
before antiTNF-α therapy – concordance 60–93%, kappa 0.08–0.56. Three studies reported between-test
agreement parameters by BCG vaccination status, which showed a lower per cent concordance and kappa
values for BCG-vaccinated participants than for non-vaccinated participants.
Recent arrivals from countries with a high incidence
of tuberculosis
Description of baseline characteristics
This section included 15 studies in total.143–147,166,183–191 Our searches identified five studies143–147 in
individuals who had recently arrived from mainly high TB incidence countries: two143,144 investigated the
incidence of active TB following testing for LTBI (incidence studies) and three145–147 investigated levels of
exposure in relationship to LTBI test outcomes (exposure studies). An additional 10 studies166,183–191 in
recently arrived immigrants were identified in CG117.10 Details of the additional studies included from
CG11710 can be found in Appendix 5.
Incidence studies
Two studies143,144 investigated the agreement of a QFT test with the TST in individuals recently arrived from
high TB incidence countries, one143 from Norway and the other144 from the Netherlands. Both studies used
a prospective cohort design and were community based. Follow-up ranged from 23 to 32 months in the
study by Harstad et al.143 whereas Kik et al.144 followed up participants for 24 months.
Harstad et al.143 compared the QFT-GIT and TST with cut-off values of ≥ 6mm and ≥ 15mm, whereas
Kik et al.144 compared the QFT-GIT, T-SPOT.TB and TST with cut-off values of ≥ 10mm and ≥ 15mm.
Around 25%143 and 43%144 of patients in the studies were female. Kik et al.144 included people who were
aged 16–45 years and Harstad et al.143 included people aged > 18 years. In the study by Kik et al.144
approximately 8% of the study population originated from Europe/North America, 8% from South
America, 36% from Asia, 29% from African countries other than sub-Saharan countries and 17% from
sub-Saharan Africa, with 1.5% of participants being of unknown geographical origin. In this study the
proportion of patients who had received a BCG vaccination was high at 81%.144 In the study by Harstad
et al.,143 13% of participants were from Europe, 42% from Africa, a further 42% from Asia and 3% from
other countries. BCG vaccination was not reported in this study. Table 18 provides further details on
these studies.
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Exposure studies
Three studies145–147 compared an IGRA test with the TST test in recent arrivals from countries with a high
incidence of TB, relating test outcome to previous level of exposure. All studies within this group were
therefore classed as having either a retrospective cohort or a cross-sectional design. The tests compared
were the QFT-GIT and TST (≥ 10mm),145–147 with Lucas et al.145 also testing the T-SPOT.TB. The studies
were undertaken in community settings in Australia145 and Italy.146,147 Lucas et al.145 studied children with
a mean age of 7.5 years from Africa (78%) and Asia (22%), with the exposed group having definite or
suspected household TB contact and the unexposed group having no contact. BCG vaccination in this
cohort was 69%. Participants in the Italian studies were young adults of whom 56% were female in
the study by Orlando et al.146 but only 4% were female in the study by Saracino et al.147 Immigrants
arrived from Latin America (50%), Eastern Europe (27%), Africa (16%) and Asia (7%) in the study by
Orlando et al.146 and from Africa (48%), Eastern Mediterranean countries (47%), Europe (3%) and
South-East Asia (2%) in the study by Saracino et al.147 Orlando et al.146 reported an overall very low rate of
BCG vaccination (6%), whereas the study by Saracino et al.147 did not report BCG vaccination of
participants.147 Both studies defined exposure groups by geographical area of origin and the level of TB
burden147 or TB prevalence146 in the country of origin. In addition, Orlando et al.146 specified a third
exposed group as contacts of TB cases and compared this with an unexposed group without TB contact.
Table 19 provides further details on these studies.
Study quality
Incidence of active tuberculosis
Only one144 of the studies provided an adequate description about study design, study participants, study
attrition, statistical analysis and reporting; this study was judged to have a low ROB. The other study143 was
judged as being at high ROB because of selection bias, confounding and selective reporting of results.
Table 20 provides further details.
Exposure levels
All three145–147 of the exposure studies identified since the publication of CG11710 concerning recent arrivals
from countries with a high incidence of TB were rated as being of low quality. There was a lack of blinding
of test results from exposure, inadequate descriptions of exposure and inadequate reporting of sample
attrition. Table 21 provides further details.
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Comparative performance of tests (diagnostic accuracy indices for
identifying latent tuberculosis infection)
Incidence of active tuberculosis
Ratios of cumulative incidence ratios
This section included two studies143,144 that followed up participants for the development of active TB.
Both studies correlated IGRA (QFT-GIT;143 QFT-GIT and T-SPOT.TB144) and TST results with the cumulative
incidence of active TB. The resulting CIRs for QFT-GIT were not significantly different from those for TST
5mm (R-CIR 2.55, 95% CI 0.57 to 11.40)143 and TST 10mm (R-CIR 0.87, 95% CI 0.17 to 4.56)144 (Table 22).
Similarly, in the study by Kik et al.,144 the R-CIR for T-SPOT.TB vs. TST 15mm was not significant (R-CIR 0.37,
95% CI 0.10 to 1.41).
The pooled estimate of the R-CIR across the two studies indicated no significant difference between
QFT-GIT and TST (5mm or 10mm) (pooled R-CIR 1.57, 95% CI 0.52 to 4.76) (Figure 42).
Sensitivity and specificity
This section included two newly identified studies.143,144 There was homogeneity in the sensitivity of both
QFT-GIT (pooled sensitivity 76%, 95% CI 50% to 93%; I2= 40.7%) and TST 5mm/10mm (pooled
sensitivity 94%, 95% CI 73% to 100%; I2= 30.8%). In contrast, specificity estimates for QFT-GIT (71%
and 46%; I2= 98.4%) and TST (49% and 15%; I2= 99.2%) were heterogeneous and these estimates
could not be pooled (Figures 43–46). In summary, QFT-GIT demonstrated greater specificity values (range
46–71%) than TST (range 15–49%) but lower sensitivity (pooled estimate 76%) than TST (pooled estimate
94%). One study144 showed that TST 15mm performed better than T-SPOT.TB in terms of both sensitivity
(87% vs. 75%) and specificity (44% vs. 40%).
TABLE 21 Summary assessment of ROB for the included exposure studies in recent arrivals from countries with a
high incidence of TB
Study ID
(burden)
Recruitment
of subjects
[consecutive
(yes),
arbitrary or
unreported
(no)]
Blinding of
test results
from
exposure
[blinded
(yes), not
blinded or
unreported
(no)]
Description of
index test
and threshold
[adequate
(yes),
inadequate or
unreported
(no)]
Definition and
description of
exposure
[adequate
(yes),
inadequate or
unreported
(no)]
Sample
attrition
[adequate
(yes),a
inadequate or
unreported
(no)]
Overall quality
score of
satisfactory
featuresb
Lucas 2010145
(low)
Yes No No No No Low quality
Orlando
2010146 (low)
Yes No Yes No No Low quality
Saracino
2009147 (low)
No No Yes No No Low quality
ID, identification.
a ≥ 90% of participants were included in the follow-up analysis (yes response) and < 90% were classified as ‘no response’.
b Studies with one or two ‘yes’ ratings= low quality; studies with three ‘yes’ ratings=moderate quality; studies with four
or five ‘yes’ ratings= high quality.
Source: adapted from Dinnes et al.44 The item ‘study design’ was removed from the original checklist as all studies were
considered to be retrospective; furthermore, the item ‘sample attrition’ was added.
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Exposure levels
Ratios of diagnostic odds ratios
Seven166,185,186,188–191 of the 10 studies reviewed in CG11710 (see Appendix 5) found significant strong
associations between exposure and positive test results, presented as DORs for both IGRA and TST (5mm,
10mm, 15mm) across exposure gradient groups defined as place of birth, racial group and country
prevalence. The estimates of R-DORs comparing IGRA with TST across these studies ranged from 0.14191 to
0.98.188 As CG11710 did not provide the 95% CIs around these estimates, it is not clear what the predictive
performance of IGRA relative to TST is in terms of identifying LTBI. With regard to the studies identified in the
present review, one study146 showed that IGRA compared with TST was more strongly correlated with the
exposure groups of geographical origin (Latin America/East Europe vs. Africa; R-DOR 1.42) and TB prevalence
(> 200/50–200 per 100,000 vs. < 50 per 100,000; R-DOR range 1.88–1.91), but this correlation across the
two tests was similar for contact with TB case (R-DOR 1.13, 95% CI 0.85 to 1.49). In two other studies145,147
the comparisons of IGRA and TST in relation to exposure to TB (R-DOR 0.60, 95% CI 0.32 to 1.12) and birth
in TB burden country (R-DOR 1.00, 95% CI 0.60 to 1.66) were not statistically significant (Table 23).
Based on the meta-analysis of the three studies,145–147 the pooled R-DOR for the IGRA (QFT-GIT) compared
with TST 10mm (contact with TB case, exposure to TB, birth in TB burden country) (R-DOR 0.96, 95% CI
0.69 to 1.33) was not statistically significant, suggesting that there is no evidence that IGRA performs
better than TST in identifying LTBI in this population (Figure 47).
Sensitivity, specificity, positive predictive value and negative predictive value
None of the three studies reported these parameters and there was not sufficient information to derive
2 × 2 table cell counts to calculate sensitivity and specificity values.
Influence of bacillus Calmette–Guérin vaccination status on test positivity
Of the three newly identified studies,145–147 only one145 reported the association between test positivity and
BCG vaccination status. Given the study results, there was no evidence indicating a differential effect of
BCG vaccination status on IGRA (QFT, T-SPOT.TB) and TST positivity. Namely, the odds of test positivity for
QFT-GIT (OR 1.70, 95% CI 0.80 to 3.60), T-SPOT.TB (OR 1.80, 95% CI 0.80 to 4.00) and TST (OR 1.70,
95% CI 0.80 to 3.50) were not significantly different between the BCG-vaccinated group and the
non-vaccinated group (Table 24).
Between-test concordance, discordance and agreement
This relevant evidence was reported for nine CG11710 studies166,183–188,190,191 (see Appendix 5) and three
newly identified studies145–147 (see Appendix 9). In overall samples, the per cent concordance between the
IGRA and the TST 10mm ranged from 63.6%188 to 84.2%.190 The corresponding concordance between
the IGRA and the TST 5mm was similar and ranged from 60.7%188 to 90%.191 The kappa values between
the IGRA and the TST (regardless of TST threshold and BCG vaccination status) ranged from 0.08
to 0.68,188 with most values being < 0.45. Both concordance and kappa were greater among
BCG-unvaccinated (or total sample) than among vaccinated-only groups146,166,183–186,188,190 (Table 25;
see Appendix 5 for CG11710 studies).
Summary of studies on recent arrivals from countries with a high incidence
of tuberculosis
Two studies that correlated IGRA (QFT-GIT and T-SPOT.TB) and TST results with cumulative incidence of
active TB showed no significant difference in CIRs for QFT-GIT compared with TST 5mm (R-CIR 2.55, 95%
CI 0.57 to 11.40) and QFT-GIT compared with TST 10mm (R-CIR 0.87, 95% CI 0.17 to 4.56). The pooled
estimate of R-CIRs across the two studies was not significant (pooled R-CIR 1.57, 95% CI 0.52 to 4.76).
Based on two studies, the QFT-GIT demonstrated greater specificity values (range 46–71%) than the TST
(range 15–49%) but lower sensitivity (pooled estimate 76%) than the TST (pooled estimate 94%). One
study showed TST 15mm to have performed better than T-SPOT.TB in terms of both sensitivity (87% vs.
75%) and specificity (44% vs. 40%).
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TABLE 24 Association between test positivity and BCG vaccination status in recent arrivals from countries with a
high incidence of TB: exposure studies
Study ID, country (burden) Sample size, n
Type of IGRA/TST
induration threshold
Association between test
positivity and BCG vaccination
status: OR (95% CI)
Crude/unadjusted Adjusted
Lucas 2010,145 Australia (low) 420 QFT-GIT 1.70 (0.80 to 3.60) NR
460 T-SPOT.TB 1.80 (0.80 to 4.00) NR
304 TST ≥ 10mm 1.70 (0.80 to 3.50) NR
Orlando 2010,146 Italy (low) 1130 QFT-GIT NR NR
1129 TST ≥ 10mm NR NR
Saracino 2009,147 Australia (low) 452 QFT-GIT NR NR
452 TST ≥ 10mm NR NR
ID, identification; NR, not reported.
TABLE 25 Between-test concordance and discordance in recent arrivals from countries with a high incidence of TB:
exposure and incidence studies
Study ID, country
(burden)
Sample size,
total or by
subgroup, n
Type of IGRA vs.
TST induration
threshold
Concordance
(95% CI) (%)
Discordance
(95% CI) (%)
Agreement
kappa
(95% CI)
Lucas 2010,145
Australia (low)
NR T-SPOT.TB vs. TST
10mm
NR NR 0.45
(0.38 to 0.53)
NR QFT-GIT vs. TST
10mm
NR NR 0.46
(0.39 to 0.53)
Orlando 2010,146
Italy (low)
887 QFT-GIT vs. TST
10mm
70.46
(67.32 to 73.43)
29.53 (NR) 0.38 (NR)
56 BCG
vaccinated
QFT-GIT vs. TST
10mm
66.07
(52.09 to 77.84)
33.92 (NR) 0.35 (NR)
789
unvaccinated
QFT-GIT vs. TST
10mm
71.36
(68.04 to 74.46)
28.64 (NR) 0.40 (NR)
Saracino 2009,147
Australia (low)
279 total QFT-GIT vs. TST
10mm
70.97
(65.39 to 75.98)
29.03
(24.02 to 34.61)
0.35
(0.23 to 0.46)
Harstad 2010,143
Norway (low)
823 QFT-GIT vs. TST
10mm
NR NR NR
823 QFT-GIT vs. TST
15mm
NR NR NR
Kik 2010,144 the
Netherlands (low)
433 QFT-GIT vs. TST
10mm
NR NR NR
ID, identification; NR, not reported.
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Seven of the 10 studies reviewed in CG117 found significant strong associations presented as DORs for
both the IGRA and the TST (5mm, 10mm, 15mm) across exposure gradient groups defined as place of
birth, racial group and country prevalence. However, the R-DORs comparing IGRA with TST across these
studies ranged from 0.14 to 0.98. As CG11710 did not provide the 95% CIs, it is not clear what the
predictive performance of IGRA relative to TST was in terms of identifying LTBI. Based on the meta-analysis
of the three more recent studies, the pooled R-DOR for IGRA (QFT-GIT) compared with TST 10mm
(contact with TB case, exposure to TB, birth in TB burden country) was not statistically significant,
suggesting that the IGRA does not perform better than the TST in identifying LTBI.
Given the results from one study, there was no evidence indicating a differential effect of BCG vaccination
on IGRA (QFT-GIT, T.SPOT.TB) and TST positivity. The odds of test positivity for the QFT-GIT (OR 1.70,
95% CI 0.80 to 3.60), T.SPOT.TB (OR 1.80, 95% CI 0.80 to 4.00) and TST (OR 1.70, 95% CI 0.80 to 3.50)
were not significantly different between the BCG-vaccinated group and the non-vaccinated group.
Based on nine CG11710 and three newly identified studies, the overall per cent concordance between the
IGRA and the TST 10mm ranged from 63.6% to 84.2%. The corresponding concordance between the IGRA
and the TST 5mm was similar (range 60.7–90%). Most kappa values between the IGRA and the TST
(regardless of TST threshold and BCG vaccination status) were < 0.45. Both concordance and kappa were
greater among BCG-unvaccinated groups.
Overall summary of results
We identified 53 studies published since the previous NICE clinical guidance work in 2011 (CG117).10 ROB
was assessed for 15 studies that evaluated the incidence of active TB and methodological quality was
assessed for the remaining 38 studies, which correlated test results with previous TB exposure. Seven of
the 15 incidence studies were identified as having a high ROB, six as having a moderate ROB and two as
having a low ROB. All had important drawbacks with regard to design, methods and reporting. Of the
38 exposure studies, 29 were generally of lower quality, six were of moderate quality and three were of
high quality.
Children and adolescents
Although the limited evidence in children and adolescents showed no significant difference in test accuracy
between QFT-GIT and TST 5mm (pooled R-CIR 1.12, 95% CI 0.72 to 1.75), QFT-GIT performed
significantly better than TST 10mm in predicting risk of active TB (pooled R-CIR 4.33, 95% CI 1.32 to
14.23). The IGRA (QFT-GIT/G) demonstrated a similar sensitivity to (range 48–100%) and a slightly better
specificity (range 49–90%) than TST 5mm (sensitivity range 57–100%; specificity range 45–65%).
Although the sensitivities of IGRA and TST 5mm were higher than those for TST 10mm (range 30–56%),
the corresponding specificities of these tests were lower than those for TST 10mm (range 63–93%).
Evidence from exposure studies suggested the superiority of IGRAs over TST in identifying LTBI in the low
TB burden setting (pooled R-DOR 4.74, 95% CI to 2.15 to 10.44) compared with high TB burden settings
(pooled R-DOR 1.13, 95% CI to 0.78 to 1.65).
Immunocompromised people
In terms of LTBI diagnosis, IGRAs (QFT-GIT or T.SPOT.TB) performed better than TST 5mm/10mm in
people receiving haemodialysis (pooled R-DOR 2.53, 95% CI 1.48 to 4.34) and people with hepatitis C
(R-DOR 8.45, 95% CI 3.71 to 19.24). In contrast, for patients with HIV/AIDS, TST 10mm performed
significantly better than QFT-GIT (pooled R-DOR 0.35, 95% CI 0.15 to 0.83). The comparative evidence on
the performance of the IGRAs and TST for the remaining subgroups (e.g. those with lupus erythematosus,
solid organ transplantation candidates, kidney transplant recipients) was inconclusive because of the high
level of uncertainty around the effect estimates.
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Recent arrivals from countries with a high incidence of tuberculosis
Overall, based on studies of incidence, there was no significant difference between the performance of
QFT-GIT and TST 5mm/10mm in identifying LTBI among newly arrived people from high TB burden
countries (pooled R-CIR 1.57, 95% CI 0.52 to 4.76). Similarly, there was no significant difference between
T.SPOT.TB and TST 10mm in predicting LTBI (R-CIR 0.37, 95% CI 0.10 to 1.41). Likewise, the pooled
result showed no significant difference between QFT-GIT and TST 10mm for the association with previous
TB exposure (pooled R-DOR 0.96, 95% CI 0.69 to 1.33).
The studies identified in this review were highly heterogeneous in terms of types of tests for LTBI, TST
cut-off levels, study settings and definitions of constructs for previous TB exposure for defining LTBI.
Previous exposure to TB was highly variable and ill-defined, lacking a description of duration and proximity
of contact to index TB cases. Overall, although the number of studies identified was substantial, extensive
heterogeneity across many potential test performance modifier factors (e.g. study methodology, test
administration, study populations and exposure-based construct definitions) precluded a more meaningful
subgroup analysis because of the scarcity of evidence for each subgroup.
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Chapter 5 Systematic review of economic
evaluation studies
Identification and selection of studies
Search methods for cost-effectiveness
A comprehensive search of the health-care literature for published economic evaluations, cost studies and
utility studies was performed. The purpose of this search was to identify existing cost-effectiveness models
and model designs, and also to identify studies that reported costs and health-related quality-of-life data
for use in generating cost per quality-adjusted life-years (QALYs).
The main cost-effectiveness search was developed and conducted as part of the wider systematic review
that aimed to compare both the clinical effectiveness and the cost-effectiveness of screening tests (IGRAs
and TST) for LTBI in high-risk groups: children, immunocompromised people or those at risk from
immunosuppression, and people recently arriving from countries with a high incidence of active TB. The
bibliographic database search strategies for the main cost-effectiveness search were the same as those
used for the clinical effectiveness review and focused on the diagnosis of LTBI using IGRAs compared with
other methods. Searches were limited to articles in English and articles that had been added to the
databases since the health economics searches for the equivalent questions in CG11710 were carried out
(5–6 January 2010; see Appendix 1). These searches automatically picked up comparisons between IGRAs
and TSTs and therefore it was not necessary to search independently for comparator technologies
(e.g. TSTs). The searches were not restricted by study type and therefore an economics search filter was
not required. The search strategies are provided in Appendix 2. Details of the databases and other sources
searched are provided in Chapter 3 (see Identification and selection of studies). Additional databases
searched for cost-effectiveness studies were:
l Research Papers in Economics
l Cost-Effectiveness Analysis Registry
l Health Economic Evaluations Database (Wiley).
A separate search in MEDLINE was performed to identify existing cost-effectiveness model designs for LTBI.
The search strategy is available in Appendix 2.
Inclusion and exclusion of relevant studies
To be included in the review, the following inclusion criteria were applied:
l Population:
¢ Children (both sexes, aged < 18 years, immunocompetent) (research question 1).
¢ People (both sexes, any age) who are immunocompromised or at risk from immunosuppression
(e.g. transplant recipients or those with HIV infection, renal disease, diabetes, liver disease,
haematological disease, cancer or autoimmune disease or who are on or about to start antiTNF-α
treatment, steroids or ciclosporins) (research question 2).
¢ People (both sexes, any age, immunocompetent) who have recently arrived from regions with a
high incidence/prevalence of TB (countries/territories with an estimated incidence rate of ≥ 40 cases
per 100,000, e.g. those in Africa, Central/South America, Eastern Europe and Asia) (research
question 3).
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l Intervention: IGRAs (QFT-G, QFT-GIT and T-SPOT.TB)
l Comparator: TST (Mantoux method)
l Outcome measures:
¢ The main outcome measure was the cost per QALY.
¢ Other outcomes such as correct diagnosis of LTBI and cost per active TB case prevented were
also considered.
l Study design: studies including a formal economic evaluation involving direct comparison between
IGRAs (QFT-G, QFT-GIT or T-SPOT.TB) and the TST and including a decision-analytic model in
identifying people with LTBI
l Type and language of publication:
¢ Full-text reports published in English.
¢ Abstracts (only if companion publications to full-text included studies).
Two reviewers (PA and AT) reviewed the titles and abstracts of the citations retrieved from the initial
database searches. Full texts of potentially relevant articles were read and those that were considered
model-based economic evaluations were reviewed.
Data extraction
Data extraction was conducted by one reviewer (PA) and further cross-checked by a second reviewer (AT).
Any disagreements were resolved by discussion or by recourse to a third-party reviewer. Data were
extracted on study details (title, author and year of study), baseline characteristics (population, intervention,
comparator and outcomes), methods (study perspective, time horizon, discount rate, measure of
effectiveness, current assumptions and analytical methods), results (study parameters, base-case and
sensitivity analysis results), discussion (study findings, limitations of the models and generalisability) and
‘other’ (source of funding and conflicts of interests). The completed data extraction sheets are presented in
Appendix 11.
Quality assessment
The economic evaluations were appraised against a framework for best practice for reporting economic
evaluation studies developed by the Consolidated Health Economic Reporting Standards (CHEERS) task
force.194 The CHEERS assessment tool consists of six dimensions: title and abstract, introduction, methods,
results, discussion and other. Under these dimensions, a series of questions check whether or not the
criteria have been clearly reported (see Appendix 12). Additionally, the models were critically appraised
against a framework for best practice for reporting decision-analytical models developed by Phillips et al.195
The Phillips et al.195 quality assessment tool includes two main dimensions: structure of the model and data
used to parameterise the model. Under these dimensions several questions assess whether or not the
criteria have been clearly reported (see Appendix 13).
Study quality was assessed by one reviewer (PA) and cross-checked by a second reviewer (AT). Any
disagreements were resolved by discussion or by recourse to a third-party reviewer.
Data synthesis
Information extracted from the included studies was summarised and tabulated. The findings from
individual studies are compared narratively and recommendations for the future modelling of LTBI
are discussed.
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Results
The electronic database searches and searches of other sources identified 5959 records (Figure 48). After
removing duplicates, 3057 records were screened for inclusion. On the basis of title and abstract, 3032
records were excluded and the remaining 25 records were included for full-text screening. A further
15 articles were excluded at the full-text stage, with the reasons for exclusion shown in Figure 48 (see
Appendix 14 for a list of excluded studies), leaving 10 studies10,77,196–203 that included a decision-analytical
model to estimate the cost-effectiveness of IGRAs compared with the TST in diagnosing people who are at
high risk of LTBI.
Records identified through
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en
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In
cl
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ed
El
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ty
Id
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ti
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ca
ti
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n
Records screened (after duplicates
removed)
(n = 3057)
Full-text articles assessed for
eligibility
(n = 25)
Full-text articles
excluded, with reasons
(n = 15)
Full-text articles included in
qualitative synthesis
(n = 10)
Studies included in 
qualitative synthesis
• Children, n = 2
• Immunocompromised, n = 6
• Recently arrived, n = 2
Records excluded at
title and abstract level
(n = 3032)
Total number of 
studies excluded 
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(n = 15)
• No model included, 
   n = 2
• Editorial, n = 1
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• Intervention not of
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   TB, n = 2
• Not full economic
   evaluation, n = 1
• No comparator, n = 2
Duplicate records
removed
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Additional records identified
through other sources
(n = 1)
Records identified (total before
deduplication)
(n = 5959)
FIGURE 48 Preferred Reporting Items for Systematic Reviews and Meta-Analyses study flow diagram.
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Summary of the general approaches to modelling latent
tuberculosis infection
The general modelling approaches used for the diagnosis of LTBI are presented in the following sections by
population of interest and in Table 26.
Children
Kowada197
Kowada197 estimated the cost-effectiveness of QFT-GIT compared with the TST and chest radiography for
the diagnosis of LTBI in children. The author developed a decision tree structure with Markov nodes to
demonstrate the clinical pathway that children would undergo for the diagnosis and treatment of LTBI. The
model started with a hypothetical cohort of children receiving one of three diagnostic strategies (QFT-GIT
alone, TST alone or chest radiography). The model structure continued with children being in the LTBI/
initial active TB or no LTBI health state, characterised by the prevalence of the disease. On positive test
results, children received chest radiography to confirm initial active TB. Children who received a negative
result on chest radiography were treated for LTBI. Children who adhered to LTBI treatment could develop
isoniazid-induced hepatotoxicity. For the state transition model, children entered the model at the no LTBI
health state and could remain or progress over time to LTBI, TB or death. Data required to populate the
model were obtained from published sources. Estimates of sensitivity and specificity of tests in this
population were obtained from a meta-analysis of developed-country studies. Cost data from published
sources were adjusted to 2009 Japanese yen and converted to US dollars. The analysis was conducted
from the societal perspective and the base-case results were expressed as an incremental cost-effectiveness
ratio (ICER) based on the outcome of cost per QALY gained. Kowada197 conducted one- and two-way
sensitivity analyses and populated with data to run the model probabilistically to represent the uncertainty
in key model input parameters. The base-case results demonstrated that the QFT-GIT-alone strategy was
less costly and more effective than the TST-alone strategy.
Mandalakas et al.203
Mandalakas et al.203 used a decision tree structure with Markov nodes to estimate the health and
economic outcomes of five screening strategies for the diagnosis of MTB infection in young household
contacts with an index case. The model started with a cohort of children aged < 5 years who received one
of five diagnostic strategies (no test, TST alone, IGRA alone, TST positive followed by IGRA and TST
negative followed by IGRA) and continued with children being in the LTBI/initial active TB or no LTBI/no
initial TB health state, characterised by the prevalence of the disease. Children with positive test results
were eligible for treatment for LTBI and could either accept or refuse treatment. For the Markov
model, children entered the model at the LTBI health state and could progress to no infection, initial
infection, subsequent infection from future exposures, pulmonary TB, disseminated TB, TB death and
death from other causes. The analysis was conducted from the third-party payer and societal perspectives,
and the base-case results were reported in terms of an ICER based on the outcome of cost per life-year
saved. Base-case results indicate that for those aged 0–2 years the no testing strategy was the dominant
strategy whereas for those aged 3–5 years an IGRA following a negative TST was the most effective
strategy but was not cost-effective compared with no testing. The authors conducted one-way sensitivity
analyses to determine the impact of data uncertainties on the results.
SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
166
TA
B
LE
26
Su
m
m
ar
y
ch
ar
ac
te
ri
st
ic
s
o
f
th
e
m
o
d
el
s
co
m
p
ar
in
g
IG
R
A
s
an
d
th
e
TS
T
in
id
en
ti
fy
in
g
LT
B
Ii
n
ch
ild
re
n
,
im
m
u
n
o
co
m
p
ro
m
is
ed
p
eo
p
le
an
d
re
ce
n
tl
y
ar
ri
ve
d
im
m
ig
ra
n
ts
St
u
d
y
ID
,
co
u
n
tr
y
A
im
o
f
th
e
st
u
d
y
St
u
d
y
ch
ar
ac
te
ri
st
ic
s
(s
tu
d
y
d
es
ig
n
,
p
er
sp
ec
ti
ve
,
se
tt
in
g
)
In
te
rv
en
ti
o
n
O
u
tc
o
m
e
m
ea
su
re
(s
)
M
o
d
el
ty
p
e
H
ea
lt
h
st
at
es
R
es
u
lt
s
(b
as
e-
ca
se
an
d
se
n
si
ti
vi
ty
an
al
ys
is
)
C
h
ild
re
n
K
ow
ad
a
20
12
,1
97
Ja
pa
n
To
as
se
ss
th
e
co
st
-e
ff
ec
tiv
en
es
s
of
sc
ho
ol
-b
as
ed
TB
sc
re
en
in
g
us
in
g
Q
FT
-G
IT
vs
.
TS
T
an
d
C
X
R
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
so
ci
et
al
pe
rs
pe
ct
iv
e,
se
tt
in
g
no
t
re
po
rt
ed
Q
FT
-G
IT
C
os
t
pe
r
Q
A
LY
D
ec
is
io
n
tr
ee
st
ru
ct
ur
e
to
m
od
el
th
e
sh
or
t-
te
rm
ev
en
ts
fo
llo
w
ed
by
a
M
ar
ko
v
m
od
el
lin
g
st
ru
ct
ur
e
H
ea
lth
y,
LT
BI
,
TB
an
d
de
ad
Q
FT
-G
IT
w
as
le
ss
co
st
ly
an
d
m
or
e
ef
fe
ct
iv
e
th
an
TS
T
M
an
da
la
ka
s
20
13
,2
03
So
ut
h
A
fr
ic
a
To
es
tim
at
e
th
e
he
al
th
an
d
ec
on
om
ic
ou
tc
om
es
of
fiv
e
TB
sc
re
en
in
g
st
ra
te
gi
es
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
th
ird
-p
ar
ty
pa
ye
r
an
d
so
ci
et
al
pe
rs
pe
ct
iv
es
IG
RA
(Q
FT
,
T-
SP
O
T.
TB
)
C
os
t
pe
r
LY
S
D
ec
is
io
n
tr
ee
st
ru
ct
ur
e
to
m
od
el
th
e
sh
or
t-
te
rm
ev
en
ts
fo
llo
w
ed
by
a
M
ar
ko
v
m
od
el
lin
g
st
ru
ct
ur
e
LT
BI
he
al
th
st
at
e
an
d
co
ul
d
pr
og
re
ss
to
no
in
fe
ct
io
n,
in
iti
al
in
fe
ct
io
n,
su
bs
eq
ue
nt
in
fe
ct
io
n
fr
om
fu
tu
re
ex
po
su
re
s,
pu
lm
on
ar
y
TB
,
di
ss
em
in
at
ed
TB
,
TB
de
at
h
an
d
de
at
h
fr
om
ot
he
r
ca
us
es
In
th
e
0–
2
ye
ar
s
co
ho
rt
,
th
e
no
te
st
in
g
st
ra
te
gy
do
m
in
at
ed
ot
he
r
st
ra
te
gi
es
.
In
th
e
3–
5
ye
ar
s
co
ho
rt
,
th
e
TS
T
ne
ga
tiv
e
fo
llo
w
ed
by
IG
RA
w
as
th
e
m
os
t
ef
fe
ct
iv
e
w
ith
a
re
po
rt
ed
IC
ER
of
ap
pr
ox
im
at
el
y
U
S$
23
3,
00
0
pe
r
LY
S
vs
.
no
te
st
in
g
Im
m
u
n
o
co
m
p
ro
m
is
ed
p
eo
p
le
K
ow
ad
a
20
10
,1
96
Ja
pa
n
To
as
se
ss
th
e
co
st
-e
ff
ec
tiv
en
es
s
of
Q
FT
-G
IT
vs
.
TS
T
fo
r
TB
sc
re
en
in
g
of
RA
pa
tie
nt
s
pr
io
r
to
in
iti
at
io
n
of
TN
F-
α
an
ta
go
ni
st
th
er
ap
y
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
so
ci
et
al
pe
rs
pe
ct
iv
e,
se
tt
in
g
no
t
re
po
rt
ed
Q
FT
-G
IT
C
os
t
pe
r
Q
A
LY
D
ec
is
io
n
tr
ee
m
od
el
w
ith
M
ar
ko
v
no
de
s
N
o
LT
BI
,
LT
BI
,
TB
an
d
de
at
h
Q
FT
-G
IT
w
as
le
ss
co
st
ly
an
d
m
or
e
ef
fe
ct
iv
e
th
an
TS
T.
A
t
so
ci
et
y’
s
W
TP
pe
r
Q
A
LY
,
th
e
Q
FT
-G
IT
te
st
in
g
st
ra
te
gy
ha
d
a
10
0%
pr
ob
ab
ili
ty
of
be
in
g
co
st
-e
ff
ec
tiv
e
co
m
pa
re
d
w
ith
th
e
TS
T
st
ra
te
gy
co
nt
in
ue
d
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
167
TA
B
LE
26
Su
m
m
ar
y
ch
ar
ac
te
ri
st
ic
s
o
f
th
e
m
o
d
el
s
co
m
p
ar
in
g
IG
R
A
s
an
d
th
e
TS
T
in
id
en
ti
fy
in
g
LT
B
Ii
n
ch
ild
re
n
,
im
m
u
n
o
co
m
p
ro
m
is
ed
p
eo
p
le
an
d
re
ce
n
tl
y
ar
ri
ve
d
im
m
ig
ra
n
ts
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
,
co
u
n
tr
y
A
im
o
f
th
e
st
u
d
y
St
u
d
y
ch
ar
ac
te
ri
st
ic
s
(s
tu
d
y
d
es
ig
n
,
p
er
sp
ec
ti
ve
,
se
tt
in
g
)
In
te
rv
en
ti
o
n
O
u
tc
o
m
e
m
ea
su
re
(s
)
M
o
d
el
ty
p
e
H
ea
lt
h
st
at
es
R
es
u
lt
s
(b
as
e-
ca
se
an
d
se
n
si
ti
vi
ty
an
al
ys
is
)
K
ow
ad
a
20
13
,1
98
Ja
pa
n
To
as
se
ss
th
e
co
st
-e
ff
ec
tiv
en
es
s
of
Q
FT
-G
IT
vs
.
TS
T
an
d
C
X
R
fo
r
TB
sc
re
en
in
g
of
ha
em
od
ia
ly
si
s
pa
tie
nt
s
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
so
ci
et
al
pe
rs
pe
ct
iv
e,
se
tt
in
g
no
t
re
po
rt
ed
Q
FT
-G
IT
C
os
t
pe
r
Q
A
LY
D
ec
is
io
n
tr
ee
m
od
el
w
ith
M
ar
ko
v
no
de
s
M
ai
nt
en
an
ce
di
al
ys
is
w
ith
no
di
so
rd
er
,
m
ai
nt
en
an
ce
di
al
ys
is
w
ith
LT
BI
,
m
ai
nt
en
an
ce
di
al
ys
is
w
ith
TB
an
d
de
at
h
Q
FT
-G
IT
w
as
do
m
in
an
t
co
m
pa
re
d
w
ith
th
e
TS
T
te
st
in
g
st
ra
te
gy
.
Re
su
lts
fr
om
th
e
se
ns
iti
vi
ty
an
al
ys
is
sh
ow
ed
th
at
th
e
ba
se
-c
as
e
re
su
lts
w
er
e
se
ns
iti
ve
to
th
e
BC
G
va
cc
in
at
io
n
ra
te
.
A
t
al
l
W
TP
th
re
sh
ol
ds
,
th
e
Q
FT
-G
IT
te
st
in
g
st
ra
te
gy
ha
d
a
10
0%
pr
ob
ab
ili
ty
of
be
in
g
co
st
-e
ff
ec
tiv
e
co
m
pa
re
d
w
ith
th
e
TS
T
te
st
in
g
st
ra
te
gy
K
ow
ad
a
20
14
,1
99
Ja
pa
n
To
as
se
ss
th
e
co
st
-e
ff
ec
tiv
en
es
s
fo
r
TB
sc
re
en
in
g
of
hi
gh
-r
is
k
H
IV
-p
os
iti
ve
pr
eg
na
nt
w
om
en
of
us
in
g
IG
RA
s
vs
.
TS
T
in
lo
w
-in
ci
de
nc
e
co
un
tr
ie
s
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
he
al
th
se
rv
ic
e
pe
rs
pe
ct
iv
e,
lo
w
in
ci
de
nc
e
of
TB
co
un
tr
y
bu
t
se
tt
in
g
no
t
re
po
rt
ed
(1
)
TS
T
al
on
e,
(2
)
Q
FT
al
on
e,
(3
)
T-
SP
O
T.
TB
,
(4
)
TS
T
fo
llo
w
ed
by
Q
FT
an
d
(5
)
TS
T
fo
llo
w
ed
by
T-
SP
O
T.
TB
C
os
t
pe
r
Q
A
LY
D
ec
is
io
n
tr
ee
m
od
el
w
ith
M
ar
ko
v
no
de
s
N
on
-L
TB
Ia
nd
no
n-
TB
,
LT
BI
,
no
n-
M
D
R
TB
,
M
D
R
TB
an
d
de
at
h
Ba
se
-c
as
e
re
su
lts
sh
ow
ed
th
at
T-
SP
O
T.
TB
is
le
ss
co
st
ly
an
d
m
or
e
ef
fe
ct
iv
e
th
an
ot
he
r
st
ra
te
gi
es
.
Se
ns
iti
vi
ty
an
al
ys
is
sh
ow
ed
th
at
co
st
-e
ff
ec
tiv
en
es
s
w
as
se
ns
iti
ve
to
th
e
se
ns
iti
vi
ty
of
T-
SP
O
T.
TB
,
th
e
se
ns
iti
vi
ty
of
Q
FT
,
th
e
sp
ec
ifi
ci
ty
of
T-
SP
O
T.
TB
an
d
th
e
sp
ec
ifi
ci
ty
of
Q
FT
in
cl
os
e
co
nt
ac
ts
SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
168
St
u
d
y
ID
,
co
u
n
tr
y
A
im
o
f
th
e
st
u
d
y
St
u
d
y
ch
ar
ac
te
ri
st
ic
s
(s
tu
d
y
d
es
ig
n
,
p
er
sp
ec
ti
ve
,
se
tt
in
g
)
In
te
rv
en
ti
o
n
O
u
tc
o
m
e
m
ea
su
re
(s
)
M
o
d
el
ty
p
e
H
ea
lt
h
st
at
es
R
es
u
lt
s
(b
as
e-
ca
se
an
d
se
n
si
ti
vi
ty
an
al
ys
is
)
La
sk
in
20
13
,2
00
U
SA
To
de
te
rm
in
e
th
e
m
os
t
co
st
-e
ff
ec
tiv
e
LT
BI
sc
re
en
in
g
st
ra
te
gy
be
fo
re
lo
ng
-t
er
m
st
er
oi
d
th
er
ap
y
in
a
ch
ild
w
ith
ne
w
-o
ns
et
id
io
pa
th
ic
ne
ph
ro
tic
sy
nd
ro
m
e
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
so
ci
et
al
pe
rs
pe
ct
iv
e,
se
tt
in
g
no
t
re
po
rt
ed
IG
RA
s
C
os
t
pe
r
Q
A
LY
D
ec
is
io
n
tr
ee
st
ru
ct
ur
e
to
m
od
el
th
e
sh
or
t-
te
rm
ev
en
ts
fo
llo
w
ed
by
a
M
ar
ko
v
m
od
el
lin
g
st
ru
ct
ur
e
W
el
l,
LT
BI
,
TB
,
ne
ph
ro
tic
re
la
ps
e
an
d
de
ad
fo
r
th
e
lo
ng
er
-t
er
m
ev
en
ts
Ba
se
-c
as
e
re
su
lts
sh
ow
ed
th
at
IG
RA
w
as
le
ss
co
st
ly
an
d
pr
od
uc
ed
m
od
er
at
el
y
m
or
e
Q
A
LY
s
th
an
un
iv
er
sa
lT
ST
Li
na
s
20
11
,2
01
U
SA
To
es
tim
at
e
th
e
co
st
-e
ff
ec
tiv
en
es
s
of
LT
BI
sc
re
en
in
g
us
in
g
th
e
TS
T
an
d
IG
RA
s
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
he
al
th
se
rv
ic
e,
se
tt
in
g
no
t
re
po
rt
ed
IG
RA
s
an
d
TS
T
N
um
be
r
ne
ed
ed
to
sc
re
en
to
pr
ev
en
t
on
e
ca
se
of
ac
tiv
e
TB
,
lif
e
ex
pe
ct
an
cy
,
qu
al
ity
-a
dj
us
te
d
lif
e
ex
pe
ct
an
cy
M
ar
ko
v
m
od
el
LT
BI
w
ith
IN
H
,
LT
BI
no
IN
H
,
is
on
ia
zi
d-
re
la
te
d
he
pa
tit
is
,
<
6
m
on
th
s’
IN
H
,
6–
8
m
on
th
s’
IN
H
,
9
m
on
th
s’
IN
H
,
ac
tiv
e
TB
,
po
st
ac
tiv
e
TB
an
d
de
at
h
Ba
se
-c
as
e
re
su
lts
sh
ow
ed
th
at
,
in
pe
op
le
w
ho
ar
e
ta
ki
ng
im
m
un
os
up
pr
es
si
ve
m
ed
ic
at
io
n,
ne
ith
er
TS
T
no
r
IG
RA
sc
re
en
in
g
w
as
co
st
-e
ff
ec
tiv
e
co
m
pa
re
d
w
ith
th
e
no
sc
re
en
in
g
st
ra
te
gy
.
Si
m
ila
r
re
su
lts
w
er
e
re
po
rt
ed
fo
r
pe
op
le
w
ith
ES
RD
Sw
am
in
at
h
20
13
,2
02
U
SA
To
co
m
pa
re
th
e
pe
rf
or
m
an
ce
of
TS
T
an
d
Q
FT
-G
sc
re
en
in
g
of
LT
BI
am
on
g
im
m
un
os
up
pr
es
se
d
IB
D
pa
tie
nt
s
ba
se
d
on
pr
ev
al
en
ce
,
m
or
ta
lit
y
ris
k
fr
om
re
ac
tiv
at
io
n
TB
an
d
co
st
s
C
os
t-
ef
fe
ct
iv
en
es
s,
he
al
th
-c
ar
e
pa
ye
r,
se
tt
in
g
no
t
re
po
rt
ed
Q
FT
-G
C
os
t
pe
r
fa
ls
e-
ne
ga
tiv
e
ca
se
of
LT
BI
av
oi
de
d,
co
st
pe
r
TB
de
at
h
av
oi
de
d,
co
st
pe
r
re
ac
tiv
at
io
n
TB
av
oi
de
d
(t
hi
s
ca
n
be
de
riv
ed
fr
om
th
e
in
fo
rm
at
io
n
pr
ov
id
ed
)
D
ec
is
io
n
tr
ee
m
od
el
Tr
ue
po
si
tiv
e,
tr
ue
ne
ga
tiv
e,
fa
ls
e
po
si
tiv
e,
fa
ls
e
ne
ga
tiv
e,
he
pa
tit
is
,
su
rv
iv
e/
de
at
h
he
pa
tit
is
Ba
se
-c
as
e
re
su
lts
sh
ow
ed
th
at
Q
FT
-G
do
m
in
at
ed
th
e
TS
T
st
ra
te
gy
.
A
dd
iti
on
al
ly
,
th
e
us
e
of
Q
FT
-G
w
ou
ld
av
oi
d
30
fa
ls
e-
ne
ga
tiv
e
ca
se
s,
4.
92
TB
re
ac
tiv
at
io
ns
an
d
1.
4
de
at
hs
co
m
pa
re
d
w
ith
th
e
TS
T
st
ra
te
gy
co
nt
in
ue
d
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
169
TA
B
LE
26
Su
m
m
ar
y
ch
ar
ac
te
ri
st
ic
s
o
f
th
e
m
o
d
el
s
co
m
p
ar
in
g
IG
R
A
s
an
d
th
e
TS
T
in
id
en
ti
fy
in
g
LT
B
Ii
n
ch
ild
re
n
,
im
m
u
n
o
co
m
p
ro
m
is
ed
p
eo
p
le
an
d
re
ce
n
tl
y
ar
ri
ve
d
im
m
ig
ra
n
ts
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
,
co
u
n
tr
y
A
im
o
f
th
e
st
u
d
y
St
u
d
y
ch
ar
ac
te
ri
st
ic
s
(s
tu
d
y
d
es
ig
n
,
p
er
sp
ec
ti
ve
,
se
tt
in
g
)
In
te
rv
en
ti
o
n
O
u
tc
o
m
e
m
ea
su
re
(s
)
M
o
d
el
ty
p
e
H
ea
lt
h
st
at
es
R
es
u
lt
s
(b
as
e-
ca
se
an
d
se
n
si
ti
vi
ty
an
al
ys
is
)
R
ec
en
t
ar
ri
va
ls
fr
o
m
co
u
n
tr
ie
s
w
it
h
a
h
ig
h
in
ci
d
en
ce
o
f
TB
C
G
11
7
20
11
,1
0
U
K
To
co
m
pa
re
th
e
co
st
s
an
d
ef
fe
ct
s
of
fo
ur
st
ra
te
gi
es
of
te
st
in
g
fo
r
pe
op
le
su
sp
ec
te
d
of
ha
vi
ng
LT
BI
in
En
gl
an
d
an
d
W
al
es
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
N
H
S
an
d
Pe
rs
on
al
So
ci
al
Se
rv
ic
es
(1
)
TS
T,
(2
)
IG
RA
,
(3
)
TS
T
fo
llo
w
ed
by
IG
RA
fo
r
pe
op
le
w
ith
po
si
tiv
e
TS
T
an
d
(4
)
no
te
st
(t
o
in
fo
rm
an
d
ad
vi
se
on
ly
)
C
os
t
pe
r
Q
A
LY
D
ec
is
io
n
tr
ee
m
od
el
Te
st
re
su
lts
,
tr
ea
tm
en
t
fo
r
LT
BI
,
tr
ea
tm
en
t
fo
r
TB
Re
su
lts
sh
ow
ed
th
at
TS
T
po
si
tiv
e
fo
llo
w
ed
by
IG
RA
an
d
IG
RA
te
st
in
g
st
ra
te
gi
es
w
er
e
as
so
ci
at
ed
w
ith
IC
ER
s
of
<
£3
0,
00
0
pe
r
Q
A
LY
co
m
pa
re
d
w
ith
no
te
st
in
g.
Th
e
re
su
lts
fr
om
th
e
se
ns
iti
vi
ty
an
al
ys
es
sh
ow
ed
th
at
va
ry
in
g
th
e
co
st
of
an
IG
RA
(f
ro
m
£5
0
to
£6
0)
ch
an
ge
d
th
e
di
re
ct
io
n
of
th
e
co
st
-e
ff
ec
tiv
en
es
s
re
su
lts
Pa
re
ek
20
13
,7
7
U
K
To
as
se
ss
th
e
co
st
-e
ff
ec
tiv
en
es
s
of
LT
BI
sc
re
en
in
g
us
in
g
di
ff
er
en
t
sc
re
en
in
g
m
od
al
iti
es
at
di
ff
er
en
t
in
ci
de
nc
e
th
re
sh
ol
ds
in
a
pr
im
ar
y
ca
re
se
tt
in
g,
w
ith
an
d
w
ith
ou
t
C
X
R
sc
re
en
in
g
on
ar
riv
al
at
po
rt
of
en
tr
y
C
os
t-
ef
fe
ct
iv
en
es
s
an
al
ys
is
,
N
H
S,
pr
im
ar
y
ca
re
se
tt
in
g
(1
)
T-
SP
O
T.
TB
al
on
e,
(2
)
Q
FT
-G
IT
al
on
e,
(3
)
TS
T
pl
us
co
nf
irm
at
or
y
T-
SP
O
T.
TB
(if
TS
T
po
si
tiv
e)
,
an
d
(4
)
TS
T
pl
us
co
nf
irm
at
or
y
Q
FT
-G
IT
(if
TS
T
po
si
tiv
e)
C
os
t
pe
r
ca
se
of
ac
tiv
e
TB
av
oi
de
d
D
ec
is
io
n
tr
ee
m
od
el
Th
e
ill
us
tr
at
iv
e
m
od
el
lin
g
st
ru
ct
ur
e
w
as
pr
es
en
te
d
in
a
su
pp
le
m
en
ta
ry
w
eb
ap
pe
nd
ix
bu
t
un
fo
rt
un
at
el
y,
th
es
e
st
ru
ct
ur
es
w
er
e
ill
eg
ib
le
Re
su
lts
sh
ow
ed
th
at
sc
re
en
in
g
of
re
ce
nt
ly
ar
riv
ed
im
m
ig
ra
nt
s
fr
om
co
un
tr
ie
s
of
or
ig
in
w
ith
a
m
od
er
at
e
(n
ot
de
fin
ed
)
TB
in
ci
de
nc
e
is
lik
el
y
to
be
co
st
-e
ff
ec
tiv
e
fo
r
th
e
us
e
of
on
e-
st
ep
IG
RA
te
st
in
g
co
m
pa
re
d
w
ith
ot
he
r
sc
re
en
in
g
st
ra
te
gi
es
C
X
R,
ch
es
t
ra
di
og
ra
ph
y,
IB
D
,
in
fla
m
m
at
or
y
bo
w
el
di
se
as
e;
IC
ER
,
in
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
;
ID
,
id
en
tif
ic
at
io
n;
IN
H
,
is
on
ia
zi
d-
in
du
ce
d
he
pa
to
to
xi
ci
ty
;
LY
S,
lif
e-
ye
ar
sa
ve
d;
M
D
R,
m
ul
tid
ru
g
re
si
st
an
t;
RA
,
rh
eu
m
at
oi
d
ar
th
rit
is
;
W
TP
,
w
ill
in
gn
es
s
to
pa
y.
SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
Immunocompromised people
Kowada196
Kowada196 used a decision tree structure with Markov nodes to assess the cost-effectiveness of using
QFT-GIT alone compared with TST alone to diagnose LTBI in patients with rheumatoid arthritis. The model
simulated a pathway for a hypothetical cohort of people with rheumatoid arthritis being screened for LTBI
and cost-effectiveness was estimated over a lifetime horizon. The model started with a cohort of people
aged 40 years who received either diagnostic strategy and continued with people being in the LTBI/initial
active TB or no LTBI/no initial TB health state, characterised by the prevalence of the disease. People with
positive or negative results on the TST or positive QFT-GIT results received chest radiography to detect
active TB. If active TB was detected they received treatment for active TB, whereas if active TB was not
detected they received treatment for LTBI. Here, the author assumed that chest radiography to diagnose
initial active TB was 100% sensitive and specific. People who adhered to LTBI treatment were at risk of
developing isoniazid-induced hepatotoxicity. Kowada196 presented an illustrative Markov structure to depict
the transitions that could occur between health states. From the structure, people could enter the model
from the no LTBI, LTBI or TB health state.
The information required to populate the model was obtained from published sources. However, the
author did not comment on/discuss the sources of prevalence of LTBI in this population. Information on
the sensitivity and specificity of the tests was obtained from secondary sources and a meta-analysis. All
costs included in the model were reported in 2009 Japanese yen and converted to US dollars using the
same price year. The primary outcome measure of effectiveness was QALYs gained over a lifetime horizon;
however, the author did not elaborate on the descriptive tools used to value these health states. All costs
and benefits were discounted at 3% per annum. The analysis was conducted from the societal perspective
and results were presented in terms of an ICER expressed as cost per QALYs gained. Kowada196 conducted
one-way and two-way sensitivity analyses by changing key model input parameters to determine the
impact on the deterministic results. Additionally, a probabilistic sensitivity analysis (PSA) was undertaken,
but the distributions and the cost-effectiveness acceptability curve (CEAC) were not presented. The author
demonstrated that QFT-GIT alone was the most cost-effective strategy for the diagnosis of LTBI in people
undergoing haemodialysis. The results from the sensitivity analyses showed that the base-case results were
robust to changes in model input parameters. Results from the probabilistic analysis showed that IGRA
was the preferred option, with a 100% probability of being cost-effective compared with TST at society’s
willingness to pay of US$50,000 per QALY.
Kowada198
In this study Kowada198 used a decision tree structure with Markov nodes to assess the costs and effects of
using QFT-GIT alone, TST alone and chest radiography alone to diagnose LTBI in patients undergoing
haemodialysis. The model simulated a pathway for a hypothetical cohort of people with haemodialysis
being screened and cost-effectiveness was estimated over a lifetime horizon. The model started with a
cohort of people who received one of the three diagnostic tests. People with positive results on the TST
or QFT-GIT received chest radiography to detect active TB. If active TB was detected they received
treatment for active TB, whereas if active TB was not detected they received treatment for LTBI. The author
assumed that chest radiography to diagnose initial active TB was 100% sensitive and specific. People who
adhered to LTBI treatment were at risk of developing isoniazid-induced hepatitis. Kowada198 did not
present the illustrative Markov structure but described the clinical health states; however, no further
comment was made on how people progressed through these health states. The information required to
populate the model was obtained from published sources. The author conducted a review of the literature
but did not state whether or not the accuracy of the tests was derived from a meta-analysis. The primary
outcome measure of effectiveness was QALYs gained; however, the author did not elaborate on the
descriptive tools used to value these health states. The analysis was conducted from the societal
perspective and the results were presented in terms of an ICER expressed as cost per QALYs gained.
Kowada198 conducted one-way and two-way sensitivity analyses by changing key model input parameters
to determine the impact on the deterministic results. Additionally, PSA was undertaken but the
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distributions and the CEAC were not presented. The author demonstrated that QFT-GIT alone was the
most cost-effective strategy for the diagnosis of LTBI in haemodialysis patients.
Kowada 2014199
Kowada used a decision tree structure with Markov nodes to estimate the cost-effectiveness of IGRAs
compared with TST for TB screening in high-risk HIV-positive pregnant women in countries with a low
incidence (< 24 cases per 100,000) of TB. The model simulated the pathway for four cohorts (BCG
vaccinated during pregnancy, non-BCG vaccinated during pregnancy, BCG vaccinated in the post-partum
period and non-BCG vaccinated in the post-partum period) separately and cost-effectiveness was
estimated over a 30-year time horizon. The starting point of the model was a hypothetical cohort of
women aged 20 years who received one of five (TST alone, QFT-G alone, T-SPOT.TB alone, TST positive
followed by QFT or TST positive followed by T-SPOT.TB) testing strategies. A result was considered positive
on TST if the induration was ≥ 5mm and ≥ 10mm in those who were non-BCG vaccinated and BCG
vaccinated respectively. Women who had positive results on the TST-, QFT-G- or T-SPOT.TB-alone
strategies received chest radiography to diagnose initial active TB. On the combination strategies, women
who received a positive result on TST further received QFT-G or T-SPOT.TB and, if the result was positive,
received chest radiography to detect initial active TB and received treatment for LTBI/TB. Women who
adhered to LTBI treatment were at risk of developing isoniazid-induced hepatotoxicity and were treated
accordingly. In the Markov structure, the author considered five health states (non-LTBI and non-TB,
LTBI, non-multidrug-resistant TB, multidrug-resistant TB and dead) that women could enter based on
proportions from the decision tree and showed the transitions between these health states.
Data required to populate the models were obtained from published sources. The analysis was conducted
from the public health payer perspective and results were presented in terms of ICERs expressed as cost
per QALYs gained. All costs included in the model were reported in 2012 Japanese yen and converted to
US dollars using the same price year. The primary outcome measure of effectiveness was QALYs gained
over a 30-year time horizon. All costs and benefits were discounted at 3% per annum. Kowada199
conducted PSA and one- and two-way sensitivity analyses by changing key model input parameters to
determine the impact on the base-case results. The base-case results showed that the TST positive
followed by QFT-G strategy was the most cost-effective strategy for the diagnosis of LTBI in occasional
screening of HIV-positive pregnant women who were non-BCG vaccinated during pregnancy. Similar
results were demonstrated in the other hypothetical cohorts. Results from the PSA showed that the TST
followed by QFT-G strategy was the preferred option, with a 100% probability of being cost-effective at all
of society’s willingness-to-pay levels per QALY. The results from the sensitivity analyses showed that the
base-case results were sensitive to changes in the sensitivity of T-SPOT.TB and the sensitivity of QFT-G in
occasional screening of non-BCG vaccinated pregnant women.
Laskin et al.200
Laskin et al.200 used a decision tree structure with Markov nodes to determine the most cost-effective
screening strategy for children with new-onset idiopathic nephrotic syndrome. The decision tree
component of the model represented the pathway that children would undertake in a 6-month time
period before they entered into the Markov model. Here, the longer-term events were simulated over a
lifetime horizon with 3-month cycle lengths. The starting point of the model was a hypothetical cohort
with new onset nephrotic syndrome. Children who received a positive test result were treated for LTBI and
were at risk of developing hepatitis. The starting points of the Markov model were derived from the
proportions of children with negative TST/IGRA results, children in whom LTBI treatment was successful
and those in whom LTBI treatment had failed. The authors assumed that effective LTBI treatment provided
long-term protection against LTBI/TB. Data required to populate the model were obtained from published
sources. The analyses were conducted from the societal perspective applying an annual discount rate
of 3% on costs and benefits. Indirect costs incurred in the analysis included travel time and loss of
productivity. Base-case results showed that the no-screen strategy was least costly and more effective than
other strategies. However, the results from this study should be interpreted with caution because the
discounted and undiscounted costs were similar. The results from the sensitivity analysis showed that the
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results were robust when indirect medical costs were excluded from the analysis. The results were sensitive
to changes in the prevalence of LTBI in this population, with the questionnaire followed by the IGRA
screening strategy being the most cost-effective strategy at a prevalence of > 4.9%. The results from the
probabilistic analysis showed that, at a prevalence of 1.1%, no screening was the preferred screening
option compared with IGRA, but the authors did not state the willingness-to-pay value used.
Linas et al. 2011201
Linas et al.201 constructed a decision tree structure with Markov nodes to estimate the cost-effectiveness of
using TST compared with IGRAs for the diagnosis of LTBI in various populations. The model begins with a
hypothetical cohort of people who received one of three diagnostic strategies (TST alone, IGRA alone or
no screening). The model continued with people characterised by their disease status (LTBI/no LTBI). People
with a positive IGRA or TST result received treatment for LTBI. The decision tree structure was used to
inform on the proportion of people who started in the Markov model structure. The Markov structure
started with people in the LTBI with isoniazid treatment state, the LTBI with no treatment state or the
active TB health state, and showed the transitions between these health states. People who received
treatment for LTBI were at risk of developing isoniazid-induced hepatitis.
Data required to populate the model were obtained from published sources. All costs included were
obtained from published sources and presented in 2011 US dollars. The primary outcome was cost per QALY
gained over a lifetime horizon. Utility values estimated were based on the Short Form questionnaire-36 items
and European Quality of Life-5 Dimensions descriptive systems. The analysis was conducted from the health
service perspective and all costs and benefits were discounted at 3% per annum. The authors further
conducted one- and two-way sensitivity analyses around the key model input parameters. Results from
the analysis showed that, in the HIV-infected cohort, screening with IGRA alone was marginally more
costly and effective than the no screening option, with an ICER of $12,800. For people who were on
immunosuppressive medication, the reported ICER for TST screening compared with no screening was
$129,000. Sensitivity analyses showed that increasing the mean age of the population to 65 years and
screening with TST remained cost-effective in people living with HIV infection. The base-case results were
sensitive to changes in the estimates of health-related quality of life for people who received treatment for
active TB. Screening with TST or IGRA resulted in ICERs that were > $100,000 for people with diabetes or
end-stage renal disease.
Swaminath et al.202
Swaminath et al.202 used a decision tree structure to estimate the costs and benefits of using QFT-G
alone compared with TST alone for the diagnosis of LTBI in people with inflammatory bowel disease.
The model simulated a cohort of people with moderate to severe active Crohn’s disease being treated with
immunosuppressive medication. The starting point of the model was a cohort of people who received one
of two tests. The structure started from disease status (LTBI/no LTBI) followed by test results. On positive
test results people received treatment for LTBI and could further develop isoniazid-induced hepatitis and
either survived or died from this event. People who were false negative could have reactivated TB and
could survive or die from this event. People who were false positive received treatment and could further
develop isoniazid-induced hepatitis. The authors suggested that people with indeterminate results on the
QFT-G would immediately receive a second QFT-G test. However, this pathway was not shown in the
decision tree structure. Data required to populate the model were obtained from secondary sources.
The prevalence of LTBI in this population was obtained from the WHO. The sensitivity and specificity of
tests were derived based on information obtained from a few sources and not from a literature review.
The analysis was conducted from the health payer perspective and the results were presented in terms of
the costs of false-negative cases avoided, TB reactivations and deaths avoided. The authors conducted
one-way sensitivity analyses around key model input parameters. They suggested that QFT-G was less
costly and more effective than the TST in this population.
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Recent arrivals from countries with a high incidence of tuberculosis
Pareek et al.77
Pareek et al.77 used a decision tree structure to simulate the costs and benefits of using T-SPOT.TB alone,
QFT-GIT alone, TST plus confirmatory T-SPOT.TB (if TST positive) or TST plus confirmatory QFT-GIT (if TST
positive) for screening immigrants for LTBI. The illustrative model structure presented by the authors in the
supplementary appendix was illegible and hence further comment on/appraisal of the structure/pathways
could not be made. The authors suggested that immigrants who were symptomatic at initial screening or
who had a positive IGRA/TST result were referred for chest radiography and further clinical assessment.
Immigrants with a positive IGRA and/or positive TST result and a normal chest radiograph without any
symptoms suggestive of active TB were considered to have LTBI. For a positive TST test, cut-offs of ≥ 6mm
and ≥ 15mm were used for BCG-unvaccinated and BCG-vaccinated participants, respectively. Additionally,
the authors used a non-stratified cut-off of ≥ 10mm to suggest a positive TST. The data required to populate
the model were obtained from an observational study undertaken by the authors and from published
sources. To be included in the observational study, participants had to be recently arrived (within the last
5 years) immigrants to the UK, aged ≥ 16 years (with symptoms of TB) or from a country with a TB incidence
of ≥ 40 per 100,000 (asymptomatic). Information on the prevalence of LTBI was derived from immigrants
aged ≤ 35 years who had been tested with the three screening tests. Cost data from published sources were
inflated to 2010 prices using the Consumer Prices Index. The analysis was undertaken from the UK NHS
perspective in a primary care setting. The outcome measures included in the analyses were the number of
cases of active TB avoided and the number of LTBI cases needed to be treated to prevent one case of active
TB, over a 20-year time horizon. The results were presented as cost per active TB cases avoided. Both costs
and benefits were discounted at 3.5% per annum. Pareek et al.77 conducted sensitivity analyses on key
model input parameters (prevalence of LTBI, progression rate from LTBI to active TB, specificity, proportion of
immigrants accepting and adhering to LTBI treatment). The base-case results showed that the screening
strategy of no port-of-entry chest radiography and screening with one-step QFT-GIT was cost-effective with
an ICER of £21,570 per case of active TB avoided for immigrants whose country of origin had an incidence
of TB of 250 per 100,000. For immigrants whose country of origin had an incidence of TB of ≤ 150 per
100,000, the strategy was not cost-effective (at a willingness to pay of £30,000 per QALY). Results from the
sensitivity analyses showed that varying the prevalence and the progression rate from LTBI to active TB
increased the cost-effectiveness of the one-step QFT-GIT strategy. Reducing the specificity of the test resulted
in the one-step T-SPOT.TB becoming the most cost-effective strategy. Reducing the proportion of people
accepting and adhering to LTBI treatment led to higher cost-effectiveness estimates.
National Collaborating Centre for Chronic Conditions, Centre for Clinical
Practice at the National Institute for Health and Care Excellence10
The authors of CG11710 used a decision tree structure to compare the costs and effects of four testing
strategies [TST alone, IGRA alone, TST followed by IGRA and no test (to provide information and advice
only)] for the diagnosis of LTBI in immigrants from countries with a high prevalence of active TB. The model
started with a cohort of recently arrived immigrants who received one of the four testing strategies.
In the TST-/IGRA-alone strategies, people who received a positive test result were treated for LTBI.
Conversely, a proportion of people who had negative test results were given the BCG vaccination. In the
combination strategy, people who tested positive on the TST received a QFT test. Immigrants who had
a positive QFT result were treated for LTBI and, of those with a negative result, a proportion were given a
BCG vaccination. The end point of the model was the proportion of people developing TB having received
a BCG vaccination or treatment for LTBI. Data required to populate the model were obtained from published
sources. Sensitivity of the tests was based on two publications and average values were used as estimates.
Costs included in the model were those related to the UK NHS and Personal Social Services. All costs were
presented in UK pounds sterling in 2008/9 prices. Costs obtained from published sources were inflated using
the Hospital and Community Health Services pay and price index. The results showed that a positive TST
result followed by IGRA and the IGRA-alone testing strategy were associated with ICERs of < £30,000 per
QALY compared with the no-testing strategy. The results from the sensitivity analyses showed that varying
the cost of an IGRA (from £50 to £60) changed the direction of the cost-effectiveness results.
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Characteristics of the included studies
The characteristics of the models included in these evaluations are summarised in Table 26. All of the
included studies used an economic model to determine the cost-effectiveness of various strategies for the
diagnosis of LTBI. Four196–199 of the economic evaluations were conducted in Japan, three200–202 in the USA,
two10,77 in the UK and one203 in South Africa. Three studies196–198 compared QFT-GIT only with TST only, two
studies200,201 compared an IGRA with TST but did not indicate the type of IGRA being used, one study202
compared QFT-G only with TST only and four studies10,77,199,203 compared various testing strategies (TST
alone, QFT alone, QFT-GIT alone, T-SPOT.TB alone, TST followed by QFT and TST followed by T-SPOT.TB,
TST negative followed by IGRA) for the diagnosis of LTBI. Two197,203 economic evaluations were conducted in
children, six196,198–202 evaluations were conducted in the immunocompromised population and two10,77 were
conducted in the recently arrived population.
Most of the decision-analytical models196–200,203 used for the analyses were decision tree structures with
Markov nodes; three studies10,77,202 used a decision tree structure alone and one study201 used a Markov
model alone to show diagnostic strategies for detecting LTBI and progression over time to active TB. The
health states included in the models represented those that people would experience while being screened
for LTBI. In the models with a cohort of children, the health states included healthy, LTBI, TB and dead.
There was some variation in the health states used for the immunocompromised population; this may be
because of the presence of various diseases/conditions when trying to assess which diagnostic strategy is
cost-effective for the diagnosis of LTBI. In the models with a cohort of recently arrived immigrants, the
health states included test results, treatment for LTBI and treatment for TB. One of the model structures
was illegible in this population.
Model time horizons ranged from 1 year to a lifetime. In the models with children, the time horizon
was a lifetime (up to 80 years) with cycle lengths of 6 months203 and 1 year.197 In the models with
immunocompromised cohorts, the time horizons ranged from 1 year to a lifetime, with 3-month or 1-year
cycle lengths, and in the models with a recently arrived cohort, the time horizons ranged from 15 years to
20 years, with annual cycle lengths. The authors stated that the time horizons chosen were long enough
to measure the costs and benefits of the diagnostic strategies.
Resource use and costs included in the economic analyses depended on the perspective taken. All studies
clearly stated the perspective or viewpoint from which the analysis was undertaken. Five studies10,77,199,201,202
conducted their analyses from the UK NHS or other national health payer perspective and the remaining
five studies196–198,200,203 conducted their analyses from the societal perspective. The five models10,77,199,201,202
that presented results based on the health payer perspective included direct costs related to the health
service (costs of diagnostic tests, chest radiography and sputum examinations, treatment for LTBI/active TB
and treatment for isoniazid-induced hepatotoxicity). Of the five models196–198,200,203 that presented results
based on the societal perspective, three models196–198 did not include indirect costs or loss of productivity.
Six10,196–200 studies reported their results in terms of cost per QALY only, three studies77,202,203 reported their
results in terms of cost per life-year saved, cost per false-negative case of LTBI avoided, cost per TB death
avoided, cost per reactivation TB case avoided or cost per TB case avoided, and in one study201 the
outcomes were based on the number needed to screen to prevent one case of active TB, life expectancy
and QALYs gained. Of the studies that reported results in terms of QALYs, utility values were obtained
from published sources to derive QALY estimates. These studies referenced the original source of the utility
values but did not elaborate on which descriptive system was used to values these health states. From the
base-case results reported in these studies, the consensus was that IGRAs were less costly and more
effective than other strategies.
Because of the uncertainty around key model input parameters and assumptions made in the models, all
authors conducted sensitivity analyses. Five studies10,77,201–203 conducted deterministic (one- and two-way)
sensitivity analyses alone. The remaining studies196–200 conducted both deterministic sensitivity analyses and
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PSAs. Sensitivity analyses were conducted around changing the prevalence of LTBI, test accuracies
(sensitivity and specificity) of diagnostic tests, the costs of the IGRAs, return rates for TST and the
progression rate from LTBI to active TB.
This review was used to inform model development for the diagnosis of LTBI in three populations.
In the following section we provide an appraisal of the modelling structures, the data used to parameterise
the models and the handling of uncertainty. We also consider relevant issues when deriving key model
input parameters (prevalence, sensitivity/specificity of diagnostic tests and combination strategies).
Quality assessment of the modelling methods
We present a summary of the reporting quality of the studies included in the current review assessed
against the Philips et al.195 checklist in Appendix 13.
Structure
The structures of the models included in this review were generally of good quality. In accordance with
best practice for developing model structures, studies clearly stated their decision problem and the
perspective of the analysis, the objectives of the model, which were consistent with the decision problem,
and the structures which represented the clinical pathway people that would follow while being
screened for LTBI. However, there were some structural issues noticed. Three studies196–198 conducted their
analyses from the societal perspective but did not include indirect costs or loss of productivity in the
analyses. Studies generally stated the location of the analyses but not the setting and this may have an
impact on the generalisability of the results. Illustrative model structures were also presented in the
majority of the studies but in one study77 the model structure was illegible. All studies clearly stated and
justified their time horizon and cycle lengths.
All authors justified their choice of model structure, which represented coherent pathways of LTBI disease
and its treatment. Six models10,196–200 used decision tree structures with Markov nodes for their analyses,
three studies77,202,203 used decision tree structures alone and one study201 used a Markov model alone. Of
the studies identified, six10,198–201,203 modelled from the test result first followed by LTBI diagnosis, whereas
four77,196,197,202 modelled from LTBI diagnosis followed by the test result. One study10 included a proportion
of people returning to have their TST result read. One study202 included a proportion of people with
indeterminate test results on an IGRA and assumed that they would receive a second IGRA immediately
(not shown in the decision tree). All studies included chest radiography to confirm whether or not active
TB was present. All studies also included treatment for LTBI and TB. As a result of adhering to LTBI
treatment, all studies included a proportion of people developing isoniazid-induced hepatotoxicity but they
did not include any other adverse events from adhering to TB treatment. Studies that included a Markov
model196–200,203 generally used similar health states (no LTBI, LTBI, active TB, reinfection, disseminated TB
and dead) to show the possible transitions over time.
Key model input parameters
The methods used to identify relevant information to populate the models were satisfactory in most
studies. Studies stated that a literature review was undertaken but did not specify the purpose/aim of the
review, that is, to search the literature to inform on the data inputs and/or to inform on the model
structure or model design. All studies provided references for their model inputs but they were not clear
on the choices between data sources or the quality of information used in the models. This may have been
a result of a paucity of information in the literature.
In the four models77,196,197,202 that started from known disease status, information required at this point was
the prevalence of LTBI in the population. Most studies used secondary sources to obtain a point estimate
or to derive an estimate of the prevalence of LTBI but they did not elaborate on what the prevalence
represented (prevalence of LTBI in contact tracing, prevalence of LTBI based on occasional screening in the
SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
176
population of interest or prevalence of LTBI that would develop to active TB). Additionally, studies that
used multiple sources were not transparent on the methods used to derive an estimate of the prevalence
of LTBI.
Test characteristics of the TST and IGRAs were required for all of the models. In most studies10,77,197,199–203 a
literature review was carried out and estimates of sensitivity and specificity were derived based on sources
identified. Most studies10,77,197,199–201 elaborated on the methods used to derive sensitivity and specificity.
These methods included calculating an estimate based on an average of sensitivity (and specificity)
obtained from the literature, obtaining estimates from sources that conducted a meta-analysis or using
Bayesian statistics to calculate an estimate of sensitivity and specificity based on confirmed TB cases.
The study77 that used Bayesian statistics acknowledged that there is no gold standard test available for the
diagnosis of LTBI in these populations and provided equations used to derive sensitivity and specificity.
Studies that included a combination strategy,10,199 for example TST positive followed by IGRA, did not
elaborate on the methods used to derive the sensitivity and specificity of a test conditional on an initial
positive/negative result.
All costs required for the models were justified and referenced. Costs obtained from published literature
were inflated using the appropriate indices. All authors clearly stated the unit costs used in the models,
but some authors196,198–200 did not elaborate on the resources used to estimate the unit costs, especially for
the treatment of LTBI/active TB. All authors stated the perspective of the analyses, but in some studies196–198
the costs included did not reflect the viewpoint/perspective of the analyses. All authors, when necessary,
discounted costs and benefits using the appropriate rates.
In the models that reported their results in terms of QALYs,10,196–201 authors provided the references used to
obtain the utility weights. However, the majority of the authors196–200 did not elaborate on the descriptive
tools/measures used to value these health states in these populations. Additionally, authors did not
elaborate whether or not the sources of utility information used were relevant to their population of interest.
Uncertainty and assumptions
Uncertainty is unavoidable in economic modelling. Briggs and Gray204 and Philips et al.195 have outlined
methods to handle the four main types of uncertainty (methodological, structural, parameter and
generalisability). All of the models attempted to address uncertainty, but none of these studies addressed
all types of uncertainty. All of the studies undertook univariate or multivariate sensitivity analysis on key
model input parameters. Four studies196–199 also undertook PSA for joint uncertainty in model parameters to
assess the impact on the base-case results.
To have a workable model structure to conduct these analyses, all studies except that by Kowada199 clearly
stated the simplifying assumptions of their models. In general, these assumptions outlined in the studies
appeared to be feasible but were strong in some cases. One study77 assumed that testing with an IGRA
would not lead to an indeterminate result whereas in CG11710 the authors assumed that treatment of
LTBI/TB was adhered to by the population and that it would not lead to any adverse events.
Conclusion
The evidence base described here offers insight on the decision-analytic models available to determine
the cost-effectiveness of an IGRA compared with the TST for the diagnosis of LTBI in children,
immunocompromised people and people from countries with a high incidence of active TB. We identified
10 model-based economic evaluations across these three populations. The majority of these models
included immunocompromised or immunosuppressed populations, with the evidence available for the
other two populations being sparse. The majority of the models used decision tree structures with Markov
nodes to simulate a cohort of people being tested for LTBI.
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We appraised these models against frameworks on best practice for reporting an economic evaluation and
economic modelling. In general, all models performed well in terms of defining the decision problem,
including the study perspective, outlining the choice of comparators, presenting an illustrative model
structure and providing a clear outline of the assumptions. These models all add to the existing literature but
are subject to limitations. First, the majority of the studies indicated the location of the study but did not
state the setting of the analysis and this may limit the generalisability of the results. Second, the majority of
the studies used QALYs as the outcome measure and referenced the source of the utility values. However,
the authors did not provide commentary on the descriptive tools used to value these health states. Third, the
perspective of the analysis was stated in all studies; however, some of the resource use and costs reported
did not reflect the viewpoint of the analysis. Fourth, the majority of the studies were transparent with regard
to the methods used to identify information to populate the models, but it was unclear if any quality
assessment of the information was undertaken. Finally, all models explored uncertainty around key model
input parameters by undertaking one- and two-way sensitivity analyses but no attempt was made to explore
the other types of uncertainty: methodological, structural or generalisability. Other concerns relate to the
derivation of prevalence, test accuracy and transition probabilities; most studies did not elaborate on these
statistical/pre-model analyses.
In Chapter 6 we outline the development of a de novo model that includes two stages to inform on the
cost-effectiveness of various strategies for the diagnosis of LTBI in our populations of interest.
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Chapter 6 Health economics methods and results
Objective
The objective of the economic evaluation was to compare the cost-effectiveness of various screening
strategies for the diagnosis of LTBI in immunocompetent children, people who are immunocompromised
or at risk of immunosuppression and people who are recent arrivals from countries with a high incidence
of active TB.
Currently in the UK, the following strategies are recommended to diagnose people with LTBI:10
l Children. Offer a Mantoux test to children aged 2–15 years. If positive, follow up with an IGRA.
l Immunocompromised. For people who are HIV negative, offer an IGRA alone or an IGRA with a
concurrent Mantoux test. If either test is positive perform a clinical assessment to exclude active TB
and treat.
l Recently arrived immigrants. Offer an IGRA alone or a dual strategy for people aged 16–35 years.
If either test is positive, refer to a TB specialist to exclude active TB and treat.
l General population. Offer an IGRA alone or IGRA testing for people whose Mantoux test shows
positive results.
Developing the model structure
To assess the cost-effectiveness of various strategies for the diagnosis of LTBI, we developed an economic
model using R (version 3.1.1; The R Foundation for Statistical Computing, Vienna, Austria).
The model was developed with clinical input and represents, as far as possible, the clinical pathways that
people would take while being screened for LTBI. The model structure for the child population is presented
in Figure 49. The model was structured in two stages: diagnosis of LTBI and disease progression to active
TB. The first stage of the model represents the clinical pathway that people would take in a
1-year time period before entering the infectious disease model. For this stage we used a decision tree
structure for the diagnosis of LTBI. Four diagnostic strategies were examined in the model for
each population:
l TST alone
l IGRA alone
l combinations of TST and IGRA
l simultaneous testing.
These strategies being compared were derived based on the strategies outlined in CG11710 and with
input from the TB Guideline Development Group. The model begins with people receiving one of these
diagnostic strategies (see Figure 49). The branches to the right of the decision node (square symbol)
represent the strategies being compared (see Figures 50–54 for the child population and Appendix 15,
Figures 60–74, for all other populations). People begin in one of the possible health states to the right of
the chance nodes (circle symbols). The decision tree is modelled from individuals who have LTBI that
progresses to active TB/no LTBI, followed by the probability of test results. However, in clinical practice the
test result is known before LTBI is diagnosed. Modelling the test result first followed by disease category or
vice versa makes no mathematical difference in terms of the expected values calculated for each diagnostic
strategy.205 In the following sections we describe each strategy in detail.
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Tuberculin skin test-alone strategy (Figure 50)
When screening with a TST, an individual may or may not return to have the test results interpreted (TST
not read). Adults with positive TST results (induration ≥ 5mm/10mm) are assessed for initial active TB by
chest radiography and sputum examination. Children with positive TST results are assessed for active TB
by chest radiography and, if that is positive, a gastric lavage procedure. Those who have a positive result
on chest radiography and sputum examination are treated for active TB. We assumed here that chest
radiography and sputum examination are 100% accurate at diagnosing people who have initial active TB.
People who adhere to TB treatment in the immunocompromised or recently arrived population may
develop hepatitis and can survive or die from this adverse event. In the model with a cohort of children,
we assumed that they would not develop hepatitis because it is a rare adverse event in this population.203
People who have a negative result on chest radiography and sputum examination (LTBI) can either accept
or refuse to be treated for LTBI. Those who accept LTBI treatment may adhere/not adhere to treatment.
If the TST is not read or the TST results are negative, the individual is not followed up.
Interferon gamma release assay-alone strategy (Figure 51)
When screening with an IGRA alone, an individual may have a determinate or an indeterminate result.
Adults with a determinate result and who are IGRA positive are assessed for initial active TB by chest
radiography and sputum examination. Children with positive IGRA results are assessed for active TB by
chest radiography and, if that is positive, a gastric lavage procedure. Those who have a positive result
on chest radiography and sputum examination are treated for active TB. Those who have a negative
result on chest radiography and sputum examination (LTBI) can either accept or refuse to be treated for
LTBI. People who accept LTBI treatment can adhere or not adhere to treatment. People with an
indeterminate IGRA result receive a second IGRA test, which is the same as the initial IGRA test. If the
IGRA result is negative or both IGRA tests are indeterminate, the individual is not followed up.
Combined strategy (Figure 52)
For children and the recently arrived population, those who had their TST results interpreted, and whose
results are positive, receive an IGRA test. Children with determinate, positive IGRA results receive chest
radiography and, if positive, the gastric lavage procedure before a sputum examination for the assessment
of active TB. Children with negative chest radiography/sputum examination results are either treated or not
treated for LTBI. Children with indeterminate results receive a second IGRA test, which is the same as the
initial IGRA test. If the TST is not read or the TST is negative, the individual is not followed up. Recent
arrivals with determinate, positive IGRA results are assessed for active TB by chest radiography and sputum
examination. If there is a positive result on chest radiography and sputum examination, they are treated for
active TB. Those who have a negative result on chest radiography and sputum examination (LTBI) can
either accept or refuse to be treated for LTBI. If people accept LTBI treatment, they may adhere/not adhere
to treatment. People with an indeterminate IGRA result receive a second IGRA test, which is the same as
the initial IGRA test. These people follow similar pathways to those who received one IGRA test. At most,
people will receive two IGRA tests. If the TST result is not read, the TST result is negative, the IGRA result is
negative or both IGRA tests are indeterminate, the individual is not followed up.
Conversely, in the immunocompromised group, people receive an IGRA test first. Those who have a
positive result on the IGRA test receive chest radiography and sputum examination to detect initial active
TB. Those with a positive result on chest radiography and sputum examination are treated for active TB.
Those who have a negative result can accept or refuse treatment for LTBI. People who have accepted and
adhered to LTBI treatment may develop hepatitis and can survive or die from this adverse event.
Individuals with a negative IGRA result undergo a TST test. People here follow similar pathways as those
who received the TST-alone strategy. Those with an indeterminate IGRA result receive a second IGRA test,
which is the same as the initial IGRA test. These people follow similar pathways to those who received one
IGRA test. At most, people will receive two IGRA tests. If the IGRA result is negative, both IGRA tests are
indeterminate, the TST result is negative or the TST result has not been read, the individual is not
followed up.
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Simultaneous testing strategy (Figures 53 and 54)
When screening with an IGRA and a TST, people can have a combination of test results: a determinate
result on the IGRA and the TST read, a determinate result on the IGRA and the TST not read, an
indeterminate result on the IGRA and the TST read or an indeterminate result on the IGRA and the TST not
read. Children with a positive result on either test receive chest radiography and, if positive, the gastric
lavage procedure and sputum examination to detect initial active TB. For the other populations, those with
a positive result on either test receive chest radiography and, if positive, a sputum examination to detect
active TB. If the IGRA result is indeterminate and the TST is not read, the individual is not followed up.
Stage 2 of the model is a disease progression model looking at progression between no TB/LTBI, LTBI that
will progress to active TB and active TB, as well as secondary infections in other individuals caused by
people with active TB. The basic model structure is shown in Figure 55. This structure is the same for
people who are/are not being treated for LTBI/active TB, although the transmission probabilities are
different in each of these cases. The outputs of the decision tree are used to determine the proportions of
people who start in each state, specifically:
1. active TB
2. LTBI – treated for LTBI
3. LTBI – untreated
4. no TB/LTBI – treated for LTBI
5. no TB/LTBI – untreated.
The model used was a discrete event simulation, modelling individual patients, built using R (version 3.1.1).
An initial simulation, starting with an identical cohort of 500,000 individuals in each arm, was run using
the mean values of each parameter. To account for parameter uncertainty, we also ran a Monte Carlo
simulation, consisting of 2000 different sampled parameter sets, each run on a starting sample of 100,000
individuals. An individual’s event risks at any time point are determined by their age, TB status and current
treatment and remain constant until one of these factors changes.
People who begin the model with LTBI and who are not treated will develop active TB at a later point
(from the definition of LTBI in our model as LTBI that progresses to active TB). The mean delay between
the diagnostic test and progression to active TB was estimated from the systematic review, with individual
activation times simulated assuming a constant activation rate over time. People who begin the model with
LTBI and who are treated for LTBI have a certain probability of not developing active TB in the future (the
effectiveness of the treatment – assumed to be 6 months of isoniazid), with activation times for those
whose treatment is unsuccessful sampled as above.
Age-specific all-cause mortality rates were taken from UK-specific data in the Human Mortality Database206
and applied to all individuals in the model. Age-specific utilities for individuals without TB were calculated
using data from the Health Survey for England.207 When an individual develops active TB, they have an
immediate, age-specific probability of death, over that of all-cause mortality. Recovery rates from active TB
were calculated from the mean length of an active TB episode, assuming a constant probability of recovery
over time. Individuals with resolved TB have an annual probability of relapse, with subsequent activations
having the same probability as the initial episode.
For each TB activation (primary or relapse), individuals generate a certain number of secondary cases of
LTBI that will progress to active TB, sampled from a Poisson distribution. These cases are assumed to occur
in the general population; hence, the age of the secondarily infected individuals was simulated from the
average age distribution of active TB cases in the UK. These secondary cases were assumed to be identical
(in terms of probability of death, average length of active TB episode, utility loss, number of secondary
cases generated) to similarly aged individuals in the initial population. We did not simulate secondary cases
of LTBI that do not progress to active TB as we have also not considered these in our initial population.
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As the model is run, any new cases of LTBI generated are included in the disease progression model from
that time forward. Costs and QALYs are accrued by individuals according to the length of time that they
spend in each state of the model. Unlike a traditional economic model, it is not possible to continue
running the simulation until all individuals have died, as there is a continuous stream of new individuals
being added as a result of new infections. Consequently, the simulation was run for 100 years, with
discounting meaning that any results over a longer time horizon than this are unlikely to make a
meaningful difference to the outcome. The parameters for the discrete event simulation are presented in
Table 27 for the child population and in Tables 64 and 65 (see Appendix 16) for the immunocompromised
and recently arrived populations respectively.
Model assumptions
A number of assumptions were required to develop a workable model structure to enable the analyses to
be undertaken:
1. We assumed that our population is similar to the population in the clinical effectiveness studies, but
excluding studies with populations with a high incidence of active TB.
2. People being assessed for initial active TB undergo chest radiography and, if positive, receive a
sputum examination.
3. Children being assessed for initial active TB undergo chest radiography and, if positive, undergo a
gastric lavage procedure.
4. The sputum examination is 100% accurate when diagnosing initial active TB.
5. Individuals with a second indeterminate result on the IGRA test are at the same risk of developing
active TB as those with a false-negative result.
6. People who have been diagnosed with initial TB accept treatment.
7. People who do not adhere to LTBI treatment take medication for 1 month.
8. People who do not adhere to LTBI treatment are not at risk of developing isoniazid-induced hepatotoxicity.
9. People who do not adhere to active TB treatment take medication for 1 month.
10. Children are not at risk of developing hepatitis as a result of treatment for active TB or LTBI.
11. No health loss is experienced by people with LTBI who do not progress to active TB.
Treatment
No LTBI/TB
LTBI
Active TB
Death – all cause
Death – all causeDeath – TB
Resolved TB New secondary infections
FIGURE 55 Dynamic transmission model.
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TABLE 27 Model input parameters required for the child population
Variable
Base-case
value Range for SA PSA distribution Source
Probabilities
Prevalence of LTBI 0.0288 0.0206–0.0384 a Derived from the current
clinical effectiveness study
Sensitivity TST (≥ 5mm) 0.7280 0.6059–0.7294 a
Specificity TST (< 5mm) 0.4903 0.4796–0.5008 a
Sensitivity TST (≥ 10mm) 0.5351 0.3821–0.6769 a
Specificity TST (< 10mm) 0.7481 0.3434–0.7618 a
Sensitivity QFT-GIT 0.6884 0.5856–0.7820 a
Specificity QFT-GIT 0.6103 0.6030–0.6176 a
Sensitivity T-SPOT.TB 0.500 0.0245–0.9764 a
Specificity T-SPOT.TB 0.7758 0.6738–0.8640 a
Sensitivity of QFT-GIT
conditional on positive TST
(LTBI arm)
0.6775 0.4674–0.9233 a
Specificity of QFT-GIT
conditional on positive TST
(no LTBI arm)
0.3213 0.3073–0.3353 a
Sensitivity of QFT-GIT
conditional on negative TST
(LTBI arm)
0.7031 0.1122–0.9921 a
Specificity of QFT-GIT
conditional on negative TST
(no LTBI arm)
0.9108 0.9013–0.9200 a
Sensitivity of CXR for
diagnosing active TB
0.7800 Not reported Not varied Kumar et al.208
Specificity of CXR for
diagnosing active TB
0.5100 Not reported Not varied Kumar et al.208
Determinate QFT-GIT 0.97 – Beta(873,27) Derived from Laskin et al.200
Determinate T-SPOT.TB 0.97 – Beta(873,27) Derived from Laskin et al.200
TST read 0.9400 0.6–1.00 Beta(164,10.5) Pareek et al.77
Initial active TB 0.00001 – Not varied Laskin et al.200
TB treatment adherence 1.0000 – Not varied Pareek et al.77
Accepting LTBI treatment 0.9400 0.50–1.00 Beta(141,9) CG11710
Adherence to LTBI treatment 0.8000 0.50–0.90 Beta(41,10) Kowada198
Isoniazid-induced hepatitis
after TB treatment
0.0040 0.001–0.010 Beta(2.7,664) Assumption
Death from isoniazid-induced
hepatitis
0.00002 0.00001–0.0001 Beta(0.5,25125) Pooran et al.209
Transmission model parameters
Proportion still infected post
LTBI treatment
0.345 – Log-normal
(–1.065,0.842)
White and Jit210
Average number of secondary
cases from one index case
0.2 0.1–0.3 Log-normal
(–1.609,0.354)
Pareek et al.6
continued
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TABLE 27 Model input parameters required for the child population (continued )
Variable
Base-case
value Range for SA PSA distribution Source
Average delay from infection
to activation (secondary cases)
2.88 – Log-normal
(1.058,0.333)
Okuonghae211
Annualised reactivation rate
from resolved TB
0.013 0.004–0.025 Beta(7,513) Oxlade et al.212
Case fatality rate for active TB
(0–4 years)
0.0477 – Beta(628,12543) Crofts et al.213
Case fatality rate for active TB
(5–14 years)
0.0034 – Beta(1,290) Crofts et al.213
Case fatality rate for active TB
(15–44 years)
0.0018 – Beta(1,564) Crofts et al.213
Case fatality rate for active TB
(45–64 years)
0.0476 – Beta(125,2500) Crofts et al.213
Case fatality rate for active TB
(65+ years)
0.1755 – Beta(413,1940) Crofts et al.213
Resource use and costs (£)
TST 17.48 – Not varied Pooran et al.209
QFT-GIT 48.73 – Not varied Pooran et al.209
T-SPOT.TB 59.57 – Not varied Pooran et al.209
CXR 35.00 – Not varied NHS reference costs 2012/13214
Gastric lavage procedure 916.00 – Not varied NHS reference costs 2012/13214
Sputum examination 7.00 – Not varied NHS reference costs 2012/13214
Cost of adherence to active
TB treatment
5461.12 – Gamma
(10.41,524.6)
Bothamley et al.215
Cost of non-adherence to
active TB treatment
910.19 – Not varied Assumption
Cost of adherence to LTBI
treatment
677.07 – Uniform
(511.69,842.45)
NHS drug tariff216
Cost of non-adherence to
LTBI treatment
112.85 – Uniform
(85.24,140.41)
Assumption
Treatment of
isoniazid-induced hepatitis
389.51 – Gamma
(7.13,55.64)
Pareek et al.77
Utility decrements
Active TB (while on treatment) 0.15b Not reported Gamma
(11.2,0.0134)
Derived from Kowada197
Treatment for LTBI 0.001 – Uniform (0,0.002) Derived from Kowada197
Other
Discount rate per annum
(costs and QALYs)
3.5%
CXR, chest radiography; SA, sensitivity analysis.
a Calculated from posterior distributions generated by Markov chain Monte Carlo methods.
b QALY decrement for people being treated for active TB.
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Data required for the model
The model was populated with clinical information from the current clinical effectiveness review and
supplemented with information from secondary sources. Information required to parameterise the model
included prevalence, sensitivity and specificity, adverse events, resource use, and costs and utilities. We
acknowledge here that there is no gold standard test for a LTBI diagnosis. Hence, we have used clinical
information from studies in this review that reported information on confirmed cases of active TB (the
proportion of untreated individuals who go on to develop active TB at a later date).
All of the data available for the child population were based on studies in which there was previous
contact with an index case. We therefore restricted our analysis to this population both because of the
lack of data and because it was thought unlikely that a general screening programme for all children,
irrespective of contact, would ever be introduced.
Prevalence
In this analysis, prevalence was defined as the proportion of people who have LTBI that will progress to
active TB, assuming that they are not treated. We derived estimates for this LTBI prevalence criterion based
on empirical data from the three cohorts separately. We used WinBUGS software (version 1.4.3; MRC
Biostatistics Unit, Cambridge, UK) to conduct Bayesian Markov chain Monte Carlo (MCMC) simulation to
derive the prevalence of LTBI in each cohort using the following formula:
Probability of a positive result = (test sensitivity × prevalence of LTBI) + ½(1− test specificity)
× (1−prevalence of LTBI).
(1)
Rearranging the above equation for prevalence of LTBI:
Prevalence of LTBI = probability of a positive result− (1− test specificity)=½(test sensitivity)
− (1− test specificity).
(2)
To avoid overestimating the prevalence of LTBI that progresses to active TB, we excluded studies with
populations with a high incidence (≥ 40 cases per 100,000) of active TB. For the recently arrived
population, we derived the prevalence from all studies on recent arrivals found in the clinical effectiveness
review, which included people with LTBI who progressed to active TB.
Performance of screening tests (sensitivity and specificity)
The sensitivities and specificities of the various strategies were derived based on information obtained from
longitudinal studies in people who received testing and developed active TB. Therefore, our calculated
sensitivities and specificities represent the sensitivities and specificities of detecting people with LTBI that
will progress to active TB, not the sensitivities and specificities of detecting LTBI in general. Bayesian
MCMC was used to derive posterior distributions for test performance assuming weakly informative priors
to derive the sensitivity and specificity of the diagnostic tests by population. Estimates for sensitivity and
specificity were derived for TST (≥ 5mm), TST (≥ 10mm), QFT-GIT and T-SPOT.TB.
To synthesise the clinical evidence in WinBUGS, there were three main components of the model: the
statistical model, priors and data. Appendix 17 provides the WinBUGS code for the child population.
Statistical model
In our models we have used distributions to represent the unknown variables in the model. For the
evidence synthesis for children, immunocompromised people and recent arrivals we used the binomial
distribution to derive the sensitivities and specificities of TST, QFT-G, QFT-GIT and T-SPOT.TB. We chose the
binomial distribution because we were interested in the probability p of the number of successes (people
with positive/negative results that progressed to active TB) from n number of longitudinal studies.
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First, we were interested in the probability ppos of the number of positive test results from n longitudinal
studies and, second, we were interested in the probability papos of the number of positive results that
progressed to active TB from n number of positive test results. Likewise, we were interested in the
probability paneg of a negative result progressing to active TB.
Logical expressions were built into the model to represent the relationship between the probability of a
positive result, the prevalence of LTBI, test sensitivity and test specificity (see Appendix 17).
We initially explored both fixed- and random-effects models. However, for two of the populations (children
and immunocompromised people) the random-effects models did not converge (most likely because in a
number of studies either no individuals or only a very small number of individuals progressed to active TB).
Hence, for consistency, we used the fixed-effects model for the three populations.
Priors
We stated in the WinBUGS model the prior distribution to be used. We chose the uniform distribution
because all possible combinations of positive and negative test results have an equal a priori probability of
occurring. In our WinBUGS code we added a logic expression to inform the model that the sensitivity of
TST (≥ 5mm) is greater than the sensitivity of TST (≥ 10mm), which is greater than the sensitivity of TST
(≥ 15mm). Likewise, the specificity of TST (< 5mm) is lower than the specificity of TST (< 10mm), which is
lower than the specificity of TST (< 15mm). We included this logic expression because the TST is a single
test with various cut-off thresholds for a positive result and, by definition, TST (≥ 5mm) would be more
sensitive and less specific than TST (≥ 10/15mm).
Data
Observed data from longitudinal studies identified in the clinical effectiveness review were entered into the
model in a list format. Data included the number of people being tested, the number of people with positive
results, the number of people with positive results who were untreated and who developed active TB and
the number of people with negative results who developed active TB. Tables 67–72 (see Appendix 18)
show the information obtained from the clinical effectiveness studies. The term ‘not applicable’ was used to
represent any missing values. After compiling the model, we specified distributions from which to sample
initial values for the model.
To obtain accurate posterior probabilities we used 60,000 simulations; a burn-in period of 30,000
simulations was used. Output from the remaining 30,000 simulations represented the posterior mean,
along with its posterior standard deviation, posterior median and 95% credible intervals. Convergence of
the model was assessed using a visual inspection of the sample trace plots (see Appendix 17).
The results of the meta-analysis are presented in Table 28. The sensitivity and specificity of TST (≥ 5mm)
for the diagnosis of LTBI in children were estimated at 72.80% and 49.03%, respectively. In the
immunocompromised group we derived estimates of 32.42% and 74.22% for the sensitivity and
specificity of TST (≥ 5mm), respectively. In the recently arrived immigrants group we derived estimates of
93.56% and 50.11% for the sensitivity and specificity of TST (≥ 5mm), respectively. In the models we have
not stratified by BCG status and hence we used a cut-off of ≥ 5mm to define a positive TST.
Similar methods were used to derive the sensitivity and specificity of TST (≥ 10mm) in these populations.
The sensitivity and specificity of QFT-GIT for the diagnosis of LTBI in children were estimated at 68.84% and
61.03%, respectively. In the immunocompromised group we derived estimates of 55.48% and 82.27% for
sensitivity and specificity, respectively, and in the recently arrived group we derived estimates of 59.15%
and 79.29% for sensitivity and specificity, respectively. In the models we used QFT-GIT values as the
base-case values for the analysis because the majority of the studies compared QFT-GIT with the TST.
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Resource use and costs
The resource use and costs included were those directly incurred by the NHS. Costs for diagnostic tests,
chest radiography, gastric lavage, sputum examination, treatment of LTBI/TB and isoniazid-induced hepatitis
were all included in the analysis. Societal costs (indirect costs, loss of productivity or cost of death) were not
included. The unit costs are presented in Table 27. The majority of the cost information used in the analyses
was obtained from secondary sources. The costs for QFT-GIT (testing kit, consumables, processing and
phlebotomy) and the TST (disposables, administration and reading) were obtained from Pooran et al.209
Estimated costs for chest radiography, the gastric lavage procedure and sputum examination were obtained
from NHS reference costs 2012/13.214 Estimated costs for the treatment of LTBI were obtained from the NHS
drug tariff 2015216 and in consultation with a clinical expert (see Appendix 16). Costs for the treatment of
TB were obtained from Bothamley et al.215 (see Appendix 16). Management of LTBI included further blood
tests (full blood count and liver function tests), doctor and nurse outpatient visits, and treatment with
300mg of isoniazid daily for 6 months. Estimated costs for treating isoniazid-induced hepatitis were
obtained from Pareek et al.77 All costs were adjusted to 2012/13 prices using the Hospital and Community
Health Services pay and price index217 and discounted at a rate of 3.5% per annum, as recommended
by NICE.91
Outcomes
Two different outcome measures were used in the analysis, QALYs and diagnostic error avoided. To
calculate QALYs, age-related utility weights for the general population were obtained from the Health
Survey for England207 and the utility decrement of 0.15 for people who received treatment for active TB
was derived from the published literature.197 With respect to the diagnostic error avoided, we did not
require any effectiveness information; the true-positive and true-negative cases were given the value of 1
and we reserved the value of 0 for an error (false positives and false negatives) in the diagnosis.
TABLE 28 Diagnostic accuracy of various tests for diagnosing LTBI that progresses to active TB
Test Sensitivity (95% credible interval) (%) Specificity (95% credible interval) (%)
Children
TST (≥ 5mm) 72.80 (60.59 to 72.94) 49.03 (47.96 to 50.08)
TST (≥ 10mm) 53.51 (38.21 to 67.69) 74.81 (34.34 to 76.18)
QFT-GIT 68.84 (58.56 to 78.20) 61.03 (60.30 to 61.76)
T-SPOT.TB 50.00 (2.45 to 97.64) 77.58 (67.38 to 86.40)
Immunocompromised people
TST (≥ 5mm) 32.42 (11.19 to 58.48) 74.22 (72.88 to 75.57)
TST (≥ 10mm) 16.82 (2.52 to 38.99) 83.97 (78.99 to 88.31)
QFT-GIT 55.48 (24.73 to 83.73) 82.27 (80.52 to 83.96)
T-SPOT.TB 66.65 (35.17 to 91.44) 68.46 (63.46 to 73.37)
Recent arrivals from countries with a high incidence of TB
TST (≥ 5mm) 93.56 (77.86 to 99.77) 50.11 (47.90 to 52.29)
QFT-GIT 59.15 (35.84 to 81.42) 79.29 (77.80 to 80.73)
T-SPOT.TB 70.01 (39.78 to 92.42) 39.92 (34.39 to 45.54)
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Analysis
The models were constructed to assess the cost-effectiveness of various strategies for the diagnosis of
LTBI in three populations (children, immunocompromised people and recently arrived immigrants).
The models estimated the mean costs and effects associated with each diagnostic strategy. For children,
we began with a hypothetical cohort of children aged 5 years, whereas for the recently arrived and
immunocompromised populations the starting distributions were representative of the UK recent arrival
and UK general populations respectively.218 The analysis was undertaken from a NHS perspective in a
primary care setting and outcomes were reported as ICERs, expressed in terms of cost per diagnostic error
avoided and cost per QALY gained. Because using QALYs allows trade-offs between the harms of false
negatives and the harms of false positives, which are treated as equal in a cost per error avoided analysis,
our primary conclusions are drawn from the ICERs expressed as cost per QALY gained. Univariate sensitivity
analyses and PSAs were undertaken to assess the impact of the uncertainty of model input parameters.
Probabilistic sensitivity analysis
A PSA was undertaken to determine the joint uncertainty in the key model input parameters of prevalence,
sensitivity and specificity, and expected QALYs. We undertook the PSA based on an outcome of cost per
QALY only. In the PSA, each model parameter is assigned a distribution, reflecting the amount and pattern
of its variation, and cost-effectiveness results are calculated by simultaneously selecting random values
from each distribution. In total, 2000 sets of parameters were simulated, each of which was run on a
starting cohort of 100,000 individuals. Because of the considerable heterogeneity of the studies included in
our meta-analysis, the results from the PSA, which explicitly includes the impact of that uncertainty, were
considered to provide more plausible estimates of costs and outcomes than our single simulation based on
mean parameter values. Therefore, costs and outcomes used to produce ICERs were calculated as the
means of the costs and outcomes in each of the 2000 PSA simulations. The distributions used in the PSA
are presented in Table 27. We also calculated the probability that each strategy is the most cost-effective
at a willingness to pay of £20,000 per QALY.
Results of the cost-effectiveness modelling
The results of the cost-effectiveness modelling of various strategies for the diagnosis of LTBI in the three
populations, based on the outcomes of cost per diagnostic error avoided and cost per QALY gained,
are presented in the following sections.
Model 1: children
The results from the 250,000 patient simulations, based on the mean value of each parameter, are
presented in Tables 29 and 30. Table 29 shows the mean per patient cost (including both the initial cohort
and subsequent secondary cases) for each of the six strategies as well as a breakdown of the total cost
into diagnosis, LTBI treatment, active TB and hepatitis costs. Table 30 shows the incidence rates of active
TB in the initial cohort, the numbers of secondary infections, mean life-years and mean QALYs for each of
the strategies.
The primary results, based on the 2000 Monte Carlo simulations, are presented in Tables 31 (diagnostic
accuracy) and 32 (QALYs). Considering diagnostic accuracy, the TST (≥ 10mm)-alone strategy dominated the
TST (≥ 5mm) negative followed by QFT-GIT, TST (≥ 5mm), QFT-GIT and TST (≥ 5mm) positive followed by
QFT-GIT strategies. The TST (≥ 10mm) strategy had a mean cost of approximately £272 with a corresponding
diagnostic error of 0.2449 compared with a mean cost of approximately £306 and a diagnostic error of
0.2322 for the T-SPOT.TB-alone strategy. The ICER for T-SPOT.TB compared with TST (≥ 10mm) indicates the
additional cost required to avoid one diagnostic error. The results for the simultaneous testing strategy and
the TST (≥ 10mm) followed by QFT-GIT are not presented because these results were dominated by the
sequential testing strategy and TST (≥ 5mm) followed by QFT-GIT, respectively.
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TABLE 30 Mean QALYs and life-years gained (discounted), incidence of active TB and numbers of
secondary infections
Strategy
Mean QALYs
(discounted)
Mean life-years
(discounted)
Number of active TB
cases (initial cohort)
Number of active TB
cases (secondary)
TST (≥ 5mm) 23.095 27.036 4722 1133
TST (≥ 10mm) 23.090 27.035 5521 1332
QFT-GIT 23.093 27.036 4804 1149
T-SPOT.TB 23.091 27.036 5620 1349
TST (≥ 5mm) positive then
QFT-GIT
23.091 27.036 5653 1367
TST (≥ 5mm) negative then
QFT-GIT
23.097 27.037 4150 996
TABLE 31 Results from the analysis based on cost per diagnostic error avoided (2012/13 prices)
Strategy Mean costa (£)
Incremental
cost (£)
False
positives
False
negatives
Effectiveness
(diagnostic
error)a
Incremental
diagnostic
error ICER (£)
TST (≥ 5mm)
negative followed
by QFT-GIT
361.42 NA 0.5032 0.0040 0.5072 NA Dominated
TST (≥ 5mm) 339.26 –22.16 0.4654 0.0084 0.4740 –0.0332 Dominated
QFT-GIT 324.07 –15.19 0.3790 0.0091 0.3880 –0.0860 Dominated
TST (≥ 5mm)
positive followed
by QFT-GIT
324.12 0.05 0.3040 0.0154 0.3194 –0.0686 Dominated
TST (≥ 10mm) 271.66 –52.46 0.2307 0.0142 0.2449 –0.0745 NA
T-SPOT.TB 306.09 34.43 0.2172 0.0150 0.2322 –0.0127 2711.02
NA, not applicable.
a Results include only the initial test population simulated and not secondary cases as diagnostic accuracy is a relevant
criterion only for those in the initial, tested population.
TABLE 29 Mean costs and cost breakdown based on a single simulation using mean parameter values
(2012/13 prices)
Strategy Mean cost (£)
Mean diagnosis
cost (£)
Mean LTBI
cost (£)
Mean active TB
cost (£)
Mean hepatitis
cost (£)
TST (≥ 5mm) 362.47 58.28 192.57 111.55 0.07
TST (≥ 10mm) 298.42 48.02 119.89 130.42 0.09
QFT-GIT 357.38 83.61 160.22 113.48 0.07
T-SPOT.TB 328.97 80.90 113.21 134.76 0.10
TST (≥ 5mm) positive
then QFT-GIT
360.47 83.16 134.23 142.98 0.10
TST (≥ 5mm) negative
then QFT-GIT
389.24 114.98 196.17 78.03 0.06
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The QALY outcomes of the Monte Carlo simulations showed that the TST (≥ 10mm) diagnostic strategy
alone was the least costly strategy and the TST (≥ 5mm) negative followed by QFT-GIT was the most
effective strategy for the diagnosis of LTBI in this population. The QFT-GIT-alone diagnostic strategy had
a mean cost of £361 with corresponding QALYs of 23.095, whereas the TST (≥ 5mm)-alone strategy had
a mean cost of £371 and 23.096 QALYs. The ICER of £11,255 indicates the additional cost required to
gain an extra QALY. In terms of the joint uncertainty in the expected mean costs and QALYs, the results
show that TST (≥ 5mm) negative followed by QFT-GIT is the most cost-effective strategy at a willingness to
pay of £20,000 per QALY in 32% of the simulations followed by TST (≥ 5mm) (27%) and QFT-GIT (21%).
The results of the univariate sensitivity analyses are presented in Table 33. In each scenario we present
costs and QALYs for each of the three most effective strategies [QFT-GIT, TST (≥ 5mm) and TST (≥ 5mm)
negative followed by QFT-GIT]. We also show which of the three strategies was the most cost-effective
in each scenario, assuming a willingness to pay of £20,000 per QALY. In the majority of scenarios, as in
the base case, the TST (≥ 5mm) negative followed by QFT-GIT strategy was the most cost-effective
strategy. However, decreases in prevalence, the sensitivity of the TST, the effectiveness of LTBI treatment or
the disutility associated with active TB, as well as increases in the sensitivity of QFT-GIT, all led to QFT-GIT
being the most cost-effective option. Conversely, decreases in the sensitivity of QFT-GIT led to the TST
(≥ 5mm) being selected as the most cost-effective option.
Finally, Figure 56 presents CEACs for each of the same three strategies, showing the proportion of
simulations in which each has the highest net benefit at different willingness-to-pay thresholds.
TABLE 32 Results from the analysis based on cost per QALY (2012/13 prices)
Strategy
Mean
costa (£)
Incremental
cost (£)
Mean
QALYsa
Incremental
QALYs ICER (£)
Probability most
cost-effectiveb
TST (≥ 10mm) 300.21 NA 23.088 NA NA 0.032
T-SPOT.TB 332.46 32.25 23.091 0.003 Extendedly
dominated
0.122
TST (≥ 5mm) positive
followed by QFT-GIT
366.45 33.99 23.092 0.001 Dominated 0.045
QFT-GIT 361.03 –5.42 23.095 0.002 8249 (vs. TST
≥ 10mm)
0.210
TST (≥ 5mm) 371.14 10.09 23.096 0.001 11,255 (vs.
QFT-GIT)
0.269
TST (≥ 5mm) negative
followed by QFT-GIT
393.03 21.89 23.097 0.001 18,871 0.322
NA, not applicable.
a Results are for the initial simulated population and any secondary TB cases generated. These values are based on the
mean of the PSA simulations to take into account parameter uncertainty.
b Based on a willingness to pay of £20,000 per QALY; results derived from PSA simulations.
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Model 2: immunocompromised people
The results from our 250,000 patient simulations, based on the mean value of each parameter, are
presented in Tables 34 and 35. Table 34 shows the mean per patient cost (including both the initial cohort
and subsequent secondary cases) for each of the six strategies as well as a breakdown of the total cost
into diagnosis, LTBI treatment, active TB and hepatitis costs. Table 35 shows the incidence rates of active
TB in the initial cohort, the numbers of secondary infections, mean life-years and mean QALYs for each of
the strategies.
The primary results, based on the 2000 Monte Carlo simulations, are presented in Tables 36 (diagnostic
accuracy) and 37 (QALYs). Considering diagnostic accuracy, QFT-GIT dominated the QFT-GIT negative
followed by TST (≥ 5mm), T-SPOT.TB and TST (≥ 5mm) strategies. The TST (≥ 10mm) strategy had a mean
cost of approximately £236 with a corresponding diagnostic error of 0.1641 whereas the QFT-GIT positive
followed by TST (≥ 5mm) strategy had a mean cost of approximately £253 and a diagnostic error of
0.1047. The ICER of £297 per diagnostic error avoided for the QFT-GIT positive followed by TST (≥ 5mm)
strategy compared with the TST (≥ 10mm) strategy shows the additional cost required to avoid a
diagnostic error. We have not presented the results for the simultaneous testing strategies because these
strategies were dominated by the equivalent sequential strategies.
TABLE 34 Mean costs and cost breakdown based on a single simulation using mean parameter values
(2012/13 prices)
Strategy Mean cost (£)
Mean diagnosis
cost (£)
Mean LTBI
cost (£)
Mean active TB
cost (£)
Mean hepatitis
cost (£)
TST (≥ 5mm) 272.79 28.59 127.86 116.00 0.35
TST (≥ 10mm) 266.96 24.35 88.91 153.50 0.20
QFT-GIT 252.93 58.67 97.50 96.52 0.24
T-SPOT.TB 287.83 61.04 134.28 92.10 0.41
QFT-GIT positive then TST
(≥ 5mm)
286.49 67.91 63.95 154.51 0.12
QFT-GIT negative then TST
(≥ 5mm)
315.00 79.99 145.50 89.08 0.43
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FIGURE 56 Cost-effectiveness acceptability curves for the child population, showing the proportion of simulations
in which each strategy is the most cost-effective at different willingness-to-pay thresholds.
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TABLE 35 Mean QALYs and life-years gained (discounted), incidence of active TB and numbers of
secondary infections
Strategy
Mean QALYs
(discounted)
Mean life-years
(discounted)
Number of active TB
cases (initial cohort)
Number of active
TB cases (secondary)
TST (≥ 5mm) 15.527 33.018 4826 1158
TST (≥ 10mm) 15.526 33.017 5228 1251
QFT-GIT 15.532 33.018 4086 987
T-SPOT.TB 15.532 33.018 3772 902
QFT-GIT positive then TST
(≥ 5mm)
15.526 33.017 5271 1254
QFT-GIT negative then TST
(≥ 5mm)
15.534 33.018 3671 886
TABLE 36 Results from the analysis based on cost per diagnostic error avoided (2012/13 prices)
Strategy
Mean
costa (£)
Incremental
cost (£)
False
positives
False
negatives
Effectiveness
(diagnostic
error)a
Incremental
diagnostic
error ICER (£)
QFT-GIT
negative then
TST (≥ 5mm)
287.77 NA 0.3100 0.0066 0.3166 NA Dominated
T-SPOT.TB 252.01 –35.76 0.3080 0.0072 0.3152 –0.0018 Dominated
TST (≥ 5mm) 249.33 –2.68 0.2371 0.0155 0.2526 –0.0626 Dominated
QFT-GIT 234.41 –14.92 0.1734 0.0084 0.1814 –0.0712 NA
TST (≥ 10mm) 236.11 1.70 0.1474 0.0167 0.1641 –0.0173 98.27
(vs. QFT-GIT)
QFT-GIT
positive then
TST (≥ 5mm)
253.77 17.66 0.0876 0.0171 0.1047 –0.0594 297.31
(vs. TST ≥ 10mm)
NA, not applicable.
a Results include only the initial test population simulated and not secondary cases as diagnostic accuracy is a relevant
criterion only for people in the initial, tested population.
TABLE 37 Results from the analysis based on cost per QALY (2012/13 prices)
Strategy
Mean
costa (£)
Incremental
cost (£)
Mean
QALYsa
Incremental
QALYs ICER (£)
Probability most
cost-effectiveb
TST (≥ 10mm) 269.42 NA 15.516 NA Dominated 0.046
QFT-GIT positive then
TST (≥ 5mm)
289.31 19.89 15.516 0.000 Dominated 0.052
TST (≥ 5mm) 276.01 –13.30 15.517 0.001 Dominated 0.067
QFT-GIT 258.61 –17.40 15.523 0.006 NA 0.187
T-SPOT.TB 280.90 12.29 15.524 0.001 10,402.63
(vs. QFT-GIT)
0.249
QFT-GIT negative then
TST (≥ 5mm)
318.26 37.36 15.526 0.002 18,746.01
(vs. T-SPOT.TB)
0.399
NA, not applicable.
a Results are for the initial simulated population and any secondary TB cases generated. These values are based on the
mean of the PSA simulations to take into account parameter uncertainty.
b Based on a willingness to pay of £20,000 per QALY; results derived from PSA simulations.
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The QALY outcomes of our Monte Carlo simulations showed that TST (≥ 10mm), QFT-GIT positive
followed by TST (≥ 5mm) and TST (≥ 5mm) were dominated by the QFT-GIT-alone strategy, which had a
mean cost of £259 with corresponding QALYs of 15.523. The ICER reported for the T-SPOT.TB-alone
strategy shows the additional cost required to gain 1 extra QALY compared with the QFT-GIT strategy.
At a willingness to pay of £20,000 per QALY, the QFT-GIT negative followed by TST (≥ 5mm) had the
highest net benefit in the largest proportion of simulations (40%), followed by the T-SPOT.TB (25%) and
QFT-GIT-alone (19%) strategies. All other strategies had the largest net benefit in < 7% of the simulations.
The results of the univariate sensitivity analyses are presented in Table 38. In each scenario we present
costs and QALYs for each of the three strategies that were not strictly dominated by another strategy in
the primary results. We also show which of the three strategies was the most cost-effective in each
scenario, assuming a willingness to pay of £20,000 per QALY. In the scenarios in which the importance of
test sensitivity was equal to or higher than that in the base case, the QFT-GIT negative followed by TST
(≥ 5mm) strategy was consistently the most cost-effective strategy at a willingness to pay of £20,000 per
QALY. In the scenarios in which the relative importance of test specificity was increased (by decreasing
LTBI prevalence, decreasing the effectiveness of LTBI treatment, increasing the cost of LTBI treatment,
decreasing the cost of active TB or ignoring the impact of secondary TB cases), QFT-GIT often became the
most cost-effective strategy.
Finally, Figure 57 presents CEACs for each of the three non-dominated treatment strategies, showing the
proportion of simulations in which each has the highest net benefit at different willingness-to-pay thresholds.
Model 3: recent arrivals from countries with a high incidence of tuberculosis
The results from our 250,000 patient simulations, based on the mean value of each parameter, are
presented in Tables 39 and 40. Table 39 shows the mean per patient cost (including both the initial cohort
and subsequent secondary cases) for each of the six strategies as well as a breakdown of the total cost
into diagnosis, LTBI treatment, active TB and hepatitis costs. Table 40 shows the incidence rates of active
TB in the initial cohort, the numbers of secondary infections, mean life-years and mean QALYs for each of
the strategies.
The primary results, based on the 2000 Monte Carlo simulations, are presented in Tables 41 (diagnostic
accuracy) and 42 (QALYs). Considering diagnostic accuracy, the QFT-GIT-alone strategy was the least costly
strategy and the TST (≥ 5mm) positive followed by QFT-GIT strategy was the most effective. The QFT-GIT
strategy had a mean cost of approximately £266 with a corresponding diagnostic error of 0.2113, whereas
the TST (≥ 5mm) positive followed by QFT-GIT strategy had a mean cost of approximately £277 and a
diagnostic error of 0.1955. The ICER for the TST (≥ 5mm) positive followed by QFT-GIT strategy compared
with the QFT-GIT-alone strategy shows an additional cost of £692 to avoid one diagnostic error. We have
not presented the results for the simultaneous testing strategies because these strategies were dominated
by the equivalent sequential strategies.
The QALY outcomes of our Monte Carlo simulations showed that the QFT-GIT strategy dominated the TST
(≥ 5mm) positive followed by QFT-GIT and T-SPOT.TB strategies. TST (≥ 5mm) had a mean cost of £299
with corresponding QALYs of 19.922. TST (≥ 5mm) negative followed by QFT-GIT was more expensive
than the TST (≥ 5mm) strategy, with corresponding QALYs of 19.923 and an ICER of £58,720 compared
with TST (≥ 5mm). At a willingness to pay of £20,000 per QALY, the TST (≥ 5mm) strategy had the
highest net benefit in the largest proportion of simulation (47%) followed by the TST (≥ 5mm) negative
then QFT-GIT strategy (28%) and the QFT-GIT-alone strategy (18%). All other strategies had the largest
net benefit in < 5% of the simulations.
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FIGURE 57 Cost-effectiveness acceptability curves for the immunocompromised population, showing the proportion
of simulations in which each strategy is the most cost-effective at different willingness-to-pay thresholds.
TABLE 39 Mean costs and cost breakdown based on a single simulation using mean parameter values
(2012/13 prices)
Strategy Mean cost (£)
Mean diagnosis
cost (£)
Mean LTBI
cost (£)
Mean active TB
cost (£)
Mean hepatitis
cost (£)
TST (≥ 5mm) 310.00 34.19 203.04 72.09 0.68
QFT-GIT 295.11 57.72 114.42 122.50 0.47
T-SPOT.TB 432.95 77.45 259.89 94.74 0.86
TST (≥ 5mm) positive
then QFT-GIT
310.83 78.88 101.04 130.07 0.84
TST (≥ 5mm) negative
then QFT-GIT
363.64 74.15 219.87 68.91 0.72
TABLE 40 Mean QALYs and life-years gained (discounted), incidence of active TB and number of
secondary infections
Strategy
Mean QALYs
(discounted)
Mean life-years
(discounted)
Number of active TB
cases (initial cohort)
Number of active TB
cases (secondary)
TST (≥ 5mm) 19.929 24.160 2883 705
QFT-GIT 19.924 24.158 4329 1041
T-SPOT.TB 19.922 24.158 4289 998
TST (≥ 5mm) positive
then QFT-GIT
19.915 24.157 4522 1091
TST (≥ 5mm) negative
then QFT-GIT
19.931 24.160 2756 660
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The results of the univariate sensitivity analyses are presented in Table 43. In each scenario we present
costs and QALYs for the three strategies that were not strictly dominated by another strategy in the
primary results. We also show which of the three strategies was the most cost-effective in each scenario,
assuming a willingness to pay of £20,000 per QALY. In the majority of scenarios, as in our base case, the
TST (≥ 5mm)-alone strategy was the most cost-effective strategy. However, a decrease in the prevalence of
LTBI, increase in the sensitivity of QFT-GIT and decrease in the sensitivity of the TST all led to strategies
involving QFT-GIT becoming the most cost-effective.
Finally, Figure 58 presents CEACs for each of the three non-dominated treatment strategies, showing the
proportion of simulations in which each has the highest net benefit at different willingness-to-pay thresholds.
TABLE 41 Results from the analysis based on cost per diagnostic error avoided (2012/13 prices)
Strategy
Mean
costa (£)
Incremental
cost (£)
False
positives
False
negatives
Effectiveness
(diagnostic
error)a
Incremental
diagnostic
error ICER (£)
T-SPOT.TB 374.60 NA 0.5669 0.0071 0.5740 NA Dominated
TST (≥ 5mm)
negative then
QFT-GIT
325.81 –48.79 0.4680 0.0016 0.4696 –0.1044 Dominated
TST (≥ 5mm) 277.46 –48.35 0.4566 0.0025 0.4391 –0.0305 Dominated
QFT-GIT 265.87 –11.59 0.2015 0.0098 0.2113 –0.2278 NA
TST (≥ 5mm)
positive then
QFT-GIT
276.80 10.93 0.1846 0.0109 0.1955 –0.0158 691.77
NA, not applicable.
a Results include only the initial test population simulated and not secondary cases as diagnostic accuracy is a relevant
criterion only for people in the initial, tested population.
TABLE 42 Results from the analysis based on cost per QALY (2012/13 prices)
Strategy
Mean
costa (£)
Incremental
cost (£)
Mean
QALYsa
Incremental
QALYs ICER (£)
Probability most
cost-effectiveb
TST (≥ 5mm) positive
then QFT-GIT
300.10 NA 19.909 NA Dominated 0.032
T-SPOT.TB 400.12 100.02 19.915 0.006 Dominated 0.042
QFT-GIT 291.13 –108.99 19.917 0.002 NA 0.177
TST (≥ 5mm) 298.75 7.62 19.922 0.005 1524
(vs. QFT-GIT)
0.469
TST (≥ 5mm) negative
then QFT-GIT
353.47 54.72 19.923 0.001 58,720
(vs. TST ≥ 5mm)
0.280
NA, not applicable.
a Results are for the initial simulated population and any secondary TB cases generated. These values are based on the
mean of the PSA simulations to take into account parameter uncertainty.
b Based on a willingness to pay of £20,000 per QALY; results derived from PSA simulations.
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Exploring sensitivity and specificity
Clearly, key drivers of differences between the models are sensitivity and specificity. To illustrate the impact
that these parameters have on the outputs of our models, Figure 59 shows graphs of sensitivity and
specificity plotted against costs, QALYs and net monetary benefit (at £20,000 per QALY) for each of the six
strategies that were simulated in the child population.
These graphs show, at first sight, the counterintuitive result that increased specificity is associated with
lower QALYs and lower net monetary benefit whereas higher sensitivity is associated with higher costs.
This is because of the high levels of correlation between sensitivity and specificity (specifically, higher
sensitivity is associated with lower specificity) in the strategies that were simulated. Therefore, both sets of
graphs are in fact showing the same result, namely that, as sensitivity increases and specificity decreases,
this leads to higher QALYs, higher costs and, on balance, a higher net monetary benefit.
To try and remove the effect of this sensitivity/specificity correlation, instead of using the different
strategies we used the outputs of the PSA simulations for one of these strategies. This gave us 2000
realisations of sensitivity, specificity, costs and QALYs and, as each of these sensitivity/specificity pairs was a
sample from the posterior distribution of our MCMC, we would expect lower correlations between
sensitivity and specificity than when comparing between different strategies. We then ran a linear
regression model for costs and QALYs, with sensitivity and specificity as the predictor variables. The results
of this regression model are shown in Table 44.
In this model, in which we jointly estimated the impact of both sensitivity and specificity on outcomes, the
results are much more intuitive. Increases in both sensitivity and specificity lead to increases in QALYs and
decreases in costs, with increases in sensitivity providing the largest QALY gains and increases in specificity
the largest cost reductions. It should be noted that the output data from the PSA simulation very likely do
not conform to the necessary assumptions (linearity, additivity, etc.) for linear regression and the models
contain a lot of noise because of the impact of varying other parameters and so the actual values of these
parameters should be treated with extreme caution. Nevertheless, they do give an indicative picture of
what the key drivers of difference between the models are.
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FIGURE 58 Cost-effectiveness acceptability curves for the recently arrived population, showing the proportion of
simulations in which each strategy is the most cost-effective at different willingness-to-pay thresholds.
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FIGURE 59 Sensitivity and specificity plotted against costs, QALYs and net monetary benefit (NMB) (at £20,000 per
QALY) for each of the six strategies in the child population. (a) Sensitivity against QALYs; (b) specificity against
QALYs; (c) sensitivity against costs; (d) specificity against costs; (e) sensitivity against NMB; and (f) specificity against
NMB. NMB, net monetary benefit.
TABLE 44 Results of the linear regression model
Parameter Costs (£) QALYs
Intercept 578.72 23.080
Sensitivity –0.99 0.00015
Specificity –2.60 0.00001
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Discussion and conclusion
The results based on the outcome of cost per diagnostic error avoided showed that, in the child
population, the TST (≥ 10mm) strategy dominated all strategies except for the T-SPOT.TB strategy alone.
T-SPOT.TB compared with TST (≥ 10mm) was more effective but more expensive, with an ICER of
approximately £2711 per diagnostic error avoided. A breakdown of effectiveness showed that the
T-SPOT.TB strategy resulted in fewer false-positive cases (0.2172) than the TST (≥ 10mm) strategy
(0.2307), but a larger number of false-negative cases (0.0150 vs. 0.0142). If the T-SPOT.TB strategy were
to be used in this population to diagnose LTBI that progresses to active TB, this would lead to a slight
reduction in the number of children being overtreated for LTBI. In the immunocompromised population,
QFT-GIT dominated QFT-GIT negative followed by TST, T-SPOT.TB and TST (≥ 5mm) in terms of diagnostic
errors avoided. The results showed that QFT-GIT resulted in fewer false positives and fewer false negatives
than the other strategies. The use of TST (≥ 10mm) in this population was more effective, with overall
diagnostic errors avoided of 0.1641. A breakdown of this effectiveness showed that TST (≥ 10mm)
resulted in fewer false-positive but more false-negative results. Likewise, the combination strategy QFT-GIT
positive followed by TST (≥ 5mm) produced fewer false-positive results but more false-negative results.
In the population of recent arrivals from countries with a high incidence of TB, QFT-GIT dominated the
T-SPOT.TB, TST (≥ 5mm) negative followed by QFT-GIT and TST (≥ 5mm) strategies. TST (≥ 5mm) positive
followed by QFT-GIT had an ICER of £692 per diagnostic error avoided compared with QFT-GIT, with more
false negatives and fewer false positives.
The cost per QALY outcomes are summarised in terms of the probability of each strategy being the most
cost-effective (at a given threshold). We used a willingness-to-pay threshold of £20,000 per QALY, a
standard threshold that is used in the UK. The results in the child population showed that TST (≥ 5mm) is
marginally more effective than the QFT-GIT-alone strategy, with an ICER of approximately £11,255 per
QALY, and has a 27% probability of being the most cost-effective strategy at a willingness to pay of
£20,000 per QALY. The most effective strategy was TST (≥ 5mm) negative followed by QFT-GIT, which
was the most cost-effective strategy in 32% of the simulations. The results in the immunocompromised
population showed that QFT-GIT negative followed by TST (≥ 5mm) was the most effective strategy, with
an ICER of approximately £18,746 compared with T-SPOT.TB, and is the most cost-effective strategy in
40% of the simulations. In the population of recent arrivals, TST (≥ 5mm) dominated the TST (≥ 5mm)
positive followed by QFT-GIT, T-SPOT.TB and QFT-GIT strategies, and had a probability of 47% of being
cost-effective at a willingness to pay of £20,000 per QALY.
Based on the current clinical evidence on people with LTBI without treatment that progressed to active TB
as well as expert opinion used to develop the model structures, the results demonstrate that TST (≥ 5mm)
was slightly more cost-effective than QFT-GIT in the child population. In the immunocompromised
population the results based on cost per QALY showed that QFT-GIT negative followed by TST (≥ 5mm)
was the most cost-effective strategy. In the recent arrivals population the results based on cost per QALY
showed that TST (≥ 5mm) dominated the TST (≥ 5mm) positive followed by QFT-GIT, T-SPOT.TB and
QFT-GIT-alone strategies.
HEALTH ECONOMICS METHODS AND RESULTS
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Chapter 7 Discussion
The purpose of the current review was to compare the clinical effectiveness and cost-effectiveness ofnew screening tests for LTBI (IGRAs vs. TST) in children, people who are immunocompromised or at risk
from immunosuppression and recent arrivals from countries with a high incidence of TB. We aimed to
address the following questions:
1. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying LTBI
in children?
2. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying LTBI in
people who are immunocompromised or at risk of immunosuppression?
3. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying LTBI in
people who are recent arrivals from countries with a high incidence of TB?
In this chapter, the principal findings of the clinical effectiveness and cost-effectiveness reviews and
economic evaluation are interpreted alongside an assessment of the strengths and limitations of the review
and the individual studies. Areas of uncertainty, implications for further research and implications for
practice are highlighted.
Main findings
Clinical effectiveness review
There is no gold standard for the accurate diagnosis of LTBI. The existing screening tests for LTBI (IGRAs
and TST) provide indirect assessment of the presence of LTBI by relying on a host’s immunological response
to TB antigens. The evaluation of the comparative effectiveness of IGRAs and TST in accurately identifying
LTBI has been a challenging task because of the absence of a gold standard for direct estimation of the
screening tests’ accuracy indices (i.e. sensitivity and specificity) and the tests’ own limitations.11–13,16,27,56,57
To address this issue, many studies have tried to estimate and compare the measures of association
between the test results (i.e. TST and/or IGRAs) and constructs of validity for LTBI (e.g. duration/proximity
of exposure to a person with active TB, risk of development of active TB).11,18,58,60
This review identified and appraised a large amount of evidence (53 new studies since CG11710 and
37 studies from CG11710) comparing IGRAs with TST for identifying LTBI in children, immunocompromised
people and recently arrived immigrants from countries with a high TB incidence. Overall, the limited evidence
from prospective studies in children showed no significant difference in the performance of QFT-GIT and TST
5mm in predicting LTBI. However, QFT-GIT was significantly better than TST 10mm in predicting LTBI. In
children, IGRAs (QFT-GIT/G) demonstrated similar sensitivity to and slightly better specificity than those of TST
5mm. Moreover, IGRAs tended to have a greater sensitivity but lower specificity than those of TST 10mm/
15mm. As the predictive value of a test is a function of its sensitivity, the greater predictive ability of IGRAs
than of TST 10mm in predicting LTBI (as a proxy for developing active TB) could be explained by the better
sensitivity of the former. Based on the exposure studies in children, IGRAs outperformed the TST in
identifying LTBI in the setting of low TB burden but not in the setting of high TB burden. This finding is
consistent with a growing body of evidence showing reduced sensitivity and specificity of IGRAs in high
compared with low TB burden areas, the former represented mostly by developing countries where BCG
vaccination is given at birth.44,59,219–221 This heterogeneity in test performance could be explained by a
higher frequency of exposure to MTB, different transmission dynamics, malnutrition, comorbidity, people
coinfected with HIV, exposure to NTMs and helminthic infection in high TB burden settings.105,220,221
Moreover, in high TB burden settings (mostly developing countries), the specificity of the TST is not greatly
reduced because BCG vaccination is given mostly at birth without repeating it. In contrast, in some low TB
burden settings (e.g. developed countries), BCG vaccination with booster shots may be offered after infancy,
which is known to compromise TST specificity.220
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Evidence comparing IGRAs with TST in predicting the incidence of active TB in immunocompromised
people was insufficient and inconclusive. The forest plot of 21 exposure-based studies showed a large
variation in the performance of IGRAs compared with the TST across different clinical subgroups. In
general, QFT-GIT and T-SPOT.TB performed better than TST 5mm/10mm in identifying LTBI among people
undergoing haemodialysis and in those with hepatitis C. In contrast, in patients with HIV/AIDS, QFT-GIT
was significantly worse than TST 10mm at identifying LTBI. One explanation of this finding could be
the reduced sensitivity of IGRA to detect LTBI because of CD4+ T-lymphocyte depletion in those with
HIV-induced immunosuppression, leading to a high proportion of indeterminate IGRA results. Interestingly,
it is not clear whether or not QFT-GIT and TST are differentially affected by CD4 depletion.40,220,222,223
Evidence on the comparative performance of IGRAs and TST in people with lupus erythematosus, those
with immune-mediated inflammatory diseases before antiTNF-α therapy, solid organ transplantation
candidates and kidney transplant recipients was inconclusive because of the high level of uncertainty
around the statistically non-significant effect estimates. The agreement between IGRAs and the TST in
immunocompromised people was low.
There was no significant difference in the performance of the IGRAs and TST in identifying LTBI among
recently arrived people from countries with a high TB burden. QFT-GIT demonstrated greater specificity but
lower sensitivity than the TST. Similarly, there was no evidence indicating a differential effect of BCG
vaccination on IGRA (QFT, T-SPOT.TB) and TST positivity. Limited evidence indicated that both concordance
and kappa were greater among BCG-unvaccinated people (or among people who have/have not been
vaccinated) than among BCG-vaccinated people.
In general, the degree of agreement (measured by the kappa statistic) between the IGRAs and the TST
across the three subgroups of children, immunocompromised people and those recently arrived from high
TB burden areas was low. Several studies indicated better between-test (IGRAs vs. TST) concordance and
agreement in unvaccinated than in BCG-vaccinated people. The higher rates of discordance between the
IGRAs and the TST in BCG-vaccinated populations could be explained by the TST having reduced specificity
(i.e. a higher false-positive rate) because of its cross-reactivity with antigens that are common to both MTB
and the BCG vaccine.219 Overall, there was no clear and convincing evidence indicating a differential
effect of BCG vaccination on IGRA and TST positivity. The evidence, if reported, was conflicting and
inconclusive, with most studies indicating non-significant differences in the odds of test positivity (with
great uncertainties) for the IGRAs and TST between BCG-vaccinated and BCG non-vaccinated people.
Cost-effectiveness review
Ten studies10,77,196–203 reported evidence on decision-analytical models to determine the cost-effectiveness
of IGRAs compared with TST for the diagnosis of LTBI in the three populations of interest. The majority of
these models were in the immunocompromised population. These results highlight that there is a paucity
of evidence available for children and recently arrived populations. The majority of the models used
decision tree structures with Markov nodes to simulate a cohort of people being tested for LTBI.
We appraised these models against frameworks for best practice for reporting model-based economic
evaluations. All performed well in terms of defining the decision problem, including the study perspective,
outlining the choice of comparators, presenting an illustrative model structure and providing a clear outline
of the assumptions. These models all add insight to the existing literature but were subject to some
limitations. First, the majority of the studies stated the location of the study but not the setting of the
analysis and this may limit the generalisability of the results. Second, the majority of the studies used
QALYs as the outcome measure but did not elaborate on the descriptive tool used to value health states.
Third, the perspective of the analysis was stated in all studies but the resource use and costs reported did
not reflect the viewpoint of the analysis in some studies. Finally, all models explored uncertainty around
key model input parameters but no attempt was made to explore methodological, generalisability or
structural uncertainty. Other concerns relate to the derivation of prevalence, test accuracy and transition
probabilities; most studies did not elaborate on these statistical/pre-model analyses.
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Economic evaluation
In the child population, the TST negative followed by QFT-GIT strategy had the lowest proportion of
false-negative results and the T-SPOT.TB strategy had the lowest proportions of false-positive results and
overall errors. TST (≥ 10mm) was the strategy with the lowest overall cost whereas TST (≥ 5mm) negative
followed by QFT-GIT produced the highest QALYs, was the most cost-effective at a willingness to pay of
£20,000 per QALY and had the highest probability of being the most cost-effective strategy.
In the immunocompromised population, the QFT-GIT negative followed by TST (≥ 5mm) strategy had the
lowest proportion of false-negative results and the QFT-GIT positive followed by TST (≥ 5mm) strategy had
the lowest proportions of false-positive results and overall errors. QFT-GIT was the strategy with the lowest
overall cost whereas the QFT-GIT negative followed by TST (≥ 5mm) strategy produced the highest QALYs,
was the most cost-effective at a willingness to pay of £20,000 per QALY and had the highest probability
of being the most cost-effective strategy.
In the recently arrived population, the TST (≥ 5mm) negative followed by QFT-GIT strategy had the lowest
proportion of false-negative results and the TST (≥ 5mm) positive followed by QFT-GIT strategy had the
lowest proportions of false-positive results and overall errors. QFT-GIT was the strategy with the lowest
overall cost, the TST (≥ 5mm) negative followed by QFT-GIT strategy produced the highest QALYs and the
TST (≥ 5mm) strategy was the most cost-effective at a willingness to pay of £20,000 per QALY and had
the highest probability of being the most cost-effective strategy.
Current findings compared with those from other
systematic reviews
In general, our findings agreed with those from three other systematic reviews59,91,221 in showing that
IGRAs have improved specificity and a greater ability to predict LTBI relative to the TST in the setting of low
(but not high) TB burden in children. All three previous reviews also highlight the lack or insufficient
amount of evidence and heterogeneity in estimates, methodology and clinical characteristics across the
studies that were reviewed.
The findings of this review could not be directly compared with those of several previously published systematic
reviews for the following reasons: (1) our review results were stratified by children, immunocompromised
people and those recently arrived from high TB burden countries, whereas other reviews18,44,57,58,219,224 did not
analyse these three populations; (2) unlike other studies40,219,222 we did not use prevalent culture-positive
active TB as a proxy for LTBI; (3) one review224 included in-house IGRAs, which we did not; (4) one review222
compared QFT-GIT with T-SPOT.TB only; and (5) two reviews225,226 reported no relevant outcomes.
Current results compared with those from other
cost-effectiveness studies
When comparing our model with others from the literature, it is important to note that our definitions of
sensitivity and specificity are not the same as those used in most studies. In the absence of a gold standard
we have used LTBI that progresses to active TB, rather than any LTBI, as in previously published papers,
and hence the numbers derived for sensitivity and specificity are not comparable. In addition, most of the
previously published papers did not include sequential testing as a possible strategy and so we have to
restrict our comparisons to the results for the TST- and IGRA-alone strategies only.
In the immunocompromised population, previous studies196,198,200,202 indicated that, when using a single
test, IGRAs were preferable to TST, a conclusion that our results concur with. In the child population our
results agree with those of Mandalakas et al.203 in that the TST (≥ 5mm) negative followed by IGRA
strategy was the most effective; however, they disagree with those of Kowada197 who found QFT-GIT to be
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
213
more cost-effective than the TST, the opposite of our conclusion. Finally, in the recently arrived population,
Pareek et al.77 found QFT-GIT to be more cost-effective than the TST whereas we found the reverse,
with the TST (≥ 5mm) strategy being the most cost-effective strategy.
The reasons for these differences, other than those that always apply (different populations modelled,
different parameter values used, etc.), can be found in the different underlying structures of the models.
First, Kowada197 considered only primary cases of TB and not secondary infections. From our univariate
sensitivity analyses in the child population we see that, when we set our secondary infection rate to zero,
we also find the QFT-GIT strategy to be the most cost-effective strategy. When comparing IGRAs with the
TST in the recently arrived population, Pareek et al.77 used indurations of 10mm and 6/15mm (stratified by
BCG status). Our results for the recently arrived population are based on an induration of 5mm, a value
not modelled in the Pareek et al.77 study, and therefore differences in conclusions may be explained by
these different thresholds used.
It is important to note that our model is designed to evaluate only which is the most cost-effective
diganostic strategy, conditional on a decision having been made to test. It does not say anything about
whether or not testing itself, compared with no testing, is cost-effective and should be undertaken in
these populations. Research addressing this question (testing/no testing) has recently been published.210
This model and our model were built to address fundamentally different questions, in different
populations, and hence the results obtained from them cannot be directly compared. In particular, the
inclusion criteria for studies in the two reviews were entirely different (our criteria included only studies on
TSTs vs. IGRAs whereas their criteria included only studies on treatment vs. no treatment) and hence
papers included in one review will have been specifically excluded from the other.
Considering parameter inputs to the models, identical parameter values were used for the effectiveness of
LTBI treatment and case fatality rates for active TB, with very similar values used for the costs of active TB,
differing by only 2%. The costs of managing hepatitis differed more substantially (by around £200), but as
isoniazid-induced hepatitis contributed only a small fraction to the costs in our model this is unlikely to
make a major impact. As progression to active TB was calculated using different methods in the two
models, it is not possible to compare the input parameters directly. However, by restricting the comparison
to a subsample of the full population that can be extracted from both models, we can compare the
number of active TB cases that each predicts. In particular, for a sample of patients aged 51–65 years with
a positive TST result, the White and Jit210 model predicts 2091 active TB cases per 100,000 in treated
patients and 5928 active TB cases per 100,000 untreated patients. Our model, in contrast, predicts 1736
cases per 100,000 treated patients and 5372 cases per 100,000 untreated patients. These differences are
most likely explained simply by the different data used to populate the two models. However, if the
incidence rate used in the White and Jit210 study is believed to be more accurate, this would have the
effect of increasing the prevalance of LTBI in our starting population, the net effect of which can be
explored from our univariate sensitivity analyses.
Strengths and limitations of the evidence
The assessment, comparison and interpretation of the clinical effectiveness of the existing tests in
identifying LTBI is hampered by the absence of a gold standard for diagnosing LTBI. The evidence relied
mostly on indirect measures of association derived between the test results (i.e. TST and/or IGRAs) and
constructs of validity for LTBI (e.g. duration/proximity of exposure to a person with active TB, risk of
development of active TB). Moreover, the existing commercially available screening tests for LTBI are
imperfect in that they measure a host’s immunological response to TB antigens, which may be affected by
a number of factors other than LTBI and which differ from study to study (such as previous BCG
vaccination, inter-/intrarater variability in interpretation of test results, boosting, conversion, reversion,
different cut-offs for test positivity, assay manufacturing, pre-analytical processing and/or incubation delay).
Thus, the findings of this review warrant a cautious interpretation.
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Although we appraised and summarised a large amount of evidence, much of it was inconclusive because
of unexplained heterogeneity in the effect estimates, poor reporting, missing data and great uncertainty
around the effect estimates for the association between test results and the constructs of validity for LTBI.
One of the difficulties in the assessment and interpretation of test performance (IGRAs vs. TST) in correctly
detecting LTBI is the inconsistent use of definitions for high compared with low risk for LTBI (i.e. construct
of validity). The heterogeneity in the measures of association between test results and previous exposure to
TB observed even at within-study level could be the result of inadequate definition of the construct of
validity for LTBI (e.g. previous exposure definition may not represent the true presence of LTBI), exposure
misclassification (e.g. not all people exposed to a TB case will become infected) or both. Furthermore,
some but not all of the observed heterogeneity in the parameters of test performance (e.g. sensitivity,
specificity, DORs, between-test agreement) could be explained by study setting, type of population, type of
test and the outcome characteristics. Some heterogeneity, especially with regard to the sensitivity and
specificity estimates derived from previous TB exposure-based categories, could not be explained, thereby
rendering some of our findings inconclusive. These factors were compounded by the scarcity of evidence in
analyses stratified by population, type of IGRA test and TST threshold.
Another concern in interpreting the evidence relates to the ROB and methodological quality of the
individual studies. In general, most studies were rated as being at high or moderate ROB (incidence
studies) or of low methodological quality (exposure studies). Apart from the issues highlighted above,
various sources of bias may have independently distorted the review findings and their interpretation.
For example, results from the studies that we reviewed may have been biased because of diagnostic review
bias (i.e. lack of blinding or knowledge of the IGRA/TST results influencing the ascertainment of exposure
status or diagnosis of incident active TB), selection bias (i.e. study sample distorted with respect to previous
TB exposure or disease spectrum because of an inadequate sampling frame, inadequate participant
recruitment, non-participation and exclusions at study baseline), partial verification bias (i.e. incomplete
outcome data assessment because of indeterminate IGRA results, missing TB exposure data, withdrawals
and/or losses to follow-up) and incorporation bias (i.e. incorporation of IGRA/TST results as a criterion for
the diagnosis of LTBI or incident active TB).18,44,90,227
Although the results from the incidence studies merit more credibility given their prospective design and
standard and uniform ascertainment of the outcome (i.e. diagnosis of incident active TB), this evidence was
scarce, the studies included small sample sizes and their follow-up was not long enough to document and
evaluate the predictive ability of the tests more reliably. Moreover, the use of incident case of active TB as
the validity construct for the presence of LTBI may also lead to misclassification as not all LTBI cases will
develop into active TB or some seemingly incident cases of active TB (assumed to have developed from
LTBI) may actually be people with newly acquired TB infection (prevalent active TB cases).
One of the limitations of this review was that we excluded non-English-language publications, which
might have led to language-related bias in the estimates. However, none of the six excluded studies
(see Appendix 6) (two in Turkish, two in Chinese, one in Spanish and one in Persian) would have been
eligible for inclusion in the clinical part of this review as three included mixed samples not stratified by the
subgroups of interest, one was a cost-effectiveness study and two did not use the LTBI constructs, such
as previous exposure group or incidence of progression to active TB. Therefore, we believe that these
language-based exclusions would not have had any impact on our findings.
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Strengths and limitations of the current reviews and
economic evaluation
We undertook a systematic review to identify all relevant studies providing evidence on the clinical
effectiveness of IGRAs compared with the TST for identifying LTBI in the prespecified populations.
The main strengths of this review were the application of systematic comprehensive searches, study
screening, data extraction, use of relevant quality/ROB assessment tools for different study designs and the
stratified analyses (by children, immunocompromised people and those recently arrived from high TB
burden countries, subgroups defined by clinical condition, type of IGRA, TST threshold, high vs. low TB
burden area and study setting). Our review, unlike other systematic reviews,40,219,222 avoided including
studies that used invalid constructs for LTBI, such as culture-confirmed active TB. Instead, this review
focused on studies that defined the construct of LTBI either through the incidence of active TB or through
study participants’ previous exposure to index TB cases (e.g. risk categories defined by exposure proximity,
duration and/or relationship to index TB case).
Our economic evaluation analyses are based on test accuracy data obtained from the current clinical
effectiveness review, which represents the best available information on the accuracy of tests for LTBI that
progresses to active TB. Our analyses represent the work of a multidisciplinary team, which includes input
from clinical experts to develop the model structure. Additionally, considerable efforts were made to
identify the most appropriate model input parameters to be used in the decision-analytic model.
The main limitation of the clinical effectiveness review is that full additional data extraction and quality
assessment were not undertaken for studies included in CG117.10 Moreover, because of a lack of relevant
reported evidence, it was not possible to evaluate the effectiveness of the two-step testing procedure
(using both IGRAs and TST) for identifying people with LTBI. Another limitation was our inability to stratify
the study findings by BCG vaccination status; the individual study publications failed to report their
results separately for vaccinated and non-vaccinated populations; even though this may have been an
important distinguishing feature in the effectiveness of the different tests. The proportions of people
vaccinated with BCG varied considerably in the included studies such that it was not possible to
dichotomise populations into, for example, vaccinated and non-vaccinated. In any case, further
stratification by BCG status was not feasible because of the scarcity of the data. With regard to the
economic evaluation, we applied a unit cost for people being tested with the TST. The unit cost included
the costs of the test consumables, administering the test and reading the result. We applied this cost both
to people who had their TST result read and to those who did not have their result read. This had the
effect of inflating the cost of an unread TST result. In addition, the model took into account the need for
two clinic visits for the TST; however, it did not take into account the need for skilled operators and the
wide intraobserver variability in interpretation. IGRAs require one visit, need fewer skilled personnel for
interpretation and have less reliance on observer interpretation. Second, to our knowledge there are no
systematic reviews on the accuracy of chest radiography for identifying people who have active TB. In our
model we used the sensitivity and specificity from the study by Kumar et al.208 for the accuracy of chest
radiography for identifying the presence/absence of active TB in our three populations. This may over/
underestimate the diagnostic accuracy of chest radiography in these populations. Third, detailed resource
use information with regard to treatment for LTBI was unavailable in the literature. We therefore estimated
resource use for LTBI treatment using input from our clinical advisors and this may have resulted in either
over- or underestimation of resource use.
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Chapter 8 Conclusion
The review draws attention to the clinical effectiveness evidence published since CG117.10 The researchadds to the existing literature but highlights the poor quality of the evidence. Surprisingly, the results
show that the two different generations of tests are broadly equivalent, although the results vary in a
number of different settings and subgroups. The limitations in the evidence (e.g. absence of a gold
standard for LTBI diagnosis, ROB in individual studies, scarcity of evidence, test administration/
interpretation, variation in the exposure-based definitions of the LTBI construct, limitations of the screening
tests) and heterogeneity in IGRA performance relative to TST performance limit the applicability of the
review findings. Generally, the findings from population-based setting studies conducted in countries of
low TB burden would be more applicable to the UK’s routine general practice of LTBI screening. The
findings of this review underscore the variability of test performance across clinical conditions within the
immunocompromised population, thereby limiting the applicability of test results from one subgroup
(e.g. those with HIV infection or rheumatoid arthritis) to another (e.g. those with hepatitis C or
lupus erythematosus).
The review of the cost-effectiveness evidence enabled the identification of previously published
methodology before we developed our model structure to determine the cost-effectiveness of IGRAs
compared with TST for the diagnosis of LTBI. These models offer insight and, in general, performed well
against the frameworks on best practice for reporting a model-based economic evaluation, but were
subjected to some limitations. Areas of concern included the perspective of the analysis, the handling of
uncertainty in the models, the derivation of prevalence, test accuracy and transition probabilities; most
studies did not elaborate on these statistical/pre-model analyses.
In the population of children who had had contact with an index case, the results based on the outcome
of cost per diagnostic error avoided showed that the TST (≥ 10mm) strategy dominated all strategies
except for the T-SPOT.TB strategy alone. T-SPOT.TB compared with TST (≥ 10mm) was more effective but
more expensive, with an ICER of approximately £2710 per diagnostic error avoided. The TST (≥ 5mm)
strategy was slightly more effective than the QFT-GIT-alone strategy, with an ICER of approximately
£11,260 per QALY, and had a 26.9% probability of being cost-effective at a willingness to pay of £20,000
per QALY.
In the immunocompromised population, QFT-GIT dominated QFT-GIT negative followed by TST (≥ 5mm),
T-SPOT.TB and TST (≥ 5mm) strategies in terms of diagnostic errors avoided. The QFT-GIT positive
followed by TST (≥ 5mm) strategy was the most effective strategy. The results in terms of cost per QALY
showed that the QFT-GIT negative followed by TST (≥ 5mm) strategy was the most effective strategy,
with an ICER of approximately £18,750 compared with T-SPOT.TB, and had a 40% probability of being
cost-effective at a willingness to pay of £20,000.
In the recent arrivals from countries with a high incidence of TB, the QFT-GIT strategy dominated all
strategies except for TST (≥ 5mm) positive followed by QFT-GIT. The TST (≥ 5mm) positive followed by
QFT-GIT strategy was more costly and resulted in more diagnostic errors avoided, with an ICER of
approximately £690 compared with the QFT-GIT-alone strategy. The results in terms of cost per QALY
showed that QFT-GIT dominated the T-SPOT.TB and TST (≥ 5mm) positive followed by QFT-GIT strategies
and had an 18% probability of being cost-effective at a willingness to pay of £20,000 per QALY. The TST
(≥ 5mm) strategy had the highest probability (47%) of being cost-effective at a willingness to pay
of £20,000.
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Implications for service provision and local commissioning
The results of the health economic analysis show which diagnostic strategy is likely to be the most
cost-effective for the diagnosis of LTBI that progresses to active TB.
Our results do not show whether or not screening compared with no screening is likely to be cost-effective
nor do they demonstrate which IGRA (e.g. QFT-GIT vs. T-SPOT.TB) is more cost-effective.
Our findings should be interpreted by clinicians, commissioners and policy makers with caution because
of the limited evidence, the lack of a gold standard diagnostic test and the assumptions made.
Clinicians should be mindful of the variation in performance of the different testing strategies among
different populations.
Suggested research priorities
A key priority is to conduct research in populations from both high and low TB burden countries to explore
and confirm whether the inconsistent performance of IGRAs is real or whether it represents a chance
finding. The natural history of the condition needs to be clarified. Prospective population-based studies
with an adequate sample size and follow-up should be conducted in people at high risk for TB. These
studies should employ standard diagnostic methodology and criteria for ascertaining incident cases of
active TB. Research is also needed to clarify the role of serial as opposed to single cross-sectional testing in
light of the comparative effectiveness of IGRAs and the TST for the diagnosis of LTBI; future studies need
to evaluate the utility of two-step compared with single testing to maximise both sensitivity and specificity
for identifying people with LTBI. Although strain and infectivity data have not been used in the present
analyses because they were not available, they are relevant to future research.
Consensus-based standard criteria or a multivariable risk prediction model for the construct of LTBI should
be developed. This would provide a standard set of all of the component exposures to classify people into
high or low risk for LTBI. This would improve retrospective or cross-sectional studies of previous TB
exposure by facilitating standardised definitions across different studies and would allow for more objective
comparisons between IGRAs and the TST in terms of detecting LTBI in subgroups of interest.
There is very little evidence on the roles of IGRAs and the TST for the diagnosis of LTBI in different clinical
subgroups of immunocompromised people (e.g. those with HIV infection or hepatitis C, solid organ
transplant recipients, those with rheumatoid arthritis) and future research could be directed at providing
this. Finally, more efforts need to be directed at identifying new more accurate markers of LTBI.
CONCLUSION
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Appendix 1 Search strategies and results
from 2011
Main searches
Diagnosis of latent tuberculosis infection using interferon gamma release
assays based on M. tuberculosis-specific antigens
Databases were searched to answer questions relating to the diagnosis of LTBI using IGRAs based on
M. tuberculosis-specific antigens (ESAT-6, CFP 10 and TB7.7), including the following commercially
available assays:
l QFT-GIT
l QFT-G
l T-SPOT.TB.
The diagnostic utility of these assays, alone or in combination with a tuberculin skin test, was compared
with that of the TST alone.
The database searches were undertaken between 7 and 14 December 2009. The databases
searched were:
l EMBASE (Ovid)
l MEDLINE (Ovid)
l MEDLINE In-Process & Other Non-Indexed Citations (Ovid)
l Cumulative Index to Nursing and Allied Health Literature (EBSCOhost)
l Database of Abstracts of Reviews of Effects (CRD)
l Health Technology Assessment database (CRD)
l The Cochrane Library (Wiley)
l Cochrane Register of Diagnostic Test Accuracy Studies (Wiley)
l Medion
l Aggressive Research Intelligence Facility.
The MEDLINE search strategy is presented below. It was translated for use in the databases listed above.
Ovid MEDLINE 1950 to November Week 3 2009
1. (laten* adj3 (tb* or tubercul*)).tw.
2. ltb*.tw.
3. Tuberculosis, Pulmonary/
4. Tuberculosis/
5. Mycobacterium tuberculosis/
6. or/1-5 (123029)
7. IGRA*.tw.
8. IGT*.tw.
9. (interferon adj3 gamma adj3 (release* or test* or assay*)).tw.
10. ((y-interferon or interferon-y) adj3 (release* or assay* or test*)).tw.
11. (quantiferon adj3 gold*).tw.
12. (quantiferon adj3 (in tube or test*)).tw.
13. QFT*.tw.
14. t spot*.tw.
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15. Interferon-gamma/
16. (enzyme* adj3 link* adj3 immunosorbent adj3 (test* or assay*)).tw.
17. ELISA*.tw.
18. (ELISPOT* or (enzyme* adj3 link* adj3 immunospot)).tw.
19. (ESAT6* or ESAT-6* or ESAT 6*).tw.
20. (early adj3 secret* adj3 antigen adj3 target-6).tw.
21. (CFP10* or (culture adj3 filtrate adj3 protein-10)).tw.
22. “TB7.7”.tw.
23. Fluorospot*.tw.
24. “region of difference”.tw.
25. Enzyme-Linked Immunosorbent Assay/
26. or/7-25
27. 6 and 26
28. mass screening/
29. (screen* adj3 (program* or mass or population* or disease*)).tw.
30. 28 or 29
31. 30 and 6
32. 27 or 31
33. Animals/ not Humans/
34. 32 not 33
35. limit 34 to english language
Health economics
The following sources were searched to identify economic evaluations and quality-of-life data relating to
IGRAs for LTBI:
l Health Economics Evaluations Database (Wiley)
l NHS Economic Evaluation Database (NHS EED) (Wiley and CRD website)
l EMBASE (Ovid)
l MEDLINE (Ovid)
l MEDLINE In-Process & Other Non-Indexed Citations (Ovid)
The searches were undertaken on 5 and 6 January 2009.
The MEDLINE search strategy is presented below. It was translated for use in other databases.
Ovid MEDLINE 1950 to December Week 4 2009
1. (laten* adj3 (tb* or tubercul*)).tw.
2. ltb*.tw.
3. Tuberculosis, Pulmonary/
4. Tuberculosis/
5. Mycobacterium tuberculosis/
6. or/1-5
7. IGRA*.tw.
8. IGT*.tw.
9. (interferon adj3 gamma adj3 (release* or test* or assay*)).tw.
10. ((y-interferon or interferon-y) adj3 (release* or assay* or test*)).tw.
11. (quantiferon adj3 gold*).tw.
12. (quantiferon adj3 (in tube or test*)).tw.
13. QFT*.tw.
14. t spot*.tw.
15. Interferon-gamma/
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16. (enzyme* adj3 link* adj3 immunosorbent adj3 (test* or assay*)).tw.
17. ELISA*.tw.
18. (ELISPOT* or (enzyme* adj3 link* adj3 immunospot)).tw.
19. (ESAT6* or ESAT-6* or ESAT 6*).tw.
20. (early adj3 secret* adj3 antigen adj3 target-6).tw.
21. (CFP10* or (culture adj3 filtrate adj3 protein-10)).tw.
22. “TB7.7”.tw.
23. Fluorospot*.tw.
24. “region of difference”.tw.
25. Enzyme-Linked Immunosorbent Assay/ [Double click to insert footer here] 23 of 315
26. or/7-25
27. 6 and 26
28. mass screening/
29. (screen* adj3 (program* or mass or population* or disease*)).tw.
30. 28 or 29
31. 30 and 6
32. 27 or 31
33. Animals/ not Humans/
34. 32 not 33
35. limit 34 to english language
36. Economics/
37. exp “Costs and Cost Analysis”/
38. Economics, Dental/
39. exp Economics, Hospital/
40. exp Economics, Medical/
41. Economics, Nursing/
42. Economics, Pharmaceutical/
43. Budgets/
44. exp Models, Economic/
45. Markov Chains/
46. Monte Carlo Method/
47. Decision Trees/
48. econom$.tw.
49. cba.tw.
50. cea.tw.
51. cua.tw.
52. markov$.tw.
53. (monte adj carlo).tw.
54. (decision adj2 (tree$ or analys$)).tw.
55. (cost or costs or costing$ or costly or costed).tw.
56. (price$ or pricing$).tw.
57. budget$.tw.
58. expenditure$.tw.
59. (value adj2 (money or monetary)).tw.
60. (pharmacoeconomic$ or (pharmaco adj economic$)).tw.
61. or/36-60
62. “Quality of Life”/
63. quality of life.tw.
64. “Value of Life”/
65. Quality-Adjusted Life Years/
66. quality adjusted life.tw.
67. (qaly$ or qald$ or qale$ or qtime$).tw.
68. disability adjusted life.tw. (571)
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69. daly$.tw.
70. Health Status Indicators/
71. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or
shortform thirty six or short form thirtysix or short form thirty six).tw.
72. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
73. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short
form twelve).tw.
74. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).tw.
75. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short
form twenty).tw.
76. (euroqol or euro qol or eq5d or eq 5d).tw.
77. (qol or hql or hqol or hrqol).tw.
78. (hye or hyes).tw.
79. health$ year$ equivalent$.tw.
80. utilit$.tw.
81. (hui or hui1 or hui2 or hui3).tw.
82. disutili$.tw.
83. rosser.tw.
84. quality of wellbeing.tw.
85. quality of well-being.tw.
86. qwb.tw.
87. willingness to pay.tw.
88. standard gamble$.tw.
89. time trade off.tw.
90. time tradeoff.tw.
91. tto.tw.
92. or/62-91
93. 61 or 92
94. 35 and 93
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Appendix 2 Search strategies and results 2014
The objective of the search strategies was to identify literature on the diagnosis of LTBI using IGRAscompared with other methods. The following sources were searched: Ovid MEDLINE, Ovid MEDLINE
In-Process & Other Non-Indexed Citations, The Cochrane Library via Wiley, Science Citation Index
Expanded (SCI-EXPANDED), Conference Proceedings Citation Index – Science (CPCI-S), Medion,
ClinicalTrials.gov, WHO ICTRP, conferences and websites.
The bibliographic database searches were undertaken on 9 and 10 April 2014 and were updated on 2 December
2014 using the same strategies. Supplementary searches were undertaken between 10 June and 5 August 2014.
MEDLINE
Update search
Ovid MEDLINE 1946 to November Week 3 2014, searched 2 December 2014.
The search in Table 45 was rerun with the following limit:
Line 24= limit 23 to ed=20140312-20141202 (222)
Total= 1288+ 222= 1510.
TABLE 45 Ovid MEDLINE 1946 to April week 1 2014, searched 9 April 2014
Search term Number of hits
1 (laten* adj3 (tb* or tubercul*)).tw. 2701
2 ltb*.tw. 6939
3 tubercul*.tw. 158,617
4 Tuberculosis/ 51,049
5 Latent Tuberculosis/ 866
6 Tuberculosis, Pulmonary/ 63,874
7 Mycobacterium tuberculosis/ 35,401
8 1 or 2 or 3 or 4 or 5 or 6 or 7 195,420
9 quantiferon*.tw. 819
10 QFT*.tw. 557
11 t spot*.tw. 261
12 exp Enzyme-Linked Immunosorbent Assay/ 122,317
13 Interferon-gamma Release Tests/ 377
14 ((interferon* or IFN*) adj3 gamma* adj3 (release* or test* or assay*)).tw. 3856
15 ((y-interferon or interferon-y) adj3 (release* or test* or assay*)).tw. 7
16 IGRA*.tw. 448
17 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 126,234
18 8 and 17 3840
19 Latent Tuberculosis/di 576
continued
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MEDLINE In-Process & Other Non-Indexed Citations
Update search
Ovid MEDLINE In-Process & Other Non-Indexed Citations 1 December 2014, searched 2 December 2014.
The search in Table 46 was rerun with the following limit:
Line 15= limit 14 to ed=20140312-20141202 (19)
Total= 263+ 19= 282.
TABLE 46 Ovid MEDLINE In-Process & Other Non-Indexed Citations 8 April 2014, searched 9 April 2014
Search term Number of hits
1 (laten* adj3 (tb* or tubercul*)).tw. 312
2 ltb*.tw. 340
3 tubercul*.tw. 10,405
4 1 or 2 or 3 10,625
5 quantiferon*.tw. 121
6 QFT*.tw. 83
7 t spot*.tw. 42
8 (enzyme* adj3 link* adj3 (immunosorbent or immunospot) adj3 (test* or assay*)).tw. 3522
9 ((interferon* or IFN*) adj3 gamma* adj3 (release* or test* or assay*)).tw. 148
10 ((y-interferon or interferon-y) adj3 (release* or test* or assay*)).tw. 1
11 IGRA*.tw. 102
12 5 or 6 or 7 or 8 or 9 or 10 or 11 3778
13 4 and 12 281
14 limit 13 to english language 263
TABLE 45 Ovid MEDLINE 1946 to April week 1 2014, searched 9 April 2014 (continued )
Search term Number of hits
20 18 or 19 4061
21 Animals/ not Humans/ 3,812,070
22 20 not 21 3480
23 limit 22 to english language 3014
24 limit 23 to ed=20091207-20140409 1288
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EMBASE
Update search
EMBASE 1980 to 2014 Week 48, searched 2 December 2014.
The search in Table 47 was rerun with the following limits:
Line 25= imit 24 to dd=20140409-20141202 (364)
Line 26= limit 24 to em=201414-201448 (387)
Line 27= 25 or 26 (387)
Total= 2483+ 387= 2870.
TABLE 47 Ovid EMBASE 1980 to 2014 week 14, searched 9 April 2014
Search term Number of hits
1 (laten* adj3 (tb* or tubercul*)).tw. 3880
2 ltb*.tw. 8397
3 tubercul*.tw. 175,055
4 tuberculosis/ 87,819
5 latent tuberculosis/ 1696
6 lung tuberculosis/ 62,789
7 Mycobacterium tuberculosis/ 47,234
8 1 or 2 or 3 or 4 or 5 or 6 or 7 227,447
9 quantiferon*.tw. 1477
10 QFT*.tw. 871
11 t spot*.tw. 442
12 enzyme linked immunospot assay/ 5911
13 *enzyme linked immunosorbent assay/ 14,220
14 exp interferon gamma release assay/ 1062
15 ((interferon* or IFN*) adj3 gamma* adj3 (release* or test* or assay*)).tw. 1925
16 ((y-interferon or interferon-y) adj3 (release* or test* or assay*)).tw. 12
17 IGRA*.tw. 841
18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 23,387
19 8 and 18 3410
20 latent tuberculosis/di 573
21 19 or 20 3619
22 animal/ not human/ 1,176,853
23 21 not 22 3556
24 limit 23 to english language 3171
25 limit 24 to dd=20091207-20140409 2280
26 limit 24 to em=200900-201414 2482
27 25 or 26 2483
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The Cochrane Library
All results 108: Cochrane reviews 0, other reviews 19, trials 53, methods studies 0, technology assessments
6, economic evaluations 30, Cochrane Groups 0.
Update search
The Cochrane Library via Wiley, searched 2 December 2014.
The search in Table 48 was rerun with the following limit:
Line 21= #18 or #19 Publication Year from 2014 to 2014 (11)
All results 11: Cochrane reviews 0, other reviews 3, trials 7, methods studies 0, technology assessments 0,
economic evaluations 1, Cochrane Groups 0.
Total= 108+ 11= 119.
TABLE 48 The Cochrane Library via Wiley, searched 9 April 2014
Search term Number of hits
#1 (laten* near/3 (tb* or tubercul*)):ti,ab,kw 186
#2 ltb*:ti,ab,kw 270
#3 tubercul*:ti,ab,kw 3404
#4 MeSH descriptor: [Tuberculosis] this term only 598
#5 MeSH descriptor: [Latent Tuberculosis] this term only 53
#6 MeSH descriptor: [Tuberculosis, Pulmonary] this term only 824
#7 MeSH descriptor: [Mycobacterium tuberculosis] this term only 306
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7 3632
#9 quantiferon*:ti,ab,kw 44
#10 QFT*:ti,ab,kw 22
#11 t next spot*:ti,ab,kw 15
#12 MeSH descriptor: [Enzyme-Linked Immunosorbent Assay] explode all trees 2107
#13 MeSH descriptor: [Interferon-gamma Release Tests] this term only 31
#14 ((interferon* or IFN*) near/3 gamma* near/3 (release* or test* or assay*)):ti,ab,kw 164
#15 ((y-interferon or interferon-y) near/3 (release* or test* or assay*)):ti,ab,kw 0
#16 IGRA*:ti,ab,kw 22
#17 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 2260
#18 #8 and #17 145
#19 MeSH descriptor: [Latent Tuberculosis] this term only and with qualifier(s): [Diagnosis - DI] 31
#20 #18 or #19 154
#21 #18 or #19 Publication Date from 2009 to 2014 108
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Science Citation Index Expanded and Conference Proceedings
Citation Index – Science
Update search
Science Citation Index Expanded (SCI-EXPANDED) 1970 to present and Conference Proceedings Citation
Index – Science (CPCI-S) 1990 to present via Web of Knowledge, searched 2 December 2014.
The search in Table 49 was rerun with the following limit:
Timespan= 2014
#14= 277
Total= 3314+ 277= 3591.
TABLE 49 Science Citation Index Expanded (SCI-EXPANDED) 1970 to present and Conference Proceedings Citation
Index – Science (CPCI-S) 1990 to present via Web of Knowledge, searched 9 April 2014
Search term Number of hits
#14 (#13) AND LANGUAGE: (English) Indexes=SCI-EXPANDED, CPCI-S Timespan=2009-2014 1608
#13 #4 and #12 Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 3139
#12 #5 or #6 or #7 or #8 or #9 or #10 or #11 Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 63,467
#11 TS=IGRA* Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 601
#10 TS=((y-interferon or interferon-y) NEAR/3 (release* or test* or assay*)) Indexes=SCI-EXPANDED,
CPCI-S Timespan=All years
5
#9 TS=((interferon* or IFN*) NEAR/3 gamma* NEAR/3 (release* or test* or assay*)) Indexes=SCI-
EXPANDED, CPCI-S Timespan=All years
5812
#8 TS=(enzyme* NEAR/3 link* NEAR/3 (immunosorbent or immunospot) NEAR/3 (test* or assay*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
56,262
#7 TS=((t-spot*) OR (t NEAR/1 spot*)) Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 464
#6 TS=QFT* Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 1894
#5 TS=quantiferon* Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 949
#4 #1 or #2 or #3 Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 108,863
#3 TS=tubercul* Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 103,332
#2 TS=ltb*Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 6278
#1 TS=(laten* NEAR/3 (tb or tubercul*)) Indexes=SCI-EXPANDED, CPCI-S Timespan=All years 3314
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Medion
Searched 10 June 2014.
Search 1
Searched in subset of Medion – systematic reviews of diagnostic studies.
Signssymp - selected:
l divers, other, general,
l Laboratory tests
Abstract:
l Tuberculosis
Total: 33.
Search 2
Searched in subset of Medion – systematic reviews of diagnostic studies.
Signssymp - selected:
l divers, other, general,
l Laboratory tests
Abstract:
l tb
Total: 37.
Both searches
l Total of both searches after duplicates removed: 47.
l Saved to Microsoft Word® 2010 (Microsoft Corporation, Redmond, WA, USA) and removed
19 pre-2009 reviews, leaving 28.
l Checked against results of other database searching in EndNote and removed 11 duplicates.
l Total unique records: 17.
World Health Organization International Clinical Trials Registry Platform
Searched 5 August 2014.
Advanced search:
(quantiferon* or QFT* or t-spot* or interferon* or IFN* or gamma* or y-interferon or interferon-y or
IGRA*) in Title
AND
(tuberculosis or latent tb) in Condition
Total: 10.
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ClinicalTrials.gov
Searched 5 August 2014.
(quantiferon* OR QFT* OR t-spot* OR interferon* OR IFN* OR gamma* OR y-interferon OR interferon-y
OR IGRA*) AND (tuberculosis or “latent tb”)
Excluded unknown status.
Total: 41.
Conferences
Specific conference proceedings, selected with input from a clinical expert (Professor Jeremy Hawker,
Public Health England, 29 April 2014), were searched on 24 and 25 June 2014 for the last 5 years:
l European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) [http://ecdc.
europa.eu/en/ESCAIDE/about_ESCAIDE/Pages/previous_conferences.aspx (accessed 25 June 2014)]
l PHE Annual Conference (previously Health Protection Agency Annual Conference) (www.phe-events.
org.uk/hpa/frontend/reg/thome.csp?pageID=117557&eventID=286&eventID=286)
l 5 Nations Health Protection Conference [http://5nations.org.uk/?page_id=44 (accessed
13 January 2016)]
l Federation of Infection Societies Annual Conference [http://fis-infection.org.uk/ (accessed
13 January 2016), e.g. www.actiononinfection.com/abstracts-and-poster-walk/ (accessed
25 June 2014)]
l British Thoracic Society [www.brit-thoracic.org.uk/bts-learning-hub/bts-summer-and-winter-meetings/
summer-meeting-2014/ (accessed 13 January 2016)]
l Annual Conferences of the Union North America Region [www.bc.lung.ca/association_and_services/
union.html (accessed 25 June 2014)].
Websites
Websites of specific organisations, selected with input from a clinical expert (Professor Jeremy Hawker),
were checked for relevant literature on 25 June 2014:
l PHE (including old Health Protection Agency site) [www.gov.uk/government/organisations/
public-health-england (accessed 13 January 2016) and www.hpa.org.uk/ (accessed 25 June 2014)].
l Centers for Disease Control and Prevention (Atlanta) [www.cdc.gov/ (accessed 13 January 2016)].
l European Centre for Disease Prevention and Control [www.ecdc.europa.eu/en/Pages/home.aspx and
www.ecdc.europa.eu/en/activities/diseaseprogrammes/programme_tuberculosis/Pages/index.aspx
(accessed 25 June 2014)].
l World Health Organization [www.who.int/en/ (accessed 13 January 2013) and http://dosei.who.int/
uhtbin/cgisirsi/tXRt5oo9vL/245820007/60/86/X (accessed 25 June 2014)].
l British Thoracic Society [(www.brit-thoracic.org.uk/ (accessed 13 January 2016)].
l Cellestis (manufacturer of QFT-G and QFT-GIT) [www.cellestis.com/ (accessed 13 January 2016)].
l Oxford Immunotec (manufacturer of T-SPOT.TB) [www.oxfordimmunotec.com/ (accessed
13 January 2016)].
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Appendix 3 Data extraction table for included
primary study reports
Name of first reviewer:  
Name of second reviewer:  
 
Study details 
First author surname year of publication:  
Country:  
Study design:  
Study setting (e.g., outbreak investigation, community-based  - specify):  
Number of centres:  
Total length of follow up (if applicable):  
Funding (government/private/manufacturer/other - specify):  
Aim of the study 
 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
 
Participants 
Recruitment dates:  
Total N of recruited patients:  
Inclusion criteria:  
Exclusion criteria:  
Total N of excluded patients:  
Total N of patients tested with both IGRA and TST:  
Total N of patients with valid results for both IGRA and TST:  
Methods of active TB diagnosis (if applicable):  
Outcomes (study-based) list:  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years):  
Women (n [%]):  
Race/ethnicity (n [%]):  
Geographic origin (n[%]): 
BCG vaccination (n [%]):  
History of anti-TB treatment (n [%]):  
Total incidence of active TB (n [%]): 
Chest radiography (yes/no):  
Clinical examination (yes/no):  
Morbidity (n [%]):  
Co-morbidity (n [%]):  
Type of during-study treatment (n [%]):  
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (specify):        
TST:      
Test 3 (specify)      
Total N of patients with valid results for both IGRA and TST:  
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed   
Exposed 1 (specify):  
Exposed 2 (specify):  
Exposed 3 (specify):  
Exposed 4 (specify):  
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Tests 
 Assay used, 
methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA     
TST    
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA +    TST +    
IGRA -    TST -    
indeterminate    indeterminate    
Total    Total    
Test performance parameters 
IGRA TST 
Sensitivity =  Sensitivity =  
Specificity =  Specificity =  
PPV =  PPV =  
NPV =  NPV =  
Cumulative Incidence IGRA+ =  Cumulative Incidence TST+ =  
Cumulative Incidence IGRA- =  Cumulative Incidence TST- =  
Cumulative Incidence Ratio IGRA =  Cumulative Incidence Ratio TST =  
Incidence density rate IGRA+ =  Incidence density rate TST+ =  
Incidence density rate IGRA- =  Incidence density rate TST- =  
Incidence density rate ratio IGRA =  Incidence density rate ratio TST =  
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios =  
Ratio of incidence density rate ratios =  
Other reported measure =  
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA +    TST +    
IGRA -    TST -    
indeterminate    indeterminate    
Total     Total     
Test performance parameters 
IGRA TST 
Sensitivity =  Sensitivity =  
Specificity =  Specificity =  
PPV =  PPV =  
NPV =  NPV =  
DOR (for T
+
 calculated) =  DOR (for T
+
 calculated) =  
OR (crude; for T
+ 
reported) =  OR (crude; for T
+ 
reported) =  
OR (regression-based; reported) =  
List of covariates: 
OR (regression-based; reported) =  
List of covariates: 
Other reported measure =  Other reported measure =  
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) =  
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Ratio of OR (crude; for T
+ 
reported) =  
Ratio of ORs (regression-based; reported) =  
Other reported measure =  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA +    
IGRA -    
indeterminate    
Total     
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold:  
Parameters 
Kappa =  
% concordance =  
% discordance =  
Stratification (specify group 1) 
 TST + TST - Total 
IGRA +    
IGRA -    
indeterminate    
Total     
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold:  
Parameters 
Kappa =  
% concordance =  
% discordance =  
Stratification (specify group 2) 
 TST + TST - Total 
IGRA +    
IGRA -    
indeterminate    
Total     
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold:  
Parameters 
Kappa =  
% concordance =  
% discordance =  
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life 
mean score 
(SD) (specify) 
IGRA:    
TST:   
Test 3 (specify):   
Conclusions 
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Authors: 
 
Reviewers: 
 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Appendix 4 Quality assessment and risk of bias
TABLE 50 Quality assessment for the exposure studies
Study ID
(burden)
Recruitment
of subjects
[consecutive
(yes),
arbitrary or
unreported
(no)]
Blinding of
test results
from exposure
[blinded (yes),
not blinded or
unreported
(no)]
Description of
index test
and threshold
[adequate
(yes),
inadequate or
unreported
(no)]
Definition and
description of
exposure
[adequate
(yes),
inadequate or
unreported
(no)]
Sample
attrition
[adequate
(yes),a
inadequate or
unreported
(no)]
Overall
quality score
of satisfactory
featuresb
ID, identification.
a ≥ 90% of participants were included in the follow-up analysis (yes response) and < 90% were classified as ‘no response’.
b Studies with one or two ‘yes’ ratings= low quality; studies with three ‘yes’ ratings=moderate quality; studies with four
or five ‘yes’ ratings= high quality.
Source: adapted from Dinnes et al.44 The item ‘study design’ was removed from the original checklist as all studies were
considered to be retrospective; furthermore, the item ‘sample attrition’ was added.
TABLE 51 Risk of bias of the incidence studies
Study ID (first author, year, ref. ID):
Reviewer 1:
Reviewer 2:
Domain of bias Question
Issues to consider for
judging overall rating of
ROB
Comments
(if issue not
satisfied)
Rating
(yes, partial,
no, unsure)
ROB (high,
moderate,
low)
Study design Prospective (yes/no)? Prospective (low ROB),
cross-sectional (moderate
ROB), case–control
(high ROB)
Study
participation (risk
of selection bias)
Does the study sample
adequately represent
the population of
interest? How likely is it
that the relationship
between the test result
and the outcome
is different for
participants and eligible
non-participants?
The source population is
adequately described
The sampling frame and
recruitment are adequately
described
The period and place of
recruitment are adequately
described
Inclusion and exclusion
criteria are adequately
described
The baseline study sample is
adequately described
Adequate participation in the
study by eligible individuals
Participants were
consecutively enrolled
continued
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TABLE 51 Risk of bias of the incidence studies (continued )
Domain of bias Question
Issues to consider for
judging overall rating of
ROB
Comments
(if issue not
satisfied)
Rating
(yes, partial,
no, unsure)
ROB (high,
moderate,
low)
Study attrition
(risk of selection
bias)
Do the study data
available (participants
not lost to follow-up)
adequately represent
the study sample?
How likely is it that the
relationship between
the test results and the
outcome is different
for completing and
non-completing
participants?
The response rate (i.e.
proportion of study sample
completing the study and
providing outcome data) is
adequate
Attempts to collect
information on participants
who dropped out are
described
Reasons for loss to follow-up
are provided
Participants lost to follow-up
are adequately described for
key characteristics
There are no important
differences between key
characteristics and outcomes
between participants who
completed the study and
those who did not
Prognostic factor
measurement
(risk of exposure
measurement
bias)
Was the test measured
in a similar way for all
participants? How
likely is it that the
measurement or
knowledge of the
outcome influenced
the test results?
A clear definition or
description of the test is
provided (e.g. type, assay,
threshold for positivity and
method of measurement)
The method of test conduct
was adequate and test
results were ascertained
adequately (e.g. raters were
blinded to outcomes in
relation to construct validity,
previous test ratings, clinical
or other characteristics not
intended to be a part of the
test)
Test thresholds used are
appropriate
The method and setting of
the test measurement are
the same for all study
participants
An adequate proportion of
the study sample has
complete data of the test
results
Appropriate methods of
imputation are used for
missing data on test results
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TABLE 51 Risk of bias of the incidence studies (continued )
Domain of bias Question
Issues to consider for
judging overall rating of
ROB
Comments
(if issue not
satisfied)
Rating
(yes, partial,
no, unsure)
ROB (high,
moderate,
low)
Outcome/
construct
measurement
(ROB in
misclassification
of individuals in
relation to
construct validity
groups)
Was the outcome of
interest (i.e. exposure
to MTB, incidence of
active TB, definition of
low-risk population)
measured in a
similar way for all
participants? How
likely is differential
measurement of the
outcome (e.g. outcome
measurement related
to the test results)?
A clear definition of
outcomes is provided,
including duration of
follow-up and level and
extent of the outcome
construct
The method of outcome
measurement used is valid
and reliable to limit
misclassification bias
(e.g. blinded measurement,
adequate methods of
outcome/construct
ascertainment – exposure
proximity plus duration
considered)
The method and setting
of outcome/construct
measurement are the same
for all study participants
Study
confounding
(ROB related to
confounding)
Were important
potential confounding
factors appropriately
accounted for? How
likely is bias because of
confounding?
All important confounders,
including treatments (key
variables in the conceptual
mode) are defined and
measured
All important confounders
are accounted for at the
design and/or analysis stage
Statistical analysis
and reporting
(ROB related to
the analysis and
selective
reporting)
Was the statistical
analysis appropriate
and were all primary
outcomes reported?
How likely is bias
related to the statistical
analysis and
presentation of the
results?
There is sufficient
presentation of data to
assess the adequacy of the
analysis
The strategy for model
building (i.e. inclusion of
variables in the statistical
model) is appropriate and
is based on a conceptual
framework or model
The selected statistical model
is adequate for the design of
the study
There is no selective
reporting of results
Total ROB (high, medium, low)
ID, identification.
Source: adapted from Hayden et al.90
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TABLE 52 Definitions for ROB ratings for each domain of bias: the QUIPS toola
Domain of
bias
Definitions for ROB ratings
High ROB Moderate ROB Low ROB
Study design Case–control study Cross-sectional study Prospective cohort study
Study
participation
The relationship between the
test results and the construct/
outcome is very likely to be
different for participants and
eligible non-participants
The relationship between the
test results and the outcome
may be different for participants
and eligible non-participants
The relationship between the
test results and the outcome is
unlikely to be different for
participants and eligible
non-participants
Study attrition The relationship between the
test results and the construct/
outcome is very likely to be
different for completing and
non-completing participants
The relationship between the
test results and the construct/
outcome may be different for
completing and non-completing
participants
The relationship between the
test results and the outcome is
unlikely to be different for
completing and non-completing
participants
Prognostic
factor
measurement
The measurement of the test is
very likely to be different for
different levels of the outcome/
construct of interest
The measurement of the test
may be different for different
levels of the outcome/construct
of interest
The measurement of the test is
unlikely to be different for
different levels of the outcome/
construct of interest
Outcome
measurement/
construct
The measurement of the
outcome/construct is very likely
to be different related to the
baseline level of the test
The measurement of the
outcome/construct may be
different related to the baseline
level of the test
The measurement of the
outcome/construct is unlikely to
be different related to the
baseline level of the test
Study
confounding
The observed association
between the test and the
outcome/construct is very likely
to be distorted by another factor
related to prognostic factor and
outcome
The observed association
between the test and the
outcome/construct may be
distorted by another factor
related to prognostic factor and
outcome
The observed association
between the test and the
outcome/construct is unlikely to
be distorted by another factor
related to prognostic factor and
outcome
Statistical
analysis and
reporting
The reported results are very
likely to be spurious or biased
related to analysis or reporting
The reported results may be
spurious or biased related to
analysis or reporting
The reported results are unlikely
to be spurious or biased related
to analysis or reporting
a Adapted from Hayden et al.90
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Appendix 5 Studies included in the clinical
effectiveness review 201110
Tables reproduced with permission from NICE CG117.10
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Appendix 6 List of studies excluded from the
clinical effectiveness review with reasons for
exclusion (n = 424)
MEDLINE
Number Author ID Details Reason(s) for exclusion
1 Abud-Mendoza C Should tuberculin skin test be positive to give latent
tuberculosis treatment before tumor necrosis
factor-alpha inhibitors in selected patients in
developing countries? J Rheumatol 2010;37:672–3;
author reply 673
Letter
2 Abu-Taleb AM Interferon-gamma release assay for detection of
latent tuberculosis infection in casual and close
contacts of tuberculosis cases. East Mediterr Health J
2011;17:749–53
Mixed population and/or no
subgroup of interest
3 Ahmadinejad Z Diagnosis of latent tuberculosis infection in
candidates for kidney transplantation (comparison of
two tests). Acta Med Iran 2012;50:305–10
No construct validity
4 Altet-Gomez N Diagnosing TB infection in children: analysis of
discordances using in vitro tests and the tuberculin
skin test. Eur Respir J 2011;37:1166–74
Results for TST and IGRA
were combined
5 American College
Health Association
Tuberculosis screening and targeted testing of
college and university students. J Am Coll Health
2011;59:670–7
Guideline
6 Andrisani G Comparison of Quantiferon-TB Gold versus
tuberculin skin test for tuberculosis screening in
inflammatory bowel disease patients. J Gastrointestin
Liver Dis 2013;22:21–5
No construct validity
7 Anibarro L Tuberculin skin test and interferon-γ release assay
show better correlation after the tuberculin ‘window
period’ in tuberculosis contacts. Scand J Infect Dis
2011;43:424–9
Mixed population and/or no
subgroup of interest
8 Anonymous Proceedings of the Second Global Symposium on
Interferon-Gamma Release Assays. Dubrovnik,
Croatia, May 30–1 June 2009. Int J Tuberc Lung Dis
2010;14(Suppl. 1):3–70
Abstract
9 Baboolal S Comparison of the QuantiFERON-TB Gold assay and
tuberculin skin test to detect latent tuberculosis
infection among target groups in Trinidad and
Tobago. Pan Am J Public Health 2010;28:36–42
Inappropriate proxy for LTBI
10 Basu Roy R Identifying predictors of interferon-γ release assay
results in pediatric latent tuberculosis: a protective
role of bacillus Calmette–Guérin?: a pTB-NET
collaborative study. Am J Respir Crit Care Med
2012;186:378–84
No construct validity
11 Belard E Prednisolone treatment affects the performance of
the QuantiFERON gold in-tube test and the
tuberculin skin test in patients with autoimmune
disorders screened for latent tuberculosis infection.
Inflamm Bowel Dis 2011;17:2340–9
No construct validity
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Number Author ID Details Reason(s) for exclusion
12 Bergot E Observational study of QuantiFERON-TB gold in-tube
assay in tuberculosis contacts in a low incidence
area. PLOS ONE 2012;7:e43520
Mixed population and/or no
subgroup of interest
13 Bienek DR Evaluation of an interferon-gamma release assay,
T-SPOT.TB, in a population with a low prevalence of
tuberculosis. Int J Tuberc Lung Dis 2009;13:1416–21
Mixed population and/or no
subgroup of interest
14 Bottger EC Interferon-γ release assays and the risk of developing
active tuberculosis. Am J Respir Crit Care Med
2012;185:786–7; author reply 787
Letter
15 Bua A Tuberculin skin test and QuantiFERON in children.
New Microbiol 2013;36:153–6
No construct validity
16 Camlar SA Performance of tuberculin skin test and interferon
gamma assay for the diagnosis of latent tuberculosis
infection in juvenile idiopathic arthritis. Clin
Rheumatol 2011;30:1189–93
No construct validity
17 Campainha S Negative predictive value of TST and IGRA in
anti-TNF treated patients. Eur Respir J
2012;40:790–1
Letter
18 Carvalho AC Contact investigation based on serial interferon-
gamma release assays (IGRA) in children from the
hematology-oncology ward after exposure to a
patient with pulmonary tuberculosis. Infection
2013;41:827–31
IGRA vs. IGRA only (no TST)
19 Cassone A High rate of Quantiferon positive and tuberculin
negative tests in infants born at a large Italian
university hospital in 2011: a cautionary hypothesis.
Pathog Glob Health 2012;106:8–11
Review
20 Cheallaigh CN Interferon gamma release assays for the diagnosis of
latent TB infection in HIV-infected individuals in a
low TB burden country. PLOS ONE 2013;8:e53330
No construct validity
21 Chou CH Comparison of 2 interferon-gamma assays and
Roche Cobas Amplicor Mycobacterium tuberculosis
assay for rapid diagnosis of tuberculosis among
patients with suspected tuberculosis in Taiwan.
J Microbiol Immunol Infect 2009;42:251–7
IGRA vs. IGRA only (no TST)
22 Chung WK Serial testing of interferon-gamma-release assays for
the diagnosis of latent tuberculosis in hemodialysis
patients. J Infect 2010;61:144–9
Serial testing, conversion and
reversion rates
23 Connell DW A comparison between interferon gamma release
assays and the tuberculin skin test in the contact
tracing of patients with chronic kidney disease.
Thorax 2011;66:729–30; author reply 730
Letter
24 Connell TG Indeterminate interferon-gamma release assay results
in children. Pediatr Infect Dis J 2010;29:285–6
Letter
25 Critselis E The effect of age on whole blood interferon-gamma
release assay response among children investigated
for latent tuberculosis infection. J Pediatr
2012;161:632–8
No construct validity
26 Dagnew AF Diagnosis of latent tuberculosis infection in healthy
young adults in a country with high tuberculosis
burden and BCG vaccination at birth. BMC Res Notes
2012;5:415
Mixed population and/or no
subgroup of interest
27 Davies MA Detection of tuberculosis in HIV-infected children
using an enzyme-linked immunospot assay. AIDS
2009;23:961–9
Active TB
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Number Author ID Details Reason(s) for exclusion
28 de Andrade Lima E Evaluation of an IFN-gamma assay in the diagnosis of
latent tuberculosis in patients with psoriasis in a
highly endemic setting. Acta Derm Venereol
2011;91:694–7
No construct validity
29 de Kantor IN Diagnosis of latent tuberculosis infection in
BCG-vaccinated subjects in China. Int J Tuberc Lung
Dis 2011;15:1560–1; author reply 1561
Letter
30 Del Tedesco E Does anti-TNF therapy influence the performance
of Mycobacterium tuberculosis antigen-specific
interferon-gamma assays? A French multicenter
experience. Inflamm Bowel Dis 2011;17:1824
Letter
31 Denholm JT Immigration screening for latent tuberculosis
infection. Med J Aus 2013;198:524
Letter
32 Denholm JT Immigration screening for latent tuberculosis
infection. Med J Aus 2013;199:654
Letter
33 Deuffic-Burban S Cost-effectiveness of QuantiFERON-TB test vs.
tuberculin skin test in the diagnosis of latent
tuberculosis infection. Int J Tuberc Lung Dis
2010;14:471–81
Economic study
34 Diel R Enhanced cost–benefit analysis of strategies for LTBI
screening and INH chemoprevention in Germany.
Respir Med 2009;103:1838–53
Economic study
35 Dilektasli AG Is the T-cell-based interferon-gamma releasing assay
feasible for diagnosis of latent tuberculosis infection
in an intermediate tuberculosis-burden country?
Jpn J Infect Dis 2010;63:433–6
Mixed population and/or no
subgroup of interest
36 Doberne D Preanalytical delay reduces sensitivity of
QuantiFERON-TB gold in-tube assay for detection of
latent tuberculosis infection. J Clin Microbiol
2011;49:3061–4
No relevant outcomes;
population ineligible
37 Dowdy DW Tests for latent tuberculosis infection and isoniazid
preventive therapy. Lancet Infect Dis 2012;12:827–8
Letter
38 Dyrhol-Riise AM Diagnosis and follow-up of treatment of latent
tuberculosis; the utility of the QuantiFERON-TB Gold
In-tube assay in outpatients from a tuberculosis
low-endemic country. BMC Infect Dis 2010;10:57
Mixed population and/or no
subgroup of interest
39 Garcia-Elorriaga G Interferon in patients with HIV/AIDS and suspicion or
latent tuberculosis infection. Asian Pac J Trop Med
2013;6:135–8
No construct validity
40 Garcia-Gasalla M Use of Quantiferon-TB-Gold in Tube test for
detecting latent tuberculosis in patients considered
as candidates for anti-TNF therapy in routine clinical
practice. Enferm Infecc Microbiol Clin 2013;31:76–81
No construct validity
41 Garcovich S Clinical applicability of Quantiferon-TB-Gold testing
in psoriasis patients during long-term anti-TNF-alpha
treatment: a prospective, observational study. J Eur
Acad Dermatol Venereol 2012;26:1572–6
No construct validity
42 Gautam M Tuberculosis infection in the indigenous elderly white
UK population: a study of IGRAs. Int J Tuberc Lung
Dis 2012;16:564
Letter
43 Gilham L Tuberculosis screening before biologics – T-SPOT for
all? J Rheumatol 2011;38:179
Letter
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Number Author ID Details Reason(s) for exclusion
44 Girlanda S ELISPOT-IFN-gamma assay instead of tuberculin skin
test for detecting latent Mycobacterium tuberculosis
infection in rheumatic patients candidate to
anti-TNF-alpha treatment. Clin Rheumatol
2010;29:1135–41
Non-standard or in-house
IGRA
45 Gogus F Comparison of tuberculin skin test and
QuantiFERON-TB gold in tube test in patients with
chronic inflammatory diseases living in a tuberculosis
endemic population. Clin Exp Med 2010;10:173–7
No construct validity
46 Gonzalez-Salazar F Snapshot of Quantiferon TB gold testing in Northern
Mexico. Tuberculosis 2011;91(Suppl. 1):34–7
Mixed population and/or no
subgroup of interest
47 Goujon C Diagnosis of latent tuberculosis infection (LTBI)
before anti-TNF-alpha treatment – the tuberculin skin
test is useful. Eur J Dermatol 2012;22:701–2
Case report
48 Grare M QuantiFERON-TB Gold In-Tube as help for the
diagnosis of tuberculosis in a French pediatric
hospital. Diagn Microbiol Infect Dis 2010;66:366–72
No construct validity
49 Greveson K Yield and cost effectiveness of mycobacterial
infection detection using a simple IGRA-based
protocol in UK subjects with inflammatory bowel
disease suitable for anti-TNFalpha therapy. J Crohns
Colitis 2013;7:412–18
IGRA only (no TST)
50 Griffin DW Immigration screening for latent tuberculosis
infection. Med J Aus 2013;199:654
Editorial
51 Grinsdale JA Programmatic impact of using QuantiFERON-TB
Gold in routine contact investigation activities.
Int J Tuberc Lung Dis 2011;15:1614–20
Mixed population and/or no
subgroup of interest
52 Gupta D Interferon gamma release assay (QuantiFERON-TB
Gold In Tube) in patients of sarcoidosis from a
population with high prevalence of tuberculosis
infection. Sarcoidosis Vasc Diffuse Lung Dis
2011;28:95–101
Active TB
53 Hanta I Detection of latent tuberculosis infection in
rheumatologic diseases before anti-TNFalpha
therapy: tuberculin skin test versus IFN-γ assay.
Rheumatol Int 2012;32:3599–603
No construct validity
54 Hardy AB Cost-effectiveness of the NICE guidelines for
screening for latent tuberculosis infection: the
QuantiFERON-TB Gold IGRA alone is more
cost-effective for immigrants from high burden
countries. Thorax 2010;65:178–80
Economic study
55 Hatemi G Quantiferon-TB Gold in tube assay for the screening
of tuberculosis before and during treatment with
tumor necrosis factor alpha antagonists. Arthritis Res
Ther 2012;14:R147
No construct validity
56 He D High incidence of tuberculosis infection in rheumatic
diseases and impact for chemoprophylactic
prevention of tuberculosis activation during biologics
therapy. Clin Vaccine Immunol 2013;20:842–7
IGRA only (no TST)
57 Helwig U Corticosteroids and immunosuppressive therapy
influence the result of QuantiFERON TB Gold testing
in inflammatory bowel disease patients. J Crohns
Colitis 2012;6:419–24
IGRA only (no TST)
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58 Hernandez-Garduno E The positive predictive value of T-SPOT.TB and
tuberculin skin test in patients with silicosis. Am J
Respir Crit Care Med 2011;183:277; author reply
277–8
Letter
59 Hernandez-Garduno E An update: the predictive value of QuantiFERON-TB-
Gold In-Tube assay and the tuberculin skin test. Am J
Respir Crit Care Med 2011;183:414; author reply
414–15
Letter
60 Hernandez-Garduno E The predictive value of interferon-γ release assays
and tuberculin skin test: what about those not
vaccinated with Bacillus Calmette–Guérin? Chest
2013;143:1514–15
Letter
61 Higuchi K Comparison of specificities between two interferon-
gamma release assays in Japan. Int J Tuberc Lung Dis
2012;16:1190–2
IGRA vs. IGRA only (no TST)
62 Hill PC Surprisingly high specificity of the PPD skin test for
M. tuberculosis infection from recent exposure in the
Gambia. PLOS ONE 2006;1:e68
Old pre-2009 study
63 Hoffmann M Assessment of an Interferon-gamma release assay for
the diagnosis of latent tuberculosis infection in
haemodialysis patient. Swiss Med Wkly
2010;140:286–92
No construct validity
64 Huang YW Latent tuberculosis infection among close contacts of
multidrug-resistant tuberculosis patients in central
Taiwan. Int J Tuberc Lung Dis 2010;14:1430–5
Mixed population and/or no
subgroup of interest
65 Inanc N Agreement between Quantiferon-TB gold test and
tuberculin skin test in the identification of latent
tuberculosis infection in patients with rheumatoid
arthritis and ankylosing spondylitis. J Rheumatol
2009;36:2675–81
Included in CG11710 and
hence excluded from our
search
66 Ingram PR Latent tuberculosis infection in travelers: is there a
role for screening using interferon-gamma release
assays? J Travel Med 2009;16:352–6
Review
67 Jacobs S The tuberculin skin test is unreliable in school
children BCG-vaccinated in infancy and at low risk of
tuberculosis infection. Pediatr Infect Dis J
2011;30:754–8
No relevant outcomes of
interest; only children with
positive TST result were given
QFT-GIT
68 Jeong YJ Positive tuberculin skin test or interferon-gamma
release assay in patients with radiographic lesion
suggesting old healed tuberculosis. J Korean Med Sci
2012;27:761–6
Mixed population and/or no
subgroup of interest
69 Jo KW Poor correlation between tuberculin skin tests and
interferon-γ assays in close contacts of patients with
multidrug-resistant tuberculosis. Respirology
2012;17:1125–30
Mixed population and/or no
subgroup of interest
70 Katsenos S Use of interferon-gamma release assay for latent
tuberculosis infection screening in older adults
exposed to tuberculosis in a nursing home. J Am
Geriatr Soc 2011;59:858–62
Mixed population and/or no
subgroup of interest
71 Kawamura LM Interferon-γ release assays for prediction of
tuberculosis. Lancet Infect Dis 2012;12:584
Letter
72 Kim EY Performance of the tuberculin skin test and
interferon-gamma release assay for detection of
tuberculosis infection in immunocompromised
patients in a BCG-vaccinated population.
BMC Infect Dis 2009;9:207
No construct validity
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Number Author ID Details Reason(s) for exclusion
73 Kim JH Factors influencing discrepancies between the
QuantiFERON-TB gold in tube test and the tuberculin
skin test in Korean patients with rheumatic diseases.
Semin Arthritis Rheum 2013;42:424–32
No construct validity
74 Klein M Quantiferon TB Gold and tuberculin skin tests for the
detection of latent tuberculosis infection in patients
treated with tumour necrosis factor alpha blocking
agents. Clin Exp Rheumatol 2013;31:111–17
No construct validity
75 Kleinert S Comparison of two interferon-gamma release assays
and tuberculin skin test for detecting latent
tuberculosis in patients with immune-mediated
inflammatory diseases. Ann Rheumatic Dis
2010;69:782–4
Letter
76 Kowada A Cost effectiveness of interferon-gamma release assay
for tuberculosis screening of rheumatoid arthritis
patients prior to initiation of tumor necrosis
factor-alpha antagonist therapy. Mol Diagn Ther
2010;14:367–73
Economic study
77 Kowada A Cost effectiveness of interferon-gamma release assay
for school-based tuberculosis screening. Mol Diagn
Ther 2012;16:181–90
Economic study
78 Kowada A Cost effectiveness of the interferon-γ release assay
for tuberculosis screening of hemodialysis patients.
Nephrol Dial Transplant 2013;28:682–8
Economic study
79 Kwakernaak AJ A comparison of an interferon-gamma release assay
and tuberculin skin test in refractory inflammatory
disease patients screened for latent tuberculosis prior
to the initiation of a first tumor necrosis factor alpha
inhibitor. Clin Rheumatol 2011;30:505–10
No construct validity
80 Lange B Indeterminate results of a tuberculosis-specific
interferon-gamma release assay in
immunocompromised patients. Eur Respir J
2010;35:1179–82
Letter
81 Laskin BL Cost-effectiveness of latent tuberculosis screening
before steroid therapy for idiopathic nephrotic
syndrome in children. Am J Kidney Dis
2013;61:22–32
Economic study
82 Latorre I IFN-γ response on T-cell based assays in
HIV-infected patients for detection of tuberculosis
infection. BMC Infect Dis 2010;10:348
No construct validity
83 Lee SS High prevalence of latent tuberculosis infection in
dialysis patients using the interferon-gamma release
assay and tuberculin skin test. Clin J Am Soc Nephrol
2010;5:1451–7
No construct validity
84 Legesse M Community–based cross-sectional survey of latent
tuberculosis infection in Afar pastoralists, Ethiopia,
using QuantiFERON-TB Gold In-Tube and tuberculin
skin test. BMC Infect Dis 2011;11:89
Mixed population and/or no
subgroup of interest
85 Legesse M Association of the level of IFN-γ produced by T cells
in response to Mycobacterium tuberculosis-specific
antigens with the size of skin test indurations among
individuals with latent tuberculosis in a highly
tuberculosis-endemic setting. Int Immunol
2012;24:71–8
Mixed population and/or no
subgroup of interest
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86 Leung CC Tests for prediction of active tuberculosis. Lancet
Infect Dis 2012;12:6–8
Editorial
87 Lienhardt C Evaluation of the prognostic value of IFN-gamma
release assay and tuberculin skin test in household
contacts of infectious tuberculosis cases in Senegal.
PLOS ONE 2010;5:e10508. [Erratum published in
PLOS ONE 2010;5(12)]
Mixed population and/or no
subgroup of interest
88 Lighter-Fisher J Performance of an interferon-gamma release assay
to diagnose latent tuberculosis infection during
pregnancy. Obstet Gynecol 2012;119:1088–95.
[Erratum published in Obstet Gynecol 2012;120:399]
Mixed population and/or no
subgroup of interest
89 Linas BP Priorities for screening and treatment of latent
tuberculosis infection in the United States. Am J
Respir Crit Care Med 2011;184:590–601
Economic study
90 Losi M Tuberculosis infection in foreign-born children: a
screening survey based on skin and blood testing.
Int J Tuberc Lung Dis 2011;15:1182–4
No construct validity
91 Maden E Evaluation of performance of quantiferon assay and
tuberculin skin test in end stage renal disease
patients receiving hemodialysis. New Microbiol
2011;34:351–6
No construct validity
92 Maeda T Usefulness and limitations of QuantiFERON-TB Gold
in Japanese rheumatoid arthritis patients: proposal
to decrease the lower cutoff level for assessing
latent tuberculosis infection. Mod Rheumatol
2010;20:18–23
Inappropriate proxy for LTBI;
definition includes previous
active TB
93 Maeda T Comparison of QuantiFERON-TB Gold and the
tuberculin skin test for detecting previous
tuberculosis infection evaluated by chest CT findings
in Japanese rheumatoid arthritis patients. J Infect
Chemother 2011;17:842–8
No construct validity
94 Mahan CS Concordance of a positive tuberculin skin test and
an interferon gamma release assay in bacille
Calmette–Guérin vaccinated persons. Int J Tuberc
Lung Dis 2011;15:174–8
Mixed population and/or no
subgroup of interest
95 Mancuso JD Cost-effectiveness analysis of targeted and sequential
screening strategies for latent tuberculosis. Int J
Tuberc Lung Dis 2011;15:1223–30
Economic study
96 Mandalakas AM Can we accurately diagnose tuberculosis infection in
children? Pediatr Infect Dis J 2011;30:817–18
Letter
97 Mandalakas AM Is screening immigrants for latent tuberculosis
cost-effective? Lancet Infect Dis 2011;11:418–19
Editorial
98 Mandalakas AM Modelling the cost-effectiveness of strategies to
prevent tuberculosis in child contacts in a
high-burden setting. Thorax 2013;68:247–55
Economic study
99 Mandalakas AM Detecting tuberculosis infection in HIV-infected
children: a study of diagnostic accuracy, confounding
and interaction. Pediatr Infect Dis J 2013;32:e111–18
No construct validity; two
samples on exposure (HIV
positive and HIV negative)
were included together
100 Mariette X Influence of replacing tuberculin skin test with ex
vivo interferon release assays on decision to
administer prophylactic antituberculosis antibiotics
before anti-TNF therapy. Ann Rheum Dis
2012;71:1783–90
No construct validity
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Number Author ID Details Reason(s) for exclusion
101 Marques CD Evaluation of an interferon gamma assay in the
diagnosis of latent tuberculosis infection in patients
with rheumatoid arthritis. Rheumatol Int
2009;30:57–62
Inappropriate proxy for LTBI
102 Martin J Comparison of interferon-γ release assays and
conventional screening tests before tumour necrosis
factor-α blockade in patients with inflammatory
arthritis. Ann Rheum Dis 2010;69:181–5
IGRA vs. IGRA only (no TST)
103 Martyn-Simmons CL Evaluating the use of the interferon-γ response to
Mycobacterium tuberculosis-specific antigens in
patients with psoriasis prior to antitumour necrosis
factor-α therapy: a prospective head-to-head cross-
sectional study. Br J Dermatol 2013;168:1012–18
No construct validity
104 Mendez-Echevarria A Interferon-γ release assay for the diagnosis of
tuberculosis in children. Arch Dis Childhood
2012;97:514–16
No construct validity; only for
IGRA
105 Milman N Quantiferon test for tuberculosis screening in
sarcoidosis patients. Scand J Infect Dis
2011;43:728–35
IGRA only (no TST)
106 Minguez S Interferon-gamma release assays in the detection of
latent tuberculosis infection in patients with
inflammatory arthritis scheduled for anti-tumour
necrosis factor treatment. Clin Rheumatol
2012;31:785–94
No construct validity
107 Molicotti P Performance of QuantiFERON TB in a student
population at low risk of tuberculosis. J Infect
Develop Countries 2012;6:100–1
Letter
108 Moran Mendoza O Interferon-γ release assays for the diagnosis of latent
Mycobacterium tuberculosis infection. Eur Respir J
2011;38:1237–8; author reply 1238–9
Letter
109 Moyo S Tuberculin skin test and QuantiFERON assay in young
children investigated for tuberculosis in South Africa.
Int J Tuberc Lung Dis 2011;15:1176–81
Active TB
110 Mrozek N Tuberculosis screening before biologic therapy.
Comment about the article entitled ‘role for
interferon-gamma release assays in latent
tuberculosis screening before TNF-alpha antagonist
therapy’ by Liote H et al. Joint Bone Spine
2011;78:655–6; author reply 656–7
Letter
111 Murakami S Screening of tuberculosis by interferon-gamma assay
before biologic therapy for rheumatoid arthritis.
Tuberculosis 2009;89:136–41
Case–control study of test
results
112 Nellore A Screening strategies for tuberculosis in children with
kidney disease: what is cost-effective? Am J Kidney
Dis 2013;61:3–5
Letter
113 Nguyen MQ What are the differences between the tuberculin
skin test and the QuantiFERON-TB Gold test? J
Occupational Environ Med 2012;54:1177–8
Editorial
114 Nkurunungi G Determining Mycobacterium tuberculosis infection
among BCG-immunised Ugandan children by
T-SPOT.TB and tuberculin skin testing. PLOS ONE
2012;7:e47340
No construct validity
115 Ohnishi T Comparison of QuantiFERON-TB Gold and the
tuberculin skin test for the detection of previous
tuberculosis infection evaluated by chest CT findings
in Japanese rheumatoid arthritis patients. J Infect
Chemother 2011;17:849–50
Letter
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116 Oni T Smoking, BCG and employment and the risk of
tuberculosis infection in HIV-infected persons in
South Africa. PLOS ONE 2012;7:e47072
Non-standard or in-house
IGRA
117 Onur H Comparison of quantiferon test with tuberculin skin
test for the detection of tuberculosis infection in
children. Inflammation 2012;35:1518–24
Inappropriate proxy for LTBI
118 Ormerod LP Further evidence supporting programmatic screening
for, and treatment of latent TB Infection (LTBI) in
new entrants to the UK from high TB prevalence
countries. Thorax 2013;68:201
Letter
119 Pareek M Screening of immigrants in the UK for imported
latent tuberculosis: a multicentre cohort study and
cost-effectiveness analysis. Lancet Infect Dis
2011;11:435–44
Economic study
120 Pareek M Community-based evaluation of immigrant
tuberculosis screening using interferon release assays
and tuberculin skin testing: observational study and
economic analysis. Thorax 2013;68:230–9
Economic study
121 Pattnaik S Agreement between skin testing and QuantiFERON-
TB Gold In-Tube assay (QFT-TB) in detecting latent
tuberculosis infection among household contacts in
India. Indian J Tuberc 2012;59:214–18
No construct validity
122 Petrescu L Tuberculin skin test, interferon-gamma assay, and T
cells subpopulations in hemodialysis patients. J Ren
Nutr 2010;20(Suppl. 5):109–17
No construct validity
123 Pooran A Different screening strategies (single or dual) for the
diagnosis of suspected latent tuberculosis: a cost
effectiveness analysis. BMC Pulm Med 2010;10:7
Economic study
124 Qumseya BJ QuantiFERON TB gold testing for tuberculosis
screening in an inflammatory bowel disease cohort in
the United States. Inflamm Bowel Dis 2011;17:77–83
No construct validity
125 Ramos JM Contribution of interferon gamma release assays
testing to the diagnosis of latent tuberculosis
infection in HIV-infected patients: a comparison of
QuantiFERON-TB Gold In Tube, T-SPOT.TB and
tuberculin skin test. BMC Infect Dis 2012;12:169
Inappropriate proxy for LTBI
126 Riazi S Rapid diagnosis of Mycobacterium tuberculosis
infection in children using interferon-gamma release
assays (IGRAs). Allergy Asthma Proc 2012;33:217–26
Active TB
127 Ringrose JS Detecting latent tuberculosis infection during
anti-tumor necrosis factor therapy. Clin Exp
Rheumatol 2011;29:790–4
No relevant outcomes
128 Santin M Detection of latent tuberculosis by the tuberculin
skin test and a whole-blood interferon-γ release
assay, and the development of active tuberculosis in
HIV-seropositive persons. Diagn Microbiol Infect Dis
2011;69:59–65
Mixed population and/or no
subgroup of interest for
construct validity
129 Sattah MV Interferon-gamma release assay T-SPOT.TB and
HIV-related tuberculosis. Int J Tuberc Lung Dis
2012;16:281–2
Letter
130 Sayarlioglu H QuantiFERON-TB Gold test for screening latent
tuberculosis infection in hemodialysis patients.
Tuberkuloz ve Toraks 2011;59:105–10
No construct validity
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Number Author ID Details Reason(s) for exclusion
131 Schneider WJ QuantiFERON-TB testing for latent tuberculosis
infection in low-prevalence countries: making the
most of an imperfect process. Infect Control Hosp
Epidemiol 2011;32:1055
Letter
132 Serrano-Escobedo CJ Performance of tuberculin skin test compared to
QFT-IT to detect latent TB among high-risk contacts
in Mexico. Arch Med Res 2013;44:242–8
Mixed population and/or no
subgroup of interest
133 Seshadri C Low sensitivity of T-cell based detection of
tuberculosis among HIV co-infected Tanzanian
in-patients. East Afr Med J 2008;85:442–9
Old pre-2009 study
134 Setiawati L Effect of BCG vaccination and non-tuberculous
Mycobacterium infection on interferon gamma
specific assay and a tuberculin skin test among
children with a tuberculosis contact in Surabaya,
Indonesia. Southeast Asian J Trop Med Public Health
2011;42:1460–8
No construct validity
135 Shah M Programmatic impact of QuantiFERON-TB Gold
In-Tube implementation on latent tuberculosis
diagnosis and treatment in a public health clinic.
PLOS ONE 2012;7:e36551
Mixed population and/or no
subgroup of interest
136 Shah M QuantiFERON-TB gold in-tube implementation for
latent tuberculosis diagnosis in a public health clinic:
a cost-effectiveness analysis. BMC Infect Dis
2012;12:360
Economic study
137 Shanaube K Risk factors associated with positive QuantiFERON-TB
Gold In-Tube and tuberculin skin tests results in
Zambia and South Africa. PLOS ONE 2011;6:e18206
Mixed population and/or no
subgroup of interest
138 Shovman O QuantiFERON-TB Gold in the identification of latent
tuberculosis infection in rheumatoid arthritis: a pilot
study. Int J Tuberc Lung Dis 2009;13:1427–32
Included in CG11710 and
hence excluded from our
search
139 Simsek H Comparison of tuberculin skin testing and T-SPOT.TB
for diagnosis of latent and active tuberculosis. Jpn J
Infect Dis 2010;63:99–102
Mixed population and/or no
subgroup of interest
140 Singanayagam A Evaluation of screening methods for identification of
patients with chronic rheumatological disease
requiring tuberculosis chemoprophylaxis prior to
commencement of TNF-alpha antagonist therapy.
Thorax 2013;68:955–61
Inappropriate proxy for LTBI
141 Song Q Evaluation of a new interferon-gamma release assay
and comparison to tuberculin skin test during
a tuberculosis outbreak. Int J Infect Dis
2012;16:e522–6
Non-standard or in-house
IGRA
142 Song S Performance of confirmatory interferon-γ release
assays in school TB outbreaks. Chest 2012;141:983–8
QFT used as confirmatory
test on subgroup of
TST-positive patients
143 Soysal A Diagnosing latent tuberculosis infection in
haemodialysis patients: T-cell based assay
(T-SPOT.TB) or tuberculin skin test? Nephrol Dial
Transplant 2012;27:1645–50
No construct validity
144 Starke JR Interferon-γ release assays for the diagnosis of
tuberculosis infection in children. J Pediatr
2012;161:581–2
Letter
145 Stefan DC Interferon-gamma release assays for the detection of
Mycobacterium tuberculosis infection in children
with cancer. Int J Tuberc Lung Dis 2010;14:689–94
No construct validity
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146 Steffen RE Cost-effectiveness of Quantiferon-TB Gold-in-Tube
versus tuberculin skin testing for contact screening
and treatment of latent tuberculosis infection in
Brazil. PLOS ONE 2013;8:e59546
Economic study
147 Sultan B Comparison of two interferon-gamma release assays
(QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in
testing for latent tuberculosis infection among
HIV-infected adults. Int J STD AIDS 2013;24:775–9
IGRA vs. IGRA only (no TST)
148 Talati NJ Diagnosis of latent tuberculosis infection among HIV
discordant partners using interferon gamma release
assays. BMC Infect Dis 2011;11:264.
No construct validity
149 Tannus Silva DG Latent tuberculosis in rheumatoid arthritis: evaluating
cellular response and high-resolution computed
tomography. Arch Bronconeumol 2012;48:144–9
No construct validity
150 Tebruegge M Interferon-γ release assays for the diagnosis of
tuberculosis in children. Arch Dis Childhood
2013;98:239–40
Letter
151 Theodoropoulos N Use of the QuantiFERON-TB Gold interferon-gamma
release assay for screening transplant candidates:
a single-center retrospective study. Transplant Infect
Dis 2012;14:1–8
IGRA only (historical TST)
152 Thomas B Concordance between tuberculin skin test and
interferon-γ assay and interferon-γ response to
mitogen in pediatric tuberculosis contacts. Pediatr
Pulmonol 2011;46:1225–32
No construct validity
153 Thomas TA Malnutrition and helminth infection affect
performance of an interferon gamma-release assay.
Pediatrics 2010;126:e1522–9
No construct validity
154 Uluk T Evaluation of an interferon-gamma release assay in
children with suspected tuberculosis in Papua New
Guinea. Pediatr Infect Dis J 2013;32:187–9
No construct validity
155 Wassie L Parasitic infection may be associated with discordant
responses to QuantiFERON and tuberculin skin test in
apparently healthy children and adolescents in a
tuberculosis endemic setting, Ethiopia. BMC Infect
Dis 2013;13:265
No construct validity
156 Weinfurter P Predictors of discordant tuberculin skin test and
QuantiFERON-TB Gold In-Tube results in various
high-risk groups. Int J Tuberc Lung Dis
2011;15:1056–61
No construct validity
157 Wolf T Tuberculosis skin test, but not interferon-γ-releasing
assays is affected by BCG vaccination in HIV patients.
J Infect 2013;66:376–80
No construct validity
158 Xie X A T-cell-based enzyme-linked immunospot assay for
tuberculosis screening in Chinese patients with
rheumatic diseases receiving infliximab therapy.
Clin Exp Med 2011;11:155–61
No construct validity
159 Yilmaz N Comparison of QuantiFERON-TB Gold test and
tuberculin skin test for the identification of latent
Mycobacterium tuberculosis infection in lupus
patients. Lupus 2012;21:491–5
No construct validity
160 Zhao J Low agreement between the T-SPOT.TB assay and
the tuberculin skin test among college students in
China. Int J Tuberc Lung Dis 2011;15:134–6
No construct validity
ID, identification.
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MEDLINE In-Process & Other Non-Indexed Citations
Number Author ID Details Reason(s) for exclusion
161 No authors listed Interferon-gamma release assays for diagnosis
of latent tuberculosis infection: evidence in
immune-mediated inflammatory disorders: erratum.
Curr Opin Rheumatol 2011;23:504
Letter
162 No authors listed Society for Adolescent Health and Medicine Annual
Meeting: Impact of Trauma on Teens: Building the
Safety Net Conference Proceedings. J Adolesc
Health 2012;50(Suppl. 2)
Irrelevant
163 No authors listed 40th Annual Conference Abstracts, APIC 2013.
Am J Infect Control 2013;41(Suppl. 6)
Abstract
164 No authors listed World Tuberculosis Day Symposium 2012.
Tuberculosis 2013;93(1)
Abstract
165 Abdel-Nabi EA QuantiFERON vs. tuberculin testing in detection of
latent tuberculous infection among chronic renal
failure patients. Egypt J Chest Dis Tuberc
2014;63:161–5
No construct validity
166 Abdel-Samea SA Comparative study between using QuantiFERON
and tuberculin skin test in diagnosis of
Mycobacterium tuberculosis infection. Egypt J Chest
Dis Tuberc 2013;62:137–43
Mixed population and/or no
subgroup of interest
167 Abraham B Monitoring and management of latent tuberculosis
in IBD patients on antiTNF therapy: a case series.
Am J Gastroenterol 2013;108:S521–2
Abstract
168 Aggarwal P Performance of an interferon-gamma release assay
to diagnose latent tuberculosis infection during
pregnancy. Obstet Gynecol 2012;120:398; author
reply 398
Letter
169 Ahmad M False-positive QuantiFERON Gold tests. Chest
2010;138:84A
Abstract
170 Ahmadinejad Z Evaluation of QuantiFERON-gold (tuberculin skin
test) for the identification of latent tuberculosis
infection in would-be transplant recipient patients
referring to an Iranian transplant clinic from
September 2007 to December 2008. Clin Microbiol
Infect 2010;16:S542
Abstract
171 Akpaka PE Evaluation of cost and methods for detecting latent
tuberculosis infection among target individual
groups in Trinidad and Tobago. Int J Infect Dis
2010;14:e148
Abstract
172 Alberte-Castineiras A Discordant QuantiFERON-TB Gold In-Tube and
tuberculin skin test results in various high-risk
groups. Clin Microbiol Infect 2012;18:548
Abstract
173 Andrisani G Tubercolosis screening in Italian patients affected by
inflammatory bowel disease: comparison of
QuantiFERON-TB Gold versus tuberculin skin test.
Digest Liver Dis 2010;42:S181–2
Abstract
174 Arias M Performance of two interferon-gamma release
assays (T-SPOT.TB and QuantiFERON-TB Gold in
Tube) increase diagnostic yield of tuberculin skin
testing for detection of latent tuberculosis in
patients with inflammatory bowel disease.
Gastroenterology 2011;1:S691
Abstract
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175 Atanassova A Screening for tuberculosis in patients candidates for
anti-TNF terapy in IBD. J Gastroenterol Hepatol
2013;28:141
Abstract
176 Awan S Can Quanti-FERON-TB replace TST (Mantoux) as a
screening tool prior to (biologics) anti-TNF therapy.
Irish J Med Sci 2012;181:S75
Abstract
177 Bakir M Use of T cell-based diagnosis of tuberculosis
infection to optimize interpretation of tuberculin
skin testing for child tuberculosis contacts.
Clin Infect Dis 2009;48:302–12
Inappropriate proxy for LTBI
178 Behar SM Use of the T-SPOT.TB assay to detect latent
tuberculosis infection among rheumatic disease
patients on immunosuppressive therapy.
J Rheumatol 2009;36:546–51
Inclusion of TST-positive
patients
179 Belard E Effects of corticosteroid treatment on the
performance of QuantiFERON Gold in-Tube test in
the screening of latent tuberculosis infection.
Gastroenterology 2010;1:S523
Abstract
180 Bergamini BM Performance of commercial blood tests for the
diagnosis of latent tuberculosis infection in children
and adolescents. Pediatrics 2009;123:e419–24
IGRA vs. IGRA only (no TST)
181 Berry MPR Systems biology approaches characterise the host
response to tuberculosis. Thorax 2009;64:A10
Abstract
182 Bianchi L Interferon-gamma release assay improves the
diagnosis of tuberculosis in children. Pediatr Infect
Dis J 2009;28:510–14
No construct validity
183 Blandinieres A Deficient IFN-gamma response to Mycobacterium
tuberculosis antigens in infants improved since
1 year of age. Immunology 2012;137:727–8
Abstract
184 Blandinieres A QuantiFERON to diagnose infection by
Mycobacterium tuberculosis: performance in infants
and older children. J Infect 2013;67:391–8
No construct validity
185 Borkowska D Interferon-gamma assays T-SPOT.TB for the
diagnosis of latent tuberculosis infection.
Pneumonol Alergol Pol 2011;79:264–71
Mixed population and/or no
subgroup of interest
186 Borra H Reliability of tuberculosis screening tests in patients
receiving tumor necrosis factor antagonist therapy in
a United States rheumatology clinic. Arthritis Rheum
2009;60:137
Abstract
187 Bortlik M Usefulness of the QuantiFERON TB Gold test in
assessing the necessity for TB prophylaxis in IBD
patients treated with biologicals. Gastroenterology
2009;1:A197
Abstract
188 Bottger EC Interferon-gamma release assays and the risk of
developing active tuberculosis. Am J Resp Crit Care
Med 2012;185:786–7
Abstract
189 Brebner J Questionable utility of T-SPOT testing in a TB
exposure incident on a clinical haematology unit.
Thorax 2010;65:A103
Abstract
190 Bruzzese E Gamma interferon release assays for diagnosis of
tuberculosis infection in immune-compromised
children in a country in which the prevalence of
tuberculosis is low. J Clin Microbiol 2009;47:2355–7
Letter
191 Bua A Epidemic of tuberculosis in a high school in
Northern Sardinia. Int J Mycobacteriol 2012;1:161–3
No relevant outcomes
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Number Author ID Details Reason(s) for exclusion
192 Bumbacea D New immunodiagnostic tests for latent and active
tuberculosis. Rev Romana Med Laborator
2011;19:267–78
Abstract
193 Buonsenso D Evaluation of a mathematical model proposed to
predict the diagnosis of tuberculosis in children with
cervical lymph node enlargement. Int J Pediatr
Otorhinolaryngol 2012;76:1068–70
Letter
194 Buonsenso D Pediatric tuberculosis in two tertiary hospitals in
Rome: a 20-year retrospective study. Arch Dis
Childhood 2012;97:A11–12
Abstract
195 Burgos JL Targeted screening and treatment for latent
tuberculosis infection using QuantiFERON-TB Gold is
cost-effective in Mexico. Int J Tuberc Lung Dis
2009;13:962–8
Economic study
196 Cagan Appak Y Comparison of tuberculin skin testing and in vitro
interferon-gamma release assay test for diagnosis of
latent tuberculosis in children. J Med Sci
2013;33:1402–7
Foreign language (Turkish)
197 Cagatay T The role of IGRA tests and tuberculin test for
determination of latent tuberculosis in TNF-alpha
antagonist users (candidates) [TNF-alpha antagonisti
kullanacak hastalarda latent tuberkulozun
belirlenmesinde IGRA testleri (quantiFERON-elispot)
ve ppd’nin yeri]. Turk Dermatoloji Dergisi
2012;6:62–4
Foreign language (Turkish)
198 Capocci S Screening for latent TB in HIV: are NICE and BHIVA
guidance effective? Thorax 2011;66:A21–2
Abstract
199 Capocci S Is testing for latent tuberculosis infection in an UK
HIV clinic cost effective? HIV Med 2012;13:44
Abstract
200 Casas S Diagnosis of tuberculosis infection in patients
awaiting transplantation. Clin Microbiol Infect
2010;16:S73
Abstract
201 Castaneda-Hernandez
DM
Importance of the use of interferon-gamma release
assays in the epidemiological surveillance of
tuberculosis Rev Med Chile 2012;140:128–9
Abstract
202 Cetin EA QuantiFERON-TB gold test may be more
advantageous than tuberculin skin test for screening
latent tuberculosis infection in psychiatry clinics.
Balkan Med J 2012;29:115–16
Abstract
203 Chang B Interferon-gamma assay in the diagnosis of latent
tuberculosis infection in arthritis patients treated
with tumor necrosis factor antagonists in Korea.
Am J Resp Crit Care Med 2010;181:A4773
Abstract
204 Chawla H Use of the interferon-gamma release assay blood
test to confirm latent tuberculosis infection in
tuberculin skin test-positive immIGRAnts: Our
experience at a Connecticut pulmonary clinic. Am J
Resp Crit Care Med 2010;181:A4774
Abstract
205 Chen JW Evaluation of a T-cell-based enzyme-linked
immunospot assay for monitoring tuberculosis in
patients with rheumatic diseases receiving Infliximab
therapy. Int J Rheum Dis 2010;13:87
Abstract
206 Chen QF Interferon-γ release assays screening for latent
tuberculosis screening: a cost-effectiveness analysis.
Chinese J Evid Based Med 2011;11:768–74
Foreign language (Chinese)
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207 Chun JK The role of a whole blood interferon-γ releasing
assay for the tracing of tuberculosis infection in
bacilli Calmette Guérin vaccinated children.
Int J Infect Dis 2010;14:e312
Abstract
208 Clark BJ Detection of latent tuberculosis infection in patients
with end stage renal disease: interferon-gamma
release assays versus tuberculin skin test. Am J Resp
Crit Care Med 2009;179:A5926
Abstract
209 Connell DW Comparison between interferon-gamma release
assays and the tuberculin skin test in the diagnosis
of tuberculosis in patients with renal disease. Thorax
2009;64:A108
Abstract
210 Connell T Interferon-γ release assays for the diagnosis of
tuberculosis. Pediatr Infect Dis J 2009;28:758–9
Abstract
211 Costantino F High level of disease activity in chronic inflammatory
rheumatisms increases the rate of indeterminate
interferon-gamma-release assay results for latent
tuberculosis infection detection. Arthritis Rheum
2010;62:768
Abstract
212 Davarpanah MA Association between PPD and QuantiFERON Gold TB
test in TB infection and disease among HIV-infected
individuals in Southern Iran. Iran Red Crescent
Med J 2009;11:71–5
Included/excluded in CG11710
213 De Francisco R Interferon-gamma release assays (T-SPOT.TB and
QuantiFERON-TB GOLD in Tube) versus tuberculin
skin testing for detection of latent tuberculosis in
patients with inflammatory bowel disease. J Crohns
Colitis 2011;5:S52–3
Abstract
214 De Leon DP Comparison of IGRAs with TST for the detection of
LTBI in RA patients in a TB endemic population.
Int J Tuberc Lung Dis 2010;14(Suppl. 1):40–1
Abstract
215 Delgado Naranjo J Comparative performance of QuantiFERON®-TB
Gold IT versus tuberculin skin test among contact
investigations for latent tuberculosis infection.
Med Clín 2011;137:289–96
Foreign language (Spanish)
216 Del Tedesco E Interferon gamma release assay (IGRA) and/or
tuberculin skin test (TST) in inflammatory bowel
disease population: discordance and performance.
Best strategy for detecting tuberculosis.
Gastroenterology 2010;1:S672–3
Abstract
217 Demkow U Interferon gamma based tests as a new tool in
diagnosis of latent tuberculosis. Pneumonol Alergol
Pol 2011;79:261–3
Editorial
218 Denholm JT Diagnosis and management of latent tuberculosis
infection. Med Today 2010;11:72–6
Review
219 Diel R The predictive value of interferon-gamma release
assays and tuberculin skin test: what about those
not vaccinated with bacillus Calmette–Guérin?
Response. Chest 2013;143:1515–16
Abstract
220 Dominguez J Role of the T-cell interferon-gamma release assays
in preventing reactivation of latent tuberculosis
infection in immunosuppressed patients in
treatment with anti-TNF agents. J Crohns Colitis
2008;2:250–4
Old pre-2009 study
221 Eather G Comparison of tuberculin skin test with an
interferon-gamma release assay (IGRA) in screening
for latent tuberculosis infection in a low prevalence
population. Respirology 2012;17:17
Abstract
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Number Author ID Details Reason(s) for exclusion
222 Eisenhut M Performance of tuberculin skin test measured
against interferon gamma release assay as reference
standard in children. Tuberc Res Treat
2014;2014:413459
Review
223 Elzi L Low sensitivity of an Interferon-gamma releasing
assay (Elispot-TB™) for the diagnosis of latent
tuberculosis in HIV-infected individuals. Swiss Med
Wkly 2009;139:39S
Abstract
224 Erkens CG Added value of interferon-gamma release assays
in screening for tuberculous infection in the
Netherlands. Int J Tuberc Lung Dis 2014;18:413–20
Mixed population and/or no
subgroup of interest
225 Evans LC IFN-gamma release assays improve detection of
latent tuberculosis infection in tuberculin-anergic
candidates for anti-TNF-alpha blockade. Am J Resp
Crit Care Med 2009;179:A5927
Non-standard or in-house
IGRA
226 Fernandez S Use of interferon-gamma release assay (IGRA) and
tuberculin skin test (TST) for tuberculosis screening
in patients candidates for anti-TNF terapy in
inflammatory bowel disease (IBD). J Crohns Colitis
2013;7:S58
Abstract
227 Ferrara G Interferon-gamma-release assays detect recent
tuberculosis re-infection in elderly contacts. Int J
Immunopathol Pharmacol 2009;22:669–77
Mixed population and/or no
subgroup of interest
228 Fontana R Diagnosis and management of latent tuberculosis
identified by the QuantiFERON assay in liver
transplant patients. Am J Transpl 2010;10:97
Abstract
229 Francois C Cost effectiveness analysis of strategies using new
immunological diagnostic tests of latent tuberculosis
infection before anti-TNF therapy. Ann Rheum Dis
2013;72:A538
Abstract
230 Gao KK Comparison of detection performances between
two kits for mycobacterium tuberculosis infection.
J Shanghai Jiaotong Uni Med Sci 2011;31:1440–3
Foreign language (Chinese)
231 Gao Y Evaluation of latent Mycobacterium tuberculosis
infection screening using TSPOT.TB assay and TST in
IMID patients prior to initiation of anti-TNF alpha
therapy. Int J Infect Dis 2011;15:S103
Abstract
232 Garcia-Garcia JM Comparison of tuberculin skin test and
QuantiFERON-TB-Gold in Tube in the diagnosis of
latent tuberculosis infection (LTBI) in a prospective
community study of contacts. Am J Resp Crit Care
Med 2010;181:A1789
Abstract
233 Garcia-Pedrazuela M Evaluation of the use of QuantiFERON TB-Gold in
the routine setting at a university hospital,
2007–2011. Clin Microbiol Infect 2012;18:544
Abstract
234 Garfein RS Latent tuberculosis among persons at risk for
infection with HIV, Tijuana, Mexico. Emerg Infect Dis
2010;16:757–63
IGRA only (no TST)
235 Gomes CMF Clinical performance of 4 methods for detecting
latent tuberculosis infection (LTbI) in patients with
active chronic inflammatory arthritis taking TNFalpha
blockers. Arthritis Rheum 2013;65:S1063
Abstract
236 Gonzalez-Diaz V Efficiency of interferon-γ release assay for screening
for latent tuberculosis in patients with systemic
lupus erythematosus. Lupus 2013;22:48
Abstract
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237 Goto N How do we manage kidney transplant recipients
with latent tuberculosis infection (LTBI)? Am J
Transpl 2010;10:426
Abstract
238 Gray JM Improvement in latent tuberculosis testing of HIV
patients after switching from the tuberculin skin test
to QuantiFERON-TB Gold-In-Tube. Am J Resp Crit
Care Med 2010;183:A1197
Abstract
239 Greveson K Comparative cost-effectiveness of IGRA to detect
latent TB infection in UK inflammatory bowel
disease patients initiating anti-TNFalpha agents.
Thorax 2012;67:A87–8
Abstract
240 Guidi L Screening inflammatory bowel disease patients
for latent tubercolosis in Italy: comparison of
QuantiFERON-TB Gold versus tuberculin skin test.
Gastroenterology 2010;1:S526
Abstract
241 Hadaya K Contribution of interferon gamma release assays to
the diagnosis of latent tuberculosis infection after
renal transplantation. Respiration 2013;85:590
Abstract
242 Hanjiu W Application of the T-SPOT.TB assay to identify
tuberculosis infection in children. Acta Med
Mediterr 2013;29:443–6
No relevant outcomes
243 Hashemi Shahri M To compare the performance of Quanti-FERON with
the tuberculin skin test for identifying latent
tuberculosis infection. Iran J Epidemiol
2012;7:57–65
Foreign language (Persian)
244 Hasunuma T New tools for old diseases comparison of positive
reaction of tuberculin skin test and QuantiFERON
among healthy adult males in Japan. Basic Clin
Pharmacol Toxicol 2010;107:321–2.
Abstract
245 Hayes, Inc. Interferon-Gamma Release Assays for Tuberculosis.
Lansdale, PA: Hayes, Inc.; 2012
Abstract
246 Hesseling AC The predictive value of the ELIspot-based
interferon-γ-release assay for tuberculosis disease.
Ann Intern Med 2009;150:428–9
Letter
247 Hesseling AC Highly discordant T cell responses in individuals with
recent exposure to household tuberculosis. Thorax
2009;64:840–6
No construct validity
248 Higuchi K Comparison of performance in two diagnostic
methods for tuberculosis infection. Med Microbiol
Immunol 2009;198:33–7
IGRA vs. IGRA only (no TST)
249 Hofland R Should screening for latent tuberculosis infection be
repeated after travel to tuberculosis endemic areas
in patients treated with TNF-alpha inhibitor therapy?
Gastroenterology 2012;1:S249
Abstract
250 Horsburgh CR Latent tuberculosis infection in the United States.
N Engl J Med 2011;364:1441–8
Editorial
251 Horvat RT From the arm to the test tube: laboratory’s new role
in tuberculosis testing. Clin Microbiol News
2012;34:117–25
Review
252 Hosker HSR How useful are interferon-gamma release assays
in cases of suspected tuberculosis? Thorax
2009;64:A108
Abstract
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Number Author ID Details Reason(s) for exclusion
253 Hsia EC QuantiFERON-TB Gold In-Tube test versus tuberculin
skin test across RA, PsA, and AS patients prior to
treatment with golimumab, a human anti-TNF
antibody. Arthritis Rheum 2010;62:908
Abstract
254 Iqbal AZ Cost-effectiveness of Using QuantiFERON Gold
(QFT-G)® versus tuberculin skin test (TST) among US
and foreign born populations at a public health
department clinic with a low prevalence of
tuberculosis. Public Health Nurs 2014;31:144–52
Economic study
255 Jackson C Diabetes and latent tuberculosis infection: nested
case–control study within the PREDICT cohort.
Thorax 2013;68:A31–2
Abstract
256 James PM The performance of QuantiFERON-TB Gold in-Tube
(QFT-IT) test compared to tuberculin skin test (TST)
in detecting latent tuberculosis infection (LTBI) in the
presence of HIV coinfection in a high TB-burden
area with BCG-vaccinated population. J Int Assoc
Provid AIDS Care 2014;13:47–55
No construct validity
257 Jan Wu YJ Different cut off of tuberculin skin test in latent
tuberculosis screening in systemic lupus
erythematosus, rheumatoid arthritis and ankylosing
spondylitis with an intermediate tuberculosis burden
population. Ann Rheum Dis 2013;72:A963–4
Abstract
258 Jegal Y The significance of whole blood interferon-gamma
assay in patients with history of pulmonary
tuberculosis. Am J Resp Crit Care Med
2009;179:A4098
Abstract
259 Jeong JC Utility of QuantiFERON-TB assay for prediction of
tuberculosis development in kidney transplant
patients in an intermediate-tuberculosis-burden
country: lack of evidence for enhanced prediction
for short-term tuberculosis development. Transplant
Proc 2014;46:583–7
IGRA only (no TST) for
construct validity
260 Jeong Y Prevalence of latent tuberculosis infection in
patients with radiographic lesions suggesting old
healed tuberculosis. Am J Resp Crit Care Med
2011;183:A1190
Abstract
261 Jordan N QuantiFERON Gold screening for latent tuberculosis:
cost comparison with mantoux testing.
Rheumatology 2009;48:i70
Abstract
262 Jung YJ The ‘either test positive’ strategy for latent
tuberculous infection before anti-tumour necrosis
factor treatment. Int J Tuberc Lung Dis
2014;18:428–34
No construct validity
263 Kadavath S Effectiveness of combining tuberculin skin test and
interferon gamma release assays as a screening
strategy for detecting latent tuberculosis infection
in high risk patients with systemic lupus
erythematosus. Ann Rheum Dis 2013;72:478
Abstract
264 Kalyoncu U Comparison of QuantiFERON-TB test and TST in
routine practice during anti-TNF treatment.
Ann Rheum Dis 2013;72:231
Abstract
265 Karabela S QuantiFERON TB Gold assay in tuberculosis
diagnosis in patients from areas with high and low
TB incidence. Clin Microbiol Infect 2009;15:S669–70
Abstract
266 Karabela S QuantiFERON TB Gold in Tube assay for TB
diagnosis: a two-year experience. Clin Microbiol
Infect 2009;15:S392–3
Abstract
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Number Author ID Details Reason(s) for exclusion
267 Karimi A Discrepancy between whole blood interferon
gamma assay and tuberculin skin test for diagnosis
of latent TB infection in BCG vaccinated children.
IUBMB Life 2009;61:314
Abstract
268 Kariminia A Comparison of QuantiFERON TB-G-test to TST for
detecting latent tuberculosis infection in a
high-incidence area containing BCG-vaccinated
population. J Eval Clin Pract 2009;15:148–51
Mixed population and/or no
subgroup of interest
269 Kashyap RS Latent TB infection diagnosis in population exposed
to TB subjects in close and poor ventilated high TB
endemic zone in India. PLOS ONE 2014;9:e89524
Abstract
270 Kawamura LM IGRAs in public health practice: economic issues.
Int J Tuberc Lung Dis 2010;14(Suppl. 1):60–3
Economic study
271 Kenney A Physicians inconsistently perform tuberculosis
screening in inflammatory bowel disease patients
managed with anti-TNF agents. Inflamm Bowel Dis
2011;17:S45
Abstract
272 Ketenci A Comparison of whole blood gamma interferon
assay and tuberculin skin testing in tuberculosis
contacts. Respirology 2013;18:71
Abstract
273 Khalilzadeh S Role of QuantiFERON-TB test in detection of
children infected with mycobacterium tuberculosis.
Tanaffos 2010;9:22–7
No construct validity
274 Kiet G Comparing T-SPOT and tuberculosis skin testing
screening methods for treatment acceptance and
cost efficacy. J Adolesc Health 2012;1:S68
Abstract
275 Kik S Predictive value of IGRAs. Enfermedades
Emergentes 2009;11:178–9
Abstract
276 Kim C Comparison of QuantiFERON-TB gold with
tuberculin skin test for detecting latent tuberculosis
infection before kidney transplantation.
Am J Transpl 2013;13:341
Abstract
277 Kim EY Performance of tuberculosis skin test and inferferon-
γ release assay for detection of tuberculosis
infection in immunocompromised patients in an
intermediate burden country. Respirology
2009;14:A188
Abstract
278 Kim H Clinical usefulness of ELISPOT assay for diagnosis of
tuberculosis in a Korean population. Clin Microbiol
Infect 2010;16:S545
Abstract
279 Kim JH Evaluation of the usefulness of interferon-gamma
release assays and tuberculin skin test for detection
of latent mycobacterium tuberculosis infection in
Korean rheumatic patients with biologic agents.
Arthritis Rheum 2013;65:S560
Abstract
280 Kleinert S Screening for latent tuberculosis infection (LTBI)
performance of tuberculous skin test and
interferon-gamma release assays (IGRA) under real
life conditions. Arthritis Rheum 2010;62:782
Abstract
281 Kowada A Cost effectiveness of IGRAs assays in Japan. Int J
Tuberc Lung Dis 2010;14(Suppl. 1):59–60
Abstract
282 Kowada A Cost effectiveness of interferon-gamma release
assay for TB screening of HIV positive pregnant
women in low TB incidence countries. J Infect
2014;68:32–42
Abstract
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Number Author ID Details Reason(s) for exclusion
283 Kruczak K QuantiFERON-TBGIT (QFT) vs TST in diagnosis of
latent tuberculosis (TB) infection (LTBI) in vaccinated
population in Poland. Am J Resp Crit Care Med
2009;179:A5925
Abstract
284 Kruczak K QuantiFERON-TBGIT (QFT) vs tuberculosis skin test
(TST) in diagnosis of latent tuberculosis (Tb)
infection (LTBI) in patients treated by oral
glucocorticosteroids. Am J Resp Crit Care Med
2010;181:A4779
Abstract
285 Kumar P Basic and clinical immunology – 3019. Gamma
interferon release assay for diagnosis of latent
tuberculosis – comparison with TB skin test.
World Allergy Organ J 2013;6(Suppl. 1):P195
Abstract
286 Lagrange PH A toolbox for tuberculosis (TB) diagnosis: an Indian
multicentric study (2006–2008). Evaluation of
QuantiFERON-TB Gold in Tube for TB diagnosis.
PLOS ONE 2013;8:e73579.
Active TB
287 Lee J Comparison of quantiferon-TB gold assay with
tuberculin skin test in Korean children. J Allergy Clin
Immunol 2010;1:AB152
Abstract
288 Lee JH Poor agreement between QuantiFERON-TB Gold
test and tuberculin skin test results for the diagnosis
of latent tuberculosis infection in rheumatoid
arthritis patients and healthy controls. Korean J
Intern Med 2014;29:76–84
No construct validity
289 Lee SJ Risk factors for latent tuberculosis infection in close
contacts of active tuberculosis patients in South
Korea. Respirology 2012;17:130
Abstract
290 Lee SSJ Positive predictive value of interferon-gamma
release assay for incident active tuberculosis in
HIV-infected persons. Retrovirology
2012;9(Suppl. 1):P133
Abstract
291 Lee SSJ Prediction of the risk of active tuberculosis in
HIV-infection with an interferon-gamma release
assay. Lancet 2013;382:16
Abstract
292 Lee T Diagnosis of latent tuberculosis infection by using
the QuantiFERON-TB Gold in-Tube test in children
whose household contact has contagious
pulmonary tuberculosis disease. Int J Infect Dis
2010;14:e307
Abstract
293 Leung CC Evaluation of the T SPOT-TB test in the targeted
screening of close contacts of smear-positive
tuberculosis patients. Am J Resp Crit Care Med
2011;183:A1186
Abstract
294 Lim S Risk of latent tuberculosis infection following
exposure to active tuberculosis in at-risk children
with rheumatic diseases. Intern Med J 2011;41:32
Abstract
295 Lim SC Risk of latent tuberculosis in at-risk children with
rheumatic diseases. Pediatr Rheumatol
2011;9(Suppl. 1):P218
Abstract
296 Linas BP The cost effectiveness of tuberculin skin test and
interferon gamma release assay screening for latent
tuberculosis infection in the US. Am J Resp Crit Care
Med 2011;183:A6337
Abstract
297 Lindemann M Diagnosis of tuberculosis infection in patients
awaiting liver transplantation. Hum Immunol
2009;70:24–8
No relevant outcomes
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Number Author ID Details Reason(s) for exclusion
298 Ling DI Interferon-gamma release assay for pediatric
tuberculosis: does it impact diagnostic and
treatment decisions? Am J Resp Crit Care Med
2010;181:A4776
Abstract
299 Liza MI Anti-TNFa therapy and tuberculosis risk: a two-centre
experience. Int J Rheum Dis 2010;13:90
Abstract
300 Lombardi G Tuberculosis infection in young children: a screening
based on skin and blood testing. Clin Microbiol
Infect 2012;18:548
Abstract
301 Lopez Y Correlation between the response to
Mycobacterium tuberculosis antigens and the
tuberculin skin test in patients with rheumatoid
arthritis in Colombia. Biomedica 2013;33:226–32
No construct validity
302 Losi M Interferon-gamma release assays for the diagnosis
of latent tuberculosis infection in patients with
rheumatic diseases. Clin Microbiol Infect
2010;16:S543
Abstract
303 Losi M Role of the QFT-IT assay for the diagnosis of latent
tuberculosis infection among adult immigrants.
Am J Resp Crit Care Med 2011;183:A1194
Abstract
304 Machado A Jr Analysis of discordance between the tuberculin skin
test and the interferon-gamma release assay. Int J
Tuberc Lung Dis 2009;13:446–53
Mixed population and/or no
subgroup of interest
305 Machado J Diagnosis of latent tuberculosis in patients with
inflammatory bowel disease: prospective
comparison between tuberculin skin test and IGRA
test QuantiFERON TB-Gold. J Crohns Colitis
2011;5:S64
Abstract
306 Mahomed H Predictive value of the TST vs. QuantiFERON-TB Gold
in-Tube in adolescents in a high-burden setting. Int J
Tuberc Lung Dis 2010;14(Suppl. 1):48–9
Presentation
307 Manosa M Current incidence of active tuberculosis in IBD
patients treated with anti-TNF agents: still room for
improvement. J Crohns Colitis 2013;7:e499–500
Letter
308 Mardani M Performance of QuantiFERON TB Gold test
compared with the tuberculin skin test for detecting
latent tuberculosis infection in lung and heart
transplant candidates. Exp Clin Transpl
2014;12:129–32
No construct validity
309 Mardani M Accuracy of QuantiFERON-TB Gold test versus
tuberculin skin test to detect latent tuberculosis
infection in HIV-positive individuals in Iran.
Clin Microbiol Infect 2009;15:S391–2
Abstract
310 Mardani M Performance of QuantiFERON-TB Gold test
compared to tuberculin skin test in detecting latent
tuberculosis infection in HIV-positive individuals in
Iran. Ann Thorac Med 2010;5:43–6
No construct validity
311 Mariette X Before beginning anti-TNF, a better targeted
screening and a twice decrease frequency of latent
tuberculosis (TB) with IFN gamma release assays
(IGRA) compared with tuberculin skin test. Results in
396 patients from the ETAT study. Arthritis Rheum
2010;62:376
Abstract
312 Maritsi D Assessment of quantiferon as a screening tool prior
to initiation of infliximab: a single centre’s
perspective. Clin Exp Rheumatol 2011;29:402–3
Abstract
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Number Author ID Details Reason(s) for exclusion
313 Marra F Cost-effectiveness of a new interferon-based blood
assay, QuantiFERON-TB Gold, in screening
tuberculosis contacts. Int J Tuberc Lung Dis
2008;12:1414–24
Economic study
314 Martinez-Morillo M Interferon-γ release assays in rheumatic patients:
baseline study and in the course of anti-tumor
necrosis factor-α agents. Arthritis Rheum
2011;63(Suppl. 10):1941
Abstract
315 Martinez-Morillo M Interferon-gamma release assays in rheumatic
patients: baseline study and in the course of anti-
tumor necrosis factor-alpha agents. Ann Rheum Dis
2014;71(Suppl. 3):277
Abstract
316 Mateo L Usefulness of in vitro interferon-release assays (IGRAS)
for diagnosis of latent tuberculosis infection in
rheumatic patients scheduled for anti-TNF-treatment.
Arthritis Rheum 2009;60:996
Abstract
317 Matsubara J Indeterminate and positivity rates of a commercially
available enzyme-linked immunospot (ELISPOT)
blood test in at-risk groups for tuberculosis
infection. Am J Infect Control 2010;38:e48–9
Abstract
318 Matsubara J Indeterminate and positivity rates of the T-SPOT.TB
test in at-risk individuals screened for tuberculosis
infection. Am J Resp Crit Care Med 2010;181:A6831
Abstract
319 Mehta B Combining tuberculin skin test and interferon
gamma release assays for latent tuberculosis
infection screening may be necessary for the
exclusion of latent tuberculosis in a high risk
individuals with rheumatoid arthritis. Arthritis
Rheum 2011;63(Suppl. 10):1190
Abstract
320 Mehta B A proposed effective strategy to screening latent
TB infection in RA patients. Ann Rheum Dis
2013;71(Suppl. 3):169
Abstract
321 Melath S Screening for latent TB in patients with rheumatic
disorders prior to biologic agents in a ‘high-risk’ TB
population: comparison of two interferon gamma
release assays. Rheumatol Int 2014;34:149–50
Abstract
322 Mendes MA Contact screening in tuberculosis: can we identify
those with higher risk? Eur Respir J 2013;41:758–60
Mixed population and/or no
subgroup of interest
323 Mendoza OM Interferon-gamma release assays for the diagnosis
of latent Mycobacterium tuberculosis infection.
Eur Respir J 2011;38:1237–8
Letter
324 Meyssonnier V Performance of Quantiferon® for the diagnosis of
TB. Med Mal Infect 2012;42:579–84
Active TB
325 Milburn H A comparison between interferon gamma release
assays and the tuberculin skin test in the contact
tracing of patients with chronic kidney disease
response. Thorax 2011;66:730
Letter
326 Miller RF Comparison of two interferon-gamma release
assays (Quantiferon-TB Gold in-Tube and T-SPOT.TB)
in screening for latent tuberculosis infection (LTBI)
among HIV-infected adults attending an inner
London HIV clinic. Thorax 2011;66:A72–3
Abstract
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327 Ministro P Diagnosis of latent tuberculosis in patients with
inflammatory bowel disease: prospective
comparison between tuberculin skin test and
interferon gamma release assay (IGRA) test.
Gastroenterology 2011;140:S776
Abstract
328 Mittal C QuantiFERON TB gold testing for latent tuberculosis
is more frequently indeterminate in patients with
inflammatory bowel disease. Inflamm Bowel Dis
2013;19:S62
Abstract
329 Mount C Mantoux or gamma interferon (IGRA) – which test is
best in children? Thorax 2011;66:A138–9
Abstract
330 Mulder C Predictive value of the tuberculin skin test
among newly arriving immigrants. PLOS ONE
2013;8 e60130
IGRA only (no TST)
331 Munoz L Prevention of tuberculosis associated with tumour
necrosis factor antagonists. An 8-year observational
cohort study. Clin Microbiol Infect 2012;18:33
Abstract
332 Neira-Munoz E Extensive transmission of mycobacterium
tuberculosis among children on a school bus.
Pediatr Infect Dis J 2008;27:836–7
Abstract
333 Ni Cheallaigh C Sensitivity, specificity and inter-test agreement of
interferon-gamma release assays for the diagnosis
of latent tuberculosis infection in HIV-infected
individuals with advanced immunodeficiency.
Clin Microbiol Infect 2010;16:S72
Abstract
334 Nicol MP Comparison of T-SPOT.TB assay and tuberculin skin
test for the evaluation of young children at high risk
for tuberculosis in a community setting. Pediatrics
2009;123:38–43
Inappropriate proxy for LTBI
335 Noorbakhsh S Evaluation of the agreement between Quantiferon-
TB assay and tuberculin skin test in TB infected
cases: Tehran, Iran. Int J Infect Dis 2012;16:e288
Abstract
336 Novak S Tuberculosis among patients treated with anti TNF
inhibitors prior and after the use of Quantiferon
test. Clin Exp Rheumatol 2009;27:710
Abstract
337 O’Flynn E Quantiferon testing in mantoux negative patients
commencing anti-TNF therapy identifies additional
at risk patients. Irish J Med Sci 2012;181:S58
Abstract
338 Ong SY How good are we at screening for infections prior
to anti-TNF-alpha therapy? J Gastroenterol Hepatol
2012;27:113–14
Abstract
339 Oon H The interferon-gamma release assay: experience
from a tertiary dermatology center in the tropics.
J Am Acad Dermatol 2013;68:AB135
Abstract
340 Ortakayla M Concordance of the interferon-γ release assay
(IGRA) and the tuberculin skin test (TST) for
the screening of tuberculosis infection in the
inflammatory rheumatic disease (IRD) population.
Chest 2012;142(Suppl. 4):211A
Abstract
341 Ozbek S Detection of latent tuberculosis infection in
rheumatologic diseases before anti-TNFalpha
therapy: tuberculin skin test versus IFN-γ assay.
Arthritis Rheum 2013;65:S577
Abstract
342 Ozen Alahdab Y Interferon-gamma release assay or tuberculin skin
test in inflammatory bowel disease patients – which
is reliable. J Crohns Colitis 2011;5:S53
Abstract
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Number Author ID Details Reason(s) for exclusion
343 Painter JA Tuberculosis screening by tuberculosis skin test or
QuantiFERON-TB Gold In-Tube assay among an
immigrant population with a high prevalence of
tuberculosis and BCG vaccination. PLOS ONE
2013;8:e82727
Active TB
344 Paluch-Oles J Identification of latent tuberculosis infection in
rheumatic patients under consideration for
treatment with anti-TNF-alpha agents. Arch Med Sci
2013;9:112–17
No construct validity
345 Papay P Immunosuppressive (IS) therapy impacts the results
of QuantiFERON and tuberculin skin test in routine
screening for latent tuberculosis (LTB) in patients
with inflamm bowel diseases (IBD). Gastroenterol
2009;1:A195.
Abstract
346 Pareek M Modelling the health impact and cost-effectiveness
of screening new entrants to the UK for latent
tuberculosis infection. J Infect 2009;59:S442
Abstract
347 Pareek M Community-based evaluation of immigrant TB
screening using interferon gamma release
assays and tuberculin skin testing: yields and
cost-effectiveness. Thorax 2011;66:A20
Abstract
348 Patel D Screening for latent tuberculosis in patients starting
anti-TNF therapy. Rheumatol 2012;51:iii175
Abstract
349 Pease E Does the dual-testing strategy under-diagnose
latent TB infection in HIV-infected individuals?
A 1-year experience in a TB high-incidence area in
the UK. HIV Med 2013;14:69
Abstract
350 Perez-Escolano E Comparison of an interferon-gamma release assay
with tuberculin skin test for the diagnosis of
tuberculosis infection in a contact investigation.
Clin Microbiol Infect 2009;15:S392
Abstract
351 Perez-Escolano E Comparison of QuantiFERON TB Gold with
tuberculin skin test for the diagnosis of tuberculosis
infection in risk groups. Clin Microbiol Infect
2010;16:S542–3
Abstract
352 Pesola GR Quantiferon gold in tube latent tuberculosis testing
in low risk healthy adults. Am J Resp Crit Care Med
2011;183:A4884
Abstract
353 Pullar ND Low prevalence of positive interferon-gamma tests
in HIV-positive long-term immigrants in Norway.
Int J Tuberc Lung Dis 2014;18:180–7
No construct validity
354 Punal Rioboo J Interferon-Gamma Release Assays (IGRAs) for
Diagnosis of Latent Tuberculosis Infection and
Active Tuberculosis. Santiago de Compostela:
Galician Agency for Health Technology Assessment
(AVALIA-T); 2010
Abstract
355 Qin LL T-SPOT.TB for detection of tuberculosis infection
among hematological malignancy patients and
hematopoietic stem cell transplant recipients.
Asian Pac J Cancer Prev 2013;14:7415–19
No construct validity
356 Richeldi L Prior tuberculin skin testing does not boost
QuantiFERON-TB results in paediatric contacts.
Eur Respir J 2008;32:524–5
Letter
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357 Rotar Z Performance of a two-step latent tuberculosis
screening algorithm in patients with rheumatoid
arthritis, psoriatic arthritis or ankylosing spondylitis
prior to treatment with tumor necrosis alpha
inhibitors: prospective observational data from the
Biorx.Si registry. Arthritis Rheum 2013;65:S578
Abstract
358 Sauzullo I Detection of M. tuberculosis infection by
interferon-gamma release assays: a comparative
study in HIV-infected patients and in
immunosuppressed candidates for anti-TNF-alpha
therapy. HIV Med 2009;10:155–6
Abstract
359 Sauzullo I Usefulness of interferon-gamma release assays for
latent tuberculosis screening in patients candidate
for TNF-α therapy. Clin Microbiol Infect 2010;16:S72
Abstract
360 Schichter-Konfino V Interferon-γ-release assay prevents unnecessary
tuberculosis therapy in individuals with positive
tuberculin skin test. J Allergy Clin Immunol
2014;133:AB244
Abstract
361 Seagar AL Assessment of the use of the Quantiferon-TB gold
in-tube assay for the diagnosis of TB infection in
Lothian, Scotland. Clin Microbiol Infect
2010;16:S544
Abstract
362 Sester M Head-to-head analysis of M. tuberculosis
interferon-γ release assays (IGRAs) and skin-testing
in immunocompromised patients: interim analysis of
a European multicenter TBNET study. Am J Transpl
2011;11:115
Abstract
363 Shakak AO Latent tuberculosis infections (LTBI): tuberculin skin
test and whole blood IFN-gamma as surrogate
markers in developing countries. Clin Chem Lab
Med 2011;49:S541
Abstract
364 Sharma N ELISPOT as a predictor for development of TB in
children with TB contact. Thorax 2009;64:320
Abstract
365 Soborg B Comparison of screening procedures for LTBI
among patients with inflammatory diseases.
Int J Tuberc Lung Dis 2010;14(Suppl. 1):38–40
Included/excluded in CG11710
366 Stavri HR Prospective comparison of two brands of tuberculin
skin tests and Quantiferon-TB Gold in-Tube assay
performances for tuberculosis infection in
hospitalized children. Medica 2010;5:271–6
Active TB
367 Swaminath A Quantiferon testing is superior to tuberculosis
skin test (TST) in identifying latent TB in
immunosuppressed patients with inflammatory
bowel disease: a decision analysis. Am J
Gastroenterol 2012;107:S688
Abstract
368 Swaminath A Cost-effectiveness of QuantiFERON testing before
initiation of biological therapy in inflammatory
bowel disease. Inflamm Bowel Dis 2013;19:2444–9
Economic study
369 Tavast E IGRA tests perform similarly to TST but cause no
adverse reactions: pediatric experience in Finland.
BMC Res Notes 2009;2:9
Active TB
370 Tavast E Immunosuppression adversely affects TST but not
IGRAs in patients with psoriasis or inflammatory
musculoskeletal diseases. Int J Rheumatol
2012;2012:381929
Non-standard or in-house
IGRA
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Number Author ID Details Reason(s) for exclusion
371 Triverio PA Interferon-gamma release assays versus tuberculin
skin testing for detection of latent tuberculosis in
chronic haemodialysis patients. Nephrol Dial Transpl
2009;24:1952–6
Included/excluded in CG11710
372 Van Zyl-Smit RN Immunodiagnosis of latent TB in HIV-infected
persons in a high burden setting. Am J Resp Crit
Care Med 2011;183:A4885
Abstract
373 Vassilopoulos D Comparison of two interferon-gamma release
assays to tuberculin skin testing for latent
tuberculosis screening in rheumatic patients starting
anti-TNF treatment. Arthritis Rheum 2009;60:1907
Abstract
374 Velizarova SA To what extent T-SPOT.TB could be used in the
diagnosis of tuberculosis in children exposed to TB
infection? Eur J Immunol 2009;39:S217
Abstract
375 Vortia E Use of the QuantiFERON-TB Gold in-Tube test for
latent tuberculosis screening in children with
inflammatory bowel disease treated with infliximab.
Gastroenterology 2013;144:S887
Abstract
376 Wang H Clinical value of a whole blood interferon-γ release
assay for the diagnosis of Mycobacterium
tuberculosis infection during antitubercular
treatment. Exp Ther Med 2013;6:455–8
Active TB
377 Wiwanitkit V QuantiFERON-TB Gold test versus tuberculin skin
test. Ann Thorac Med 2010;5:119
Abstract
378 Wollman J The effect of the severity of psoriasis on screening
for latent tuberculosis: a comparison study between
psoriasis and rheumatoid arthritis patients. Ann
Rheum Dis 2013;71(Suppl. 3):692
Abstract
379 Wong SH Tuberculosis screening with interferon-gamma
release assay in inflammatory bowel disease in a
tuberculosis-endemic population. Gastroenterology
2013;144:S418
Abstract
380 Yilmaz N Comparison of QuantiFERON-TB Gold test and
tuberculin skin test for identification of latent
Mycobacterium tuberculosis infection in lupus
patients. Arthritis Rheum 2009;60:286
Abstract
381 Zapantis E What is the optimal screening test to detect latent
tuberculosis infection in high risk patients with
systemic lupus erythematosus? Findings from a US
inner city high-risk SLE cohort. Lupus 2013;22:61
Abstract
382 Zelinkova Z Effectiveness of the screening for latent tuberculosis
in inflammatory bowel disease patients with
previous BCG vaccination. Gastroenterology
2013;144:S413–14
Abstract
383 Zlnay M The risk of tuberculosis in patients with ankylosing
spondylitis during anti-TNF therapy: data from
national database in Slovakia. Ann Rheum Dis
2013;72(Suppl. 3):513
Abstract
ID, identification.
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December 2014 update
Number Author ID Details Reason(s) for exclusion
384 Al-Taweel T A pilot study of optimal screening for latent
tuberculosis in patients with inflammatory bowel
disease. Gastroenterology 2014;1:S–582
Abstract
385 Al Wakeel JS The use of QuantiFERON TB Gold in-Tube test in
screening latent and active tuberculosis among
saudi dialysis patients. Nephrol Dial Transpl
2014;29:iii477–8
Abstract
386 Arenas Miras MDM Diagnosis of latent tuberculosis in patients with
systemic lupus erythematosus: T.SPOT.TB versus
tuberculin skin test. Biomed Res Int
2014;2014:291031
No construct validity;
immunocompromised:
concordance information
387 Arstikyte I The value of the Quantiferon TB Gold In-Tube test
in the identification of latent tuberculosis in
rheumatic patients before treatment with TNF-alpha
blockers in Vilnius University Hospital Santariskiu
Clinics. Scand J Rheumatol 2014;43:44–5
Abstract
388 Belknap R Interferon-gamma release assays. Clin Lab Med
2014;34:337–49
Review
389 Bennett A Does the tuberculin skin test increase the detection
of TB infection when screening HIV positive
patients? Three years’ experience in a district
general hospital. Thorax 2014;69:A209
Abstract
390 Calzada-Hernandez J PReS-FINAL-2265: tuberculosis in pediatric patients
who are receiving anti-TNF agents. Pediatr Rheumat
2013;11(Suppl. 2):P255
Abstract
391 Chuke SO Tuberculin skin tests versus interferon-gamma
release assays in tuberculosis screening among
immigrant visa applicants. Tuberc Res Treat Print
2014;2014:217969
No construct validity; recently
arrived: concordance
information
392 Cruz AT Relationship between tuberculin skin test (TST) size
and interferon gamma release assay (IGRA) result:
when should clinicians obtain IGRAs in children with
positive TSTs? Clin Pediatr 2014;53:1196–9
No construct validity for LTBI
(prior TB is not a construct of
LTBI); study aim was to
compare the tests in
predicting chest radiography
result suggesting the
presence of MTB
393 Duman N Screening for latent tuberculosis infection in
psoriasis and psoriatic arthritis patients in a
tuberculosis-endemic country: a comparison of the
Quantiferon-TB Gold In-Tube test and tuberculin
skin test. Int J Dermatol 2014;53:1286–292
No construct validity
394 Elfrink F Screening travellers to high-endemic countries for
infection with Mycobacterium tuberculosis using
interferon gamma release assay; a prospective
study. BMC Infect Dis 2014;14:515
Repeat testing
395 Elmahdy MMGF Tuberculin skin test and QuantiFERON test for
detection of latent Mycobacterium tuberculosis.
Int J Infect Dis 2014;21:349
Abstract
396 Golovics PA Is the tuberculin skin test alone accurate in
moderate-to-severe BCG vaccinated patients with
inflammatory bowel disease to test for latent
tuberculosis? J Crohns Colitis 2014;8:S144
Abstract
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
311
Number Author ID Details Reason(s) for exclusion
397 Islam S Tuberculin skin test and QuantiFERON performance,
and testing of populations at low risk for
tuberculosis infection. Clin Infect Dis 2014;59:
1187–8
Letter to the editor
398 Jenum S The frequencies of IFNγ+IL2+TNFα+ PPD-specific
CD4+CD45RO+ T-cells correlate with the
magnitude of the QuantiFERON Gold In-Tube
response in a prospective study of healthy Indian
adolescents. PLOS ONE 2014;9:e101224
Comparing antigens
399 Julian AN Diagnosis of tuberculosis infection in pediatric
patients treated with inhibitors of the tumour
necrosis factor alpha. A multicenter national study
comparing tuberculin skin test and igra tests. Pediatr
Rheumatol 2014;12:P282
Abstract
400 Marquez C Tuberculosis infection in early childhood in Uganda
and the influence of HIV exposure. Topics Antiviral
Med 2014;22:47–8
Abstract
401 Mathad JS Effect of HIV on latent TB screening of pregnant
women in Pune, India. Topics Antiviral Med
2014;22:425–6
Abstract
402 McMullen SE Performance of QuantiFERON-TB Gold and
tuberculin skin test relative to subjects’ risk of
exposure to tuberculosis. Clin Infect Dis
2014;58:1260–6
Population aged > 18 years
403 Mendy A Higher specificity of tuberculin skin test compared
with QuantiFERON-TB Gold for detection of
exposure to Mycobacterium tuberculosis. Clin Infect
Dis 2014;59:1188–9
Letter to editor
404 Nassiri AA Re: Interferon-gamma release assay agreement with
tuberculin skin test in pretransplant screening for
latent tuberculosis in a high-prevalence country.
Iran J Kidney Dis 2014;8:432–3
Letter
405 O’Flynn E Performance and benefits of replacing Mantoux test
with QuantiFERON in screening for latent TB in
patients prior to anti-TNF therapy. Ann Rheum Dis
2014;73(Suppl. 2):2–1247
Abstract
406 O’Flynn E Performance and benefits of replacing Mantoux test
with QuantiFERON in screening for latent TB in
patients prior to anti TNF therapy. Irish J Med Sci
2014;183:S105
Abstract
407 Opris D Is tuberculosis screening sufficient for preventing TB
reactivation in biologic treated patients? Ann
Rheum Dis 2014;73:497
Abstract
408 O’Shea MK Tuberculin skin testing and treatment modulates
interferon-gamma release assay results for latent
tuberculosis in migrants. PLOS ONE 2014;9:e97366
Military recruits
409 Panchal RK The effectiveness of primary care based risk
stratification for targeted latent tuberculosis
infection screening in recent immigrants to the UK:
a retrospective cohort study. Thorax
2014;69:354–62
No comparison between
IGRA and TST
410 Pease E Does the dual testing strategy under-diagnose latent
tuberculosis infection in UK HIV-infected
individuals?: a one year experience in a tuberculosis
high incidence area. Int J STD AIDS 2013;24:56
Poster
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Number Author ID Details Reason(s) for exclusion
411 Prignano F Latent tuberculosis infection in psoriasis and other
dermatological immunomediated diseases: a
combined approach by QuantiFERON-TB Gold and
tuberculin skin tests. Int J Dermatol 2014;53:e372–4
Letter
412 Rose W QuantiFERON Gold-in-Tube assay for TB screening in
HIV infected children: influence of quantitative
values. BMC Infect Dis 2014;14:516
Repeat testing, proportion of
people had self-read TST
results
413 Sanchez Riera L QuantiFERON-TB more useful than tuberculin skin
test for latent tuberculosis screening: a hospital
experience. Ann Rheum Dis 2014;73:950–1
Abstract
414 Santoro-Lopes G Screening for latent tuberculosis infection in
low-incidence areas. Am J Transpl 2014;14:1709
Letter to the editor
415 Savaj S Interferon-gamma release assay agreement with
tuberculin skin test in pretransplant screening for
latent tuberculosis in a high-prevalence country.
Iranian J Kidney Dis 2014;8:329–32
No construct validity
416 Scholman T Analysis of agreement between IGRAs and
tuberculin skin-testing by the use of PPD as the
same antigen. Transplantation 2014;90:540
Abstract
417 Senturk T Comparison of diagnostic test for latent tuberculosis
infection. Int J Rheum Dis 2014;17:103
Abstract
418 Shokrollahi MR Diagnosis of latent tuberculosis in individuals with
recent exposure: tuberculin skin test versus
interferon-gamma release assay. Br J Biomed Sci
2014;71:125–6
Not population of interest
419 Soare A Preventing active tuberculosis in rheumatoid arthritis
patients receiving TNF inhibitors: TB screening at
baseline is not enough. Ann Rheum Dis
2014;73:325
Abstract
420 Sztajnbok F PReS-FINAL-2054: latent tuberculosis infection in
patients with juvenile idiopathic arthritis undergoing
methotrexate therapy: a longitudinal study with
TST and ELISPOT. Pediatr Rheumatol Online J
2013;11(Suppl. 2):P67
Repeat testing at 3 and
12 months
421 Sztajnbok F Tuberculin skin test and ELISPOT/T.SPOT.TB in
children and adolescents with juvenile idiopathic
arthritis. Pediatr Rheumatol 2014;12:17
Repeat testing at 3 and
12 months
422 Verhagen LM Agreement between QuantiFERON-TB Gold in-Tube
and the tuberculin skin test and predictors of
positive test results in Warao Amerindian pediatric
tuberculosis contacts. BMC Infect Dis 2014;14:383
Repeat testing
423 Zelinkova Z Screening for latent tuberculosis is effective but
does not fully protect against tuberculosis
reactivation during anti-TNF treatment in areas with
high background incidence of tuberculosis. J Crohns
Colitis 2014;8:S212
Abstract
424 Zelinkova Z Screening for latent tuberculosis is effective but
does not fully protect against tuberculosis
reactivation during anti-TNF treatment in areas with
high background incidence of tuberculosis.
Gastroenterology 2014;1:S585
Abstract
ID, identification.
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Appendix 7 ClinicalTrials.gov and the World
Health Organization International Clinical Trials
Registry Platform list of excluded ongoing
studies (n = 30)
TABLE 56 ClinicalTrials.gov and WHO ICTRP list of excluded ongoing studies
Number Study title
Recruitment
status URLa
Reason(s) for
exclusion
1 Screening for latent tuberculosis infection
(LTBI) in US army recruits
Active, not
recruiting
http://ClinicalTrials.gov/
show/NCT00804713
Army recruits
2 Diagnosis of tuberculosis infection in
health care workers using ex-vivo
interferon-gamma assay
Completed http://ClinicalTrials.gov/
show/NCT01007396
Health-care workers,
active TB
3 Comparison of the Quantiferon®-TB
GOLD (in Tube) assay with tuberculin
skin testing for detecting latent
tuberculosis infection in patients with
chronic liver disease being evaluated for
or awaiting liver transplantation
Withdrawn http://ClinicalTrials.gov/
show/NCT00424684
Withdrawn
4 Surveillance and follow-up for latent
tuberculosis infection and risk of
developing active tuberculosis in patients
receiving long-term dialysis
Completed http://ClinicalTrials.gov/
show/NCT01311999
No comparison
between IGRAs and
TST
5 QuantiFERON®-TB Gold in-Tube for the
diagnosis of tuberculosis infection in
contact tracing study (OPTIMIST)
Active, not
recruiting
http://ClinicalTrials.gov/
show/NCT01223534
No subgroup of
interest
6 QuantiFERON for detection of latent
tuberculosis in healthcare workers
Completed http://ClinicalTrials.gov/
show/NCT00797836
Health-care workers
7 Is tuberculin skin testing effective in
screening for latent tuberculosis (TB) in
elderly residents of nursing homes?
Completed http://ClinicalTrials.gov/
show/NCT00756808
No subgroup of
interest
8 QuantiFERON Gold test for detecting
tuberculosis (TB) infection in HIV/AIDS
patients in South Africa
Recruiting http://ClinicalTrials.gov/
show/NCT02119130
Active TB
9 Diagnosis and treatment of co-infection
with human immunodeficiency virus/
latent tuberculosis infection (HIV/TBL)
Active, not
recruiting
http://ClinicalTrials.gov/
show/NCT01875952
No comparison
between IGRAs and
TST
10 The role of IGRA in screening and
monitoring for TB during anti TNF
therapy in patients with IMID
Recruiting http://ClinicalTrials.gov/
show/NCT02135289
No comparison
between IGRAs and
TST
11 Immune response to Mycobacterium
tuberculosis infection
Completed http://ClinicalTrials.gov/
show/NCT00257907
Active TB
12 Performance of IGRAs for TB infection
diagnosis in elderly (IGRage)
Recruiting http://ClinicalTrials.gov/
show/NCT01895582
Active TB
13 Monthly follow up of interferon gamma
releasing assay (IGRA) among health-care
workers treating tuberculosis (TB) patients
Completed http://ClinicalTrials.gov/
show/NCT01121068
Health-care workers
14 Vitamin A supplementation for modulation
ofMycobacterium tuberculosis immune
responses in latent tuberculosis
Withdrawn http://ClinicalTrials.gov/
show/NCT00558480
Withdrawn
continued
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TABLE 56 ClinicalTrials.gov and WHO ICTRP list of excluded ongoing studies (continued )
Number Study title
Recruitment
status URLa
Reason(s) for
exclusion
15 Diagnosis of latent tuberculosis (TB)
infection in health care workers using
TST and whole blood interferon-γ assay
Completed http://ClinicalTrials.gov/
show/NCT00962793
Health-care workers
16 Latent tuberculosis infection in bone
marrow transplant recipients
Completed http://ClinicalTrials.gov/
show/NCT01021124
No comparison
between IGRAs and
TST
17 Conversion rate of (TST) tuberculin skin
test and QuantiFERON-TB Gold in Tube
assay in health care workers
Completed http://ClinicalTrials.gov/
show/NCT01376843
Health-care workers
18 Determining risk in latent tuberculosis Terminated http://ClinicalTrials.gov/
show/NCT01571739
Study terminated
19 Treatment of latent tuberculosis infection
with isoniazid
Completed http://ClinicalTrials.gov/
show/NCT00293228
Focus on the effect
of treatment
20 Effects of vitamin D supplementation on
antimycobacterial immunity
Completed http://ClinicalTrials.gov/
show/NCT00157066
Focus on the effect
of treatment
21 A Phase I/IIa safety and immunogenicity
of AERAS-456 in HIV-negative adults
with and without latent tuberculosis
infection (C-035–456)
Completed http://ClinicalTrials.gov/
show/NCT01865487
Comparing antigen
and placebo
22 Isoniazid (INH) treatment based on
ELISPOT assay
Completed http://ClinicalTrials.gov/
show/NCT01087190
Focus on the effect
of treatment
23 A safety and immunogenicity trial with
an adjuvanted TB subunit vaccine
(Ag85B-ESAT-6+ IC31) (THYB-03)
Completed http://ClinicalTrials.gov/
show/NCT01049282
Comparing antigens
24 IFN-gamma-releasing assay based
approach in patients with suspected
tuberculous peritonitis
Recruiting http://ClinicalTrials.gov/
show/NCT02175134
Diagnosis of
tuberculous
peritonitis
25 A Phase III contact tracing trial
comparing the diagnostic performance of
C-Tb to QuantiFERON®-TB Gold in-Tube,
in combination with a double blind
randomized split body safety assessment
of C-Tb versus 2 TU tuberculin PPD
RT23 SSI
Authorised www.clinicaltrialsregister.eu/
ctr-search/trial/2011-
005617-36/ES
Active TB
26 Ensayo clínico de dos estrategias para la
toma de decisiones terapéuticas en el
estudo de contactos de tuberculosis:
estrategia estándar, basada en la prueba
de la tuberculina (PT) sola frente a la
combinación de PT y QuantiFERON-TB-
Gold in-Tube
Authorised www.clinicaltrialsregister.eu/
ctr-search/trial/2009-
017430-49/ES
Not English
language
27 Interferon-gamma release assays in
tuberculosis (TB) – HIV co-infected
children
Recruiting http://ClinicalTrials.gov/
show/NCT00604617
Active TB
28 Screening for latent tuberculosis in
healthcare workers with QuantiFERON-
Gold assay: a cost-effectiveness analysis
Recruiting http://ClinicalTrials.gov/
show/NCT00449345
Health-care workers
and economic
analysis
29 Use TST and QFT-RD1 test to monitor the
tuberculous infection in patients, close
contact people and health care workers
Recruiting http://ClinicalTrials.gov/
show/NCT00311220
Health-care workers
30 Diagnosis of active tuberculosis by
ELISPOT
Recruiting http://ClinicalTrials.gov/
show/NCT00174083
Active TB
a All accessed 13 January 2016.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
316
Appendix 8 Included ongoing trials comparing
interferon gamma release assays with the tuberculin
skin test (n = 20)
TABLE 57 Included ongoing trials comparing IGRAs with the TST
Number Study title Recruitment status URL
1 Interferon gamma release assays (IGRA) testing versus
tuberculin skin test in renal transplant recipients
Completed http://ClinicalTrials.gov/
show/NCT01608685
2 Latent tuberculosis in second generation immigrants
from high risk countries compare to low-risk young
Israeli adults
Not yet recruiting http://ClinicalTrials.gov/
show/NCT02073669
3 Evaluation of 2 interferon γ assays in the diagnosis of
latent tuberculosis in HIV-infected patients (ANRS EP 40
QUANTI SPOT)
Completed http://ClinicalTrials.gov/
show/NCT00647205
4 The usefulness of interferon-γ release assays and
tuberculin skin test for detection of latent tuberculosis
infection
Unknown http://ClinicalTrials.gov/
show/NCT01685905
5 Use of a gamma-IFN assay in contact tracing for
tuberculosis in a low-incidence, high immigration area
Completed http://ClinicalTrials.gov/
show/NCT00557765
6 Detection of latent tuberculosis in haemodialysis patients Completed http://ClinicalTrials.gov/
show/NCT00695734
7 Improving latent tuberculosis (TB) diagnosis in Thai
children (TB Px)
Completed http://ClinicalTrials.gov/
show/NCT00947609
8 Is tuberculin skin testing effective in screening for latent
tuberculosis in patients with HIV?
Completed http://ClinicalTrials.gov/
show/NCT00763295
9 Prevalence of latent tuberculosis (TB) infection diagnosed
by interferon-gamma release assay and tuberculin skin
tests in patients with old healed TB
Completed http://ClinicalTrials.gov/
show/NCT01099098
10 T cell interferon-gamma release assay (TIGRA) in
immunocompromised individuals (TBNET-TIPS)
Completed http://ClinicalTrials.gov/
show/NCT00707317
11 A study on changes in IFN-gamma levels following
anti-TNF treatment in patients undergoing serial
QuantiFERON-TB Gold in-Tube
Completed http://ClinicalTrials.gov/
show/NCT01475409
12 Medical and economical impact of IGRAs diagnosis of
latent tuberculosis in HIV-infected patients
Completed http://ClinicalTrials.gov/
show/NCT00805272
13 Comparison of Quantiferon-TB Gold assay with
tuberculin skin testing in patients with chronic liver
disease
Completed http://ClinicalTrials.gov/
show/NCT00402402
14 Tuberculosis (TB) screening for the diagnosis of latent TB
in immunocompromised populations
Completed http://ClinicalTrials.gov/
show/NCT00134342
15 Impact of new immunological diagnosis tests of latent
tuberculosis before anti TNF therapy
Completed http://ClinicalTrials.gov/
show/NCT00811343
16 Latent tuberculosis infection in cancer patients Completed http://ClinicalTrials.gov/
show/NCT00507754
17 Latent tuberculosis infection in renal transplant recipients Completed http://ClinicalTrials.gov/
show/NCT00682045
continued
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TABLE 57 Included ongoing trials comparing IGRAs with the TST (continued )
Number Study title Recruitment status URL
18 Prognostic value of interferon gamma release assays in
predicting active tuberculosis among individuals with, or
at risk of, latent tuberculosis infection (PREDICT)
Not yet recruiting http://clinicaltrials.gov/
show/NCT01162265
19 Comparison of the tuberculin skin test (TST) and
QuantiFERON®-TB Gold Test (QFT-G) in patients with
rheumatoid arthritis being considered for anti-TNF-alpha
therapy
Unknown http://clinicaltrials.gov/
show/NCT00925249
20 Quantiferon-TB Gold in the assessment of latent TB in
patients candidate to treatment or treated with TNFα
antagonists
Unknown http://clinicaltrials.gov/
show/NCT00491933
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Appendix 9 Data extraction tables for included
clinical effectiveness studies
Children 
 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Adetifa 2010105 
Country: Gambia 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Community-based   
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Medical Research Council (MRC) labs 
UK 
Aim of the study 
To compare TSPOT, QFT-GIT, and TST for diagnosis of LTBI in Gambian childhood contacts of TB 
patients 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children 
Participants 
Recruitment dates: NR 
Total N of recruited patients: 285 
Inclusion criteria: Household contacts (< 16 yrs) of newly diagnosed TB index cases  
Exclusion criteria: History of treatment for active TB, TB diagnosis within 1 month of recruitment  
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 215 (for TST) and 245 (for IGRAs) 
Methods of active TB diagnosis (if applicable): Sputum smears and mycobacterial cultures 
examined using standard methods 
Outcomes (study-based) list: Agreement; associations of test results with risk factors; combining 
two tests to explore gains in sensitivity and loss in specificity 
Characteristics of participants (total study sample) 
Mean (range or SD) Age (years): NR 
Women (n [%]): 145 [51] 
Race/ethnicity (n [%]):NR  
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 127/199 [59.1] 
History of anti-TB treatment (n [%]): NR  
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): HIV positive (3 [1.1]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N (indeterminate) Total N  
(test 
results 
available) 
IGRA 
(QFT-
GIT):   
NR 72 143 2 215 
IGRA NR 71 144 0 215 
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(TSPO
T):   
TST 
(≥10m
m): 
NR 57 158 0 215 
Test 3 
(specif
y): 
NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 215 for all three tests 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – sleep proximity 
Non-
exposed  
Different house (reference group) 
Exposed 1 
(specify): 
Same house – different room 
Exposed 2 
(specify): 
Same house – same room 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(TSPOT) 
Carried out according to manufacturer’s 
instructions. The spot unit counting 
performed using ELISPOT reader (AID 
GmbH, Strassburg, Germany) 
Where the negative 
control had 0-5 spots, a 
positive result was 
defined as ≥6 spots in 
either the ESAT-6 or 
CFP-10 panel after 
subtracting the number of 
spots in the negative 
control panel 
 
In case of >6 spots in 
negative control panel, 
ESAT-6 or CFP-10 panel 
had to contain at least 
twice the number of spots 
in negative control panel 
to obtain a positive result 
NA 
IGRA 
(QFT-GIT) 
Carried out according to manufacturer’s 
instructions. IFN gamma levels 
measured using Dynex ELISA reader 
ver. 6.0 (Dynex Technologies, West 
Sussex, UK) 
Positive result was 
defined as ≥0.35 IU/ml 
NA 
TST 
(≥10mm) 
Carried out with 2 TU (PPD RT23, 
Statens Serum Institut, Copenhagen, 
Denmark) immediately after blood 
samples’ completion. Indurations were 
recorded at 48-72 hours 
≥10mm threshold for 
positivity 
NA 
Association between test results and incidence of active TB (if applicable) 
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IGRA TST 
 Incidence of active 
TB 
Total  Incidence of active TB Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indetermi
nate 
NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Sleep proximity Total  Sleep proximity Total 
Same 
house – 
same 
room 
Differ
ent 
house 
Same 
house – 
same room 
Differe
nt 
house 
IGRA + 14 19 33 TST + 15 10 25 
IGRA - NR NR NR TST - NR NR NR 
Indetermi
nate 
NR NR NR Indeterminat
e 
NR NR NR 
Total  NR NR 215 Total  NR NR 215 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T
+
 calculated) = NR  DOR (for T
+
 calculated) = NR  
Same house same room vs. Different 
house 
OR (crude; for T
+ 
reported) = 3.20 (95% CI: 
1.20, 9.10) 
Same house same room vs. Different house 
OR (crude; for T
+ 
reported) = 10.10 (95% CI: 3.20, 
32.10) 
Same house same room vs. Different 
house 
OR (regression-based; reported) = 4.00 (95% 
Same house same room vs. Different house 
OR (regression-based; reported) = 15.00 (95% CI: 
4.70, 47.20) 
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CI: 1.40, 11.40) 
List of covariates: age, sex, ethnic group 
List of covariates: age, sex, ethnic group 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.58 (0.28, 0.90) 
Ratio of ORs (regression-based; reported) = 0.52 (0.29, 0.91) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 Sleep proximity Total  Sleep proximity Total 
Same 
house – 
different 
room 
Differ
ent 
house 
Same 
house – 
different 
room 
Differe
nt 
house 
IGRA + 39 18 57 TST + 32 10 42 
IGRA - NR NR NR TST - NR NR NR 
Indetermi
nate 
NR NR NR Indeterminate NR NR NR 
Total  NR NR 215 Total  NR NR 215 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T
+
 calculated) = NR  DOR (for T
+
 calculated) = NR  
Same house different room vs. 
Different house 
OR (crude; for T
+ 
reported) = 2.00 (95% 
CI: 0.80, 5.10) 
Same house different room vs. Different house 
OR (crude; for T
+ 
reported) = 2.40 (95% CI: 1.00, 5.80) 
Same house different room vs. 
Different house 
OR (regression-based; reported) = 2.60 
(95% CI: 0.90, 7.10) 
List of covariates: age, sex, ethnic group 
Same house different room vs. Different house 
OR (regression-based; reported) = 2.90 (95% CI: 1.30, 
6.70) 
List of covariates: age, sex, ethnic group 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.83(0.43, 1.60) 
Ratio of ORs (regression-based; reported) = 0.90(0.46, 1.76) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 Sleep proximity Total  Sleep proximity Total 
Same 
house – 
same room 
Differen
t house 
Same house 
– same 
room 
Different 
house 
IGRA 
+ 
14 18 32 TST + 15 10 25 
IGRA 
- 
NR NR NR TST - NR NR NR 
Indeter NR NR NR Indetermina NR NR NR 
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minate te 
Total  NR NR 215 Total  NR NR 215 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T
+
 calculated) = NR  DOR (for T
+
 calculated) = NR  
Same house same room vs. Different house 
OR (crude; for T
+ 
reported) = 5.30 (95% CI: 
1.50, 18.50) 
Same house same room vs. Different house 
OR (crude; for T
+ 
reported) = 10.10 (95% CI: 3.20, 
32.10) 
Same house same room vs. Different house 
OR (regression-based; reported) = 6.60 (95% 
CI: 1.70, 25.20) 
List of covariates: age, sex, ethnic group 
Same house same room vs. Different house 
OR (regression-based; reported) = 15.00 (95% CI: 
4.70, 47.20) 
List of covariates: age, sex, ethnic group 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.52(0.22, 1.25) 
Ratio of ORs (regression-based; reported) = 0.44(0.18, 1.09) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 Sleep proximity Total  Sleep proximity Total 
Same house 
– same 
room 
Differen
t house 
Same house 
– same 
room 
Different 
house 
IGRA 
+ 
14 18 32 TST + 15 10 25 
IGRA 
- 
NR NR NR TST - NR NR NR 
Indeter
minate 
NR NR NR Indeterminate NR NR NR 
Total  NR NR 215 Total  NR NR 215 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T
+
 calculated) = NR  DOR (for T
+
 calculated) = NR  
Same house same room vs. Different 
house 
OR (crude; for T
+ 
reported) = 5.30 (95% 
CI: 1.50, 18.50) 
Same house same room vs. Different house 
OR (crude; for T
+ 
reported) = 10.10 (95% CI: 3.20, 
32.10) 
Same house same room vs. Different 
house 
OR (regression-based; reported) = 6.60 
(95% CI: 1.70, 25.20) 
List of covariates: age, sex, ethnic group 
Same house same room vs. Different house 
OR (regression-based; reported) = 15.00 (95% CI: 4.70, 
47.20) 
List of covariates: age, sex, ethnic group 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
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Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.52 (0.22, 1.25) 
Ratio of ORs (regression-based; reported) = 0.44 (0.18, 1.09) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeter
minate 
NR NR NR Indetermi
nate 
NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T
+ 
reported)QFT = 1.10 (95% CI: 0.60, 
2.00) 
OR (crude; for T
+ 
reported)TSPOT = 1.10 (95% CI: 
0.61, 2.09) 
OR (crude; for T+ reported) = 0.89 (95% CI: 
0.50, 1.70) 
OR (regression-based; reported) IGRA = NR 
List of covariates:  
OR (regression-based; reported) TST = NR 
List of covariates:  
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample: QFT-GIT 
 TST (≥10mm) + TST - Total 
IGRA 
(QFT-GIT) 
+ 
43 29 72 
IGRA 
(QFT-GIT) 
- 
14 129 143 
Indetermina
te 
NR NR 2 
Total    217 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total – QFT-GIT 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.52 (95% CI: 0.39, 0.65) 
% concordance = 80.00% (95% CI: 74.15, 84.8) 
% discordance = 20.00% (95% CI: 15.2, 25.85) 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample : TSPOT 
 TST (≥10mm) + TST - Total 
IGRA 
(TSPOT) + 
43 28 71 
IGRA 
(TSPOT) - 
14 130 144 
Indetermina
te 
0 0 0 
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Total  57 158 215 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total -TSPOT 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.53 (95% CI: 0.40, 0.66) 
% concordance = 80.47% (95% CI: 74.65, 85.21) 
% discordance = 19.53% (95% CI: 14.79, 25.35) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indetermina
te 
NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indetermina
te 
NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
TST was most responsive of the 3 tests; none of the tests was affected by prior BCG vaccination 
Reviewers: 
Similar moderate agreement between TSPOT vs. TST and QFT vs. TST; TSPOT and TST were more 
strongly correlated with sleep proximity than QFT; none of the tests was influenced by BCG 
vaccination 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Cruz 2011106 
Country: US 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Pediatric tuberculosis clinics 
Number of centres: 3 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Cellestis, Ltd, Oxford Immunotec, Inc 
Aim of the study 
To compare the performance of 1 IGRA, the T-SPOT.TB assay with the tuberculin skin test (TST) in 
children with different epidemiologic  risk factors for tuberculosis 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children 
Participants 
Recruitment dates: 2005 to 2006 
Total N of recruited patients: NR 
Inclusion criteria: Children (aged 1 month to 18 years) with LTBI or tuberculosis disease and 
children uninfected with tuberculosis 
Exclusion criteria: Children on any tuberculosis medication for 2 or more months were not eligible 
for enrollment 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 215 (22 did not have valid results) 
Total N of patients with valid results for both IGRA and TST: 193 (of these, 30 had diagnosis of 
TB) 
Methods of active TB diagnosis (if applicable): Children with tuberculosis disease was 
subcategorized as those with confirmed or clinically diagnosed tuberculosis. Children with confirmed 
tuberculosis had a positive culture or polymerase chain reaction result for Mycobacterium 
tuberculosis. Clinically diagnosed case subjects were defined as children without positive 
mycobacterial culture results who had radiographic or clinical findings consistent with tuberculosis 
and at least 1 or more of the following: (1) exposure to a known tuberculosis case; (2) a positive TST 
result (≥5 mm); or (3) histopathologic findings compatible with tuberculosis (eg, caseating  
granulomas) 
and the exclusion of reasonable alternative diagnoses 
Outcomes (study-based) list: Agreement, exposure-based 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median 8.6 (range: 1 mo to 18 yrs) 
Women (n [%]): 94 [51] 
Race/ethnicity (n [%]): Hispanic 115 [62.5], Non-Hispanic black 36 [19.6], Non-Hispanic white 19 
[10.3], Asian 6 [3] 
Geographic origin (n[%]): Low prevalence regions (US/UK) (121 [65.7]) 
BCG vaccination (n [%]): 68 [37] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): None 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NA 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
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available) 
IGRA 
(TSPOT):   
185 
(30 TB pts not 
counted) 
94 69 22 163 
TST (≥15mm): 185 
(30 TB pts not 
counted) 
94 69 22 163 
Test 3 
(specify) 
NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 163 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  No contact with an identifiable source case 
Exposed 1 
(specify): 
contact with an identifiable source case 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(TSPOT) 
The commercially available T-
SPOT.TB assay (Oxford 
Immunotec, Oxford, United 
Kingdom) was performed within 5 
hours of specimen collection in 
the laboratory of 1 of the 
investigators (per manufacturer 
instructions. Briefly, this assay 
used 2 M tuberculosis–specific 
antigens, early secreted antigenic 
target 6-kDa protein (ESAT-6) 
and culture filtrate protein 10 
(CFP10), to stimulate interferon- 
production in washed and 
enumerated peripheral blood 
mononuclear cells; 8 mL of blood 
was drawn from children 10 years 
old or older and 4 mL from 
children younger than 10 years. 
Peripheral blood mononuclear 
cells were counted to ensure that a 
standardized cell number was 
added in the assay to control for 
low T-cell volumes. General T-
cell reactivity was confirmed by a 
positive mitogen control 
(phytohemagglutinin). A negative 
control was used to identify 
nonspecific cell activation 
Spots were counted manually 
by using a microscope and 
confirmed by using an 
automated plate counter by the 
manufacturer. Assays with 8 or 
more spots were considered 
positive, and assays with less 
than 5 spots were considered 
negative. Borderline results 
(5–7 spots) were excluded 
from concordance analyses but 
were analyzed separately. A 
subgroup analysis was 
performed for specimens with 
6 to 7 spots, because these 
specimens are sometimes 
considered positive 
internationally. 
NA 
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TST (≥15mm) Trained clinic or health 
department personnel placed and 
interpreted Mantoux tests. 
Transverse induration was 
measured at 48 to 72 hours and 
interpreted according to the 
American Thoracic Society 
criteria 
TSTs were considered positive 
for all children who had results 
of 15 mm or more, 10 mm or 
more for children with chronic 
medical problems or exposure 
to people at high risk, and 5 
mm or more for children with 
suspected disease or who were 
immunocompromised 
or children with identifiable 
source cases 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST≥15mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR  
NPV = NR NPV = NR 
DOR (for T
+
 calculated) = NR DOR (for T
+
 calculated) = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR  
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OR (regression-based; reported) = 4.41 [95% 
CI: 1.78, 10.94]) 
List of covariates: NR 
OR (regression-based; reported) = 0.48 [95% CI: 
0.26, 0.91] 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = 9.19 (95% CI: 5.23, 16.3) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = 4.77 [95% CI: 
2.29, 9.95] 
OR (regression-based; reported) IGRA = 0.69 [95% 
CI: 0.37, 1.31] 
List of covariates: NR 
OR (regression-based; reported) TST = 4.32 
[95% CI: 1.02, 
18.35] 
 List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥15mm 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
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% concordance = NR 
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
T-SPOT.TB was more specific than the TST for children who were immunized with BCG. Contact 
with a source case was associated with T-SPOT.TB result but not TST 
Reviewers: 
BCG influenced TST but not TSPOT in terms of false positives; TSPOT performed better than TST in 
terms of the association with exposure (contact with TB case) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Kasambira 2011107 
Country: South Africa 
Study design: Retrospective cohort/cross-sectional study (with limited follow-up of 6 months) 
Study setting (e.g., outbreak investigation, community-based - specify): Community based 
Number of centres: 3 
Total length of follow up (if applicable): 6 months 
Funding (government/private/manufacturer/other - specify): The United States Agency for 
International Development 
Aim of the study 
To determine and compare the prevalence of M. tuberculosis infection as assessed by TST and by 
QFT-GIT. Secondary objectives were to assess agreement between the two test methods and identify 
factors associated with various patterns of test results 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children  
Participants 
Recruitment dates: October 2006 and December 2009 
Total N of recruited patients: NR 
Inclusion criteria: Children aged 6-16 years whose parents/guardians were TB index cases aged 18 
years, with diagnosis of pulmonary TB within the preceding 3 months, willingness to have the child 
undergo study testing and provision of informed consent 
Exclusion criteria: Children’s prior diagnosis or treatment of active or latent TB. 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 270 
Total N of patients with valid results for both IGRA and TST: 254 
Methods of active TB diagnosis (if applicable): Microbiological tests, histopathology, clinician 
diagnosis or a combination of these. Performance of diagnostic testing for adult TB suspects was not a 
component of this study, and diagnoses of pulmonary TB in the adult index cases were made by non-
study clinicians. The study team reviewed medical records and interviewed adult index cases to 
corroborate the diagnosis 
Outcomes (study-based) list: LTBI prevalence, agreement, association of test positivity with 
different index case- and child-related baseline factors 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median 6 [3–9] 
Women (n [%]): 141 [52] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 257 [95] 
History of anti-TB treatment (n [%]): None  
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): HIV 14 [5] 
Co-morbidity (n [%]): NA 
Type of during-study treatment (n [%]): Active TB treatment 37 [19%] and LTBI treatment 19 [10%]  
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (GIT):   270 79 172 19 251 
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TST ( 5 mm):  270 71 183 16 254 
Test 3 (specify) NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 254 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group –  
 Adult index case type of 
TB diagnosis 
Adult index case 
smear grade 
Exposure to index case 
during the day 
Non-exposed  Smear-positive TB Negative Minority of day (< 6 h) 
 
Exposed 1 
(specify): 
Smear-negative, culture-
positive TB 
Scanty 
 
Majority of day (> 7 h) 
Exposed 2 
(specify): 
Clinical TB 1+ NA 
Exposed 3 
(specify): 
NA 2+ NA 
Exposed 4 
(specify): 
NA 3+ NA 
Tests 
 Assay used, methodology, timing for test 
measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(QFT-GIT) 
All children underwent QFT-GIT testing 5–30 
min after TST placement. Blood was drawn 
from the right arm. QFT-GIT testing was 
performed according to the manufacturer’s 
instructions, and included nil control, mitogen 
control and TB antigen tubes. Assays were 
conducted in a single laboratory at the study site 
by the same trained technician. Average interval 
between blood collection and initiation of 
incubation was 8.3 min (median 5, range 2–60, 
interquartile range 3–10). Following stimulation 
and centrifugation, harvested plasma specimens 
were stored at 4°C for up to 28 days prior to 
ELISA testing 
Results were 
calculated 
and interpreted by 
the assay software 
as positive, negative 
or indeterminate 
NA 
TST 5 mm the Mantoux method using Tuberculin purified 
protein derivative (PPD) RT-23 (2 units, Statens 
Serum Institut, Copenhagen, Denmark) was 
injected subcutaneously into the left forearm and 
the test was read 48–96 h later 
An induration of 5 
mm was considered 
a positive test 
during the study 
 
 
 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
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PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 46 32 78 TST + 42 29 71 
IGRA - 108 81 189 TST - 99 81 180 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  154 113 267 Total  141 110 251 
Test performance parameters 
IGRA TST 
Exposure to index case during the day (see 
2 x 2 above) 
Sensitivity = 46/154 = 29.87% (95% CI: 23.2, 
37.52) 
Exposure to index case during the day (see 2 x 2 
above) Sensitivity = 42/141 = 29.79% (95% CI: 
22.86, 37.79) 
Exposure to index case during the day (see 
2 x 2 above) 
Specificity = 81/113 = 71.68% (95% CI: 
62.77, 79.17) 
Exposure to index case during the day (see 2 x 2 
above) Specificity = 81/110 = 73.64% (95% CI: 
64.71, 80.97) 
Exposure to index case during the day (see 
2 x 2 above) 
PPV = 46/78 = 58.97% (95% CI: 47.89, 
69.22) 
Exposure to index case during the day (see 2 x 2 
above) PPV = 42/71 = 59.15% (95% CI: 47.54, 
69.83) 
Exposure to index case during the day (see 
2 x 2 above) 
NPV = 81/189 = 42.86% (95% CI: 36.01, 
49.99) 
Exposure to index case during the day (see 2 x 2 
above) NPV = 45.00% (95% CI: 37.91, 52.30) 
DOR (for T
+
 calculated) = not calculated DOR (for T
+
 calculated) = not calculated 
OR (crude; for T
+ 
reported) =  
Adult index case type of TB diagnosis 
Smear-positive TB: 1.00 (reference group) 
Smear-negative, culture-positive TB: 0.18 
(95% CI: 0.05, 0.70) 
Clinical TB: 0.81 (95% CI: 0.45, 1.50)  
 
Adult index case smear grade 
Negative: 1.00 (reference group) 
Scanty: 0.3 (95% CI: 0.05, 1.60) 
1+: 1.50 (95% CI: 0.70, 3.60) 
2+: 1.50 (95% CI: 0.50, 4.90) 
3+: 3.20 (95% CI: 1.40, 7.40) 
OR (crude; for T
+ 
reported) =  
Adult index case type of TB diagnosis 
Smear-positive TB: 1.00 (reference group) 
Smear-negative, culture-positive TB: 0.17 (95% CI: 
0.05, 0.60) 
Clinical TB: 0.46 (95% CI: 0.24, 0.89)  
 
Adult index case smear grade 
Negative: 1.00 (reference group) 
Scanty: NR 
1+: 2.81 (95% CI: 1.20, 6.70) 
2+: 2.90 (95% CI: 0.80, 10.60) 
3+: 4.10 (95% CI: 1.50, 11.10) 
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 Exposure to index case during the day 
Minority of day (< 6 h) – 1.00 reference group 
Majority of day (> 7 h): 1.1 (95% CI: 0.63, 
1.80) 
 
Exposure to index case during the day 
Minority of day (< 6 h) – 1.00 reference group 
Majority of day (> 7 h): 1.20 (95% CI: 0.67, 2.10) 
OR (regression-based; reported) =  
Adult index case type of TB diagnosis 
Smear-positive TB: 1.00 (reference group) 
Smear-negative, culture-positive TB: 0.84 
(95% CI: 0.09, 7.80) 
Clinical TB: 3.90 (95% CI: 0.67, 23.5)  
 
Adult index case smear grade 
Negative: 1.00 (reference group) 
Scanty: NR 
1+: 5.50 (95% CI: 0.89, 34.70) 
2+: 8.70 (95% CI: 1.20, 62.00) 
3+: 11.40 (95% CI: 1.80, 72.00) 
 
Exposure to index case during the day 
Minority of day (< 6 h) – 1.00 reference group 
Majority of day (> 7 h): 1.30 (95% CI: 0.69, 
2.30) 
List of covariates: NR 
OR (regression-based; reported) =  
Adult index case type of TB diagnosis 
Smear-positive TB: 1.00 (reference group) 
Smear-negative, culture-positive TB: 2.70 (95% CI: 
0.56, 13.0) 
Clinical TB: NR 
 
Adult index case smear grade 
Negative: 1.00 (reference group) 
Scanty: NR 
1+: 7.90 (95% CI: 1.50, 41.00) 
2+: 15.70 (95% CI: 2.60, 92.0) 
3+: 11.70 (95% CI: 2.20, 62.00) 
 
Exposure to index case during the day 
Minority of day (< 6 h) – 1.00 reference group 
Majority of day (> 7 h): 1.10 (95% CI: 0.58, 2.10) 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NR 
Ratio of OR (crude; for T
+ 
reported) = 0.78 (95% CI: 0.40, 1.52)  [Adult index case smear grade: 3+ 
vs. negative] 
Ratio of ORs (regression-based; reported) = 0.97 (95% CI: 0.27, 3.47) [Adult index case smear grade: 
3+ vs. negative] 
Ratio of OR (crude; for T
+ 
reported) = 0.92 (0.62, 1.36) [Exposure to index case during the day (>7 
h)] 
Ratio of ORs (regression-based; reported) = 1.18 (0.75, 1.85) [Exposure to index case during the day 
(>7 h)] 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 75 2 77 TST + 68 2 70 
IGRA - 182 3 185 TST - 175 2 177 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  257 5 262 Total  243 4 247 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = 0.61 (95% CI: 
0.10, 3.77) 
DOR (for T+ calculated)TST = 0.38 (95% CI: 0.05, 
2.81)  
OR (crude; for T
+ 
reported) = 0.62 (95% CI: 
0.08, 4.76) reference group flipped (yes vs. 
no) 
OR (crude; for T+ reported) = 0.38 (95% CI: 0.05, 
2.85) 
reference group flipped (yes vs. no) 
OR (regression-based; reported) IGRA = 0.83 
(95% CI: 0.08, 8.33) 
reference group flipped (yes vs. no) 
OR (regression-based; reported) TST = 0.52 (95% CI: 
0.06, 4.00) 
reference group flipped (yes vs. no) 
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List of covariates: NR  List of covariates:  
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥5mm) TST - Total 
IGRA (QFT-GIT) + 56 19 75 
IGRA - 12 149 161 
Indeterminate 3 15 18 
Total  71 183 254 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.68 (95% CI: 0.56, 0.81) indeterminate excluded 
% concordance = 205/236 = 86.86% (95% CI: 81.96, 90.59) ; indeterminate excluded 
% discordance = 31/236 = 13.14% (95% CI: 9.41, 18.04) indeterminate excluded 
Stratification (≥10mm)):  
 TST +(≥10mm) TST - Total 
IGRA + 48 27 75 
IGRA - 7 154 161 
Indeterminate 2 16 18 
Total  57 197 254 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.64 (95% CI: 0.51, 0.76) 
% concordance = 202/236 = 85.59% (95% CI: 80.54, 89.5) 
% discordance = 34/236 = 14.41% (95% CI: 10.5, 19.46) 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Prevalence of M. tuberculosis infection in paediatric contacts was high regardless of the diagnostic 
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method used. TST should not be excluded for the detection of paediatric M. tuberculosis infection in 
this setting, but QFT-GIT may be a feasible alternative in children aged 2 years 
Reviewers: 
Similar performance of TST and IGRA for exposure DORs; BCG did not affect TST or IGRA 
positivity differentially; TST threshold did not influence the agreement between the two tests 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Data extraction sheet for included primary study reports 
 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Laniado-Laborin 2014148 
Country: Mexico 
Study design: Cross-sectional/retrospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Tuberculosis (TB) clinic 
Number of centres: one 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To compare the prevalence of LTBI between paediatric contacts of drug-resistant cases and drug 
susceptible cases  
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children 
Participants 
Recruitment dates: From August 2011 to June 2013  
Total N of recruited patients: NR  
Inclusion criteria: Family contacts of culture–proven cases age ≤16 years  
Exclusion criteria: Subjects with a history of TB, a previous diagnosis of LTBI or the administration 
of TST in the past year 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 173 
Total N of patients with valid results for both IGRA and TST: 172 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: concordance between TST and QFT-GIT test, association between 
exposure and test results  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): drug susceptible (7.79 SD4.28); drug resistant (7.36 SD4.46) 
Women (n [%]): 86/173 [50.0%] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 164 [95%] 
History of anti-TB treatment (n [%]): None 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NA 
Co-morbidity (n [%]): NA 
Type of during-study treatment (n [%]): 77/173 [44.5%] contacts of multidrug susceptible index cases 
were treated for LTBI with INH or rifampicin (RMP). 96/173 [55.5%] contacts of multidrug resistant 
cases did not receive treatment for LTBI 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   173 71 101 1 172 
TST (≥5mm): 173 136 36 1 172 
Total N of patients with valid results for both IGRA and TST: 172 
Levels/groups of exposure to TB in increasing order (if applicable): 
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Definition of exposure group – various definitions (see below) 
Non-exposed  NR 
Exposed 1 (specify): Exposure to source 
Exposed 2 (specify): Hours/day exposure 
Exposed 3 (specify): Cohabitants, n 
Exposed 4 (specify): Rooms, n 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(QFT-GIT) 
QuantiFERON Gold In-Tube assay 
(QFT-GIT) (QIAGEN Inc., Valencia, 
CA, USA) 
 
Each participant had 73 ml of blood 
drawn which was performed 
according to the manufacturer’s 
instructions 
 
QFT-GIT result was 
considered positive 
if the interferon-gamma 
response to TB antigens 
minus the negative 
control was ≥0.35 IU/ml 
and also >25% of the 
negative control, 
negative if these criteria 
were not met and 
indeterminate if either 
the negative control had 
a result of >8 IU/ml or 
the positive control had 
a result of <0.5 IU/ml 
 
TST(≥5mm) TST (5 tuberculin units purified 
protein derivative [PPD]; Tubersol, 
Sanofi Pasteur Lt, Toronto, ON, 
Canada) was performed using the 
Mantoux method. An intradermal 
injection of 0.1 ml PPD was 
administered to the volar surface of 
the forearm. The transverse diameter 
of induration was recorded 
in mm 48 h after administration 
An induration of ≥5 mm 
was considered positive, 
as every  subject was a 
close contact of a 
culture-proven case 
Association between test results and incidence of active TB (if applicable) 
IGRA TST (>5mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
NPV= NA NPV= NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA  Cumulative Incidence Ratio TST = NA   
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
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Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
 
Association between test results and levels of TB exposure (if applicable) 
IGRA-GIT TST≥5mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NR  Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR NPV = NR 
DOR (for T
+
 calculated) = NR  DOR (for T
+
 calculated) = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR 
OR (regression-based; reported) =  
Exposure to source: 0.91 (95% CI 0.57, 1.45) 
Hours/day exposure: 1.03 (95% CI 0.96, 1.10) 
# of cohabitants: 0.91 (95% CI 0.79, 1.05) 
# of rooms: 1.12 (95% CI 0.77, 1.61) 
 
List of covariates: age, sex, history of 
BCG vaccination, intensity of exposure, 
exposure time of the contacts to a source case, 
exposure to a drug-susceptible case, and 
exposure to a drug-resistant case 
OR (regression-based; reported) =  
Exposure to source: NR (p=NR; NS) 
Hours/day exposure: NR (p=NR; NS) 
# of cohabitants: NR (p=NR; NS) 
# of rooms: NR (p=NR; NS) 
 
List of covariates: age, sex, history of 
BCG vaccination, intensity of exposure, exposure 
time of the contacts to a source case, exposure to a 
drug-susceptible case, and exposure to a drug-
resistant case 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T
+ 
reported) = NA OR (crude; for T+ reported) = NA  
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OR (regression-based; reported) IGRA = NA  
List of covariates: NA 
OR (regression-based; reported) TST = NA  
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST +≥5mm TST - Total 
IGRA + 69 2 71 
IGRA - 67 34 101 
indeterminate NR NR 1 
Total  136 36 172 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥ 5mm  
Parameters 
Kappa = 0.27 (95% CI: 0.17, 0.38) 
% concordance = [69+34]/172 = 59.88% (95% CI: 52.42, 66.92) 
% discordance = 69/172 = 40.12% (95% CI: 33.08, 47.58) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
The only variables predictive of a positive QFT-GIT were older age and TST positivity. Logistic 
regression analysis with TST as a dependent variable had similar results, with a positive QFT-GIT 
test as the only predictor of a positive TST (results not shown). 
 
The main finding in our study is that overall prevalence of LTBI in paediatric contacts in our region is 
high, and not significantly different among contacts of drug-susceptible and those of drug resistant 
patients 
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Reviewers: 
There was no associations between exposure to TB and GIT test results; likewise for TST (but no 
results reported); inconclusive results; between test agreement was poor 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer:  Tara Gurung 
 
Study details 
First author surname year of publication: Mahomed 2011b108 
Country: South Africa 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): High schools 
Number of centres: 11 
Total length of follow up (if applicable): NA  
Funding (government/private/manufacturer/other - specify): The Aeras Global TB Vaccine 
Foundation and the Gates Grand Challenge 6 and Gates Grand Challenge 12 grants for QuantiFERON 
testing 
Aim of the study 
To determine the prevalence of and predictive factors associated with latent TB infection in 
adolescents 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children (adolescents in a high TB burden area) 
Participants 
Recruitment dates: NA 
Total N of recruited patients: 6363 enrolled, 5244 enrolled for analysis 
Inclusion criteria: All adolescents aged 12-18 years 
Exclusion criteria: Diagnosed with active TB 
Total N of excluded patients: 13 (an indeterminate QFT results), 639 (TST was not performed with 
past TB), 22 (TST was not performed with current TB, 22 (diagnosed with active TB) 
Total N of patients tested with both IGRA and TST: 5244 
Total N of patients with valid results for both IGRA and TST: 5244 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: TST and QFT results 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 12-18 years 
Women (n [%]): 2842 [54.2] 
Race/ethnicity (n [%]): Indian/White (410 [7.8]); Mixed race (3839 [73.2]); Black (995 [19.0]) 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): No (46 [0.9]); yes (4917 [93.8]); unknown  (281 [5.4]) 
History of anti-TB treatment (n [%]): NR  
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): No 
Clinical examination (yes/no): No 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): Chronic allergy related condition e.g. asthma, hay fever, eczema yes (53 [1.0]); 
No (5191 [99.0]) 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indetermina
te) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):  Unclear 2669 2562 13 5244 
TST (≥5mm):  Unclear 2894 2350 0 5244 
Test 3 (specify):  NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 5244 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
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Exposed 1 (specify): Current or prior TB household contact 
Exposed 2 (specify):  BCG scar 
Exposed 3 (specify):  BCG reported as being given 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
informatio
n 
IGRA  QuantiFERON- TB Gold In-Tube (QFT-
GIT, Cellestis, Carnegie, Victoria, 
Australia) 
A result was considered 
positive if the QFT-
GIT was ≥ 0.35 IU 
NA 
TST Mantoux method on either forearm, using 
2 tuberculin units of RT23 (Statens Serum 
Institut, Copenhagen, Denmark).  
Induration at the TST site was read 48-96 
hours later with a ruler or a caliper, by 
trained personnel 
A result was considered 
positive if induration ≥ 
5mm 
 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence 
of active 
TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminat
e 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (current or prior TB household 
contact) 
IGRA (QFT-GIT) TST≥ 5mm 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 888 1781 2669 TST + 950 1944 2894 
IGRA - 444 2118 2562 TST - 382 1968 2350 
Indeterminate 0 13 13 Indeterminat 0 0 0 
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(excluded) e 
Total  1332 3912 5244 Total  1332 3912 5244 
Test performance parameters 
IGRA TST 
Sensitivity = 888/1332 = 66.67%, 95% CI (64.09, 
69.15) 
Sensitivity = 950/1332 = 71.32%, 95% CI 
(68.83, 73.69) 
Specificity = 2118/3899 = 54.32%, 95% CI (52.75, 
55.88) 
Specificity = 1968/3912 = 50.31%, 95% CI 
(48.74, 51.87) 
PPV = 888/2669 = 33.27%, 95% CI (31.51, 35.08) PPV = 950/2894 = 32.83%, 95% CI (31.14, 
34.56) 
NPV = 2118/2562 = 82.67%, 95% CI (81.16, 
84.09) 
NPV = 1968/2350 = 83.74%, 95% CI (82.2, 
85.18) 
DOR (for T+ calculated) = 2.38, 95% CI (2.09, 
2.71) 
DOR (for T+ calculated) = 2.52, 95% CI (2.20, 
2.88) 
OR (crude; for T+ reported) = 2.40, 95% CI (2.11, 
2.74) 
OR (crude; for T+ reported) = 2.52, 95% CI 
(2.20, 2.88) 
OR (regression-based; reported) = 1.90, 95% CI 
(1.70, 2.20) 
List of covariates: NR  
OR (regression-based; reported) = 2.00 (1.70, 
2.30) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.94 (95% CI: 0.86, 1.04) 
Ratio of OR (crude; for T+ reported) = 0.94 (95% CI: 0.86, 1.04) 
Ratio of ORs (regression-based; reported) = 0.95 (95% CI: 0.86, 1.05) 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥ 5mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  2064 1490 3554 Total  2064 1490 3554 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = 0.99, 95% CI (0.86, 
1.12) 
OR (crude; for T+ reported) = 1.16, 95% CI 
(1.0, 1.33) 
OR (regression-based; reported) IGRA = NR 
List of covariates:  
OR (regression-based; reported) TST = NR 
List of covariates:  
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample ≥ 5mm 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥ 5mm 
Parameters 
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Kappa = 0.70, 95% CI: 0.68, 0.71 
% concordance = 84.8% (95% CI NR) 
% discordance = NR 
Total sample (≥ 10mm) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥ 10mm 
Parameters 
Kappa = 0.63, 95% CI: 0.61, 0.65 
% concordance = 81.4% (95% CI NR) 
% discordance = NR 
Total sample (≥ 15mm) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold: ≥ 15mm 
Parameters 
Kappa = 0.30, 95% CI: 0.27, 0.32 
% concordance = 64.3% (95% CI NR) 
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The predictive factor profile for both measures was similar 
Reviewers: 
TST was slightly influenced by BCG vaccination, but not IGRA; Both tests performed similarly in 
detection LTBI; 5mm threshold TST had better agreement than 10 and 15mm 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Metin Timur 2014150 
Country: Turkey  
Study design: prospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): community based contact 
study  
Number of centres: NR  
Total length of follow up (if applicable): 3 years as outpatients with 3 months intervals  
Funding (government/private/manufacturer/other - specify): NR  
Aim of the study 
To compare QuantiFeron-TB gold in tube test (QFT-GIT) and tuberculin skin test (TST) as a diagnosis 
of latent tuberculosis infection in the children with Bacille Calmette-Guerin (BCG) vaccine 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children 
Participants 
Recruitment dates: between 2008 and 2011 
Total N of recruited patients: NR 
Inclusion criteria: children with positive TST results, children without a history of contact with a TB 
case, active TB case in the household was not detected through the family screening, children having no 
medical reason for immunosuppression, children who had diagnosed TB disease without a contact with 
active TB case 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 81 
Total N of patients with valid results for both IGRA and TST: 81 
Methods of active TB diagnosis (if applicable): LTBI as defined both TST and QFT-GIT test positive 
in a children who had no abnormality on the chest x-ray. Active TB disease was defined both TST and 
QFT-GIT test positive in a child who had symptoms of TB disease and/or abnormal findings on chest 
radiograph, CT or proven M. tuberculosis culture, PCR or histo- pathological examination. 
Outcomes (study-based) list: diagnosis of prevalent TB, incidence of active TB 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 94.8 ±51.9 months (range: 6-193) 
Women (n [%]): 33 [40.7%] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): one BCG scar (69 [85.2%]; two BCG scars (12 [14.8%] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): None 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes  
Morbidity (n [%]): NA 
Co-morbidity (n [%]): acute appendicitis (1 [1.2%]) 
Type of during-study treatment (n [%]): no treatment (n=69 children with TST
+/QFT- results); isoniazid 
(n=8 children with TST+/QFT+ results but no symptoms – assumed with LTBI); isoniazid, rifampicin 
and pyrazinamide (n=4 children with TST+/QFT+ results with symptoms –with TB) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   81 12 69 0 81 
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TST (≥15mm): 81 81 0 0 81 
Total N of patients with valid results for both IGRA and TST: 81 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test 
measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other information 
IGRA (QFT-
GIT) 
Peripheral blood samples 
were taken in the laboratory, 
where they were processed by 
trained physicians and 
performed according to 
manufacturer’s instructions. 
For each child, total 3 mL 
whole blood was taken, then 
blood was collected 
in three special tubes: gray- 
(negative control, ‘‘nil’’), 
red- (test tube), and purple-
cap (positive control; 
mitogen-coated) tubes. Test 
tube is specially designed 
for blood collection which is 
coated with M. tuberculosis- 
specific antigens (ESAT-6, 
CFP-10, and a portion of TB 
7.7). Once blood was 
collected it is essential to 
provide adequate shaking for 
antigens to dissolve. They 
were incubated at 37°C for 16 
to 24 hours and centrifugation 
at 3000 g for 15 minutes, then 
plasma was separated. The 
amount of IFN-γ was 
measured by using the QFT 
ELISA 
A positive result was defined 
if the difference in the IFN-γ 
levels between the test tube 
and negative control is 
greater than or equal to 
0.35 IU/mL and is greater 
than 25% of the nil value. 
Also for determinate results, 
nil control must be < 8.0 
IU/mL 
 
TST(≥15mm) All children underwent a TST 
with 5 TU of purified protein 
derivative, according to 
intradermal Mantoux method  
 
When interpreting a TST 
result, the widest diameter of 
induration, not erythema, 
was measured in millimetres 
after 72 hours by trained 
physician or nurses. TST 
was considered as positive if 
an induration was ≥ 15mm, 
regardless of BCG 
vaccination scar numbers 
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Association between test results and incidence of active TB (if applicable) 
IGRA-GIT TST (≥15mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 0 0 0 TST + 0 69 69 
IGRA - 0 69 69 TST - 0 0 0 
indeterminate 0 0 0 indeterminate 0 0 0 
Total 0 69 69 Total 0 69 69 
Test performance parameters 
IGRA-GIT TST≥15mm  
Sensitivity = NA Sensitivity = NA 
Specificity = 69/69 = 100% (95% CI: NR) Specificity = 0/69 = 0.0% (95% CI: NR) 
PPV= NA  PPV = 0/69=0.0% (95% CI: NR) 
NPV= 69/69 = 100% (95% CI: NR) NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = 0/69 = 0.0% (95% 
CI: NR)  
Cumulative Incidence IGRA- = 0/69 = 0.0% (95% 
CI: NR)  
Cumulative Incidence TST- = NA  
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA 
Other reported measure IGRA = NR Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios= NA 
Other reported measure= NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
NPV= NA NPV= NA 
DOR (for T
+
 calculated) = NA DOR (for T
+
 calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) = NA  
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA  
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
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IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA= NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) =  NA 
OR (regression-based; reported) IGRA= NA  
List of covariates: NA 
OR (regression-based; reported) TST = NA  
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
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% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
Study suggests that confirmation of positive TST results with QFT- GIT test may enhance the accuracy 
of diagnosing both active TB and LTBI, particularly among BCG vaccinated children. The correct 
diagnosis of LTBI prevents unnecessary treatment and treatment complications 
Reviewers: 
None of the 69 children with TST positive results and QFT-GIT negative results developed active TB, 
indicating better specificity of QFT-GIT vs. TST (100% vs. 0%) 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Pavic 2011109 
Country: Croatia  
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Children hospital and 
general hospital  
Number of centres: 2  
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): None 
Aim of the study 
To evaluate an IGRA for diagnosis of LTBI in BCG –vaccinated children up to 5 years of age, with 
documented exposure to active TB 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Younger children with history of exposure to active TB 
Participants 
Recruitment dates: Between January 2008 and December 2009 
Total N of recruited patients: 142 
Inclusion criteria: Pediatric patients’ ≤5 years of age and a documented exposure (close or distant 
contact) to a case of active TB. Close contact (household contact with aggregate exposure to a patient 
with active TB of not < 40 hours in closed room and distant contact (occasional or unclear exposure 
time of <40 hours during the presumed period of infectiousness) 
Exclusion criteria: Children >5 years, immunocompromised children, inadequate blood sampling 
and diagnosis of active TB 
Total N of excluded patients: 1 (diagnosed with pneumonia: data were not included in further 
statistical analysis) 
Total N of patients tested with both IGRA and TST: 142 
Total N of patients with valid results for both IGRA and TST: 141 
Methods of active TB diagnosis (if applicable): Induration of ≥10mm  
Outcomes (study-based) list: Test results, impact of age and on results of IGRA and level of 
agreement between IGRA and TST results 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 29 ± 16 months 
Women (n [%]): 57 [40.1] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 142 [100] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): Pneumonia 1 [0.7] 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   142 18 123 1 141 
TST (≥10mm): 142 24 118 0 142 
Test 3 (specify) NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 142 
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Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  Distant contact was defined as occasional or unclear exposure time or < 40 
hours during the presumed period of infectiousness. 
Exposed 1 (specify): Close contact was defined as household contact with aggregate exposure to 
a patient with active TB ≥40 hours in closed rooms 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA 
(QFT-GIT) 
QFT-GIT (Cellestis Limited, 
Chadstone, Australia) 
≥ 0.35 IU/mL as 
recommended by the 
manufacturer. 
Blood samples for QFT-
GIT were drawn under 
standardized condition in 
our hospital at the same 
day as TST.  The test was 
considered indeterminate 
if the value of the 
positive-control well was 
less than 0.5 IU/mL, 
and/or nil negative control 
was more than 8 IU/L 
TST≥ 10 
mm 
Two tuberculin units of 
standardized purified protein 
derivative solution (Tuberculin 
PPD RT 23, Statens Serum 
Institute, Copenhagen, Denmark) 
injected into the volar aspect of 
the forearm and transverse 
induration and was measured by a 
trained healthcare worker 68 to 
72 hours later 
Induration ≥ 10 mm NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA  
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
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Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (close contact) 
IGRA (QFT-GIT) TST≥ 10 mm 
 Exposure level Total  Exposure level Total  
Close Distant Close Distant 
IGRA + 17 1 18 TST + 23 1 24 
IGRA - 70 53 123 TST - 64 54 118 
Indeterminate 0 1 1 
(excluded) 
Indeterminate 0 0 0 
Total  87 54 141 Total  87 55 142 
Test performance parameters 
IGRA TST 
Sensitivity = 17/87 = 19.54%, 95% (12.57, 
29.08) 
Sensitivity = 23/87 = 26.44%, 95% (18.31, 36.56) 
Specificity = 53/54 = 98.15%, 95% (90.23, 
99.67) 
Specificity = 54/55 = 98.18%, 95% (90.39, 99.68) 
PPV = 17/18 = 94.44%, 95% (74.24, 99.01) PPV = 23/24 = 95.83%, 95% CI (79.76, 99.26) 
NPV = 53/123 = 43.09%, 95% (34.68, 51.92) NPV = 54/118 = 45.76%, 95% CI (37.05, 54.74) 
DOR (for T+ calculated) = 12.87, 95% CI 
(1.66, 99.80) 
DOR (for T+ calculated) = 19.41, 95% CI (2.53, 
148.40) 
OR (crude; for T+ reported) = 1.66, 95% CI 
(0.92, 3.35) error 
OR (crude; for T+ reported) = 1.75, 95% CI (0.92, 
3.35) error 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.66 (95% CI: 0.15, 2.89) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT) TST (>10 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (TSPOT/QFT) TST (>5 mm) 
DOR (for T+ calculated)TSPOT/QFT = NR DOR TST (for T+ calculated) = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported)QFT = NR  
OR (regression-based; reported)TSPOT = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
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This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 14 4 18 
IGRA - 11 112 123 
Indeterminate 0 1 1 (excluded) 
Total  25 116 141 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold:  ≥10 mm in duration 
Parameters 
Kappa = 0.59, 95% CI (0.42, 0.75) 
% concordance = 126/141 = 89.36%, 95% CI (83.19, 93.45) 
% discordance = 15/141 = 10.64%, 95% CI (6.554, 16.81) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Authors concluded that in a high-risk population of children ≤ 5 years, both the TST and IGRA 
should be performed and a positive result on either test a suggestive of LTBI 
Reviewers: 
Tests performed similarly well in identifying LTBI by association with the active TB exposure 
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Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Perez-Porcuna 2014151 
Country: Brazil 
Study design: Cross-sectional/retrospective 
Study setting (e.g., outbreak investigation, community-based  - specify): community-based   
Number of centres: 2 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): the Brazilian National Counsel of 
Technological and Scientific Development (CNPq), the Foundation of Research Support of the State 
of Amazonas (FAPEAM), and the University of Barcelona. Cellestis Ltd. donated QuantiFERON test 
kits. The funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript 
Aim of the study 
To evaluate the response of the IGRA QuantiFERON-TB Gold In-Tube (QFT) and TST tests in young 
children with recent exposure to an index case 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children  
Participants 
Recruitment dates: from March 2009 to February 2010 
Total N of recruited patients: 140 
Inclusion criteria: children from 0–6 years of age with recent contact with an adult symptomatic TB 
index case within the last 12 months 
Exclusion criteria: Subjects receiving treatment or prophylaxis for TB  
Total N of excluded patients: 3 
Total N of patients tested with both IGRA and TST: 135 
Total N of patients with valid results for both IGRA and TST: 116 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: between-test agreement, discordance, concordance, associations 
between different factors and test results 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 46 (28.0; 64.5) months 
Women (n [%]): 74 (54.8%) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 118 (90.8%) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NA 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate
) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   135 36 80 19 116 
TST: ≥ 10mm 135 47 88 0 135 
Total N of patients with valid results for both IGRA and TST: 116 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – Time of exposure to the index case 
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Non-exposed  NA 
Exposed (specify): # months measured as continuous covariate 
Definition of exposure group – mycobacterium tuberculosis contact (MTC) score: 0-15 
Non-exposed  NA 
Exposed (specify): MTC score measured as continuous covariate. The score is composed of 
infectivity of the index case (0–4), the duration of exposure hours per day 
(0–4), the relationship to the index case (0–4) and the type of exposure (0–
3) 
Tests 
 Assay used, 
methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA [QFT-GIT] The QFT (Cellestis, 
Carnegie, Australia) 
was 
carried out and 
interpreted according 
to the manufacturer’s 
instructions  
was considered 
indeterminate if there 
was excessive IFN-c 
production with the 
negative control tube 
$8.0 IU/mL 
The result was positive 
(QFT+) if the net value of 
IFN-c to the TB antigens 
(after subtracting the 
negative control) was 
≥0.35 U/mL and ≥25% of 
the value of the negative 
control, independently of 
the response of the 
mitogen.  
 
The result was negative if 
the net value of the IFN-c 
was <0.35 IU/mL and 
mitogen response was 
sufficient (≥0.50 IU/mL).  
 
The result was 
indeterminate if there was 
excessive IFN-c production 
with the negative control 
tube ≥8.0 IU/mL 
(indeterminate 
hypereactive) or with 
insufficient net mitogen 
response <0.50 IU/mL plus 
insufficient net response of 
the TB antigen < 0.35 
IU/mL (indeterminate 
hyporeactive) 
 
When the QFT result was 
indeterminate the test was 
repeated to confirm the 
result 
Experienced 
laboratory 
technicians who 
were unaware of 
the data of the 
study subjects 
TST≥ 10mm  The TST was 
performed with an 
intradermic injection of 
2 tuberculin units (TU) 
of PPD RT23 (Statens 
Serum Institut, 
≥ 10mm positivity 
threshold 
 
according to the protocols 
of the WHO 
 
Experienced 
laboratory 
technicians who 
were unaware of 
the data of the 
study subjects  
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Copenhagen, 
Denmark) and read 72 
hours thereafter 
≥ 5-9 mm weak reaction 
≥ 10mm strong reaction 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level (# of 
months of exposure 
to the index case) 
Total  Exposure level (# of 
months of exposure 
to the index case) 
Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
indeterminate NR NR NR indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T
+
 calculated)= NA DOR (for T
+
 calculated) = NA  
OR (crude; for T+ reported)= NR (p=0.024)  
OR is associated with one unit increase in # of 
exposure months 
OR (crude; for T+ reported) = NR (p<0.001)  
OR is associated with one unit increase in # of 
exposure months 
OR (regression-based; reported) = NR (p = 0.537);  
OR is associated with one unit increase in # of 
exposure months 
List of covariates: NR 
OR (regression-based; reported) = 1.15 (95% CI 
1.04, 1.27; p = 0.009) 
OR is associated with one unit increase in # of 
exposure months  
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List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level (MTC 
score) 
Total  Exposure level 
(MTC score) 
Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
indeterminate NR NR NR indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
NPV= NA NPV= NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA  
OR (crude; for T+ reported) = NR (p = 0.021)  
OR is associated with one unit increase in MTC 
score 
OR (crude; for T+ reported) = NR (p<0.001)  
OR is associated with one unit increase in # 
MTC score 
OR (regression-based; reported) = 1.16 (95% CI 
1.01, 1.33; p = 0.035);  
OR is associated with one unit increase in MTC 
score  
List of covariates: NR 
OR (regression-based; reported) = 1.29 (95% CI 
1.08, 1.54; p = 0.005) 
OR is associated with one unit increase in MTC 
score  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = 0.90 (95% CI: 0.80, 1.01) 
Other reported measure= NA 
Association between test results and BCG status (if applicable) 
IGRA (GIT) TST (10mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 35 1 36 TST + 37 2 39 
IGRA - 72 8 80 TST - 70 7 77 
indeterminate NR NR NR indeterminate NR NR NR 
Total  107 9 116 Total  107 9 116 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 3.89 (95% CI: 
0.46, 32.33)  
DOR (for T+ calculated)TST = 1.85 (95% 
CI: 0.36, 9.36) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) =  NR 
OR (regression-based; reported) IGRA = NR 
List of covariates:  
OR (regression-based; reported) TST = NR 
List of covariates:  
Other reported measure = NR Other reported measure = NR 
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Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥10mm) TST - Total 
IGRA + 21 15 36 
IGRA - 18 62 80 
indeterminate 8 11 19 
Total  47 88 135 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.35 (95% CI: 0.16, 0.53) p<0.001 
% concordance = [21+62]/116=71.55 (95% CI: 62.75, 78.97) 
% discordance = [18+15]/116 = 28.44 (95% CI: 21.03, 37.25) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
We observed that the results of both tests were related to the intensity of exposure, although, as 
previously reported, the TST was more strongly influenced by exposure than QFT. Another factor we 
observed was that TST+ results were related to a greater time of exposure while the same was not 
observed for QFT. Likewise, we did not observe any association between the TST results and the 
presence of a BCG scar. Analysis of our data supports the contention that QFT probably undergoes 
more rapid conversion (step from negative to positive) after primary infection than the TST and would 
explain most of the discordant test results in this group 
Reviewers: 
Both the TST and QFT were associated with the intensity of exposure (MTC score) with only the TST 
being significantly associated with the time of exposure (regression-based analyses). Concordance 
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between the TST and QFT (excluding the indeterminate cases) was fair (Kappa = 0.35); presence of 
BCG scar did not significantly influence the odds of TST or IGRA 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Rutherford 2012a110 and Rutherford 2012b111 (same study but plus 
neighborhood contacts; agreement analysis) 
Country: Indonesia 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Out-patient-based clinic 
Number of centres: One  
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
aimed to quantify M. tuberculosis infection in children living with a smear-positive adult TB case and identify risk 
factors for TST and QFT-GIT positivity 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children  
Participants 
Recruitment dates: NR 
Total N of recruited patients: 320 
Inclusion criteria: Child contacts living for more than 3 months with newly diagnosed TB cases (index case) who 
were smear and chest X-ray (CXR) positive  
Exclusion criteria: Child contacts who had received a diagnosis of TB disease within the past year or who were 
aged <6 months were excluded (the latter due to known poor parental acceptability of blood collection) 
Total N of excluded patients: 16 (active TB) 
Total N of patients tested with both IGRA and TST: 304 
Total N of patients with valid results for both IGRA and TST: 288 
Methods of active TB diagnosis (if applicable): Active TB was defined by CXR findings consistent with TB 
according to the consultants 
Outcomes (study-based) list: Association of test positivity with exposure factors (Rutherford 2012a), agreement 
(Rutherford 2012b) 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median [IQR] 58 [31–81] months 
Women (n [%]): 152 [50.7] 
Race/ethnicity (n [%]): Sundanese (284 [93.7]), Other (19 [6.3]) 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): With scar (221 [73.2]), unknown BCG status (30 [9.9]) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes (Children who were symptomatic and test-negative (on either IGRA or TST) 
were referred to the children’s clinic for further assessment according 
to clinic policy 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   304 152 138 14 290 
TST (≥10mm): 304 145 157 2 302 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 288 
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Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – Characteristics of TB case smear positivity 
Non-exposed  Scanty and 1+ 
Exposed 1 (specify): 2+ 
Exposed 2 (specify): 3+  
Definition of exposure group – Relationship to child 
Non-exposed  Other 
Exposed 1 (specify): Aunt/uncle 
Exposed 2 (specify): Parent 
Definition of exposure group – Sleeping proximity to child 
Non-exposed  Different room 
Exposed 1 (specify): Same room 
Exposed 2 (specify): Same bed 
Definition of exposure group – Time spent with child (# hrs/day) 
Non-exposed  < 2 
Exposed 1 (specify): 2 - 8 
Exposed 2 (specify): > 8 
Tests 
 Assay used, methodology, timing for test measurement, 
manufacturer 
Cut-off 
values/thresho
lds Definition 
of test+ 
Other 
informati
on 
IGRA (QFT-
GIT) 
For QFT-GIT, 3 ml of venous blood was collected into a syringe; 1 
ml was immediately transferred to each of the QFT-GIT tubes (nil, 
mitogen and antigen). The tubes were vigorously hand-shaken and 
placed in an incubator within 3 h. Incubated samples were 
centrifuged and stored at 4°C for up to 1 month. The QFT-GIT assay 
was conducted and interpreted according to the manufacturer’s 
instructions using specific software 
NR NA 
TST 
(≥10mm) 
TST was performed by the study nurse following blood collection 
using two tuberculin units of purified protein derivative (PPD; RT23 
Biofarma®, Bandung, Indonesia). Induration was measured 48–72 h 
after administration and confirmed by the study doctor 
An induration 
of 10 mm 
was considered 
positive 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of active 
TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indetermi
nate 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA  
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
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Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level 
characteristics of TB 
case 
Smear positivity 
Total  Exposure level  
characteristics of TB case 
Smear positivity 
Total 
3+  2+ Scanty/1+ 3+  2+ Scant
y/1+ 
IGRA + 75 36 40 152 TST + 78 34 33 145 
IGRA - 45 34 59 138 TST - 48 38 71 157 
Indeterminate NR NR NR 14 (excluded) Indetermin
ate 
NR NR NR 2 
(excluded) 
Total  120 70 99 290 Total  126 72 104 302 
Test performance parameters 
IGRA TST 
Trend in ORs across the gradient of exposure (p = 0.001) 
 
Scanty/1+: OR (crude; reported) = 1.00 (reference group) 
2+: OR (crude; reported) = 1.56 (95% CI: 0.78, 3.11) 
3+: OR (crude; reported) = 2.43 (95% CI: 1.21, 4.86) 
 
3+ vs. scanty/1+ 
Sensitivity = 75/120 = 62.5% (95% CI: 53.58, 70.65) 
Specificity = 59/99 = 59.6% (95% CI: 49.75, 68.73) 
PPV = 75/115 = 65.22% (95% CI: 56.15, 73.3) 
NPV = 59/104 = 56.73% (95% CI: 47.14, 65.85) 
DOR (for T
+ calculated) = 2.46 (95% CI: 1.42, 4.24) 
OR (crude; for T+ reported) = 2.43 (95% CI: 1.21, 4.86) 
OR (regression-based; reported) = 2.28 (95% CI: 1.06, 4.90) 
List of covariates: TB case’s relationship to child, marital 
status of household head 
Other reported measure = NR 
Trend in ORs across the gradient of exposure (p = 
0.000) 
 
Scanty/1+: OR (crude; reported) = 1.00 (reference 
group) 
2+: OR (crude; reported) = 1.80 (95% CI: 0.89, 3.63) 
3+: OR (crude; reported) = 3.35 (95% CI: 1.81, 6.21) 
 
3+ vs. scanty/1+ 
Sensitivity = 78/126 = 61.9% (95% CI: 53.19, 69.91) 
Specificity = 71/104 = 68.27% (95% CI: 58.81, 
76.43) 
PPV = 78/111 = 70.27% (95% CI: 61.21, 77.98) 
NPV = 71/119 = 59.66% (95% CI: 50.68, 68.04) 
DOR (for T
+ calculated) = 3.50 (95% CI: 2.02, 6.04) 
OR (crude; for T+ reported) = 3.35 (95% CI: 1.81, 
6.21) 
OR (regression-based; reported) = 2.93 (95% CI: 
1.59, 5.39) 
List of covariates: TB case’s relationship to child 
Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
3+ vs. scanty/1+ 
Ratio of DORs (for T+ calculated) = 0.70 (95% CI: 0.47, 1.04) 
3+ vs. scanty/1+ 
Ratio of OR (crude; for T+ reported) = 0.73 (95% CI: 0.45, 1.17) 
3+ vs. scanty/1+ 
Ratio of ORs (regression-based; reported) = 0.78(95% CI: 0.47, 1.28) 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level Total  Exposure level  Total 
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relationship to child relationship to child 
parent Aunt or 
uncle 
Other  parent Aunt 
or 
uncle 
Other  
IGRA + 134 8 10 152 TST + 128 9 8 145 
IGRA - 85 19 34 138 TST - 101 19 37 157 
Indeterminate NR NR NR 14 (excluded) Indetermi
nate 
NR NR NR 2 
(excluded) 
Total  219 27 44 290 Total  229 28 45 302 
Test performance parameters 
IGRA TST 
Trend in ORs across the gradient of exposure (p = 0.000) 
 
Other: OR (crude; reported) = 1.00 (reference group) 
Aunt/uncle: OR (crude; reported) = 1.51 (95% CI: 0.44, 5.17) 
Parent: OR (crude; reported) = 5.61 (95% CI: 2.40, 13.12) 
 
Parent vs. Other 
Sensitivity = 134/219 = 61.19% (95% CI: 54.59, 67.4) 
Specificity = 34/44 = 77.27% (95% CI: 63.01, 87.16) 
PPV = 134/144 = 93.06% (95% CI: 87.69, 96.18) 
NPV = 34/119 = 28.57% (95% CI: 21.22, 37.26) 
DOR (for T+ calculated) = 5.36 (95% CI: 2.52, 11.41) 
OR (crude; for T+ reported) = 5.61 (95% CI: 2.40, 13.12) 
OR (regression-based; reported) = 4.30 (95% CI: 1.48, 12.45) 
List of covariates: marital status of household head, smear 
positivity of household head 
Other reported measure = NR 
Trend in ORs across the gradient of exposure (p = 
0.000) 
 
Other: OR (crude; reported) = 1.00 (reference 
group) 
Aunt/uncle: OR (crude; reported) = 2.31 (95% CI: 
0.77, 6.79) 
Parent: OR (crude; reported) = 5.85 (95% CI: 2.56, 
13.38) 
 
Parent vs. Other 
Sensitivity = 128/229 = 55.9% (95% CI: 49.42, 
62.18) 
Specificity = 37/45 = 82.22% (95% CI: 68.67, 
90.71) 
PPV = 128/136 = 94.12% (95% CI: 88.82, 96.99) 
NPV = 37/138 = 26.81% (95% CI: 20.12, 34.76) 
DOR (for T+ calculated) = 5.86 (95% CI: 2.61, 
13.14) 
OR (crude; for T+ reported) = 5.85 (95% CI: 2.56, 
13.38) 
OR (regression-based; reported) = 7.04 (95% CI: 
2.23, 22.28) 
List of covariates: marital status and smear 
positivity of household head  
Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Parent vs. Other 
Ratio of DORs (for T
+
 calculated) = 0.91 (95% CI: 0.52, 1.61) 
Parent vs. Other 
Ratio of OR (crude; for T+ reported) = 0.96 (95% CI: 0.52, 1.75) 
Parent vs. Other  
Ratio of ORs (regression-based; reported) = 0.61 (95% CI: 0.27, 1.36) 
Other reported measure = NR  
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level 
Sleeping proximity to 
child 
Total  Exposure level  
Sleeping proximity to child 
Total 
Same 
bed 
Same 
room 
Different 
room  
Same 
bed 
Same 
room 
Different 
room  
IGRA + 93 15 43 152 TST + 85 13 47 145 
IGRA - 64 12 62 138 TST - 80 15 62 157 
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Indeterminat
e 
NR NR NR 14 (excluded) Indeterminate NR NR NR 2 
(exclud
ed) 
Total  157 27 105 290 Total  165 28 109 302 
Test performance parameters 
IGRA TST 
Trend in ORs across the gradient of exposure (p = 0.006) 
 
Different room: OR (crude; reported) = 1.00 (reference 
group) 
Same room: OR (crude; reported) = 1.87 (95% CI: 0.70, 
5.02) 
Same bed: OR (crude; reported) = 2.01 (95% CI: 1.12, 
3.61) 
 
Same bed vs. different room 
Sensitivity = 93/157 = 59.24% (95% CI: 51.42, 66.61) 
Specificity = 62/105 = 59.05% (95% CI: 49.48, 67.97) 
PPV = 93/136 = 68.38% (95% CI: 60.15, 75.6) 
NPV = 62/126 = 49.21% (95% CI: 40.63, 57.83)  
DOR (for T
+ calculated) = 2.09 (95% CI: 1.26 , 3.46) 
OR (crude; for T+ reported) = 2.01 (95% CI: 1.12, 3.61) 
OR (regression-based; reported) = 1.45 (95% CI: 0.70, 
2.99) 
List of covariates: case’s relationship to child, age of child, 
smear positivity  
Other reported measure = NR 
Trend in ORs across the gradient of exposure (p = 
0.186) 
 
Different room: OR (crude; reported) = 1.00 
(reference group) 
Same room: OR (crude; reported) = 1.21 (95% CI: 
0.41, 3.53) 
Same bed: OR (crude; reported) = 1.35 (95% CI: 0.79, 
2.32) 
 
Same bed vs. different room 
Sensitivity = 85/165 = 51.52% (95% CI: 43.94, 59.02) 
Specificity = 62/109 = 56.88% (95% CI: 47.51, 65.79) 
PPV = 85/132 = 64.39% (95% CI: 55.92, 72.05) 
NPV = 62/142 = 43.66% (95% CI: 35.78, 51.88) 
DOR (for T
+ calculated) = 1.40 (95% CI: 0.86, 2.28) 
OR (crude; for T+ reported) = 1.35 (95% CI: 0.79, 
2.32) 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Same bed vs. different room 
Ratio of DORs (for T+ calculated) = 1.49 (95% CI: 1.04, 2.14) 
Same bed vs. different room 
Ratio of OR (crude; for T+ reported) = 1.47 (95% CI: 1.05, 2.16) 
Same bed vs. different room 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level 
Time spent with child 
h/day 
Total  Exposure level  
Time spent with child 
h/day 
Total 
>8 2-8 <2 >8 2-8 <2 
IGRA + 78 46 27 152 TST + 75 42 28 145 
IGRA - 72 46 20 138 TST - 83 54 20 157 
Indeterminat
e 
NR NR NR 14 (excluded) Indeterminate NR NR NR 2 
(excluded
) 
Total  150 92 47 290 Total  158 96 48 302 
Test performance parameters 
IGRA TST 
Trend in ORs across the gradient of exposure (p = 0.948)  
<2 h: OR (crude; reported) = 1.00 (reference group) 
2-8 h: OR (crude; reported) = 0.78 (95% CI: 0.33, 1.80) 
>8 h: OR (crude; reported) = 0.83 (95% CI: 0.38, 1.79) 
 
Trend in ORs across the gradient of exposure (p = 
0.494) 
<2 h: OR (crude; reported) = 1.00 (reference group) 
2-8 h: OR (crude; reported) = 0.55 (95% CI: 0.24, 
1.24) 
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>8 vs. <2 
Sensitivity = 78/150 = 52.00% (95% CI: 44.06, 59.85) 
Specificity = 20/47 = 42.55% (95% CI: 29.51, 56.72) 
PPV = 78/105 = 74.29% (95% CI: 65.17, 81.68) 
NPV = 20/92 = 21.74% (95% CI: 14.54, 31.21) 
DOR (for T+ calculated) = 0.80 (95% CI: 0.41, 1.55) 
OR (crude; for T+ reported) = 0.83 (95% CI: 0.38, 1.79) 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR 
>8 h: OR (crude; reported) = 0.64 (95% CI: 0.31, 
1.36) 
 
>8 vs. <2 
Sensitivity = 75/158 = 47.47% (95% CI: 39.83, 55.22) 
Specificity = 20/48 = 41.67% (95% CI: 28.85, 55.72) 
PPV = 75/103 = 72.82% (95% CI: 63.52, 80.47) 
NPV = 20/103 = 19.42% (95% CI: 12.94, 28.1) 
DOR (for T+ calculated) = 0.64 (95% CI: 0.33, 1.24) 
OR (crude; for T+ reported) = 0.64 (95% CI: 0.31, 
1.36) 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
>8 vs. <2 
Ratio of DORs (for T+ calculated) = 1.25 (95% CI: 0.77, 2.02) 
>8 vs. <2 
Ratio of OR (crude; for T+ reported) = 1.30 (95% CI: 0.75, 2.24) 
>8 vs. <2 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 104 34 138 TST + 105 29 134 
IGRA - 105 17 122 TST - 116 22 138 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  209 51 260 Total  221 51 272 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 0.49  (95% CI: 0.26, 0.94) DOR (for T+ calculated)TST = 0.68 (95% CI: 0.37, 
1.27) 
OR (crude; for T+ reported) = 0.51 (95% CI: 0.26, 1.00)  OR (crude; for T+ reported) = 0.68 (95% CI: 0.35, 
1.35) 
OR (regression-based; reported) IGRA = 0.60 (95% CI: 0.26, 
1.38) 
List of covariates: TB case’s relationship to child, marital 
status of household head   
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
From Rutherford 2012b TST + TST - Total 
IGRA + 121 35 156 
IGRA - 22 114 136 
Indeterminate 1 (excluded) 6 (excluded) 7 (excluded) 
Total  143 149 292 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (household contacts of TB cases) 
TST + threshold: ≥10mm 
Parameters 
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Kappa = 0.61 (95% CI: 0.49, 0.72) 
% concordance = 235/292 = 80.48% (95% CI: 75.55, 84.62) 
% discordance = 57/292 = 19.52%  (95% CI: 15.38, 24.45) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
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% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
In this setting, M. tuberculosis infection by either test was high in children living with a smear-positive TB case. 
Test positivity was driven by high index case infectivity levels and intimacy of exposure (if the index case was the 
child contact’s parent). Child contacts whose parent was the index case were over four times as likely to be positive 
by both or either tests. High increased risk of M. tuberculosis infection when the index case is the parent, particularly 
the mother, has been reported elsewhere. Both the TST and QFT-GIT responded as expected to most hypothesised 
risk factors, and neither test performed significantly better than the other along any of the gradients 
Reviewers: 
IGRA and TST performed well showing similar strong associations with a) characteristics of TB case smear 
positivity and b) relationship to child. IGRA did better than TST for sleeping proximity. Neither test showed 
association with time spent with child. None of the tests was influenced by BCG status 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = tuberculosis; BCG = 
Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative predictive value; FPR = false positive 
rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication:  Talbot 2012112 
Country: US 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): College health setting 
Number of centres: 1 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Oxford Immunotec 
Aim of the study 
To test the specificity of the tuberculin skin test and the T-SPOT.TB assay among students at low risk 
for TB exposure 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children (student at low risk for TB exposure) 
Participants 
Recruitment dates: NA 
Total N of recruited patients: 184 
Inclusion criteria: Students with history of exposure to TB 
Exclusion criteria: NR 
Total N of excluded patients: 4 (procedural errors at the laboratory) 
Total N of patients tested with both IGRA and TST: 180 
Total N of patients with valid results for both IGRA and TST: 143 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Test results, specificity test 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median age 20 [17-47] 
Women (n [%]): 97 [53.9] 
Race/ethnicity (n [%]): US-born (165 [91.7]); White (135 [75]) 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 7 [3.9] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): NR 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR  
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (T-SPOT.TB):  180 5 138 15 143 
TST ( > 15mm): 180 6 137 22 143 
Test 3 (specify):  NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 143 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  Low-TB exposure risk group 
Exposed 1 (specify): Non-low-TB exposure risk (any history of exposure to TB through 
country of birth, 
residence, or visits>3 weeks to high–TB burden areas [>40 cases/100,000 
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population], or occupational exposure) 
Exposed 2 (specify):  NA 
Exposed 3 (specify):  NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for test 
measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA (T-
SPOT.TB) 
Blood was tested for LTBI by using T-
SPOT.TB according to the manufacturer’s 
instructions for use. Peripheral blood 
mononuclear cells (PBMCs) were harvested by 
Ficoll density gradient centrifugation, washed, 
counted, and plated at 2.5 × 105 cells per well 
into a membrane-bottomed plate coated with 
anti-interferon-γ antibody. PBMCs from each 
study participant were incubated overnight in 
the presence of the provided TB antigens 
ESAT-6 and CFP-10, along with controls 
(positive mitogen control and a nil control). 
The PBMCs producing interferon-γ were 
revealed as spots by incubation with an 
enzyme-conjugated secondary antibody for 
interferon-γ and a color-producing enzyme 
substrate. Spots were counted, and clinical 
results recorded according to the approved 
algorithm in the package insert where, 
compared to the nil control, 8 spots and above 
is positive and 4 spots and below is negative 
Results with spot 
counts of 5–7 are 
regarded as 
borderline, and results 
with a low mitogen 
response or a high nil 
control response are 
indeterminate 
 
NA 
TST> 
15mm 
TSTs were administered by trained 
professionals who used the Mantoux method 
intradermally according to published 
guidelines 
A TST was considered 
positive if there was 
an induration > 15mm 
for students with no 
risk factors for TB 
exposure 
 
 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
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Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (TB exposure risk group) 
IGRA (T-SPOT.TB) TST≥15mm 
 Exposure level Total  Exposure level Total 
Non-
low 
Low Non-low Low 
IGRA (T-
SPOT.TB) + 
NR 0 NR TST + NR 2 NR 
IGRA (T-
SPOT.TB) - 
NR 124 NR TST - NR 122 NR 
Indeterminate NR NR 0 Indeterminate NR NR 0 
Total  NR 124 NR Total  NR 124 NR 
Test performance parameters 
IGRA TST 
Sensitivity = NA  Sensitivity = NA 
Specificity = 124/124 = 100.00% (95% CI: 97, 
100.00) 
Specificity = 122/124 = 98.39% (95% CI: 94.31, 
99.56) 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA  DOR (for T+ calculated) = NA  
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA  
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA  
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA  
Ratio of OR (crude; for T+ reported) = NA  
Ratio of ORs (regression-based; reported) = NA  
Other reported measure = NA  
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (>15 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST 
DOR (for T
+
 calculated)TSPOT/QFT = NR DOR TST (for T+ calculated) = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported)QFT = NR  
OR (regression-based; reported)TSPOT = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
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Total sample 
 TST + TST - Total 
IGRA + 4 1 5 
IGRA - 2 136 138 
Indeterminate 0 0 0 
Total  6 137 143 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: >15mm induration  
Parameters 
Kappa = 0.71, 95% CI (0.55, 0.88) 
% concordance = 140/143 = 97.9%, 95% CI (94.01, 99.28) 
% discordance = 3/143 = 2.01%, 95% CI (0.72, 5.99) 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The authors concluded that T-SPOT.TB specificity in a low-TB incidence, largely immunocompetent, 
non-BCG-vaccinated population, is high.   Further research is required to inform on the policy 
decisions for LTBI screening 
Reviewers: 
TBSPOT specificity was slightly higher than that of TST 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Tieu 2014154 
Country: Thailand 
Study design: cross-sectional/retrospective cohort study 
Study setting (e.g., outbreak investigation, community-based  - specify): community-based 
Number of centres: 3 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): This study was funded by a competitive, 
investigator-initiated research grant from Tibotec REACH Initiative. The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the manuscript 
Aim of the study 
To compare the performances of the IGRAs (T-Spot.TB, QuantiFERON-TB Gold In-tube) and TST at 
two different cut-off thresholds (10 mm and 15 mm) in Thai children who had recent exposure to an 
adult index case with TB 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children  
Participants 
Recruitment dates: Between September 2009 and December 2011 
Total N of recruited patients: 137 [TB exposed] 
Inclusion criteria: Children between the ages of 2 months and 16 years with recent exposure (defined 
as having lived with and/or having had close contact with) to adults with active pulmonary TB 
(confirmed by 
positive AFB stain, PCR for TB, or TB culture), with or without extra-pulmonary TB manifestations 
Exclusion criteria: Children’s caregivers refused study participation, if they were receiving anti-TB 
medications for TB disease (including isoniazid [INH] for latent TB), or if they had recently been 
diagnosed with active TB 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 137 
Total N of patients with valid results for both IGRA and TST: 136 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: between test agreement, association between prior exposure and test 
results 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 7.6 (4.3) 
Women (n [%]): 67 (49.3) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 132 (96.4) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): None [for TB exposed] 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate
) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   136 40 96 0 136 
TST:≥10mm 136 88 48 0 136 
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TST:≥15mm 136  48 88 0 136 
TSPOT 136 36 100 0 136 
Total N of patients with valid results for both IGRA and TST: 136 
Levels/groups of exposure to TB in increasing order (if applicable): 
1. Definition of exposure group – TB contact score (range 6-19) 
Non-exposed  TB contact score (8-10) 
Exposed 1 (specify): TB contact score (11-12) 
Exposed 2 (specify): TB contact score (13-14) 
Exposed 3 (specify): TB contact score (15-16) 
2. Definition of exposure group – TB contact score (range 6-19) 
Non-exposed  TB contact score (8-12) 
Exposed 1 (specify): TB contact score (≥13) 
3. Definition of exposure group – relationship to TB index case 
Non-exposed  Relative other contact in household with TB 
Exposed 1 (specify): Second caregiver in household with TB 
Exposed 2 (specify): Primary caregiver in household with TB 
4. Definition of exposure group – Duration of average contact per day with TB index case 
Non-exposed  0-7 hours 
Exposed 1 (specify): ≥8 hours 
5. Definition of exposure group – Duration of contact with TB index case in last 12 months 
Non-exposed  ≤7 months 
Exposed 1 (specify): >7 months 
6. Definition of exposure group – Index TB case history 
Non-exposed  Sputum acid fast smear negative 
Exposed 1 (specify): Sputum acid fast smear positive 
Tests 
 Assay used, methodology, 
timing for test 
measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA (QFT-
GIT) 
The children had whole blood 
and peripheral blood 
mononuclear cells collection 
for the interferon-gamma 
release assay (QFNGIT)  
 
The blood samples were sent 
on the same day of collection 
to the laboratory for testing 
according to the 
manufacturers’ instructions 
using positive and negative 
controls 
 
Results were reported 
as positive, negative, 
or indeterminate 
according to the 
manufacturers’ 
guidelines 
 
Positive cutoff 
values for the tests 
were defined using 
the manufacturers’ 
standard guidelines 
Study investigators, 
site coordinators, and 
clinicians were blinded 
to the results of the 
IGRAs until the study 
had completed 
enrollment and 9-
month follow-up 
TST≥10mm 
TST≥15mm 
At the baseline visit, the 
children had a TST (0.1 ml 
solution or 10 international 
units of tuberculin purified 
protein derivative) implanted 
on the forearm followed by 
result reading by trained 
health care personnel in 48–
72 hours, in accordance with 
Thai 
The size of TST 
induration was 
determined 
by measuring the 
maximum width (or 
transverse diameter) 
of an indurated lesion; 
test positivity was 
defined at 
≥10mm or ≥15mm 
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national guidelines 
T-SPOT.TB The children had whole blood 
and peripheral blood 
mononuclear cells collection 
for the interferon-gamma 
release assay (TSPOT).  
 
The blood samples were sent 
on the same day of collection 
to the laboratory for testing 
according to the 
manufacturers’ instructions 
using positive and negative 
controls 
Results were reported 
as positive, negative, 
or indeterminate  
 
Positive cutoff values 
were defined using 
the manufacturers’ 
standard guidelines 
 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA  
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
indeterminate NR NR NR indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
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NPV= NA NPV= NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA  
OR (crude; for T+ reported) =  
TB contact score (range 6-19) 
Score 8-10 (reference/non-exposed): 1.0 
Score 11-12: 2.00 (95% CI: 0.38, 10.61) 
Score 13-14: 3.64 (95% CI: 0.75,17.77) 
Score 15-16: 7.50 (95% CI: 1.35, 41.71) 
 
TB contact score (range 6-19) 
Score 8-12 (reference/non-exposed): 1.0 
Score ≥13: 4.04 (95% CI: 1.81, 8.99) 
 
Relationship to TB index case 
Relative other contact (reference/non-exposed): 1.0 
Second caregiver: 3.95 (95% CI: 1.50, 10.43) 
Primary caregiver: 3.25 (95% CI: 1.36, 7.77)  
 
Duration of average contact per day with TB 
index case 
0-7 hours (reference/non-exposed): 1.0 
≥8 hours: 1.75 (95% CI: 0.78, 4.00) 
 
Duration of contact with TB index case in last 12 
months 
≤7 months (reference/non-exposed): 1.0 
>7 months: 1.96 (95% CI: 0.99, 3.84)  
 
Index TB case history 
Sputum acid fast smear negative (reference/non-
exposed): 1.0  
Sputum acid fast smear positive: 0.97 (95% CI: 
0.27, 3.33) 
OR (crude; for T+ reported) = 
TB contact score (range 6-19) 
Score 8-10 (reference/non-exposed): 1.0 
Score 11-12: 3.97 (95% CI: 1.19, 13.28) 
Score 13-14: 4.40 (95% CI: 1.38, 14.08) 
Score 15-16: 7.33 (95% CI: 1.67,32.21) 
 
TB contact score (range 6-19) 
Score 8-12 (reference/non-exposed): 1.0 
Score ≥13: 2.59 (95% CI: 1.28, 5.23)  
 
Relationship to TB index case 
Relative other contact (reference/non-exposed): 
1.0 
Second caregiver: 0.87 (95% CI: 0.34, 2.23) 
Primary caregiver: 1.44 (95% CI: 0.61, 3.41) 
 
Duration of average contact per day with TB 
index case 
0-7 hours (reference/non-exposed): 1.0 
≥8 hours: 2.27 (95% CI: 1.08, 4.76) 
 
Duration of contact with TB index case in 
last 12 months 
≤7 months (reference/non-exposed): 1.0 
>7 months: 2.04 (95% CI: 1.00, 4.16)  
 
Index TB case history 
Sputum acid fast smear negative 
(reference/non-exposed): 1.0  
Sputum acid fast smear positive: 2.38 (95% CI: 
0.49, 11.11) 
OR (regression-based; reported) =  
TB contact score (range 6-19) 
Score 8-10 (reference/non-exposed): 1.0 
Score 11-12: NR 
Score 13-14: NR 
Score 15-16: NR 
 
TB contact score (range 6-19) 
Score 8-12 (reference/non-exposed): 1.0 
Score ≥13: 1.98 (95% CI: 0.64, 6.11) 
 
Relationship to TB index case 
Relative other contact (reference/non-exposed): 1.0 
Second caregiver: 3.95 (95% CI: 1.25, 12.52) 
Primary caregiver: 4.07 (95% CI: 1.38, 11.99)  
 
Duration of average contact per day with TB 
index case 
0-7 hours (reference/non-exposed): 1.0 
≥8 hours: NR 
OR (regression-based; reported) = 
TB contact score (range 6-19) 
Score 8-10 (reference/non-exposed): 1.0 
Score 11-12: NR 
Score 13-14: NR 
Score 15-16: NR 
 
TB contact score (range 6-19) 
Score 8-12 (reference/non-exposed): 1.0 
Score ≥13: 2.21 (95% CI: 0.99, 4.98) 
 
Relationship to TB index case 
Relative other contact (reference/non-exposed): 
1.0 
Second caregiver: NR 
Primary caregiver: NR 
 
Duration of average contact per day with TB 
index case 
0-7 hours (reference/non-exposed): 1.0 
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 Duration of contact with TB index case in last 12 
months 
≤7 months (reference/non-exposed): 1.0 
>7 months: 1.47 (95% CI: 0.62, 3.44)  
 
Index TB case history 
Sputum acid fast smear negative (reference/non-
exposed): 1.0  
Sputum acid fast smear positive: NR 
List of covariates: NR 
≥8 hours: 1.61 (95% CI: 0.68, 3.84)  
 
Duration of contact with TB index case in 
last 12 months 
≤7 months (reference/non-exposed): 1.0 
>7 months: NR 
 
Index TB case history 
Sputum acid fast smear negative 
(reference/non-exposed): 1.0  
Sputum acid fast smear positive: NR 
List of covariates: NR 
Other reported measure = NR Other reported measure =NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated)=NA 
Ratio of OR (crude; for T+ reported)= TB contact score: 13+ vs. 8-12 [GIT vs. TST-10mm]=1.56 
(95% CI: 0.91, 2.69)  
Ratio of OR (crude; for T+ reported)=TB contact score: 13+ vs. 8-12 [GIT vs. TST-15mm]=1.84 
(95% CI: 1.07, 3.18) 
Ratio of ORs (regression-based; reported)=TB contact score: 13+ vs. 8-12 [GIT vs. TST-10mm]= 
0.90 (95% CI: 0.44, 1.82) 
Ratio of ORs (regression-based; reported)=TB contact score: 13+ vs. 8-12 [GIT vs. TST-15mm]=2.39 
(95% CI: 1.15, 4.93) 
Other reported measure= NR 
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
indeterminate NR NR NR indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) =  NR 
OR (regression-based; reported) IGRA= NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST ≥10mm TST - Total 
IGRA [QFT-GIT] + 36 2 38 
IGRA - 51 42 93 
indeterminate NR NR NR 
Total  87 44 131 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.29 (95% CI 0.18, 0.40) 
% concordance = [36+42]/131=59.54% (95% CI: 50.98, 67.56) 
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% discordance = 53/131=40.46% (95% CI: 32.44, 49.02) 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST ≥15mm TST - Total 
IGRA [QFT-GIT] + 29 9 38 
IGRA - 18 75 93 
indeterminate NR NR NR 
Total  47 84 131 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥15mm 
Parameters 
Kappa = 0.53 (95% CI 0.38, 0.69)  
% concordance = [29+75]/131=79.39% (95% CI 71.67, 85.43) 
% discordance = 27/131=20.61% (95% CI 14.57, 28.33) 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST ≥10mm TST - Total 
IGRA [TSPOT] + 32 3 35 
IGRA - 55 41 96 
indeterminate NR NR NR 
Total  87 44 131 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.23 (95% CI 0.12, 0.34)  
% concordance = [32+41]/131=55.73% (95% CI 47.18, 63.95) 
% discordance = 58/131=44.27% (95% CI 36.05, 52.82) 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST ≥15mm TST - Total 
IGRA [TSPOT] + 27 8 35 
IGRA - 20 76 96 
indeterminate NR NR NR 
Total  47 84 131 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥15mm 
Parameters 
Kappa = 0.51 (95% CI 0.35, 0.66)  
% concordance = [27+76]/131 = 78.63% (95% CI 70.84, 84.78) 
% discordance = 28/131 = 21.37% (95% CI 15.22, 29.16) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
379
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR  
% concordance = NR  
% discordance = NR 
Conclusions 
Authors: 
Both QFNGIT and T-Spot.TB performed well in our generally healthy Thai pediatric study population 
with recent exposure to adults with active pulmonary TB, with no indeterminate or 
equivocal/borderline results. No significant differences were found between the performances of the 
IGRAs and TST at the two cut-offs with increasing TB exposure. Concordance for positive IGRAs 
and TST ranged from 42–46% for TST≥10 mm and 62–67% for TST≥15 mm. On multivariable 
analyses, exposure to household secondary caregiver with TB was associated with positive QFNGIT. 
Higher TB contact score was associated with positive T-Spot.TB. 
Reviewers: 
QFT and TSPOT had similar concordance with TST (at both thresholds); however, this concordance 
was higher when TST threshold was 15mm (vs. 10mm). On average, TSPOT and QFT performed 
similarly better in relation to TST, especially compared to TST 15mm 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Tsolia 2010113 
Country: Greece 
Study design: Retrospective cohort/cross sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): TB clinic 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): The Bienmoyo Foundation  
Aim of the study 
To evaluate and compare the performance of the QFT-GIT assay and the TST among children with 
active TB or possible latent TB infection in a low endemicity setting. 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children 
Participants 
Recruitment dates: 1st January 2007 to 31st December 2003 
Total N of recruited patients: 295 
Inclusion criteria: Adolescents ≤ 15 years 
Exclusion criteria: NR 
Total N of excluded patients: 9 (refusal, lost specimen, sample processing delay) 
Total N of patients tested with both IGRA and TST:  
Total N of patients with valid results for both IGRA and TST: 286 (total sample including active 
TB patients) 
Methods of active TB diagnosis (if applicable): Based on CDC criteria and MTB isolation from 
culture 
Outcomes (study-based) list: Agreement; association between test results and risk factors 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): NR 
Women (n [%]): NR 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total 
N 
 (test-) 
Total N 
(indetermina
te) 
Total N  
(test results available) 
IGRA (QFT-
GIT):   
99 (patients in 
contact with 
adult TB) 
32 63 4 95 
TST (≥ 5mm): 99 (patients in 
contact with 
adult TB) 
55 44 0 99 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 95 (patients in contact with adult 
TB) 
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Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group - Contact with an adult TB 
Non-exposed  Non-household occasional contact 
Exposed 1 
(specify): 
Non-household regular contact 
Exposed 2 
(specify): 
Household contact  
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off 
values/threshold
s Definition of 
test+ 
Other information 
IGRA (QFT-GIT) QFT-GIT (Cellestis Limited, 
Carnegie, Victoria, Australia) 
> 10 IU/mL Indeterminate results on 
the QFT-GIT were 
excluded from the 
analysis 
TST ≥ 5mm or 
≥10mm  
Purified protein derivative 
(PPD) RT23 (Statens Serum 
Institut, Copenhagen, 
Denmark) 
≥ 10mm for BCG 
immunized 
children 
≥ 5mm for non-
BCG immunized 
children 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence 
of active 
TB 
Total  Incidence of active 
TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
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Association between test results and levels of TB exposure (Type of contact with TB case) 
IGRA (QFT-GIT) TST≥5mm 
 Exposure level Total  Exposure level Total 
Non-
household 
regular  
Non-
household 
occasional  
Non-
household 
regular  
Non-
household 
occasional  
IGRA + 9 1 10 TST + 18 7 25 
IGRA - 18 10 28 TST - 10 4 14 
Indetermi
nate 
1 0 1 Indete
rminat
e 
0 0 0 
Total  28 11 39 Total  28 11 39 
Test performance parameters 
IGRA TST 
Sensitivity = 9/27 = 33.33% (95% CI: 18.64, 
52.18) 
Sensitivity = 18/28 = 64.29% (95% CI: 45.83, 
79.29) 
Specificity = 10/11 = 90.91% (95% CI: 62.26, 
98.38) 
Specificity = 4/11 = 36.36% (95% CI: 15.17, 
64.62) 
PPV = 9/10 = 90.00% (95% CI: 59.58, 98.21) PPV = 18/25 = 72.00% (95% CI: 52.42, 85.72) 
NPV = 10/28 = 35.71% (95% CI: 20.71, 54.17) NPV = 4/14 = 28.57% (95% CI: 11.72, 54.65) 
DOR (for T+ calculated) = 5.00 (95% CI: 0.55, 
45.39) 
DOR (for T+ calculated) = 1.03 (95% CI: 0.24, 
4.39) 
OR (crude; for T
+ 
reported) = NR  OR (crude; for T
+ 
reported) = NR  
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 4.85 (95% CI: 1.26, 18.69) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (Type of contact with TB case) 
IGRA (QFT-GIT) TST≥5mm 
 Exposure level Total  Exposure level Total 
Household  Non-
household 
occasional  
Household  Non-
household 
occasional  
IGRA + 22 1 23 TST + 30 7 37 
IGRA - 35 10 45 TST - 30 4 34 
Indetermi
nate 
3 0 3 Indete
rminat
e 
0 0 0 
Total  60 11 71 Total  60 11 71 
Test performance parameters 
IGRA TST 
Sensitivity = 22/57 = 38.6% (95% CI: 27.06, 
51.57) 
Sensitivity = 30/60 = 50.00% (95% CI: 37.73, 
62.27) 
Specificity = 10/11 = 90.91% (95% CI: 62.26, 
98.38) 
Specificity = 4/11 = 36.36% (95% CI: 15.17, 
64.62) 
PPV = 22/23 = 95.65% (95% CI: 79.01, 99.23) PPV = 30/37 = 81.08% (95% CI: 65.79, 90.52) 
NPV = 10/45 = 22.22% (95% CI: 12.54, 36.27) NPV = 4/34 = 11.76% (95% CI: 4.67, 26.62) 
DOR (for T+ calculated) = 6.28 (95% CI: 0.75, 
52.56) 
DOR (for T+ calculated) = 0.57 (95% CI: 0.15, 
2.15) 
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OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR   
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR  
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 11.02 (95% CI: 3.07, 39.60) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST≥5mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indetermin
ate 
NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST 
DOR (for T+ calculated)QFT = NR DOR TST (for T+ calculated) = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported)QFT = 0.19, 95% CI 
(0.06, 0.60) 
List of covariates: NR 
OR (regression-based; reported) TST = 
20.34, 95% CI (5.60, 73.89) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 29 3 32 
IGRA - 24 39 63 
Indeterminate 2 2 4 
Total  55 44 99 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.45, 95% CI (0.27, 0.63) 
% concordance = 68/95 = 71.58%, 95% CI (61.81, 79.67) 
% discordance = 27/95 = 28.42%, 95% CI (20.33, 38.19) 
Stratification (BCG vaccinated) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR 43 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥10 mm 
Parameters 
Kappa = 0.13 (p = 0.06) 
% concordance = 20/43 = 46.50% (95% CI NR)  
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% discordance = NR 
Stratification (non-BCG vaccinated) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR 52 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.91 (p = 0.06) 
% concordance = 50/52 = 96.20% (95% CI NR)  
% discordance = NR 
Stratification (Household contact) 
 TST + TST - Total 
IGRA + 20 2 22 
IGRA - 8 27 35 
Indeterminate 2 1 3 
Total  30 30 60 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Household contact with TB 
case 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.65, 95% CI (0.39, 0.90) 
% concordance = 47/53 = 82.46%, 95% CI (70.63, 90.18) 
% discordance = 10/53 = 17.54%, 95% CI (9.81, 29.37) 
Stratification (Non-household regular contact) 
 TST + TST - Total 
IGRA + 8 1 9 
IGRA - 10 8 18 
Indeterminate 0 1 1 
Total  18 10 28 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Non-household regular 
contact with TB case 
TST + threshold: ≥5 mm  
Parameters 
Kappa = 0.27, 95% CI (-0.03, 0.56) 
% concordance = 16/27 = 59.26%, 95% CI (40.73, 75.49) 
% discordance = 11/27 = 40.74%, 95% CI (24.51, 59.27) 
Stratification (Non-household occasional contact) 
 TST + TST - Total 
IGRA + 1 0 1 
IGRA - 6 4 10 
Indeterminate 0 0 0 
Total  7 4 11 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold:  
Parameters 
Kappa = 0.11, 95% CI (-0.15, 0.37) 
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% concordance = 5/11 = 45.45%, 95% CI (21.27, 71.99) 
% discordance = 6/11 = 54.55%, 95% CI (28.01, 78.73) 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
QFT may improve the diagnosis of LTBI especially in BCG vaccinated children 
Reviewers: 
There was a better agreement in BCG non-immunized vs. BCG immunized children; QFT suggested 
strong associations with TB contact exposure but they were NS; TST was not associated with 
exposure (contact with TB); odds of TST positivity (unlike QFT-GIT) was greater in BCG vaccinated 
vs. not vaccinated 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Diel 2011102 
Country: Germany 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based  - specify): Community based contact 
study 
Number of centres: Multi-center (NR) 
Total length of follow up (if applicable): 2-4 yrs 
Funding (government/private/manufacturer/other - specify): NR (None of the authors has a financial 
relationship with a commercial entity that has an interest in the subject of this manuscript) 
Aim of the study 
To compare the QuantiFERONTB Gold in-tube assay (QFT) with the tuberculin skin test (TST) in 
close contacts of patients with TB and evaluate progression to active TB for up to 4 years 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children (close contacts of smear-positive index cases) 
Participants 
Recruitment dates: May 2005 to April  2010 
Total N of recruited patients: 141 
Inclusion criteria: Close contacts of smear-positive and subsequently culture-confirmed source MTB 
index cases; aggregate exposure time of the contact in the 3 months before the diagnosis of respective 
index case (presumed 
period of infectiousness > 40 hours indoors with shared air) 
Exclusion criteria: Contacts with an exposure time of < 40 hours to the source 
Total N of excluded patients: 15 
Total N of patients tested with both IGRA and TST: 126 
Total N of patients with valid results for both IGRA and TST: 106  
Methods of active TB diagnosis (if applicable): CXR (and computerized tomography), 
identification of AFB in sputum samples by bronchoscopy or lavage of gastric secretions, 
conventional culture of M. tuberculosis, nucleic acid amplification assays and/or histopathology, 
assessment of preceding clinical suspicion of TB. In culture-negative cases, and given a CXR 
consistent with TB, subsequent clinical and radiographic response to multidrug therapy over an 
appropriate time course (1–3 mo) was considered sufficient to confirm the diagnosis of TB 
Outcomes (study-based) list: Incidence of active TB, predictive values of IGRA and TST 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 10.4 (4.3) years 
Women (n [%]): NR 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Germany (84 [66.7]) 
BCG vaccination (n [%]): 45 [35.7] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): 6/104 [5.7] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): anti TB chemoprophylaxis (2/106 [1.8]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
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IGRA (QFT-GIT):   126 23 83 NR 106 
TST (>5mm): 126 40 66 NR 106 
TST (>10mm): 126 20 86 NR 106 
Total N of patients with valid results for both IGRA and TST: 104 (2 patients receiving 
chemoprophylaxis excluded) 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
Exposed 1 (specify): NR 
Exposed 2 (specify): NR 
Exposed 3 (specify): NR 
Exposed 4 (specify): NR 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA 
(QFT-GIT) 
Performed according to the 
manufacturer’s instructions 
(Cellestis Ltd, Carnegie, Australia)  
 
The maximal level of IFN-g accurately 
detected by the 
QFT ELISA is 10 IU/ml, and thus 
values greater than this are reported as 
10 IU/ml 
IFN-g of 0.35 
IU/ml or greater 
Assessors of the TST 
were blinded to QFT 
results and vice versa. 
Induration was read by 
trained and well-
experienced public 
health nurses. If there 
was a borderline result 
(e.g., 5 mm exactly), a 
second reading was 
performed by a 
different nurse to 
verify this result. If 
there was 
disagreement, a third 
nurse read the TST 
and the consensus 
result used 
TST Administered by the Mantoux method; 
0.1 ml of Tuberculin-10-GT (Chiron 
Behring, Marburg, Germany; 
bioequivalent to 5 units of the 
international purified protein 
derivative-Seifert [PPD-S] standard), 
and subsequently 0.1 ml (2 tuberculin 
units) of purified protein derivative 
RT23 (Statens Serum Institute, 
Copenhagen, Denmark), which is 
equivalent to Tuberculin-10-GT 
(Chiron Behring) 
TST reaction was 
scored as positive 
at > 5mm or > 
10mm 
Association between test results and incidence of active TB (if applicable) 
IGRA TST (>5mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 6 15 21 TST + 6 34 40 
IGRA - 0 83 83 TST - 0 64 64 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total 6 98 104 Total 6 98 104 
Test performance parameters 
IGRA TST 
Sensitivity = 6/6 = 100% (95% CI: 60.97, 100) Sensitivity = 6/6 = 100% (95% CI: 60.97, 100) 
Specificity = 83/98 = 84.69% (95% CI: 76.27, 
90.5) 
Specificity = 64/98 = 65.31% (95% CI: 55.47, 
73.99) 
PPV = 6/21 = 28.57% (95% CI: 13.81, 49.96) PPV = 6/40 = 15.00% (95% CI: 7.06, 29.07) 
NPV = 83/83 = 100% (95% CI: 95.58, 100) NPV = 64/64 = 100% (95% CI: 94.34, 100) 
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Cumulative Incidence IGRA+ = 6/21 = 28.57% 
(95% CI: 13.81, 49.96)  
Cumulative Incidence TST+ = 6/40 = 15.00% (95% 
CI: 7.06, 29.07)  
Cumulative Incidence IGRA- = 0/83 = 1.20% (95% 
CI: 0.03, 6.53) 
Cumulative Incidence TST- = 0/64 = 1.55% (95% 
CI: 0.04, 8.4) 
Cumulative Incidence Ratio IGRA = 23.7%  (95% 
CI: 2.57, 110.3) 
Cumulative Incidence Ratio TST = 9.6% (95% CI: 
1.08, 448.2) 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR  Incidence density rate ratio TST = NR 
Other reported measure IGRA = NR Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = 2.47(95% CI: 0.40, 15.12) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and incidence of active TB (if applicable) 
IGRA TST (>10mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 6 15 21 TST + 4 36 40 
IGRA - 0 83 83 TST - 2 62 64 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total 6 98 104 Total 6 98 104 
Test performance parameters 
IGRA TST 
Sensitivity = 6/6 = 100% (95% CI: 60.97, 100) Sensitivity = 4/6 = 66.67% (95% CI: 30.00, 
90.32) 
Specificity = 83/98 = 84.69% (95% CI: 76.27, 
90.5) 
Specificity = 62/98 = 63.27% (95% CI: 53.39, 
72.14) 
PPV = 6/21 = 28.57% (95% CI: 13.81, 49.96) PPV = 4/40 = 10% (95% CI: 3.96, 23.05) 
NPV = 83/83 = 100% (95% CI: 95.58, 100) NPV = 62/64 = 96.88% (95% CI: 89.3, 99.14) 
Cumulative Incidence IGRA+ = 6/21 = 28.57% 
(95% CI: 13.81, 49.96)  
Cumulative Incidence TST+ = 4/40 = 10.00% (95% 
CI: 3.958, 23.05)  
Cumulative Incidence IGRA- = 0/83 = 1.20% (95% 
CI: 0.03, 6.53) 
Cumulative Incidence TST- = 2/64 = 3.12% (95% 
CI: 0.22, 11.33 
Cumulative Incidence Ratio IGRA = 23.7%  (95% 
CI: 2.57, 110.3) 
Cumulative Incidence Ratio TST = 3.20% (95% CI: 
0.61, 16.67) 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR  Incidence density rate ratio TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = 7.41(95% CI: 2.06,  26.57) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
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IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T
+ 
reported) = NA OR (crude; for T
+ 
reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) IGRA = NA 
List of covariates: NA 
OR (regression-based; reported) TST = NA  
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
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TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Results suggest that QFT is more reliable than the TST for identifying those who will soon progress 
to active TB, especially in children 
Reviewers: 
Overall, QFT performed better (sensitivity, specificity, predictive values) than TST in identifying 
LTBI by predicting the occurrence of active TB 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Tara Gurung 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Mahomed 2011a103 
Country:  South Africa 
Study design: Longitudinal cohort study 
Study setting (e.g., outbreak investigation, community-based  - specify): High school (TB vaccine 
trial site in the town of Worcester (and surrounding villages) (high burden of TB) 
Number of centres: 11 
Total length of follow up (if applicable): 3.8 years  
Funding (government/private/manufacturer/other - specify): The Aeras Global TB Vaccine 
Foundation with some support from the Gates Grand Challenge 6 and Gates Grand Challenge 12 
grants for the QuantiFERON testing.  
Aim of the study 
To compare the predictive value of a baseline tuberculin skin test (TST) with that of the 
QuantiFERON TB Gold (In-tube) assay (QFT) for subsequent microbiologically confirmed TB 
disease among adolescents. 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Adolescents from high burden TB area 
Participants 
Recruitment dates: From 2005 to 2006  
Total N of recruited patients: 6,363  
Inclusion criteria: adolescents aged 12 to 18 years 
Exclusion criteria: NR 
Total N of excluded patients: 1,119 (those with prior or current TB, indeterminate QFT results, or 
missing QFT or TST results) 
Total N of patients tested with both IGRA and TST: 5,244 
Total N of patients with valid results for both IGRA and TST: 5,244 
Methods of active TB diagnosis (if applicable): Two sputum samples for smear microscopy on two 
separate occasions. If any single sputum was smear positive, a mycobacterial culture, chest x-ray, and 
HIV test were performed 
Outcomes (study-based) list: Test results, concordance between TST and QTB, TB disease 
incidence rate 
Characteristics of participants (total study sample)  
Mean (range or SD) age (years):  NR 
Women (n [%]): 2842 [54.2] 
Race/ethnicity (n [%]): Black (995 [19.0]); Mixed race (3839 [73.2]); Indian/white (410 [7.8])  
BCG vaccination (n [%]): Yes (4917 [93.8]; Unknown (281 [5.4]) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): 52 [1.0] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no):  Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (specify):  QFT-
GIT 
5244 2669 2575 NR 5244 
TST≥5mm: 5244 2894 2350 NR 5244 
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Test 3 (specify) NR NR NR NR NR 
Total N of patients with valid results for both IGRA and TST: 5244 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, 
methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA  QFT-GIT, In-tube 
method, (Cellestis 
Limited, Carnegie, 
Victoria, Australia) 
≥ 0.35 IU/mL  
NA 
TST Mantoux method on 
either forearm, using 2 
tuberculin units of 
RT23, induration was 
read 48-96 hours later 
with a ruler or caliper by 
trained personnel, 
(Statens Serum Institut, 
Denmark)  
≥ 5mm People with a recent 
household contact, TB 
related symptoms, a 
positive TST ≥10 mm 
induration or a positive 
QFT were referred for 
two sputum smears.  If 
results of either or both 
were sputum positive for 
acid fast bacilli, the 
sputum were cultured, 
and a chest x-ray and 
HIV test were 
undertaken. 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-GIT) TST≥5mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 39 2630 2669 TST + 40 2854 2894 
IGRA - 13 2562 2575 TST - 12 2338 2350 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total 52 5192 5244 Total 52 5192 5244 
Test performance parameters 
IGRA TST 
Sensitivity = 39/52 = 75.00%, 95% CI (61.79, 
84.77) 
Sensitivity = 40/52 = 76.92%, 95% CI (63.87, 
86.28) 
Specificity = 2562/5192 = 49.35%, 95% CI 
(47.99, 50.71) 
Specificity = 2338/5192 = 45.03%, 95% CI 
(43.68, 46.39)   
PPV = 39/2669 = 1.46%, 95% CI (1.07, 1.99) PPV = 40/2894 = 1.38%, 95% CI (1.02, 1.88) 
NPV = 2562/2575 = 99.50%, 95% CI (99.14, 
99.7) 
NPV = 2338/2350 = 99.49%, 95% CI (99.11, 
99.71) 
Cumulative Incidence IGRA+ = 39/2669 = 1.46%, 
95% CI (1.07, 1.99) 
Cumulative Incidence TST+ = 40/2894 = 1.38%, 
95% CI (1.02, 1.87) 
Cumulative Incidence IGRA- = 13/2575 = 0.50%, Cumulative Incidence TST- = 12/2350 = 0.51%, 
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95% CI (0.28, 0.87) 95% CI (0.28, 0.90) 
Cumulative Incidence Ratio IGRA = 2.89, 95% CI 
(1.55, 5.40)   
Cumulative Incidence Ratio TST = 2.71 (95% CI: 
1.42, 5.14) 
Incidence density rate IGRA+ = 0.64 per 100 person 
years, 95% CI (0.45, 0.87) 
Incidence density rate TST+ = 0.60 per 100 person 
years, 95% CI (0.43, 0.82) 
Incidence density rate IGRA- = 0.22 per 100 person 
years, 95% CI (0.12, 0.38) 
Incidence density rate TST- = 0.22 per 100 person 
years, 95% CI (0.11, 0.39) 
Incidence density rate ratio IGRA = 2.92, 95% CI 
(1.58, 5.67)   
Incidence density rate ratio TST = 2.73, 95% CI 
(1.45, 5.42)   
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence = 1.07, (95% CI: 0.68, 1.68) 
Ratio of incidence density rate ratios = 1.07, (95% CI: 0.67, 1.71) 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 2383 286 2669 
IGRA - 511 2064 2575 
Indeterminate 0 0 0 
Total  2894 2350 5244 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold:  ≥5 mm induration 
Parameters 
Kappa = 0.69 95% CI, (0.66, 0.72) 
% concordance = 4447/5244 = 84.80%, 95% CI (83.80, 85.75) 
% discordance = 797/5244 = 15.20%, 95% CI (14.25, 16.20) 
Stratification (specify group 1) 
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 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Based on the findings from this study, these authors concluded/demonstrated that TST and QFT-GIT 
are equally predictive of progression to active TB in a cohort of adolescents in a high TB burden 
population.  They further stated that their results do not support that QFT-GIT is more superior to 
TST in its predictive value 
Reviewers: 
Authors reported that Isoniazid prevention therapy is not standard care for people with LTBI except 
for children under the age of five years old. TST and QFT-GIT are equally predictive of progression 
to active TB in a cohort of adolescents in a high TB burden population 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Tara Gurung 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Noorbakhsh 2011104 
Country:  Iran 
Study design: Cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Pulmonary and infectious 
diseases department of Rasul hospital in Tehran 
Number of centres: 1 
Total length of follow up (if applicable): 1 year 
Funding (government/private/manufacturer/other - specify): Research Centre of Paediatric Infectious 
Diseases, Iran University of Medical Sciences. 
Aim of the study 
To detect the agreement between TST and QTB in young household contacts (aged < 20 years) of 
cases of proven active pulmonary TB in a BCG-vaccinated population in Tehran, Islamic Republic of 
Iran, and to compare subjects progressing to TB with non-progressive subjects 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children 
Participants 
Recruitment dates: 2006-2008 
Total N of recruited patients: NR 
Inclusion criteria: all young (< 20 years old) close or household contacts of people (as any person 
who had lived with the index case for more than 3 months) with confirmed active pulmonary TB and 
previous BCG vaccination received at birth. The subjects were invited to our research centre for 
clinical and laboratory follow-up 
Exclusion criteria: Household contacts were excluded if they had been treated for TB in the past year 
or had a known immunodeficiency state on history or clinical signs (malignancy, corticosteroid 
therapy, HIV, etc.). 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 58 
Methods of active TB diagnosis (if applicable): Person diagnosed by an internist in the pulmonary 
and infectious ward of Rasht hospital. The index cases were confirmed by positive culture for M. 
tuberculosis or sputum smear-positive TB 
Outcomes (study-based) list: Test results, concordance between TST and QTB, progression to TB 
disease 
Characteristics of participants (total study sample)  
Mean (range or SD) age (years): NR 
Women (n [%]): 34 [57.6] 
Race/ethnicity (n [%]): NR 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): 10 [16.9] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes  
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
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IGRA (QFT-G):   NR 18 41 NR 59 
TST (≥ 10mm): NR 8 50 1 58 
Test 3 (specify) NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 48 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
Exposed 1 (specify): NR 
Exposed 2 (specify): NR 
Exposed 3 (specify): NR 
Exposed 4 (specify): NR 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-G) For the QTB fresh blood samples 
from all of the participants were 
processed on site according to the 
manufacturer’s instruction (Gold 
Quantiferon-TB, Cellestis). First, 1 
mL of heparinized whole blood was 
incubated with aliquots of antigen-
free control and antigens for 16–24 
hours at 37 °C in a carbon dioxide 
incubator. After overnight incubation, 
200 µL plasma was removed from 
each well and the concentration of 
IFN-γ was determined using the assay 
kits 
Not reported NA 
TST (≥ 10mm) For the TST a test dose (0.1 mL) of 5 
tuberculin units of purified protein 
derivative solution (Pasteur Institute, 
Tehran) was injected intradermally 
into the volar aspect of the forearm 
with a 26–27 gauge needle by trained 
field worker. The induration diameter 
of the raised, blanched weal (not the 
erythema) was read after 48–72 hours 
A reactive TST was an 
induration diameter of 
≥ 10mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-G) TST≥ 10mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 10 8 18 TST + 3 5 8 
IGRA - 0 41 41 TST - 7 43 50 
Indeterminate NR NR NR Indeterminate 0 1 1 
Total 10 49 59 Total 10 49 59 
Test performance parameters 
IGRA TST 
Sensitivity = 10/10 = 100.00%, 95% CI (72.25, 
100.00) 
Sensitivity = 3/10 = 30.00%, 95% CI (10.78, 
60.32) 
Specificity = 41/49 = 83.67%, 95% CI (70.96, 
91.49) 
Specificity = 43/48 = 89.58%, 95% (77.83, 
95.47) 
PPV = 10/18 = 55.56%, 95% CI (33.72, 75.44) PPV = 3/8 = 37.50%, 95% CI (13.68, 69.43) 
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NPV = 41/41 = 100%, 95% CI (91.43, 100) NPV = 43/50 = 86.00%, 95% CI (73.81, 93.05) 
Cumulative Incidence IGRA+ = 10/18 = 55.56%, 
95% CI (33.72, 75.44) 
Cumulative Incidence TST+ = 3/8 = 37.5%, 95% 
CI (13.49, 69.62) 
Cumulative Incidence IGRA- = 0/41 = 2.41% (95% 
CI: 0.06, 12.9) 
Cumulative Incidence TST- = 7/50 = 14.00%, 95% 
CI (6.63, 26.50) 
Cumulative Incidence Ratio IGRA = 22.78% (95% 
CI: 2.75, 101.1) 
Cumulative Incidence Ratio TST = 2.68% (95% 
CI: 0.86, 8.27)   
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence = 8.50% (95% CI: 2.87, 25.17) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T
+ 
reported) = NA OR (crude; for T
+ 
reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR 18 
IGRA - NR NR 41 
Indeterminate NR NR NR 
Total  8 51 59 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
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Stratification (non-progressive) 
 TST + TST - Total 
IGRA + 39 4 43 
IGRA - 2 3 5 
Indeterminate 0 0 0 
Total  41 7 48 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): 49 children who did not 
progress to active TB 
TST + threshold: ≥10mm  
Parameters 
Kappa = 0.43 (95% CI: 0.15, 0.70) 
% concordance = 42/48 = 87.60% (95% CI:75.3, 94.14) 
% discordance = 6/48 = 12.5% (95% CI: 5.85, 24.70) 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
From this study, the authors demonstrated that QTB assay can reflect recent rather than remote TB 
infections compared with TST in an adolescent population who had previously received BCG 
vaccination 
Reviewers: 
QFT performed better than TST in detecting LTBI by predicting development of active TB 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Song 2014152 
Country: South Korea 
Study design: prospective cohort study 
Study setting (e.g., outbreak investigation, community-based  - specify): community-based 
Number of centres: 1 (children sampled from 45 schools) 
Total length of follow up (if applicable): 24 months 
Funding (government/private/manufacturer/other - specify): This research was supported by a fund 
(2008-E00226-00, 2009-E46002-00, 2010-E46003-00, 2011-E46006-00, and 2012-E46001-00) by 
Research of Korea 
Centers for Disease Control and Prevention. The funders had no role in study design, data collection 
and analysis, decision to publish, or preparation of the manuscript 
Aim of the study 
To determine the agreement between IGRA (QFT-GIT) and TST and identify the relationships 
between the results of these tests and the development of active tuberculosis in middle and high 
school students in close contact with tuberculosis patients in South Korea 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Children  
Participants 
Recruitment dates: Between 2008 and 2012  
Total N of recruited patients: 3,202 
Inclusion criteria: Close contacts of identified smear-positive tuberculosis cases with normal chest 
X-ray aged 11–19 years  
Exclusion criteria: Participants showing (1) abnormal findings in simple chest radiographs, (2) they 
had taken immunosuppressive agents or anticancer drugs earlier, and (3) they had been treated with 
antituberculous drugs or chemoprophylaxis earlier 
Total N of excluded patients: 220 (at baseline) 
Total N of patients tested with both IGRA and TST: 2,982 
Total N of patients with valid results for both IGRA and TST: 2,966 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: between test agreement, incidence of active TB 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 15.1 (1.3) 
Women (n [%]): 1,356 (45.5) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 1,818 (61.0) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): 23/2,982 (0.77) 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): 5/215 [2.32] (isoniazid) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   2982 317 2649 16 2966 
TST≥10mm 2982 663 2319 0 2982 
TST≥15mm 2982 231 2751 0 2982 
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Test 3 (specify)      
Total N of patients with valid results for both IGRA and TST: 2,966 
Levels/groups of exposure to TB in increasing order (if applicable): NA 
Definition of exposure group –  
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, 
methodology, timing for 
test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA –[QFT-
GIT] 
QFT Gold In-Tube 
(Cellestis Inc, Valencia, 
CA) tests were performed 
according to the 
manufacturer’s 
instructions. Briefly, 
whole blood was 
collected by venipuncture 
from each subject at the 
date of injection of PPD 
and incubated for 16–24 
hours in 3 separate 
conditions: 1) a mixture 
of 
3 TB antigens from RD1 
and RD11 (ESAT-6, 
CFP-10, and 
TB7.7); 2) a mitogen as a 
positive control; and 3) a 
mock stimulation as a 
negative control (nil). 
Following the 
stimulations, 150 mL of 
the supernatant was 
harvested from each tube. 
Then, 50 mL of each 
supernatant was used to 
determine its interferon 
gamma (IFN-c) 
concentration by the 
ELISA 
A QuantiFERON value 
of 0.35 international 
units or more was 
deemed positive 
according to 
manufacturer’s 
instructions 
To eliminate the 
possibility of false-
positive IGRA results 
due to PPD reagents, 
blood samples were 
collected before PPD 
injection 
TST≥10mm Intradermal injection (0.1 
ml) of 2 tuberculin units 
of purified protein 
derivative (RT 23; 
Statens Serum Institute, 
Copenhagen, Denmark) 
into the anterior surface 
of the forearm with a 
disposable syringe and a 
The maximal transverse 
size of induration was 
read 48–72 hours later 
with a ruler or a caliper 
by a research nurse  
 
≥10mm 
≥15mm 
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27-gauge needle by using 
the Mantoux technique 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-GIT) TST≥10mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 11 306 317 TST + 13 650 663 
IGRA - 12 2637 2649 TST - 10 2309 2319 
indeterminate NR NR 16 indeterminate 0 0 0 
Total 23 2943 2966 Total 23 2959 2982 
Test performance parameters 
IGRA TST 
Sensitivity = 11/23=47.83% (95% CI: 29.24, 
67.04) 
Sensitivity =13/23=56.52% (95% CI: 36.81, 74.37) 
Specificity = 2637/2943=89.6% (95% CI: 
88.45, 90.65) 
Specificity = 2309/2959=78.03% (95% CI: 76.51, 
79.49) 
PPV= 11/317=3.47% (95% CI: 1.94, 6.10) PPV= 13/663=1.96% (95% CI: 1.14, 3.32) 
NPV= 2637/2649=99.55% (95% CI: 99.21, 
99.74) 
NPV= 2309/2319=99.57% (95% CI: 99.21, 99.77) 
Cumulative Incidence IGRA+ = 11/317=3.47% 
(95% CI: 1.87, 6.17) 
Cumulative Incidence TST+ = 13/663=1.96% (95% 
CI: 1.11, 3.36) 
Cumulative Incidence IGRA- = 12/2649=0.45% 
(95% CI: 0.24, 0.79) 
Cumulative Incidence TST- = 10/2319=0.43% (95% 
CI: 0.22, 0.80) 
Cumulative Incidence Ratio IGRA =7.66 (95% 
CI: 3.41, 17.21) 
Cumulative Incidence Ratio TST =4.55 (95% CI: 
2.00, 10.32) 
Incidence density rate IGRA+ = NR Incidence density rate TST+= NR 
Incidence density rate IGRA- = NR  Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST= NR  
Other reported measure IGRA =OR=7.90 (95% 
CI: 3.46, 18.06)  
Other reported measure TST = OR=4.62 (95% CI: 
2.02, 10.58) 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios=1.68 (95% CI: 0.94, 3.03) 
Ratio of incidence density rate ratios=NA 
Other reported measure= OR = 1.71 (95% CI: 0.94, 3.11) 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-GIT) TST≥15mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 11 306 317 TST + 13 218 231 
IGRA - 12 2637 2649 TST - 10 2741 2751 
indeterminate NR NR 16 indeterminate 0 0 0 
Total 23 2943 2966 Total 23 2959 2982 
Test performance parameters 
IGRA TST 
Sensitivity = 11/23=47.83% (95% CI: 29.24, 67.04) Sensitivity =13/23=56.52% (95% CI: 36.81, 
74.37) 
Specificity = 2637/2943=89.6% (95% CI: 88.45, 
90.65) 
Specificity = 2741/2959=92.63% (95% CI: 
91.64, 93.52) 
PPV= 11/317=3.47% (95% CI: 1.94, 6.10) PPV= 13/231=5.62% (95% CI: 3.31, 9.38) 
NPV= 2637/2649=99.55% (95% CI: 99.21, 99.74) NPV= 2741/2751=99.64% (95% CI: 99.33, 
99.80) 
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Cumulative Incidence IGRA+ = 11/317=3.47% 
(95% CI: 1.87, 6.17) 
Cumulative Incidence TST+ = 13/231=5.62% 
(95% CI: 3.23, 9.47) 
Cumulative Incidence IGRA- = 12/2649=0.45% 
(95% CI: 0.24, 0.79) 
Cumulative Incidence TST- = 10/2741=0.36% 
(95% CI: 0.18, 0.67) 
Cumulative Incidence Ratio IGRA =7.66 (95% CI: 
3.41, 17.21) 
Cumulative Incidence Ratio TST =15.48 (95% 
CI: 6.86, 34.92) 
Incidence density rate IGRA+ = NR Incidence density rate TST+= NR 
Incidence density rate IGRA- = NR  Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST= NR  
Other reported measure IGRA =OR=7.90 (95% CI: 
3.46, 18.06) 
Other reported measure TST = OR=16.35 (95% 
CI: 7.08, 37.71) 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios=0.49 (95% CI: 0.28, 0.89) 
Ratio of incidence density rate ratios=NA 
Other reported measure= 0.48 (95% CI: 0.27, 0.88) 
Association between test results and levels of TB exposure (if applicable) 
IGRA (specify) TST (specify) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) = NA  
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) IGRA = NA  
List of covariates: NA 
OR (regression-based; reported) TST = NA 
List of covariates: NA 
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Other reported measure = NA  Other reported measure = NA  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST ≥10mm TST - Total 
IGRA + 231 86 317 
IGRA - 430 2,219 2,649 
indeterminate 2 14 16 
Total  663 2,319 2982 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.38 (95% CI: 0.342, 0.424) 
% concordance = [231+2,219]/2,966 = 82.6% (95% CI: 81.2, 83.92) 
% discordance = [430+86]/2,966 = 17.4% (95% CI: 16.08, 18.80) 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST ≥15mm TST - Total 
IGRA + 163 154 317 
IGRA - 68 2,581 2,649 
indeterminate 0 16 16 
Total  231 2,751 2,982 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥15mm 
Parameters 
Kappa = 0.55 (95% CI: 0.50, 0.61) 
% concordance = [163+2581]/2,966 = 92.52% (95% CI: 91.51, 93.41) 
% discordance = [68+154]/2,966 = 7.48% (95% CI: 6.59, 8.48) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
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Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
TST at 15 mm had a higher OR for the development of active tuberculosis compared to TST 10mm 
and QFT-GIT. The agreement between TST and QFT was better when TST had 15 mm threshold 
Reviewers: 
Children testing positive on both tests had a greater risk of developing active TB; TST at 15mm 
performed better in diagnosing LTBI compared to TST 10mm or QFT-GIT; TST 15mm agreed with 
QFT GIT better than TST 10 mm 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
  
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
405
Immunocompromised 
 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Ahmadinejad 2013120 
Country: Iran 
Study design: Cross sectional/retrospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Tertiary care teaching 
hospital 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Tehran University of Medical Sciences 
and Health Services grant 
Aim of the study 
To compare the QFT and TST in diagnosis of LTBI in solid organ transplant (SOT) candidates 
(kidney, liver, lung) 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (SOT candidates: kidney, liver, lung) 
Participants 
Recruitment dates: March 2008 through September 2011 
Total N of recruited patients: 187 
Inclusion criteria: SOT candidates who were referred to the transplant clinic 
Exclusion criteria: (i) failure to return to the clinic for reading the results of TST within 5 days of the 
initial intradermal injection, or (ii) unwillingness to continue the study at any stage 
Total N of excluded patients: 23 (dropouts) 
Total N of patients tested with both IGRA and TST: 164  
Total N of patients with valid results for both IGRA and TST:TST (n = 164), IGRA (n = 159) 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Agreement/disagreement, association between test results and 
exposure to active TB 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 39.9 (12.7) yrs 
Women (n [%]): 76 [46.3] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 151 [92.1] 
History of anti-TB treatment (n [%]): 1/164 [0.6] 
Total incidence of active TB (n [%]): 1/164 [0.6] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): End-stage renal disease (64 [39.0]), chronic hepatic failure (97 [59.2]), Pulmonary 
failure (3 [1.8]) 
Co-morbidity (n [%]): NA 
Type of during-study treatment (n [%]): Patients with positive TST received chemoprophylaxis with 
300 mg isoniazid for 9 months; immunosuppressive medication (24 [14.6]) 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total 
N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   164 33 126 5 159 
TST: 164 26 138 0 164 
Test 3 (specify): NA NA NA NA NA 
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Total N of patients with valid results for both IGRA and TST: 164 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  No history of exposure to active TB 
Exposed 1 (specify): Exposure history to active TB 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA 
(QFT-
GIT) 
QuantiFERON-TB Gold In-Tube test 
(QFT-GiT)  
 
Blood sample of 3 mL was obtained, 
and 1 mL was added to each of the 3 tubes 
designated as the nil, mitogen, and antigen 
tubes. After vigorous shaking of the tubes, 
they were sent to the laboratory up to 6 h 
after acquisition  
 
The tubes were reshaken and incubated 
for 24 h at 37°C. Then the samples were 
centrifuged at 2000–3000 RCF rate for 15 
min, and the resulting plasma samples 
were kept at >70°C for the measurement 
of interferon-gamma (IFN-c) with 
enzyme-linked immunosorbant assay 
(ELISA) 
NR 
For prevention of 
potential 
boosting effect of 
TST on QFT, blood 
sampling and 
purified protein 
derivative (PPD) 
injection were done 
simultaneously for all 
patients 
TST 0.1 mL from 5 tuberculin units of PPD 
solution was injected intradermally 2–4 
inches (~5–10 cm) lower than the elbow, 
with an angle of about 5–15 degrees, and 
the induration size was measured after 
48–72h 
If the induration is ≥10 
mm in largest 
diameter, the test was 
considered positive 
 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
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Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 0 33 33 TST + 0 26 26 
IGRA - 5 121 126 TST - 5 133 138 
Indeterminate 0 5 5 Indeterminate 0 0 0 
Total  5 159 164 Total  5 159 164 
Test performance parameters 
IGRA TST 
Sensitivity = 0/5 = 0.00%  Sensitivity = 0/5 = 0.00% 
Indeterminate excluded 
Specificity = 121/154 = 78.57% (95% CI: 
71.44, 84.32) 
Indeterminate included 
Specificity = 126/159 = 79.25% (95% CI: 
72.29, 84.82) 
Specificity = 133/159 = 83.65% (95% CI: 77.12, 
88.59) 
PPV = 0/33 = 0.00% PPV = 0/26 = 0.00% 
Indeterminate excluded 
NPV = 121/126 = 96.03% (95% CI: 91.05, 
98.29) 
Indeterminate included 
NPV = 126/131 = 96.18% (95% CI: 91.38, 
98.36) 
NPV = 133/138 = 96.38% (95% CI: 91.8, 98.44) 
DOR (for T
+
 calculated) = 0.00 DOR (for T
+
 calculated) = 0.00 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR   
OR (regression-based; reported) = NR 
List of covariates: 
OR (regression-based; reported) = NR 
List of covariates: 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 28 5 33 TST + 23 3 26 
IGRA - 118 8 126 TST - 128 10 138 
Indeterminate 5 0 5 Indeterminate 0 0 0 
Total  151 13 164 Total  151 13 164 
Test performance parameters 
IGRA  TST  
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DOR (for T+ calculated)IGRA = 0.38 (95% CI: 0.11, 
1.24) 
DOR (for T+ calculated)TST = 0.60 (95% CI: 
0.15, 2.34) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR   
OR (regression-based; reported) IGRA = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 13 20 33 
IGRA - 12 114 126 
Indeterminate 1 4 5 
Total  26 138 164 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Indeterminate excluded 
Kappa = 0.32 (95% CI: 0.17, 0.48) 
Indeterminate included 
Kappa = 0.32 (95% CI: 0.17, 0.47) 
Indeterminate excluded 
% concordance = 127/159 = 79.87% (95% CI: 72.97, 85.37) 
 Indeterminate included 
% concordance = 131/164 = 79.88% (95% CI: 73.09, 85.3) 
% discordance = 20.13% (95% CI: 14.63, 27.03) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
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Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Considering the fair overall agreement between the 2 tests, and greater ease of the QFT from the 
patient’s point of view, QFT is recommended for detection of LTBI in SOT candidates 
Reviewers: 
The tests performed similarly in relation to construct of validity (exposure to active TB) in terms of 
sensitivity (low), specificity (high), DOR (low), and NPV (high); agreement between the tests was 
fair (0.32); neither test was influenced by BCG status 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Al Jahdali 2013121 
Country: Saudi Arabia 
Study design: retrospective cohort/cross-sectional study  
Study setting (e.g., outbreak investigation, community-based  - specify): outpatient hemodialysis unit 
hospital-based 
Number of centres: one 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): No funding sources 
Aim of the study 
To compare the performance of the QTF-GIT test and the TST for detecting LTBI among 
hemodialysis patients and to investigate the agreement between these 2 tests in the detection of 
tuberculosis infection in a population showing an intermediate TB prevalence 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (hemodialysis patients) 
Participants 
Recruitment dates: August to December 2010 
Total N of recruited patients: 215 
Inclusion criteria: Hemodialysis patients 
Exclusion criteria: NR 
Total N of excluded patients: 15 (active TB) 
Total N of patients tested with both IGRA and TST: 215 
Total N of patients with valid results for both IGRA and TST: 200 
Methods of active TB diagnosis (if applicable): positive tuberculosis culture or biopsy showing 
granuloma and good response to anti-tuberculosis therapy 
Outcomes (study-based) list: test result association with construct of  validity (high likelihood of 
LTBI) and between-test agreement 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 58.42 (17.65) yrs  
Women (n [%]):103 [51.5] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 28 [14.0] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): Hemodialysis patients 
Co-morbidity (n [%]): diabetic nephropathy (127 [63.5]), kidney transplant failed (21 [10.5]), NR (52 
[26.0]) 
Type of during-study treatment (n [%]): Immunosuppressant in the last 12mo (2 [1.0]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   NR 65 135 NR  200 
TST (≥10mm): NR 26 174 NR  200 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 200 
Levels/groups of exposure to TB in increasing order (if applicable): 
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Definition of exposure group - High likelihood of LTBI 
Non-exposed  No high likelihood of LTBI 
Exposed 1 (specify): High likelihood of LTBI (contact with TB case, abnormal chest X-ray, 
DM, immunosuppressant in the last 12 M, failed kidney transplant or 
BMI≤20) 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA  Test was performed according to the 
manufacturer’s instructions. One ml 
of whole blood was collected in each 
of 3 separate test tubes: 1 containing 
no antigen (nil control), 1 with a 
mitogen (phytohemagglutinin, 
positive control) and 1 with TB 
antigens (ESAT-6, CFP-10 and 
TB7.7). The 3 tubes were incubated 
overnight for 18-20 h at 37 ◦C. 
Following incubation, the tubes were 
centrifuged, and the plasma was 
removed from each tube and frozen at 
−20 ◦C. Measurement of IFN-γ via 
ELISA was subsequently performed 
in batch testing  
A value of 0.35 IU/ml or more 
for the relationship ([IFN-γ in the 
TB antigen tube] − [IFN-γ in the 
negative control tube]) was 
considered to be a positive result. 
If the IFN- γ level was <0.35 
IU/ml in the TB antigen tube and 
the mitogen control was positive 
(≥0.5 IU/ml), the test was 
recorded as negative 
 
IGRA blood 
was collected 
before the 
administration 
of 
the TST 
TST The TST employed in this study was 
Tubersol —Tuberculin Purified 
Protein Derivative (Mantoux), 5 TU 
per 0.1 ml, test manufactured by 
Sanofi Pasteur 
 
Limited, Toronto, Ontario, Canada. 
A trained and experienced public 
health nurse performed all TSTs. Five 
tuberculin units (0.1 ml) of the 
purified protein derivative (PPD) 
were administered via intradermal 
injection on the volar surface of the 
forearm that did not have the 
arteriovenous vessel. The responses 
were read within 72 h by the same 
nurse, usually during the next 
regularly scheduled 
HD visit 
 
An induration of 10mm or more 
in transverse diameter was used 
as the threshold to classify the 
test results as positive for LTBI.  
 
Patients with an induration of 
less than 10mm upon initial 
testing were considered to be 
negative and were administered a 
second TST within 3—6 weeks 
to elicit a potential booster 
response. The results obtained 
from the 2-step testing were used 
in all further analyses. The TST 
was considered to be positive if 
either the 1st or 2nd test showed 
a response of 10mm or more 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
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IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA  
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 51 14 65 TST + 19 7 26 
IGRA - 103 32 135 TST - 135 39 174 
indeterminate NR NR NR  indeterminate NR NR NR  
Total  154 46 200 Total  154 46 200 
Test performance parameters 
IGRA TST 
Sensitivity = 51/154 = 33.12% (95% CI: 26.00, 
41.00) 
Sensitivity = 19/154 = 12.34% (95% CI: 8.04, 
18.47) 
Specificity = 32/46 = 69.57% (95% CI: 55.19, 
80.92) 
Specificity = 39/46 = 84.78% (95% CI: 71.78, 
92.43) 
PPV = 51/65 = 78.46% (95% CI: 67.03, 86.71) PPV = 19/26 = 73.08% (95% CI: 53.92, 86.3) 
NPV = 32/135 = 23.70% (95% CI: 17.32, 
31.54) 
NPV = 39/174 = 22.41% (95% CI: 16.85, 29.17) 
DOR (for T+ calculated) = 1.13 (95% CI: 0.55, 
2.31) 
DOR (for T
+
 calculated) = 0.78 (95% CI: 0.31, 
2.00) 
OR (crude; for T+ reported) = NR  OR (crude; for T+ reported) = NR   
OR (regression-based; reported) = NR 
List of covariates: 
OR (regression-based; reported) = NR 
List of covariates: 
Other reported measure = NR   Other reported measure = NR  
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.45 (95% CI: 0.79, 2.64) 
Ratio of OR (crude; for T
+ 
reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
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IGRA - NR NR NR TST - NR NR NR 
indeterminate NR NR NR indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 21 44 65 
IGRA - 5 130 135 
indeterminate NR NR NR 
Total  26 174 200 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.34 (95% CI: 0.22, 0.45) 
% concordance = 151/200 = 75.50% (95% CI: 69.10, 80.94) 
% discordance = 49/200 = 24.5% (95% CI: 19.06, 30.90) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if Adverse events n/N (%) Health related quality 
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applicable)  (specify) of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The discriminatory ability of the QTF-G test is superior to that of the TST. The QTFG test was more 
sensitive but less specific than the TST in predicting LTBI 
Reviewers: 
There was fair agreement between the tests (k = 0.34); In general, QFT-GIT performed better than 
TST in terms of sensitivity; specificity was higher for TST vs. QFT-GIT 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Ates 2009122 
Country: Turkey 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based  - specify): Outpatient hemodialysis 
hospital centers 
Number of centres: 5 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Grant from University of Dicle 
Aim of the study 
To assess the efficacy of QTF-GIT test for detection of LTBI and determine the degree of agreement 
between the results of TST and QTFGIT tests in hemodialysis patients 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (hemodialysis patients) 
Participants 
Recruitment dates: March 15 and April 15 of 2008 
Total N of recruited patients: 290 
Inclusion criteria: Hemodialysis patients 18 yrs or older  
Exclusion criteria: The patients diagnosed with active tuberculosis and receiving treatment for the 
last 12 months, or taking immunosuppressive medicine or younger than 18 years old were excluded 
from the present study 
Total N of excluded patients: 15 (rejected tests, improper blood sampling, and unsuccessful 
phlebotomy) 
Total N of patients tested with both IGRA and TST: 275 
Total N of patients with valid results for both IGRA and TST: 230 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Agreement, risk factors for positive test 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 51.9 (16.2) yrs 
Women (n [%]):137 [50.0] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 134 [48.72] 
History of anti-TB treatment (n [%]): 17 [7.4%] 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): hemodialysis 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   275 115 131 29 246 
TST (≥10mm): 275 92 167 16 259  
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 230 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
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Non-exposed  No Tuberculosis exposure 
Exposed 1 (specify): Tuberculosis exposure 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA  The QTF-GIT test was performed in two 
steps. Whole blood was collected first into 
each of the QTF-GIT blood collection 
tubes, consisting of a nil control tube, a 
tuberculosis antigen tube, and a mitogen 
tube. The tubes were incubated at 37oC as 
soon as possible. After a 16-20 hours 
incubation period, the tubes were 
centrifuged and the plasma was removed 
and frozen at -70oC until the ELISA was 
performed. The ELISA for IFN-g was 
performed according to manufacturer’s 
specifications and the ELISA readout was 
analyzed using the QTF-GIT analysis 
software 
According to the QTF-GIT 
analysis software results 
were recorded as positive, 
negative and indeterminate. 
The whole blood was drawn 
just before hemodialysis 
Observers were 
blinded to the 
results of the 
TST 
TST TST were administered and its results 
were interpreted in relation to American 
Thoracic Society Guidelines (1). Briefly, a 
trained nurse performed one-step 
tuberculin skin test using the Mantoux 
technique through the injection of 0.1 ml 
(5 tuberculin units) of purified protein 
derivative (PPD; Tween 
80, BB-NCIPD Ltd, Sofia, Bulgaria) into 
the volar surface of the forearm 
A skilled nurse measured 
the transverse axis of 
indurations with a flexible 
ruler, and an experienced 
physician verified all the 
results. A positive TST 
result was defined as an 
induration diameter of 10 
mm or larger 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
417
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST≥10mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 10 105 115 TST + 5 87 92 
IGRA - 7 124 131 TST - 12 155 167 
Indeterminate NR NR 29 Indeterminate NR NR 16 
Total    275 Total    275 
Test performance parameters 
IGRA TST 
Sensitivity = 10/17 = 58.82% (95% CI: 36.01, 
78.39) 
Sensitivity = 5/17 = 29.41% (95% CI: 13.28, 
53.13) 
Specificity = 124/229 = 54.15% (95% CI: 
47.68, 60.48) 
Specificity = 155/243 = 64.05% (95% CI: 57.83, 
69.83) 
PPV = 10/115 = 8.69% (95% CI: 4.792, 15.27) PPV = 5/92 = 5.43% (95% CI: 2.34, 12.10) 
NPV = 124/131 = 94.66% (95% CI: 89.38, 
97.39) 
NPV = 155/167 = 92.81% (95% CI: 87.86, 
95.84) 
DOR (for T
+
 calculated) = 1.68 (95% CI: 0.62, 
4.58) 
DOR (for T
+
 calculated) = 0.74 (95% CI: 0.25, 
2.17) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR   
OR (regression-based; reported) = 1.30 (0.43, 
3.91) 
List of covariates: NR 
OR (regression-based; reported) = 0.49 (0.17, 
1.45) 
List of covariates: NR  
Other reported measure = NR Other reported measure = NR  
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 2.27 (95% CI: 1.07, 4.81) 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = 2.65 (95% CI: 1.21, 5.82) 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 57 58 115 TST + 45 47 92 
IGRA - 61 70 131 TST - 88 79 167 
Indeterminate NR NR 29 Indeterminate NR NR 16 
Total    275 Total    275 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 1.13 (95% CI: 0.68, 
1.86)  
DOR (for T+ calculated)TST = 0.85 (95% CI: 
0.51, 1.43) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR   
OR (regression-based; reported) IGRA = 1.14 (95% 
CI: 0.68, 1.92) 
List of covariates: NR 
OR (regression-based; reported) TST = 0.87 (95% 
CI: 0.50, 1.51)  
List of covariates: NR  
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
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This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 58 49 107 
IGRA - 25 98 123 
indeterminate NR NR 29 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.34 (95% CI: 0.21, 0.47) 
% concordance = 156/230 = 67.83% (95% CI: 61.54, 73.53) 
% discordance = 74/230 = 32.17% (95% CI: 26.47, 38.46) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
QTF-GIT is more sensitive than TST in the detection of LTBI among renal dialysis patients; both 
QTF-GIT and TST results were not correlated with contact to the patients with tuberculosis; we 
observed no association among the results of both TST & QTF-GIT and BCG vaccination status; 
agreement between tests was fair (k = 0.34) 
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Reviewers: 
See above 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Casas 2011a123 
Country: Spain 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based  - specify): Outpatient clinics  
Number of centres: 4 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): The first author received research grant 
from the University Barcelona (October 2006–January 2010). This study was supported by the 
Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III-FEDER, Spanish Network for the 
Research in Infectious Diseases (REIPI RD06/0008) 
Aim of the study 
To assess the prevalence of LTBI obtained by the whole blood-based QFT-GIT and TST in patients 
with IMID, and second, to determine whether QFT-GIT performs in the same way as in healthy 
people 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (immune-mediated inflammatory diseases [IMID] before anti–TNF-α 
therapy) 
Participants 
Recruitment dates: NR 
Total N of recruited patients: 323  
Inclusion criteria: Patients with immune-mediated inflammatory diseases (IMID) before anti–TNF-α 
therapy 
Exclusion criteria: NR 
Total N of excluded patients: n = 9 (no IMID: n = 2 and problems with QFT-GIT plasma sample 
storage: n = 7) 
Total N of patients tested with both IGRA and TST: 323 
Total N of patients with valid results for both IGRA and TST: 314 (214 IMID and 100 healthy 
controls) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Associations between test positivity and risk factors of LTBI, BCG 
status, type of treatment; agreement; influence of  risk factors on indeterminate results  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 49.1 (12.9) 
Women (n [%]): 109 [50.9] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Born in a high TB incidence country (16 [7.5]) 
BCG vaccination (n [%]): 56 [26.2] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): NR 
Morbidity (n [%]): Rheumatoid arthritis (91 [42.5]); Cutaneous psoriasis (57 [26.6]); 
Spondylarthropathies (29 [13.6]); Psoriatic arthropathy (21 [9.8]); Inflammatory bowel disease (14 
[6.5]); Others (2 [0.9]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Immunosuppressive treatment (163 [76.2]); Corticosteroids 
(91 [42.5]); Methotrexate (91 [42.5]); Leflunomide (36 [16.8]); Cyclosporine A (22 [10.3]); 
azathioprine/efalizumab (13 [6.1]) 
Number of patients tested 
 Total N  Total Total N Total N Total N  
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(tested) N 
 
(test+) 
 (test-) (indeterminate) (test results 
available) 
IGRA (QFT-GIT): 214 45 157 12 214 
TST (≥5 mm): 214 52 162 0 214 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 214 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group - risk factors for TB infection 
Non-exposed  No risk factors for TB infection 
Exposed 1 (specify): Risk factors for TB infection (birth or residence for ≥6 months in a high 
TB incidence country, TB contact, prior prison stay, intravenous drug 
abuse, health care worker, abnormal chest X-ray, and history of past TB)  
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(QFT-
GIT) 
QuantiFERON®-TB Gold in-Tube 
test samples were collected just 
before TST was performed (Nil, TB-
antigens [ESAT-6, CFP-10 and TB-
7.7] and phytohemagglutinin [PHA] 
tubes). All plasma samples were 
stored and analyzed in the 
Mycobacterial Laboratory (Clinical 
Microbiology Department) in 
accordance with the manufacturer's 
instructions 
According to 
manufacturer QFT-GIT results 
could be positive, negative, or 
indeterminate depending on the 
IFN-γ production. Plasma samples 
with indeterminate results were 
retested 
 
NA 
TST TST was performed according to the 
Mantoux method using 2 U of 
tuberculin RT-23 (Statens Serum 
Institute, Copenhagen, Denmark) 
 
TST was administered and read by 
experienced staff following the 
standard protocol (in the left 
forearm and transverse diameter 
measurement).  Any induration of 
≥5 mm at 48–72 h was considered 
as positive 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
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Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR 45 TST + NR NR 52 
IGRA - NR NR 157 TST - NR NR 162 
indeterminate NR NR 12 indeterminate 0 0 0 
Total  NR NR 214 Total  NR NR 214 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR  DOR (for T+ calculated) = NR  
OR (crude; for T+ reported) = 2.50 (95% CI: 
1.20, 5.10) 
OR (crude; for T+ reported) = 2.80 (95% CI: 1.40, 
5.50) 
OR (regression-based; reported) = 2.90 (95% 
CI: 1.30, 6.30) 
List of covariates: age, gender, BCG 
vaccination, and immunosuppressive treatment 
OR (regression-based; reported) = 2.90 (95% CI: 
1.40, 6.00) 
List of covariates: age, gender, BCG vaccination, 
and immunosuppressive treatment 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.89 (95% CI: 0.54, 1.48) 
Ratio of ORs (regression-based; reported) = 1.00 (95% CI: 0.58, 1.73) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR 45 TST + NR NR 52 
IGRA - NR NR 157 TST - NR NR 162 
indeterminate NR NR 12 indeterminate 0 0 0 
Total  NR NR 214 Total  NR NR 214 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = 1.20 (95% CI: 
0.50, 3.20) 
OR (crude; for T+ reported) = 1.70 (95% CI: 0.90, 
3.40) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = 1.50 (95% 
CI: 0.70, 3.40) 
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List of covariates: age, gender, risk factors for TB, 
and immunosuppressive treatment 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 32 13 45 
IGRA - 19 138 157 
indeterminate 1 (excluded) 11 (excluded) 12 (excluded) 
Total  51 151 202 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (IMID n = 202)  
TST + threshold: ≥5mm  
Parameters 
Kappa = 0.56 (95% CI: 0.42, 0.70) 
% concordance = 170/202 = 84.16% (95% CI: 78.49, 88.55) 
% discordance = 32/202 = 15.84% (95% CI: 11.45, 21.51) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
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 Reviewers: 
Association between immunosuppression therapy and TST positivity (adjusted OR, 0.50, 95% CI 
0.24, 1.04; P = 0.07) was lower compared with that for QFT-GIT positivity (adjusted OR 0.53, 95% 
CI 0.24, 1.19); similar results in corticosteroid users (OR for TST was lower than OR for QFT); 
immunosuppression therapy was a predictor of indeterminate results (OR 4.87, 95% CI 1.05, 22.60); 
agreement was 0.56; there was no association between test positivity (for QFT or TST) and BCG 
status (no influence of BCG status on test positivity); TST and QFT had a similar association with 
risk of LTBI (risk factor for TB) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Casas 2011b124 
Country: Spain  
Study design: Retrospective/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based  - specify): hospital-based 
Number of centres: one 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify)  grants from the Spanish Ministry for 
Health and Consumer Affairs and the Carlos III Health Institute through the Fund for Health 
Investigations (PI070810, 2007-2010) and from the Carlos III Health Institute and Spanish 
Federation for Rare Diseases through the Spanish Network for Research in Infectious Diseases; 
research grant from the University of Barcelona  
Aim of the study 
To compare the performance of the TST and the QuantiFERON-TB Gold In-Tube (QFT-IT) test (a 
commercially available, whole blood–based IGRA) in detecting latent TB infection in patients with 
end-stage liver disease (ESLD) requiring liver transplant (LT) 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people: ESLD patients requiring LT 
Participants 
Recruitment dates: From July 2008 to July 2010 
Total N of recruited patients: 110 
Inclusion criteria: All patients with ESLD who were being considered for LT were invited to 
participate in the study  
Exclusion criteria: Patients younger than 18 years, patients with a previous history of TB, patients 
who had recently been tested with the TST, and patients with known immunosuppressive conditions  
Total N of excluded patients: 15 (previous TB infection, HIV, dropouts, anti-TNF-alpha agents, 
incomplete IGRA results) 
Total N of patients tested with both IGRA and TST: 95 
Total N of patients with valid results for both IGRA and TST: 95 
Methods of active TB diagnosis (if applicable): all patients underwent a chest x-ray examination; 
the findings were defined as normal or abnormal according to the presence or absence of lesions 
suggestive of past TB 
Outcomes (study-based) list: associations between test positivity and risk factors of LTBI, BCG 
status, agreement 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 56.4 (7.6)  
Women (n [%]): 23 [24.2] 
Race/ethnicity (n [%]): Spanish (89 [93.7]) 
Geographic origin (n[%]): Born or residing in a country with a high TB burden (6 [6.3]) 
BCG vaccination (n [%]): 30 [31.6] 
History of anti-TB treatment (n [%]): None 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): Cirrhosis (52 [54.7]), hepatocellular carcinoma (35 [36.8]), and other 
hepatopathies (8 [8.4]) 
Co-morbidity (n [%]): Diabetes mellitus 28 [29.5], chronic pulmonary obstructive disease 3 (3.2), 
renal failure 12 [12.6]  
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  Total Total N Total N Total N  
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(tested) N 
(test+
) 
 (test-) (indeterminate) (test results 
available) 
IGRA (QFT-GIT):   95 42 51 2 95 
TST (2 step; 
≥5mm): 
95 44 51 0 95 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 95 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group - risk factors for TB 
Non-exposed  No risk factors for TB 
Exposed 1 
(specify): 
Risk factors for TB (previous contact with TB, abnormal chest x-rays, birth 
or prolonged residence in a country with a high TB burden, alcoholism, drug 
abuse, a previous stay in prison, and involvement with health care) 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, timing for test 
measurement, manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
informat
ion 
IGRA 
(QFT-
GIT) 
The QFT-IT test was performed in 
accordance with the manufacturer’s 
instructions. Briefly, 3 tubes with 1 mL of 
whole blood were filled for each patient: a 
tube with no antigens (the nil tube), a tube 
with M. tuberculosis–specific antigens, and a 
tube with phytohemagglutinin (the mitogen 
tube). The blood samples were stored and 
analyzed at the Mycobacterial Laboratory.  
The blood samples for QFT-IT testing were 
collected immediately before the TST was 
performed 
Results were scored as 
positive [interferon-c level 
≥0.35 IU/mL (the M. 
tuberculosis–specific antigen 
tube minus the nil tube)], 
negative [interferon-c level < 
0.35 IU/mL (the M. 
tuberculosis–specific antigen 
tube minus the nil tube)], or 
indeterminate [interferon-c 
level < 0.5 (the mitogen tube 
minus the nil tube) or > 8.0 
IU/mL (the nil tube)] 
according to the production of 
interferon-c. Plasma samples 
with indeterminate results 
were retested 
NA 
TST (2 
step; ≥ 
5 mm)  
The TST was performed in the left forearm 
according to the Mantoux method with 
purified protein derivative RT-23 (2 U/0.1 
mL; Statens Serum Institute, Copenhagen, 
Denmark). In all cases, the TST was 
administered and evaluated by experienced 
staff. If the result for the first test was 
negative, the test was administered again 7 
to 10 days later (the 2-step TST), and that 
result was considered definitive 
Any induration ≥ 5 mm at 48 
to 72 hours was considered a 
positive result in accordance 
with the national transplant 
guidelines 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence Total  Incidence of Total 
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of active 
TB 
active TB 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (2 step; ≥ 5 mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 27 15 42 TST + 30 14 44 
IGRA - 33 20 53 TST - 30 21 51 
Indetermin
ate 
NR NR 2 
(excluded) 
Indetermina
te 
0 0 0 
Total  60 35 95 Total  60 35 95 
Test performance parameters 
IGRA TST 
Sensitivity = 27/60 = 45.00% (95% CI: 33.09, 
57.51) 
Sensitivity = 30/60 = 50.00% (95% CI: 37.73, 
62.27) 
Specificity = 20/35 = 57.14% (95% CI: 40.86, 
72.02) 
Specificity = 21/35 = 60.00% (95% CI: 43.57, 
74.45) 
PPV = 27/42 = 64.29% (95% CI: 49.17, 77.01) PPV = 30/44 = 68.18% (95% CI: 53.44, 80.00) 
NPV = 20/53 = 37.74% (95% CI: 25.94, 51.19) NPV = 21/51 = 41.18% (95% CI: 28.75, 54.83) 
DOR (for T+ calculated) = 1.01 (95% CI: 0.47, 
2.52) 
DOR (for T+ calculated) = 1.50 (95% CI: 0.64, 
3.49) 
OR (crude; for T+ reported) = 1.66 (95% CI: 
0.66, 3.33) 
OR (crude; for T+ reported) = 1.25 (95% CI: 
0.50, 2.50) 
OR (regression-based; reported) = 1.50 (95% CI: 
0.50, 4.10)  
List of covariates: age, sex, albumin, BCG 
status, Model for End-Stage Liver Disease 
(MELD) score  
OR (regression-based; reported) = 1.80 (95% CI: 
0.60, 5.10) 
List of covariates: age, sex, albumin, BCG status, 
Model for End-Stage Liver Disease (MELD) 
score 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.67 (95% CI: 0.37, 1.24) 
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Ratio of OR (crude; for T+ reported) = 1.33 (95% CI: 0.74, 2.38) 
Ratio of ORs (regression-based; reported) = 0.83 (95% CI: 0.39, 1.79) 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 11 31 42 TST + 13 31 44 
IGRA - 19 34 53 TST - 17 34 51 
Indeterminate NR NR 2 
(excluded) 
Indeterminat
e 
0 0 0 
Total  30 65 95 Total  30 65 95 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 0.63 (95% CI: 0.26, 
1.54) 
DOR (for T+ calculated)TST = 0.83 (95% CI: 
0.35, 2.00) 
OR (crude; for T+ reported) = 0.62 (95% CI: 0.26, 
1.42)  
OR (crude; for T+ reported) = 0.83 (95% CI: 
0.35, 2.00) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR  
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 33 9 42 
IGRA - 11 42 53 
Indeterminate NR NR 2 (excluded) 
Total  44 51 95 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥ 5 mm 
Parameters 
Kappa = 0.57 (95% CI: 0.37, 0.77) 
% concordance = 75/95 = 78.95% (95% CI: 69.71, 85.94) 
% discordance = 20/95 = 36.36% (95% CI: 24.93, 49.58) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
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Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
We conclude that the QFT-IT test and the TST detect latent TB infection at similar rates in patients 
with ESLD who require LT, but the QFT-IT test performs better in patients with more severe liver 
disease 
Reviewers: 
No difference in performance of the two tests irrespective of disease severity; however, in patients 
with more severe disease (MELD =>18), the QFT positivity rates were higher (OR = 0.20, 95% CI: 
0.04, 0.70) compared to TST positivity rates (OR = 0.80, 95% CI: 0.20, 2.80) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Chkhartishvili 2013125 
Country: Georgia 
Study design: Retrospective/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): National referral institution 
for HIV diagnosis, treatment and care 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): the U.S. Civilian Research and 
Development Foundation (CRDF) award; the NIH/FIC through the Emory AIDS International 
Training and Research Program award and the Emory-Georgia Tuberculosis Research Training 
Program award 
Aim of the study 
To assess the performance of two commercially available IGRAs (QuantiFERON-TB Gold in Tube 
[QFT-GIT] and TSPOT. TB [TSPOT]) compared to the TST for the diagnosis of LTBI in HIV-
infected patients, and to identify risk factors for LTBI in effort to improve the TB prevention and care 
among HIV patients 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people: HIV patients  
Participants 
Recruitment dates: November 2009 and June 2011 
Total N of recruited patients: NR 
Inclusion criteria: Age ≥18 years old, confirmed HIV infection, and ability to provide written 
informed consent  
Exclusion criteria: Patients with a history of active TB disease  
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 240 (QFT, TST), 238 (TSPOT) 
Total N of patients with valid results for both IGRA and TST: 237 (QFT), 238 (TST), 218 
(TSPOT) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Agreement, test positivity and risk factor association 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median 38.0 (range 32.8-43.8) 
Women (n [%]): 81 [33.75] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 219 [94%] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): NR 
Morbidity (n [%]): HIV 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT)  240 70 167 3 237 
IGRA (TSPOT) 240 56 162 22 218 
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TST ( ≥ 5 mm) 240 41 195 4 236 
Total N of patients with valid results for both IGRA and TST: 240 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group - Household Member treated for TB 
Non-exposed  No household member treated for TB 
Exposed 1 (specify): Household member treated for TB 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, 
methodology, timing for 
test measurement, 
manufacturer 
Cut-off values/thresholds Definition of 
test+ 
Other 
information 
IGRA 
(QFT-
GIT) 
Each participant had 
approximately 12 ml of 
blood drawn, which was 
performed according to 
the manufacturer’s 
instructions  
the QFT-GIT result was considered positive 
if the 
interferon-gamma response to TB antigens 
minus the negative control was ≥ 0.35 
IU/ml and also > 25% of the negative 
control; negative if these criteria were not 
met; and indeterminate if either the 
negative control had a result of > 8 IU/ml 
or the positive control had a result of < 0.5 
IU/ml 
Blood was 
drawn for 
the IGRAs 
prior to the 
placement 
of the TST 
IGRA 
(TSPOT) 
Each participant had 
approximately 12 ml of 
blood drawn, which was 
performed according to 
the manufacturer’s 
instructions 
For TSPOT 250,000 peripheral blood 
mononuclear cells (PBMCs) were isolated 
and plated per well: a nil control, a positive 
control containing phytohemagglutinin and 
TB specific antigens (CFP-10 and ESAT-
6). Spot forming units were counted using 
AID Eli-Spot Reader System (Autoimmun 
Diagnostika, Germany). The test result was 
considered reactive if the response to either 
CFP-10 or ESAT-6 minus the nil control 
was ≥ 6 spot forming cells, or twice the nil 
control. The result was considered 
indeterminate if nil control spot count was 
> 10 spot forming cells or if the reading in 
the positive control was < 20 spot forming 
cells 
Blood was 
drawn for 
the IGRAs 
prior to the 
placement 
of the TST 
TST The TST was performed 
using the Mantoux 
method. An intradermal 
injection of 0.1 ml 
purified protein 
derivative was 
administered into the 
volar surface of the 
forearm. The transverse 
diameter of induration 
was recorded in 
millimeters 48–72 hours 
after administration 
An induration of ≥ 5 mm of induration was 
considered positive  
 
Association between test results and incidence of active TB (if applicable) 
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IGRA  TST  
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST ≥ 5 mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR 70 TST + NR NR 41 
IGRA - NR NR 167 TST - NR NR 195 
Indeterminate NR NR 3 Indeterminate NR NR 4 
Total  13 227 240 Total  13 227 240 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR 
DOR (for T
+
 calculated) = NR  DOR (for T
+
 calculated) = NR  
OR (crude; for T+ reported) = 0.43 (95% CI: 
0.09, 1.97) 
OR (crude; for T+ reported) = 1.48 (95% CI: 0.39, 
5.62) 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.29 (95% CI: 0.10, 0.82) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST ≥ 5 mm 
 Exposure level Total  Exposure level Total 
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High/Yes Low/No High/Yes Low/No 
IGRA + NR NR 56 TST + NR NR 41 
IGRA - NR NR 162 TST - NR NR 195 
Indeterminate NR NR 22 Indeterminate NR NR 4 
Total  13 227 240 Total  13 227 240 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR 
DOR (for T+ calculated) = NR  DOR (for T+ calculated) = NR  
OR (crude; for T+ reported) = 1.48 (95% CI: 
0.44, 5.00) 
OR (crude; for T+ reported) = 1.48 (95% CI: 0.39, 
5.62) 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T+ reported) = 1.00 (95% CI: 0.40, 2.51) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST ≥ 5 mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR 70 TST + NR NR 41 
IGRA - NR NR 167 TST - NR NR 195 
Indeterminate NR NR 3 Indeterminate NR NR 4 
Total  173 67 240 Total  173 67 240 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = 1.41 (95% CI: 
0.38, 5.29) 
OR (crude; for T+ reported) = 2.55 (95% CI: 
0.32, 20.18) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST ≥ 5 mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR 56 TST + NR NR 41 
IGRA - NR NR 162 TST - NR NR 195 
Indeterminate NR NR 22 Indeterminate NR NR 4 
Total  173 67 240 Total  173 67 240 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = 1.78 (95% CI: 
0.38, 8.28) 
OR (crude; for T+ reported) = 2.55 (95% CI: 
0.32, 20.18) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
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Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥ 5 mm) TST - Total 
IGRA (QFT-GIT) + 25 44 69 
IGRA (QFT-GIT) -  16 148 164 
Indeterminate 0 3 3 
Total  41 195 236 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): QFT-GIT (total) 
TST + threshold: ≥ 5 mm 
Parameters 
Kappa = 0.30 (95% CI: 0.17, 0.42) calculated – indeterminate excluded 
Kappa = 0.29 (95% CI: 0.16, 0.42) reported  
% concordance = 173/233 = 74.25% (95% CI: 68.27, 79.44) calculated– indeterminate excluded 
% discordance = 60/233 = 25.75% (95% CI: 20.56, 31.73) calculated– indeterminate excluded 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥ 5 mm) TST - Total 
IGRA (TSPOT) + 20 36 56 
IGRA (TSPOT) - 18 143 161 
Indeterminate 3 16 19 
Total  41 195 236 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): TSPOT (total) 
TST + threshold: =>5mm 
Parameters 
Kappa = 0.27 (95% CI: 0.14, 0.40) calculated – indeterminate excluded 
Kappa = 0.22 (95% CI: 0.07, 0.29) reported 
% concordance = 163/217 = 75.12% (95% CI: 68.96, 80.4) calculated– indeterminate excluded 
% discordance = 54/217 = 24.88%  (95% CI: 19.6, 31.04) calculated– indeterminate excluded 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
435
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
There was very poor agreement among all tests. This lack of agreement makes it difficult to know 
which test is superior and most appropriate for LTBI testing among HIV-infected patients; 
Multivariate analysis did not identify one specific population subgroup at higher risk of LTBI 
Reviewers: 
There were no differences in the association between the test results for QFT (or TSPOT) vs. TST and 
risk of LTBI (exposure measured as household member treated for TB); BCG vaccination status did 
not appear to influence test positivity for either of the tests; agreement measured with kappa was fair 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Chung 2010a126 
Country: Korea  
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Medical Centre 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): funding from the Gil Medical Centre 
Aim of the study 
Two IGRAs (QFT-GIT and TSPOT) were simultaneously compared with the TST for their diagnostic 
efficacy for latent TB infection in Korea, an intermediate TB-burden country 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people - haemodialysis patients with end stage renal disease (ESRD) 
Participants 
Recruitment dates: 1 March to 30 April 2008 
Total N of recruited patients: NR 
Inclusion criteria: Hemodialysis patients with ESRD 
Exclusion criteria: Those patients who had taken empirical anti-TB medications and patients taking 
anti-TB medication for active TB infection  
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 167 (total), 146 (review-relevant 
population), 21 (patients with a cured TB infection) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list:  
Characteristics of participants (total study sample): n = 167 
Mean (range or SD) age (years): 54.1 (14.4) 
Women (n [%]): 71 [42.5] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 111 [67.3] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): ESRD due to Diabetes mellitus (67 [40.1]), Hypertension (18 [10.8]), 
Glomerulonephritis (12 [7.2]), Others (11 [6.6]), Unknown (59 [35.3]) 
Co-morbidity (n [%]): History of cancer (12 [7.2]), Cardiac disease (46 [27.5]), Cerebrovascular 
accident (13 [7.8]), History of TB infection (21 [12.6]) 
Type of during-study treatment (n [%]): Immunosuppressant medication (9 [5.4]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total 
N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   NR 56 90 NR (for n = 146) 146 
IGRA (TSPOT): NR 83 63 NR (for n = 146) 146 
TST ≥10 mm: NR 32 114 NR (for n = 146) 146 
Total N of patients with valid results for both IGRA and TST: 146 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – High vs. low risk 
Non-exposed  Low risk 
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Exposed 1 (specify): The high-risk group for latent TB infection consisted of patients with a 
history of close contact with TB patients, old TB lesions on CXR, or a 
history of TB infection 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(QFT-GIT) 
Whole blood was extracted just 
before dialysis for the two IFN-c 
tests. The QFT-G was performed 
according to the manufacturer’s 
instructions (Cellestis Ltd., Carnegie, 
Victoria, Australia)  
Results of each test were 
classified as positive, negative 
or indeterminate, as previously 
described 
NA 
IGRA 
(TSPOT) 
The TSPOT was also performed 
according to the manufacturer’s 
instructions (Oxford Immunotec, 
Oxford, UK)  
Results of each test were 
classified as positive, negative 
or indeterminate, as previously 
described 
NA 
TST Within a week after the IGRAs, 2-TU 
of purified protein derivative RT23 
(Statens Serum Institute, 
Copenhagen, Denmark) was 
intradermally injected on the volar 
side of the forearm contralateral to 
the patient’s vascular access. Two 
physicians, blind to the patients’ 
clinical information, measured the 
main diameter of the induration after 
48 h independently 
The positive criterion was ≥10 
mm size of the mean values of 
two measurements 
 
 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
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Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST≥10mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 9 47 56 TST + 2 30 32 
IGRA - 8 82 90 TST - 15 99 114 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  17 129 146 Total  17 129 146 
Test performance parameters (based on 146 patients; 21 with previous TB excluded) 
IGRA TST 
Sensitivity = 9/17 = 52.94% (95% CI: 30.96, 
73.84) 
Sensitivity = 2/17 = 11.76% (95% CI: 3.28, 34.34) 
Specificity = 82/129 = 63.57% (95% CI: 54.98, 
71.37) 
Specificity = 99/129 = 76.74% (95% CI: 68.75, 
83.20) 
PPV = 9/56 = 16.07% (95% CI: 8.69, 27.81) PPV = 2/32 = 6.25% (95% CI: 1.73, 20.15) 
NPV = 82/90 = 91.11% (95% CI: 83.43, 95.43) NPV = 99/114 = 86.84% (95% CI: 79.42, 91.86)  
DOR (for T+ calculated) = 1.96 (95% CI: 0.71, 
5.43) 
DOR (for T+ calculated) = 0.44 (95% CI: 0.09, 
2.03) 
OR (crude; for T+ reported) = NA (reported 
only for total sample of 167 patients that 
included 21 previous TB patients) 
OR (crude; for T+ reported) = NA (reported only for 
total sample of 167 patients that included 21 
previous TB patients) 
OR (regression-based; reported) = NA 
(reported only for total sample of 167 patients 
that included 21 previous TB patients) 
List of covariates: NA 
OR (regression-based; reported) = (reported only 
for total sample of 167 patients that included 21 
previous TB patients) 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 4.45 (95% CI: 1.72, 11.51) 
Ratio of OR (crude; for T+ reported) = NA  
Ratio of ORs (regression-based; reported) = NA  
Other reported measure = NA  
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST≥10mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 8 75 83 TST + 2 30 32 
IGRA - 9 54 63 TST - 15 99 114 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  17 129 146 Total  17 129 146 
Test performance parameters (based on 146 patients; 21 with previous TB excluded) 
IGRA TST 
Sensitivity = 8/17 = 47.06% (95% CI: 26.16, 
69.04) 
Sensitivity = 2/17 = 11.76% (95% CI: 3.28, 34.34) 
Specificity = 54/129 = 41.86% (95% CI: 33.70, 
50.49) 
Specificity = 99/129 = 76.74% (95% CI: 68.75, 
83.20) 
PPV = 8/83 = 9.64% (95% CI: 4.96, 17.88) PPV = 2/32 = 6.25% (95% CI: 1.73, 20.15) 
NPV = 54/63 = 85.71% (95% CI: 75.03, 92.30) NPV = 99/114 = 86.84% (95% CI: 79.42, 91.86)  
DOR (for T
+
 calculated) = 0.64 (95% CI: 0.23, 
1.76)  
DOR (for T
+
 calculated) = 0.44 (95% CI: 0.09, 
2.03) 
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OR (crude; for T+ reported) = NA (reported 
only for total sample of 167 patients that 
included 21 previous TB patients) 
OR (crude; for T+ reported) = NA (reported only for 
total sample of 167 patients that included 21 
previous TB patients) 
OR (regression-based; reported) = NA 
(reported only for total sample of 167 patients 
that included 21 previous TB patients) 
List of covariates: NA 
OR (regression-based; reported) = (reported only 
for total sample of 167 patients that included 21 
previous TB patients) 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.45 (95% CI: 0.56, 3.76) 
Ratio of OR (crude; for T
+ 
reported) = NA  
Ratio of ORs (regression-based; reported) = NA  
Other reported measure = NA  
Association between test results and BCG status (if applicable) 
IGRA (QFT-G) TST ≥10mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR 47 TST + NR NR 30 
IGRA - NR NR 82 TST - NR NR 99 
Indeterminate NR NR  Indeterminate NR NR  
Total  NR NR 129 Total  NR NR 129 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NA (reported only for 
129 low risk patients that also included 21 previous 
TB patients) 
OR (crude; for T+ reported) = NA (reported 
only for 129 low risk patients that also included 
21 previous TB patients) 
OR (regression-based; reported) IGRA = NA 
(reported only for 129 low risk patients that also 
included 21 previous TB patients) 
List of covariates: NA 
OR (regression-based; reported) TST = NA 
(reported only for 129 low risk patients that 
also included 21 previous TB patients) 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR 75 TST + NR NR 30 
IGRA - NR NR 54 TST - NR NR 99 
Indeterminate NR NR  Indeterminate NR NR  
Total  NR NR 129 Total  NR NR 129 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NA (reported only for 
129 low risk patients that also included 21 previous 
TB patients) 
OR (crude; for T+ reported) = NA (reported 
only for 129 low risk patients that also included 
21 previous TB patients) 
OR (regression-based; reported) IGRA = NA 
(reported only for 129 low risk patients that also 
included 21 previous TB patients) 
List of covariates: NA 
OR (regression-based; reported) TST = NA 
(reported only for 129 low risk patients that 
also included 21 previous TB patients) 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
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Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total of 167 
TST + threshold: =>10mm 
Parameters 
Kappa = NA (reported only for total 167 patient sample that included 21 patients with previous TB) 
% concordance = NA 
% discordance = NA 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality of life 
mean score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Previous BCG vaccination increased the TST-positive rate in the low-risk group (OR 4.438), whereas 
it affected neither QFT nor TSPOT. The QFT was associated with the high-risk group (OR 2.578), 
whereas the TST and TSPOT were not. The frequency of indeterminate results was higher for the 
QFT (12.6%) compared with the TSPOT (4.8%). In conclusion, the IGRAs can be useful for the 
diagnosis of latent TB infection in haemodialysis patients 
Reviewers: 
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The only relevant data available in this study was for the association between test positivity and 
exposure groups (n = 146; which excluded 21 patients with previous TB). All the other analyses 
(agreement, BCG status influence) were based on a total sample of 167 patients that included 21 
patients with previously cured TB 
QFT performed better than TST and TSPOT (in DORs) due its higher sensitivity relative to the other 
tests; TST had better specificity than the two IGRAs 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Costantino 2013127 
Country: France 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Rheumatology Department 
of Nancy University Hospital 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To compare TST and IGRA results in screening for LTBI in a large population of patients with 
chronic inflammatory 
arthritis requiring biologic treatment and to investigate predictive factors of results of these 2 tests, 
with special 
attention for indeterminate IGRA results 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people: chronic inflammatory arthritis before anti TNF treatment 
Participants 
Recruitment dates: Between 2005 and 2009 
Total N of recruited patients: NR 
Inclusion criteria: Patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA)requiring TNF 
antagonists (first-line therapy or switch) 
Exclusion criteria: Patients with previous antituberculous chemoprophylaxis 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 563 
Total N of patients with valid results for both IGRA and TST: IGRA (n = 475), TST (n = 514) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Association between test positivity and conventional risk factors (CRF) 
of LTBI; agreement; association between test positivity and patient characteristics  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 51.0 (39.0–59.0) 
Women (n [%]): 321 [57.0] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Birth in endemic zone of TB (52 [9.2]) 
BCG vaccination (n [%]): 439 [78.0] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): Rheumatoid arthritis (293 [52.0]), spondyloarthritis (270 [48.0]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): DMARD (277 [49.2]), Corticosteroids (254 [45.1]), NSAID 
(255 [45.4]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test 
results 
available
) 
IGRA (TSPOT):   563 122 353 88 475 
TST (≥ 5 mm): 563 196 318 49 514 
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Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 563 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group - conventional risk factors (CRF) of LTBI 
Non-exposed  No CRF of LTBI 
Exposed 1 (specify): CRF of LTBI: history of active TB treated before 1970 or not treated for at 
least 6 months including 2 months with a combination of rifampicine and 
pyrazinamide, close contact with a patient with active TB, and chest 
radiograph suggestive of previous TB infection 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off values/thresholds Definition of 
test+ 
Other 
information 
IGRA 
(TSPOT
) 
T-SPOT.TB assays were 
performed according to the 
manufacturer’s instructions  
 
Assays were considered indeterminate if 
the negative control (cell suspension in 
medium alone) spot count yielded more 
than 10 spots (referred to hereafter as a 
high nil control) or if the positive 
control (cell suspension stimulated with 
phytohemagglutinin) spot count yielded 
fewer than 20 spots (low positive 
control). For determinate tests, T-
SPOT.TB assays were interpreted 
according to the manufacturer’s 
recommendations by subtracting the 
spot count of the negative control from 
the highest spot count between panels A 
(TB-specific antigen ESAT-6) and B 
(TB-specific antigen CFP-10). A test 
was considered positive if this 
difference was equal to, or higher than, 
6 spots; otherwise, the test was 
considered negative 
To avoid any 
potential 
boosting 
effect of TST 
on IGRA 
results, all T-
SPOT.TB 
assays were 
performed 
before 
initiating 
TST 
 
TST ≥ 5 
mm 
The TST was performed with 
5 tuberculin units 
corresponding to 0.1 ml of 
purified protein derivative 
(Tubertest, Sanofi Pasteur 
MSD, SNC) according to the 
Mantoux method. Tuberculin 
was injected intradermally in 
the forearm, and 72 h later the 
diameter of skin induration 
was recorded  
An induration diameter of 5 mm or more 
was considered a positive test 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
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Indeterminate NA NA NA Indetermin
ate 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA  Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST ≥ 5 mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 23 99 122 TST + 31 165 196 
IGRA - 25 328 353 TST - 18 300 318 
Indeterminate 16 72 88 Indeterminate 15 34 49 
Total  64 499 563 Total  64 499 563 
Test performance parameters 
IGRA TST 
Indeterminate included 
Sensitivity = 23/64 = 35.94% (95% CI: 25.29, 
48.18) 
Indeterminate excluded 
Sensitivity = 23/48 = 47.92% (95% CI: 34.47, 
61.67) 
Indeterminate included 
Sensitivity = 31/64 = 48.44% (95% CI: 36.63, 
60.42) 
Indeterminate excluded 
Sensitivity = 31/49 = 63.27% (95% CI: 49.27, 
75.34) 
Indeterminate included 
Specificity = 400/499 = 80.16% (95% CI: 
76.44, 83.42) 
Indeterminate excluded 
Specificity = 328/427 = 76.81% (95% CI: 
72.58, 80.57) 
Indeterminate included 
Specificity = 334/499 = 66.93% (95% CI: 62.69, 
70.92) 
Indeterminate excluded 
Specificity = 300/465 = 64.52% (95% CI: 60.06, 
68.73) 
PPV = 23/122 = 18.85% (95% CI: 12.9, 26.70) PPV = 31/196 = 15.82% (11.37, 21.58) 
Indeterminate included 
NPV = 400/441 = 90.70% (95% CI: 87.63, 
93.07) 
Indeterminate excluded 
NPV = 328/353 = 92.92% (95% CI: 89.75, 
95.16) 
Indeterminate included 
NPV = 334/367 = 91.01% (95% CI: 87.64, 93.53) 
Indeterminate excluded 
NPV = 300/318 = 94.34% (95% CI: 91.23, 96.39) 
Indeterminate included 
DOR (for T
+
 calculated) = 2.26 (95% CI: 1.30, 
3.95)  
Indeterminate excluded 
Indeterminate included 
DOR (for T
+
 calculated) = 1.90 (95% CI: 1.12, 
3.21) 
Indeterminate excluded 
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DOR (for T+ calculated) = 3.05 (95% CI: 1.65, 
5.60) 
DOR (for T+ calculated) = 3.13 (95% CI: 1.70, 
5.77) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = 2.70 (95% 
CI: 1.49, 4.89) 
List of covariates: NR 
OR (regression-based; reported) = 1.95 (95% CI: 
1.13, 3.36) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.97 (95% CI: 0.63, 1.51) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = 1.38 (95% CI: 0.92, 2.09) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST ≥ 5 mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 80 NR 122 TST + 162 NR 196 
IGRA - NR NR 353 TST - NR NR 318 
Indeterminate NR NR 88 Indeterminate NR NR 49 
Total  439 124 563 Total  439 124 563 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = 0.39 
(95% CI: 0.24, 0.62) 
List of covariates: NR 
OR (regression-based; reported) TST = NR (p = 
0.11, NS) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + ≥ 5 mm TST - Total 
IGRA (TSPOT) + 59 51 110 
IGRA (TSPOT) - 114 220 334 
Indeterminate    
Total  173 271 444 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥ 5 mm 
Parameters 
Kappa = 0.16 (95% CI: 0.07, 0.25) 
% concordance = 279/444 = 62.84% (95% CI: 58.25, 67.2) 
% discordance = 165/444 = 37.16%  (95% CI: 32.8, 41.75) 
Stratification (BCG vaccinated) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥ 5 mm 
Parameters 
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Kappa = 0.15 (95% CI: NA) 
% concordance = NA 
% discordance = NA 
Stratification (BCG not vaccinated) 
 TST + TST - Total 
IGRA (TSPOT) + NR NR NR 
IGRA (TSPOT) - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG not vaccinated 
TST + threshold: ≥ 5 mm 
Parameters 
Kappa = 0.22 (95% CI: NA) 
% concordance = NA 
% discordance = NA 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
It is confirmed that there is poor agreement between TST and IGRA results, especially in a population 
largely vaccinated by BCG. The results suggest that IGRA should be included in the strategy to 
identify LTBI in patients with chronic inflammatory diseases before starting anti-TNF therapy. The 
data indicate that replacement of TST by IGRA in the screening would have led to a 27% reduction of 
antibiotics prophylaxis introduction  
Reviewers: 
T-SPOT.TB was less influenced by BCG than TST; specificity and DOR of T-SPOT.TB was higher 
than those of TST; sensitivity of TST was slightly higher than that of T-SPOT.TB; kappa for 
agreement was low, especially for BCG-vaccinated patients 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Hadaya 2013128 
Country: Switzerland 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Geneva University Hospital 
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Ligue Pulmonaire Genevoise, a non-profit 
organisation 
Aim of the study 
To compare the diagnostic performance of the TST and two IGRAs (T-SPOT.TB and QuantiFERON 
Gold In-Tube [QGIT]) in renal transplant recipients (RTRs) under stable immunosuppression 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people - renal transplant recipients (RTRs) 
Participants 
Recruitment dates: November 2009 and December 2011 
Total N of recruited patients: 205 
Inclusion criteria: > 18 years, being able to provide informed consent, having had a renal transplant at 
least 12 months before inclusion, and having a stable immunosuppression.  
Exclusion criteria: treatment for acute rejection within the preceding 3 months and signs or symptoms 
of acute infection 
Total N of excluded patients: 5 (indeterminate IGRAs) 
Total N of patients tested with both IGRA and TST: 205 
Total N of patients with valid results for both IGRA and TST: 200 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Agreement; association of test results with the risk of LTBI 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 59.0 (13.2) 
Women (n [%]): 84 (42.0) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): High incidence of TB in country of origin (24 [12.0]) 
BCG vaccination (n [%]): 155 [77.5] 
History of anti-TB treatment (n [%]): Active therapy (9 [4.5]), LTBI treatment (12 [6.0]) 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): Renal transplant recipients 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Prednisone (88 [44.0]), Tacrolimus, (127 [63.5]), Cyclosporine 
(41 [20.5]) Mycophenolate mofetil (159 [79.5]), Azathioprine (17 [8.5]), Sirolimus (12 [6.0]) 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminat
e) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   205 47 155 3 202 
IGRA (TSPOT):   205 41 162 2 203 
TST (≥5 mm): 205 9 191 0 200 
Total N of patients with valid results for both IGRA and TST: 200 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group- Composite outcome 2 (risk for LTBI) 
Non-exposed  No risk for LTBI 
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Exposed 1 (specify): Risk for LTBI: Chest X-ray suggestive of prior infection (calcified granuloma 
or adenopathy, suggestive fibrotic scars) and/or close contact with TB patient 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA 
(QFT-
GIT) 
Blood samplings for determination of 
M. tuberculosis-specific QGIT 
(Cellestis) were processed, and scored 
according to the manufacturer’s 
recommendations. Peripheral venous 
blood samples were processed by our 
laboratory within 3 hr 
According to the 
manufacturer’s 
recommendations 
Blood samplings for 
determination of M. 
tuberculosis-specific 
QGIT (Cellestis) and 
interferon- 
F-secreting T cells (T-
SPOT.TB (Oxford 
Immunotec) were 
performed 
simultaneously 
IGRA 
(TSPOT) 
Blood samplings for determination of 
M. tuberculosis-specific interferon-F-
secreting T cells (T-SPOT.TB (Oxford 
Immunotec) were processed, and 
scored according to the manufacturer’s 
recommendations. Peripheral venous 
blood samples were processed by our 
laboratory within 3 hr 
According to the 
manufacturer’s 
recommendations 
NA 
TST≥5m
m 
A TST was performed intradermally, 
according to the Mantoux technique, 
using two units of purified protein 
derivative (RT-23; Statens Serum 
Institute, Copenhagen, Denmark), 
which is the biological equivalent of 
five units of US purified protein 
derivative 
Results of TST were 
considered positive if 
the transverse 
diameter, measured 48 
to 72 hr after injection, 
was ≥ 5 mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indetermina
te 
NA NA NA Indetermin
ate 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
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Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = Na Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST≥5mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 14  
(calculated) 
28 
(calculated) 
42 
(calculated) 
TST + 3  
(calculated) 
6 
(calculated) 
9 
(calculated) 
IGRA - 28  
(calculated) 
113 
(calculated) 
141 
(calculated) 
TST - 39  
(calculated) 
135 
(calculated) 
174 
(calculated) 
Indetermina
te 
NR NR 3 (excluded) Indetermin
ate 
NR NR 0 
Total  42 141 183 Total  42 141 183 
Test performance parameters 
IGRA TST 
Sensitivity = 33.30% (95% CI: 19.60, 49.50) 
reported 
Sensitivity = 7.10% (95% CI: 1.50, 19.50)  
Specificity = 80.10% (95% CI: 72.90, 86.20) 
reported 
Specificity = 95.50% (95% CI: 90.80, 98.20) 
PPV = 33.33% (95% CI: 21.01, 48.45) calculated   PPV = 33.33% (95% CI: 12.06, 64.58) calculated 
NPV = 81.10% (95% CI: 73.80, 87.00) reported NPV = 78.40% (95% CI: 71.70, 84.20)  
DOR (for T+ calculated) = 2.01 (95% CI: 0.94, 
4.32) 
DOR (for T+ calculated) = 1. 73 (95% CI: 0.41, 
7.24) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = 1.16 (95% CI: 0.51, 2.66) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST≥5mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 14 
(calculated) 
20 
(calculated) 
34 
(calculated) 
TST + 3 
(calculated) 
6 
(calculated) 
9 
(calculated) 
IGRA - 28 
(calculated) 
121 
(calculated) 
149 
(calculated) 
TST - 39 
(calculated) 
135 
(calculate) 
174 
(calculated) 
Indetermina
te 
NR NR 2 (excluded) Indetermin
ate 
NR NR 0 
Total  42 141 183 Total  42 141 183 
Test performance parameters 
IGRA TST 
Sensitivity = 33.30% (95% CI: 19.60, 49.50)  Sensitivity = 7.10% (95% CI: 1.50, 19.50)  
Specificity = 85.50% (95% CI: 78.90, 90.70) Specificity = 95.50% (95% CI: 90.80, 98.20) 
PPV = 41.18% (95% CI: 26.37, 57.78) calculated PPV = 33.33% (95% CI: 12.06, 64.58) calculated 
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NPV = 81.90% (95% CI: 75.00, 87.60) NPV = 78.40% (71.70, 84.20) 
DOR (for T+ calculated) = 3.02 (95% CI: 1.36, 
6.71)  
DOR (for T+ calculated) = 1.73 (95% CI: 0.41, 
7.24) 
OR (crude; for T+ reported) = NR  OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR  
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.75 (95% CI: 0.76, 4.04) 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indetermina
te 
NR NR NR Indeterminat
e 
NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA (QFT-GIT) 
+ 
NR NR 47 
IGRA (QFT-GIT)  
- 
NR NR 153 
indeterminate NR NR 3 (excluded) 
Total  9 191 200 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (n = 200) 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.11 (P = 0.010) 
% concordance = NR 
% discordance = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA (TSPOT) + NR NR 41 
IGRA (TSPOT)  - NR NR 159 
Indeterminate NR NR 2 (excluded) 
Total  9 191 200 
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Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (n = 200) 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.09 (P = 0.034) 
% concordance = NR 
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Neither the TST nor the IGRAs are sensitive enough in RTRs to exclude a diagnosis of TB or LTBI. 
Combining IGRAs did not significantly improve sensitivity 
Reviewers: 
Although low (33.3%), sensitivities of IGRAS were greater than that of TST (7%); agreement between 
IGRAs and TST was low (kappa = 0.09-0.11) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Hsia 2012129 
Country: US 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): NR 
Number of centres: 340 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Johnson & Johnson, honoraria from 
Genentech, Pfizer, Celgene, Corrona, Amgen, Bristol-Myers Squibb, and Janssen 
Aim of the study 
To evaluate the performance of an interferon- release assay (IGRA) versus the standard tuberculin skin 
test (TST) as a screening tool for latent tuberculosis (TB) infection prior to the initiation of anti–tumor 
necrosis factor therapy in patients with autoimmune inflammatory diseases 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis prior 
to the initiation of anti–tumor necrosis factor therapy) 
Participants 
Recruitment dates: NR 
Total N of recruited patients: 2303 
Inclusion criteria: No history of latent/active TB prior to screening (except in GO-AFTER, which 
allowed the inclusion of patients with a history of latent TB who had been treated within the last 3 
years) and having no signs or symptoms of active TB or no recent close contact with anyone with 
active TB. All patients were required to have a chest radiograph, obtained within 3 months before the 
first dose of study agent, that showed no evidence of active TB or old inactive TB. 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 2282 
Total N of patients with valid results for both IGRA and TST: 2241 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Agreement; exposure-based 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 48.58 (12.6) 
Women (n [%]): 1515 [65.7] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): North America (962 [41.8]), Western Europe (440 [19.1]), Eastern Europe 
(432 [18.8]), Latin America (203 [8.8]), Asia (266 [11.6]) 
BCG vaccination (n [%]): 788 [34.2] 
History of anti-TB treatment (n [%]): 317 [13.8] 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): Rheumatoid arthritis (1,542 [67.0]), Psoriatic arthritis (405 [17.6]), Ankylosing 
spondylitis (356 [15.5]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Methotrexate (571 [24.8]), Corticosteroids (1,000 [43.4]) 
Number of patients tested 
 Total N  
(tested) 
Tota
l N 
 
(test
+) 
Total N 
 (test-) 
Total N (indeterminate) Total N  
(test 
results 
availab
le) 
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IGRA (QFT-GIT):   2282 160 2081 41 2241 
TST (≥5mm): 2282 215 2067 0 2282  
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 2241 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – geographic region 
Non-exposed  North America 
Exposed 1 (specify): Western Europe 
Exposed 2 (specify): Asia 
Exposed 3 (specify): Eastern Europe 
Exposed 4 (specify): Latin America 
Tests 
 Assay used, methodology, timing for test 
measurement, manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
inform
ation 
IGRA 
(QFT-
GIT) 
The QFT-GIT test was the IGRA assay used. For 
this procedure, standard venipuncture is 
performed at a single visit to collect blood in 
tubes that contain the M tuberculosis–specific 
antigens. The QFT-GIT test also contains an extra 
antigen, TB7.7 (p4) that was not present in the 
original version of this IGRA and is thought to 
improve sensitivity. In addition, this version of 
the IGRA shortens the manual processing time, 
since antigens are already present in the tubes. 
Initial IGRA sample-handling procedures were 
performed at investigational sites, and a central 
laboratory performed the enzyme-linked 
immunosorbent assay–based testing and reported 
the results for each patient according to the 
manufacturer’s interpretation criteria 
According to the 
manufacturer  
Positive results were 
confirmed by duplicate 
testing of the same sample. 
Any results initially 
indeterminate on the IGRA 
required a second sample to 
be drawn and tested, and the 
final results were used to 
determine study eligibility 
NA 
TST The TST was performed according to the 
Mantoux method, using 5 tuberculin units (TU) of 
purified protein derivative (PPD) standard or 2 
TU of PPD RT-23 (Statens Serum Institut). A 
trained health-care worker recorded each patient’s 
reaction to the TST at 48–72 hours after 
placement 
 
 
The TST was deemed 
positive for latent TB 
infection according to the 
local country guidelines for 
defining an 
immunosuppressed 
host or, in the absence of 
local guidelines, according to 
the presence of induration  5 
mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Ye
s 
No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeter
minate 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
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Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA  
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST≥5 mm 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR 160 TST + NR NR 215 
IGRA - NR NR 2081 TST - NR NR 2067 
Indetermina
te 
NR NR 41 Indeter
minate 
NR NR 0 
Total  Vary by geographic region 2282 Total  Vary by geographic 
region 
2282 
Test performance parameters 
IGRA TST 
Sensitivity = NR  Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR  
NPV = NR NPV = NR 
DOR (for T+ calculated) = NR  DOR (for T+ calculated) = NR  
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR 
OR (regression-based; reported) =  
Western Europe vs. North America: 3.41 (95% CI: 
1.99, 5.83) 
Latin America vs. North America: 3.43 (95% CI: 1.64, 
7.19) 
Eastern Europe vs. North America: 3.58 (95% CI: 
1.93, 6.63) 
Asia vs. North America: 8.48 (95% CI:  4.78, 15.03) 
 
List of covariates: baseline methotrexate use, baseline 
steroid use, disease type, age, and prior BCG 
vaccination 
OR (regression-based; reported) =  
Western Europe vs. North America: 2.10 
(95% CI: 1.30, 3.38) 
Latin America vs. North America: 1.56 (95% 
CI: 0.80, 3.05) 
Eastern Europe vs. North America: 0.95 
(95% CI: 0.53, 1.70) 
Asia vs. North America: 7.47 (95% CI: 4.61, 
12.08) 
 
List of covariates: : baseline methotrexate 
use, baseline steroid use, disease type, age, 
and prior BCG vaccination 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) =  
Western Europe vs. North America:  1.62 (95% CI: 1.13, 2.34) 
Latin America vs. North America: = 2.20 (95% CI: 1.32, 3.66) 
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Eastern Europe vs. North America: = 3.77 (95% CI: 2.44, 5.81) 
Asia vs. North America: = 1.14 (95% CI: 0.77, 1.66) 
Other reported measure = NR  
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST ≥5 mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 71 72 143 TST + 119 62 181 
IGRA - NR NR 1853 TST - NR NR 1848 
Indeterminate 9 24 33 Indeterminat
e 
NR NR 0 
Total  781 1248 2029 Total  781 1248 2029 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = 1.00 (95% CI: 
0.66, 1.51) 
List of covariates: baseline methotrexate use, baseline 
steroid use, disease type, age, and geographic region 
OR (regression-based; reported) TST = 2.47 
(95% CI: 1.71, 3.55) 
 
List of covariates: baseline methotrexate use, 
baseline steroid use, disease type, age, and 
geographic region 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 59 101 160 
IGRA - NR NR 2081 
Indeterminate NR NR 41 
Total  215 2067 2282 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total  
TST + threshold: ≥5 mm  
Parameters 
Kappa = 0.22 (95% CI: 0.15, 0.27)  
% concordance = NR 
% discordance = NR 
Stratification (specify group 1): BCG-vaccinated 
 TST + TST - Total 
IGRA + 28 43 71 
IGRA - 91 619 710 
Indeterminate 0 (excluded) 9 (excluded) 9 (excluded) 
Total  119 662 781 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.20 (95% CI: 0.13, 0.27) calculated 
% concordance = 647/781 = 82.84% (95% CI: 80.04, 85.32) calculated 
% discordance = 134/781 = 17.16% (95% CI: 14.68, 19.96) calculated 
Stratification (specify group 2): BCG non-vaccinated 
 TST + TST - Total 
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IGRA + 24 48 72 
IGRA - 38 1138 1176 
Indeterminate 6 (excluded) 18 (excluded) 24 (excluded) 
Total  62 1186 1248 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG non-vaccinated 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.32 (95% CI: 0.26, 0.37) calculated 
% concordance = 1162/1248 = 93.11% (95% CI: 91.57, 94.39) calculated 
% discordance = 86/1248 = 6.89% (95% CI: 5.61, 8.43) calculated 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality of 
life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Thus, in the absence of a true gold standard test to screen for latent TB infection, results of this large 
cohort comparison of an IGRA (the QFT-GIT test) and the TST in patients with rheumatic disease 
suggest that the IGRA provides greater specificity and possibly greater sensitivity than the TST 
Reviewers: 
BCG vaccination influenced TST but not IGRA (indicating better specificity of IGRA); agreement 
was higher in BCG non-vaccinated vs. vaccinated patients; exposure-based (geographic location) ORs 
were stronger for IGRA vs. TST, indicating better specificity and/or sensitivity of IGRA vs. TST 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Kim 2010130 
Country: Korea  
Study design: Retrospective/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Clinic based 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Korea Research Foundation 
Aim of the study 
To compare the results of the ELISPOT assay T-SPOT.TB with those of the TST in renal transplant 
candidates before transplantation in a country with an intermediate TB burden 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (kidney transplant candidates before transplantation) 
Participants 
Recruitment dates: June 2008 and May 2009 
Total N of recruited patients: 213 
Inclusion criteria: Kidney transplant adult candidates before transplantation 
Exclusion criteria: If abnormal chest radiograph findings were observed, a sputum acid-fast bacilli 
smear and a computed tomography scan were performed to rule out active pulmonary TB 
Total N of excluded patients: 4 (n = 1 refusal, n = 1 active TB, n = 2 cancer) 
Total N of patients tested with both IGRA and TST: 209 
Total N of patients with valid results for both IGRA and TST: 184 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Agreement, association of test positivity with risk factors, influence of 
BCG vaccination 
Characteristics of participant (total study sample) 
Mean (range or SD) age (years): NR 
Women (n [%]): NR 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 163 [78.0] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): End-stage renal disease 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Isoniazid for 9 months immediately after renal transplantation 
(5 [19%]) 
Number of patients tested 
 Total 
N  
(tested) 
Tota
l N 
 
(test
+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (TSPOT):   209 65 119 25 184 
TST (≥5mm): 209 47 162 0 209 
TST (≥10mm): 209 21 188 0 209 
Total N of patients with valid results for both IGRA and TST: 209 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – LTBI group 
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Non-exposed  No LTBI group 
Exposed 1 (specify): (i) close contact with a person with pulmonary tuberculosis within the last 
year, (ii) abnormal chest radiography, (iii) a history of untreated or 
inadequately treated TB, or (iv) newly acquired infection (recent 
conversion of the tuberculin skin test to positive status) 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(TSPOT) 
A peripheral venous blood sample was 
collected from each patient for the 
ELISPOT assay for the IFN-g-
producing T-cell response (i.e., T-
SPOT.TB, Oxford Immunotec, 
Abingdon, UK). Peripheral blood 
mononuclear cells (PBMC) were 
separated from peripheral venous blood 
within 4 h from sampling, and 2.5 x 105 
PBMC were plated per well in wells 
precoated with anti-human IFN-g 
antibody 
The PBMC were cultured at 37◦C for 
18h, and spots were counted with an 
automated microscope (ELiSpot04 HR, 
Autoimmun Diagnostika GmbH, 
Strassberg, Germany) 
We used the criteria for 
positive, negative, and 
indeterminate outcomes 
that were recommended 
by the manufacturer 
All blood 
samples were 
collected 
before TST to 
avoid the 
possible 
boosting 
effect of TST 
on the 
ELISPOT 
assay 
TST (≥5mm 
or ≥10mm) 
The Mantoux technique, injecting a 
2-TU dose of purified protein derivative 
RT23 (Statens Serum Institut, 
Copenhagen, Denmark) intradermally 
into the forearm  
The positive criterion for 
TST was ≥10 mm size of 
induration 48-72 h after 
injection 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indetermin
ate 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
459
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/
No 
IGRA + 10 55 65 TST + 8 39 47 
IGRA - 9 110 119 TST - 14 148 162 
Indetermin
ate 
3 
(excluded) 
22 
(excluded) 
25 
(excluded) 
Indeterminate 0 0 0 
Total  22 187 209 Total  22 187 209 
Test performance parameters 
IGRA TST 
Sensitivity = 10/19 = 52.63% (95% CI: 31.71, 
72.67) 
Sensitivity = 8/22 = 36.36% (95% CI: 19.73, 
57.05) 
Specificity = 110/165 = 66.67% (95% CI: 59.17, 
73.41) 
Specificity = 148/187 = 79.14% (95% CI: 
72.76, 84.35) 
PPV = 10/65 = 15.38% (95% CI: 8.57, 26.06) PPV = 8/47 = 17.02% (95% CI: 8.88, 30.14) 
NPV = 110/119 = 92.44% (95% CI: 86.25, 
95.97) 
NPV = 148/162 = 91.36% (95% CI: 
86.02, 94.78) 
DOR (for T+ calculated) = 2.22 (95% CI: 0.85, 
5.78) 
DOR (for T+ calculated) = 2.17 (95% CI: 0.85, 
5.54) 
OR (crude; for T+ reported) = 2.35 (95% CI: 0.90, 
6.12) 
OR (crude; for T+ reported) = 2.17 (95% CI: 
0.85, 5.54) 
OR (regression-based; reported) = 2.38 (95% CI: 
0.87, 6.52) 
List of covariates: age 
OR (regression-based; reported) = 2.11 (95% 
CI: 0.82, 5.46) 
List of covariates: age 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = 1.02 (95% CI: 0.52, 2.03) 
Ratio of OR (crude; for T
+ 
reported) = 1.08 (95% CI: 0.55, 2.15) 
Ratio of ORs (regression-based; reported) = 1.13 (95% CI: 0.56, 2.28) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/
No 
IGRA + 10 55 65 TST + 4 17 21 
IGRA - 9 110 119 TST - 18 170 188 
Indetermin
ate 
3 
(excluded) 
22(exclud
ed) 
25(exclud
ed) 
Indeterminate 0 0 0 
Total  22 187 209 Total  22 187 209 
Test performance parameters 
IGRA TST 
Sensitivity = 10/19 = 52.63% (95% CI: 31.71, 
72.67) 
Sensitivity = 4/22 = 18.18% (95% CI: 7.31, 
38.52) 
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Specificity = 110/165 = 66.67% (95% CI: 59.17, 
73.41) 
Specificity = 170/187 = 90.91% (95% CI: 
85.92, 94.25) 
PPV = 10/65 = 15.38% (95% CI: 8.57, 26.06) PPV = 4/21 = 19.05% (95% CI: 7.66, 40.00) 
NPV = 110/119 = 92.44% (95% CI: 86.25, 
95.97) 
NPV = 170/188 = 90.43% (95% CI: 85.37, 
93.86) 
DOR (for T
+
 calculated) = 2.22 (95% CI: 0.85, 
5.78) 
DOR (for T
+
 calculated) = 2.22 (95% CI: 0.67, 
7.32) 
OR (crude; for T+ reported) = 2.35 (95% CI: 0.90, 
6.12) 
OR (crude; for T+ reported) = 2.22 (95% CI: 
0.67, 7.32) 
OR (regression-based; reported) = 2.38 (95% 
CI:0.87, 6.52) 
List of covariates: age 
OR (regression-based; reported) = 2.12 (95% 
CI: 0.60, 7.49) 
List of covariates: age 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.00 (95% CI: 0.46, 2.19) 
Ratio of OR (crude; for T+ reported) = 1.06 (95% CI: 0.48, 2.31) 
Ratio of ORs (regression-based; reported) = 1.12 (95% CI: 0.49, 2.56) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (≥5mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 48 17 65 TST + 38 9 47 
IGRA - 97 22 119 TST - 125 37 162 
Indeter
minate 
18 
(excluded) 
7 
(excluded) 
25 
(excluded) 
Indeterminat
e 
0 0 0 
Total  163 46 209 Total  163 46 209 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 0.64 (95% CI: 0.31, 
1.32) 
DOR (for T+ calculated)TST = 1.25 (95% 
CI: 0.55, 2.82) 
OR (crude; for T+ reported) = 0.69 (95% CI: 0.36, 
1.34) 
OR (crude; for T+ reported) = 1.25 (95% CI: 
0.55, 2.82) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 48 17 65 TST + 16 5 21 
IGRA - 97 22 119 TST - 147 41 188 
Indeter
minate 
18 
(excluded) 
7 
(excluded) 
25 
(excluded) 
Indeterminat
e 
0 0 0 
Total  163 46 209 Total  163 46 209 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 0.64 (95% CI: 0.31, 
1.32) 
DOR (for T+ calculated)TST = 0.89 (95% CI: 
0.30, 2.58) 
OR (crude; for T+ reported) = 0.69 (95% CI: 0.36, 
1.34) 
OR (crude; for T+ reported) = 0.89 (95% CI: 
0.31, 2.58) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
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Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥10mm) TST - Total 
IGRA (TSPOT) + 15 48 63 
IGRA (TSPOT) - 5 116 121 
Indeterminate  1 (excluded) 24 (excluded) 25 (excluded) 
Total  20 164 184 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.23 (95% CI: 0.12, 0.34) 
% concordance = 131/184 = 71.2% (95% CI: 64.27, 77.25) 
% discordance = 53/184 = 28.8% (95% CI: 22.75, 35.73) 
Stratification (BCG vaccinated):  
 TST + (≥10mm) TST - Total 
IGRA (TSPOT) + 10 38 48 
IGRA (TSPOT) - 5 92 97 
Indeterminate NR NR NR 
Total  15 130 145 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.19 (95% CI: 0.06, 0.31) 
% concordance = 102/145 = 70.34% (95% CI: 62.46, 77.18) 
% discordance = 43/145 = 29.66% (95% CI: 22.82, 37.54) 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality of 
life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
T-SPOT.TB test was more frequently positive than TST in renal transplant candidates. However, 
further longitudinal studies are awaited to determine whether the ability of T-SPOT.TB assay to detect 
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LTBI in renal transplant recipients can better predict the development of TB than can TST after 
transplantation. Neither univariate nor multivariate analysis showed any association between the 
clinical risk for LTBI and positivity on TSPOT or TST 
Reviewers: 
TSPOT had better sensitivity but lower specificity than TST regardless of the two thresholds; the 
DORs showed similar strength of association with LTBI composite risk factor; BCG status did not 
influence the test positivity of TST and IGRA differentially, neither did it influence corresponding 
kappas 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Kim 2013b131 
Country: Korea  
Study design: Retrospective/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based  - specify): Clinic based 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Grant of the Korean Health Technology 
R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea 
Aim of the study 
To compare the results of the TST and QFTGIT as methods for screening for LTBI and determined 
the agreement between the TST and QFT-GIT in renal transplant candidates before transplantation in 
a country with an intermediate TB burden 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (kidney transplant candidates before transplantation) 
Participants 
Recruitment dates: May 2010 and February 2012 
Total N of recruited patients: NR 
Inclusion criteria: Kidney transplant adult candidates before transplantation 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 126 
Total N of patients with valid results for both IGRA and TST: 113 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Agreement, association of test positivity with risk factors, influence of 
BCG vaccination 
Characteristics of participant (total study sample) 
Mean (range or SD) age (years): 47 (20–69) 
Women (n [%]): 55 [43.6] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 115 [91.3] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): End-stage renal disease (100 [79.4]),  hemodialysis, (12 [9.5]),  PD peritoneal 
dialysis, no dialysis (14 [11.1]) 
Co-morbidity (n [%]): Hypertension (60 [47.6]), Diabetes (31 [24.6])  
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Tot
al N  
(test
ed) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   126 53 67 6 120 
TST (≥10mm): 126 35 91 7 119 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 113 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – LTBI group 
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Non-exposed  No LTBI group 
Exposed 1 (specify): (1) patients with a history of LTBI or active TB; (2) patients with abnormal 
chest 
radiograph findings consistent with previously healed TB; and (3) patients 
with a history of close contact with active pulmonary TB patients within 
the past year 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for test 
measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-
GIT) 
QuantiFERON-TB Gold In-Tube test 
Peripheral venous blood samples were 
collected from all patients for QFT-GIT 
assays. We performed the test according to the 
manufacturer’s instructions (Cellestis Ltd., 
Carnegie, Victoria, Australia). Blood samples 
were divided into three blood collection tubes 
(1 mL each): one containing heparin alone (Nil 
tube, negative control), one with 
phytohemagglutinin (mitogen tube, positive 
control), and one with TB-specific antigens 
(ESAT-6, CFP-10, and TB 7.7). The three 
tubes were incubated for 20 h at 37◦C. The 
concentration of IFN-c was measured by the 
QFT enzymelinked immunosorbent assay. 
QFT-GIT software provided by the 
manufacturer was used for calculating the 
results 
A positive QFT-
GIT result was 
defined as IFN-c 
response of TB 
antigen minus that 
of the Nil tube 
≥0.35 IU/mL and 
≥25 % of the 
negative control 
value 
 
NA 
TST (≥5mm 
or ≥10mm) 
The TST was performed by injecting a 2-TU 
dose of PPDRT 23 (Statens Serum Institut, 
Copenhagen, Denmark) intradermally into the 
forearm, which was in accordance with the 
Mantoux method  
The transverse 
induration site was 
measured by a 
trained nurse in 
mm after 48–72 h 
Induration ≥10 mm 
was defined as a 
positive TST result 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence 
of active 
TB 
Total  Incidence of active 
TB 
Total 
Yes N
o 
Yes No 
IGRA + NA N
A 
NA TST + NA NA NA 
IGRA - NA N
A 
NA TST - NA NA NA 
Indeterminate NA N
A 
NA Indetermi
nate 
NA NA NA 
Total NA N
A 
NA Total NA NA NA 
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Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low
/No 
High/Yes Low/
No 
IGRA + 11 42 53 TST + 13 10 23 
IGRA - 4 63 67 TST - 2 94 96 
Indetermina
te 
1 5 6 
(excluded
) 
Indeterminate 1 6 7 
(exclud
ed) 
Total  16 110 126 Total  16 110 126 
Test performance parameters 
IGRA TST 
Sensitivity = 11/15 = 73.33% (95% CI: 48.05, 
89.1) 
Sensitivity = 13/15 = 86.67% (95% CI: 62.12, 96.26) 
Specificity = 63/105 = 60.00% (95% CI: 
50.44, 68.86) 
Specificity = 94/104 = 90.38% (95% CI: 83.2, 
94.69) 
PPV = 11/53 = 20.75% (95% CI: 12.00, 
33.46) 
PPV = 13/23 = 56.52% (95% CI: 36.81, 74.37) 
NPV = 63/67 = 94.03% (95% CI: 85.63, 
97.65) 
NPV = 94/96 = 97.92% (95% CI: 92.72, 99.43) 
DOR (for T+ calculated) = 4.12 (95% CI: 1.23, 
13.82) 
DOR (for T+ calculated) = 61.1 (95% CI: 12.03, 
310.4)  
OR (crude; for T+ reported) = 4.13 (95% CI: 
1.23, 13.82) 
OR (crude; for T+ reported) = 0.61 (95% CI: 0.13, 
2.91) -error 
OR (regression-based; reported) = 4.62 (95% 
CI: 1.15, 18.64) 
List of covariates: NR 
OR (regression-based; reported) = 0.40 (95% CI: 
0.07. 2.20) -error 
List of covariates: NR  
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.07 (95% CI: 0.02, 0.19) 
Ratio of OR (crude; for T
+ 
reported) = NA  
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
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 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 50 3 53 TST + 22 1 23 
IGRA - 60 7 67 TST - 86 10 96 
Indetermi
nate 
5 1 6 
(excluded) 
Indetermina
te 
7 0 7 
(excluded) 
Total  115 11 126 Total  115 11 126 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 1.94 (95% CI: 
0.47, 7.91) 
DOR (for T+ calculated)TST = 2.55 (95% CI: 
0.32, 21.06) 
OR (crude; for T+ reported) = 1.94 (95% CI: 
0.48, 7.91) 
OR (crude; for T+ reported) = 2.56 (95% CI: 0.31, 
21.06) 
OR (regression-based; reported) IGRA = 2.32 
(95% CI: 0.50, 10.66) 
List of covariates: NR 
OR (regression-based; reported) TST = 3.32 (95% CI: 
0.38, 28.97) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + 
(≥10mm) 
TST - Total 
IGRA (QFT-GIT) + 17 33 50 
IGRA (QFT-GIT) - 6 57 63 
Indeterminate 0 6 6 (excluded) 
Total  23 96 119 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.26 (95% CI: 0.10, 0.41) 
% concordance = 74/113 = 65.49% (95% CI: 56.34, 73.61) 
% discordance = 39/113 = 34.51% (95% CI: 26.39, 43.66) 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality of 
life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
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Conclusions 
Authors: 
The positive results for QFT-GIT were associated with risk for LTBI, however not for TST (error); 
agreement between the two tests was fair 
Reviewers: 
TST better performed than GIT in accuracy measures (sensitivity, PPV, specificity, DOR); BCG did 
not influence TST and IGRA differentially 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Kim 2013c132 
Country: Korea 
Study design: Retrospective cohort/cross-sectional study (with prospective part) 
Study setting (e.g., outbreak investigation, community-based  - specify): NR 
Number of centres: NA 
Total length of follow up (if applicable): Mean 24.6 ±14.4 months  
Funding (government/private/manufacturer/other - specify): The Korea health care technology R & 
D project, ministry for health, welfare and family affair, republic of Korea. 
Aim of the study 
To compare the QuantiFERON-TB Gold In tube test (QFT-GIT) with the tuberculin skin test (TST) 
for screening of LTBI in kidney transplant recipients (KTRs) 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Kidney transplant recipients (KTRs) 
Participants 
Recruitment dates: Between July 2008 and July 2012 
Total N of recruited patients: 109 
Inclusion criteria: Kidney transplant recipients 
Exclusion criteria: NR 
Total N of excluded patients: 4 with indeterminate QFT-GIT results (excluded for analysis) 
Total N of patients tested with both IGRA and TST: 97 
Total N of patients with valid results for both IGRA and TST: 93 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Test results, concordance between TST and QFT-GIT 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 44.7 ±11.5 
Women (n [%]): 41 (38) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]):NR 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): 3 [2.8]  
Total incidence of active TB (n [%]):1 [0.9] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): Glomerulonephritis (19 [17.4]); hypertensive nephrosclerosis (11 [10.1]); 
diabetes mellitus (31 [28.4]); Unknown (34 [31.2]); polycystic kidney disease (2 [1.8]); Others (12 
[11.0]) 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (specify): QFT-
GIT 
106 21 81 4 102 
TST≥10mm:  97 12 81 0 93 
Test 3 (specify):  NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 97 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
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Exposed 1 (specify): History of treated tuberculosis 
Exposed 2 (specify):  Abnormal chest radiograph 
Exposed 3 (specify):  NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA  QuantiFERON- Gold In-Tube 
(QFT-GIT) was performed 
according to the manufacturer’s 
instructions (Cellestic Ltd, 
Carnegie, Victoria, Australia)   
A positive QFT-GIT was defined 
as ≥ 0.35 IU/mL and ≥ 25% in 
the presence of TB-specific 
antigen minus that of the Nil 
tude 
NA 
TST≥10 
mm 
TST was performed on the volar 
side of the forearm by injection of 
a 2 tuberculin unit dose of perified 
protein derivative RT-23 according 
to the Mantoux method 
The TST was considered positive 
if the size of the induration was 
≥10 mm at 48 to 72 hours after 
the injection. 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence 
of active 
TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (History of treated tuberculosis) 
IGRA (QFT-GIT) TST≥10 mm 
 Exposure 
level 
Total  Exposure level Total 
Yes No Yes No 
IGRA + 2 17 19 TST + NR NR 12 
IGRA - 0 74 74 TST - NR NR 81 
Indeterminate NR NR 4 Indeterminate NR NR 0 
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(excluded) 
Total  2 91 93 Total  NR NR 93 
Test performance parameters 
IGRA TST 
Sensitivity = 2/2 = 100%, 95% CI (34.24, 100) Sensitivity = NR 
Specificity = 74/91 = 81.32%, 95% CI (72.10, 
88.00) 
Specificity = NR 
PPV = 2/19 = 10.53%, 95% CI (2.93, 31.39) PPV = NR 
NPV = 74/74 = 100%, 95% CI (95.06, 100) NPV = NR  
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NR  
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR  
OR (regression-based; reported) = 9.21, 95% 
CI (NR) 
List of covariates: NR 
OR (regression-based; reported) = NR (NS) 
List of covariates: 
Other reported measure = NR Other reported measure = NR  
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (Abnormal chest radiograph) 
IGRA (QFT-GIT) TST TST≥10 mm 
 Exposure 
level 
Total  Exposure level Total 
Yes No Yes No 
IGRA + 3 16 19 TST + NR NR 12 
IGRA - 1 73 74 TST - NR NR 81 
Indeterminate 0 0 4 
(excluded)  
Indeterminate NR NR 0 
Total  4 89 93 Total  NR NR 93 
Test performance parameters 
IGRA TST 
Sensitivity = 3/4 = 75.00%, 95% CI (30.06, 
95.44) 
Sensitivity = NR 
Specificity = 73/89 = 82.02%, 95% CI (72.77, 
88.62) 
Specificity = NR 
PPV = 3/19 = 15.79%, 95% CI (5.52, 37.57) PPV = NR 
NPV = 73/74 = 98.65%, 95% CI (92.73, 99.76) NPV = NR  
DOR (for T+ calculated) = 13.69, 95% CI (1.33, 
140.30) 
DOR (for T+ calculated) = NR  
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR  
OR (regression-based; reported) = 27.95, 95% 
CI (1.22, 636.62) 
List of covariates: NR 
OR (regression-based; reported) = NR (NS) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR  
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT/QFT) TST (≥10 mm) 
 BCG status Total  BCG status Total 
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Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (TSPOT/QFT) TST (>5 mm) 
DOR (for T+ calculated)TSPOT/QFT = NR DOR TST (for T+ calculated) = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported)QFT = NR  
OR (regression-based; reported)TSPOT = NR 
List of covariates:NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 6 13 19 
IGRA - 6 68 74 
Indeterminate 0 0 0 
Total  12 81 93 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total less Indeterminate 
results 
TST + threshold: ≥10 mm 
Parameters 
Kappa = 0.27, 95% CI (0.07, 0.46) 
% concordance = 74/93 = 79.57%, 95% CI (70.28, 86.51) 
% discordance = 19/93 = 20.43%, 95% CI (13.49, 29.72) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
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% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The authors concluded that there was overall fair agreement between the QFT-GIT and TST.  
Furthermore, they stated that a superiority of QFT-GIT [and] TST was not demonstrated and this may 
be a result of the clinical risk factors for LTBI 
Reviewers: 
No TST based ORs data reported 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
 
 
 
 
 
 
  
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
473
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Kleinert 2012133 
Country: Germany 
Study design: Retrospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Hospital-based 
Number of centres: 62 
Total length of follow up (if applicable): NA (no prospective follow-up) 
Funding (government/private/manufacturer/other - specify): Abbott, Pfizer, Roche and Wyeth, 
Chugai, Cellestis Ltd, Oxford Immunotec Ltd, Pharmore Ltd, and Roche  
Aim of the study 
To compare the utility of IGRA and TST in LTBI screening in a large cohort of patients with 
rheumatic diseases receiving immunosuppressive therapy 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic 
arthritis (PsA) prior to the initiation of anti-tumour necrosis factor therapy) 
Participants 
Recruitment dates: NR 
Total N of recruited patients: NR 
Inclusion criteria: Patients with rheumatic diseases 
Exclusion criteria: NR 
Total N of excluded patients: None 
Total N of patients tested with both IGRA and TST: 1609 
Total N of patients with valid results for both IGRA and TST: 1529 (80 had indeterminate IGRA) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Influence of risk factors on test results, agreement/disagreement (total, 
by age, sex, and risk factor), association between test and clinical risk factors for LTBI (construct) 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): mean age range (50.8-59.5) 
Women (n [%]): 937 [61.3] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 204 [13.3] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): 852 [55.7] Rheumatoid arthritis (RA), (294 [19.2]),  ankylosing spondylitis (AS) 
(215 [14.0]), psoriatic arthritis (PsA) (92 [6.0]),  undifferentiated spondyloarthropathy (SpA) and (76 
[5.0]) various other rheumatologic disorders 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Immunosuppressive therapy (not specified) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-G): NR 50 635 NR 685 
IGRA (TSPOT): NR 70 774 NR  844 
TST (≥5mm): 1609 173 1356 80 (QFT + TSPOT) 1529 
Total N of patients with valid results for both IGRA and TST: 1529 
Levels/groups of exposure to TB in increasing order (if applicable): 
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Definition of exposure group 
Non-exposed  None of the compound risk factors (CRF) were present 
Exposed 1 (specify): A compound risk factor (CRF) defined as the presence of at least one of 
these three risk factors: 1) history of prior TB, 2) close contact to a patient 
with TB, or 3) CXR suggestive of LTBI 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test 
measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA (QFT-
G)   
Quantiferon TB Gold 
administered in accordance 
with contemporary 
guidelines for 
immunosuppressed patients; 
IGRAs were mainly based on 
the two peptide 
antigens ESAT-6 and CFP-
10 
NR All patients received one 
type of IGRA, either 
TSPOT.TB or  
QFT, depending on what 
was available in the 
corresponding laboratory 
IGRA 
(TSPOT) 
TSPOT.TB (TSPOT) 
administered in accordance 
with contemporary 
guidelines for 
immunosuppressed patients; 
IGRAs were mainly based on 
the two peptide 
antigens ESAT-6 and CFP-
10 
The cut-off for TSPOT 
positivity was ≥6 spots 
All patients received one 
type of IGRA, either 
TSPOT.TB or  
QFT, depending on what 
was available in the 
corresponding laboratory 
TST NR TST with a diameter of 
≥5 mm skin induration 
was considered positive 
All patients received a 
TST 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
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Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-G) TST (≥5 mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 9 41 50 TST + 48 125 173 
IGRA - 45 590 635 TST - 74 1282 1356 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  54 631 685 Total  122 1407 1529 
Test performance parameters 
IGRA(QFT-G) TST (>5 mm) 
Sensitivity = 9/54 = 16.67% (95% CI: 9.02, 
28.74) 
Sensitivity = 48/122 = 39.34% (95% CI: 31.13, 
48.21) 
Specificity = 590/631 = 93.5% (95% CI: 91.3, 
95.17) 
Specificity = 1282/1407 = 91.12%  (95% 
CI: 89.52, 92.49) 
PPV = 9/50 = 18.00% (95% CI: 9.77, 30.8) PPV = 48/173 = 27.75% (95% CI: 21.61, 34.85) 
NPV = 590/635 = 92.91% (95% CI: 90.65, 94.66)  NPV = 1282/1356 = 94.54% (95% CI: 93.2, 
95.63) 
DOR (for T+ calculated) = 2.88 (95% CI: 1.31, 
6.29) 
DOR (for T+ calculated) = 6.65 (95% CI: 4.42, 
9.99) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR  
OR (regression-based; reported) = 2.63 (95% CI: 
1.15, 5.98) 
List of covariates: NR 
OR (regression-based; reported) = 6.20 (95% CI: 
4.08, 9.44) 
List of covariates: NR  
Other reported measure = NR Other reported measure = NR 
Comparison between tests (QFT vs. TST) 
Ratio of DORs (for T+ calculated) = 0.43 (95% CI: 0.28, 0.68) 
Ratio of OR (crude; for T+ reported) = NR  
Ratio of ORs (regression-based; reported) = 0.42 (95% CI: 0.26, 0.68) 
Other reported measure = NR  
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥5 mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 24 46 70 TST + 48 125 173 
IGRA - 44 730 774 TST - 74 1282 1356 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  68 776 844 Total  122 1407 1529 
Test performance parameters 
IGRA (TSPOT) TST (≥5 mm) 
Sensitivity = 24/68 = 35.29% (95% CI: 25.00, 
47.16) 
Sensitivity = 48/122 = 39.34% (95% CI: 31.13, 
48.21) 
Specificity = 730/776 = 94.07% (95% CI: 92.18, 
95.53) 
Specificity = 1282/1407 = 91.12% (95% CI: 
89.52, 92.49) 
PPV = 24/70 = 34.29% (95% CI: 24.25, 45.96) PPV = 48/173 = 27.75% (95% CI: 21.61, 34.85) 
NPV = 730/774 = 94.32% (95% CI: 92.45, 
95.74) 
NPV = 1282/1356 = 94.54% (95% CI: 93.2, 
95.63) 
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DOR (for T+ calculated) = 8.65 (95% CI: 4.84, 
15.46) 
DOR (for T+ calculated) = 6.65 (95% CI: 4.42, 
9.99) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR  
OR (regression-based; reported) = 8.74 (95% CI: 
4.83, 15.82) 
List of covariates: NR 
OR (regression-based; reported) = 6.20 (95% CI: 
4.08, 9.44) List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.30 (95% CI: 0.91, 1.87) 
Ratio of OR (crude; for T+ reported) = NR  
Ratio of ORs (regression-based; reported) = 1.41 (95% CI: 0.97, 2.04) 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT/QFT) TST (≥5 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 14 106 120 TST + 50 123 173 
IGRA - 190 1219 1409 TST - 154 1202 1356 
Indeterminate    Indeterminate    
Total  204 1325 1529 Total  204 1325 1529 
Test performance parameters 
IGRA (TSPOT/QFT) TST (≥5 mm) 
DOR (for T+ calculated)TSPOT/QFT = 0.84 (95% CI: 
0.47, 1.51)  
DOR TST (for T+ calculated) = 3.17 (95% 
CI: 2.19, 4.58) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR  
OR (regression-based; reported)QFT = 0.43 (95% CI: 
0.17, 1.10) 
OR (regression-based; reported)TSPOT = 1.07 (95% 
CI: 0.47, 2.43) 
List of covariates: NR 
OR (regression-based; reported) TST = 2.95 
(95% CI: 2.00, 4.35) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥5 mm) TST - Total 
IGRA (QFT/TSPOT) + 66 54 120 
IGRA (QFT/TSPOT) -  107 1302 1409 
Indeterminate NR NR NR 
Total  173 1356 1529 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total  
TST + threshold: >5 mm 
Parameters 
Kappa = 0.39 (95% CI: 0.34, 0.44) 
% concordance = 1368/1529 = 89.47% (95% CI: 87.83, 90.91) between IGRA (QFT/TSPOT) vs. TST 
% concordance = 87.60% (95% CI: NR) between QFT vs. TST (raw 2 x 2 cell counts: NR) 
% concordance = 91.10% (95% CI: NR) between TSPOT vs. TST (raw 2 x 2 cell counts: NR) 
% discordance = 161/1529 = 10.53% (95% CI: 9.09, 12.17) 
Stratification (BCG vaccinated) 
 TST + TST - Total 
IGRA (QFT/TSPOT) + 11 3 14 
IGRA (QFT/TSPOT)  - 39 152 191 
Indeterminate    
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Total  50 155 205 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.26 (95% CI: 0.15, 0.37) 
% concordance = 163/205 = 79.5% (95% CI: 73.47, 84.47) 
% discordance = 42/205 = 20.49% (95% CI: 15.53, 26.53) 
Stratification (non-BCG vaccinated) 
 TST + TST - Total 
IGRA (QFT/TSPOT) + 55 51 106 
IGRA (QFT/TSPOT) - 68 1150 1218 
Indeterminate NR NR NR 
Total  123 1201 1324 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): non-BCG vaccinated 
TST + threshold:≥5 mm 
Parameters 
Kappa = 0.43 (95% CI: 0.37, 0.48) 
% concordance = 1205/1324 = 91.01% (95% CI: 89.35, 92.44) 
% discordance = 119/1324 = 8.98% (95% CI: 7.56, 10.65) 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
In patient populations with low rates of TB incidence and BCG vaccination, the use of both TST and 
IGRA may maximise sensitivity in detecting LTBI but may also reduce specificity; CRF influenced 
the results for all three of the tests but had less influence on QFT than on the other test systems. By 
this standard, TSPOT appears to perform better than QFT due to its greater correlation with known 
LTBI risk factors. Nevertheless, we cannot exclude the possibility that a poorer correlation with 
clinical risk factors is due to a higher specificity rather than a lower sensitivity. A better understanding 
of the relative merit of QFT versus TSPOT will require head-to-head tests under real-world conditions 
Reviewers: 
DOR of TST was higher than DOR for QFT, but it was similar to DOR of TSPOT; BCG influenced 
TST positivity (odds of TST positivity was higher in BCG vaccinated vs. non-vaccinated; OR>1) but 
not IGRA positivity (odds of IGRA positivity was the same in BCG vaccinated vs. non-vaccinated; 
OR = 1); between test agreement was higher in non-vaccinated vs. vaccinated group 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Laffitte 2009134 
Country: Switzerland 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Hospital-based 
Number of centres: 2 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
The aim of this study was (i) to determine the frequency of LTBI in a population of patients with 
psoriasis before anti-TNF treatment, (ii) to compare the TST with T-SPOT.TB for detecting LTBI, 
and (iii) to evaluate the tolerance and effectiveness of treatment for LTBI under anti-TNF therapy in 
our patients. 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (patients with psoriasis before anti-TNF treatment) 
Participants 
Recruitment dates: November 2004 and March 2008 
Total N of recruited patients: NR 
Inclusion criteria: Patients with moderate to severe psoriasis qualifying for anti-TNF-a therapy 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 50 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Agreement, association between test positivity and selected patient 
characteristics 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 48 (17–74) 
Women (n [%]): 15 [30] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): High TB incidence in country of origin (10 [20]) 
BCG vaccination (n [%]): 45 (90) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): None 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): Psoriasis 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): 12 patients treated for LTBI (9 with rifampicin and 3 with 
isoniazid) before anti TNF 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (TSPOT):   NR 10 40 NR 50 
TST (≥5mm): NR 20 30 NR 50 
TST (≥10mm): NR 18 32 NR 50 
Total N of patients with valid results for both IGRA and TST: 50 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – probable LTBI 
Non-exposed  No probable LTBI 
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Exposed 1 
(specify): 
Probable LTBI defined as having a history of definite exposure to a case of 
active tuberculosis and ⁄or having a chest X-ray suggestive of prior 
tuberculosis infection (granulomas, calcified adenopathy) and ⁄or originating 
from a high-incidence country (defined as > 40 cases in 100 000 per year) 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, 
methodology, 
timing for test 
measurement, 
manufacturer 
Cut-off values/thresholds Definition of 
test+ 
Other 
information 
IGRA (TSPOT) NR NR NA 
TST (≥ 5mm or 
≥10mm) 
NR The TST was considered positive if the 
induration diameter was ≥ 5mm or 
≥10mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 8 2 10 TST + 11 9 20 
IGRA - 14 26 40 TST - 11 19 30 
Indeterminate NR NR NR Indeterminate NR NR NR 
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Total  22 28 50 Total  22 28 50 
Test performance parameters 
IGRA TST 
Sensitivity = 8/22 = 36.36% (95% CI: 
19.73, 57.05) 
Sensitivity = 11/22 = 50.00% (95% CI: 30.72, 69.28) 
Specificity = 26/28 = 92.86% (95% CI: 
77.35, 98.02) 
Specificity = 19/28 = 67.86% (95% CI: 49.34, 82.07) 
PPV = 8/10 = 80.00% (95% CI: 49.02, 
94.33) 
PPV = 11/20 = 55.00% (95% CI: 34.21, 74.18) 
NPV = 26/40 = 65.00% (95% CI: 49.51, 
77.87) 
NPV = 19/30 = 63.33% (95% CI: 45.51, 78.13) 
DOR (for T+ calculated) = 7.43 (95% CI: 
1.38, 39.87) 
DOR (for T+ calculated) = 2.11 (95% CI: 0.67, 6.68) 
OR (crude; for T+ reported) = 7.43 (95% 
CI: 1.38, 39.90) 
OR (crude; for T+ reported) = 3.00 (95% CI: 0.93, 9.70) 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 3.52 (95% CI: 1.25, 9.96) 
Ratio of OR (crude; for T+ reported) = 2.48 (95% CI: 0.87, 7.05) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 8 2 10 TST + 12 6 18 
IGRA - 14 26 40 TST - 10 22 32 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  22 28 50 Total  22 28 50 
Test performance parameters 
IGRA TST 
Sensitivity = 8/22 = 36.36% (95% CI: 
19.73, 57.05) 
Sensitivity = 12/22 = 54.55% (95% CI: 34.66, 73.08) 
Specificity = 26/28 = 92.86% (95% CI: 
77.35, 98.02) 
Specificity = 22/28 = 78.57% (95% CI: 60.46, 89.79) 
PPV = 8/10 = 80.00% (95% CI: 49.02, 
94.33) 
PPV = 12/18 = 66.67% (95% CI: 43.75, 83.72) 
NPV = 26/40 = 65.00% (95% CI: 49.51, 
77.87) 
NPV = 22/32 = 68.75% (95% CI: 51.43, 82.05) 
DOR (for T+ calculated) = 7.43 (95% CI: 
1.38, 39.87) 
DOR (for T+ calculated) = 4.40 (95% CI: 1.28, 15.09) 
OR (crude; for T+ reported) = 7.43 (95% 
CI: 1.38, 39.90) 
OR (crude; for T+ reported) = 2.08 (95% CI: 0.64, 6.73) 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.69 (95% CI: 0.58, 4.89) 
Ratio of OR (crude; for T+ reported) = 3.57 (95% CI: 1.25, 10.18) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
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Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (≥5mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 9 1 10 TST + 19 1 20 
IGRA - 36 4 40 TST - 26 4 30 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  45 5 50 Total  45 5 50 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 1.00 (95% 
CI: 0.01, 10.07) 
DOR (for T+ calculated)TST = 2.92 (95% CI: 0.30, 28.29) 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = NR  
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 9 1 10 TST + 17 1 18 
IGRA - 36 4 40 TST - 28 4 32 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  45 5 50 Total  45 5 50 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 1.00 (95% 
CI: 0.01, 10.07) 
DOR (for T+ calculated)TST = 2.43 (95% CI: 0.25, 23.57) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR  
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST (≥5mm) + TST - Total 
IGRA (TSPOT) + 8 2 10 
IGRA (TSPOT) - 12 28 40 
Indeterminate NR NR NR 
Total  20 30 50 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.36 (95% CI: 0.12, 0.61) calculated 
Kappa = 0.33 (CI NR) reported 
% concordance = 36/50 = 72.00% (95% CI: 58.33, 82.53) 
% discordance = 14/50 = 28.00% (95% CI: 17.47, 41.67) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
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Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
T-SPOT.TB IGRA is strongly associated with the presence of risk factors for LTBI. This association 
was not found for the TST, and agreement between the T-SPOT.TB and TST was poor, probably 
because of a high rate of BCG-vaccinated patients (90%) acting as a confounding factor 
Reviewers: 
T-SPOT.TB IGRA is strongly associated with the presence of risk factors for LTBI (but not 
TST≥5mm). Strong association was also found for the TST≥10mm. Agreement between the T-
SPOT.TB and TST≥5mm was poor. Influence of BCG on test positivity was slightly higher for TST 
(both thresholds) than TSPOT, but given the small sample and that 90% were BCG vaccinated, there 
results are inconclusive due to wide CIs  
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
First author surname year of publication: Maritsi 2011135 
Country: UK 
Study design: Retrospective case study 
Study setting (e.g., outbreak investigation, community-based  - specify): Pediatric rheumatology 
centre 
Number of centres: One centre 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Authors report that there is no source of 
funding 
Aim of the study 
To describe the findings of QTB test when applied to a paediatric rheumatology population and to 
assess the efficacy of this test versus the methods previously used for the exclusion of TB infection 
prior to starting anti-TNFα treatment 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (Paediatric Rheumatology prior to  Initiation of Infliximab) 
Participants 
Recruitment dates: NR 
Total N of recruited patients: 27 
Inclusion criteria: Children on infliximab since 2007 
Exclusion criteria: NR 
Total N of excluded patients: 4 (no record of the QTB test) 
Total N of patients tested with both IGRA and TST: 27 
Total N of patients with valid results for both IGRA and TST: 23 
Methods of active TB diagnosis (if applicable):  
Outcomes (study-based) list: Test results 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median age 8.9 years (1.5 to 13 years) 
Women (n [%]): 12 (52.1) 
Race/ethnicity (n [%]): Caucasian [55%], Afro-Caribbean [19%], Asian [26%] 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 5 [22%] 
History of anti-TB treatment (n [%]): 5 [22] 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): No 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Methotrexate (5 [22]), infliximab (23 [100])  
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-
GIT):  
23 1 20 2 23 
TST (NR):  14 0 14 0 14 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 23 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – Risk for LTBI  
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Non-exposed  Low-risk group 
Exposed 1 
(specify): 
High-risk group (TB risk evaluation was performed using the questionnaire 
formulated by the United States Pediatric Tuberculosis Collaborative 
Group, which was published in 2004 [3]) 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, 
timing for test 
measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA (QFT-GIT) Quantiferon-TB gold in-tube 
(QTB), Cellestis Corp. 
Australia. The methodology 
and timing of the test have not 
been reported. 
Not reported Authors suggested that 
results for the QTB are 
reported as positive, 
negative and 
indeterminate. 
TST Not reported Not reported Not reported 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (high-risk group) 
IGRA (GIT) TST (NR) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 1 0 1 TST + 0 0 0 
IGRA - 2 18 20 TST - 3 11 14 
Indeterminate 0 2 2 Indeterminate NR NR 9 
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(exclude) 
Total  3 20 23 Total  3 11 14 
Test performance parameters 
IGRA (exclude indeterminate) TST (exclude indeterminate) 
Sensitivity = 1/3 = 33.33%, 95% (6.149, 79.23) Sensitivity = 0/3 = 0.0%, 95% CI (0.0, 56.15) 
Specificity = 18/18 = 100.00%, 95% CI (82.41, 
100.00) 
Specificity = 11/11 = 100.00%, 95% CI (74.12, 
100.00) 
PPV = 1/1 = 100.00%, 95% CI (20.65, 100.00) PPV = NA 
NPV = 18/20 = 90.00%, 95% CI (69.9, 97.21) NPV = 11/14 = 78.57%, 95% CI (52.41, 92.43) 
DOR (for T+ calculated) = Undefined DOR (for T+ calculated) = Undefined 
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NA 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NR  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT/QFT) TST (NR mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (TSPOT/QFT) TST (NR mm) 
DOR (for T+ calculated)TSPOT/QFT = NR DOR TST (for T+ calculated) = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported)QFT = NR 
OR (regression-based; reported)TSPOT = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
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IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The authors concluded that QTB is a useful screening tool for LTBI. Additionally, indeterminate 
results warrant careful assessment and re-evaluation, but should not preclude from initiation of anti-
TNF treatment.  Furthermore, the authors suggested that a negative TST in children receiving 
immunosuppressive treatment is not adequate in excluding LTBI 
Reviewers: 
 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Mutsvangwa 2010136 
Country: Zimbabwe 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): NR 
Number of centres: NR 
Total length of follow up (if applicable): NR 
Funding (government/private/manufacturer/other - specify): The Wellcome Trust 
Aim of the study 
We tested for LTBI using ELISpot and TST, correlated test results with TB exposure in household 
contacts of TB cases and assessed the impact of HIV co-infection on test results in these contacts 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (HIV positive adult contacts) 
Participants 
Recruitment dates: February 2002 to November 2004 
Total N of recruited patients: NR 
Inclusion criteria: All consenting individuals over the age of 10 years living with the TB cases 
(index case household contacts) and those (household contacts of controls) living with controls (no 
TB), TB cases were sampled from factories in Harare and controls samples randomly from the same 
factories 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 73 (HIV positives) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Agreement, association of test positive results with exposure to TB, 
degree of TB exposure 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): NR 
Women (n [%]): 65 [89.0] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Sub-Saharan Africa 
BCG vaccination (n [%]): 63 [86.0] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): NR 
Morbidity (n [%]): HIV infected 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (TSPOT):  NR 22 51 NR 73 
TST (≥10mm): NR 33 40 NR 73 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 73 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – household contact 
Non-exposed  Contact of index control (no TB) 
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Exposed 1 
(specify): 
Contact of index TB case 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Definition of exposure group – smear status of index cases 
Non-exposed  Smear negative, culture negative 
Exposed 1 
(specify): 
Smear negative, culture positive 
Exposed 2 
(specify): 
Smear positive, culture positive 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(TSPOT) 
Blood was drawn for ELISpot 
testing before or after the TST was 
placed. ELISpot assays were carried 
out as described elsewhere. 
Duplicate wells contained no 
antigen (negative control), 
phytohaemagglutinin (positive 
control) (ICN Biomedical, Aurora, 
Ohio, USA) at 5 mg/ml or 13 pairs 
of duplicate wells each containing 
one of 13 peptide pools 
incorporating 5-7 overlapping 15-
mer peptides spanning the length of 
early secretory antigenic target-6 
and culture filtrate protein-10, on 
which T-SPOT.TB is based. The 
final concentration of each peptide 
was 10 mg/ml 
ELISpot plates were sent to 
Oxford for automated spot 
counting (AID, Strassberg, 
Germany) 
 
Persons 
performing 
and reading 
the assays 
were blind 
to all 
personal 
identifiers 
and TST 
results 
TST (two 
stage; 
≥10mm) 
A two-step TST protocol was used 
to provide a suitable baseline for 
identifying subsequent TST 
conversions. As recommended by 
the manufacturer, 2 units of RT-23 
PPD (purified protein derivative) in 
Tween-80 (Statens Serum Institut, 
Copenhagen, Denmark) were 
injected intradermally into the 
forearm and results read at 48-72h. 
Placement and assessment followed 
recommended techniques 
If the first reaction was <10 
mm, then a second TST was 
placed after 7-14 days. Results 
were expressed as the greater 
of the two reactions. Reaction 
sizes ≥10 mm were considered 
positive 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
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IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10 mm; two step) 
 Exposure level Total  Exposure level Total 
Index 
case 
Index 
control 
Index 
case 
Index 
control 
IGRA + 19 3 22 TST + 27 6 33 
IGRA - 36 15 51 TST - 28 12 40 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  55 18 73 Total  55 18 73 
Test performance parameters 
IGRA TST 
Sensitivity = 19/55 = 34.55% (95% CI: 23.36, 
47.75) 
Sensitivity = 27/55 = 49.09% (95% CI: 36.38, 
61.92) 
Specificity = 15/18 = 83.33% (95% CI: 60.78, 
94.16) 
Specificity = 12/18 = 66.67% (95% CI: 43.75, 
83.72) 
PPV = 19/22 = 86.36% (95% CI: 66.66, 95.25) PPV = 27/33 = 81.82% (95% CI: 65.61, 91.39) 
NPV = 15/51 = 29.41% (95% CI: 18.71, 43.0) NPV = 12/40 = 30.00% (95% CI: 18.07, 45.43) 
DOR (for T
+
 calculated) = 2.64 (95% CI: 0.67, 
10.27) 
DOR (for T
+
 calculated) = 1.93 (95% CI: 0.63, 
5.87) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.37 (95% CI: 0.56, 3.36) 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10 mm; two-step) 
 Exposure level Total  Exposure level Total 
High Low High Low 
IGRA + NR NR NR TST + NR NR NR 
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IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA  
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA  
OR (crude; for T+ reported) =  
Smear – culture – = 1.00 (reference group) 
Smear – culture + = 1.60 (95% CI: 0.20, 12.69) 
Smear + culture + = 4.80 (95% CI: 1.05, 21.91) 
OR (crude; for T+ reported) =  
Smear – culture – = 1.00 (reference group) 
Smear – culture + = 1.50 (95% CI: 0.24, 9.46) 
Smear + culture + = 3.50 (95% CI: 0.88, 13.93) 
OR (regression-based; reported) =  
Smear – culture – = 1.00 (reference group) 
Smear – culture + = 1.87 (95% CI: 0.22, 16.16) 
Smear + culture + = 5.36 (95% CI: 1.11, 25.93) 
List of covariates: NR 
OR (regression-based; reported) =  
Smear – culture – = 1.00 (reference group) 
Smear – culture + = 1.09 (95% CI: 0.13, 9.42) 
Smear + culture + = 3.43 (0.76 to 15.52) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 1.37 (95% CI: 0.48, 3.91) [Smear + culture + vs. Smear – 
culture –] 
Ratio of ORs (regression-based; reported) = 1.56 (95% CI: 0.51, 4.76) [Smear + culture + vs. Smear – 
culture –] 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
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Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (contacts with TB index case):  
 TST + (≥ 10mm) TST - Total 
IGRA (TSPOT) + 15 4 19 
IGRA (TSPOT) - 12 24 36 
Indeterminate NR (excluded) NR (excluded) NR (excluded) 
Total  27 28 55 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): contacts with TB index 
case 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.41 (95% CI: 0.16, 0.66) 
% concordance = 39/55 = 70.91% (95% CI: 57.86, 81.23) 
% discordance = 16/55 = 29.09% (95% CI: 18.77, 42.14) 
Stratification (contacts with control index):  
 TST + (≥ 10mm) TST - Total 
IGRA (TSPOT) + 2 1 3 
IGRA(TSPOT)  - 4 11 15 
Indeterminate NR (excluded) NR (excluded) NR (excluded) 
Total  6 12 18 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): contacts with control index 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.28 (95% CI: -0.13, 0.70) 
% concordance = 13/18 = 72.22% (95% CI: 49.13, 87.5) 
% discordance = 5/18 = 27.78% (95% CI: 12.5, 50.87) 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Our findings suggest that ELISpot is a more accurate test than TST in HIV-infected persons recently 
infected with TB in a high-burden setting for both these infections. The increased accuracy of 
ELISpot testing compared with TST could improve targeting of preventive treatment to HIV-infected 
recent contacts of TB with LTBI which could further reduce the risk of active TB 
Reviewers: 
TSPOT performed better than TST in correctly identifying LTBI amongst HIV infected adult contacts 
due to higher specificity; agreement was higher amongst index case contacts vs. control contacts  
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Papay 2011137 
Country: Austria 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Outpatient clinic  
Number of centres: One 
Total length of follow up (if applicable): NR 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To evaluate the impact of IM treatment on results from TST and IGRA in IBD patients before starting 
therapy with a biologic agent 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Inflammatory bowel disease (IBD) patients 
Participants 
Recruitment dates: December 2006 to August 2009 
Total N of recruited patients: 208 
Inclusion criteria: IBD patients 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 208 
Total N of patients with valid results for both IGRA and TST: 192 
Methods of active TB diagnosis (if applicable):  
Outcomes (study-based) list: Test results, concordance of TST and IGRA, risk factor for LTB 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): age at screening 36.6 ± 11.3 
Women (n [%]): 107 [51.4] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]):NR 
BCG vaccination (n [%]): All subjects underwent BCG vaccination during childhood 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): Medically confirmed active TB (1 [0.5]) 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): Crohn’s disease (152 [73.1]); Ulcerative colitis (56 [26.9]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Immunotherapy  
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   192 15 177 0 192 
TST: 192 26 166 0 192 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 192 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
Exposed 1 (specify): Origin from a high-prevalent country 
Exposed 2 (specify): History of contact with active TB 
Exposed 3 (specify): Chest x-ray indicative of LTBI 
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Exposed 4 (specify): NA 
Tests 
 Assay used, 
methodology, timing for 
test measurement, 
manufacturer 
Cut-off values/thresholds Definition 
of test+ 
Other 
information 
IGRA  QFT-GIT, Cellestis, 
Carnegie, Australia 
≥0.35 IU/mL 
NA 
TST Tuberculin purified 
protein derivative (PPD 
RT23, Staten Serum 
Institute, Copenhagen, 
Denmark), Mantoux 
method 
For people with IM, TST was 
considered positive if the size of the 
induration was ≥ 5mm.  For people 
without IM but have IBD a positive 
test result was >10 mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA  
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA 
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Presence of risk factors for LTBI) 
IGRA (QFT-GIT) TST (≥5 mm) 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 9 6 15 TST + 15 11 26 
IGRA - 56 121 177 TST - 54 128 182 
Indeterminate 4 12 16 
(excluded) 
Indeterminate 0 0 0 
Total  69 139 208 Total  69 139 208 
Test performance parameters 
IGRA (excluding Indeterminate) TST  
Sensitivity = 9/65 = 13.85% (95% CI: 7.45, 24.27) Sensitivity = 15/69 = 21.74% (95% CI: 13.64, 
32.82) 
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Specificity = 121/127 = 95.28% (95% CI: 90.08, 
97.82) 
Specificity = 128/139 = 92.09% (95% CI: 86.38, 
95.52) 
PPV = 9/15 = 60.00% (95% CI: 35.75, 80.18) PPV = 15/26 = 57.69% (95% CI: 38.95, 74.46) 
NPV = 121/177 = 68.36% (95% CI: 61.18, 74.76)  NPV = 128/182 = 70.33% (95% CI: 63.33, 
76.49)  
DOR (for T
+
 calculated) = 3.24 (95% CI: 1.10, 
9.54) 
DOR (for T
+
 calculated) = 3.23 (95% CI: 1.39, 
7.49) 
OR (crude; for T+ reported) = 3.20 (95% CI: 1.10, 
10.10) 
OR (crude; for T+ reported) = 3.20 (95% CI: 
1.40, 7.50) 
OR (regression-based; reported) = 3.50 (95% CI: 
1.20, 11.30) 
List of covariates: NR 
OR (regression-based; reported) = 3.70 (95% 
CI: 1.50, 9.60) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.00 (95% CI: 0.50, 2.02) 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (origin from a high-incidence 
country) 
IGRA (QFT-GIT) TST (≥5 mm) 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 4 11 15 TST + 11 15 26 
IGRA - 24 153 177 TST - 18 164 182 
Indeterminate 1 15 16 
(excluded) 
Indeterminate 0 0 0 
Total  29 179 208 Total  29 179 208 
Test performance parameters 
IGRA (excluding indeterminate) TST (excluding indeterminate) 
Sensitivity = 4/28 = 14.29%, 95% CI (5.69, 31.49) Sensitivity = 11/29 = 37.93%, 95% CI (22.69, 
56) 
Specificity = 153/164 = 93.29%, 95% CI (88.39, 
96.21) 
Specificity = 164/179 = 91.62%, 95% CI (86.64, 
94.86) 
PPV = 4/15 = 26.67%, 95% CI (10.9, 51.95) PPV = 11/26 = 42.31%, 95% CI (25.54, 61.05) 
NPV = 153/177 = 86.44%, 95% CI (80.62, 90.72) NPV = 164/182 = 90.11%, 95% CI (84.91, 
93.65) 
DOR (for T+ calculated) = 2.32, 95% CI (0.68, 
7.87) 
DOR (for T+ calculated) = 6.68, 95% CI (2.67, 
16.73) 
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.35 (95% CI: 0.16, 0.76) 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (history of contact with active TB) 
IGRA (QFT-GIT) TST(≥5 mm) 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 2 13 15 TST + 4 22 26 
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IGRA - 8 169 177 TST - 7 175 182 
Indeterminate 1 15 16 Indeterminate 0 0 0 
Total  11 197 208 Total  11 197 208 
Test performance parameters 
IGRA (excluding indeterminate) TST (excluding indeterminate) 
Sensitivity = 2/10 = 20.00%, 95% CI (5.668, 
50.98) 
Sensitivity = 4/11 = 36.36%, 95% CI (15.17, 
64.62) 
Specificity = 169/182 = 92.86%, 95% CI (88.16, 
95.78) 
Specificity = 175/197 = 88.83%, 95% CI (83.67, 
92.51) 
PPV = 2/15 = 13.33%, 95% CI (3.736, 37.88) PPV = 4/26 = 15.38%, 95% CI (6.15, 33.53) 
NPV = 169/177 = 95.48%, 95% CI (91.34, 
97.69) 
NPV = 175/182 = 96.15%, 95% CI (92.27, 98.12) 
DOR (for T+ calculated) = 3.25, 95% CI (0.62, 
16.91) 
DOR (for T+ calculated) = 4.54, 95% CI (1.23, 
16.78) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = 0.72 (95% CI: 0.24, 2.10) 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Chest x-ray indicative of LTBI) 
IGRA (QFT-GIT) TST(≥5 mm) 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 1 14 15 TST + 5 21 26 
IGRA - 10 167 177 TST - 6 176 182 
Indeterminate 0 16 16 
(excluded) 
Indeterminate 0 0 0 
Total  11 197 208 Total  11 197 208 
Test performance parameters 
IGRA (excluding indeterminate) TST 
Sensitivity = 1/11 = 9.09%, 95% CI (1.62, 37.74) Sensitivity = 5/11 = 45.45%, 95% CI (21.27, 
71.99) 
Specificity = 167/181 = 92.27%, 95% CI (87.44, 
95.34) 
Specificity = 176/197 = 89.34%, 95% CI (84.25, 
92.92) 
PPV = 1/15 = 6.66%, 95% CI (1.18, 29.82) PPV = 5/26 = 19.23%, 95% CI (8.50, 37.88) 
NPV = 167/177 = 94.35%, 95% CI (89.91, 96.9) NPV = 176/182 = 96.7%, 95% CI (93, 98.48) 
DOR (for T+ calculated) = 1.19, 95% CI (0.14, 
10.01) 
DOR (for T+ calculated) = 6.98, 95% CI (1.96, 
24.87) 
OR (crude; for T+ reported) = 1.20, 95% CI: 0.10, 
6.90 
OR (crude; for T+ reported) = 6.30, 95% CI: 
1.70, 22.90 
OR (regression-based; reported) = 1.10, 95% CI: 
0.10, 7.70 
List of covariates: NR 
OR (regression-based; reported) = 4.90, 95% 
CI: 1.10, 19.9 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.17 (95% CI: 0.05, 0.61) 
Ratio of OR (crude; for T+ reported) = 0.19 (95% CI: 0.05, 0.68) 
Ratio of ORs (regression-based; reported) = 0.22 (95% CI: 0.06, 0.85) 
Other reported measure = NR 
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Association between test results and levels of TB exposure (IM treatment) 
IGRA (QFT-GIT) TST(≥5 mm) 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 7 8 15 TST + 18 8 26 
IGRA - 130 47 177 TST - 131 51 182 
Indeterminate 12 4 16 
(excluded) 
Indeterminate 0 0 0 
Total  149 59 208 Total  149 59 208 
Test performance parameters 
IGRA (excluding indeterminate) TST 
DOR (for T+ calculated) = 0.31 (95% CI: 0.10, 
0.92) 
DOR (for T+ calculated) = 0.87 (95% CI: 0.35, 
2.14)  
OR (crude; for T+ reported) = 0.30 (95% CI: 0.10, 
0.90) 
OR (crude; for T+ reported) = 0.90 (95% CI: 
0.40, 2.30)  
OR (regression-based; reported) = 0.30 (95% CI: 
0.10, 0.90) 
List of covariates: NR 
OR (regression-based; reported) = 0.90 (95% 
CI: 0.40, 2.60) 
List of covariates: NR 
Other reported measure =  Other reported measure =  
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 157 20 177 
IGRA - 9 6 15 
Indeterminate 0 0 0 
Total  166 26 192 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5 mm 
Parameters 
Kappa = 0.21, 95% CI (0.07, 0.34) 
% concordance = 163/192 = 84.90%, 95% CI (79.15, 89.27) 
% discordance = 29/192 = 15.10%, 95% CI (10.73, 20.85) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
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Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
These authors demonstrated that there is an association of positive results from TST and IGRA with 
the presence of risk factors for LTBI.  Additionally, their results showed that there is a negative 
impact of therapy with IM on IGRA results (not on TST).  They further concluded that LTBI 
screening should be undertaken at the diagnosis of IBD, and before treatment for IM 
Reviewers: 
IGRA positivity rate was lower in patients on IM vs. no IM treatment; TST was not affected by IM 
treatment 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Ramos 2013138 
Country: Spain 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Outpatient infectious 
diseases clinic of a university hospital 
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Grants from Conselleria de Sanidad 
(051/2007), and FIS (PI08/90778) 
Aim of the study 
To evaluate the performance of QFG compared with the TST for the diagnosis of LTBI in patients 
with immune-mediated inflammatory disease (IMID) before TNF-a antagonist therapy. Additionally, 
the impact of immunosuppressive therapy on QFG and TST performance in different IMID was 
evaluated 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (patients with IMID before TNF-a antagonist therapy) 
Participants 
Recruitment dates: From January 2009 to May 2011 
Total N of recruited patients: NR 
Inclusion criteria: All adults (age C 15 years) candidates for anti-TNF-a therapy who attended the 
clinic 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 153 
Total N of patients with valid results for both IGRA and TST: 152 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Agreement; association of test positivity with exposure; influence of 
immunosuppressive treatment on test positivity and agreement; influence of underlying disease on test 
positivity  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median 52 (16–82) 
Women (n [%]): 73 [47.7] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Born in a TB endemic area (8 [5.2]) 
BCG vaccination (n [%]): 29 [19] 
History of anti-TB treatment (n [%]): 5 [3.3] 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): Rheumatoid arthritis (RA) (53 [43.6]), psoriasis/psoriatic arthritis (45 [29.4]), 
inflammatory bowel diseases (IBD) (25 [16.3]), spondyloarthropathy (SA) (22 [14.4]), severe 
hidradenitis (3 [2.0]), systemic lupus erythematosus (2 [1.3]), polymyositis (1 [0.6]), sarcoidosis (1 
[0.6]), and mixed connective tissue disease (1 [0.6]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Immunosuppressive drug (91 [59.5]), methotrexate (57 
[37.3]), corticosteroids (28 [18.3]), leflunomide (21 [13.7]), azathioprine (19 [12.4]), cyclosporine (6 
[3.9]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
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(test+
) 
available) 
IGRA (QFT-
GIT):   
153 15 137 1 152 
TST (≥5mm): 153 43 110 0 153 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 152 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – Born in a TB endemic area 
Non-exposed  Not born in a TB endemic area 
Exposed 1 
(specify): 
Born in a TB endemic area 
Definition of exposure group – History of contact with TB patients 
Non-exposed No contact with TB patients 
Exposed 1 
(specify): 
Contact with TB patients 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-
GIT) 
For QFG, three aliquots of 1 ml 
of undiluted heparinized whole 
blood were collected in three 
tubes: one containing TB 
antigens (ESAT-6, CFP-10, 
and TB7.7), a positive control 
tube containing 
phytohemagglutinin, and a 
negative control tube. Blood 
samples were incubated for 
16–20 h at 37◦C. Plasma 
samples were then harvested 
for IFN-c quantification by a 
single-step sandwich-type 
ELISA  
 
The test was performed 
according to the 
manufacturer’s instructions 
(Cellestis, Carnegie, Australia) 
 
 
According to the instructions, the 
result was considered to be 
positive if the IFN-c level after 
stimulation with TB antigens 
minus negative control was 
≥0.35 IU/ml. The test was 
considered negative if the IFN-c 
level was <0.35 IU/ml after 
subtraction of the negative 
control 
 
The test result was considered to 
be indeterminate if (1) the 
negative control was ≥8.0 IU/ml 
or (2) the positive control was 
<0.5 IU/ml  
 
Moreover, the test result was 
considered to be 
intermediate if IFN-c level was 
≥0.10 IU/ml but <0.35 IU/ml  
QFG and 
TST were 
performed 
simultaneousl
y in a blinded 
fashion 
TST( ≥5mm) Study participants were 
injected with 0.1 ml of 
tuberculin (2 tuberculin units 
of PPD) (Tuberculina PPD; 
Evans 2UT, UCB Pharma, S.A. 
Madrid, Spain) in accordance 
with the American Thoracic 
Society guidelines. The 
transverse skin induration 
diameter was measured 
48–72h later 
TST was deemed positive if the 
induration 
diameter was more than 5 mm 
QFG and 
TST were 
performed 
simultaneousl
y in a blinded 
fashion 
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Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of active TB Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indetermina
te 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
Born in 
TB 
endemic 
area 
Not born in 
TB 
endemic 
area 
Born in 
TB 
endemic 
area 
Not born 
in TB 
endemic 
area 
IGRA + 4 11 15 TST + 4 39 43 
IGRA - 4 133 137 TST - 4 106 110 
Indeterminat
e 
NR 
(excluded) 
NR 
(excluded) 
1  
(excluded) 
Indetermi
nate 
0 0 0 
Total  8 144 152 Total  8 145 153 
Test performance parameters 
IGRA TST 
Sensitivity = 4/8 = 50.00% (95% CI: 21.52, 78.48) Sensitivity = 4/8 = 50.00% (95% CI: 21.52, 
78.48) 
Specificity = 133/144 = 92.36% (95% CI: 86.84, 95.68) Specificity = 106/145 = 73.1% (95% CI: 
65.36, 79.66) 
PPV = 4/15 = 26.67% (95% CI: 10.90, 51.95) PPV = 4/43 = 9.30% (95% CI: 3.67, 21.60) 
NPV = 133/137 = 97.08% (95% CI: 92.73, 98.86) NPV = 106/110 = 96.36% (95% CI: 91.02, 
98.58) 
DOR (for T+ calculated) = 12.09 (95% CI: 2.65, 55.07) DOR (for T+ calculated) = 2.72 (95% CI: 
0.65, 11.40) 
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR 
OR (regression-based; reported) = 29.30 (95% CI: 
4.60, 18.5) error 
OR (regression-based; reported) = 3.10 
(95% CI: 0.70, 13.70) 
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List of covariates: age, sex List of covariates: age, sex 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 4.44 (95% CI: 1.53, 12.89) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
Contact 
with TB 
No contact 
with TB 
Contact 
with TB 
No 
contact 
with TB 
IGRA + 3 12 15 TST + 4 39 43 
IGRA - 4 133 137 TST - 3 107 110 
Indeterminat
e 
NR 
(excluded) 
NR 
(excluded) 
1  
(excluded) 
Indetermi
nate 
0 0 0 
Total  7 145 152 Total  7 146 153 
Test performance parameters 
IGRA TST 
Sensitivity = 3/7 = 42.86% (95% CI: 15.82, 74.95) Sensitivity = 4/7 = 57.14% (95% CI: 25.05, 
84.18) 
Specificity = 133/145 = 91.72% (95% CI: 86.09, 95.20) Specificity = 107/146 = 73.29% (95% CI: 
65.58, 79.8) 
PPV = 3/15 = 20.00% (95% CI: 7.04, 45.19) PPV = 4/43 = 9.30% (95% CI: 3.67, 21.6) 
NPV = 133/137 = 97.08% (95% CI: 92.73, 98.86) NPV = 107/110 = 97.27% (95% CI: 92.29, 
99.07) 
DOR (for T+ calculated) = 8.31 (95% CI: 1.66, 41.56) DOR (for T+ calculated) = 3.66 (95% CI: 
0.78, 17.08) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = 8.00 (95% CI: 1.40, 
47.00) 
List of covariates: age, sex 
OR (regression-based; reported) = 3.20 
(95% CI: 0.70, 15.50) 
List of covariates: age, sex 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = 2.27 (95% CI: 0.73, 7.08) 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = 2.50 (95% CI: 0.76, 8.26) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 7 8 15 TST + 13 30 43 
IGRA - 22 115 137 TST - 16 94 110 
Indetermi
nate 
NR 
(excluded) 
NR 
(excluded
) 
1  
(excluded) 
Indeterminate 0 0 0 
Total  29 123 152 Total  29 124 153 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = 4.57 (95% CI: 1.50, 
13.91) 
DOR (for T+ calculated)TST = 2.54 (95% CI: 
1.10, 5.89) 
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OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = 5.10 (95% 
CI: 1.50, 17.50) 
List of covariates: Age, sex 
OR (regression-based; reported) TST = 2.40 
(95% CI: 1.01, 5.80)  
List of covariates: Age, sex  
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥5mm) TST - Total 
IGRA (QFT-GIT) + 13 2 15 
IGRA (QFT-GIT) - 30 107 137 
Indeterminate NR (excluded) NR (excluded) 1 (excluded) 
Total  43 109 152 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.35 (95% CI: 0.22, 0.48) 
% concordance = 120/152 = 78.95% (95% CI: 71.79, 84.67) 
% discordance = 32/152 = 21.05% (95% CI: 15.33, 28.21) 
Between-test agreement, concordance, and discordance (if applicable) 
Patients not receiving immunosuppressant  
Total sample 
 TST + (≥5mm) TST - Total 
IGRA (QFT-GIT) + 11 0 11 
IGRA (QFT-GIT) - 10 41 51 
Indeterminate NR (excluded) NR (excluded) 1 (excluded) 
Total  21 41 62 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Patients not receiving 
immunosuppressant 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.59 (95% CI: 0.36, 0.82) 
% concordance = 52/62 = 83.87% (95% CI: 72.79, 91.00) 
% discordance = 10/62 = 16.13% (95% CI: 9.00, 27.21) 
Between-test agreement, concordance, and discordance (if applicable) 
Patients receiving immunosuppressant  
Total sample 
 TST + (≥5mm) TST - Total 
IGRA (QFT-GIT) + 2 2 4 
IGRA (QFT-GIT) - 20 66 86 
Indeterminate NR (excluded) NR (excluded) 1 (excluded) 
Total  22 68 90 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Patients receiving 
immunosuppressant 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.08 (95% CI: -0.05, 0.22) 
% concordance = 68/90 = 75.56% (95% CI: 65.75, 83.27) 
% discordance = 22/90 = 24.44% (95% CI: 16.73, 34.25) 
Other outcomes 
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Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Test positivity odds for QFT was decreased in immunosuppressant recipients vs. those not on 
immunosuppressant (OR = 0.20, 95% CI: 0.06, 0.80). In contrast, test positivity odds for TST 
between these groups was similar (OR = 0.70, 95% CI: 0.30, 1.40). Therefore, immunosuppressant 
therapy impaired preferentially the sensitivity of the QFG test, since the rate of positive results was 
significantly lower in patients on immunosuppressive therapy 
 
We observed a worse agreement between TST and QFG in patients on immunosuppressive therapy. 
The TST positive and QFG-negative results in immunosuppressive patients may be explained due to a 
false positivity of TST related to atypical mycobacteria 
 
In patients with IMID, QFG may have a limited role for screening of LTBI. We found a negative 
effect of immunosuppressive therapy on QFG performance (sensitivity) 
Reviewers: 
QFT performed better than TST in correctly identifying LTBI with better specificity (stronger 
associations with exposures: born in endemic area; contact with TB case); however, QFT test 
positivity rate (not necessarily sensitivity) was influenced by immunosuppressant therapy, i.e., it was 
lower in patients on this therapy vs. patients without the therapy. This influence was not observed for 
TST 
 
BCG vaccination influenced both QFT and TST positivity odds similarly (increased positivity odds in 
vaccinated vs. not vaccinated for both tests) 
 
Agreement was lower in patients on immunosuppressant therapy vs. without the therapy due to lower 
specificity of TST vs. QFT 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; IBD = inflammatory bowel diseases; PPV = positive 
predictive value; NPV = negative predictive value; RA = rheumatoid arthritis; SA = 
spondyloarthropathy; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Seyhan 2010139 
Country: Turkey 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based  - specify): NR 
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): None 
Aim of the study 
To compare the results of QFT-G with TST for detecting LTBI in hemodialysis patients 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Hemodialysis patients 
Participants 
Recruitment dates: Between November 2008 and December 2008 
Total N of recruited patients: NR 
Inclusion criteria: Hemodialysis patients 
Exclusion criteria: Suspicion of active TB infection, use of immunosuppressive drugs, and other 
known immunodeficiency status (human immunodeficiency virus [HIV], malignancy, etc 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 100 
Methods of active TB diagnosis (if applicable):  
Outcomes (study-based) list: Test results, TST or QFT-G and risk factors, concordance between 
TST and QFT-G test 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 56.2±15.3 
Women (n [%]): 53 [53] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 72 [72] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-G):   100 43 57 0 100 
TST (≥10mm): 100 34 66 0 100 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 100 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group-1 
Non-exposed  No prior history of active TB 
Exposed 1 (specify): Prior history of active TB 
Definition of exposure group-2 
Non-exposed  No previous contact of the patient with TB cases 
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Exposed 1 (specify): Previous contact of the patient with TB cases (details of any contact with a 
person having TB, individuals who had household contact with or who had 
worked in the same rooms as patients with smear-positive pulmonary TB, 
and elapsed time after the contact) 
Definition of exposure group-3 
Non-exposed No chest radiograph changes consistent with old TB 
Exposed 1 (specify): Chest radiograph changes consistent with old TB 
Tests 
 Assay used, methodology, 
timing for test 
measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA (QFT-
GIT) 
QFT-G, not reported ≥0.35 IU/mL of IFN-γ 
in the TB antigen tube 
minus the negative 
control tube was 
considered to be a 
positive test result 
Blood was collected before 
TST placement. 
TST≥ 10mm Mantoux method was 
performed intradermally on 
the volar surface of the 
forearm with 0.1 mL (5TU) 
of PPD material (Intervax 
Biologicals, Markham, 
Ontario, Canada), induration 
was measured 48-72 hours 
after TST placement 
≥ 10mm induration was 
considered to be a 
positive test result 
People with an initial 
induration of less than 
10mm were administered a 
second TST one week later 
to cause a potential booster 
response.  Results from the 
two-step testing were used 
in all further analyses 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence 
of active 
TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
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Other reported measure = NR 
Association between test results and levels of TB exposure (Previous TB disease) 
IGRA (QFT-GIT) TST≥ 10mm 
 Exposure 
level 
Total  Exposure level Total 
Yes No Yes No 
IGRA + 6 37 43 TST + 3 31 34 
IGRA - 2 55 57 TST - 5 61 66 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  8 92 100 Total  8 92 100 
Test performance parameters 
IGRA TST 
Sensitivity = 6/8 = 75%, 95% CI (40.93, 
92.85) 
Sensitivity = 3/8 = 37.5%, 95% CI (13.68, 69.43) 
Specificity = 55/92 = 59.78%, 95% CI 
(49.57, 69.22) 
Specificity = 61/92 = 66.3%, 95% CI (56.17, 75.14) 
PPV = 6/43 = 13.95%, 95% CI (6.556, 
27.26) 
PPV = 3/34 = 8.824%, 95% CI (3.047, 22.96 ) 
NPV = 55/57 = 96.49%, 95% CI (88.08, 
99.03) 
NPV = 61/66 = 92.42%, 95% CI (83.46, 96.72) 
DOR (for T+ calculated) = 4.46, 95% CI 
(0.85, 23.31) 
DOR (for T+ calculated) = 1.18, 95% CI (0.26, 5.26) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR (NS) 
OR (regression-based; reported) = 2.06, 95% 
CI (0.30, 12.80) 
List of covariates: NR 
OR (regression-based; reported) = NR (NS) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 3.78 (95% CI: 1.21, 11.83) 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Previous contact with TB) 
IGRA (QFT-GIT) TST (≥10mm) 
 Exposure 
level 
Total  Exposure level Total 
Yes No Yes No 
IGRA + 10 33 43 TST + 6 28 34 
IGRA - 3 54 57 TST - 7 59 66 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  13 87 100 Total  13 87 100 
Test performance parameters 
IGRA TST 
Sensitivity = 10/13 = 76.92%, 95% CI (49.74, 
91.82) 
Sensitivity = 6/13 = 46.15%, 95% CI (23.21, 70.86) 
Specificity = 54/87 = 62.07%, 95% CI (51.57, 
71.55) 
Specificity = 59/87 = 67.82%, 95% CI (57.43, 76.7) 
PPV = 10/43 = 23.26%, 95% CI (13.15, 
37.74) 
PPV = 6/34 = 17.65%, 95% CI (8.349, 33.51) 
NPV = 54/57 = 94.74%, 95% CI (85.63, 
98.19) 
NPV = 59/66 = 89.39%, 95% CI (79.69, 94.77) 
DOR (for T+ calculated) = 5.45, 95% CI 
(1.40, 21.27) 
DOR (for T+ calculated) = 1.81, 95% CI (0.55, 5.87) 
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OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR (NS) 
OR (regression-based; reported) = 5.08, 95% 
CI (1.20, 21.20) 
List of covariates: NR 
OR (regression-based; reported) = NR (NS) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 3.01 (95% CI: 1.20, 7.56) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Chest X-ray with changes) 
IGRA (QFT-GIT) TST≥10mm 
 Exposure 
level 
Total  Exposure level Total 
Yes No Yes No 
IGRA + 11 32 43 TST + 4 30 34 
IGRA - 5 52 57 TST - 12 54 66 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  16 84 100 Total  16 84 100 
Test performance parameters 
IGRA TST 
Sensitivity = 11/16 = 68.75%, 95% CI (44.40, 
85.84) 
Sensitivity = 4/16 = 25.00%, 95% CI (10.18, 49.50) 
Specificity = 52/84 = 61.90%, 95% CI (51.22, 
71.55)   
Specificity = 54/84 = 64.29%, 95% CI (53.62, 73.70) 
PPV = 11/43 = 25.58%, 95% CI (14.93, 
40.24) 
PPV = 4/34 = 11.76%, 95% CI (4.67, 26.62) 
NPV = 52/57 = 91.23%, 95% CI (81.05, 
96.19) 
NPV = 54/66 = 81.82%, 95% CI (70.85, 89.28) 
DOR (for T+ calculated) = 3.57, 95% CI 
(1.14, 11.24) 
DOR (for T+ calculated) = 0.60, 95% CI (0.18, 2.02) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR (NS) 
OR (regression-based; reported) = 3.06, 95% 
CI (2.10, 11.90) 
List of covariates: NR 
OR (regression-based; reported) = NR (NS) 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 5.95 (95% CI: 2.54, 13.91) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST ≥10mm 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 34 9 43 TST + 30 4 34 
IGRA - 38 19 57 TST - 42 24 66 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  72 28 100 Total  72 28 100 
Test performance parameters 
IGRA TST 
DOR (for T
+
 calculated)QFT = 1.89 (95% CI: 
0.75, 4.73) 
DOR TST (for T+ calculated) = 4.28 (95% CI: 1.35, 
13.64) 
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OR (crude; for T+ reported) = NR (NS) OR (crude; for T+ reported) = NR (SS) 
OR (regression-based; reported)QFT = NR 
(NS) 
List of covariates: NR 
OR (regression-based; reported) TST = 4.10 (1.30, 
13.90) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 21 22 43 
IGRA - 13 44 57 
Indeterminate 0 0 0 
Total  34 66 100 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥ 10mm 
Parameters 
Kappa = 0.27, 95% CI (95% CI: 0.07, 0.46) 
% concordance = 65/100 = 65.00%, 95% CI (55.25, 73.64) 
% discordance = 35/100 = 35.00%, 95% CI (26.36, 44.75) 
Stratification (BCG vaccinated) 
 TST + TST - Total 
IGRA + 17 17 34 
IGRA - 13 25 38 
Indeterminate 0 0 0 
Total  30 42 72 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG 
TST + threshold: ≥ 10mm 
Parameters 
Kappa = 0.16, 95% CI (-0.07, 0.39) 
% concordance = 42/72 = 58.33%, 95% CI (46.81, 69.01) 
% discordance = 30/72 = 41.67%, 95% CI (30.99, 53.19) 
Stratification (non-BCG vaccinated) 
 TST + TST - Total 
IGRA + 4 5 9 
IGRA - 0 19 19 
Indeterminate 0 0 0 
Total  4 24 28 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Unvaccinated 
TST + threshold: ≥ 10mm 
Parameters 
Kappa = 0.52, 95% CI (0.19, 0.84) 
% concordance = 23/28 = 82.14%, 95% CI (64.41, 92.12) 
% discordance = 5/28 = 17.86%, 95% CI (7.878, 35.59) 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
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Conclusions 
Authors: 
These authors concluded that there was poor agreement between TST and QFT-G for LTBI in HD 
patients.  Additionally, unlike the TST, the QFT-G results were significantly related to LTBI risk 
factors, but not related to the BCG status.  They further concluded that QFT-G was a superior to the 
TST test for detecting LTBI in HD patients 
Reviewers: 
QFT-GIT performed better than TST in identifying LTBI correctly showing stronger associations 
between test positivity odds and the exposures. Also, IGRA was not dependent on BCG vaccination 
unlike TST positivity. Agreement was higher in BCG non vaccinated patients 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Shen 2012140 
Country: China 
Study design: Retrospective study 
Study setting (e.g., outbreak investigation, community-based  - specify): University hospital 
Number of centres: 1 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): None 
Aim of the study 
To evaluated the diagnostic value of an enzyme-linked immunosorbent spot (ELISPOT) assay 
measuring interferon-Y in hepatitis C patients with LTBI 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Hepatitis C patients 
Participants 
Recruitment dates: From January 2009 to December 2010 
Total N of recruited patients: NR 
Inclusion criteria: Hepatitis patients with (TB exposure group-patients who had history of exposure 
to TB and did not do clinical diagnosis of TB, with obvious clinical symptoms; non-TB exposure 
group- patients who had no history of exposure to TB and no clinical symptoms; TB group-patients 
who were clinically diagnosed with TB and with apparent clinical symptoms) 
This review focuses on 70 patients (TB exposure group-patients), n = 31 (suspected LTBI; excluding 
9 TB patients) and n = 39 non-exposed patients (no history of exposure to TB and no clinical 
symptoms) 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 160 (TST and ELISPOT) 
Total N of patients with valid results for both IGRA and TST: 160  (TST and ELISPOT) 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Test results, sensitivity and specificity of TST and ELISPOT 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): TB exposure group n = 40 (42.9 No TB exposure group (n 
= 39) 37.8 17.6 
Women (n [%]): TB exposure (37 [47]); No TB exposure (17 [45]) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): NR  
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]):NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): Hepatitis C 
Co-morbidity (n [%]): Heart disease, diabetes, liver cirrhosis, solid tumor, chronic renal failure 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (TSPOT): 
ELISPOT 
70 26 44 0 70 
TST  (≥5 mm):  70 34 36 0 70 
Test 3 (specify):  NA NA NA NA NA 
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Total N of patients with valid results for both IGRA and TST:  
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  No history of TB exposure and no clinical symptoms (n = 39) 
Exposed 1 (specify): History of exposure to tuberculosis (suspected having TB, but no 
symptoms of TB, n = 31) 
Exposed 2 (specify):  NA 
Exposed 3 (specify):  NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(TSPOT) 
IFN-γ ELISPOT assay (Beijing 
Gaoke Life and Technology Inc., 
China) was performed according to 
the manufacturer’s recommendations 
Not stated NA 
TST≥5 
mm 
TST was performed by intradermal 
injection (Mantoux method) of 0.1 
mL (5U) of PPD according to current 
recommendations.  The induration 
was measured with a ruler by a 
trained physician 72 hours after the 
injection 
TST was considered 
positive when the 
transverse diameter of 
induration was ≥5 mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA  
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Suspected TB disease) 
IGRA (TSPOT) TST≥5mm 
 Exposure level Total  Exposure level Total 
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Yes No Yes No 
IGRA + 22 4 26 TST + 19 15 34 
IGRA - 9 35 44 TST - 12 24 36 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  31 39 70 Total  31 39 70 
Test performance parameters 
IGRA TST 
Sensitivity = 22/31 = 70.97%, 95% CI (53.41, 
83.9) 
Sensitivity = 19/31 = 61.29%, 95% CI (43.82, 
76.27) 
Specificity = 35/39 = 89.74% (95% CI: 76.42, 
95.94) 
Specificity = 24/39 = 61.54% (95% CI: 45.9, 75.11) 
PPV = 22/26 = 84.62% (95% CI: 66.47, 
93.85)  
PPV = 19/34 = 55.88% (95% CI: 39.45, 71.12) 
NPV = 35/44 = 79.55% (95% CI: 65.5, 88.85) NPV = 24/36 = 66.67% (95% CI: 50.33, 79.79) 
DOR (for T+ calculated) = 21.39 (95% CI: 
5.87, 77.93) 
DOR (for T+ calculated) = 2.53 (95% CI: 0.96, 6.67) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 8.45 (95% CI: 3.71, 19.28) 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT/QFT) TST (>5 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (TSPOT/QFT) TST (>5 mm) 
DOR (for T+ calculated)TSPOT/QFT = NR DOR TST (for T+ calculated) = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported)QFT = NR  
OR (regression-based; reported)TSPOT = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
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Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Based on the results from this study the ELISPOT assay had a high diagnostic sensitivity and a low 
false positive rate in the diagnosis of LTBI.  They concluded that the use of this assay may be 
effective in diagnosing LTBI in this patient group to prevent LTBI developing into active TB 
Reviewers: 
IGRA performed better than TST for LTBI identification (on all parameters) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Souza 2014153 
Country: Brazil  
Study design: cross-sectional/retrospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): outpatient clinics 
Number of centres: 8  
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): This research was supported by 
Fundacao de Apoio `a Pesquisa do Distrito Federal, FAPDF funded by SUS-PPSUS Grant no. 
193.000.353/2010. 
Aim of the study 
To evaluate the added value of QFT-GIT over the TST for detecting LTBI among persons living with 
HIV/AIDS (PLWHA); also to explore the factors associated with a positive QFT-GIT and with 
discordant QFT-GIT/TST results 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised 
people) 
Immunocompromised (HIV/AIDS) 
Participants 
Recruitment dates: between May 2011 and March 2013 
Total N of recruited patients: NR 
Inclusion criteria: People with HIV/AIDS over 17 years who were not submitted to TST in the 
previous five weeks 
Exclusion criteria: Patients with history of other immunosuppression conditions (severe AIDS-
related opportunistic infections, acute viral infections, those submitted to any vaccination in the 
previous two months, and those using immunosuppressive drugs), patients with present or past active 
TB and those with a history of a previous positive TST  
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 299 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: between test agreement, association between factors and test results 
(positive, discordant tests) 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): median 40 (IQR = 32–46) years 
Women (n [%]): 85 [28.3] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 228 [76.0] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): NR 
Morbidity (n [%]): HIV/AIDS 
Co-morbidity (n [%]):  NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT) 300 14 285 1 299 
TST: ≥5mm 300 10 290 0 300 
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Test 3 (specify)      
Total N of patients with valid results for both IGRA and TST: 299 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – History of contact with index case 
Non-exposed  No 
Exposed 1 (specify): Yes 
Exposed 2 (specify): NR 
Exposed 3 (specify): NR 
Exposed 4 (specify): NR 
 
Tests 
 Assay used, methodology, 
timing for test 
measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-
GIT) 
QFT-GIT was performed 
according to the 
manufacturer’s instruction 
 
Positive result was considered 
if the difference between 
interferon response to TB 
antigens and negative control 
was ≥0.35 UI/mL and 
interferon response to TB 
antigens was ≥25% compared 
to the negative control 
response 
 
QFT-GIT was considered 
to be indeterminate if the 
interferon response to the 
negative control was ≥8UI/mL 
or <0.5UI/mL compared to the 
positive control 
 
TST≥5mm  Participants were submitted 
to TST using 0.1mL of 
PPD-RT 23 (2 units of 
tuberculin) 
 
Injection and reading of 
induration 72 to 96 hours after 
injection were performed by a 
trained HCW 
 
Positive result was TST 
induration was ≥5mm 
 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
NPV= NA NPV= NA 
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Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+= NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST= NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥5mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 0 13 13 TST + 1 8 9 
IGRA - 35 245 280 TST - 34 251 285 
indeterminate NR NR 1 indeterminate 0 0 0 
Total  35 258 293 Total  35 259 294 
Test performance parameters 
IGRA TST 
Sensitivity = 0/35=0.00% (95% CI: 0.0, 9.89)  Sensitivity = 1/35=2.86% (95% CI: 0.50, 14.53) 
Specificity = 245/258=94.96% (95% CI: 91.57, 
97.03) 
Specificity =251/259=96.91% (95% CI: 94.02, 
98.43) 
PPV= 0/13=0.00% (95% CI: 0.0, 22.81) PPV=1/9= 11.11% (95% CI: 1.99, 43.5) 
NPV= 245/280=87.5% (95% CI: 83.11, 90.87) NPV=251/285=88.07% (95% CI: 83.79, 91.34)  
DOR (for T+ calculated)= 0.50 (95% CI: 0.06, 
4.24) 
DOR (for T+ calculated)= 0.93 (95% CI: 0.11, 
7.61) 
OR (crude; for T
+ 
reported)= 0.49 (95% CI: 0.06, 
3.82) 
OR (crude; for T
+ 
reported)= 0.92 (95% CI: 0.11, 
7.61) 
OR (regression-based; reported)= NR 
 
List of covariates: NR 
OR (regression-based; reported)= 1.21 (95% CI: 
0.13, 11.16) 
List of covariates: NR 
Other reported measure = NR Other reported measure =NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.54 (95% CI: 0.12, 2.49) 
Ratio of OR (crude; for T+ reported) = 0.53 (95% CI: 0.12, 2.42) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) =  NA 
OR (regression-based; reported) IGRA = NA  OR (regression-based; reported) TST = NA 
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List of covariates: NA List of covariates: NA 
Other reported measure = NA  Other reported measure = NA  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or 
condition 
Total sample 
 TST +(≥5mm) TST - Total 
IGRA + 6 8 14 
IGRA - 4 281 285 
indeterminate 0 1 1 
Total  10 289 299 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.48 (95% CI: 0.37, 0.59) 
% concordance = 287/299 = 96.00% (95% CI: 93.12, 97.69) 
% discordance = 12/299 = 4.01% (95% CI: 2.31, 6.88) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
QFT-GIT alone was more effective to detect LTBI than TST (QFT yielded more positives), assuming 
that any test is a marker of LTBI 
Reviewers: 
The authors used invalid assumption of test positivity as a marker of LTBI; the results are 
inconclusive regarding the strength of association between test positivity and prior exposure to index 
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case (ORs and 95% CIs are too wide) 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
First author surname year of publication: Takeda 2011141 
Country: Japan 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Hospital based 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Ministry of Health, Labor, and Welfare 
Aim of the study 
To evaluate whether QFT-GIT is useful in detecting LTBI in systemic lupus erythematosus (SLE) 
patients  
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (patients with SLE) 
Participants 
Recruitment dates: July 2006 to September 2008 
Total N of recruited patients: NR 
Inclusion criteria: Systemic lupus erythematosus (SLE) patients; non-SLE connective tissue disease 
(rheumatoid arthritis, myositis, vasculitides, systemicscleroderma, Sjoegren’s syndrome, Behcet’s 
disease, adult-onset Still’s disease) 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 71 (IGRA) and 43 (TST) 
Total N of patients with valid results for both IGRA and TST: NR 
Methods of active TB diagnosis (if applicable): Positive culture for MTB or a positive result on a 
polymerase chain reaction test for MTB DNA in any clinical specimen associated with compatible TB 
symptoms and radiographic findings 
Outcomes (study-based) list: Association of test positivity and risk for LTBI, factors influencing 
indeterminate QFT results 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 38.3 (15.2) 
Women (n [%]): 58 [81.7] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): SLE 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Corticosteroids (37 [52.1]), immunosuppressive drugs (19 
[26.8]), prednisolone pulse therapy (2 [2.8]), NSAIDs or no therapy (13 [18.3]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-2G):   71 2 46 23 71 
TST ( ≥10 mm): 43 3 40 0 43 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: Unclear 
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Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  Without risk of LTBI 
Exposed 1 (specify): With risk factors for LTBI (history of household TB contact; chest X ray 
suggestive of previous TB showing nodules, fibrotic scars, calcified 
granulomas, basal thickening;  history of active TB) 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA 
(QFT-
GIT) 
Quantiferon-TB Gold (QFT-2G), 
Cellestis, Carnegie, Australia 
≥ 0.35 IU/mL Negative result if the IFN-γ 
level in the antigen stimulated 
wells was <0.35 IU/mL and in 
the mitogen wells was ≥0.5 
IU/mL.  Results were 
considered indeterminate if 
the IFN-γ level in the antigen 
stimulated wells was <0.5 
IU/mL, or if the IFN-γ level 
in the antigen-stimulated 
wells was below half of the 
level of the negative control 
was > 0.7 IU/mL 
TST≥10 
mm 
0.1 mL of tuberculin purified 
protein derivative (PPD) 
(approximately 3 tuberculin units 
of PPD-S), Nippon BCG 
Manufacturing, Tokyo, Japan) 
into the venral surface of the 
forearm.  The induration was 
measured 48 hours later 
≥10 mm, according 
to the usual 
criterion of the TST 
in Japan 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
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Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (risk for LTBI) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + 2 0 2 TST + 1 2 3 
IGRA - 16 30 46 TST - 13 27 40 
Indeterminate 8 15 23 Indeterminate 0 0 0 
Total  26 45 71 Total  14 29 43 
Test performance parameters 
IGRA  TST 
Including indeterminate-as test negative 
Sensitivity = 2/26 = 7.70% (95% CI: 2.13, 
24.14) 
Excluding indeterminate 
Sensitivity = 2/18 = 11.11% (95% CI: 3.10, 
32.80) 
Sensitivity = 1/14 = 7.14%, 95% CI (1.27, 31.47) 
Including indeterminate-as test negative 
Specificity = 45/45 = 100.00% (95% CI: 92.13, 
100.00) 
Excluding indeterminate 
Specificity = 30/30 = 100.00% (95% CI: 88.65, 
100.00) 
Specificity = 27/29 = 93.10%, 95% CI (78.04, 
98.09) 
PPV = 2/2 = 100.00%, 95% CI (34.24, 100.00) PPV = 1/3 = 33.33%, 95% CI (6.15, 79.23) 
Including indeterminate-as test negative 
NPV = 45/69 = 65.22% (95% CI: 53.45, 75.38) 
Excluding indeterminate 
NPV = 30/46 = 65.22% (95% CI: 50.77, 77.32) 
NPV = 27/40 = 67.50%, 95% CI (52.02, 79.92) 
DOR (for T
+
 calculated) = 3.75 (95% CI: 0.31, 
44.6) 
DOR (for T
+
 calculated) = 1.04, 95% CI (0.08, 
12.53) 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 3.61 (95% CI: 0.59, 21.99) 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT/QFT) TST (>5 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
522
Test performance parameters 
IGRA (TSPOT/QFT) TST (>5 mm) 
DOR (for T+ calculated)TSPOT/QFT = NA DOR TST (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported)QFT = NA 
OR (regression-based; reported)TSPOT = NA 
List of covariates: NA 
OR (regression-based; reported) TST = NA  
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
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IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The authors concluded that the QFT-2G test may have more potential to assist in the diagnosis of 
active MTB infection and LTBI than TST in people who have systemic lupus.  Additionally, the 
authors suggested that the results should be taken in caution in this patient group because one-third of 
the patients had an indeterminate test result, and care should be taken especially for those patients 
who have parallel or subsequent flares of the disease 
Reviewers: 
The authors did not report on the number of people who had valid results for both the IGRA and TST. 
TST was done on a subsample of 71 patients 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Vassilopolous 2011142 
Country: Greece 
Study design: Retrospective cohort study/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based  - specify): Outpatient rheumatology 
clinic of Hippokration general hospital 
Number of centres: One 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Supported in part by research grants 
from the Hellenic Society for Rheumatology and the Special Account for Research Grants (SARG), 
National and Kapodistrian University of Athens, Athens, Greece 
Aim of the study 
To compare the latest IGRAs (QFT-GIT and T-SPOT.TB assays) and TST for LTBI diagnosis in 
rheumatic patients starting anti –TNF treatment 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Rheumatic patients starting anti-TNF therapies 
Participants 
Recruitment dates: Between September 2008 and September 2010 
Total N of recruited patients: 157 
Inclusion criteria: Patients with various rheumatic diseases who were seen at the Outpatient 
Rheumatology Clinic of Hippokration General Hospital (2nd Department of Medicine, Athens 
University School of Medicine, Athens, Greece) and scheduled for anti-TNF treatment 
Exclusion criteria: Patients with active TB, a history of treatment with anti-TB agents, including 
isoniazid (INH) for LTBI, or a history of previous treatment with anti-TNF agents or other biologics  
Total N of excluded patients: 2 (indeterminate QFT-GIT results from the analysis: 
spondyloarthropathy related to UC on high dose methylprednisolone) 
Total N of patients tested with both IGRA and TST: 157 
Total N of patients with valid results for both IGRA and TST: 155 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Test results, concordance of agreement between two assays 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 52 ±16 
Women (n [%]): 90 [58] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]):NR 
BCG vaccination (n [%]): 81 [76] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]):  NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): 15 [21.4] 
Type of during-study treatment (n [%]): Immunosuppressive therapy (DMARDs/steroids (98 [63]); 
DMARDs (80 [52]) steroids (66 [43]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   157 32 123 2 155 
IGRA (T-
SPOT.TB):  
157 39 116 2 155 
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TST (≥ 5mm): 157 58 97 2 155 
Total N of patients with valid results for both IGRA and TST: 155 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  No history of previous TB contact 
Exposed 1 (specify): History of previous TB contact 
Definition of exposure group 
Non-exposed Chest x-ray without signs suggestive of old TB 
Exposed 2 (specify):  Chest x-ray suggestive of old TB 
Definition of exposure group 
Non-exposed  No risk factor for TB (≥ 1) 
Exposed 3 (specify): Any risk factor for TB (≥ 1) including: age >50 years, chest X-ray suggestive 
of old/healed TB, contact with a person with TB, and birth or residence in a 
country with a high TB prevalence (non-Greek nationality) 
Tests 
 Assay used, 
methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of 
test+ 
Other information 
IGRA (QFT-
GIT) 
QFT-GIT was 
performed according to 
the manufacturer’s 
instructions 
NR The blood draw for both IGRAs was 
performed just prior to TST 
application in order to avoid 
potential interference with the IGRA 
results 
IGRA 
(TSPOT) 
The T-SPOT.TB assay 
was performed as 
previously described 
NR The blood draw for both IGRAs was 
performed just prior to TST 
application in order to avoid 
potential interference with the IGRA 
results 
TST≥ 5mm Mantoux method of 0.1 
mL (2 IU) of purified 
protein derivative (PPD) 
RT 23; Statens Serum 
Institute, Copenhagen, 
Denmark) 
A TST was 
considered 
positive when the 
diameter of 
transverse 
induration was ≥ 
5mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
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Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (TB exposure) 
IGRA (T-SPOT.TB) TST≥ 5mm 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 5 34 39 TST + 10 48 58 
IGRA - 15 101 116 TST - 10 87 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  20 135 155 Total  20 135 155 
Test performance parameters 
IGRA TST 
Sensitivity = 5/20 = 25.00%, 95% CI (11.19, 
46.87) 
Sensitivity = 10/20 = 50.00%, 95% CI (29.93, 
70.07) 
Specificity = 101/135 = 74.81%, 95% CI 
(66.88, 81.38) 
Specificity = 87/135 = 64.44%, 95% CI (56.07, 
72.02) 
PPV = 5/39 = 12.82%, 95% CI (5.60, 26.71) PPV = 10/58 = 17.24%, 95% CI (9.64, 28.91) 
NPV = 101/116 = 87.07%, 95% CI (79.76, 
92.00) 
NPV = 87/97 = 89.69%, 95% CI (82.05, 94.3) 
DOR (for T+ calculated) = 0.99, 95% CI (0.33, 
2.92) 
DOR (for T+ calculated) = 1.81, 95% CI (0.70, 
4.66) 
OR (crude; for T+ reported) = 0.99, 95% CI 
(NR; p = 0.99) 
OR (crude; for T+ reported) = 1.81, 95% CI (NR; p 
= 0.22) 
OR (regression-based; reported) = 0.89, 95% CI 
(NR; p = 0.86) 
List of covariates: NR 
OR (regression-based; reported) = 1.73, 95% CI 
(NR; p = 0.30) 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.55 (95% CI: 0.26, 1.14) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (TB exposure) 
IGRA (QFT-GIT) TST≥ 5mm 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 3 29 32 TST + 10 48 58 
IGRA - 17 106 123 TST - 10 87 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  20 135 155 Total  20 135 155 
Test performance parameters 
IGRA TST 
Sensitivity = 3/20 = 15.00%, 95% CI (5.23, 
36.04) 
Sensitivity = 10/20 = 50.00%, 95% CI (29.93, 
70.07) 
Specificity = 106/135 = 78.52%, 95% CI 
(70.85, 84.61) 
Specificity = 87/135 = 64.44%, 95% CI (56.07, 
72.02) 
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
527
PPV = 3/32 = 9.37%, 95% CI (3.24, 24.22) PPV = 10/58 = 17.24%, 95% CI (9.64, 28.91) 
NPV = 106/123 = 86.18%, 95% CI (78.98, 
91.19) 
NPV = 87/97 = 89.69%, 95% CI (82.05, 94.3) 
DOR (for T+ calculated) = 0.64, 95% CI (0.17, 
2.35) 
DOR (for T+ calculated) = 1.81, 95% CI (0.70, 
4.66) 
OR (crude; for T
+ 
reported) = 0.64, 95% CI 
(NR; p = 0.5) 
OR (crude; for T
+ 
reported) = 1.81, 95% CI (NR; p 
= 0.22) 
OR (regression-based; reported) = 0.55, 95% CI 
(NR; p = 0.41) 
List of covariates: NR 
OR (regression-based; reported) = 1.73, 95% CI 
(NR; p = 0.30) 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.35 (95% CI: 0.15, 0.81) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Chest x-ray suggestive of old TB) 
IGRA (T-SPOT.TB) TST≥ 5mm 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 4 35 39 TST + 9 49 58 
IGRA - 10 106 116 TST - 5 92 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  14 141 155 Total  14 141 155 
Test performance parameters 
IGRA TST 
Sensitivity = 4/14 = 28.57%, 95% CI (11.72, 
54.65) 
Sensitivity = 9/14 = 64.29%, 95% CI (38.76, 
83.66) 
Specificity = 106/141 = 75.18%, 95% CI 
(67.44, 81.58) 
Specificity = 92/141 = 65.25%, 95% CI (57.08, 
72.61) 
PPV = 4/39 = 10.26%, 95% CI (4.06, 23.58) PPV = 9/58 = 15.52%, 95% CI (8.38, 26.93) 
NPV = 106/116 = 91.38%, 95% CI (84.86, 
95.25) 
NPV = 92/97 = 94.85%, 95% CI (88.5, 97.78) 
DOR (for T+ calculated) = 2.21, 95% CI (0.35, 
4.10) 
DOR (for T+ calculated) = 3.38, 95% CI (1.07, 
10.64) 
OR (crude; for T
+ 
reported) = 2.21, 95% CI 
(NR; p = 0.76) 
OR (crude; for T
+ 
reported) = 3.38, 95% CI (NR; p 
= 0.04) 
OR (regression-based; reported) = 0.48, 95% CI 
(NR; p = 0.31) 
List of covariates: NR 
OR (regression-based; reported) = 3.50, 95% CI 
(NR; p = 0.05) 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 0.65 (95% CI: 0.28, 1.54) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (Chest x-ray suggestive of old TB) 
IGRA (QFT-GIT) TST≥ 5mm 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 14 28 32 TST + 9 49 58 
IGRA - 10 113 123 TST - 5 92 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
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Total  24 141 155 Total  14 141 155 
Test performance parameters 
IGRA TST 
Sensitivity = 58.33% (95% CI: 38.83, 75.53) Sensitivity = 9/14 = 64.29%, 95% CI (38.76, 
83.66) 
Specificity = 80.14% (95% CI: 72.8, 85.89) Specificity = 92/141 = 65.25%, 95% CI (57.08, 
72.61) 
PPV = 33.33% (95% CI: 21.01, 48.45) PPV = 9/58 = 15.52%, 95% CI (8.38, 26.93) 
NPV = 91.87% (95% CI: 85.68, 95.52) NPV = 92/97 = 94.85%, 95% CI (88.5, 97.78) 
DOR (for T
+
 calculated) = 5.65 (95% CI: 2.27, 
14.05) 
DOR (for T
+
 calculated) = 3.38, 95% CI (1.07, 
10.64) 
OR (crude; for T
+ 
reported) = 1.61, 95% CI 
(NR; p = 0.44) 
OR (crude; for T
+ 
reported) = 3.38, 95% CI (NR; p 
= 0.04) 
OR (regression-based; reported) = 1.29, 95% CI 
(NR; p = 0.72) 
List of covariates: NR 
OR (regression-based; reported) = 3.50, 95% CI 
(NR; p = 0.05) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.67 (95% CI: 0.79, 3.53) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA  
Other reported measure = NR 
Association between test results and levels of TB exposure (any risk factor for TB ≥ 1) 
IGRA (T-SPOT.TB) TST≥ 5mm 
 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 34 5 39 TST + 42 16 58 
IGRA - 68 48 116 TST - 60 37 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  102 53 155 Total  102 53 155 
Test performance parameters 
IGRA TST 
Sensitivity = 34/102 = 33.33%, 95% CI (24.94, 
42.94) 
Sensitivity = 42/102 = 41.18%, 95% CI (32.12, 
50.88) 
Specificity = 48/53 = 90.57%, 95% (79.75, 
95.9) 
Specificity = 37/53 = 69.81%, 95% CI (56.46, 
80.48) 
PPV = 34/39 = 87.18%, 95% CI (73.29, 94.4) PPV = 42/58 = 72.41%, 95% CI (59.80, 82.25) 
NPV = 48/116 = 41.38%, 95% CI (32.83, 
50.48) 
NPV = 37/97 = 38.14%, 95% CI (29.10, 48.09) 
DOR (for T+ calculated) = 4.80, 95% CI (1.75, 
13.16) 
DOR (for T+ calculated) = 1.61, 95% CI (0.79, 
3.28) 
OR (crude; for T+ reported) = 4.80, 95% CI 
(NR; p = 0.02) 
OR (crude; for T+ reported) = 1.60, 95% CI (NR; p 
= 0.12) 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 2.98 (95% CI: 1.59, 5.60) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and levels of TB exposure (any risk factor for TB ≥ 1) 
IGRA (QFT-GIT) TST≥ 5mm 
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 Exposure level Total  Exposure level Total 
Yes No Yes No 
IGRA + 26 6 32 TST + 42 16 58 
IGRA - 76 47 123 TST - 60 37 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  102 53 155 Total  102 53 155 
Test performance parameters 
IGRA TST 
Sensitivity = 26/102 = 25.49%, 95% (18.03, 
34.73) 
Sensitivity = 42/102 = 41.18%, 95% CI (32.12, 
50.88) 
Specificity = 47/53 = 88.68%, 95% CI (77.42, 
94.71) 
Specificity = 37/53 = 69.81%, 95% CI (56.46, 
80.48) 
PPV = 26/32 = 81.25%, 95% CI (64.69, 91.11) PPV = 42/58 = 72.41%, 95% CI (59.80, 82.25) 
NPV = 47/123 = 38.21%, 95% CI (30.10, 
47.03) 
NPV = 37/97 = 38.14%, 95% CI (29.10, 48.09) 
DOR (for T
+
 calculated) = 2.68, 95% CI (1.02, 
6.99) 
DOR (for T
+
 calculated) = 1.61, 95% CI (0.79, 
3.28) 
OR (crude; for T+ reported) = 2.68, 95% CI 
(NR; p = 0.04) 
OR (crude; for T+ reported) = 1.60, 95% CI (NR; p 
= 0.12) 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = 1.66 (95% CI: 0.90, 3.07) 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA  
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (T-SPOT.TB) TST 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 24 15 39 TST + 41 17 58 
IGRA - 79 37 116 TST - 62 35 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  93 52 155 Total  103 52 155 
Test performance parameters 
IGRA (T-SPOT.TB) TST (>5 mm) 
DOR (for T+ calculated)TSPOT = 0.74, 95% CI 
(0.35, 1.59) 
DOR TST (for T+ calculated) = 1.36, 95% CI 
(0.67, 2.74) 
OR (crude; for T+ reported) = 0.75, 95% CI (NR; p 
= 0.45) 
OR (crude; for T+ reported) = 1.36, 95% CI 
(NR; p = 0.39) 
OR (regression-based; reported)TSPOT = 0.51, 95% 
CI (NR; p = 0.17) 
List of covariates: NR 
OR (regression-based; reported) TST = 1.43, 95% 
CI (NR; p = 0.34) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 22 10 32 TST + 41 17 58 
IGRA - 81 42 123 TST - 62 35 97 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total  103 52 155 Total  103 52 155 
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Test performance parameters 
IGRA (QFT-GIT) TST (>5 mm) 
DOR (for T+ calculated)QFT = 1.14, 95% CI (0.49, 
2.63) 
DOR TST (for T+ calculated) = 1.36, 95% CI 
(0.67, 2.74) 
OR (crude; for T+ reported) = 1.14, 95% CI (NR; p 
= 0.76) 
OR (crude; for T+ reported) = 1.36, 95% CI 
(NR; p = 0.39) 
OR (regression-based; reported)QFT = 1.05, 95% CI 
(NR; p = 0.90) 
List of covariates: NR 
OR (regression-based; reported) TST = 1.43, 95% 
CI (NR; p = 0.34) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST +≥5mm TST - Total 
IGRA + (TSPOT) 26 13 39 
IGRA - 32 84 116 
Indeterminate 0 0 0 
Total  58 97 155 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify):  
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.34 (95% CI: 0.17, 0.50) 
% concordance = 110/155 = 71.0% (95% CI: 63.38, 77.54) 
% discordance = 45/155 = 29.03%  (95% CI: 22.46, 36.62) 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST +≥5mm TST - Total 
IGRA + (QFT-GIT) 17 15 32 
IGRA - 41 82 123 
Indeterminate 0 0 0 
Total  58 97 155 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.15 (95% CI: 0.01, 0.29) 
% concordance = 99/155 = 63.87% (95% CI: 56.06, 71.01) 
% discordance = 56/155 = 36.13% (95% CI: 28.99, 43.94) 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
These authors demonstrated that IGRAs appeared to be correlated better with TB risk than TST and 
should be included in LTBI screening of patients who are about to commence anti-TNF therapies. 
Furthermore, they suggested that in view of the high risk of TB in this patient group, a combination of 
one IGRA and TST is probably more appropriate for LTBI  
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Reviewers:  
Steroid use was negatively associated with a positive QFT-GIT assay 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
 
 
 
 
 
 
  
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
532
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
First author surname year of publication: Anibarro 2012117 
Country: Spain 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Outbreak investigation 
Number of centres: One 
Total length of follow up (if applicable): 18 months 
Funding (government/private/manufacturer/other - specify): University of Vigo and SUDOE-FEDER 
(IMMUNONET-SOE1/P1/E014) 
Aim of the study 
To compare the results of an IGRA with those for the TST in patients with early stage renal disease 
(ESRD) after a TB outbreak at a dialysis centre 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised (people undergoing haemodialysis treatment) 
Participants 
Recruitment dates: NR 
Total N of recruited patients: 58 
Inclusion criteria: All patients who attended the dialysis unit while index case was on duty 
Exclusion criteria: Patients who had a previous +ve TST test 
Total N of excluded patients: 6 
Total N of patients tested with both IGRA and TST: 52 
Total N of patients with valid results for both IGRA and TST: 52 
Methods of active TB diagnosis (if applicable): Microscopic examination of sputum and sputum 
culture 
Outcomes (study-based) list: Test results, relationship between TST and erythema, concordance 
between diagnostic tests 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 62 (16.8) 
Women (n [%]): 21 [40.4] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 7 [13.5] 
History of anti-TB treatment (n [%]): NR  
Total incidence of active TB (n [%]): None 
Chest radiography (yes/no):  Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): End stage renal disease (58 [100]) 
Co-morbidity (n [%]): Diabetes mellitus (8 [15.4]) 
Type of during-study treatment (n [%]): Immunosuppressive therapy (8[15.3]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (specify):  
QFT-GIT 
52 18 34 0 52 
TST:  ( ≥5 mm)  52 11 41 0 52 
Test 3 (specify):      
Total N of patients with valid results for both IGRA and TST: 52 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
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Non-exposed   
Exposed 1 
(specify): 
NA 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, 
timing for test 
measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA  QFT-GIT, one ml of whole 
blood, blood collected 
immediately before TST, 
Cellestic Ltd, Carnegie, 
Australia 
0.35 IU/mL 
 
TST (one and two-
step) 
Mantoux method, 0.1ml (2 
TU) of PPD injected 
intradermally to the volar 
surface of the forearm, TST 
results read 72h after testing, 
Statens serum Institute, 
Copenhagen, Denmark 
TST ≥ 5mm, a second 
test was performed five 
days later if the first 
TST-1 was <5 mm 
Study does not 
mention how soon 
after the result will 
be read for the 
second TST 
Association between test results and incidence of active TB (if applicable) 
IGRA TST≥5mm (two-step) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + N/A N/A 11 LTBI 
treated 
TST + N/A N/A 11 LTBI treated 
IGRA - 0 32 32 TST - 0 32 32 
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total 0 32 32 Total 0 32 32 
Test performance parameters 
IGRA TST 
Sensitivity = N/A Sensitivity = N/A 
Specificity = N/A Specificity = N/A  
PPV = N/A PPV = N/A 
NPV = 100%, 95% CI (89.28, 100.00) NPV = 100%, 95% CI (89.28, 100.00) 
Cumulative Incidence IGRA+ = N/A Cumulative Incidence TST+ = N/A 
Cumulative Incidence IGRA- = 0/32 = 0 Cumulative Incidence TST- = 0/32 = 0 
Cumulative Incidence Ratio IGRA = N/A Cumulative Incidence Ratio TST = N/A 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR  
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence = NA 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
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IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T
+ 
reported) = NA OR (crude; for T
+ 
reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 3 15 18 
IGRA - 0 34 34 
Indeterminate 0 0 0 
Total  3 49 52 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (One-step TST) 
TST + threshold: ≥ 5mm induration 
Parameters 
Kappa = 0.21, 95% CI: 0.04, 0.37 
% concordance = 37/52 = 71.15% (95% CI: 57.73, 81.67) 
% discordance = 15/52 = 28.85% (95% CI: 18.33, 42.27) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + 9 9 18 
IGRA - 2 32 34 
Indeterminate 0 0 0 
Total  11 41 52 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (Two-step test) 
TST + threshold: ≥ 5mm induration 
Parameters 
Kappa = 0.49, 95% CI: 0.22, 0.74) 
% concordance = 41/52 = 78.85% (95% CI: 65.97, 87.76)  
% discordance = 11/52 = 21.15%  (95% CI: 12.24, 34.03) 
Stratification (specify group 2) 
 TST + TST - Total 
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IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
This study demonstrated that QFT-GIT had a better sensitivity than TST in detecting latent TB in 
haemodialysis patients, after exposure to Mycobacterium tuberculosis.  TST administered a second 
time can be performed to increase the sensitivity 
Reviewers: 
Authors have not presented results stratified by the level of exposure to TB.  
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Chang 2011119 
Country: South Korea 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Hospital-based 
Number of centres: One 
Total length of follow up (if applicable): 18 mo (median) 
Funding (government/private/manufacturer/other - specify): IN-SUNG Foundation for Medical 
Research (CA98051) 
Aim of the study 
To evaluate the usefulness of IGRA for the diagnosis of LTBI in arthritis patients who received TNF 
antagonists in South Korea where the incidence of tuberculosis is intermediate (70–90/105 per year) 
and BCG vaccination is mandatory at birth 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) before 
starting TNF antagonist 
Participants 
Recruitment dates: August 2007–July 2009 
Total N of recruited patients: 108 
Inclusion criteria: Inflammatory arthritis including RA and AS who visited our facility to evaluate 
LTBI before starting TNF antagonist 
Exclusion criteria: Active TB 
Total N of excluded patients: 1 
Total N of patients tested with both IGRA and TST: 107 
Total N of patients with valid results for both IGRA and TST: 100 
Methods of active TB diagnosis (if applicable): Medical history (current symptoms, prior history of 
treatment for tuberculosis, and recent history of contact with a case of active TB) and TST (according 
to the recommendation of the Korea Food and Drug Administration) 
Outcomes (study-based) list: Test results, concordance/discordance, incidence of active TB, 
prognostic test accuracy indices (sensitivity, specificity, predictive values, false negative/false positive 
rates)  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 39 (median) 
Women (n [%]): 44 [41] 
Race/ethnicity (n [%]): Asian 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 63 [59] 
History of anti-TB treatment (n [%]): 4 [3.8] 
Total incidence of active TB (n [%]): 1 [0.9%] 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): RA (46 [43]) and AS (61 [57]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment: RA (Glucocorticoid: 31/46, Methotrexate: 39/46),  AS 
(Glucocorticoid: 6/61, Methotrexate: 3/61) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-IT):  107 36 64 7 100 
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TST: 107 36 71 0 107 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 100 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-
IT) 
The QuantiFERON-TB Gold In-
Tube test (QFT-GIT test; 
Cellestis Ltd., Carnegie, Australia) 
performed according to the 
manufacturer instructions 
Positive test result was 
defined as ≥0.35 IU/mL 
Both the TST 
and QFT-IT 
were performed 
on the same day 
as the screening 
examination in 
all patients 
before initiating 
TNF 
antagonists  
TST The TST was performed on the 
volar side of the forearm using the 
Mantoux method with 2 tuberculin 
units (TU) of purified protein 
derivative RT23 (Statens Serum 
Institut; Copenhagen, Denmark). 
This dose is approximately 
equivalent to the international 
standard of 5 TU tuberculin PPD-S  
Induration size was 
measured after 48–72h, and 
we used a 10-mm 
induration as a positive cut-
off value for the TST 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + NA NA 37 LTBI 
treated 
TST + 0 16 16 
IGRA - 0 64 64 TST - 0 54 54 
Indeterminate 0 6 6 Indeterminate 0 0  
Total 0 70 70 Total 0 70 70 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = 70/70 = 100% (95% CI: 94.8, 100) Specificity = 54/70 = 77.14 (95% CI: 66.05, 
85.41) 
PPV = NA PPV = 0/16 = 0 
NPV = 64/64 = 100% (95% CI: 94.8, 100) NPV = 54/54 = 100% (95% CI: 93.4, 100)  
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = 0/16 = 0  
Cumulative Incidence IGRA- = 0/64 = 0 Cumulative Incidence TST- = 0/54 = 0 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR 
Other reported measure IGRA = NR  Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
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Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR 
List of covariates: NR 
OR (regression-based; reported) TST = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 19 17 36 
IGRA - 16 48 64 
Indeterminate 1 6 7 
Total  36 71 107 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: > 10mm 
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Parameters 
Kappa = 0.26, 95% CI: 0.07, 0.45 
% concordance = 67/100 = 67.0%, 95% CI: 57.31, 75.44 
% discordance = 33/100 = 33.0%, 95% CI: 24.56, 42.69 
Rheumatoid arthritis (RA) 
 TST + TST - Total 
IGRA + 8 9 17 
IGRA - 1 24 25 
Indeterminate NR NR NR 
Total  9 33 42 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): RA 
TST + threshold: > 10mm 
Parameters 
Kappa = 0.46, 95% CI: 0.21, 0.72 
% concordance = 32/42 = 76.20%, 95% CI: 61.47, 86.52 
% discordance = 10/42 = 23.80%, 95% CI: 13.48, 38.53 
Ankylosing spondylitis (AS) 
 TST + TST - Total 
IGRA + 11 8 19 
IGRA - 15 24 39 
Indeterminate NR NR NR 
Total  26 32 58 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Ankylosing spondylitis 
TST + threshold: > 10mm 
Parameters 
Kappa = 0.14, 95% CI: -0.10, 0.39 
% concordance = 35/58 = 60.34%, 95% CI: 47.49, 71.91 
% discordance = 23/58 = 39.66%, 95% CI: 28.09, 52.51 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
IGRA performed better in terms of specificity than TST, but several observations of IGRA  were 
indeterminate; in general, the agreement between IGRA and TST was low; better agreement was 
observed for rheumatoid arthritis and ankylosing spondylitis 
Reviewers:  
See above 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Elzi 2011114 
Country: Switzerland 
Study design: Retrospective case only study (no control group) 
Study setting (e.g., outbreak investigation, community-based - specify): Community-based cohort   
Number of centres: One  
Total length of follow up (if applicable): 2 years 
Funding (government/private/manufacturer/other - specify): Grants/honoraria received from private 
manufacturers (Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Roche. M. 
Hoffmann, Janssen, Pfizer) 
Aim of the study 
To evaluate the sensitivity of T-SPOT.TB in comparison to TST to identify HIV-infected individuals 
with latent TB, who therefore qualify for preventive treatment 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (HIV) 
Participants 
Recruitment dates: 1993 to 2005 
Total N of recruited patients: 64 
Inclusion criteria: NR 
Exclusion criteria: NR 
Total N of excluded patients: None 
Total N of patients tested with both IGRA and TST: 64 
Total N of patients with valid results for both IGRA and TST: 44 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Sensitivity, agreement, influence of age, CD count and other covariates 
on test positivity 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median of 33 (IQR: 31-42) yrs 
Women (n [%]): 20/64 [31] 
Race/ethnicity (n [%]): White 29/64 [45.3] 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): NR 
Morbidity (n [%]): HIV 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test 
results 
available) 
IGRA (T-
SPOT.TB):    
64 25 18 21 43 
TST: Mantoux 44 22 22 0 44 
Test 3 (specify):      
Total N of patients with valid results for both IGRA and TST: 44 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
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Non-exposed   
Exposed 1 
(specify): 
NA 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, timing for test 
measurement, manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
informati
on 
IGRA (T-
SPOT.TB) 
T-SPOT.TB was retrospectively performed 
using frozen viable lymphocytes of HIV-
infected individuals stored within 6 months 
before culture-confirmed 
TB occurred 
 
T-SPOT.TB was performed by using a 
commercial kit according to the 
manufacturer’s instructions. Each patient 
test required 4 wells: 2 for the negative 
(containing no antigen control) and positive 
controls and 2for the MTB antigens, Panel 
A (ESAT-6) and B (CFP-10) 
 
Evaluating the number of spots obtained 
provided a measurement of the frequency 
of MTB tuberculosis sensitive cells 
The test result was 
considered “positive” if the 
number of spots per test well 
was ≥ 6 in either of both 
Panel A and B. The test 
result was considered 
“negative” if both Panel A 
and B showed < 6 spots. 
Where the positive control 
was < 20 spots, or the 
negative control 
≥ 10 spots, the test was 
scored as “indeterminate” 
NR 
TST NR ≥ 5mm for positivity NR 
Association between test results and incidence of active TB (if applicable) 
IGRA (T-SPOT.TB) TST (≥ 5mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 25 NA  TST + 22 NA  
IGRA - 18 NA  TST - 22 NA  
Indeterminate 21 NA  Indetermi
nate 
0 NA  
Total 64 NA  Total 44 NA  
Test performance parameters 
IGRA TST (≥ 5mm) 
indeterminate excluded  
Sensitivity = 25/43 = 58.14% (95% CI: 43.33, 71.62)  
indeterminate included  
Sensitivity = 25/64 = 39.06% (95% CI: 28.06, 51.31) 
Sensitivity = 22/44 = 50.00% (95% CI: 
35.83, 64.17) 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA  
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA  Cumulative Incidence TST- = NA  
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR  
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Incidence density rate IGRA- = NR  Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NA 
Other reported measure IGRA = NR Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and incidence of active TB (if applicable) 
TST (≥ 5mm) and IGRA combined (at least one test positive) 
 Incidence of active TB Total 
Yes No 
TST or 
IGRA + 
29 NA NA 
TST and 
IGRA - 
15 NA NA 
Indetermin
ate 
0 NA NA 
Total 44 NA NA 
 
Test performance parameters (TST and IGRA combined) 
Sensitivity = 29/44 = 65.91% (95% CI: 51.14, 78.12) 
Specificity, PPV, NPV, others = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Tota
l 
 Exposure level Total 
High/Yes Low/No High/Yes Low/N
o 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indetermina
te 
NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Tot
al Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
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IGRA - NR NR NR TST - NR NR NR 
Indeterminat
e 
NR NR NR Indeterm
inate 
NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR 
List of covariates: NR 
OR (regression-based; reported) TST = 
NR  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + (≥ 5mm) TST - Total 
IGRA + 10 7 17 
IGRA - 7 8 15 
Indeterminate 5 7 12 
Total  22 22 44 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥ 5mm 
Parameters 
Indeterminate excluded 
Kappa = 0.12 (95% CI: -0.22, - 0.46) 
% concordance = 18/32 = 56.25% (95% CI: 39.33, 71.83) 
% discordance = 14/32 = 43.75% (95% CI: 28.17, 60.67) 
Indeterminate included 
Kappa = 0.14 (95% CI: -0.15, - 0.42) 
% concordance = 25/44 = 57.00% (95% CI: 42.22, 70.32) 
% discordance = 19/44 = 43.20% (95% CI: 29.68, 57.78) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
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TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life 
mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
T-SPOT.TB has a similar sensitivity to TST to detect latent TB in HIV infected individuals. There 
was poor agreement between T-SPOT.TB and TST results. The combination of TST and TSPOT. 
TB (at least one test positive) resulted in improved sensitivity over TST or IGRA alone 
Reviewers: 
This is a retrospective case only study which does not allow to estimate incidence of active TB 
between test positive vs. negative groups from baseline (no denominators provided). Likewise, no 
specificity and predictive values could be estimated; the sample (64 out of 242) may have been highly 
selected, thus prone to selection bias and limitation in regards to applicability of its results; moreover, 
for IGRA frozen blood samples were analysed 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Kim 2011116 
Country: Korea 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based  - specify): Tertiary-care hospital 
Number of centres: One 
Total length of follow up (if applicable): median 14 mo (IQR: 8-19) 
Funding (government/private/manufacturer/other - specify): Basic Science Research Program 
through National Research Foundation (NRF) funded by the Ministry of Education, Science and 
Technology (MEST) (grant 2008-E00136 
Aim of the study 
To assess whether an enzyme-linked immunosorbent spot (ELISPOT) assay is capable of predicting 
active TB development in kidney transplant (KT) recipients with negative TST results and without 
LTBI risk factors  
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised people (kidney transplant [KT] recipients) 
Participants 
Recruitment dates: June 2008 and December 2009 
Total N of recruited patients: 324 
Inclusion criteria: KT patients (age≥16 yrs) with TST – (<10mm) and without TB risk factors 
(history of close contact with TB case, abnormal CXR, history of untreated or inadequately treated 
TB, newly infected persons) 
Exclusion criteria: Refusal of informed consent, presence of active TB, presence of skin disease that 
precluded TST, pediatric renal transplant candidates (<16 years old), TB risk factors, and presence of 
any contraindication for KT (e.g. malignancy) 
Total N of excluded patients: 28 (n = 12 refusal, pediatric, pancreas transplants, transplantation not 
done, donor kidney problem; n = 16 LTBI risk factors who received anti-TB preventive therapy) 
Total N of patients tested with both IGRA and TST: 272 (out of 296, 24 with TST + [≥10mm] 
received anti-TB preventive therapy before KT, leaving 272 KT patients with TST-[<10mm] also 
tested with IGRA who did not receive anti-TB preventive therapy) 
Total N of patients with valid results for both IGRA and TST: 242 (out of 272 patients, 30 had 
indeterminate IGRA results) 
Methods of active TB diagnosis (if applicable): Symptoms/signs, sputum AFB smear, and a CT 
scan 
Outcomes (study-based) list: Development of TB, mortality, KT rejection 
Characteristics of participants (total study sample): 272 patients 
Mean (range or SD) age (years): Mean age range (40.4-46.0 yrs) 
Women (n [%]): 126 (46.3) 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 215 [79.0] 
History of anti-TB treatment (n [%]): None 
Total incidence of active TB (n [%]): 4/272 [1.47] (incidence rate: 0.83 per person-years, 95% CI: 
0.23, 2.12) 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes  
Morbidity (n [%]): Glomerulonephritis 72 [26.5], hypertension 65 [23.9], diabetes mellitus 48 [17.6], 
unknown 58 [21.3], polycystic kidney 12 [4.4], other 11 [4.0] 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): anti-IL-2 receptor antibodies (238 [87.5]), antithymocyte 
antibodies (21 [7.7]), rituximab (11 [4.0]) 
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Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test 
results 
available) 
IGRA (T-
SPOT.TB):   
272 71 171 30 242 
TST 
(Mantoux): 
272 0 
(≥10mm) 
272 
(<10mm) 
0 272 
Test 3 (specify): Nr NR NR NR NR 
Total N of patients with valid results for both IGRA and TST: 242 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 
(specify): 
NA 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA (T-
SPOT.TB) 
A peripheral venous blood sample 
was collected from each patient for 
an ELISPOT assay for the IFN-c -
producing T-cell response (i.e. T-
SPOT.TB, Oxford Immunotec, 
Abingdon, UK) 
 
All blood samples were collected 
prior to TST to avoid a possible 
boosting effect of TST on the 
ELISPOT assay 
NR The development 
of TB after KT 
was observed by 
attending 
surgeons, 
nephrologists and 
infectious 
diseases 
specialists blind 
to the results of 
ELISPOT assays, 
to avoid a 
verification bias 
TST 
(Mantoux) 
The TST was performed by the 
Mantoux technique, injecting a 2-
TU (tuberculin unit) dose of 
purified protein derivative RT23 
(Statens Serum Institut, 
Copenhagen, Denmark) 
intradermally into the forearm 
 
The positive criterion 
for TST was 10 mm or 
greater size of induration 
48–72 h after injection, 
and in accordance with 
Korea Centers for 
Diseases Control and 
Prevention guidelines  
NR 
Association between test results and incidence of active TB (if applicable) 
IGRA TST (≥10mm) 
 Incidence of 
active TB 
Total  Incidence 
of active 
TB 
Total 
Yes No Yes No 
IGRA + 4 67 71 TST + NA NA NA 
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IGRA - 0 171 171 TST - 4 268 272 
Indeterminate 0 30 30 Indeterminate 0 0 0 
Total 4 268 272 Total 4 NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = 4/4 = 100.00% (95% CI: 51.01, 
100.00) 
Sensitivity = NA 
Indeterminate excluded 
Specificity = 171/238 = 71.84% (95% CI: 65.82, 
77.18) 
Indeterminate included 
Specificity = 201/268 = 75.00% (95% CI: 69.49, 
79.81) 
Specificity = NA 
PPV = 4/71 = 5.63% (95% CI: 2.21, 13.61) PPV = NA 
Indeterminate excluded 
NPV = 171/171 = 100.00% (95% CI: 97.80, 
100.00 ) 
Indeterminate included 
NPV = 201/201 = 100.00% (95% CI: 98.12, 
100.00) 
NPV = 268/272 = 98.53% (95% CI: 96.28, 
99.43) 
Cumulative Incidence IGRA+ = 4/71 = 5.63% (95% 
CI: 2.21, 13.61) 
Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = 0/171 = X  Cumulative Incidence TST- = 4/272 = 1.47% 
(95% CI: 0.43, 3.85) 
Cumulative Incidence Ratio IGRA = X  Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = 4/122.10 p-yrs = 
0.0328 p-yrs = 3.28/100 p-yrs (95% CI: 0.89, 8.39) 
Incidence density rate TST+ = NA 
Indeterminate excluded 
Incidence density rate IGRA- = 0/307.83 p-yrs = 
0.00/100 p-yrs 
Indeterminate included 
Incidence density rate IGRA- = 0/361.16 p-yrs = 
0.00/100 p-yrs 
Incidence density rate TST- = 4/483.25 p-yrs = 
0.0083 p-yrs = 0.83/100 p-yrs (95% CI: 0.23, 
2.12) 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA 
Other reported measure IGRA =   
Indeterminate excluded 
Incidence density rate difference IGRA = 3.3/100 p-
yrs (95% CI: 1.3, 5.3) 
Indeterminate included 
Incidence density rate difference IGRA = 3.3/100 p-
yrs (95% CI: 1.4, 5.1) 
Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
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Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR NPV = NR 
DOR (for T
+
 calculated) = NR DOR (for T
+
 calculated) = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NR 
Ratio of OR (crude; for T+ reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure =  
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
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Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Positive ELISPOT results predict subsequent development of TB in KT recipients in whom LTBI 
cannot be detected by TST or who lack clinical risk factors for LTBI 
Reviewers: 
The available data did not allow the proper direct comparison between IGAA and TST (no relevant 
data for TST positives); however, IGRA correctly identified the incidence of 4 TB cases as opposed 
to TST which was negative in all 4 TB cases 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Peter Auguste 
Name of second reviewer: Tara Gurung 
 
Study details 
First author surname year of publication: Lee 2009118 
Country: Taiwan 
Study design: Prospective, matched, double cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): NR   
Number of centres: One 
Total length of follow up (if applicable): 2 yrs follow-up 
Funding (government/private/manufacturer/other - specify): National health research institutes, 
Department of Health, Executive Yuan, republic of China (NHRI-CN-CL-094-PP13) and Kaohsiung 
Veterans General Hospital, Kaohsuing, Taiwan (VGHKS95-012) 
Aim of the study 
To compare QFT-G, T-SPOT.TB, and TST in terms of their ability to diagnose LTBI in end stage 
renal disease(ESRD) patients, and to determine the prevalence of LTBI in ESRD patients compared 
with healthy controls, the risk factors for QFT-G and TST positivity, and the predictive value of a 
positive QFT-G, ELISPOT, or TST for active TB disease over a two-year period 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised (ESRD) 
Participants 
Recruitment dates: September 2005 
Total N of recruited patients: 64 patients 
Inclusion criteria: Patients with ESRD 
Exclusion criteria: NR 
Total N of excluded patients: None 
Total N of patients tested with both IGRA and TST: 32 
Total N of patients with valid results for both IGRA and TST: 32 
Methods of active TB diagnosis (if applicable): Asymptomatic cases are diagnosed with a chest x-
ray, and symptomatic cases are diagnosed with a sputum TB smear, culture and chest radiography 
Outcomes (study-based) list: Primary outcome was LTBI and secondary outcomes was development 
of active TB, concordance between tests, risk factors for a positive result  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 53.8 (34.4-77.7) 
Women (n [%]): 24 [37.5] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Kaohsiung 
BCG vaccination (n [%]): 53 [82.8] 
History of anti-TB treatment (n [%]): NR   
Total incidence of active TB (n [%]): NR   
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): End stage renal dialysis 
Co-morbidity (n [%]): Diabetes mellitus (7 [10.9]) 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-G):   32 12 18 2 30 
IGRA (ELISPOT):  32 15 17 0 32 
TST (≥ 10mm): 32 20 12 0 32 
Total N of patients with valid results for both IGRA and TST:  
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Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
Exposed 1 (specify): NR 
Exposed 2 (specify): NR 
Exposed 3 (specify): NR 
Exposed 4 (specify): NR 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-
GIT) 
Whole blood was drawn prior to 
carrying out the TST. The QFT-G 
was performed according to the 
respective manufacturer’s 
instructions 
A QFT-G analysis 
software, available for 
download from the 
Cellestis Ltd website, 
was used for quality 
control assessment and 
to calculate the test 
results  
NA 
TSPOT Whole blood was drawn prior to 
carrying out the TST. The 
T-SPOT.TB was performed 
according to the respective 
manufacturer’s instructions  
NR NA 
TST (two step; ≥ 
10mm) 
A two-step TST using the Mantoux 
method with two tuberculin units of 
tuberculin RT-23 (PPD RT 23 SSI; 
Statens Serum Institut, Copenhagen, 
Denmark) was performed according 
to standard protocol. The reactions 
were read after 48–72 h. Second 
TST test was performed 1-3 weeks 
later for initial negative TST result 
≥ 10mm induration for 
ESRD patients and 
BCG-unvaccinated 
individuals, 
≥ 15mm induration for 
BCG-vaccinated, 
healthy individuals 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-G) TST (two-step; ≥10mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 1 11 12 TST + 1 19 20 
IGRA - 0 18 18 TST - 1 11 12  
Indeterminate 1 1 2 
(excluded) 
Indeterminate    
Total 2 30 32 Total 2 30 32 
Test performance parameters 
IGRA (exclude indeterminate) TST  
Sensitivity = 1/1 = 100.00%, 95% CI: 20.65, 
100.00 
Sensitivity = 1/2 = 50.00% (95% CI: 9.45, 
90.55) 
Specificity = 18/30 = 60.00%, 95% CI: 44.00, 
77.31 
Specificity = 11/30 = 36.67%, 95% CI: 21.87, 
54.49 
PPV = 1/12 = 8.33%, 95% CI: 1.49, 35.39 PPV = 1/20 = 5.00%, 95% CI: 0.89, 23.61 
NPV = 18/18 = 100.00%, 95% CI: 82.41, 100.00 NPV = 11/11 = 100.00%, 95% CI:74.12, 100.00 
Cumulative Incidence IGRA+ = 1/12 = 8.33%, 95% 
CI (1.49, 35.39) 
Cumulative Incidence TST+ = 1/20 = 5.00%, 95% 
CI (0.89, 23.61) 
Cumulative Incidence IGRA- = 0/18 = 5.56% (95% Cumulative Incidence TST- = 0/11 = 9.09% (95% 
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CI: 5.40, 27.29) CI: 0.23, 41.3) 
Cumulative Incidence Ratio IGRA = 1.55% (95% CI: 
0.02, 124.2) 
Cumulative Incidence Ratio TST = 0.55% (95% 
CI: 0.01, 47.06) 
Incidence density rate IGRA+ = 3.40 per 100 PYS Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NR  Incidence density rate ratio TST = NR  
Other reported measure IGRA = NR  Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence = 2.82% (95% CI: 0.13, 62.64) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and incidence of active TB (if applicable) 
IGRA (TSPOT) TST (two-step; ≥10mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 0 15 15 TST + 1 19 20 
IGRA - 2 15 17 TST - 1 11 12  
Indeterminate 0 0 0 Indeterminate 0 0 0 
Total 2 30 32 Total 2 30 32 
Test performance parameters 
IGRA  TST  
Sensitivity = 0/2 = 0.00% (95% CI: 0.00, 65.76) Sensitivity = 1/2 = 50.00% (95% CI: 9.45, 
90.55) 
Specificity = 15/30 = 50.00% (95% CI: 33.15, 
66.85) 
Specificity = 11/30 = 36.67%, 95% CI: 21.87, 
54.49 
PPV = 0/15 = 0.00% (95% CI: 0.00, 20.39) PPV = 1/20 = 5.00%, 95% CI: 0.89, 23.61 
NPV = 15/17 = 88.24% (95% CI: 65.66, 96.71) NPV = 11/11 = 100.00%, 95% CI:74.12, 100.00 
Cumulative Incidence IGRA+ = 0/15 = 6.67% (95% 
CI: 0.17, 31.9) 
Cumulative Incidence TST+ = 1/20 = 5.00%, 95% 
CI (0.89, 23.61) 
Cumulative Incidence IGRA- = 2/17 = 11.76% (95% 
CI: 2.03, 35.59) 
Cumulative Incidence TST- = 0/11 = 9.09% (95% 
CI: 0.23, 41.3) 
Cumulative Incidence Ratio IGRA = 0.57% (95% CI: 
0.01, 12.1) 
Cumulative Incidence Ratio TST = 0.55% (95% 
CI: 0.01, 47.06) 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NR  Incidence density rate ratio TST = NR  
Other reported measure IGRA = NR  Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence = 1.04% (95% CI: 0.06, 17.34) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
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Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA (QFT-G) + NR NR 12 
IGRA (QFT-G)  - NR NR 18 
Indeterminate NR NR 2 
Total  20 12 32 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥ 10mm induration for ESRD patients and BCG-unvaccinated patients 
Parameters 
Kappa = 0.25, 95% CI (-0.06,- 0.56) 
% concordance = 60.0% 
% discordance = NR (40.0%) 
Stratification (ESRD on hemodialysis) 
 TST + TST - Total 
IGRA (ELISPOT) + NR NR 15 
IGRA  (ELISPOT)- NR NR 17 
Indeterminate NR NR 0 
Total  20 12 32 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): ESRD on hemodialysis 
TST + threshold: ≥ 10mm induration for ESRD patients and BCG-unvaccinated patients 
Parameters 
Kappa = 0.32 95% CI (-0.01, -0.65) 
% concordance = 65.6% 
% discordance = NR (34.4%) 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
Indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
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% discordance = NA 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
This pilot study compared test results of TST, QFT-G, and ELISPOT and showed that there was 
moderate agreement between QFT-G and ELISPOT, but fair agreement between TST and either QFT-
G or ELISPOT 
Reviewers: 
 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Lee 2014149 
Country: South Korea 
Study design: Prospective longitudinal study 
Study setting (e.g., outbreak investigation, community-based - specify): tertiary hospital-based 
Number of centres: One 
Total length of follow up (if applicable): 391 patients followed up for 581.7 person –years; median 
duration 1.3 years (IQR 0.6-2.3) 
Funding (government/private/manufacturer/other - specify): supported by grant from the National 
Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning  
Aim of the study 
To test the hypothesis that hematopoietic stem cell transplant (HCT) recipients who are QFT-TB 
positive develop active TB more frequently than QFT-TB negative or indeterminate patients; to 
evaluate whether the QFT-TB assay can predict active TB development in HCT recipients without 
any clinical risk factors for LTBI 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Hematopoietic stem cell transplant (HCT) recipients 
Participants 
Recruitment dates: January 2010 and December 2012. Resulting cohort observed until June 2013. 
Total N of recruited patients: 409 
Inclusion criteria: adult patients admitted for allogeneic HCT  
Exclusion criteria: patients with history of close contact with active TB, history of untreated or 
inadequate treated TB, and the radiograph evidence of old TB. Patients who refused informed 
consent, presence of active TB, presence of skin disease that precluded the TST (between January 
2010 and December 2011), and pediatric HCT candidates (<16 years old) 
Total N of excluded patients: 18  
Total N of patients tested with both IGRA and TST: 169  
Total N of patients with valid results for both IGRA and TST: 159 
Methods of active TB diagnosis (if applicable): chest x-ray, a sputum AFB smear and CT scan 
(pulmonary TB) 
Outcomes (study-based) list: development of active TB 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 42.3 [13.8] 
Women (n [%]): 183 [46.8%] 
Race/ethnicity (n [%]): Korean 409 [100%] 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): History of scars (353 [90.7%]) 
History of anti-TB treatment (n [%]): None 
Total incidence of active TB (n [%]): 8/391 [2.04%] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): HCT 
Co-morbidity (n [%]): Acute or chronic graft-versus-host disease (151 [38.6%]); diabetes mellitus (32 
[8.2%]); liver cirrhosis (4[1.0%]); Solid organ transplant (2[0.5%]); HIV (0) 
Type of during-study treatment (n [%]): isoniazid prophylaxis to 5/409 [1.22%] patients with clinical 
risk factors for LBTI (who were excluded from the analyses) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
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IGRA (QFT-GIT)  
1st year enrollment cohort:   
391 45 315 31 360 
IGRA (QFT-GIT):   
2nd year enrollment cohort:   
169 26 133 10 159 
TST (>5mm):  
2nd year enrollment cohort:   
169 19 150 0 169 
TST (>10mm):  
2nd year enrollment cohort:   
169 12 157 0 169 
Total N of patients with valid results for both IGRA and TST: 159 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA (QFT-
GIT) 
A peripheral venous blood sample was 
collected from each patient for the 
QFT-TB assay (Cellestis, Carnegie, 
Victoria, 
Australia), and placed directly into 
three 1 mL tubes containing, 
respectively, Mycobacterium 
tuberculosis early secreted antigenic 
target of 6 kDa (ESAT)-6, culture 
filtrate protein (CFP)-10 and TB 7.7, 
phytohemagglutinin (a mitogen used as 
a positive control), and (3) saline (Nil 
used as a negative control). The 
samples were incubated at 37◦C for 16-
18 h, then processed and tested for 
quantitative interferon-g levels 
(IU/mL). The assay was interpreted 
according to the manufacturer’s 
instructions. All blood samples were 
collected prior to the TST to avoid a 
possible boosting effect of the TST on 
the QFT-TB assay 
NR 
 
TST≥5mm 
≥10mm 
The TST was performed by the 
Mantoux technique, injecting a 2-TU 
dose of purified protein derivative 
RT23 (Statens Serum Institut, 
Copenhagen, Denmark) intradermally 
into the forearm 
The positive 
criterion for the 
TST was a 5mm or 
greater in duration 
48-72h after 
injection 
The results of TSTs 
were measured by 
the trained nurse 
Association between test results and incidence of active TB (if applicable) 
IGRA [QFT-GIT] TST (≥5mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 3 23 26 TST + 0 19 19 
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IGRA - 2 131 133 TST - 5 145 150 
indeterminate 0 10 10 indeterminate 0 0 0 
Total 5 154 159 Total 5 164 169 
Test performance parameters 
IGRA (QFT-GIT) TST≥5mm 
Sensitivity = 3/5= 60.00% (95% CI: 23.07, 88.24) Sensitivity = 0/5=0.0% (95% CI: 0.0, 43.45) 
Specificity =131/154= 85.06% (95% CI: 78.59, 
89.84) 
Specificity = 145/164=88.41% (95% CI: 82.61, 
92.46) 
PPV= 3/26=11.54% (95% CI: 4.00, 28.98) PPV= 0/19=0.0% (95% CI: 0.0, 16.82) 
NPV= 131/133=98.5% (95% CI: 94.68, 99.59) NPV=145/150=96.67% (95% CI: 92.43, 98.57) 
Cumulative Incidence IGRA+ = 3/26=11.54% (95% 
CI: 3.17, 29.80) 
Cumulative Incidence TST+ = 0/19=2.63% (95% 
CI: 0.0, 23.22) 
Cumulative Incidence IGRA- = 2/133=1.50% (95% 
CI: 0.07, 5.66)  
Cumulative Incidence TST- = 5/150=3.33% (95% 
CI: 1.22, 7.77) 
Cumulative Incidence Ratio IGRA = 7.67 (95% CI: 
1.34, 43.67) 
Cumulative Incidence Ratio TST =  0.79 (95% 
CI: 0.04, 13.89) 
Incidence density rate IGRA+ = 5.43 per 100 p-y 
(95% CI: 1.12, 15.88)  
Incidence density rate TST+= 0 per 100 p-y (95% 
CI: 0.00, 8.41) 
Incidence density rate IGRA- = 0.80 per 100 p-y 
(95% CI: 0.10, 2.88) 
Incidence density rate TST- = 1.79 per 100 p-y 
(95% CI: 0.58, 4.18)  
Incidence density rate ratio IGRA = 6.78 per 100 p-y 
(95% CI: NR) 
Incidence density rate ratio TST=0.00 per 100 p-y 
(95% CI: NR) 
Other reported measure IGRA = incidence density 
rate difference: 4.7 per 100 person-years (95% CI: 
1.10, 8.30) 
Other reported measure TST = incidence density 
rate difference: -1.79 per 100 person-years (95% 
CI: NR) 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = 9.71 (95% CI: 1.71, 55.15) 
Ratio of incidence density rate ratios= NA 
Other reported measure= NR 
Association between test results and incidence of active TB (if applicable) 
IGRA [QFT-GIT] TST (≥10mm) 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 3 23 26 TST + 0 12 12 
IGRA - 2 131 133 TST - 5 152 157 
indeterminate 0 10 10 indeterminate 0 0 0 
Total 5 154 159 Total 5 164 169 
Test performance parameters 
IGRA TST 
Sensitivity = 3/5= 60.00% (95% CI: 23.07, 88.24) Sensitivity = 0/5=0.0% (95% CI: 0.0, 43.45) 
Specificity =131/154= 85.06% (95% CI: 78.59, 
89.84) 
Specificity = 152/164= 92.68% (95% CI: 87.65, 
95.77) 
PPV= 3/26=11.54% (95% CI: 4.00, 28.98) PPV= 0/12= 0.0% (95% CI: 0.0, 24.25) 
NPV= 131/133=98.5% (95% CI: 94.68, 99.59) NPV=152/157=96.82% (95% CI: 92.76, 98.63) 
Cumulative Incidence IGRA+ = 3/26=11.54% (95% 
CI: 3.17, 29.80) 
Cumulative Incidence TST+ = 0/12=4.16% (95% 
CI: 0.0, 33.00)  
Cumulative Incidence IGRA- = 2/133=1.50% (95% 
CI: 0.07, 5.66)  
Cumulative Incidence TST- = 5/157=3.18% (95% 
CI: 1.16, 7.43) 
Cumulative Incidence Ratio IGRA = 7.67 (95% CI: 
1.34, 43.67) 
Cumulative Incidence Ratio TST = 1.31 (95% CI: 
0.07, 22.55) 
Incidence density rate IGRA+ = 5.43 per 100 p-y 
(95% CI: 1.12, 15.88)  
Incidence density rate TST+= 0.0% (95% CI: 0.0, 
14.93) 
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Incidence density rate IGRA- = 0.80 per 100 p-y 
(95% CI: 0.10, 2.88) 
Incidence density rate TST- =  NR 
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST= NA 
Other reported measure IGRA = incidence density 
rate difference: 4.7 per 100 person-years (95% CI: 
1.10, 8.30) 
Other reported measure TST == incidence density 
rate difference: -3.18 per 100 person-years (95% 
CI: NR) 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = 5.85 (95% CI: 1.05, 32.70) 
Ratio of incidence density rate ratios= NA 
Other reported measure=NR  
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
NPV= NA NPV= NA 
DOR (for T+ calculated)= NA DOR (for T+ calculated)= NA 
OR (crude; for T+ reported)= NA OR (crude; for T+ reported)= NA 
OR (regression-based; reported)= NA  
List of covariates: NA 
OR (regression-based; reported)= NA  
List of covariates: NA 
Other reported measure = NA Other reported measure = NA  
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated)= NA 
Ratio of OR (crude; for T
+ 
reported)= NA 
Ratio of ORs (regression-based; reported) = NA  
Other reported measure= NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) =  NA 
OR (regression-based; reported) IGRA = NA  
List of covariates: NA 
OR (regression-based; reported) TST = NA  
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA  
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST +≥5mm TST - Total 
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IGRA + 6 20 26 
IGRA - 12 121 133 
indeterminate 1 9 10 
Total  18 141 159 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥5mm 
Parameters 
Kappa = 0.16 (95% CI: 0.01, 0.31) 
% concordance = 127/159 = 79.87% (95% CI: 72.97, 85.37) 
% discordance = 32/159 = 20.13% (95% CI: 14.63, 27.03) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA 
% discordance = NA 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
Positive QFT predicts the incidence of active TB, whereas positive TST does not 
Reviewers: 
QFT performed better than TST at 5 or 10mm in predicting LTBI; sensitivity of QFT was better than 
that for TST at both thresholds; between test agreement was poor 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Name of first reviewer: Tara Gurung 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Moon 2013115 
Country:  Korea 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Asan Medical Center 
Number of centres: One 
Total length of follow up (if applicable): Median 0.8 years (IQR: 0.1–2.6) 
Funding (government/private/manufacturer/other - specify): Basic science research program through 
the National Research Foundation (NRF) funded by the Ministry of Education, Science and 
Technology (MEST) (grant 2010-0005898 
Aim of the study 
To compare the QFT-GIT with the TST in HCT candidates for detecting LTBI   
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Hematopoietic stem cell transplant (HCT) candidates 
Participants 
Recruitment dates: Between April 2009 and July 2011 
Total N of recruited patients: NR  
Inclusion criteria: All adult patients admitted for HCT 
Exclusion criteria: NR 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 244 
Total N of patients with valid results for both IGRA and TST: 210 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Test results, concordance between the TST and QFT-GIT results, 
development of tuberculosis 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 47 (35-55) 
Women (n [%]): 107 [44] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 201 [82] 
History of anti-TB treatment (n [%]): 10 [4] 
Total incidence of active TB (n [%]):  2 [0.80] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes  
Morbidity (n [%]): Acute myelogenous leukemia (72 [30]), acute lymphoblastic leukemia (28 [11]), 
chronic myelogenous leukemia (4 [2]), aplastic anemia (17 [7]), myelodysplastic syndrome (19 [8]), 
non-hodgkin’s lymphoma (58 [24]), hodgkin’s lymphoma (3 [1]), multiple myeloma (38 [16]), 
plasmacytoma (2 [1]), others (3 [1]) 
Co-morbidity (n [%]): Diabetes mellitus (25 [10]), hypertension (38 [16]), chronic kidney disease (21 
[9]), ESRD with dialysis (1 [0.4]), hepatitis (16 [7]), HIV infection (0 [0.0]), non-hematologic 
malignancy (9 [4]) 
Type of during-study treatment (n [%]): Cyclosporine (71 [29]), cyclosporine-MTX (65 [27]), 
cyclosporine-corticosteroid (8 [3]), corticosteroid therapy (111 [46]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (specify):  QFT- 244 40 170 34 210 
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GIT 
TST: ≥5mm 244 39 205 0 244 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 210 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA 
(QFT-GIT) 
QFT-GIT (Cellestis Limited, 
carnegie, Australia 
We used the criteria for 
positive, negative, and 
indeterminate outcomes 
recommended by the 
manufacturer 
 
Blood samples were 
collected before 
performing the TST to 
avoid a possible 
boosting effect of the 
TST on theQFT-GIT 
test. The lab technicians 
did not know the results 
of TST 
TST (≥ 
5mm) 
The TST was carried out using 
the Mantoux technique, injecting 
a 2-TU dose of purified protein 
derivative RT23 (Statens Serum 
Institut, Copenhagen, Denmark) 
intradermally into the forearm 
≥ 5mm induration 48-
72h after injection 
NR 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-GIT) TST≥5mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 1 39 40 TST + 0 39 39 
IGRA - 1 169 170 TST - 2 203 205 
Indeterminate 0 34 34 
(excluded) 
Indeterminate 0 0 0 
Total 2 208 210 Total 2 242 244 
Test performance parameters 
IGRA TST 
Sensitivity = 1/2 = 50.00%, 95% CI (9.45, 90.55) Sensitivity = 0/2 = 0.00%, 95% CI (0.00, 65.76) 
Specificity = 169/208 = 81.25%, 95% CI (75.4, 
85.97) 
Specificity = 203/242 = 83.88% (95% CI: 78.73, 
87.98) 
PPV = 1/40 = 2.50%, 95% CI (0.44, 12.88) PPV = 0/39 = 0.00% (95% CI: 0.0, 8.96) 
NPV = 169/170 = 99.41%, 95% CI (96.74, 99.9) NPV = 203/205 = 99.02% (95% CI: 96.51, 
99.73) 
Cumulative Incidence IGRA+ = 1/40 = 2.50% (0.44, 
12.88) 
Cumulative Incidence TST+ = 0/39 = 2.56% (95% 
CI: 0.06, 13.5) 
Cumulative Incidence IGRA- = 1/170 = 0.58%, 
95% CI (0.00, 3.59) 
Cumulative Incidence TST- = 2/205 = 0.97% (95% 
CI: 0.03, 3.71) 
Cumulative Incidence Ratio IGRA = 4.25, 95% CI Cumulative Incidence Ratio TST = 2.63% (95% 
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(0.27, 66.49)   CI: 0.04, 51.4) 
Incidence density rate IGRA+ = 2.80 per 100 
person-years, 95% CI (0.07, 15.81) 
Incidence density rate TST+ = 0 per 100 person-
years, 95% CI (0.00, 8.00) 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence = 1.62% (95% CI: 0.16, 16.18) 
Ratio of incidence density rate ratios = 1.62% (95% CI: 0.16, 16.18) 
Other reported measure (risk difference between QFT + and TST +) = 2.80 [95% CI: -2.39, 8.00]; NS 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = NA OR (crude; for T+ reported) = NA  
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA  Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample (≥5 mm induration) 
 TST + TST - Total 
IGRA + 9 31 40 
IGRA - 24 146 170 
Indeterminate 6 28 34 (excluded) 
Total  33 177 210 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (indeterminate 
excluded) 
TST + threshold: ≥ 5mm induration 
Parameters 
Kappa = 0.09, 95% CI (-0.04, - 0.22) indeterminate excluded 
Kappa similar if indeterminate considered as QFT-negative 
% concordance = 155/210 = 73.81%, 95% CI (67.47, 79.29) 
% discordance = 55/210 = 26.19%, 95% CI (20.71, 32.53) 
Stratification (≥10 mm induration) 
 TST + TST - Total 
IGRA + 8 32 40 
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IGRA - 13 157 170 
Indeterminate 4 30 34 (excluded) 
Total  21 189 210 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total (indeterminate 
excluded) 
TST + threshold: ≥ 10mm induration 
Parameters 
Kappa = 0.15, 95% CI (0.02, 0.27) indeterminate excluded  
Kappa similar if indeterminate considered as QFT-negative 
% concordance = 165/210 =  = 78.57%, 95% CI (72.53, 83.58) 
% discordance = 45/210 = 21.43%, 95% CI (16.42, 27.47) 
Stratification (Patients with BCG scars) 
 TST + ≥ 5mm TST - Total 
IGRA + 9 23 32 
IGRA - 22 122 144 
Indeterminate 0 0 0 
Total  31 145 176 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Patients with BCG scars 
TST + threshold: ≥5 mm induration 
Parameters 
Kappa = 0.13, 95% CI (-0.02,  0.27) 
Kappa similar if threshold ≥10 mm 
% concordance = 131/176 = 74.43%, 95% CI (67.51,  80.31) 
% discordance = 45/176 = 25.57%, 95% CI (19.69, 32.49) 
Stratification (Patients without BCG scars or history of BCG vaccination)  
 TST≥ 5mm  + TST - Total 
IGRA + 0 8 8 
IGRA - 2 24 26 
Indeterminate 0 0 0 
Total  2 32 34 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Patients without BCG scars 
or history of BCG vaccination 
TST + threshold: ≥ 5mm induration 
Parameters 
Kappa = -0.10, 95% CI  (-0.35, 0.14) 
Kappa similar if threshold ≥10 mm  
% concordance = 70.59%, 95% CI (53.83, 83.17) 
% discordance = 29.41%, 95% CI (16.83, 46.17) 
Other outcomes 
Test and cut-off (if 
applicable)  
Adverse events n/N (%) 
(specify) 
Health related 
quality of life mean 
score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NA NA 
Conclusions 
Authors: 
The authors demonstrated that the frequencies of positive outcomes in the two TB screening tests 
were similar, but the overall agreement between the TST and the QFT-GIT test was poor, regardless 
of BCG vaccination. 
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Reviewers: 
The overall agreement between the TST and the QFT-GIT test was poor, regardless of BCG 
vaccination and TST threshold; tests were similar in detecting LTBI through predicting incidence of 
active TB (risk difference NS) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; ESRD = end stage renal disease; PPV = positive 
predictive value; NPV = negative predictive value; FPR = false positive rate; FNR = false negative 
rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Sherkat 2014155 
Country: Iran 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Hospital-based 
Number of centres: NR 
Total length of follow up (if applicable): 21 months (FU included 9 months prophylactic treatment 
and 12 months post transplantation)  
Funding (government/private/manufacturer/other - specify): Nil  
Aim of the study 
To compare IGRA (T-SPOT .TB) and TST test in detection of LTBI in kidney transplant candidates 
and evaluate the agreement between the two tests 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Immunocompromised (kidney transplant candidates – end stage renal disease) 
Participants 
Recruitment dates: March 2010 to February 2011 
Total N of recruited patients: NR 
Inclusion criteria: Candidates for receiving a kidney transplant 
Exclusion criteria: Active pulmonary and extrapulmonary TB, history of prior TB or isoniazid 
prophylactic treatment, refusal to continue prophylactic treatment, symptoms of isoniazid-induced 
hepatitis or drug reaction  
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 44 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: between test agreement, incidence of active TB 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 44 (15.5) 
Women (n [%]): 15 [66] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): NR 
BCG vaccination (n [%]): 12 [27.3] 
History of anti-TB treatment (n [%]): None 
Total incidence of active TB (n [%]): 1/44 [2.27] 
Chest radiography (yes/no): NR 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): End stage renal disease 
Co-morbidity (n [%]): Dialysis (30 [68.2]), hypertension (10 [22.7]), diabetes (10 [22.7]), obstructive 
uropathy (6 [13.6]), polycystic kidney (6 [13.6]), other renal etiologies (17 [38.6]), others (3 [6.8]) 
Type of during-study treatment (n [%]): isoniazid prophylaxis (10 [22.7]) 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (TSPOT):   NR 6 38 NR 44 
TST:≥10mm NR 8 36 NR 44 
Test 3 (specify)      
Total N of patients with valid results for both IGRA and TST: 44 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – NA 
Non-exposed   
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Exposed 1 (specify): NR 
Exposed 2 (specify): NR 
Exposed 3 (specify): NR 
Exposed 4 (specify): NR 
 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
[TSPOT] 
T-SPOT .TB assay (Oxford 
Immunotec, Oxford, UK) was 
performed according to the 
manufacturers’ recommendation 
and defined as positive, negative or 
indeterminate based on 
manufacturers’ recommended 
criteria. Briefly, before the TST, 8 
ml peripheral venous blood was 
collected and processed within 4 h. 
The peripheral blood mononuclear 
cells) were isolated by standard 
ficoll-hypaque density-gradient 
centrifugation. The PBMCs were 
counted and adjusted to a cell 
number of 2.5 × 10 PBMCs/1 ml. 
Four wells of the 96-well Microtitre 
plates (nil control, positive control, 
panel A and panel B), precoated 
with monoclonal antibody to 
gamma IFN, were seeded with 100 
µl of 2.5 × 10 PBMCs/well. Two 
wells contained different peptide 
antigens (ESAT-6 [panel A] and 
CFP-10 [panel B]), the nil control 
well contained the cell in medium 
alone, and the positive control well 
contained the cell that was 
stimulated with 
phytohemagglutinin. After the 
appropriate incubation time (16-20 
h) at in a humidified incubator at 
37°C and 5% CO, the plates were 
washed with phosphate-buffered 
saline (PBS) four times. An 
appropriate volume of conjugate 
working solution was prepared 
(1:200 dilution in PBS) for the 
secondary incubation (60 min at 2-
8°C) after which the wells was 
washed again (×4), as suggested 
above. Results are presented as the 
number of spot-forming cells and 
the reaction was observed visually 
 
 
TST≥10mm TST was performed using the 5 IU If induration size was  
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purified protein derivative (PPD) 
(Pasteur Institute, Tehran, Iran) 
injection into the volar aspect of the 
forearm intradermally by trained 
personnel. A positive test was 
defined by the size of induration 
(not the erythema) induced by PPD 
48-72 h after the injection 
≥10 mm, test was 
considered positive as 
recommended by local 
guidelines (Ministry of 
Health and Medical 
Education) 
Association between test results and incidence of active TB (if applicable) 
IGRA [TSPOT] TST≥10mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 1 5 6 TST + 1 7 8 
IGRA - 0 38 38 TST - 0 36 36 
indeterminate NR NR NR indeterminate NR NR NR 
Total 1 43 44 Total 1 43 44 
Test performance parameters 
IGRA TST 
Sensitivity =1/1= 100% (95% CI: 20.65, 100) Sensitivity = 1/1=100% (95% CI: 20.65, 100) 
Specificity = 38/43=88.37% (95% CI: 75.52, 
94.93) 
Specificity = 36/43=83.72% (95% CI: 70.03, 
91.88) 
PPV= 1/6=16.67% (95% CI: 3.00, 56.35) PPV= 1/8=12.5% (95% CI: 2.24, 47.09) 
NPV= 38/38=100% (95% CI: 90.82, 100) NPV= 36/36=100% (95% CI: 90.36, 100) 
Cumulative Incidence IGRA+ = 1/6=16.67% (95% 
CI: 3.00, 56.35)  
Cumulative Incidence TST+ = 1/8=12.5% (95% CI: 
0.11, 47.09) 
Cumulative Incidence IGRA- = 0/38=1.31 (95% 
CI: 0.00, 12.86) 
Cumulative Incidence TST- = 0/36=1.39 (95% CI: 
0.00, 13.49)  
Cumulative Incidence Ratio IGRA =12.67 (95% 
CI: 0.47, 337.8) 
Cumulative Incidence Ratio TST =9.00 (95% CI: 
0.33, 245.7) 
Incidence density rate IGRA+ =NR Incidence density rate TST+= NR 
Incidence density rate IGRA- = NR Incidence density rate TST- = NR 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST= NA 
Other reported measure IGRA =NR  Other reported measure TST =NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios=1.41 (95% CI: 0.13, 15.20) 
Ratio of incidence density rate ratios=NA 
Other reported measure= NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (specify) TST (specify) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
indeterminate NA NA NA indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV= NA PPV= NA 
NPV= NA NPV= NA 
DOR (for T+ calculated)= NA DOR (for T+ calculated)= NA 
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OR (crude; for T+ reported)= NA OR (crude; for T+ reported)= NA 
OR (regression-based; reported) = NA  
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (≥10mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + 2 4 6 TST + 2 6 8 
IGRA - 10 28 38 TST - 10 26 36 
indeterminate NR NR NR indeterminate NR NR NR 
Total  12 32 44 Total  12 32 44 
Test performance parameters 
IGRA  TST  
DOR (for T
+
 calculated)IGRA= 1.40 (95% CI: 0.22, 
8.85) 
DOR (for T+ calculated)TST = 0.86 (95% CI: 0.14, 
5.03) 
OR (crude; for T+ reported)= NR (p=0.658) OR (crude; for T+ reported) = NR (p=1.00) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST +≥10mm  TST - Total 
IGRA [TSPOT] + 4 2 6 
IGRA [TSPOT]  - 4 34 38 
indeterminate NR NR NR 
Total  8 36 44 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.49 (95% CI: 0.20, 0.78) 
% concordance = 38/44=86.36% (95% CI: 73.29, 93.6) 
% discordance = 6/44=13.64% (95% CI: 6.40, 26.71) 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
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Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NA NA NA 
IGRA - NA NA NA 
indeterminate NA NA NA 
Total  NA NA NA 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NA 
TST + threshold: NA 
Parameters 
Kappa = NA 
% concordance = NA  
% discordance = NA 
Conclusions 
Authors: 
In kidney transplant candidates both TST and T-SPOT .TB test were comparable for the diagnosis of 
LTBI with reasonable agreement between the tests. However, further studies are needed to determine 
the ability of T-SPOT .TB test to detect LTBI and to evaluate the need for prophylaxis in these 
patients 
Reviewers: 
There was no evidence indicating the superiority of  IGRA over TST or vise versa in detecting LTBI; 
the between test agreement was good; BCG status did not influence TST differentially from TSPOT 
Abbreviations: DOR=diagnostic odds ratio; 95% CI= 95 percent confidence intervals; 
TB=tuberculosis; BCG=Bacillus Calmette–Guérin; PPV= positive predictive value; NPV=negative 
predictive value; FPR=false positive rate; FNR=false negative rate; SD=standard deviation 
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Recently arrived 
 
Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Lucas 2010145 
Country: Australia 
Study design: Retrospective cohort/cross sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Community based 
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): Oxford Immunotech. 
Aim of the study 
Comparative study of IGRAs and TST for the diagnosis of LTBI in 524 recently resettled refugee 
children 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Recently arrived people 
Participants 
Recruitment dates: January 2007 and March 2008 
Total N of recruited patients: 524 
Inclusion criteria: Children aged from 5 months to 16 years from refugee families attending the Migrant 
Health Unit 
Exclusion criteria: NR 
Total N of excluded patients: Incomplete TSPOT (n = 57) and TST (n = 37) 
Total N of patients tested with both IGRA and TST: NR 
Total N of patients with valid results for both IGRA and TST: 239 (three tests) 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: Association of test positivity with exposure, agreement  
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 7.5 (2.8-11.9) 
Women (n [%]): 260 [49.6] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): African (411 [78.4]) and Asian (113 [21.56]) 
BCG vaccination (n [%]): 361 [69.0] 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NR 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): Malaria (486 [92.7]), hepatitis B (356 [68.0]), hepatitis C (492 [94.0]), 
schistosomiasis (431 [82.2]) 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (TSPOT):   420 completed 
tests 
38 374 8 412 
IGRA (QFT-GIT):   460 completed 
tests 
45 345 70 390 
TST: 304 completed 
tests 
54 250 0 304 
Total N of patients with valid results for both IGRA and TST: 239 
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Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group – Household TB contact 
Non-exposed  none 
Exposed 1 
(specify): 
definite/suspected 
Exposed 2 
(specify): 
NA 
Exposed 3 
(specify): 
NA 
Exposed 4 
(specify): 
NA 
Tests 
 Assay used, methodology, timing 
for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(TSPOT) 
In keeping with the manufacturer’s 
instructions, 4 ml of blood were 
drawn for the T-SPOT.TB assay, 
except for children <2 years when 2-3 
ml were drawn depending on ease of 
venepuncture  
 
Inconclusive assays were defined 
by an inability to complete the test 
due to inadequate peripheral blood 
mononuclear cell (PBMC) yield 
after PBMC separation, high 
background, machine failure or 
red blood cell contamination. 
Indeterminate assays were defined 
as a low mitogen-positive control 
response or a high response to the 
negative control 
NA 
IGRA 
(QFT-GIT) 
A 3 ml aliquot of blood was drawn 
from all study children and the assay 
was performed according to the 
manufacturers’ protocols 
Indeterminate assays were defined 
as a high IFNg response to the 
negative control or a low IFNg 
response to mitogen stimulation in 
the absence of a positive antigen 
response 
NA 
TST≥10mm TST was performed with purified 
protein derivative (PPD) by 
administration of 5 tuberculin units 
following the Mantoux method. The 
transverse diameter of skin induration 
was measured at 48-72 h 
NR NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No   Yes No  
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
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Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA  Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (TSPOT) TST (≥10 mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR 8 Indeterminate NR NR 0 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR NPV = NR  
DOR (for T
+
 calculated) = NA  DOR (for T
+
 calculated) = NA 
OR (crude; for T+ reported) = 2.50 (95% CI: 0.90, 
6.50) 
OR (crude; for T+ reported) = 4.00 (95% CI: 1.70, 
9.50)  
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 0.63 (95% CI: 0.32, 1.22) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10 mm) 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR 70 Indeterminate NR NR 0 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR NPV = NR  
DOR (for T+ calculated) = NA  DOR (for T+ calculated) = NA 
OR (crude; for T+ reported) = 2.40 (95% CI: 1.00, 
5.80) 
OR (crude; for T+ reported) = 4.00 (95% CI: 1.70, 
9.50) 
OR (regression-based; reported) = NR OR (regression-based; reported) = NR 
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List of covariates: NA List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 0.60 (95%CI: 0.32, 1.12) 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (TSPOT) TST (≥10 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR 70 Indeterminate NR NR 70 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = 1.80 (95% CI: 0.80, 
4.00) 
OR (crude; for T+ reported) = 1.70 (95% CI: 0.80, 
3.50) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA (QFT-GIT) TST (≥10 mm) 
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR 70 Indeterminate NR NR 70 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NA DOR (for T+ calculated)TST = NA 
OR (crude; for T+ reported) = 1.70 (95% CI: 0.80, 
3.60) 
OR (crude; for T+ reported) = 1.70 (95% CI: 0.80, 
3.50) 
OR (regression-based; reported) IGRA = NR 
List of covariates: NA 
OR (regression-based; reported) TST = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + ≥10mm TST - Total 
IGRA (TSPOT) + NR NR NR 
IGRA (TSPOT) - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.45 (95% CI: 0.38, 0.53) 
% concordance = NR 
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% discordance = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + ≥10mm TST - Total 
IGRA (QFT-GIT) + NR NR NR 
IGRA (QFT-GIT) - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.46 (95% CI: 0.39, 0.53) 
% concordance = NR 
% discordance = NR 
Stratification (specify group 1):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2):  
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality of life 
mean score (SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The two IGRAs showed similar positivity rates across all age groups. Both IGRAs gave an unacceptably 
high proportion of inconclusive results. Failed tests were the primary cause of inconclusive T-SPOT.TB 
assays whereas indeterminate results were the primary cause of inconclusive QFT-GIT assays. It is 
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reasonable to screen using either IGRA with follow-up by the alternative if the test fails. In general, the 
QFT-GIT is the preferred option for non-African populations but the T-SPOT.TB is recommended when 
there are epidemiological and/or clinical high risk factors for TB infection. However, both IGRAs have 
methodological and performance characteristics that limit their usefulness in refugee children, 
highlighting the need for continued development of screening strategies 
Reviewers: 
Three tests performed similarly 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Orlando 2010146 
Country: Italy 
Study design: Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Community-based 
(outpatient ward) 
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): The Provincia di Milano, Assessorato 
alle Politiche Sociali 
Aim of the study 
To compare the efficiency and efficacy of TST and QFT-IT for the detection of LTBI in recent 
immigrants from highly endemic countries by intention-to-treat (strategy efficiency) and per-protocol 
(test efficacy) analyses; this was achieved through the assessment of LTBI prevalence using the one-
step TST and QFT-IT, analysis of test results’ association, determinants of drop-out and influence of 
variables related to increased risk of TB exposure on the TST or QFT-IT strategy 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Recently arrived people  
Participants 
Recruitment dates: July 2005 and July 2007 
Total N of recruited patients: NR 
Inclusion criteria: NR 
Exclusion criteria: Active TB 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 1130 
Total N of patients with valid results for both IGRA and TST: 899 
Methods of active TB diagnosis (if applicable): Clinical evaluation and chest X-rays were 
performed by experienced pneumologists  
Outcomes (study-based) list: Agreement, association of test positivity with exposure 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): Median 35.3 years (IQR: 27.7–44.5) 
Women (n [%]): 630 [55.7] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Latin America (562 [49.73]), Eastern Europe (308 [27.26]), Africa (181 
[16.02%]), Asia (79 [6.99]) 
BCG vaccination (n [%]): 72 [6.37], Unknown (46 [4.07]) 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): Treatment for LTBI was offered to 57 of the 79 eligible 
patients according to standard guidelines 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-
GIT):   
1130 337 778 15 
(undetermined) 
1115 
TST (≥10mm): 1129 407 (≥10mm) 492 230 (dropouts) 899 
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Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST: 899 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group - Continent 
Non-exposed  Africa (reference group) 
Exposed 1 
(specify): 
Asia 
Exposed 2 
(specify): 
East Europe 
Exposed 3 
(specify): 
Latin America 
 Definition of exposure group – TB prevalence 
Non-exposed  <50 (reference group) 
Exposed 1 
(specify): 
50-200 
Exposed 2 
(specify): 
>200 
 Definition of exposure group – contact with TB patient 
Non-exposed  No (reference group) 
Exposed 1 
(specify): 
Yes 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA  QuantiFERON-TB Gold In-
Tube (QFT-IT) test (Cellestis 
Limited, Victoria, Australia): 1 
ml of blood was drawn directly 
into QFT-IT blood collection 
tubes coated with saline (Nil-
control), peptides of ESAT-6, 
CFP-10 and TB7.7(p4) proteins 
(MTB specific antigens—TB-
antigen) and phytohaemaglutinin 
(PHA) (Mitogen-control) 
 
After overnight incubation at 
37◦C, blood collection tubes 
were centrifuged for 15 min at 
2,000–3,000g and stored at -
80◦C before testing. The 
concentration of IFN-c (IU/ml) 
was determined using an ELISA 
assay  
 
QFT-GIT Analysis Software 
Version 2.50 (Cellestis Limited, 
Victoria, Australia) was used to 
analyse raw data and calculate 
results 
The results were defined 
positive if the INF-c value 
after stimulation with TB-
antigen minus the value in 
the Nilcontrol was ≥0.35 
UI/ml and ≥25% of Nil; 
negative if value of TB-
antigen minus Nil was<0.35 
UI/ml or if that difference 
was ≥0.35 UI/ml and <25% 
of Nil, with Mitogen minus 
Nil ≥0.5 UI/ml; 
indeterminate for TB antigen 
minus Nil<0.35 UI/ml or 
≥0.35 UI/ml and <25% of 
Nil, with Mitogen minus 
Nil<0.5 UI/ml, or every time 
Nil was >0.8 UI/ml 
NA 
TST For TST, 0.1 mL (5U) of 
tuberculin purified protein 
derivative (Biocine test PPD 
A TST ≥ 10 mm of 
induration was considered 
positive in persons recently 
NA 
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Liofilo, Novartis Vaccines and 
Diagnostics) was injected 
intradermally into the forearm. 
Participants were asked to come 
back for the evaluation of the 
delayed type hypersensitivity 
reaction (mean of the induration 
transverse diameters) 72 h later 
arrived from highly endemic 
areas 
 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of 
active TB 
Total  Incidence 
of active 
TB 
Total 
Yes No Yes No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA  Incidence density rate ratio TST = NA  
Other reported measure IGRA = NA  Other reported measure TST = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Continent Total  Continent Total 
Asia  Africa Asia  Africa 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  79 181 260 Total  79 181 260 
Test performance parameters 
IGRA (QFT-GIT) TST (≥10mm) 
Sensitivity = NR Sensitivity = NR 
Specificity = NR  Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR DOR (for T+ calculated) =  
Asia vs. Africa 
OR (crude; for T
+ 
reported) = 1.61 (95% CI: 
0.90, 2.88) 
Asia vs. Africa 
OR (crude; for T
+ 
reported) = 0.91 (95% CI: 0.50, 
1.64) 
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Asia vs. Africa 
OR (regression-based; reported) = 1.07 (95% 
CI: 0.52, 2.23) 
List of covariates: NR 
Asia vs. Africa 
OR (regression-based; reported) = 0.72 (95% CI: 
0.34, 1.53) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T+ reported) = 1.77 (95% CI: 1.16, 2.70) 
Ratio of ORs (regression-based; reported) = 1.49 (95% CI: 0.87, 2.53) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Continent Total  Continent Total 
East 
Europe 
Africa East 
Europe  
Africa 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  308 181 489 Total  308 181 489 
Test performance parameters 
IGRA (QFT-GIT) TST (≥10mm) 
Sensitivity = NR Sensitivity = NR 
Specificity = NR  Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR DOR (for T+ calculated) = NR 
East Europe vs. Africa 
OR (crude; for T
+ 
reported) = 1.46 (95% CI: 
0.96, 2.23) 
East Europe vs. Africa 
OR (crude; for T
+ 
reported) = 0.83 (95% CI: 0.55, 
1.25) 
East Europe vs. Africa 
OR (regression-based; reported) = 1.68 (95% 
CI: 0.91, 3.08) 
List of covariates: NR 
East Europe vs. Africa 
OR (regression-based; reported) = 1.19 (95% CI: 
0.66, 2.14) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T
+
 calculated) = NA 
Ratio of OR (crude; for T
+ 
reported) = 1.76 (95% CI: 1.30, 2.37) 
Ratio of ORs (regression-based; reported) = 1.41 (95% CI: 0.92, 2.18) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Continent Total  Continent Total 
Latin 
America 
Africa Latin 
America 
Africa 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  562 181 743 Total  562 181 743 
Test performance parameters 
IGRA (QFT-GIT) TST (≥10mm) 
Sensitivity = NR Sensitivity = NR 
Specificity = NR  Specificity = NR 
PPV = NR PPV = NR 
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NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR DOR (for T+ calculated) = NR 
Latin America vs. Africa 
OR (crude; for T+ reported) = 1.46 (95% CI: 
0.99, 2.16) 
Latin America vs. Africa 
OR (crude; for T+ reported) = 0.86 (95% CI: 0.59, 
1.26) 
Latin America vs. Africa 
OR (regression-based; reported) = 0.81 (95% 
CI: 0.46, 1.42) 
List of covariates: NR 
Latin America vs. Africa 
OR (regression-based; reported) = 0.57 (95% CI: 
0.33, 1.00) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 1.70 (95% CI: 1.29, 2.24) 
Ratio of ORs (regression-based; reported) = 1.42 (95% CI: 0.95, 2.24) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 TB prevalence Total  TB prevalence Total 
50-200  <50 50-200  <50 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (QFT-GIT) TST (≥10mm) 
Sensitivity = NR Sensitivity = NR 
Specificity = NR  Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR DOR (for T+ calculated) = NR 
50-200 vs. <50 
OR (crude; for T+ reported) = 1.76 (95% CI: 
1.10, 2.80) 
50-200 vs. <50 
OR (crude; for T+ reported) = 0.66 (95% CI: 0.44, 
1.01) 
50-200 vs. <50 
OR (regression-based; reported) = 1.34 (95% 
CI: 0.72, 2.49) 
List of covariates: NR 
50-200 vs. <50 
OR (regression-based; reported) = 0.70 (95% CI: 
0.39, 1.25) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 2.67 (95% CI: 1.94, 3.67) 
Ratio of ORs (regression-based; reported) = 1.91 (95% CI: 1.24, 2.95) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 TB prevalence Total  TB prevalence Total 
>200  <50 >200  <50 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (QFT-GIT) TST (≥10mm) 
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Sensitivity = NR Sensitivity = NR 
Specificity = NR  Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR DOR (for T+ calculated) = NR 
>200 vs. <50 
OR (crude; for T+ reported) = 2.31 (95% CI: 
1.48, 3.61) 
>200 vs. <50 
OR (crude; for T+ reported) = 0.99 (95% CI: 0.66, 
1.48) 
>200 vs. <50 
OR (regression-based; reported) = 2.72 (95% 
CI: 1.70, 5.02) 
List of covariates: NR 
>200 vs. <50 
OR (regression-based; reported) = 1.45 (95% CI: 
0.80, 2.62) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 2.33 (95% CI: 1.72, 3.17) 
Ratio of ORs (regression-based; reported) = 1.88 (95% CI: 1.25, 2.83) 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT) TST (≥10mm) 
 Contact with TB 
case 
Total  Contact with TB 
case  
Total  
Yes  No Yes  No  
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA (QFT-GIT) TST (≥10mm) 
Sensitivity = NR Sensitivity = NR 
Specificity = NR  Specificity = NR 
PPV = NR PPV = NR 
NPV = NR  NPV = NR  
DOR (for T+ calculated) = NR DOR (for T+ calculated) = NR 
Contact vs. No contact 
OR (crude; for T+ reported) = 2.54 (95% CI: 
1.82, 3.54) 
Contact vs. No contact 
OR (crude; for T+ reported) = 1.87 (95% CI: 1.30, 
2.69) 
Contact vs. No contact 
OR (regression-based; reported) = 2.11 (95% 
CI: 1.47, 3.03) 
List of covariates: NR 
Contact vs. No contact 
OR (regression-based; reported) = 1.87 (95% CI: 
1.24, 2.80) 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 1.36 (95% CI: 1.06, 1.75) 
Ratio of ORs (regression-based; reported) = 1.13 (95% CI: 0.85, 1.49) 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
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Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR  
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR 887 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥ 10mm 
Parameters 
Kappa = 0.38 (95% CI: NR) 
% concordance = 625/887 = 70.46% (95% CI: 67.32, 73.43) 
% discordance = 262/887 = 29.53% (95% CI: NR) 
Stratification (BCG vaccinated) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR 56 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG vaccinated 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.35 (95% CI: NR) 
% concordance = 37/56 = 66.07% (95% CI: 52.09, 77.84) 
% discordance = 19/56 = 33.92% (95% CI: NR) 
Stratification (BCG non-vaccinated) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR 789 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): BCG non-vaccinated 
TST + threshold: ≥ 10mm 
Parameters 
Kappa = 0.40 (95% CI: NR) 
% concordance = 563/789 = 71.36% (95% CI: 68.04, 74.46) 
% discordance = 226/789 = 28.64% (95% CI: NR) 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score (SD) 
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(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
Continent of origin, class of TB prevalence in the country of origin and contacts with TB patients 
were found to be significantly associated with the probability of TST and QFT-IT positive result; The 
drawback of the TST screening strategy in recent immigrants from highly endemic countries is due to 
low sensitivity/specificity of the test and to high drop-out rate with an overall significant lowering in 
strategy efficacy/efficiency. Disagreement is due to differences in sensitivity/specificity and in rate of 
drop-out which is higher for the TST 
Reviewers: 
Kappa was influenced by BCG status which was higher in non-vaccinated people; QFT performed 
better than TST in relation to contact with TB and TB prevalence; TST was better than QFT in 
relation to continent 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Saracino 2009147 
Country: Italy 
Study design:  Retrospective cohort/cross-sectional study 
Study setting (e.g., outbreak investigation, community-based - specify): Community-based 
Number of centres: NR 
Total length of follow up (if applicable): NA 
Funding (government/private/manufacturer/other - specify): NR 
Aim of the study 
To evaluate the agreement between QFT-GIT and TST for latent TB screening in a population of 
recent immigrants to Italy from high-incidence countries 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Recently arrived people 
Participants 
Recruitment dates: September 2004 and December 2005  
Total N of recruited patients: NR 
Inclusion criteria: Recent (less than two months) immigrants to Italy 
Exclusion criteria: Active TB, HIV 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST: 452 
Total N of patients with valid results for both IGRA and TST: 279 
Methods of active TB diagnosis (if applicable): NA 
Outcomes (study-based) list: Agreement, associations of test positivity and risk factors (born in a 
country of TB burden, region of origin) 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 27.1 (6.2) 
Women (n [%]): 11 [4] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): African (135 [48.4]), Eastern Mediterranean (131 [46.95]), European (7 
[2.5]), South-East Asian (6 [2.2]) 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): NA 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total 
N 
 
(test+) 
Total N 
 (test-) 
Total N 
(indetermi
nate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   452 107 172 173 (169 
dropouts 
and 4 
HIV/active 
TB) 
279 
TST (≥10mm): 452 72 207 173 (169 
dropouts 
and 4 
279 
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HIV/active 
TB) 
Total N of patients with valid results for both IGRA and TST: 279 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NR 
Exposed 1 (specify): 30-100 
Exposed 2 (specify): 101-200  
Exposed 3 (specify): 201-300  
Exposed 4 (specify): >301  
 Definition of exposure group – Region of origin 
Non-exposed NR 
Exposed 1 (specify): African  
Exposed 2 (specify): Eastern Mediterranean  
Exposed 3 (specify): European  
Exposed 4 (specify): South-East Asian 
Tests 
 Assay used, methodology, timing for 
test measurement, manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other 
information 
IGRA 
(QFT-
GIT) 
QFT-GIT (Cellestis, Carnegie, 
Australia) was performed, according to 
the manufacturer’s instructions, by 
collecting 1mL of whole heparinized 
blood in two tubes, one containing 
only heparin as negative control, and 
the other containing three MT specific 
antigens: ESAT-6, CFP-10 and TB 7.7 
(p4). Tubes were kept at room 
temperature for a maximum of 16 
hours and then incubated at 37°C for 
16-24 hours; the tubes were then 
centrifuged, and the plasma removed 
and harvested to perform the ELISA. 
The IFN-γ value for TB-specific 
antigens was corrected by subtracting 
the value obtained for the respective 
negative controls 
the test was considered 
positive if the IFN-γ 
level was above the 
cut-off test value 
(≥0.35 IU/mL) 
NA 
TST 
(≥10mm) 
TST was administered by injecting 0.1 
mL of the standard test dose (5 
tuberculin unit, TU) of PPD 
(BiocineTest-PPD®; Chiron S.r.l., 
Sovicille, Siena, Italy) according to the 
Mantoux method 
 
Skin induration was 
evaluated after 72 
hours and considered 
positive if ≥10 mm. 
Cut-off points of 5 
mm and 15 mm,  
respectively, were also 
used for comparison 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA TST 
 Incidence of active 
TB 
Total  Incidence 
of active 
TB 
Total 
Yes No Yes No  
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
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Indeterminate NA NA NA Indetermin
ate 
NA NA NA 
Total NA NA NA Total NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
Cumulative Incidence IGRA+ = NA Cumulative Incidence TST+ = NA 
Cumulative Incidence IGRA- = NA Cumulative Incidence TST- = NA 
Cumulative Incidence Ratio IGRA = NA Cumulative Incidence Ratio TST = NA 
Incidence density rate IGRA+ = NA Incidence density rate TST+ = NA 
Incidence density rate IGRA- = NA Incidence density rate TST- = NA 
Incidence density rate ratio IGRA = NA Incidence density rate ratio TST = NA  
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = NA 
Ratio of incidence density rate ratios = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level  
Region of origin 
Total  Exposure level 
Region of origin 
Total 
Sout
h-
East 
Asia 
Euro
pe 
Easter
n 
Medite
rranea
n 
Afric
a 
Sout
h-
East 
Asia 
Europe Easter
n 
Medit
errane
an 
A
fri
ca 
 
IG
RA 
+ 
NR NR NR NR 107 TST 
+ 
NR NR NR N
R 
72 
IG
RA 
- 
NR NR NR NR 172 TST - NR NR NR N
R 
207 
Ind
eter
min
ate 
NR NR NR NR 173 
(exclu
ded) 
Indet
ermin
ate 
NR NR NR N
R 
173 
(exclude
d) 
Tot
al  
6 7 131 135 279 Total  6 7 131 13
5 
279 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA  
DOR (for T+ calculated) = NA DOR (for T+ calculated) = NA  
OR (crude; for T+ reported) =  
Africa:  OR = 1.00, 95% CI: 0.60, 1.70 
Eastern Mediterranean:  OR = 1.00, 95% CI: 
0.60, 1.70 
Europe: OR = 1.20, 95% CI: 0.20, 7.30 
South-East Asia: OR = 0.30, 95% CI:  0.01, 
OR (crude; for T+ reported) =  
Africa:  OR = 1.10, 95% CI: 0.60, 1.90 
Eastern Mediterranean: OR = 0.80, 95% CI: 0.50, 
1.40 
Europe: OR = 4.00, 95% CI: 0.70, 27.80 
South-East Asia: OR = 0.60, 9% CI: 0.10, 5.20 
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2.90 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 0.91 (95% CI: 0.61, 1.35) [Africa vs. reference group] 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and levels of TB exposure (if applicable) 
IGRA (QFT-GIT)  TST (≥10mm) 
 Exposure level  
Born in a country with a TB 
burden  
(# cases per 100,000) 
Total Exposure level  
Born in a country with a TB burden  
(# cases per 100,000) 
Total 
 >301 201-
300 
101-200 30-
100 
  >30
1 
201-
300 
101
-
200 
30-
100 
72 
IG
RA 
+ 
NR NR NR NR 107 TST + NR NR NR NR 207 
IG
RA 
- 
NR NR NR NR 172 TST - NR NR NR NR 173 
(excl
uded
) 
Ind
eter
min
ate 
NR NR NR NR 173 
(exclu
ded) 
Indeterminate NR NR NR NR 279 
Tot
al 
54 197 15 12 279 Total  54 197 15 12 72 
 Test performance parameters 
IGRA  TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA  
DOR (for T
+
 calculated) = NA DOR (for T
+
 calculated) = NA  
30-100:  OR (crude; for T+ reported) = 1.20, 
95% CI: 0.30, 4.30 
101-200: OR (crude; for T+ reported) = 0.80, 
95% CI: 0.20, 2.60 
201-300: OR (crude; for T+ reported) = 1.00, 
95% CI: 0.60, 1.80 
>301: OR (crude; for T+ reported) = 1.00, 95% 
CI: 0.50, 2.00 
30-100:  OR (crude; for T+ reported) = 3.00, 95% 
CI: 0.80, 11.8 
101-200: OR (crude; for T+ reported) = 1.00, 
95% CI: 0.20, 3.70 
201-300: OR (crude; for T+ reported) = 0.80, 
95% CI: 0.40, 1.40 
>301: OR (crude; for T+ reported) = 1.00, 95% 
CI: 0.50, 2.10 
OR (regression-based; reported) = NR 
List of covariates: NA 
OR (regression-based; reported) = NR 
List of covariates: NA 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = 1.00 (95% CI: 0.60, 1.66)  [>301 vs. reference group] 
Ratio of ORs (regression-based; reported) = NA 
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Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA (specify) TST (specify) 
 BCG status Total  BCG status Total 
Yes No Yes No  
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeter
minate 
NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA TST 
DOR (for T
+
 calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = 
NR  
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + 49 58 107 
IGRA - 23 149 172 
Indeterminate NR NR 173 (excluded) 
Total  72 207 279 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): Total 
TST + threshold: ≥10mm 
Parameters 
Kappa = 0.35 (95% CI: 0.23, 0.46) 
% concordance = 198/279 = 70.97% (95% CI: 65.39, 75.98) 
% discordance = 81/279 = 29.03% (95% CI: 24.02, 34.61) 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
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Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related 
quality of life 
mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
The findings indicate that QFT-GIT could be useful for screening recent immigrants with a high rate 
of unavailable TST results. The overall agreement between QFT-GIT and TST was 70.9%, with a k 
statistics of 0.35. No single demographic characteristic including sex, age, region of origin and TB 
burden in the country of origin, was associated with TST and/or QFT-GIT positivity 
Reviewers: 
None of the risk factors was associated with test positivity of either IGRA or TST 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: AlexanderTsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Harstad 2010143 
Country: Norway 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based - specify): Community - based   
Number of centres: NR 
Total length of follow up (if applicable): 23-32 months 
Funding (government/private/manufacturer/other - specify): Norwegian Health Association; The 
Regional Health Authorities 
Aim of the study 
To compare PPV and NPV between QuantiFERON®-TB Gold (QFT-G) and the TST in asylum 
seekers in Norway 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Recently arrived people 
Participants 
Recruitment dates: September 2005 to June 2006 
Total N of recruited patients: NR 
Inclusion criteria: Asylum seekers aged ≥18 years 
Exclusion criteria: Active TB 
Total N of excluded patients: NR 
Total N of patients tested with both IGRA and TST:  NR  
Total N of patients with valid results for both IGRA and TST: 823 
Methods of active TB diagnosis (if applicable): NR 
Outcomes (study-based) list: PPV and NPV 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): 18–34 yrs (n = 587), 35–49 yrs (n = 201), and ≥ 50 yrs (n = 35) 
Women (n [%]): 206 [25.0] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Europe (103[12.5]), Africa (347[42.0]), Asia (346[42.0]), other (27[3.3]) 
BCG vaccination (n [%]): NR 
History of anti-TB treatment (n [%]): NR 
Total incidence of active TB (n [%]): 9/823 [1.1] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): NR 
Morbidity (n [%]): NA 
Co-morbidity (n [%]): NA 
Type of during-study treatment (n [%]): NR 
Number of patients tested 
 Total N  
(tested) 
Total N 
 (test+) 
Total N 
 (test-) 
Total N 
(indeterminate) 
Total N  
(test results 
available) 
IGRA (QFT-GIT):   NR 246 577 NR 823 
TST: NR 426 (≥ 
6mm) 
128 
(≥15mm) 
395 
(<6mm) 
693 
(<15mm) 
NR 821 
Test 3 (specify): NA NA NA NA NA 
Total N of patients with valid results for both IGRA and TST:  
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
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Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off 
values/thresholds 
Definition of test+ 
Other information 
IGRA  QuantiFERON-TB 
Gold In-Tube, Cellestis Ltd, 
Carnegie, VIC, Australia) 
NR NA 
TST TSTs (purified protein derivative 
RT 23, 2 tuberculin units [TU] 
from Statens Serum Institute, 
Copenhagen, Denmark) 
≥ 6mm 
≥15mm 
 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA (QFT-GIT) TST ≥ 6mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 8 230 238 TST +(≥ 
6mm) 
8 407 415 
IGRA - 1 576 577 TST – 
(<6mm) 
1 394 395 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total 9 806 815 Total 9 801 810 
Test performance parameters 
IGRA TST 
Sensitivity = 8/9 = 88.89% (95% CI: 56.5, 98.01) Sensitivity = 8/9 = 88.89% (95% CI: 56.5, 98.01) 
Specificity = 576/806 = 71.46% (95% CI: 68.25, 
74.47) 
Specificity = 394/801 = 49.19% (95% CI: 45.74, 
52.65) 
PPV = 8/238 = 3.36% (95% CI: 1.71, 6.49) PPV = 8/415 = 1.92% (95% CI: 0.98, 3.75) 
NPV = 576/577 = 99.83% (95% CI: 99.02, 
99.97) 
NPV = 394/395 = 99.75% (95% CI: 98.58, 99.96) 
Cumulative Incidence IGRA+ = 8/238 =  
3.36% (95% CI: 1.71, 6.49)  
Cumulative Incidence TST+ = 8/415 = 1.92% (95% 
CI: 0.98, 3.75) 
Cumulative Incidence IGRA- = 1/577 =  
0.17% (95% CI: 0.00, 1.08) 
Cumulative Incidence TST- = 1/395 = 0.25% (95% 
CI: 0.00, 1.57) 
Cumulative Incidence Ratio IGRA =  
19.39 (95% CI: 2.43, 154.2) 
Cumulative Incidence Ratio TST =  
7.61 (95% CI: 0.95, 60.59) 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR  Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR 
Other reported measure IGRA = NR Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST 6mm) 
Ratio of cumulative incidence ratios = 2.55(95% CI: 0.57, 11.40) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and incidence of active TB (if applicable) 
TST (≥ 15mm)  
 Incidence of active TB Total 
Yes No 
TST + (≥ 3 118 121 
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15mm) 
TST -(< 15mm) 6 686 692 
Indeterminate NR NR NR 
Total 9 804 813 
Test performance parameters (TST≥ 15mm) 
Sensitivity = 3/9 = 33.33% (95% CI: 12.06, 64.58) 
Specificity = 686/804 = 85.32%  (95% CI: 82.71, 87.60) 
PPV = 3/121 = 2.48% (95% CI: 0.84, 7.03) 
NPV = 686/692 = 99.13% (95% CI: 98.12, 99.6) 
Cumulative Incidence IGRA+ 3/121 = 2.48% (95% CI: 0.84, 7.03) 
Cumulative Incidence IGRA- = 6/692 = 0.86% (95% CI: 0.35, 1.92) 
Cumulative Incidence Ratio IGRA = 2.86 (95% CI: 0.725, 11.28) 
Incidence density rate IGRA+ = NR 
Incidence density rate IGRA- = NR  
Incidence density rate ratio IGRA = NR 
Comparison between tests (IGRA vs. TST 15mm) 
Ratio of cumulative incidence ratios = 0.38(95% CI: 0.11, 1.34) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NA NA NA TST + NA NA NA 
IGRA - NA NA NA TST - NA NA NA 
Indeterminate NA NA NA Indeterminate NA NA NA 
Total  NA NA NA Total  NA NA NA 
Test performance parameters 
IGRA TST 
Sensitivity = NA Sensitivity = NA 
Specificity = NA Specificity = NA 
PPV = NA PPV = NA 
NPV = NA NPV = NA 
DOR (for T
+
 calculated) = NA DOR (for T
+
 calculated) = NA 
OR (crude; for T
+ 
reported) = NA OR (crude; for T
+ 
reported) = NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
OR (regression-based; reported) = NA 
List of covariates: NA 
Other reported measure = NA Other reported measure = NA 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NA 
Ratio of OR (crude; for T+ reported) = NA 
Ratio of ORs (regression-based; reported) = NA 
Other reported measure = NA 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
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DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality 
of life mean score 
(SD) (specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
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Conclusions 
Authors: 
Neither PPV nor NPV differed significantly from the corresponding values for TST 
Reviewers: 
Small sample; differences in follow up between test positives and negatives may have biased the 
results; some cases may have been prevalent (not incident) 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Name of first reviewer: Alexander Tsertsvadze 
Name of second reviewer: Peter Auguste 
 
Study details 
First author surname year of publication: Kik 2010144 (companion: Kik 2009) 
Country: The Netherlands 
Study design: Prospective cohort study 
Study setting (e.g., outbreak investigation, community-based  - specify): Community-based   
Number of centres: Multicenter (n = 15) 
Total length of follow up (if applicable): 24 mo 
Funding (government/private/manufacturer/other - specify): Unrestricted grants from the Netherlands 
Organization for Health Research and Development (ZonMw; the Hague, the Netherlands) 
Aim of the study 
To assess the positive/negative predictive values (PPV/NPV), sensitivity, and specificity for TB 
disease of QFT-GIT, T-SPOT.TB1 and TST in immigrant individuals in the Netherlands who were 
recently exposed to infectious pulmonary TB patients 
Subgroup of interest (i.e., children, recently arrived people, immunocompromised people) 
Recently arrived people  
Participants 
Recruitment dates: April 2005 to July 2007 
Total N of recruited patients: 433 
Inclusion criteria: Close contacts (aged ≥16 yrs and born in a TB endemic country) of sputum 
smear-positive pulmonary TB patients who tested positive on TST (≥5mm) 
Exclusion criteria: Contacts with known conditions associated with an increased risk of progression 
to disease (including diabetes and HIV infection) and individuals who were given preventive 
treatment 
Total N of excluded patients: 94 (TST<5mm) 
Total N of patients tested with both IGRA and TST: 339 
Total N of patients with valid results for both IGRA and TST: 327 
Methods of active TB diagnosis (if applicable): Contacts diagnosed with TB ≥ 3 months after the 
diagnosis of the index patient were considered to be incident cases, whereas TB cases diagnosed < 3 
months after the diagnosis of the index patient were considered to be co-prevalent and were excluded 
from the analysis. The diagnosis of TB disease was based on chest radiography, symptoms, smear 
and/or culture results 
Outcomes (study-based) list: PPV/NPV, sensitivity, and specificity for the incidence of TB disease 
for QFT-GIT, T-SPOT.TB1 and TST 
Characteristics of participants (total study sample) 
Mean (range or SD) age (years): n = 53 [15.6%] (range: 16–24), n = 80 [23.6%] (range: 25–34), n = 
115 [33.9%] (range: 35–44), and n = 91 [26.8%] (range: ≥45)  
Women (n [%]): 147 [43.4] 
Race/ethnicity (n [%]): NR 
Geographic origin (n[%]): Europe/North America (27 [8.0]), South America (27 [8.0]), Asia (123 
[36.3]), Other Africa (98 [28.9]), Sub-Saharan Africa (59 [17.4]), Unknown (5 [1.5]) 
BCG vaccination (n [%]): 274 [80.8] 
History of anti-TB treatment (n [%]): None 
Total incidence of active TB (n [%]): 9/339 [2.65] 
Chest radiography (yes/no): Yes 
Clinical examination (yes/no): Yes 
Morbidity (n [%]): NR 
Co-morbidity (n [%]): NR 
Type of during-study treatment (n [%]): None 
Number of patients tested 
 Total N 
(tested) 
Total 
N 
Total N 
(test-) 
Total N 
(indeterminate) 
Total N 
(test results 
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(test+) available) 
IGRA (QFT-GIT) 339 178 149 12 327 
IGRA (T-SPOT.TB) 339 181 118 40 299 
TST (≥10mm) 339 288 51 0 339 
TST (≥15mm) 322 184 138 0 322 
Total N of patients with valid results for both IGRA and TST: TST (n = 339), QFT-GIT (n = 
327), and T-SPOT.TB (n = 299) 
Levels/groups of exposure to TB in increasing order (if applicable): 
Definition of exposure group 
Non-exposed  NA 
Exposed 1 (specify): NA 
Exposed 2 (specify): NA 
Exposed 3 (specify): NA 
Exposed 4 (specify): NA 
Tests 
 Assay used, methodology, 
timing for test measurement, 
manufacturer 
Cut-off values/thresholds 
Definition of test+ 
Other 
information 
IGRA (QFT-
GIT) 
Performed according to the 
instructions of the manufacturers 
and tested in a single laboratory 
(Leiden University Medical 
Center, Leiden, the Netherlands) 
Two-tube format positive test 
was defined as ≥ 0.35 
IU/mL-1 
 
NA 
IGRA (T-
SPOT.TB) 
Performed according to the 
instructions of the manufacturers 
and tested in a single laboratory 
(Leiden University Medical 
Center, Leiden, the Netherlands) 
Interpretation of results was 
according to the latest criteria 
defined by the manufacturer 
NA 
TST two tuberculin units, purified 
protein derivative RT23 in 
Tween-80; Statens 
Serum Institute, Copenhagen, 
Denmark) and read after 48–72 
h 
≥ 10mm 
≥ 15mm 
NA 
Association between test results and incidence of active TB (if applicable) 
IGRA(QFT-GIT) TST≥10mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 5 173 178 TST + 9 279 288 
IGRA - 3 146 149 TST - 0 51 51 
Indeterminate 1 11 12 Indeterminate 0 0 0 
Total 9 330 339 Total 9 330 339 
Test performance parameters 
IGRA (excluding indeterminate) TST 
Sensitivity = 5/8 = 62.50% (95% CI: 30.57, 
86.32) 
Sensitivity = 9/9 = 100.00% (95% CI: 70.08, 
100.00) 
Specificity = 146/319 = 45.77% (95% CI: 40.38, 
51.25) 
Specificity = 51/330 = 15.45% (95% CI: 11.95, 
19.75) 
PPV = 5/178 = 2.80% (95% CI: 1.20, 6.40)  PPV = 9/288 = 3.12% (95% CI: 1.65, 5.83) 
NPV = 146/149 = 98.0% (95% CI: 94.20, 99.31)  NPV = 51/51 = 100.00% (95% CI: 93.00, 
100.00) 
Cumulative Incidence IGRA+ = 5/178 = 2.80% Cumulative Incidence TST+ = 9/288 = 3.12% 
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(95% CI: 1.20, 6.40)  (95% CI: 1.65, 5.83)  
Cumulative Incidence IGRA- = 3/149 = 2.00% 
(95% CI: 0.42, 6.02) 
Cumulative Incidence TST- = 0/51 = 1.96 (95% 
CI:0.21, 10.4) 
Cumulative Incidence Ratio IGRA = 1.39 (95% CI: 
0.34, 5.74) 
Cumulative Incidence Ratio TST = 1.59 (95% CI: 
0.21, 71.2) 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR  Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR  
Other reported measure IGRA = NR Other reported measure TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = 0.87 (95% CI: 0.17, 4.56) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR 
Association between test results and incidence of active TB (if applicable) 
IGRA (T-SPOT.TB) TST≥15mm 
 Incidence of 
active TB 
Total  Incidence of 
active TB 
Total 
Yes No Yes No 
IGRA + 6 175 181 TST + 7 177 184 
IGRA - 2 116 118 TST - 1 137 138 
Indeterminate 1 39 40 Indeterminate 0 0 0 
Total 9 330 339 Total 8 314 322 
Test performance parameters 
IGRA (excluding indeterminate) TST 
Sensitivity = 6/8 = 75.00% (95% CI: 40.93, 
92.85) 
Sensitivity = 7/8 = 87.5% (95% CI: 52.91, 97.76) 
Specificity = 116/291 = 39.86% (95% CI: 34.4, 
45.58) 
Specificity = 137/314 = 43.63%  (95% CI: 38.25, 
49.16) 
PPV = 6/181 = 3.31% (95% CI: 1.52, 7.04) PPV = 7/184 = 3.80% (95% CI: 1.85, 7.64) 
NPV = 98.31% (95% CI: 94.03, 99.53) NPV = 137/138 = 99.28% (95% CI: 96.01, 
99.87) 
Cumulative Incidence IGRA+ = 6/181 = 3.31% 
(95% CI: 1.52, 7.04)  
Cumulative Incidence TST+ = 7/184 = 3.80% 
(95% CI: 1.85, 7.64)  
Cumulative Incidence IGRA- = 2/118 = 1.69% 
(95% CI: 0.08, 6.35) 
Cumulative Incidence TST- = 1/138 = 0.72% (95% 
CI:0.00, 4.39) 
Cumulative Incidence Ratio IGRA = 1.95 (95% CI: 
0.40, 9.52) 
Cumulative Incidence Ratio TST = 5.25 (95% CI: 
0.65, 42.17) 
Incidence density rate IGRA+ = NR Incidence density rate TST+ = NR 
Incidence density rate IGRA- = NR  Incidence density rate TST- = NR  
Incidence density rate ratio IGRA = NR Incidence density rate ratio TST = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of cumulative incidence ratios = 0.37(95% CI: 0.10, 1.41) 
Ratio of incidence density rate ratios = NR 
Other reported measure = NR  
Association between test results and levels of TB exposure (if applicable) 
IGRA TST 
 Exposure level Total  Exposure level Total 
High/Yes Low/No High/Yes Low/No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
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IGRA TST 
Sensitivity = NR Sensitivity = NR 
Specificity = NR Specificity = NR 
PPV = NR PPV = NR 
NPV = NR NPV = NR 
DOR (for T+ calculated) = NR DOR (for T+ calculated) = NR 
OR (crude; for T
+ 
reported) = NR OR (crude; for T
+ 
reported) = NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
OR (regression-based; reported) = NR 
List of covariates: NR 
Other reported measure = NR Other reported measure = NR 
Comparison between tests (IGRA vs. TST) 
Ratio of DORs (for T+ calculated) = NR 
Ratio of OR (crude; for T
+ 
reported) = NR 
Ratio of ORs (regression-based; reported) = NR 
Other reported measure = NR 
Association between test results and BCG status (if applicable) 
IGRA TST  
 BCG status Total  BCG status Total 
Yes No Yes No 
IGRA + NR NR NR TST + NR NR NR 
IGRA - NR NR NR TST - NR NR NR 
Indeterminate NR NR NR Indeterminate NR NR NR 
Total  NR NR NR Total  NR NR NR 
Test performance parameters 
IGRA  TST  
DOR (for T+ calculated)IGRA = NR DOR (for T+ calculated)TST = NR 
OR (crude; for T+ reported) = NR OR (crude; for T+ reported) = NR 
OR (regression-based; reported) IGRA = NR  
List of covariates: NR 
OR (regression-based; reported) TST = NR 
List of covariates: NR 
Other reported measure = NR  Other reported measure = NR 
Between-test agreement, concordance, and discordance (if applicable) 
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition 
Total sample 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 1) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
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TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR  
% discordance = NR 
Stratification (specify group 2) 
 TST + TST - Total 
IGRA + NR NR NR 
IGRA - NR NR NR 
Indeterminate NR NR NR 
Total  NR NR NR 
Description  
Sample definition (e.g., total, if stratified by BCG or condition – specify): NR 
TST + threshold: NR 
Parameters 
Kappa = NR 
% concordance = NR 
% discordance = NR 
Other outcomes 
Test and cut-off (if applicable)  Adverse events n/N (%) 
(specify) 
Health related quality of 
life mean score (SD) 
(specify) 
IGRA:  NR NR 
TST: NR NR 
Test 3 (specify): NR NR 
Conclusions 
Authors: 
PPVs of QFT-GIT and T-SPOT.TB for subsequent development of TB disease during the first 2 yrs 
after a contact investigation were comparable to that of the TST, irrespective of the TST cut off (10 or 
15 mm) 
Reviewers: 
The three tests demonstrated similar performance in predicting active TB incidence (PPV and 
sensitivity); TST (≥15mm) and QFT-GIT demonstrated  better specificity compared to TST (≥15mm) 
and  TSPOT.TB 
Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = 
tuberculosis; BCG = Bacillus Calmette–Guérin; PPV = positive predictive value; NPV = negative 
predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation 
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Appendix 10 Included studies and incidence
of tuberculosis228
TABLE 58 Included studies and incidence of TB
Study ID, country Categorya Estimated rate per 100,000 population
Studies in children and adolescents: incidence studies
Diel 2011,102 Germany Low incidence 5.6
Mahomed 2011,103 South Africa High incidence 1003
Metin Timur 2014,150 Turkey Intermediate incidence 22
Noorbakhsh 2011,104 Iran Intermediate incidence 21
Song 2014,152 South Korea High incidence 409
Studies in children and adolescents: exposure studies
Adetifa 2010,105 Gambia High incidence 284
Cruz 2011,106 USA Low incidence 3.6
Kasambira 2011,107 South Africa High incidence 1003
Laniado-Laborın 2014,148 Mexico Intermediate incidence 23
Mahomed 2011,108 South Africa High incidence 1003
Pavic 2011,109 Croatia Low incidence 14
Perez-Porcuna 2014,151 Brazil High incidence 46
Rutherford 2012,110,111 Indonesia High incidence 185
Talbot 2012,112 USA Low incidence 3.6
Tieu 2014,154 Thailand High incidence 119
Tsolia 2010,113 Greece Low incidence 4.5
Studies in immunocompromised people: incidence studies
Anibarro 2012,117 Spain Low incidence 14
Chang 2011,119 South Korea High incidence 409
Elzi 2011,114 Switzerland Low incidence 6
Kim 2011,116 South Korea High incidence 409
Lee 2009,118 Taiwan High incidence 73
Lee 2014,149 South Korea High incidence 409
Moon 2013,115 South Korea High incidence 409
Sherkat 2014,155 Iran Intermediate incidence 21
continued
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TABLE 58 Included studies and incidence of TB (continued )
Study ID, country Categorya Estimated rate per 100,000 population
Studies in immunocompromised people: exposure studies
Ahmadinejad 2013,120 Iran Intermediate incidence 21
Al Jahdali 2013,121 Saudi Arabia Low incidence 15
Ates 2009,122 Turkey Intermediate incidence 22
Casas 2011,123 Spain Low incidence 14
Casas 2011,124 Spain Low incidence 14
Chkhartishvili 2013,125 Georgia High incidence 116
Chung 2010,126 South Korea High incidence 409
Costantino 2013,127 France Low incidence 8.2
Hadaya 2013,128 Switzerland Low incidence 6
Hsia 2012,129 USA Low incidence 3.6
Kim 2010,130 South Korea High incidence 409
Kim 2013,131 South Korea High incidence 409
Kim 2013,132 South Korea High incidence 409
Kleinert 2012,133 Germany Low incidence 5.6
Laffitte 2009,134 Switzerland Low incidence 6
Maritsi 2011,135 UK Low incidence 15
Mutsvangwa 2010,136 Zimbabwe High incidence 562
Papay 2011,137 Austria Low incidence 7.9
Ramos 2013,138 Spain Low incidence 14
Seyhan 2010,139 Turkey Intermediate incidence 22
Shen 2012,140 China High incidence 83
Souza 2014,153 Brazil High incidence 46
Takeda 2011,141 Japan Low incidence 19
Vassilopoulos 2011,142 Greece Low incidence 4.5
Studies in people recently arrived from high burden TB countries: incidence studies
Harstad 2010,143 Norway Low incidence 7.5
Kik 2010,144 the Netherlands Low incidence 6.3
Studies in people recently arrived from high burden TB countries: exposure studies
Lucas 2010,145 Australia Low incidence 6.5
Orlando 2010,146 Italy Low incidence 6.7
Saracino 2009,147 Italy Low incidence 6.7
ID, identification.
a ‘Low incidence’ defined as countries with an incidence of TB of < 20 cases per 100,000 population; ‘intermediate
incidence’ defined as countries with an incidence of TB of ≥ 20 but < 40 cases per 100,000; ‘high incidence’ defined as
countries with an incidence of TB of ≥ 40 cases per 100,000.229,230
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Appendix 11 Data extraction tables for included
cost-effectiveness studies
Date:   
Name of first reviewer:  
Name of second reviewer:  
 
Study details 
Study title  
First author  
Co-authors  
Source of publication 
Journal yy;vol(issue):pp 
 
Language  
Publication type  
Baseline characteristics  
Population  
Intervention(s)  
Comparator(s)  
Outcome(s)  
Study design  
Methods 
Target population and subgroups  
Setting and location  
Study perspective  
Comparators  
Time horizon  
Discount rate  
Outcomes  
Measurement of effectiveness  
Measurement and valuation of 
preference based outcomes 
 
Resource use and costs  
Currency, price date and 
conversion 
 
Model type  
Assumptions   
Analytical methods  
Results 
Study parameters  
Incremental costs and outcomes  
Characterising uncertainty  
Discussion 
Study findings  
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Limitations  
Generalizability  
Other 
Source of funding  
Conflicts of interest  
Comments  
Authors conclusion 
 
Reviewer’s conclusion 
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Date: 18th August, 2014  
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Cost-effectiveness of interferon-gamma release assay for tuberculosis 
screening of rheumatoid arthritis patients prior to initiation of tumour 
necrosis factor-α antagonist therapy 
First author Kowada 
Co-authors None 
Source of publication 
Journal yy;vol(issue):pp 
Molecular diagnosis and therapy  
2010;14(16):367-373 
Language English language 
Publication type Journal article 
Baseline characteristics 
Population Immunocompromised (Rheumatoid arthritis patients prior to tumour 
necrosis factor-α (TNF- α) therapy 
Intervention(s) QuantiFERON gold-in-tube (QFT-GIT) 
Comparator(s) Tuberculin skin test (TST) 
Outcome(s) Cost per quality-adjusted life-year (cost per QALY) 
Study design Cost-effectiveness analysis  
Methods 
Setting and location Not reported 
Study perspective Societal perspective 
Time horizon Lifetime horizon with one-year time cycle lengths 
Discount rate 3% per annum 
Measurement of effectiveness Quality-adjusted life-years 
Measurement and valuation of 
preference based outcomes 
Not reported 
Resource use and costs Screening test for QFT-GIT and TST, costs for treatment of LTBI/TB and 
adverse events 
Currency, price date and 
conversion 
US dollars, costs were adjusted to 2009 Japanese Yen and converted to US 
dollars in 2009, 1 US$  = 93 Japanese Yen 
Model type Decision tree model with Markov nodes (No LTBI, LTBI, TB and death) 
Assumptions  1) The sensitivities for QFT-GIT and TST in people with rheumatoid 
arthritis are assumed to be lower than the sensitivities for an 
immunocompetent population. 
Analytical methods The author conducted one-way and two-way sensitivity analyses by 
changing key model input parameters to determine the impact on the 
deterministic results.  Additionally, probabilistic sensitivity analysis (PSA) 
was undertaken to determine the uncertainty in the key model input 
parameters 
Results 
Study parameters Sensitivity and specificity for QFT and TST.  Other parameters included 
probability of successful treatment, probability of recurrence of active TB 
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after TB adherence to rate of treatment 
Incremental costs and outcomes In the base-case analysis, QFT was less costly and more effective than TST, 
US$1040 vs. US$1820 and 23.0350 vs. 22.9815 QALYs, respectively   
Characterising uncertainty The results from the PSA showed that at society’s willingness-to-pay per 
QALY, the probability of QFT testing strategy has a 100% probability of 
being cost-effective compared to the TST strategy 
Discussion 
Study findings The results showed/demonstrated that QFT was less costly and more 
effective than TST strategy 
Limitations 1) The sensitivities for QFT-GIT and TST in people with rheumatoid 
arthritis are assumed to be lower than the sensitivities for an 
immunocompetent population 
2) There was a lack of information to populate the model on the 
natural history of TB regarding QFT-GIT conversion and reversion 
rate 
3) A paucity of information exists on the incidence of LTBI and 
active TB in people with rheumatoid arthritis treated with TNF-α 
antagonists and this may have an impact on the results 
Generalizability The model presented here may be useful to determine the cost-effectiveness 
of QFT-GIT compared with TST for the diagnosis of LTBI in patients with 
rheumatoid arthritis prior to TNF-α treatment.  The results presented here 
suggested that QFT is the dominant strategy compared to TST alone, but 
some of the key inputs are questionable, for example the utility value of 0.9 
for nonfatal TB in people with rheumatoid arthritis.  This utility value 
appears to be high for people who have rheumatoid arthritis. The model may 
be useful, but these results should be interpreted with caution 
Other 
Source of funding No source of funding 
Conflicts of interest No conflicts of interest 
Comments In table 1, Kowada presented the utility value of non-fatal TB, but have not 
presented other utility values for other health states 
  
Additionally, the starting age of the hypothetical cohort is 40 years, but the 
author included information on the mortality due to people ages 20-29 years 
and 30-39 years 
 
The author conducted probabilistic sensitivity analysis (PSA) on the 
outcome measure of cost per QALY.  However, the distributions placed 
around the key model inputs have not been reported 
Authors conclusion 
The author concluded that the QFT testing strategy is more effective and less costly than TST testing strategy 
for diagnosing LTBI in people with rheumatoid arthritis prior to treatment with TNF-α antagonists for both 
BCG vaccinated and unvaccinated groups 
Reviewer’s conclusion 
The author used an appropriate modelling technique to demonstrate the cost-effectiveness of QFT compared to 
TST in people with rheumatoid arthritis.  Various key health states which relate to LTBI/TB have been included 
in the model structure, but there is some uncertainty in key model input parameters.  The authors have attempted 
to address this uncertainty by using sensitivity analysis and PSA, but have not presented information on the 
distribution used around these model parameters.  Hence, we believe that these results should be interpreted 
with caution 
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Date: 15 August 2014  
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Cost-effectiveness of interferon-gamma release assay for school-based 
tuberculosis screening  
First author Kowada 
Co-authors None 
Source of publication 
Journal yy;vol(issue):pp 
Molecular diagnosis and therapy 
2012;16(3):181-190 
Language English Language 
Publication type Journal article 
Baseline characteristics 
Population Children/adolescents: Immunocompetent children/adolescents aged 16-19 
years old; Students divided into BCG-vaccinated individuals and non BCG-
vaccinated individuals 
Intervention(s) QFT-GIT, chest x-ray 
Comparator(s) TST 
Outcome(s) Cost per quality-adjusted life-years  
Study design Cost-effectiveness analysis 
Methods 
Setting and location Not reported  
Study perspective Societal perspective 
Time horizon Life time horizon (up to 80 years old), one-year cycle length 
Discount rate 3% discount rate per annum 
Measurement of effectiveness Quality-adjusted life-years (QALYs) 
Measurement and valuation of 
preference based outcomes 
Not reported 
Resource use and costs Cost of TST and QFT screening and cost of treatment and adverse events  
Currency, price date and 
conversion 
2009 Japanese yen, converted to US$, using the OECD purchasing power 
parity rate in 2009 
Model type Markov model (Healthy, LTBI, TB and dead) 
Assumptions  The author assumed a high prevalence of LTBI in the Japanese population 
Analytical methods One-way and two-way sensitivity analyses were performed on key model 
input parameters 
Probabilistic sensitivity analyses was undertaken to address the uncertainty 
around key model input parameters and was based on the outcome measure 
of cost per quality-adjusted life-year 
Results 
Study parameters Sensitivity and specificity for QFT, TST and chest x-ray.  Other parameters 
included probability of successful treatment, probability of recurrence of 
active TB after TB adherence to rate of treatment 
Incremental costs and outcomes In the 16-year old sub-group QFT was less costly and more effective than 
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TST, US$628 vs. US$944 and 29.6984 vs. 29.6977 QALYs, respectively   
Characterising uncertainty Results from the sensitivity analyses showed that the results were robust to 
changes made to model input parameters.  From the PSA, the author 
suggested that there was a 100% probability that QFT was cost-effective 
compared to TFT at all society’s willingness-to-pay levels 
Discussion 
Study findings Base-case results showed that in the 16-year old sub-group the QFT test was 
cheaper and produced a moderate benefit in terms of QALYs 
Limitations 1) The author assumed that the prevalence of LTBI was high in this 
Japanese population, this estimate was based on the TST positivity 
rates 
2) The Markov model did not include health states for people who 
received treatment for LTBI 
3) The distress for LTBI testing was not measured in this study.  
Generalizability The author suggested that the results may be applicable to other countries 
where school-based TB testing is being conducted 
Other 
Source of funding No sources of funding 
Conflicts of interest No conflicts of interest 
Comments The author mentioned that in 2008 over 95% of the population had received 
BCG vaccination at least once.  Specificity of TST were stratified by BCG-
vaccinated and non-BCG vaccinated people, however, this was not done for 
QFT or chest x-ray 
Authors conclusion 
The author demonstrated that the use of QFT provided greater benefits than screening with TST or chest x-ray 
in terms of lower costs and identifying more cases of LTBI in this population 
Reviewer’s conclusion 
The author used an appropriate modelling technique to demonstrate the cost-effectiveness of QFT compared to 
TST.  There were some limitations in the model which the author alluded to, for example, not including health 
states where people have received treatment for LTBI/TB.  The author did not state the study setting within 
which the analysis would be undertaken, hence compromising the generalizability of these results.  Additionally, 
we assumed the perspective of the study was the societal perspective because the author suggested that indirect 
costs relating to loss of productivity would be included, these costs were not reported in this paper. We did not 
think it would have been necessary to include indirect costs due to loss of productivity because these 
children/adolescents are assumed to be full-time students 
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Date: 18th August, 2014 
Name of first reviewer: Peter Auguste  
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Cost-effectiveness of interferon-ɣ release assay for tuberculosis screening of 
hemodialysis patients 
First author Kowada 
Co-authors None 
Source of publication 
Journal yy;vol(issue):pp 
Nephrology Dialysis Transplantation  
2013;28:682-688 
Language English language 
Publication type Journal article 
Baseline characteristics 
Population Immunocompromised (haemodialysis patients 40 years of age); sub-groups 
for people who were BCG-vaccinated 
Intervention(s) QFT-GIT,  
Comparator(s) Tuberculin skin test (TST), chest x-ray (CXR) 
Outcome(s) Cost per quality-adjusted life-year (Cost per QALY) 
Study design Cost-effectiveness analysis 
Methods 
Setting and location Not reported 
Study perspective Societal perspective 
Time horizon Lifetime horizon 
Discount rate 3% per annum for costs and benefits 
Measurement of effectiveness QALY 
Measurement and valuation of 
preference based outcomes 
Not reported 
Resource use and costs Direct (inpatient/outpatient) and indirect (loss of productivity) costs, 
screening costs for QFT, TST and CXR.  Other costs included treatment for 
active TB, costs of smear and culture examinations of sputum and treatment 
of adverse events 
Currency, price date and 
conversion 
US$, 2012, costs adjusted to 2012 Japanese Yen, then converted to US 
dollars, using the OECD purchasing power parity rate in 2009 
Model type Markov model (maintenance dialysis with no disorder, maintenance dialysis 
with LTBI, maintenance dialysis with TB and death) 
Assumptions  1) Kowada assumed that the risk of TB-related mortality in ESRD 
patients will increase with age 
2) Key model input parameters (probability of developing TB from 
LTBI, adherence rate of standard treatment, the probability of 
treatment-induced hepatitis, the efficacy if the standard treatment, 
and the recurrence of active TB after treatment) were 
assumed/derived 
3) Further assumptions were on the sensitivity and specificity of QFT, 
TST and CXR 
Analytical methods The author conducted one-way and two-way sensitivity analyses by 
changing key model input parameters to determine the impact on the 
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deterministic results.  Additionally, probabilistic sensitivity analysis (PSA) 
was undertaken to determine the uncertainty in the key model input 
parameters 
Results 
Study parameters Sensitivity and specificity for QFT, TST and chest x-ray.  Other parameters 
included probability of successful treatment, probability of recurrence of 
active TB after TB adherence to rate of treatment 
Incremental costs and outcomes In the base-case analysis, QFT was less costly and more effective than TST, 
US$7690 vs. US$9340 and 4.1926 vs. 4.1854 QALYs, respectively    
Characterising uncertainty One-way sensitivity analysis 
The cost effectiveness of the QFT compared with the TST was sensitive to 
the BCG vaccination rate.  TST strategy was more cost-effective than QFT 
strategy at the willingness-to-pay level of US$50,000 per QALY gained 
when the BCG vaccination rate was o.18 or lower 
 
Probabilistic sensitivity analysis 
The cost-effectiveness acceptability curve of 40-year-old patients by Monte 
Carlo simulations for 10,000 trials demonstrated that the QFT was the most 
cost-effective, with a value of 100% at all willingness-to-pay level 
compared with TST and CXR strategies 
Discussion 
Study findings Base-case results showed that the QFT test was cheaper and produced a 
moderate benefit in terms of QALYs. The QFT testing strategy was 
dominant compared to TST testing strategy 
Limitations 1) No gold standard to diagnose LTBI in the end stage renal disease 
(ESRD) population 
2) Paucity of information on the sensitivity and specificity of QFT-
GIT and TST in people with ESRD 
3) The parameters included in the model may be changeable in more 
precise investigations of TB dynamics 
Generalizability The model presented here may be useful to determine the cost-effectiveness 
of QFT-GIT compared with TST/CXR for the diagnosis of LTBI, but given 
the limitations highlighted on the key model input parameters, results should 
be interpreted here with caution 
Other 
Source of funding Not reported 
Conflicts of interest None declared 
Comments Author has not provided an illustrative structure of the Markov nodes used 
in the model.  The author mentioned that in the TST testing strategy, BCG –
vaccinated people with an induration of ≥5mm and unvaccinated people 
would have undergone a CXR.  However, this has not been illustrated in the 
model. The author conducted PSA around the outcome measure cost per 
QALY.  However, the distributions used around key model input parameters 
were not stated in this paper.  Additionally, the cost-effectiveness 
acceptability curve was not provided in this paper  
Authors conclusion 
The results demonstrated that that QFT screening strategy produced greater benefits in terms of QALYs and 
lower costs compared to TST/CXR for people who have ESRD 
Reviewer’s conclusion 
The author used an appropriate modelling technique to demonstrate the cost-effectiveness of QFT compared to 
TST/CXR in people with ESRD.  The author did not state the study setting within which the analysis would be 
undertaken, hence compromising the generalizability of these results.  Additionally, we assumed the perspective 
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of the study was the societal perspective because the author suggested that indirect costs relating to loss of 
productivity would be included, these costs were not reported in this paper 
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Date: 21st August, 2014  
Name of first reviewer: Peter Auguste  
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Cost-effectiveness of interferon-gamma release assay for TB screening of 
HIVE positive pregnant women in low TB incidence countries 
First author Kowada 
Co-authors None 
Source of publication 
Journal yy;vol(issue):pp 
Journal of infection 2014;68:32-42 
Language English language 
Publication type Journal article 
Baseline characteristics 
Population Immunosuppression (HIV positive pregnant women).  Immunosuppressed 
(20-year old HIV positive pregnant women)  four sub-groups were analysed: 
non-BCG vaccinated cohort during pregnancy, BCG-vaccinated cohort 
during pregnancy, non-BCG vaccinated cohort postpartum period and BCG 
vaccinated cohort in postpartum period 
Intervention(s) Five strategies 
1) TST alone, 2) QFT alone, 3) T-SPOT.TB, 4) TST followed by QFT and 
5) TST followed by T-SPOT.TB 
Comparator(s) See above five compared strategies 
Outcome(s) Cost per QALY 
Study design Cost-effectiveness analysis 
Setting and location Hypothetical cohort followed until age 50 years in three most common 
screening situations; close contacts, immigrants from high burden countries 
and occasional screening in low TB incidence countries 
Methods 
Study perspective Health service perspective 
Comparators TST alone 
Time horizon 30-year time horizon with yearly cycles 
Discount rate 3% per annum for costs and benefits 
Measurement of effectiveness QALY 
Measurement and valuation of 
preference based outcomes 
Not reported 
Resource use and costs Screening test for TST, QFT, T-SPOT.TB, chest x-ray, costs for treatment 
of LTBI/TB and adverse events (Hepatitis). 
Currency, price date and 
conversion 
US$, 2012, 1US$ = ¥ 103.9 (OECD purchasing power parity rate in 2012) 
Model type Markov model (Non-LTBI and non-TB, LTBI, non MDR-TB, MDR-TB and 
Dead) 
Assumptions  Not clearly stated 
Analytical methods The author conducted one-way sensitivity analyses by changing key model 
input parameters to determine the impact on the deterministic results.  
Additionally, probabilistic sensitivity analysis (PSA) was undertaken to 
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determine the uncertainty in the key model input parameters 
Results 
Study parameters Probability of having LTBI among HIV positive pregnant women, incidence 
of TB among HIV positive pregnant, increased mortality among HIV 
positive pregnant women, probability of successful treatment, adherence rate 
of treatment, sensitivity and specificity for TST, QFT, T-SPOT.TB and 
chest x-ray 
Incremental costs and outcomes The results from the base-case analysis showed that T-SPOT.TB was least 
costly and more effective with an incremental cost of US$ 596 and 
incremental QALYs of 0.00705 compared with TST in HIV positive 
pregnant women (non-BCG vaccinated) in close contacts 
Characterising uncertainty Results from the one-way sensitivity analysis showed that the cost-
effectiveness was sensitive to the sensitivity of T-SPOT.TB, the sensitivity 
of QFT, specificity of T-SPOT.TB and the specificity of QFT in close 
contacts during pregnancy and other changes in key model input parameters 
The results from the PSA showed that at society’s willingness-to-pay per 
QALY, there was a 100% probability that TST followed by QFT strategy is 
likely to be cost-effective compared to other testing strategies   
Discussion 
Study findings The results showed that the T-SPOT.TB is less costly and was more 
effective compared to other strategies 
Limitations There were some assumptions which the author acknowledged:- 
1) The probability estimates used in the model were obtained from 
different countries 
2) Estimates on sensitivity and specificity of IGRAs and TST were 
values based on meta-analysis of published literature and 
assumptions made.  The author further suggested that there is little 
evidence to suggest the impact of pregnancy on the 
sensitivity/specificity of IGRAs and TST to diagnose LTBI. 
3) The cost of the side effect by MDR-TB therapy was not calculated 
in the model 
4) The use of chemoprophylaxis for pregnant women is still a 
controversial issue 
5) A paucity of information on the incidence of TB in pregnant 
women and the prevalence of LTBI in HIV positive pregnant 
women 
Generalizability Given the assumptions and the limitations, the model presented may be 
generalizable in a population with women who are pregnant and have HIV 
Other 
Source of funding Author reported no source of funding 
Conflicts of interest Author reported no conflict of interest 
Comments None 
Authors conclusion 
Kowada concluded that the use of IGRA to screen for TB in HIV positive pregnant women is cost-effective in 
countries with low incidence of TB 
Reviewer’s conclusion 
The model presented here is very useful to inform on the cost-effectiveness of IGRAs compared with TST for 
the diagnosis of TB in this patient group.  The author has used an appropriate modelling structure to show LTBI 
progression 
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Date: 18th August 2014 
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Cost-effectiveness of latent tuberculosis screening before steroid therapy for 
idiopathic nephrotic syndrome in children 
First author Laskin 
Co-authors J Goebel, JR Starke, DP Schauer 
Source of publication 
Journal yy;vol(issue):pp 
American journal of kidney diseases 
2013;61(1):22-32 
Language English language 
Publication type Journal article 
Baseline characteristics  
Population Immunosuppressed (Idiopathic nephrotic syndrome in children): children up 
to five years old with idiopathic syndrome 
Intervention(s) Interferon-gamma release assays (second model) 
Comparator(s) Tuberculin skin test 
Outcome(s) Marginal cost per quality-adjusted life-years (cost per QALY) 
Study design Cost-effectiveness analysis 
Methods 
Setting and location Not reported 
Study perspective Societal perspective 
Time horizon Life-time horizon with a three-month cycle length 
Discount rate 3% per annum on costs and benefits 
Measurement of effectiveness Quality- adjusted life-years 
Measurement and valuation of 
preference based outcomes 
Not reported 
Resource use and costs Screening tests, nephrotic onset, nephrotic relapse and treatment of 
LTBI/TB 
Currency, price date and 
conversion 
US$, 2010 prices 
Model type Decision tree structure to model the short term events followed by a Markov 
modelling structure (Well, LTBI, TB, nephrotic relapse and dead) for the 
longer-term events 
Assumptions  1) Children in the model are assumed to be adherent to the medication 
2) Initial risk of reactivation decreases by 10% per decade 
3) Children can only develop active TB on one occasion throughout 
their lifetime 
4) After presentation with LTBI, children were not allowed to be 
screened again for LTBI 
5) In the model, children did not develop multidrug-resistant disease 
6) Authors assumed that people surviving acute infection have 
decreased lung function, hence, lower utility values 
Analytical methods These authors conducted one-way and two-way sensitivity analyses by 
changing key model input parameters to determine the impact on the 
deterministic results.  Additionally, probabilistic sensitivity analysis (PSA) 
was undertaken to determine the uncertainty in the key model input 
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parameters 
Results 
Study parameters Screening test characteristics, prevalence, nephrotic onset, nephrotic relapse, 
mortality and treatment of LTBI/TB 
Incremental costs and outcomes In the base-case analysis, universal IGRA was less costly and more effective 
than universal TST, US$2300 vs. US$2480 and 29.3355 vs. 29.3347 
QALYs, respectively.  However the ‘no screening’ strategy dominated the 
other strategies (universal IGRA, universal TST) being less costly and more 
effective    
Characterising uncertainty The base-case results were robust when indirect medical costs were 
excluded from the analysis 
In the secondary model, targeted screening with a questionnaire followed by 
IGRA was cost-effective compared with no screening at a prevalence >4.9% 
Discussion 
Study findings These authors demonstrated that universal IGRA was less costly and 
produced moderately more QALYs compared to universal TST 
Limitations 1) Lack of gold standard for the diagnosis of LTBI in this patient 
population 
2) The authors acknowledged that indeterminate results and the need 
for venepuncture.  They suggested that indeterminate results which 
can lead to false-negative results in children may have an impact on 
the overall results   
Generalizability The model presented here may be useful to determine the cost-effectiveness 
of IGRAs compared with TST for the diagnosis of LTBI in children with 
idiopathic nephrotic syndrome. The results presented here suggested that the 
‘no screen’ strategy was the dominant strategy compared to universal IGRA 
and universal TST alone.  However, these results should be interpreted with 
caution because the discounted and undiscounted costs were similar in the 
base case results  
Other 
Source of funding No source of funding to conduct study has been stated 
Conflicts of interest No conflicts of interest declared 
Comments A discount rate of 3% per annum was applied both to the costs and benefits.  
These authors presented results both on the undiscounted and discounted 
costs and benefits.  From these results presented, the undiscounted and 
discounted costs are identical.  
These authors have not distinguished between the IGRAs being used in the 
model. They justified this by suggesting that the use of IGRAs in this 
population has not yet been approved 
Authors conclusion 
Based on the results, these authors demonstrated that at a LTBI prevalence of 1.1%, both universal testing and 
targeted TST testing are not cost-effective prior to commencing treatment for five-year olds who are newly 
diagnosed with idiopathic nephrotic syndrome  
Reviewer’s conclusion 
The model used here may be useful, and adds to the existing literature to demonstrate the various screening 
strategies for the diagnosis of LTBI in a population at risk of immunosuppression.  The model includes key 
health states to show the disease progression of LTBI.  Given the limitations outlined by the authors, these 
results showed that the no screening strategy dominated other strategies compared in the model.  However, these 
results should be interpreted with caution because the undiscounted and discounted costs are similar  
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Date: 19th August, 2014 
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Priorities for screening and treatment of latent tuberculosis infection in the 
United States 
First author Linas  
Co-authors AY Wong, KA Freedberg and CR Horsburgh 
Source of publication 
Journal yy;vol(issue):pp 
American journal respiratory and critical care medicine 
2011;184:590-601 
Language English language 
Publication type Journal article 
Baseline characteristics  
Population Various risk groups (immunocompromised and recently arrived immigrants) 
Intervention(s) Interferon-gamma release assays (IGRAs), Tuberculin skin test (TST) 
Comparator(s) No screening  
Outcome(s) Number needed to screen to prevent one case of active TB, life expectancy, 
quality-adjusted life expectancy 
Study design Cost-effectiveness analysis 
Methods 
Setting and location Setting not reported 
Study perspective Health service  
Time horizon Lifetime horizon 
Discount rate 3% per annum for costs and benefits 
Measurement of effectiveness Health-related quality of life 
Measurement and valuation of 
preference based outcomes 
Euroqol five dimensions (EQ-5D) and Medical Outcomes Study (SF-36) 
Resource use and costs Costs for screening LTBI with TST, IGRA, costs of treatment of LTBI and 
active TB, costs of treatment of adverse events 
Currency, price date and 
conversion 
US$, 2011 
Model type Markov model (health states included, LTBI with Isoniazid (INH), LTBI no 
INH, INH related hepatitis, < 6 months INH, 6-8 months INH, 9 months 
INH, Active TB, post active TB and death) 
Assumptions  1) People who did not return for TST reading were not eligible for 
INH therapy 
2) Approximately 10% of TST-positive persons lose their skin test 
reactivity over a decade of follow-up. People here are believed to 
have self-cured.  These authors assumed that a 10% reduction in 
the rate of reactivation each year 
3) The health-related quality of life for people cured for active TB was 
assumed to be the same for healthy people 
4) High-risk groups for screening were already identified and 
managed by existing resources, and did not require programmatic 
costs associated with expanded screening interventions 
Analytical methods Authors conducted one- and two-way sensitivity analysis by varying all 
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model input parameters to explore the uncertainty in these parameter 
estimates 
Results 
Study parameters Estimates of the prevalence of true LTBI in each risk-group, sensitivity and 
specificity for IGRA and TST, probability of people with TST +ve who start 
INH treatment, probability of INH-related hepatitis and utility values for 
various health states 
Incremental costs and outcomes People who had end-stage renal disease (ESRD), the reported ICER for TST 
screen compared to no screen was $824, 500 and $1, 168, 300 for the IGRA 
strategy compared with no screen 
In the base-case analysis, for people who are HIV-infected, TST screen was 
marginally more costly and more effective than the no screen option with an 
ICER of $12, 800.  In this same sub-group, IGRA was marginally more 
costly and more effective than the no screen option with an ICER of $23, 
800 
For people who were on immunosuppressive medication, the reported ICER 
for TST screen compared to no screen was $129, 000 and $227, 900 for the 
IGRA screen compared with no screen 
For people who were recent immigrant adults, TST screening strategy 
dominated the no screen strategy.  Whilst IGRA was marginally more costly 
and more effective than the no screen strategy with an ICER of $35, 200 
Characterising uncertainty Various sensitivity analyses were conducted.  Results from the sensitivity 
analysis showed that increasing the reactivation TB rate in people who are 
immunosuppressive reduced the ICER to below $100, 000 per QALY. 
Additionally, increasing the proportion of people with INH-induced 
hepatitis did not have an impact on the results.  The base-case results were 
sensitive to changes in the health-related quality of life of people treated for 
active TB.  The authors applied a 10% decrement on utility instead of 
assuming people returned to full health.  The results demonstrated that 
screening with IGRA or TST the ICER was less than $100, 000 per QALY 
Discussion 
Study findings Based on the results reported by these authors, people who are taking 
immunosuppressive medications, TST screen was not likely to be cost-
effectives to the no screening strategy.  Similar results were reported for 
people with ESRD 
Limitations There were some limitations to which the authors acknowledged 
1) There are no prospective observational data in the united stated to 
inform on the rate of reactivation TB.  The availability of INH 
prophylaxis for patients with identified LTBI renders natural 
history cohorts unethical 
2) There is no gold standard available to confirm the diagnosis of 
LTBI 
3) The model included direct medical costs, but not indirect costs, 
such as loss of productivity time and transportation costs 
Generalizability Authors may have used information relevant to setting and location that the 
study was conducted.  However, they have not reported the setting the 
analysis was undertaken.  Hence, compromising the generalizability of the 
results 
Other 
Source of funding Supported by the National Institute of Allergy and Infectious Diseases 
(K01AI073193, K24AI062476, R37AI42006) 
Conflicts of interest No conflicts of interest declared 
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Comments The model presented here adds to the existing literature on the cost-
effectiveness of IGRA compared to TST for the diagnosis of LTBI in 
various high-risk populations.  The model incorporates key health states for 
the treatment pathway for people being screened and treated for LTBI.  
Table 3 presents the base-case results, these authors have presented 
information on the number needed to screen to prevent a case of active TB, 
discounted lifetime costs per person, undiscounted per person life 
expectancy, discounted per person quality-adjusted life expectancy (in 
months) and cost per QALY.  From this table of results, we question the 
authors’ values to estimate the ICER given the values presented in this table 
Authors conclusion 
These authors concluded that the use of IGRA in screening people who are close contacts, infected with HIV, 
and foreign-born is likely to be cost-effective when compared to TST  
Reviewer’s conclusion 
The model seems useful and adds to the existing literature on the diagnosis of LTBI.  However, these authors 
have not suggested which IGRA is being used in the model.  In terms of diagnosing LTBI, the sensitivity and/or 
specificity may differ between these populations 
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Date: 28th August, 2014  
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Clinical diagnosis and management of tuberculosis, and measures for its 
prevention and control: cost-effectiveness analysis of interferon gamma 
release assay (IGRA) testing for latent tuberculosis 
First author CG117 
Co-authors Not applicable 
Source of publication 
Journal yy;vol(issue):pp 
Clinical guideline 
Language English language 
Publication type Clinical guideline 
Baseline characteristics  
Population Recently arrived adults from high endemic countries with active TB 
Intervention(s) IGRA, tuberculin (TST) followed by IGRA for people with +ve TST results, 
no testing 
Comparator(s) TST 
Outcome(s) Cost per quality adjusted life-year (cost per QALY) 
Study design Cost-effectiveness analysis 
Methods 
Setting and location UK 
Study perspective National Health Service (NHS) and Personal Social Service (PSS) 
perspective 
Time horizon 15-year time horizon 
Discount rate 3.5% per annum on costs and benefits 
Measurement of effectiveness QALY 
Measurement and valuation of 
preference based outcomes 
Not reported 
Resource use and costs Cost of assessment of active TB, cost of tests (IGRA and TST), cost of 
treatment (LTBI and active TB) 
Currency, price date and 
conversion 
UK £ sterling, 2008/2009 prices 
Model type Decision tree structure 
Assumptions  1) Authors used a decision tree model structure which does not take 
into account the dynamic transmission of tuberculosis.  Assumed 
that each primary case of active TB is associated with a fixed 
number of secondary cases 
2) People who did not have a TST test result were assumed to have 
the same prevalence of LTBI and of active disease as those who do 
3) An average time delay of 0.5 years before people with LTBI who 
go on to develop active TB 
4) For people without current LTBI or active TB who develop TB 
later in life, authors assumed this will occur after an average time 
delay of 0.5 years 
5) The number of secondary cases is assumed to be reduced when the 
index case is detected through contact tracing 
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6) Side-effects as a result of treatment were ignored 
7) People who started treatment for LTBI/TB were assumed to have 
adhere to treatment 
Analytical methods One-way and two-way sensitivity analyses were performed on key model 
input parameters (costs of the IGRA, return rate of the TST results, 
secondary cases, test accuracies, varying the prevalence of LTBI and 
varying the transformation from LTBI to active TB) 
Results 
Study parameters Prevalence of LTBI in population, proportion of infected people with active 
TB. Proportion of TST results read, sensitivity and specificity (IGRA and 
TST), cost of assessment of active TB, cost of tests, cost of treatment 
Incremental costs and outcomes TST/IGRA compared with the no testing strategy was more costly and 
produced more QALYs, £316 vs. £403 and 9.08686 vs. 9.99015, 
respectively. IGRA compared with no testing strategy was more costly, and 
produced more QALYs.  Both strategies were likely to be cost-effective 
with incremental cost-effectiveness ratios (ICERs) below the £30, 000 per 
QALY threshold 
Characterising uncertainty There was no impact on the results when the return rate for TST test results 
where changed.  The increase in the number of secondary cases had a 
positive effect on the cost-effectiveness results. Results from varying the 
accuracy of the tests showed that at high levels of specificity of an IGRA 
test the results showed to be cost-effective at £20, 000 per QALY.  For the 
TST test alone, when the specificity was increased to 80% or above, the 
results showed to be cost-effective.  Conversely, the specificity of the 
combined strategy needed to be low to achieve £20, 000 per QALY 
Discussion 
Study findings The results showed that TST +ve followed by IGRA and IGRA testing 
strategies were associated with ICERs below £30, 000 per QALY compared 
with no testing strategy.  The results from the sensitivity analyses showed 
that varying the cost of an IGRA (£50 to £60) changes the direction of the 
cost-effectiveness results    
Limitations The model used here is subject to limitations, but these were not 
acknowledged by the authors 
Generalizability The model structure used here may be helpful to show the cost-effectiveness 
between testing strategies for LTBI in this population.  The authors have 
stated assumptions made in the model but have not fully accounted for 
uncertainty in the analyses, hence compromising the generalizability of the 
model 
Other 
Source of funding NICE 
Conflicts of interest Not reported 
Comments The model here adds to the existing literature on the use of IGRA and TST 
for the diagnosis of LTBI in the recently arrived immigrants from high 
prevalence of TB countries.  The model structure used here, along with 
some of the assumptions are subject to limitations which were not 
highlighted by the authors 
Authors conclusion 
These authors concluded that IGRA and the TST followed by IGRA testing strategies are likely to be cost-
effective 
Reviewer’s conclusion 
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Given the assumptions and the limitations of the model, these results demonstrated that TST +ve followed by 
IGRA and IGRA testing strategies are likely to be cost-effective in a population with people from high endemic 
TB countries.  The decision tree structure may be subject to some limitations, for example, introducing too 
much static for people developing active TB 
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Date: 15th August 2014  
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Modelling the cost-effectiveness of strategies to prevent tuberculosis in 
child contacts in a high-burden setting 
First author A Mandalakas 
Co-authors A Hesseling, R Gie, H Schaaf, B Marais 
Source of publication 
Journal yy;vol(issue):pp 
Thorax 2012;68(3):247-255 
Language English Language 
Publication type Journal article 
Inclusion criteria/study eligibility/PICOS  
Population Children  
Intervention(s) QFT and T-SPOT.TB 
Comparator(s) TST 
Outcome(s) Cost per life year saved (LYS) 
Study design Cost-effectiveness analysis 
Methods 
Setting and location High-burden TB setting  
Study perspective Provider and societal perspectives 
Comparators TST alone, IGRA alone, +ve TST followed by IGRA and –ve TST followed 
by IGRA 
Time horizon 15 year time horizon 
Discount rate 3% discount rate per annum 
Measurement of effectiveness Life years saved 
Measurement and valuation of 
preference based outcomes 
Not applicable 
Resource use and costs Tests for infection, chest radiography, culture, HIV testing, in/outpatient 
visits, laboratory tests, treatment for LTBI and TB 
Currency, price date and 
conversion 
US dollars, 2009 prices, conversion not stated 
Model type Decision tree structure with Markov nodes (no infection, re-infection, LTBI, 
PTB, disseminated TB, death and death from other causes) 
Assumptions  When used as a confirmatory test following an accurate tuberculin skin test 
(TST), the interferon γ release assay (IGRA) is 100% accurate (sensitive and 
specific) 
Test properties do not vary by age 
The duration of protection offered by a 6-month course of IPT is limited to 
the initial exposure and for the duration of treatment only 
Following Mycobacterium tuberculosis infection and completion of IPT, 
children remain M tuberculosis infected  
Following the initial exposure, children cannot progress from the M 
tuberculosis infection state to active disease states unless they are re-infected 
Children with a history of household TB exposure have the same subsequent 
annual risk of infection as calculated by formal surveys in the setting 
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Children can only progress to the TB death state from the pulmonary or 
disseminated TB states. The disseminated disease state includes TB 
meningitis and other forms of non-pulmonary TB 
Children have the same risk of disease progression following each 
subsequent TB exposure 
Isoniazid-related adverse events are negligible/rare in children 
 
Results 
Study parameters Sensitivity and specificity for TST, IGRA, TST +ve followed by IGRA, 
TST –ve followed by IGRA.  Transition probabilities between health states 
Incremental costs and outcomes In the 0-2 cohort, the no testing strategy dominated other strategies, it was 
least costly and most effective 
In the 0-3 cohort, the TST –ve followed by IGRA was the most cost-
effective with a reported ICER of approximately US$233 000 per LYS 
Characterising uncertainty One-way sensitivity analysis 
In the 0-2 cohort, TST –ve followed by IGRA strategy was the most 
effective strategy when reducing the sensitivity of TST 
In the 3-5 cohort, the no testing strategy dominated the TST –ve followed by 
IGRA when increasing the estimates of sensitivity of TST 
Increasing the rates of LTBI, the IGRA after negative TST became more 
effective that the no testing strategy in both age cohorts 
Discussion 
Study findings In the 0-2 cohort, the no testing strategy dominated other strategies.  In the 
3-5 cohort, the TST –ve strategy followed by IGRA was the most cost-
effective 
Limitations Test performance estimates were derived from studies that examined the test 
accuracy for the identification of TB disease.  These authors assumed that 
IPT usage was similar across strategies 
Generalizability Unclear 
Other 
Source of funding Thrasher Research Fund 
Conflicts of interest No conflicts of interest 
Comments Authors have not conducted probabilistic sensitivity analysis 
Authors conclusion 
Screening for TB infection and provision of IPT in young children < 5 years is highly cost-effective 
Reviewer’s conclusion 
These authors used an appropriate modelling technique to estimate the cost-effectiveness of various strategies 
for the prevention of TB.  The model was subject to some limitations, for which the authors acknowledge and 
the impact these would have made to the results.  Authors have conducted one-way sensitivity analysis, but have 
not undertaken probabilistic sensitivity analysis to show the joint parameter uncertainty and its impact on the 
base-case results 
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Date: 20th August, 2014  
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Community-based evaluation of immigrant tuberculosis screening using 
interferon-gamma release assays and tuberculin skin testing: observational 
study and economic analysis 
First author M Pareek 2013 
Co-authors M Bond, J Shorey, S Seneviratne et al. 
Source of publication 
Journal yy;vol(issue):pp 
Thorax 201;68:230-239 
Language English language 
Publication type Journal article 
Baseline characteristics 
Population Recently arrived immigrants to the UK: Recently arrived immigrants to the 
UK (arrival within the last five years, aged ≥ 16 years (with symptoms of 
TB) or from a country with a TB incidence of ≥ 40/100 000 (asymptomatic) 
Intervention(s) T-SPOT.TB alone, QFT-GIT alone, TST plus confirmatory T-SPOT.TB (if 
TST positive), and TST plus confirmatory QFT-GIT (if TST positive) 
Comparator(s) No screen 
Outcome(s) Cost per case of active TB avoided 
Study design Cost-effectiveness analysis 
Methods 
Setting and location Primary care setting and UK 
Study perspective National health service (NHS) perspective 
Time horizon 20-year time horizon 
Discount rate 3.5% per annum for costs and benefits 
Measurement of effectiveness Cases of active TB  
Measurement and valuation of 
preference based outcomes 
Not applicable 
Resource use and costs Costs for screening LTBI with TST, IGRA, costs of treatment of LTBI and 
active TB, costs of treatment of adverse events 
Currency, price date and 
conversion 
UK £ sterling, 2010 
Model type Decision tree model 
Assumptions  A number of assumptions were made for which the authors acknowledged:- 
1) Immigrants are screened for LTBI once at the start of the time 
horizon 
2) Tuberculin skin test positivity is classified as per UK guidelines 
(≥6mm in BCG unvaccinated and ≥15mm in BCG vaccinated 
3) All IGRA results are determinate and no repeat testing is required 
4) The proportion of immigrants with HIV is reflective of the HIV 
prevalence in their country of origin 
5) A proportion of immigrants with LTBI are infected by a resistant 
strain of Mycobacterium tuberculosis 
6) A proportion of active tuberculosis cases are drug resistant 
7) Amongst those individuals identified with LTBI and treated with 
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chemoprophylaxis, a three month course of rifampicin and 
isoniazid is considered to have equivalent efficacy to six months of 
isoniazid 
8) Individuals who commence chemoprophylaxis and subsequently 
develop drug induced liver injury which does not resolve are 
assumed to only complete 4 weeks of therapy which affords no 
reduction in the risk of progressing from LTBI to active TB 
9) No individuals who develop drug induced liver injury die due to 
this adverse effect 
10) Equal proportions of HIV negative and positive immigrants 
develop drug induced liver injury from chemoprophylaxis 
11) Chemoprophylaxis will have no efficacy in those immigrants who 
have a resistant strain causing their LTBI 
12) An individual with LTBI who has completed successful 
chemoprophylaxis is assumed to have cleared the infection with 
Mycobacterium tuberculosis and will not experience any further 
outcomes during the time course of the model (such as reinfection) 
13) An individual who does not have LTBI on arrival in the UK does 
not become infected during the time-period considered by the 
model 
14) Drug sensitive and drug resistant strains are assumed to be equally 
transmissible (in other words drug resistance does not result in any 
fitness cost) 
15) There is no HIV acquisition within the cohort during the time 
horizon of the model 
16) Data on the test performance of the IGRA was based on the most 
recent meta analysis obtained from meta analyses where sensitivity 
was calculated using culture confirmed active TB as the reference 
standard whilst specificity was calculated from BCG vaccinated 
individuals at low risk of infection 
17) Point estimates for test sensitivity were assumed to be different for 
HIV positive individuals 
18) All individuals diagnosed with drug sensitive active tuberculosis 
are assumed to accept treatment for active TB and to complete the 
6 month course of drugs 
19) All individuals diagnosed with drug resistant active tuberculosis 
are assumed to accept treatment for active TB and to complete the 
course of drugs 
Analytical methods Authors conducted one-way sensitivity analyses on key model input 
parameters to explore the impact on the results of the cost-effectiveness 
Results 
Study parameters HIV prevalence, drug-resistant tuberculosis, sensitivity and specificity of 
various screening tests, prevalence of LTBI and progression rate from LTBI 
to active tuberculosis disease 
Incremental costs and outcomes Base-case results of the cost-effectiveness showed that the screening 
strategy no port-of-entry chest x-ray and screening with one-step QFT-GIT 
was cost-effective with an ICER of 21,570 per case of TB avoided and the 
no port-of-entry chest x-ray and screening with one-step QFT-GIT was cost-
effective, with an ICER of £31,870 per case of active TB avoided.  These 
strategies were cost-effective in immigrants whose country of origin had an 
incidence of TB of 250/100,000 and 150/100,000, respectively 
Characterising uncertainty Results from the sensitivity analyses showed that varying some key model 
input parameters affected the ICER for each of the strategies, but the order 
of the cost-effectiveness results remained the same. The authors found that 
varying the diagnostic specificity of the different screening tests. Reducing 
the specificity of the screening strategies resulted in high ICERs.  
Additionally, changing the proportion of immigrants who commenced, and 
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adhered ti treated also had an impact of the results, making them less cost-
effective.  Furthermore, the estimates for ICERs were sensitive to changes in 
the costs of screening tests 
Discussion 
Study findings Using the decision analytical model, these authors demonstrated that 
screening of recently arrived immigrants from countries of origin with 
moderate (not defined) TB incidence is likely to be cost-effective by the use 
of one-step IGRA testing for LTBI 
Limitations There were some limitations to which the authors have acknowledged while 
undertaking this study.  They highlighted that the sample size was relatively 
small and not all of the immigrants received the three tests. Additionally, 
other areas in the UK may have a greater number of immigrants compared 
to the areas that have been included in the study.  Finally, in line with the 
UK guidelines, the HIV status of immigrants was not tested 
Generalizability The model structure used here may be helpful to show the cost-effectiveness 
between testing strategies for LTBI in this population.  The authors have 
stated assumptions made in the model, and have used information relevant 
to the setting in which the analyses were undertaken  
Other 
Source of funding This study was conducted at St. Mary’s Hospital, Imperial College 
Healthcare NHS Trust which is supported by the NIHR Biomedical 
Research Centre funding scheme.  Westminster Primary Care Trust provided 
funding for this project 
Conflicts of interest AL is inventor for patents underpinning T-cell-based diagnosis. The ESAT-
6/CFP-10 ELISpot was commercialised by an Oxford University spin-out 
company (Oxford Immunotec, Abingdon, UK) in which Oxford University 
and Professor Lalvani have a minority share of equity. All other authors 
have no conflict of interest 
Comments Drug induced liver injury as a result of treatment for active TB/LTBI.  The 
authors suggested that this may be a rare occurrence in this population.  
However, they have not included other adverse events such as hepatitis C   
Authors have not conducted any probabilistic sensitivity analysis  
The illustrative modelling structure was presented in a supplementary web-
appendix, but unfortunately, these figures were illegible 
Authors conclusion 
The authors concluded that immigrant screening may be cost-effective in the UK by removing the mandatory 
chest x-ray on arrival of immigrants and to screen for LTBI with an IGRA.  They suggested that this screening 
should be undertaken in recently arrived people from countries where the incidence is greater than 250, 150 or 
40 cases per 100,000 of active TB 
Reviewer’s conclusion 
These authors evaluated, with the aid of a decision analytical model, the cost-effectiveness of various screening 
strategies for LTBI.  They have collected data to inform on the performance (sensitivity and specificity) of these 
test based on immigrants from three areas in the UK. The methods used to undertake these analyses seem to be 
robust, but due to the illegibility of the modelling structure, it was difficult to appraise the model 
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Date: 22nd August, 2014 
Name of first reviewer: Peter Auguste 
Name of second reviewer: Alexander Tsertsvadze 
 
Study details 
Study title Cost-effectiveness of quantiferon testing before indication of biological 
therapy in inflammatory bowel disease 
First author A Swaminath 
Co-authors N Bhadelia and C Wang 
Source of publication 
Journal yy;vol(issue):pp 
Inflammatory bowel diseases 2013;19(11):2444-2449 
Language English language 
Publication type Journal article 
Baseline characteristics  
Population Immunosuppression (inflammatory bowel disease before anti-TNF-α): 
Hypothetical cohort of people with moderate to severe active Crohn’s 
disease currently being treated with immunomodulators or prednisone 
Intervention(s) QuantiFERON- Gold (QFT-G) 
Comparator(s) Tuberculin skin test (TST) 
Outcome(s) Cost per false negative cases of LTBI avoided, cost per TB deaths avoided, 
cost per reactivation TB avoided (this can be derived from the information 
provided) 
Study design Cost-effectiveness analysis  
Methods 
Setting and location Not reported 
Study perspective Health care payer  
Time horizon One-year time horizon 
Discount rate Not applicable 
Measurement of effectiveness Reduction of reactivation of tuberculosis (TB), death from reactivation of 
TB, false positive test results 
Measurement and valuation of 
preference based outcomes 
Not applicable 
Resource use and costs Costs for screening LTBI with QFT-G, TST, costs of treatment of LTBI and 
, costs of treatment of adverse events, survival of reactivation and death 
from reactivation 
Currency, price date and 
conversion 
US$, price year unknown 
Model type Decision tree structure 
Assumptions  1) If the model showed superiority of testing within the first year, 
benefits will increase over longer periods 
2) An indeterminate test result would lead to a second test 
immediately 
3) A second indeterminate result would lead to a consultation rather 
than treatment with anti-TNF-α 
4) Some outcomes were not modelled because they were considered 
rare: secondary cases of TB from reactivation, reactivation TB 
despite successful treatment with INH, outcomes resulting from 
indeterminate tests or non-adherence with LTBI prophylaxis 
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5) The authors suggested that multidrug resistance is rare in the USA, 
hence this was not modelled 
Analytical methods Authors conducted one-way sensitivity analysis by varying key model input 
parameters to explore the uncertainty in these parameter estimates.  Two-
way sensitivity analyses were also conducted and the results were presented 
in an online supplement of the paper 
Results 
Study parameters Estimates of the prevalence of true LTBI in the USA, sensitivity and 
specificity for QFT-G and TST, anergy TST in immunosuppressed people, 
reactivation TB with biological exposure, probability of death from 
reactivation, side-effect (hepatitis) of INH treatment, probability of 
surviving from hepatitis, costs (QFT-G, TST, LTBI treatment, survival of 
reactivation and death from reactivation) 
Incremental costs and outcomes In a cohort of 1000 immunosuppressed IBD people being screened for 
LTBI, the QFT-G strategy was cheaper than the TST strategy, $84, 850 
compared with $156, 370, respectively.  The use of QFT-G would avoid 30 
false-negative cases, 4.92 TB reactivations and 1.4 deaths compared with 
TST 
Characterising uncertainty From the sensitivity analysis, the QFT-G strategy continued to dominate the 
TST strategy by varying key model input parameters.  The authors 
suggested that the results would change at extreme values, but these 
variations are unlikely to be unrealistic in reality 
Discussion 
Study findings The base-case results showed that QFT-G dominated the TST strategy.  
QFT-G was least costly, and produced greater benefits  
Limitations 1) The accuracy of the model structure to reflect what happens in 
reality is based on the model input parameters used.  
2) There is no gold standard for the diagnosis of LTBI. 
3) The costs used in the model are specific to the USA 
Generalizability The generalizability of these results may be compromised here because of 
the lack of reporting on the setting and location and not presenting the cost-
year for which these costs represent 
Other 
Source of funding Dr. Wang is partially funded by NIH grant KM1 CA156709-01 
Conflicts of interest No conflicts of interest declared 
Comments The authors here have presented a model that illustrates the testing and 
treatment pathway that someone with IBD will undergo if being screened 
for LTBI.  The model demonstrates that the QFT strategy is cheaper and 
offers greater benefits in this patient population.  However, these authors 
have not suggested the year for which these costs represent, hence making 
these results less generalizable 
Authors conclusion 
Based on the results of the cost-effectiveness analysis, they concluded that the QFT-G strategy dominated TST 
in this population, and suggested that QFT-G should be the choice of testing strategy for identifying LTBI in 
people who are immunosuppressed 
Reviewer’s conclusion 
This model adds to the existing literature on the diagnosis of LTBI in an immunosuppressed population.  The 
model is subject to some limitations to which the authors acknowledged.  However, the generalizability of the 
model is somewhat compromised by no suggesting the study setting within which the analyses were conducted, 
and the cost year was not mentioned.  Furthermore, these authors have not stated in this paper the index used to 
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inflate the cost information that was obtained from published sources 
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Appendix 12 Critical appraisal of the economic
evaluation using the Consolidated Health Economic
Reporting Standards checklist
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
631
TA
B
LE
59
C
o
n
so
lid
at
ed
H
ea
lt
h
Ec
o
n
o
m
ic
R
ep
o
rt
in
g
St
an
d
ar
d
s
q
u
al
it
y
as
se
ss
m
en
t
ch
ec
kl
is
t
fo
r
ec
o
n
o
m
ic
ev
al
u
at
io
n
st
u
d
ie
s
A
ss
es
sm
en
t
K
o
w
ad
a
20
10
19
6
K
o
w
ad
a
20
12
19
7
K
o
w
ad
a
20
13
19
8
K
o
w
ad
a
20
14
19
9
La
sk
in
20
13
20
0
Li
n
as
20
11
20
1
M
an
d
al
ak
as
20
13
20
3
C
G
11
71
0
Pa
re
ek
20
13
77
Sw
am
in
at
h
20
13
20
2
Ti
tle
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
A
bs
tr
ac
t
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
In
tr
o
d
u
ct
io
n
Ba
ck
gr
ou
nd
an
d
ob
je
ct
iv
es
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
M
et
h
o
d
s
Ta
rg
et
po
pu
la
tio
n
an
d
su
bg
ro
up
s
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Se
tt
in
g
an
d
lo
ca
tio
n
U
N
C
U
N
C
U
N
C
U
N
C
U
N
C
U
N
C
Y
Y
Y
Y
St
ud
y
pe
rs
pe
ct
iv
e
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
C
om
pa
ra
to
rs
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Ti
m
e
ho
riz
on
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
D
is
co
un
t
ra
te
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
C
ho
ic
e
of
he
al
th
ou
tc
om
es
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
M
ea
su
re
m
en
t
of
ef
fe
ct
iv
en
es
s
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
M
ea
su
re
m
en
t
an
d
va
lu
at
io
n
of
pr
ef
er
en
ce
-b
as
ed
ou
tc
om
es
N
N
N
N
N
Y
N
A
N
Y
Y
Es
tim
at
in
g
re
so
ur
ce
s
an
d
co
st
s
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
C
ur
re
nc
y,
pr
ic
e
da
te
an
d
co
nv
er
si
on
Y
Y
Y
Y
Y
Y
Y
Y
Y
U
N
C
C
ho
ic
e
of
m
od
el
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
A
ss
um
pt
io
ns
Y
Y
Y
U
N
C
Y
Y
Y
Y
Y
Y
A
na
ly
tic
al
m
et
ho
ds
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
APPENDIX 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
632
A
ss
es
sm
en
t
K
o
w
ad
a
20
10
19
6
K
o
w
ad
a
20
12
19
7
K
o
w
ad
a
20
13
19
8
K
o
w
ad
a
20
14
19
9
La
sk
in
20
13
20
0
Li
n
as
20
11
20
1
M
an
d
al
ak
as
20
13
20
3
C
G
11
71
0
Pa
re
ek
20
13
77
Sw
am
in
at
h
20
13
20
2
R
es
u
lt
s
St
ud
y
pa
ra
m
et
er
s
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
In
cr
em
en
ta
lc
os
ts
an
d
ou
tc
om
es
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
C
ha
ra
ct
er
is
in
g
un
ce
rt
ai
nt
y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
D
is
cu
ss
io
n
St
ud
y
fin
di
ng
s
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Li
m
ita
tio
ns
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
G
en
er
al
is
ab
ili
ty
Y
Y
U
N
C
Y
U
N
C
U
N
C
U
N
C
Y
Y
N
O
th
er
So
ur
ce
of
fu
nd
in
g
Y
Y
U
N
C
Y
Y
Y
Y
Y
Y
Y
C
on
fli
ct
s
of
in
te
re
st
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
,
no
;
N
A
,
no
t
ap
pl
ic
ab
le
;
U
N
C
,
un
cl
ea
r;
Y
,
ye
s.
DOI: 10.3310/hta20380 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 38
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
633

Appendix 13 Critical appraisal of the economic
models using an adapted Philips et al.195 checklist
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Appendix 14 List of studies excluded from the
cost-effectiveness review with reasons for
exclusion (n = 15)
TABLE 61 List of studies excluded from the cost-effectiveness review
Number Author ID Details Reason(s) for exclusion
1 Burgos JL Targeted screening and treatment for latent tuberculosis
infection using QuantiFERON-TB Gold is cost-effective in
Mexico. Int J Tuberc Lung Dis 2009;13:962–8
No comparator
2 Deuffic-Burban Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin
test in the diagnosis of latent tuberculosis infection. Int J
Tuberc Lung Dis 2010;14:471–81
Close contacts
3 Diel R Enhanced cost–benefit analysis of strategies for LTBI
screening and INH chemoprevention in Germany. Respir Med
2009;103:1838–53
Cost analysis
4 Hardy AB Cost-effectiveness of the NICE guidelines for screening for
latent tuberculosis infection: the QuantiFERON-TB Gold IGRA
alone is more cost-effective for immigrants from high burden
countries. Thorax 2010;65:178–80
No economic model
5 Iqbal AZ Cost-effectiveness of using QuantiFERON Gold (QFT-G) versus
tuberculin skin test (TST) among US and foreign born
populations at a public health department clinic with a low
prevalence of tuberculosis. Public Health Nurs
2014;31:144–52
No economic model
6 Jit M Dedicated outreach service for hard to reach patients with
tuberculosis in London: observational study and economic
evaluation. BMJ 2011;343:d5376
Active TB
7 Kawamura LM IGRAs in public health practice: economic issues. Int J Tuberc
Lung Dis 2010;14(Suppl. 1):60–3
Letter to editor
8 Langley I Modelling the impacts of new diagnostic tools for
tuberculosis in developing countries to enhance policy
decisions. Health Care Manag Sci 2012;15:239–53
Active TB
9 Mancuso JD Cost-effectiveness analysis of targeted and sequential
screening strategies for latent tuberculosis. Int J Tuberc Lung
Dis 2011;15:1223–30
Military recruits
10 Pareek M Screening of immigrants in the UK for imported latent
tuberculosis: a multicentre cohort study and cost-effectiveness
analysis. Lancet Infect Dis 2011;11:435–44
No comparator
11 Pooran A Different screening strategies (single or dual) for the diagnosis
of suspected latent tuberculosis: a cost-effectiveness analysis.
BMC Pulm Med 2010;10:7
Close contacts
12 Shah M QuantiFERON-TB Gold in-Tube implementation for
latent tuberculosis diagnosis in a public health clinic:
a cost-effectiveness analysis. BMC Infect Dis 2012;12:360
TST-positive referrals
continued
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TABLE 61 List of studies excluded from the cost-effectiveness review (continued )
Number Author ID Details Reason(s) for exclusion
13 Steffen RE Cost-effectiveness of QuantiFERON-TB Gold-in-Tube versus
tuberculin skin testing for contact screening and treatment
of latent tuberculosis infection in Brazil. PLOS ONE
2013;8:e59546
Immunocompetent close
contacts
14 van der Have M Optimizing screening for tuberculosis and hepatitis B prior to
starting tumor necrosis factor-alpha inhibitors in Crohn’s
disease. Dig Dis Sci 2014;59:554–63
Intervention not of
interest
15 Verma G Tuberculosis screening for long-term care: a cost-effectiveness
analysis. Int J Tuberc Lung Dis 2013;17:1170–7
Compared screening
strategies (no screening,
LTBI screening and active
TB screening)
ID, identification.
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Appendix 15 Illustrative structures for the
immunocompromised population, recent arrivals from
countries with a high incidence of active tuberculosis
and the general population
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DDeterminate result and TST read
Determinate result and TST not read
Indeterminate result and TST read
Indeterminate result and TST not read
+ve IGRA and +ve TST
+ve IGRA and –ve TST
–ve IGRA and –ve TST
+ve IGRA
+ve TST
–ve TST
–ve IGRA
–ve IGRA and +ve TST
FIGURE 64 Pathway for the diagnostic strategy IGRA and TST in the immunocompromised population.
–ve, negative; +ve, positive.
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DDeterminate result and TST read
Determinate result and TST not read
Indeterminate result and TST read
Indeterminate result and TST not read
+ve IGRA and +ve TST
+ve IGRA and –ve TST
–ve IGRA and –ve TST
+ve IGRA
+ve TST
–ve TST
–ve IGRA
–ve IGRA and –ve TST
FIGURE 69 Pathway for the diagnostic strategy of IGRA and TST in the recently arrived population. –ve, negative;
+ve, positive.
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DDeterminate result and TST read
Determinate result and TST not read
Indeterminate result and TST read
Indeterminate result and TST not read
+ve IGRA and +ve TST
+ve IGRA and –ve TST
–ve IGRA and –ve TST
+ve IGRA
+ve TST
–ve TST
–ve IGRA
–ve IGRA and –ve TST
FIGURE 74 Pathway for the diagnostic strategy of IGRA and TST in the general population. –ve, negative;
+ve, positive.
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Appendix 16 Resources used to derive unit costs
for the treatment of latent tuberculosis infection and
tuberculosis and model input parameters
TABLE 62 Treatment for LTBI
Resource use Quantity Description
Unit costs
(£, 2013) Source
Investigations
Full blood
count
2 DAPS08 – Phlebotomy 4 Assumptions and consultation
with clinical expert on the number
of full blood counts, liver function
tests and outpatient visits (NICE
TB Guideline Development Group,
12 January 2015, personal
communication); NHS reference
costs 2012/13;214 Curtis217
Liver function
test
4 DAPS08 – Phlebotomy 4
Outpatient
visits
2 visits Weighted average of all
outpatient procedures
135
Nurse contact
(in clinic)a,b
3 visits 15 minutes 12.25 Assumption and consultation with
clinical expert; Curtis217
Drug treatment
Isoniazid 18 packs (28 × 100-mg
tablets per pack)
6 months of isoniazidc 19.24 NHS electronic drug tariff216
Estimated cost per person for treatment of LTBI 677.07 (6H)
a We assumed that a nurse specialist employed on the NHS scale Agenda for Change band 6 point 27 would require
15 minutes of contact time with a LTBI patient.
b People who refuse treatment are informed and advised. We assumed that a nurse specialist employed on the NHS scale
Agenda for Change band 6 point 27 would require 15 minutes to inform and advise an individual.
c Based on a requirement of 300mg daily for 6 months.
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TABLE 63 Treatment for TB
Resource use Quantity Description
Unit costs
(£, 2013) Source
Investigations
Chest radiography 3 DAPF – Direct access plain
film
28 NHS reference costs
2012/13214
Sputum examination 6 DAPS07 – Microbiology 7
Full blood count 2 DAPS08 – Phlebotomy 4
Liver function test 8 DAPS08 – Phlebotomy 4
Inpatient stay 7.28 days DZ14E – Pulmonary, Pleural
or Other Tuberculosis, with
CC Score 0–1
492 Bothamley et al.215
Outpatient visits 8 visits Weighted average of all
outpatient procedures
135
Drug treatment
Ethambutol 6 packs 1200mg daily for 2 months 256.44 BNF231
Pyrazinamide 8 packs 2 g daily for 2 months 250.80 BNF231
Rifinah® (300mg/150mg)
(Sanofi) (isoniazid 150mg,
rifampicin 300mg)
6 packs Two tablets daily for
6 months
126.12 BNF231
Estimated cost for treatment of active TB per person 5461.12
BNF, British National Formulary; CC, complication and comorbidity.
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TABLE 64 Model input parameters required for the immunocompromised population
Variable
Base-case
value Range for SA PSA distribution Source
Probabilities
Prevalence of LTBI 0.0222 0.0152–0.0306 a Derived from the current
clinical effectiveness study
Sensitivity TST (≥ 5mm) 0.3242 0.1119–0.5848 a
Specificity TST (< 5mm) 0.7422 0.7288–0.7557 a
Sensitivity TST (≥ 10mm) 0.1682 0.0252–0.3899 a
Specificity TST (< 10mm) 0.8397 0.7899–0.8831 a
Sensitivity QFT-GIT 0.5548 0.2473–0.8373 a
Specificity QFT-GIT 0.8227 0.8052–0.8396 a
Sensitivity T-SPOT.TB 0.6665 0.3517–0.9144 a
Specificity T-SPOT.TB 0.6846 0.6346–0.7331 a
Sensitivity of TST conditional on
negative QFT-GIT (LTBI arm)
0.2775 0.0121–0.7989 Not varied
Specificity of TST conditional on
negative QFT-GIT (no LTBI arm)
0.4465 0.3909–0.4993 Not varied
Sensitivity of TST conditional on
positive QFT-GIT (LTBI arm)
0.4206 0.0023–0.3891 Not varied
Specificity of TST conditional on
positive QFT-GIT (no LTBI arm)
0.8058 0.00006–0.8058 Not varied
Determinate QFT-GIT 0.97 – Beta(873,27) Derived from Laskin
et al.200
Determinate T-SPOT.TB 0.97 – Beta(873,27) Derived from Laskin
et al.200
TST read 0.9400 0.6–1.00 Beta(164,10.5) Pareek et al.77
Initial active TB 0.00001 – Not varied Laskin et al.200
TB treatment adherence 1.0000 – Not varied Pareek et al.77
Accepting LTBI treatment 0.9400 0.50–1.00 Beta(141,9) CG11710
Adherence to LTBI treatment 0.8000 0.50–0.90 Beta(41,10) Kowada198
Isoniazid-induced hepatitis after
TB treatment
0.0040 0.001–0.010 Beta(2.7,664) Assumption
Isoniazid-induced hepatitis after
LTBI treatment
0.0040 0.001–0.010 Beta(2.7,664) Laskin et al.200
Death from isoniazid-induced
hepatitis
0.00002 0.00001–0.0001 Beta(0.5,25125) Pooran et al.209
Transmission model parameters
Proportion still infected post
LTBI treatment
0.345 – Log-normal
(–1.065,0.842)
White and Jit210
Average number of secondary
cases from one index case
0.2 0.1–0.3 Log-normal
(–1.609,0.354)
Pareek et al.6
Average delay from infection to
activation
2.88 – Log-normal
(1.058,0.333)
Okuonghae et al.211
continued
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TABLE 64 Model input parameters required for the immunocompromised population (continued )
Variable
Base-case
value Range for SA PSA distribution Source
Annualised reactivation rate
from resolved TB
0.013 0.004–0.025 Beta(7,513) Oxlade et al.212
Case fatality rate for active TB
(0–4 years)
0.0477 – Beta(628,12543) Crofts et al.213
Case fatality rate for active TB
(5–14 years)
0.0034 – Beta(1,290) Crofts et al.213
Case fatality rate for active TB
(15–44 years)
0.0018 – Beta(1,564) Crofts et al.213
Case fatality rate for active TB
(45–64 years)
0.0476 – Beta(125,2500) Crofts et al.213
Case fatality rate for active TB
(≥ 65 years)
0.1755 – Beta(413,1940) Crofts et al.213
Resource use and costs (£)
TST 17.48 Not varied Pooran et al.209
QFT-GIT 48.73 Not varied Pooran et al.209
T-SPOT.TB 59.57 Not varied Pooran et al.209
Chest radiography 35.00 Not varied NHS reference costs
2012/13214
Sputum examination 7.00 Not varied NHS reference costs
2012/13214
Adherence to active TB
treatment
5461.12 Gamma
(10.41,524.6)
Bothamley et al.215
Cost of non-adherence to
active TB treatment
910.19 Not varied Assumption
Adherence to LTBI treatmentb 677.07 Uniform
(511.69,842.45)
NHS electronic drug
tariff216
Cost of non-adherence to LTBI
treatment
112.85 Uniform
(85.24,140.41)
Assumption
Treatment of isoniazid-induced
hepatitis
389.51 Gamma
(7.13,55.64)
Pareek et al.77
Utility decrements
Active TB (while on treatment) 0.15c Not reported Gamma
(11.2,0.0134)
Derived from Kowada197
Treatment for LTBI 0.0010 Not reported Uniform(0,0.002)
Other
Discount rate per annum (costs
and QALYs)
3.5%
SA, sensitivity analysis.
a Calculated from posterior distributions generated by MCMC.
b Management of LTBI in children includes drug treatment alone.
c QALY decrement for people being treated for active TB.
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TABLE 65 Model input parameters required for the recently arrived population
Variable
Base-case
value Range for SA PSA distribution Source
Probabilities
Prevalence of LTBI 0.0237 0.0150–0.0345 a Derived from the current
clinical effectiveness study
Sensitivity TST (≥ 5mm) 0.9356 0.7786–0.9977 a
Specificity TST (< 5mm) 0.5011 0.4790–0.5229 a
Sensitivity TST (≥ 10mm) 0.5915 0.3584–0.8172 a
Specificity TST (< 10mm) 0.7929 0.7780–0.8073 a
Sensitivity T-SPOT.TB 0.7001 0.3978–0.9242 a
Specificity T-SPOT.TB 0.3992 0.3439–0.4554 a
Sensitivity of QFT-GIT
conditional on negative TST
(LTBI arm)
0.6009 0.3465–0.8514 a
Specificity of QFT-GIT
conditional on positive TST
(no LTBI arm)
0.6102 0.5775–0.6421 a
Sensitivity of QFT-GIT
conditional on negative TST
(LTBI arm)
0.4807 0.0225–0.9724 a
Specificity of QFT-GIT
conditional on negative TST
(no LTBI arm)
0.9746 0.9555–0.9893 a
Sensitivity of CXR for
diagnosing active TB
0.7800 Not reported Not varied Kumar et al.208
Specificity of CXR for
diagnosing active TB
0.5100 Not reported Not varied Kumar et al.208
Determinate QFT-GIT 0.97 – Beta(873,27) Derived from Laskin et al.200
Determinate T-SPOT.TB 0.97 – Beta(873,27) Derived from Laskin et al.200
TST read 0.9400 0.6–1.00 Beta(164,10.5) Pareek et al.77
Initial active TB 0.00001 – Not varied Laskin et al.200
TB treatment adherence 1.0000 – Not varied Pareek et al.77
Accepting LTBI treatment 0.9400 0.50–1.00 Beta(141,9) CG11710
Adherence to LTBI treatment 0.8000 0.50–0.90 Beta(41,10) Kowada198
Isoniazid-induced hepatitis
after TB treatment
0.0040 0.001–0.010 Beta(2.7,664) Assumption
Isoniazid-induced hepatitis
after LTBI treatment
0.0040 0.001–0.010 Beta(2.7,664) Laskin et al.200
Death from isoniazid-
induced hepatitis
0.00002 0.00001–0.0001 Beta(0.5,25125) Pooran et al.209
Transmission model parameters
Proportion still infected post
LTBI treatment
0.345 – Log-normal
(–1.065,0.842)
White and Jit210
Average number of
secondary cases from one
index case
0.2 0.1–0.3 Log-normal
(–1.609,0.354)
Pareek et al.6
continued
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TABLE 65 Model input parameters required for the recently arrived population (continued )
Variable
Base-case
value Range for SA PSA distribution Source
Average delay from infection
to activation
2.88 – Log-normal
(1.058,0.333)
Okuonghae et al.211
Annualised reactivation rate
from resolved TB
0.013 0.004–0.025 Beta(7,513) Oxlade et al.212
Case fatality rate for active
TB (0–4 years)
0.0477 – Beta(628,12543) Crofts et al.213
Case fatality rate for active
TB (5–14 years)
0.0034 – Beta(1,290) Crofts et al.213
Case fatality rate for active
TB (15–44 years)
0.0018 – Beta(1,564) Crofts et al.213
Case fatality rate for active
TB (45–64 years)
0.0476 – Beta(125,2500) Crofts et al.213
Case fatality rate for active
TB (≥ 65 years)
0.1755 – Beta(413,1940) Crofts et al.213
Resource use and costs
TST 17.48 – NA Pooran et al.209
QFT-GIT 48.73 – NA Pooran et al.209
T-SPOT.TB 59.57 – NA Pooran et al.209
CXR 35.00 – NA NHS reference costs
2012/13214
Sputum examination 7.00 – NA NHS reference costs
2012/13214
Cost of adherence to active
TB treatment
5461.12 – Gamma
(10.41,524.6)
Bothamley et al.215
Cost of non-adherence to
active TB treatment
910.19 – Not varied Assumption
Adherence to LTBI treatment 677.07 – Uniform
(511.69,842.45)
NHS electronic drug tariff216
Cost of non-adherence to
LTBI treatment
112.85 – Gamma
(85.24,140.41)
Assumption
Treatment of INH-induced
hepatitis
389.51 – Gamma
(7.13,55.64)
Pareek et al.77
Utility decrements
Active TB (while on
treatment)
0.15b Not reported Gamma
(11.2,0.0134)
Derived from Kowada197
Treatment for LTBI 0.001 Not reported Uniform(0,0.002)
Other
Discount rate per annum
(costs and QALYs)
3.5%
CXR, chest radiography; NA, not applicable; SA, sensitivity analysis.
a Calculated from posterior distributions generated by MCMC.
b QALY decrement for people being treated for active TB.
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Appendix 17 WinBUGS code
In this appendix we report on the WinBUGS code used in the evidence synthesis for the child population.The WinBUGS codes used for the immunocompromised and recently arrived populations are very similar
but use different sample data. Table 66 shows the variables and descriptions used in the models.
TABLE 66 Variables and descriptions used in the WinBUGS model
Variable name Description
Prev Prevalence
pposQFTG Probability of a positive QFT-G result
sensQFTG Sensitivity of QFT-G
specQFTG Specificity of QFT-G
ATBposQFTG Number of active TB cases given a positive result on QFT-G
pATBposQFTG Probability of active TB given a positive result on QFT-G
ATBnegQFTG Number of active TB cases given a negative result on QFT-G
pATBnegQFTG Probability of active TB given a negative result on QFT-G
pposQFTGIT Probability of a positive QFT-GIT result
sensQFTGIT Sensitivity of QFT-GIT
specQFTGIT Specificity of QFT-GIT
ATBposQFTGIT Number of active TB cases given a positive result on QFT-GIT
pATBposQFTGIT Probability of active TB given a positive result on QFT-GIT
ATBnegQFTGIT Number of active TB cases given a negative result on QFT-GIT
pATBnegQFTGIT Probability of active TB given a negative result on QFT-GIT
pposTSPOTTB Probability of a positive T-SPOT.TB result
sensTSPOTTB Sensitivity of T-SPOT.TB
specTSPOTTB Specificity of T-SPOT.TB
ATBposTSPOTTB Number of active TB cases given a positive result on T-SPOT.TB
pATBposTSPOTTB Probability of active TB given a positive result on T-SPOT.TB
ATBnegTSPOTTB Number of active TB cases given a negative result on T-SPOT.TB
pATBnegTSPOTTB Probability of active TB given a negative result on T-SPOT.TB
pposTST5 Probability of a positive TST5 result
sensTST5 Sensitivity of TST5
specTST5 Specificity of TST5
ATBposTST5 Number of active TB cases given a positive result on TST5
pATBposTST5 Probability of active TB given a positive result on TST5
ATBnegTST5 Number of active TB cases given a negative result on TST5
pATBnegTST5 Probability of active TB given a negative result on TST5
pposTST10 Probability of a positive TST10 result
sensTST10 Sensitivity of TST10
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WinBUGS code used in the child population
model{
for (study in 1:Nstudy){
prev[study] <- mprev
#Binomial link between the number of positive results and probability of a positive result
rplusTST10[study] ∼dbin(pposTST10[study],Npats[study,1])
rminusTST10[study] <- Npats[study,1] - rplusTST10[study]
TABLE 66 Variables and descriptions used in the WinBUGS model (continued )
Variable name Description
specTST10 Specificity of TST10
ATBposTST10 Number of active TB cases given a positive result on TST10
pATBposTST10 Probability of active TB given a positive result on TST10
ATBnegTST10 Number of active TB cases given a negative result on TST10
pATBnegTST10 Probability of active TB given a negative result on TST10
pposTST15 Probability of a positive TST15 result
sensTST15 Sensitivity of TST15
specTST15 Specificity of TST15
ATBposTST15 Number of active TB cases given a positive result on TST15
pATBposTST15 Probability of active TB given a positive result on TST15
ATBnegTST15 Number of active TB cases given a negative result on TST15
pATBnegTST15 Probability of active TB given a negative result on TST15
TST5QFTGIT Probability of positive QFT-GIT following a positive result on TST5
TST10QFTGIT Probability of positive QFT-GIT following a positive result on TST10
APPENDIX 17
NIHR Journals Library www.journalslibrary.nihr.ac.uk
666
pposTST10[study] <- prev[study]*sensTST10 + (1-prev[study])*(1-specTST10)
ATBposTST10[study]∼dbin(pATBposTST10[study],rplusTST10[study])
pATBposTST10[study] <- prev[study]*sensTST10/pposTST10[study]
ATBnegTST10[study]∼dbin(pATBnegTST10[study],rminusTST10[study])
pATBnegTST10[study] <- prev[study]*(1-sensTST10)/(prev[study]*(1-sensTST10)+specTST10*(1-prev[study]))
rplusTST10IT[study] ∼dbin(pposTST10IT[study],Npats[study,2])
rminusTST10IT[study] <- Npats[study,2] - rplusTST10IT[study]
pposTST10IT[study] <- prev[study]*sensTST10IT + (1-prev[study])*(1-specTST10IT)
ATBposTST10IT[study]∼dbin(pATBposTST10IT[study],rplusTST10IT[study])
pATBposTST10IT[study] <- prev[study]*sensTST10IT/pposTST10IT[study]
ATBnegTST10IT[study]∼dbin(pATBnegTST10IT[study],rminusTST10IT[study])
pATBnegTST10IT[study] <- prev[study]*(1-sensTST10IT)/(prev[study]*(1-sensTST10IT)+specTST10IT*(1-prev
[study]))
rplusTSPOTTB[study] ∼dbin(pposTSPOTTB[study],Npats[study,3])
rminusTSPOTTB[study] <- Npats[study,3] - rplusTSPOTTB[study]
pposTSPOTTB[study] <- prev[study]*sensTSPOTTB + (1-prev[study])*(1-specTSPOTTB)
ATBposTSPOTTB[study]∼dbin(pATBposTSPOTTB[study],rplusTSPOTTB[study])
pATBposTSPOTTB[study] <- prev[study]*sensTSPOTTB/pposTSPOTTB[study]
ATBnegTSPOTTB[study]∼dbin(pATBnegTSPOTTB[study],rminusTSPOTTB[study])
pATBnegTSPOTTB[study] <- prev[study]*(1-sensTSPOTTB)/(prev[study]*(1-sensTSPOTTB)+specTSPOTTB*
(1-prev[study]))
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rplusTST10[study] ∼ dbin(pposTST10[study],Npats[study,4])
rminusTST10[study] <- Npats[study,4] - rplusTST10[study]
pposTST10[study] <- prev[study]*sensTST10 + (1-prev[study])*(1-specTST10)
ATBposTST10[study]∼dbin(pATBposTST10[study],rplusTST10[study])
pATBposTST10[study] <- prev[study]*sensTST10/pposTST10[study]
ATBnegTST10[study]∼dbin(pATBnegTST10[study],rminusTST10[study])
pATBnegTST10[study] <- prev[study]*(1-sensTST10)/(prev[study]*(1-sensTST10)+specTST10*(1-prev[study]))
rplusTST10[study] ∼dbin(pposTST10[study],Npats[study,5])
rminusTST10[study] <- Npats[study,5] - rplusTST10[study]
pposTST10[study] <- prev[study]*sensTST10 + (1-prev[study])*(1-specTST10)
ATBposTST10[study]∼dbin(pATBposTST10[study],rplusTST10[study])
pATBposTST10[study] <- prev[study]*sensTST10/pposTST10[study]
ATBnegTST10[study]∼dbin(pATBnegTST10[study],rminusTST10[study])
pATBnegTST10[study] <- prev[study]*(1-sensTST10)/(prev[study]*(1-sensTST10)+specTST10*(1-prev[study]))
rplusTST15[study] ∼dbin(pposTST15[study],Npats[study,6])
rminusTST15[study] <- Npats[study,6] - rplusTST15[study]
pposTST15[study] <- prev[study]*sensTST15 + (1-prev[study])*(1-specTST15)
ATBposTST15[study]∼dbin(pATBposTST15[study],rplusTST15[study])
pATBposTST15[study] <- prev[study]*sensTST15/pposTST15[study]
ATBnegTST15[study]∼dbin(pATBnegTST15[study],rminusTST15[study])
pATBnegTST15[study] <- prev[study]*(1-sensTST15)/(prev[study]*(1-sensTST15)+specTST15*(1-prev[study]))
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}for (i in 1:N.cs){
rplusTST10TST10IT[i]∼dbin(pplusTST10TST10IT[i],rplusTST10[cs.index[i]])
pplusTST10TST10IT[i] <-prev[cs.index[i]]*sensTST10*cpos.sensTST10IT5+((1-specTST10)*(1-prev[cs.index[i]])
*(1-cpos.specTST10IT5))/pposTST10[cs.index[i]]
rnegTST10TST10IT[i]∼dbin(pnegTST10TST10IT[i],rminusTST10[cs.index[i]])
pnegTST10TST10IT[i] <-((1-prev[cs.index[i]])*specTST10*cneg.specTST10IT5+(1-sensTST10)*prev[cs.index[i]]
*(1-cneg.sensTST10IT5))/((1-prev[cs.index[i]])*specTST10+prev[cs.index[i]]*(1-sensTST10))
}
for (i in 1:N.cs2){
rplusTST10TST10IT[i]∼dbin(pplusTST10TST10IT[i],rplusTST10[cs2.index[i]])
pplusTST10TST10IT[i] <-prev[cs2.index[i]]*sensTST10*cpos.sensTST10IT10+((1-specTST10)*(1-prev
[cs2.index[i]])*(1-cpos.specTST10IT10))/pposTST10[cs2.index[i]]
rnegTST10TST10IT[i]∼dbin(pnegTST10TST10IT[i],rminusTST10[cs2.index[i]])
pnegTST10TST10IT[i] <-((1-prev[cs2.index[i]])*specTST10*cneg.specTST10IT10+(1-sensTST10)*prev
[cs2.index[i]]*(1-cneg.sensTST10IT10))/((1-prev[cs2.index[i]])*specTST10+prev[cs2.index[i]]*(1-sensTST10))
}
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sensTST10IT <- cpos.sensTST10IT5*sensTST10 + cneg.sensTST10IT5*(1-sensTST10)
specTST10IT <- cpos.specTST10IT5*(1-specTST10) + cneg.specTST10IT5*(specTST10)
#Prior at baseline
sensTST10∼dunif(0,1)
specTST10∼dunif(0,1)
logit(sensTST10)<-logit(sensTST10)-dsens510
dsens510∼dunif(0,5)
logit(specTST10)<-logit(specTST10)+dspec510
dspec510∼dunif(0,5)
sensTST15∼dunif(0,1)
specTST15∼dunif(0,1)
sensTST10∼dunif(0,1)
specTST10∼dunif(0,1)
sensTSPOTTB∼dunif(0,1)
specTSPOTTB∼dunif(0,1)
cpos.sensTST10IT5∼dunif(0,1)
cpos.specTST10IT5∼dunif(0,1)
cneg.sensTST10IT5∼dunif(0,1)
cneg.specTST10IT5∼dunif(0,1)
cpos.sensTST10IT10∼dunif(0,1)
cpos.specTST10IT10∼dunif(0,1)
cneg.sensTST10IT10∼dunif(0,1)
cneg.specTST10IT10∼dunif(0,1)
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mprev ∼ dbeta(1,1)
}
#Sample data from the clinical evidence
list(Nstudy=13,Npats=structure(.Data=c(84,84,73,84,84,84,306,306,306,306,306,306,104,104,104,104,
104,104,5244,5244,5244,5244,5244,5244,59,59,59,59,59,59,69,69,69,69,69,69,204,204,204,204,204,
204,195,195,195,195,195,195,184,184,184,184,184,184,1073,1073,1073,1073,1073,1073,104,104,
104,104,104,104,50,50,50,50,50,50,2982,2966,2982,2982,2982,2982),.Dim=c(13,6)),N.cs=6,cs.index=
c(1,4,6,9,10,11),N.cs2=4,cs2.index=c(7,8,12,13), rplusTST10=c(NA,6,NA,NA,18,NA,NA,NA,NA,NA,NA,
NA,NA),rplusTST10IT=c(20,NA,21,2669,NA,10,31,33,61,331,21,30,317),rplusTSPOTTB=c(16,NA,NA,NA,
NA,NA,NA,NA,NA,NA,NA,NA,NA), rplusTST10=c(38,200,40,2894,NA,42,NA,NA,84,645,27,NA,NA),
rplusTST10=c(NA,90,40,NA,8,NA,115,47,NA,NA,NA,32,663),rplusTST15=c(NA,NA,NA,NA,NA,NA,NA,NA,
NA,NA,NA,NA,231),ATBposTST10=c(NA,0,NA,NA,10,NA,NA,NA,NA,NA,NA,NA,NA),ATBposTST10IT=c(NA,
NA,6,39,NA,NA,NA,NA,NA,NA,NA,NA,11),ATBposTSPOTTB=c(NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,
NA,NA),ATBposTST10=c(NA,0,6,40,NA,NA,NA,NA,NA,NA,NA,NA,NA),ATBposTST10=c(NA,0,4,NA,3,NA,NA,
NA,NA,NA,NA,NA,13),ATBposTST15=c(NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13),ATBnegTST10=
c(NA,0,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA),ATBnegTST10IT=c(NA,NA,0,13,NA,NA,NA,NA,NA,NA,NA,
NA,12),ATBnegTSPOTTB=c(NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA),ATBnegTST10=c(NA,0,0,12,NA,
NA,NA,NA,NA,NA,NA,NA,NA), ATBnegTST10=c(NA,0,2,NA,7,NA,NA,NA,NA,NA,NA,NA,10),ATBnegTST15=
c(NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10),rplusTST10TST10IT=c(18,2383,10,51,266,19),
rnegTST10TST10IT=c(44,2064,27,90,363,75), rplusTST10TST10IT=c(27,28,30,231),rnegTST10TST10IT=
c(85,143,18,2219))
#Sample initial values
list(dsens510=0.5,dspec510=0.5)
The robustness of the model was assessed by examining the convergence diagnostics for evidence of when
the simulation appeared to mix. This was examined based on visual inspection of the sample trace plots.
A burn-in period of 30,000 simulations was used followed by a further 30,000 simulations.
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FIGURE 75 Sample traces of chains for sensitivity of TST (≥ 5mm) where convergence/mixing looks reasonable.
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FIGURE 76 Sample traces of chains for specificity of TST (< 5mm) where convergence/mixing looks reasonable.
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FIGURE 77 Sample traces of chains for sensitivity of TST (≥ 10mm) where convergence/mixing looks reasonable.
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FIGURE 78 Sample traces of chains for specificity of TST (< 10mm) where convergence/mixing looks reasonable.
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FIGURE 79 Sample traces of chains for sensitivity of QFT-GIT where convergence/mixing looks reasonable.
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FIGURE 80 Sample traces of chains for specificity of QFT-GIT where convergence/mixing looks reasonable.
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Appendix 18 Information required to derive the
diagnostic accuracy of various testing strategies
by population
Children and adolescents
TABLE 67 Information used to derive sensitivity in the child and adolescent population
Test
Total
tested
Number of
positives
Number of positives who
developed active TB
Length of follow-up
(years) Source
QFT-G 306 6 0 3 Higuchi et al.161
TST (≥ 5mm) 306 200 0
TST (≥ 10mm) 306 90 0
QFT-GIT 104 21 6 2–4 Diel et al.102
TST (≥ 5mm) 104 40 6
TST (≥ 10mm) 104 40 4
QFT-GIT 5244 2669 39 3.8 Mahomed et al.103
TST (≥ 5mm) 5244 2894 40
QFT-G 59 18 10 1 Noorbakhsh et al.104
TST (≥ 10mm) 59 8 3
QFT-GIT 2966 317 11 2 Song et al.152
TST (≥ 10mm) 2982 663 13
TST (≥ 15mm) 2982 231 13
TABLE 68 Information used to derive specificity in the child population
Test
Total
tested
Number of
positives
Number of positives who
developed active TB
Length of follow-up
(years) Source
QFT-G 306 300 0 3 Higuchi et al.161
TST (< 5mm) 306 106 0
TST (< 10mm) 306 216 0
QFT-GIT 104 83 0 2–4 Diel et al.102
TST (< 5mm) 104 64 0
TST (< 10mm) 104 64 2
QFT-GIT 5244 2575 13 3.8 Mahomed et al.103
TST (< 5mm) 5244 2350 12
QFT-G 59 41 0 1 Noorbakhsh et al.104
TST (< 10mm) 59 50 7
QFT-GIT 2966 2649 12 2 Song et al.152
TST (< 10mm) 2982 2319 10
TST (< 15mm) 2982 2751 10
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Immunocompromised people
TABLE 69 Information used to derive sensitivity in the immunocompromised population
Test
Total
tested
Number of
positives
Number of positives who
developed active TB
Length of follow-up
(years) Source
T-SPOT.TB 265 89 4 1.17 (median) Kim et al.116
TST (≥ 5mm) 288 26 1
QFT-G 30 12 1 2 Lee et al.118
T-SPOT.TB 32 15 0
TST (≥ 10mm) 32 20 1
QFT-GIT 210 40 1 0.8 (median) Moon et al.115
TST (≥ 5mm) 244 39 0
QFT-GIT 159 26 3 1.3 (median) Lee et al.149
TST (≥ 10mm) 169 19 0
TST (≥ 15mm) 169 12 0
T-SPOT.TB 44 6 1 1.75 Sherkat et al.155
TST (≥ 10mm) 44 8 1
TABLE 70 Information used to derive specificity in the immunocompromised population
Test
Total
tested
Number of
positives
Number of negatives
that developed active TB
Length of follow-up
(years) Source
T-SPOT.TB 265 176 0 1.17 (median) Kim et al.116
TST (< 5mm) 288 262 3
QFT-G 30 18 0 2 Lee et al.118
T-SPOT.TB 32 17 2
TST (< 10mm) 32 12 1
QFT-GIT 210 170 1 0.8 (median) Moon et al.115
TST (< 5mm) 244 205 2
QFT-GIT 159 133 2 1.3 (median) Lee et al.149
TST (≤ 10mm) 169 150 5
TST (≤ 15mm) 169 157 5
T-SPOT.TB 44 38 0 1.75 Sherkat et al.155
TST (≤ 10mm) 44 36 0
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Recently arrived population
TABLE 71 Information required to derive sensitivity in the recently arrived population
Test
Total
tested
Number of
positives
Number of positives who
developed active TB
Length of follow-up
(years) Source
QFT-GIT 815 238 8 2.67 Harstad et al.143
TST (≥ 6mm) 810 415 8
QFT-GIT 327 178 5 2 Kik et al.144
T-SPOT.TB 299 181 6
TST (≥ 15mm) 322 184 7
TABLE 72 Information required to derive specificity in the recently arrived population
Test
Total
tested
Number of
positives
Number of positives who
developed active TB
Length of follow-up
(years) Source
QFT-GIT 815 577 1 2.67 Harstad et al.143
TST (≤ 6mm) 810 395 1
QFT-GIT 327 149 3 2 Kik et al.144
T-SPOT.TB 299 118 2
TST (≤ 15mm) 322 138 1
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